

**REASON FOR EARLY TERMINATION OF THE G1T28-210 STUDY
DATED 05 OCTOBER 2022**

EUDRACT NUMBER: 2021-000186-32

**G1T28-210: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, CLINICAL TRIAL OF
TRILACICLIB VERSUS PLACEBO IN PATIENTS WITH METASTATIC NON-
SMALL CELL LUNG CANCER (NSCLC) TREATED WITH DOCETAXEL IN THE
2ND/3RD LINE SETTING (PRESERVE 4)**

G1 Therapeutics, Inc.

CONFIDENTIAL INFORMATION

This document contains confidential and/or trade secret information that is disclosed only in connection with the licensing and/or registration of products for G1 Therapeutics, Inc. This document should not be disclosed or used, in whole or in part, for any other purpose without the prior written consent of G1 Therapeutics, Inc.

Introduction

The G1T28-210 study was a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib compared with placebo on overall survival (OS) in patients with metastatic NSCLC receiving docetaxel in the 2nd or 3rd line setting. In the original protocol design, approximately 146 patients were planned to be randomly assigned (1:1) to receive trilaciclib or placebo intravenously (IV) prior to docetaxel on Day 1 of each 21-day cycle.

Study drugs administered were as follows:

- Trilaciclib (240 mg/m²) or placebo – administered as a 30-minute IV infusion no more than 4 hours prior to chemotherapy on each day chemotherapy was administered
- Docetaxel 75 mg/m² –IV, Day 1

Number of patients enrolled prior to termination

The first patient in the study was dosed on 03 June 2021. A total of 7 patients were randomized (United States only) and received at least one dose of study drug:

- 3 patients received placebo + docetaxel
- 4 patients received trilaciclib + docetaxel

Reason for early termination

Due to the rapidly evolving treatment landscape for patients with metastatic NSCLC in the 2nd/3rd line setting, G1 Therapeutics announced the decision to terminate this study on 03 November 2021. This study was not terminated for reasons related to safety. At the time of study termination, 10 patients had been screened, 7 were randomized, and 2 of the 7 had already discontinued from the study. At the time of study termination, it was also decided that there would be no statistical analyses of the efficacy or safety data due to the limited number of patients enrolled (N=7).

As of the final database lock (27 April 2022; last patient last visit date of 02 February 2022), there were no patients who continued to receive study drug or who remained ongoing in the study. All 7 patients (100%) discontinued study drug, including 3 patients who received placebo + docetaxel and 4 patients who received trilaciclib + docetaxel.

All safety and efficacy data as collected during the study are presented in data listings. Overall, the safety data summary and patient data listings from this study suggested trilaciclib in combination with docetaxel was safe for this patient population. No new trilaciclib safety signals or concerns were identified.

Attached below is the synoptic clinical study report (CSR) for study G1T28-210.

**1. TITLE PAGE****SYNOPTIC CLINICAL STUDY REPORT
G1T28-210****A PHASE 2 RANDOMIZED, DOUBLE-BLIND, CLINICAL
TRIAL OF TRILACICLIB VERSUS PLACEBO IN PATIENTS
WITH METASTATIC NON-SMALL CELL LUNG CANCER
(NSCLC) TREATED WITH DOCETAXEL IN THE 2ND/3RD
LINE SETTING (PRESERVE 4)**

Indication studied:	Non-Small Cell Lung Cancer
Investigational product:	Trilaciclib (G1T28)
Developmental phase of study:	2
ClinicalTrials.gov identifier:	NCT04863248
EudraCT number:	2021-000186-32
First patient enrolled (signed informed consent):	30 April 2021
Last patient observation for this report:	02 February 2022
Release date of report:	27 July 2022
Company/sponsor signatory:	Andrew Beelen, MD Executive Director, Clinical Development G1 Therapeutics, Inc.

This study was conducted in accordance with the ethical principles of Good Clinical Practice, including archiving of essential documents, according to the International Council for Harmonisation (ICH) Harmonized Tripartite Guideline.

2. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

The following abbreviations and specialist terms are used in this report.

Table 1: Abbreviations and Specialist Terms

Abbreviation or Specialist Term	Explanation
AE	adverse event
AESI	adverse events of special interest
ALK	anaplastic lymphoma kinase
ALT	alanine aminotransferase
AST	aspartate aminotransferase
CR	complete response
D5W	dextrose 5% in water
DMC	Data Monitoring Committee
DOR	duration of objective response
ECG	electrocardiogram
ECOG	Eastern Cooperative Oncology Group
EGFR	epidermal growth factor receptor
EORTC QLQ-C30	European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire
EORTC QLQ-LC13	European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module
EORTC IL118	European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module with supplemental weight loss item
EQ-5D-5L	5-level EQ-5D
FACIT-Fatigue	Functional Assessment of Chronic Illness Therapy - Fatigue
GCP	Good Clinical Practice
IEC	independent ethics committee
IRB	institutional review board
ICH	International Council for Harmonisation
IV	intravenous(ly)
mAB	monoclonal antibody
MedDRA	Medical Dictionary for Regulatory Activities
NCI-CTCAE	National Cancer Institute Common Terminology Criteria
NSCLC	non-small cell lung cancer
ORR	objective response rate
OS	overall survival

Abbreviation or Specialist Term	Explanation
PD-1	programmed cell death protein 1
PD-L1	programmed death ligand 1
PFS	progression-free survival
PGIC	Patient Global Impression of Change
PGIS	Patient Global Impression of Severity
PR	partial response
PRO	patient-reported outcome
PT	preferred term
QTcF	QT corrected using Fridericia's formula
RECIST	Response Evaluation Criteria in Solid Tumors
ROS1	c-ROS oncogene 1
SAE	serious adverse event
SD	stable disease
SOC	system organ class
ULN	upper limit of normal
US	United States

3. TABLE OF CONTENTS FOR THE INDIVIDUAL CLINICAL STUDY REPORT

TABLE OF CONTENTS

1.	TITLE PAGE.....	1
2.	LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.....	2
3.	TABLE OF CONTENTS FOR THE INDIVIDUAL CLINICAL STUDY REPORT	4
4.	ETHICS	6
4.1.	Independent Ethics Committee or Institutional Review Board	6
4.2.	Ethical Conduct of the Study	6
4.3.	Patient Information and Consent	6
5.	SYNOPSIS	7
6.	APPENDICES	21
6.1.	Study Information.....	21
6.1.1.	Protocol and protocol amendments	21
6.2.	Patient Data Listings.....	21
6.2.1.	Discontinued patients.....	21
6.2.2.	Protocol deviations	21
6.2.3.	Demographic data.....	21
6.2.4.	Individual efficacy response data	21
6.2.5.	Adverse event listings (each patient).....	21
6.2.6.	Listing of individual laboratory measurements by patient, when required by regulatory authorities	21
6.3.	CIOMS for serious adverse events	21
6.4.	Individual Patient Data Listings and Data Tables	21

LIST OF TABLES

Table 1:	Abbreviations and Specialist Terms	2
Table 2:	Objectives and Endpoints	7
Table 3:	Demographic and Baseline Disease Characteristics (All Randomized Patients)	17
Table 4:	Overall Summary of Adverse Events	19

LIST OF FIGURES

Figure 1:	Study Schema	10
Figure 2:	Patient Disposition for Study G1T28-210 (All Enrolled Patients).....	16

4. ETHICS

4.1. Independent Ethics Committee or Institutional Review Board

The protocol and all associated amendments and consent/assent, and any other study related materials such as advertising or information leaflets, were reviewed and approved by the investigative site's local or a central institutional review board (IRB) or independent ethics committee (IEC) prior to the initiation of the study. Any modifications made to the protocol after receipt of the IRB/IEC approval were submitted by the investigator to the IRB/IEC in accordance with local procedures and regulatory requirements. Any updates to the protocol received IRB/IEC approval or favorable opinion prior to implementation.

As applicable according to local regulations, the protocol and all protocol amendments were reviewed and approved by each pertinent competent authority.

4.2. Ethical Conduct of the Study

This study was conducted in full conformance with the principles of the Declaration of Helsinki (as amended in Tokyo, Venice, Hong Kong, and South Africa) or with the laws and regulations of the country in which the research was conducted, whichever afforded the greater protection to the individual. The investigator ensured adherence to the basic principles of Good Clinical Practice (GCP), as outlined in the current version of 21 Code of Federal Regulations, Part 312, Subpart D (Responsibilities of Sponsors and Investigators), Part 50 (Protection of Human Subjects), Part 54 (Financial Disclosure by Clinical Investigators), and Part 56 (IRBs), and International Council for Harmonisation (ICH) E6 GCP. The investigator followed all national, state, and local laws of the pertinent regulatory authorities.

4.3. Patient Information and Consent

It was the responsibility of the investigator to obtain written informed consent from each patient participating in this study, after adequate explanation of the goals, methods, potential benefits, and hazards of the study. The investigator or designee also explained that the patients could withdraw from the study at any time and for any reason. All patients were given a copy of the informed consent form and any updates.

5. SYNOPSIS

Name of Sponsor/Company: G1 Therapeutics, Inc.	Individual Study Table Referring to Part of the Dossier Volume: Page:	<i>(For National Authority Use Only)</i>
Name of Finished Product: Trilaciclib		
Name of Active Ingredient: G1T28		
Title of Study: A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2 nd /3 rd Line Setting (PRESERVE 4)		
Coordinating Investigator:		
Study centers: Approximately 60 centers were planned. The study was conducted at 2 centers in the United States (US).		
Publications: . None at the time of this synoptic clinical study report		
Studied period (years): ~9 months, 2 days Date first patient enrolled: 30 April 2021 Date last patient completed: 02 February 2022		Phase of development: 2
Objectives: <p>The primary, secondary, safety, and exploratory objectives of this study and their associated endpoints, for patients with metastatic NSCLC receiving docetaxel in the 2nd or 3rd line, are presented in Table 2.</p>		
Table 2: Objectives and Endpoints		
Objectives	Endpoints	
Primary Objective		
<ul style="list-style-type: none"> To assess the effect of trilaciclib on OS compared with placebo 	<ul style="list-style-type: none"> OS in the ITT population defined as time from randomization to death due to any cause for those who died; or time to last contact known as alive for those who survived in the study (censored cases). 	
Secondary Objectives: Other Anti-Tumor Efficacy		
<ul style="list-style-type: none"> To assess the effect of trilaciclib on PFS compared with placebo 	<ul style="list-style-type: none"> PFS in ITT population defined as time from randomization to disease progression using RECIST v1.1 or death due to any cause, whichever occurs first; for patients without disease progression or death, PFS will be calculated per censoring rules. 	

<ul style="list-style-type: none"> To assess the effect of trilaciclib on other anti-tumor endpoints compared with placebo 	<ul style="list-style-type: none"> ORR defined as percentage of patients with confirmed CR and PR per RECIST v1.1 DOR defined as duration of objective response
Secondary Objective: to evaluate the myelopreservation effect of trilaciclib compared with placebo	
<ul style="list-style-type: none"> To assess the effects of trilaciclib on the neutrophil lineage compared with placebo 	<ul style="list-style-type: none"> Duration of severe (Grade 4) neutropenia in Cycle 1 Occurrence of severe (Grade 4) neutropenia Occurrence of febrile neutropenia AEs Occurrence of G-CSF administration
<ul style="list-style-type: none"> To assess the effects of trilaciclib on the RBC lineage compared with placebo 	<ul style="list-style-type: none"> Occurrence of Grade 3 or 4 decreased hemoglobin laboratory values RBC transfusions on or after Week 5 (occurrence and number of transfusions) Occurrence of ESA administration
<ul style="list-style-type: none"> To assess the effects of trilaciclib on the platelet lineage compared with placebo 	<ul style="list-style-type: none"> Occurrence of Grade 3 or 4 decreased platelet count laboratory values Platelet transfusions (occurrence and number of transfusions)
<ul style="list-style-type: none"> To assess the effects of trilaciclib on chemotherapy dosing compared with placebo 	<ul style="list-style-type: none"> All-cause dose reductions (occurrence and number of reductions) All-cause cycle delays (occurrence and number of delays)
<ul style="list-style-type: none"> To assess the effects of trilaciclib on hospitalizations due to chemotherapy-induced myelosuppression compared with placebo 	<ul style="list-style-type: none"> Occurrence and number of hospitalizations due to chemotherapy-induced myelosuppression
Secondary Objective: to evaluate the safety of trilaciclib compared with placebo	
<ul style="list-style-type: none"> To assess the safety and tolerability of trilaciclib compared with placebo 	<ul style="list-style-type: none"> Occurrence and severity of AEs by NCI-CTCAE v5 Study treatment discontinuation due to AEs Changes in laboratory parameters (hematology, chemistry), vital signs and ECG parameters Grade 3 or 4 abnormalities in laboratory parameters Trilaciclib AESIs Chemotherapy infusion interruptions Relative dose intensity for docetaxel

Exploratory Objectives	
<ul style="list-style-type: none"> To assess the anti-tumor efficacy of trilaciclib by CDK4/6-dependence status 	<ul style="list-style-type: none"> OS, PFS, and ORR (per RECIST v1.1) in patients with each of the following CDK4/6 dependence signatures: <ul style="list-style-type: none"> CDK4/6 dependent CDK4/6 independent CDK4/6 indeterminant
<ul style="list-style-type: none"> To assess the anti-tumor efficacy of trilaciclib by PD-L1 subgroups 	<ul style="list-style-type: none"> OS, PFS, ORR, and DOR in ITT population by PD-L1 subgroups (as measured by retrospective analysis)
<ul style="list-style-type: none"> To characterize the population PK of trilaciclib and identify important determinants of variability 	<ul style="list-style-type: none"> Exposure-response relationship between trilaciclib and response or safety endpoints
<ul style="list-style-type: none"> Estimate the PK parameters of docetaxel using a population PK model 	<ul style="list-style-type: none"> Clearance Volume of distribution
<ul style="list-style-type: none"> To assess the effect of trilaciclib on CIM- and disease-related symptoms and functional limitations 	<p>Change from baseline and/or time to deterioration in:</p> <ul style="list-style-type: none"> EORTC QLQ-C30 domain scores EORTC QLQ-LC13 with supplemental weight loss item (EORTC IL118) domain scores FACIT-Fatigue total score EQ-5D-5L <p>Percent of patients reporting deterioration and improvement using:</p> <ul style="list-style-type: none"> PGIC fatigue item PGIS fatigue item
<ul style="list-style-type: none"> To assess the pharmacodynamic effects, including immune based mechanism, of trilaciclib when added to docetaxel in peripheral blood 	<ul style="list-style-type: none"> Differences in pharmacodynamic parameters, including those relating to immune-based mechanisms, in peripheral blood

AE=adverse event; AESI=adverse event of special interest; CDK=cyclin-dependent kinase; CIM=chemotherapy-induced myelosuppression; CR=complete response; DOR=duration of response; ECG=electrocardiogram; EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire; EORTC QLQ-LC13=European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module; EORTC IL118= European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module with supplemental weight loss item; EQ-5D-5L=5-level EQ-5D; ESA=erythropoiesis stimulating agent; FACIT-Fatigue=Functional Assessment of Chronic Illness Therapy – Fatigue; G-CSF=granulocyte colony-stimulating factor; ITT=intent to treat; NCI-CTCAE=National Cancer Institute Common Terminology Criteria; ORR=objective response rate; OS=overall survival; PD-L1=programmed death ligand 1; PFS=progression-free survival; PGIC=Patient Global Impression of Change; PGIS=Patient Global Impression of Severity; PK=pharmacokinetic(s); PR=partial response; RBC=red blood cell; RECIST=Response Evaluation Criteria in Solid Tumors

Methodology:

This was a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib compared with placebo on overall survival (OS) in patients with metastatic NSCLC receiving docetaxel in the 2nd or 3rd line setting. Patients must have had documented disease progression during or after 1 or 2 lines of systemic therapy for recurrent or metastatic NSCLC. Prior treatment must have included, either in the same line or as separate lines of therapy: 1) a maximum of 1 line of platinum-containing chemotherapy in the recurrent/metastatic setting and 2) a maximum of 1 line of a locally approved/authorized programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb)-containing regimen in the recurrent/metastatic setting.

In the original protocol design, approximately 146 patients were planned to be randomly assigned (1:1) to receive trilaciclib or placebo intravenously (IV) prior to docetaxel on Day 1 of each 21-day cycle. There were 2 stratification factors for randomization: Country, and Eastern Cooperative Oncology Group (ECOG) performance status (0-1 versus 2). Within each country, patient randomization was stratified by ECOG performance status (0-1 versus 2). The study was to include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase (Figure 1). The Treatment Phase began on the day of randomization for the first patient and was to complete at the Post--Treatment Visit for the last patient. The first Survival Follow-up assessment was planned to occur approximately 2 months after the last dose of study drug.


Study drugs administered are as follows:

- Trilaciclib (240 mg/m²) or placebo – administered as a 30-minute IV infusion no more than 4 hours prior to chemotherapy on each day chemotherapy was administered
- Docetaxel 75 mg/m² –IV, Day 1

Treatment cycles were to occur consecutively without interruption, except when necessary to manage toxicities or for administrative reasons. Study drug administration was to continue until disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or clinical progression as determined by the Investigator, unacceptable toxicity, withdrawal of consent, discontinuation by Investigator, or the end of the trial, whichever occurred first.

The duration of total follow-up relative to the first patient being randomized was planned to be approximately 30 months to collect the target number of deaths per sample size calculation. The study was terminated early by the Sponsor for reasons other than safety.

Figure 1: Study Schema



D=day; DC=discontinue; PD=progressive disease; PI=Principal Investigator; WD=withdraw

An unblinded, independent Data Monitoring Committee (DMC) was planned to monitor accumulating safety and disposition data with the first meeting planned for when approximately 20 patients had enrolled and completed at least 2 cycles of study treatment. Details of the DMC, including objectives, composition, scope, and frequency, are described in the DMC charter.

Details of the study plan and data collection are provided in the protocol and protocol amendments provided in [Appendix 16.1.1](#).

Number of patients (planned and actual):

Planned: Overall, approximately 146 patients with histologically or cytologically-confirmed metastatic NSCLC were planned to be randomly assigned in a 1:1 ratio to 1 of 2 groups, as follows: trilaciclib administered IV prior to docetaxel or placebo administered IV prior to docetaxel.

Safety Outcomes Summary:

A total of 7 patients were randomized and received at least one dose of study drug (3 patients received placebo + chemotherapy and 4 patients received trilaciclib + chemotherapy).

Diagnosis and main criteria for inclusion:

In order to be eligible, female or male patients ≥ 18 with a histologically or cytologically confirmed metastatic NSCLC (squamous or nonsquamous) with no known actionable driver mutations (e.g., epidermal growth factor receptor [EGFR], c-ROS oncogene 1 [ROS1], anaplastic lymphoma kinase [ALK]), must have had all of the following:

- Documented disease progression during or after 1 or 2 lines of systemic treatment for recurrent or metastatic disease.
- Two components of treatment must have been received in the same line or as separate lines of therapy: (i) a maximum of 1 line of platinum-containing chemotherapy regimen for recurrent/metastatic disease, and (ii) a maximum of 1 line of a locally approved/authorized PD-1/PD-L1 mAb containing regimen for recurrent/metastatic disease.
- Maintenance therapy following platinum doublet-based chemotherapy was not considered as a separate line of therapy. Maintenance therapy was defined as therapy given within 42 days after the last dose of platinum-based chemotherapy in patients with ongoing clinical benefit (complete response [CR], partial response [PR] or stable disease [SD]).
- Measurable or non-measurable disease per RECIST v1.1
- ECOG Performance Status of 0 to 2
- A formalin-fixed paraffin-embedded tumor specimen (from archival or fresh biopsy) with an associated pathology report documenting NSCLC must have been available to send to the Sponsor, within the protocol specified timeframe, for planned retrospective biomarker analyses
- Hemoglobin ≥ 9.0 g/dL in the absence of red blood cell transfusion or erythropoiesis-stimulating agent administration within 14 days prior to first dose of trilaciclib/placebo
- Absolute neutrophil count $\geq 1.5 \times 10^9/L$
- Platelet count $\geq 100 \times 10^9/L$

- Total bilirubin \leq upper limit of normal (ULN)
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) $<1.5 \times$ ULN if alkaline phosphatase $>2.5 \times$ ULN
- If alkaline phosphatase $<2.5 \times$ ULN then AST, ALT $<2.5 \times$ ULN in the absence of liver metastasis or $<5 \times$ ULN in the presence of liver metastasis
- Estimated glomerular filtration rate ≥ 30 mL/minute/1.73 m²
- Resolution of nonhematologic toxicities per National Cancer Institute Common Terminology Criteria Version 5.0 (NCI-CTCAE) from prior therapy or surgical procedures to \leq Grade 1 or baseline (except alopecia).

Patients were not eligible if they had any of the following:

- Prior therapy with docetaxel.
- Any contraindication to the administration of docetaxel at the discretion of the investigator.
- Mixed NSCLC/small cell lung cancer, or lung tumors whose predominant histology was sarcomatoid, or neuroendocrine.
- Any chemotherapy, immunotherapy, biologic, investigational, or hormonal therapy for cancer treatment (except for adjuvant hormonal therapy for breast cancer or prostate cancer defined as M0 disease or prostate-specific antigen persistence/recurrence without metastatic disease) within 3 weeks prior to the first dose of trilaciclib/placebo.
- Any radiotherapy within 2 weeks prior to the first dose of trilaciclib/placebo.
- Presence of central nervous system metastases requiring immediate treatment with radiation therapy or steroids (i.e., patient must have been off steroids administered for brain metastases for at least 14 days prior to the first dose of trilaciclib/placebo).
- Presence of leptomeningeal disease.
- Significant third-space fluid retention (ex. ascites or pleural effusion) not amenable to required repeat drainage.
- QT corrected using Fridericia's formula (QTcF) interval >480 msec at screening (confirmed on repeat). For patients with ventricular pacemakers, QTcF >500 msec.
- Symptomatic peripheral neuropathy (\geq Grade 2 NCI-CTCAE v5.0)
- History of interstitial lung disease
- Clinically significant (i.e., active) cardiovascular disease at the time of signing the informed consent; for example cerebrovascular accidents (≤ 6 months before the first dose of trilaciclib/placebo), myocardial infarction (≤ 6 months before the first dose of trilaciclib/placebo), unstable angina, serious cardiac arrhythmia requiring medication, or uncontrolled symptomatic congestive heart failure [Class II or higher as defined by the New York Heart Association functional classification system])
- Known serious active infection (e.g., human immunodeficiency virus, hepatitis B or C, tuberculosis, etc.)

- Prior allogeneic or autologous hematopoietic stem cell or bone marrow transplantation
- Receipt of any low-dose systemic chemotherapeutic agent (e.g., low-dose methotrexate for rheumatoid arthritis) administered for a nononcologic purpose within 3 weeks prior to the first dose of trilaciclib/placebo.
- Receipt of any live attenuated vaccines within 4 weeks prior to first dose of study treatment or anticipation that such a vaccine were required during the study treatment period.
- Known hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80 or any excipients of trilaciclib
- Pregnant or lactating women
- Legal incapacity or limited legal capacity
- Other uncontrolled serious chronic disease or psychiatric condition that in the Investigator's opinion could affect patient safety, compliance, or follow-up in the protocol
- Concurrent participation in any other interventional clinical trial.

Test product, dose and mode of administration, and batch number:

Patients received trilaciclib 240 mg/m² or placebo administered as a 30-minute IV infusion no more than 4 hours prior to chemotherapy on each day chemotherapy was administered.

There were no inpatient dose modifications of trilaciclib during the study.

Trilaciclib for Injection, 300 mg/vial (also referred to as "Trilaciclib Sterile Powder for concentrate for solution for IV infusion, 300 mg/vial") was supplied as a sterile, preservative-free, yellow, lyophilized cake in a single-dose vial (300 mg/20 mL). Each vial should have been reconstituted with 250 mL of either dextrose 5% in water (D5W) or normal saline (sodium chloride solution 0.9%).

There should have been no more than 5 weeks (for toxicity and/or administrative reasons) between doses of chemotherapy; however dosing delays >5 weeks may have been permitted on a case by-case basis with the documented approval of the Investigator and Medical Monitor.

Trilaciclib/placebo was always administered first, followed by docetaxel and was to be completed within 4 hours prior to the start docetaxel. Docetaxel may have been administered immediately following trilaciclib/placebo, but not until the completion of the trilaciclib/placebo infusion. If administration of trilaciclib/placebo was delayed or discontinued, docetaxel was also delayed or discontinued. Likewise, if docetaxel was delayed or discontinued, trilaciclib/placebo was also delayed or discontinued.

Duration of treatment: Study drug administration continued for each patient until disease progression, unacceptable toxicity, withdrawal of consent, discontinuation by Investigator, or the end of the trial, whichever occurred first. Treatment cycles were to occur consecutively without interruption, except when necessary to manage toxicities or for administrative reasons.

Reference therapy, dose and mode of administration, batch number:

Patients received docetaxel 75 mg/m² administered IV on Day 1 of each 21-day cycle.

Dose modifications allowed for docetaxel are described in the protocol.

The placebo, either 250 mL of D5W or sodium chloride solution 0.9%, was prepared by the pharmacist/designee on site.

Descriptions of the formulations of commercially available docetaxel are provided in the current prescribing information.

Criteria for evaluation:**Efficacy:**

Antitumor efficacy was planned to be assessed by OS, progression-free survival (PFS), objective response rate (ORR), and duration of objective response (DOR). Tumor response criteria was planned to be based on RECIST v1.1.

Myelopreservation efficacy was planned to be assessed based on hematology assessments, myelosuppression-related adverse event (AE) details, dose reductions/delays and supportive care interventions (including transfusions).

Safety:

Safety was evaluated by monitoring AEs, clinical laboratory test results (hematology, clinical chemistry), vital sign measurements (blood pressure, heart rate, and body temperature), 12-lead safety electrocardiogram (ECG) results, dose intensity, and physical examination findings.

PROs:

Patient-reported outcomes were planned to be assessed using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30), EORTC Quality of Life Lung Cancer Module (QLQ-LC13), with supplemental weight loss item (EORTC IL118), Functional Assessment of Chronic Illness Therapy – Fatigue Scale (FACIT-Fatigue), Patient Global Impression of Change (PGIC), Patient Global Impression of Severity (PGIS), and 5-level EQ-5D (EQ-5D-5L).

Pharmacodynamics:

Pharmacodynamic analyses were planned to examine the relationship(s) between exposure to trilaciclib and efficacy and safety endpoints as well as the relationship(s) between peripheral blood biomarkers and trilaciclib's immune-based mechanisms of action(s).

Statistical methods:

Data were summarized by treatment group. The descriptive summary for the categorical variables included counts and percentages.

Stratification factors:

There were two stratification factors for randomization: country and ECOG performance status (0-1 versus 2). Within each country, patient randomization was stratified by ECOG performance status (0-1 versus 2). A randomization schema was in place to ensure the best possible balance of treatment assignment within each stratum produced by these stratification factors. Countries were grouped into the factor of "region" with 3 components: US, Europe, and Asia. The factor "region" was used instead of "country" in the statistical analysis models to account for regional differences in clinical practice.

Analysis population

The safety population included all randomized patients who received at least one dose of study drug. Summaries of the safety population were based on the actual treatment received. All safety summaries were completed with the safety population.

Analysis for safety endpoints

Safety and tolerability were assessed by AEs, dose modifications, laboratory tests, vital signs, and ECG. Safety data were summarized using descriptive statistics by treatment group based on the safety population. AEs were defined as those events occurring or worsening after treatment had begun on this study. AE data was coded to system organ class (SOC) and preferred term (PT) using the latest version of Medical Dictionary for Regulatory Activities (MedDRA). The severity (toxicity grades 1-5) was summarized by SOC, PT and NCI-CTCAE grade, as appropriate. In the tabulation of severity and causality for an AE, if the same AE occurred on multiple occasions, the highest grade

and strongest relationship to study drug was used. Concomitant medications, as well as prior and subsequent anticancer therapies, were coded to Anatomical Therapeutic Classification using the World Health Organization-Drug Dictionary and summarized by treatment group.

An overall summary of AEs, AEs related to each study drug, AEs leading to study drug discontinuation, and trilaciclib AEs of special interests (AESIs) was generated. For laboratory assessments, vital signs, and ECG intervals, observed values were listed by patient. For serum chemistry and hematology laboratory parameters, clinical labs were characterized according to v5.0 NCI-CTCAE toxicity grade from 1 to 5, when possible. Safety data collected through scheduled or unscheduled visits was included in the safety evaluation.


Analysis for other endpoints

Due to the early termination of the study by the Sponsor, planned analyses for endpoints other than safety were not conducted.

Study Status:

Due to the changing landscape of treatments for patients with metastatic NSCLC treated with docetaxel in the 2nd/3rd line setting, the Sponsor announced the decision to terminate this study on 03 November 2021. This study was not terminated for reasons related to safety. At the time of study termination, 10 patients had been screened, 7 were randomized, and 2 of the 7 had already discontinued from the study. At the time of study termination, it was also decided that there would be no statistical analyses of the efficacy or safety data collected from this extremely small number of patients.

As of the final database lock (27 April 2022; last patient last visit date of 02 February 2022), there were no patients who continued to receive study drug or who remained ongoing in the study. All 7 patients (100%) discontinued study drug, including 3 patients who received placebo + docetaxel and 4 patients who received trilaciclib + docetaxel (Figure 2). The most common reason for study treatment discontinuation was Sponsor terminated study (3 out of 4 patients who received trilaciclib + docetaxel and 1 out of 3 patients who received placebo + docetaxel). All patients were also discontinued from the study, with the most common reason for study discontinuation being Sponsor terminated study (5 patients [71.4%]), followed by death and withdrawal by patient (1 patient [14.3%, each]).

Figure 2: Patient Disposition for Study G1T28-210 (All Enrolled Patients)

n=number of patients.

^a Only treated patients were included. Patients were treated until disease progression, unacceptable toxicity, or discontinuation by patient or Investigator decision; therefore, there is no definition of completion for this clinical trial.

Source: [Table 14.1.1.1](#).

A by-patient listing of disposition for all enrolled patients is provided in [Listing 16.2.1.1](#). The patient enrollment and randomization schedule is provide in [Listing 16.1.7.1](#).

Demographics for all treated patients are summarized in [Table 3](#). The median age of patients at baseline was 60 years (range: 45 to 73 years). The majority were male (57.1%) and white (57.1%). The majority were not Hispanic or Latino (71.4%) and all were enrolled in the US.

A by-patient listing of demographic and baseline characteristics for all enrolled patients is provided in [Listing 16.2.2](#).

A by-patient listing of protocol deviations for all randomized patients is provided in [Listing 16.2.1.2](#).

Table 3: Demographic and Baseline Disease Characteristics (All Randomized Patients)

Category	Placebo + Docetaxel (N=3)	Trilaciclib + Docetaxel (N=4)	Overall (N=7)
Age (years)			
n	3	4	7
Mean (SD)	62.7 (2.52)	58.3 (11.47)	60.1 (8.57)
Median	63.0	57.5	60.0
Min, Max	60, 65	45, 73	45, 73
Age Group, n (%)			
18-65	2 (66.7)	3 (75.0)	5 (71.4)
≥65	1 (33.3)	1 (25.0)	2 (28.6)
Gender, n (%)			
Male	2 (66.7)	2 (50.0)	4 (57.1)
Female	1 (33.3)	2 (50.0)	3 (42.9)
Unknown	0	0	0
Race, n (%)			
White	2 (66.7)	2 (50.0)	4 (57.1)
Black or African American	1 (33.3)	2 (50.0)	3 (42.9)
Ethnicity, n (%)			
Hispanic or Latino	1 (33.3)	1 (25.0)	2 (28.6)
Not Hispanic or Latino	2 (66.7)	3 (75.0)	5 (71.4)
ECOG score, n (%)			
0	1 (33.3)	1 (25.0)	2 (28.6)
1	2 (66.7)	2 (50.0)	4 (57.1)
2	0	1 (25.0)	1 (14.3)
Stage at Diagnosis, n (%)			
I	0	0	0
II	0	0	0
III	0	0	0
IV	3 (100.0)	4 (100.0)	7 (100.0)
Unknown	0	0	0
Stage at Screening, n (%)			
I	0	0	0
II	0	0	0
III	0	0	0
IV	3 (100.0)	4 (100.0)	7 (100.0)
Unknown	0	0	0
Histopathologic Type, n (%)			
Adenocarcinoma	2 (66.7)	3 (75.0)	5 (71.4)
Large Cell Carcinoma	0	0	0
Squamous Cell Carcinoma	1 (33.3)	1 (25.0)	2 (28.6)
Undifferentiated	0	0	0

Unknown	0	0	0
Other	0	0	0
Country, n (%)			
United States	3 (100.0)	4 (100.0)	7 (100.0)

ECOG=Eastern Cooperative Oncology Group; Max=maximum; Min=minimum; N=total number of patients in each treatment group; n=subset (defined in table title) of total number of patients; SD=standard deviation.

Source: [Table 14.1.3.1](#)

By-patient listings for medical history, lung cancer history, smoking history, concomitant surgeries/procedures/radiotherapy, and prior and concomitant medications for all randomized patients are provided in [Listing 16.2.4.1](#), [Listing 16.2.4.2](#), [Listing 16.2.4.3](#), [Listing 16.2.4.4](#), and [Listing 16.2.4.5](#), respectively.

By patient listings for timepoint and best overall response, new and target lesions by Investigator assessment, and non-target lesions by Investigator assessment for all randomized patients are provided in [Listing 16.2.13.1](#), [Listing 16.2.13.2](#), and [Listing 16.2.13.3](#), respectively.

Safety Results:

The median number of cycles completed in each treatment group was the same and the median duration of exposure was 102.5 days for patients who received trilaciclib + docetaxel and 94 days for patients who received placebo + docetaxel ([Listing 16.2.5.3](#)). There were no dose reductions or interruptions during the study for docetaxel ([Listing 16.2.5.2](#)). One patient receiving trilaciclib experienced myalgias leading to a dose interruption ([Listing 16.2.5.1](#) and [Listing 16.2.6.1](#)).

An overall summary of AEs reported during the study is presented in [Table 4](#). All patients experienced at least 1 AE, and all patients experienced at least 1 AE related to study drug. No patients had AEs that led to discontinuation of study drug.

Five of 7 patients had an AE of Grade ≥ 3 . Of these, 2 patients (50.0%) who received trilaciclib + docetaxel had 3 Grade 3 AEs (neutropenia and pneumonia in 1 patient and xeroderma in the other patient) that were considered related to trilaciclib; these events were considered by the Investigator to also be related to docetaxel. All 3 patients who received placebo + docetaxel had 7 AEs (leukopenia, lymphopenia, staphylococcal sepsis, and 2 events of neutropenia in 1 patient, leukopenia in 1 patient, and neutropenia in 1 patient) that were considered related to placebo and docetaxel; 1 patient also had a Grade 3 AE of renal failure considered related to docetaxel.

Two of the 3 patients who received placebo + docetaxel also had Grade 4 AEs (leukopenia and neutropenia in 1 patient, and 2 events of neutropenia in the other patient) that were considered related to placebo and to docetaxel ([Listing 16.2.6.1](#)). One patient who received placebo + docetaxel had a Grade 5 serious adverse event (SAE) of urosepsis; the event was considered by the Investigator to be related to placebo and to docetaxel ([Listing 16.2.6.7](#)). There were no Grade 4 or 5 events in patients receiving trilaciclib.

A total of 5 SAEs were reported: Grade 3 staphylococcal sepsis in 1 patient who received placebo + docetaxel; Grade 3 acute kidney injury and Grade 5 urosepsis in 1 patient who received placebo + docetaxel; Grade 3 renal failure in 1 patient who received placebo + docetaxel; and Grade 3 pneumonia in 1 patient who received trilaciclib + docetaxel. The events of staphylococcal sepsis and urosepsis were considered related to placebo and docetaxel, the event of renal failure was considered related to docetaxel, and the event of pneumonia was considered related to both trilaciclib and docetaxel. With the exception of the fatal event of urosepsis that was ongoing at the time of death, all SAEs were resolved ([Listing 16.2.6.7](#)).

One patient who received trilaciclib + docetaxel had an AESI of phlebitis that was Grade 1, considered related to both trilaciclib and docetaxel and did not resolve ([Listing 16.2.6.2](#)).

Table 4: Overall Summary of Adverse Events

Category	Placebo + Docetaxel (N=3)	Trilaciclib + Docetaxel (N=4)	Overall (N=7)
Any AE	3 (100.0)	4 (100.0)	7 (100.0)
Any AE of Grade \geq 3	3 (100.0)	2 (50.0)	5 (71.4)
Any AE of Grade \geq 4	3 (100.0)	0	3 (42.9)
Any study drug-related AE	3 (100.0)	4 (100.0)	7 (100.0)
Trilaciclib/placebo-related AE	3 (100.0)	4 (100.0)	7 (100.0)
Docetaxel-related AE	3 (100.0)	4 (100.0)	7 (100.0)
Any serious AE	3 (100.0)	1 (25.0)	4 (57.1)
Number of patients with AE leading to discontinuation of any study drug	0	0	0
Leading to Trilaciclib/placebo discontinuation	0	0	0
Leading to Docetaxel discontinuation	0	0	0
Number of patients with AE leading to death	1 (33.3)	0	1 (14.3)
Number of patients with AE of special interest for trilaciclib	0	1 (25.0)	1 (14.3)

AE=adverse event; MedDRA=Medical Dictionary for Regulatory Activities.

Adverse Events were coded using MedDRA Version 24.0. Adverse events were defined as those AEs that started on or after the day of the first dose of study drug. Adverse events with an unknown/not reported onset date were also included.

Adverse events with missing information concerning relationship, severity, or action taken were excluded from any specific analysis related to those parameters; however, these were included where appropriate in the overall summary.

Related refers to those events that were “Possibly”, “Probably”, or “Definitely Related”.

Percentages were based on the number of patients in each treatment group (i.e., N).

Source: [Table 14.3.1.1](#)

Overall, there were no clear clinically meaningful and unexpected changes in chemistry/pregnancy laboratory values, vital signs values, ECOG scores, or ECG parameters during the study ([Listing 16.2.7.1](#), [16.2.8](#), [16.2.9](#), [Listing 16.2.11](#), and [Listing 16.2.10](#)). As expected, patients experienced laboratory evidence of bone marrow toxicity secondary to chemotherapy ([Listing 16.2.7.2](#)).

No patient met Hy’s Law criteria. Most reported liver enzyme increase AEs were Grade 1 or 2, none of which were considered related to trilaciclib ([Listing 16.2.6.1](#)).

By-patient listings for AEs leading to dose reductions and cycle delays for the safety population are provided in [Listing 16.2.6.3](#) and [Listing 16.2.6.4](#), respectively. By-patient listings for AEs leading to discontinuation of any study drug and AEs leading to dose interruptions for the safety population are provided in [Listing 16.2.6.5](#) and [Listing 16.2.6.6](#), respectively. A by-patient listing of physical examination dates for all subjects randomized is provided in [Listing 16.2.12](#).

Conclusions:

In this study that was terminated early by the Sponsor for reasons other than safety concerns, 7 patients were randomized and treated, therefore, only limited safety summary tables were generated and no efficacy analyses were conducted. All efficacy and safety data as collected during the study are presented in data listings. Overall, the safety data summary and patient data listings from this

study suggested trilaciclib in combination with docetaxel was safe for this patient population. No new trilaciclib safety signals or concerns were identified.

Date of the report: 27 July 2022

6. APPENDICES

6.1. Study Information

6.1.1. Protocol and protocol amendments

6.2. Patient Data Listings

6.2.1. Discontinued patients

6.2.2. Protocol deviations

6.2.3. Demographic data

6.2.4. Individual efficacy response data

6.2.5. Adverse event listings (each patient)

6.2.6. Listing of individual laboratory measurements by patient, when required by regulatory authorities

6.3. CIOMS for serious adverse events

6.4. Individual Patient Data Listings and Data Tables



Protocol Title: A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)

Protocol Number: G1T28-210

Compound: Trilaciclib for Injection, 300 mg/vial

Study Phase: 2

Study Name: PRESERVE 4

Sponsor Name: G1 Therapeutics, Inc.

Legal Registered Address: G1 Therapeutics, Inc.
700 Park Offices Dr. Suite 200
PO Box 110341
Research Triangle Park, NC 27709

Regulatory Agency Identifier Numbers: IND: 154630
EudraCT: 2021-000186-32

Approval Date: 01 Feb 2021 (Version 1.0)

This document contains confidential and/or trade secret information that is disclosed only in connection with the licensing and/or registration of products for G1 Therapeutics, Inc. This document should not be disclosed or used, in whole or in part, for any other purpose without the prior written consent of G1 Therapeutics, Inc.

PROTOCOL SIGNATURE PAGE

Sponsor's Approval

I have read and understand the contents of this clinical protocol, Version 1.0 for Study G1T28-210 dated 01 Feb 2021 and I agree to meet all obligations of the Sponsor as detailed in all applicable regulations and guidelines. In addition, I will inform the Principal Investigator and all other investigators of all relevant information that becomes available during the conduct of the study.

Janet Horton, MD, MHSc
Director, Clinical Development
Physician Sponsor Representative
G1 Therapeutics, Inc.

Date

INVESTIGATOR'S AGREEMENT

Clinical Study Protocol G1T28-210: A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)

Original Protocol (Version 1.0) Issue Date: 01 Feb 2021

I have read the G1T28-210 protocol and agree to conduct the study as outlined. I agree to maintain the confidentiality of all information received or developed in connection with this protocol.

Principal Investigator Signature

Date

Principal Investigator Name

Institution

1. SYNOPSIS

Name of Sponsor/Company: G1 Therapeutics, Inc.		
Name of Investigational Product: Trilaciclib for Injection, 300 mg/vial		
Name of Active Ingredient: Trilaciclib dihydrochloride (hereafter referred to as trilaciclib) (G1T28)		
Protocol Number: G1T28-210	Phase: 2	Country: Worldwide
Title of Study: A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2 nd /3 rd Line Setting (PRESERVE 4)		
Study center(s): Approximately 60 centers		
Study period: Estimated date first patient enrolled: 2Q2021 Estimated date last patient completed: 1Q2024		
Objectives: Primary: To assess the effect of trilaciclib administered prior to docetaxel compared with placebo administered prior to docetaxel on overall survival (OS) in patients with metastatic NSCLC receiving docetaxel in the 2 nd or 3 rd line. Study Design: This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib compared with placebo on OS in metastatic NSCLC patients receiving docetaxel in the 2 nd or 3 rd line setting. Patients must have documented disease progression during or after one or two lines of systemic therapy for recurrent or metastatic NSCLC. Prior treatment must have included, either in the same line or as separate lines of therapy: 1) a maximum of 1 line of platinum-containing chemotherapy for recurrent/metastatic disease and 2) a maximum of 1 line of a locally approved/authorized programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) containing regimen for recurrent/metastatic disease. Patients will be randomly assigned (1:1) to receive trilaciclib or placebo intravenously (IV) prior to docetaxel on Day 1 of each 21-day cycle. There will be 2 stratification factors for randomization: Country and Eastern Cooperative Oncology Group (ECOG) performance status (0-1 versus 2). Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2). Study drugs will be administered as follows: <ul style="list-style-type: none"> • Trilaciclib (240 mg/m²) or placebo – administered as a 30-minute IV infusion no more than 4 hours prior to chemotherapy on each day chemotherapy is administered. • Docetaxel 75 mg/m² – IV, Day 1 The study will include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of randomization for the first patient and completes at the Post-Treatment visit for the last patient. The first Survival Follow-up assessment should occur ~2 months after the last dose of study drug. The patient may continue to receive treatment on study until disease progression, unacceptable toxicity, withdrawal of consent, discontinuation by Investigator, or the end of the trial, whichever		

occurs first. Treatment cycles will occur consecutively without interruption, except when necessary to manage toxicities or for administrative reasons.

Upon discontinuation of study treatment, patients will be followed for survival, i.e., patients or their caregivers will be contacted approximately every 2 months until the end of the study (or death) to record their status (alive or dead) as well as details of any subsequent systemic anti-cancer therapy initiated.

Methodology:

Sample Size Justification:

The sample size is determined to support the primary objective of the study. That is, to evaluate the effect of trilaciclib compared to placebo on the OS of patients with metastatic NSCLC receiving docetaxel in the 2nd/3rd line setting. A total of 104 deaths will be required to achieve 85% power to detect a hazard ratio (HR) of 0.55 in OS at a 2-sided significance level of 0.05. A HR of 0.55 corresponds to a median OS of 16.5 months for the trilaciclib group assuming a median OS of 9.1 months for the placebo group (Garon, 2014). With a 12-month enrollment period and a 30-month study duration (after the first patient is randomized), a total of 146 patients are required for randomization at a 1:1 ratio to trilaciclib or placebo. This sample size has taken into consideration an interim analysis for OS at the information fraction of 0.70 using the O'Brien-Fleming method for α -spending to ensure strong control of Type I error rate at 1-sided 0.025 between the interim and the final analysis for OS. In the sample size calculation, it is also assumed that about 5% of patients are lost-to-follow-up during the 30-month study duration.

Number of patients (planned):

Approximately 146 patients with NSCLC are planned in this study.

Diagnosis and main criteria for inclusion:

Patients ≥ 18 years of age at the time of signing the informed consent with histologically or cytologically-confirmed metastatic NSCLC. Patients of any histology appropriate for treatment with docetaxel in the 2nd/3rd line will be eligible. Patients must have documented disease progression during or after treatment with platinum-based chemotherapy and a locally approved/authorized PD-1/PD-L1 inhibitor. Patients should not have been previously treated with docetaxel or with therapy targeted to driver mutations. Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is permitted as is ECOG performance status of 0 to 2. At the time of providing informed consent, a formalin-fixed paraffin-embedded (FFPE) tumor specimen (from archival or fresh biopsy) with an associated pathology report documenting NSCLC must be available to send to Sponsor, within the timeframe specified, for planned retrospective biomarker analyses.

Investigational product, dosage and mode of administration:

On Day 1 of each 21-day cycle, a dose of trilaciclib 240 mg/m² diluted in 250 mL of dextrose 5% in water or sodium chloride solution 0.9% will be administered as a 30-minute IV infusion no more than 4 hours prior to docetaxel administration.

Duration of treatment:

Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, discontinuation by Investigator, or the end of the trial, whichever occurs first.

Reference therapy, dosage and mode of administration:

On Day 1 of each 21-day cycle, a dose of placebo (250 mL of dextrose 5% in water or sodium chloride solution 0.9%) will be administered by IV infusion over approximately 30 minutes no more than 4 hours prior to docetaxel administration.

On Day 1 of each 21-day cycle, docetaxel will be administered IV in accordance with the prescribing information and institutional guidelines.

Criteria for evaluation:

Efficacy:

Antitumor efficacy will be assessed by OS, PFS, objective response rate (ORR), and duration of objective response (DOR). Tumor response criteria will be based on RECIST v1.1.

Myelopreservation efficacy will be assessed based on hematology assessments, myelosuppression-related adverse event (AE) details, dose reductions/delays and supportive care interventions (including transfusions).

Safety:

Safety will be evaluated by monitoring AEs, clinical laboratory test results (hematology, clinical chemistry), vital sign measurements (blood pressure, heart rate, and body temperature), 12-lead safety electrocardiogram (ECG) results, dose intensity, and physical examination findings.

PROs:

Patient-reported outcomes (PROs) will be assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-LC13 with supplemental weight loss item, Functional Assessment of Chronic Illness Therapy – Fatigue Scale (FACIT-Fatigue), Patient Global Impression of Change (PGIC), Patient Global Impression of Severity (PGIS), and 5-level EQ-5D (EQ-5D-5L).

Pharmacodynamics:

Pharmacodynamics will be assessed using peripheral blood to evaluate potential markers of response and resistance, including immune effects.

Statistical methods:

Data will be summarized by treatment group. The descriptive summary for the categorical variables will include counts and percentages. The descriptive summary for the continuous variables will include means, standard deviations, medians, 25% and 75% percentiles, and minimum and maximum values.

Stratification factors and factors used in statistical models:

There are two stratification factors for randomization: country and ECOG performance status (0-1 versus 2). Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2). A randomization schema will be in place to ensure the best possible balance of treatment assignment within each stratum produced by these stratification factors. Countries will be grouped into the factor of “region” with 3 components: United States (US), Europe, and Asia. The factor “region” will be used instead of “country” in the statistical analysis models to account for regional differences in clinical practice.

Analysis population

The intent-to-treat (ITT) population includes all randomized patients. Analyses for the ITT population will be conducted based on the randomly assigned treatment regardless of whether the patient received study treatment or was compliant with the protocol. Unless otherwise specified, the ITT population is the primary population for all efficacy analyses.

The response evaluable (RE) population will include patients in the ITT population who have a measurable lesion (target lesions) at the baseline tumor assessment, and either (i) have at least 1 post-dose tumor assessment, or (ii) do not have post-dose tumor assessment but have clinical progression as noted by the Investigator, or (iii) have died due to disease progression before their first post-dose tumor scan. RE population will be the primary analysis set to evaluate tumor response and the data will be analyzed based on the randomly assigned treatment.

The safety population includes all randomized patients who received at least one dose of study drug. Analyses conducted on the safety population will be based on the actual treatment received. All safety analyses will be conducted using the safety population.

The pharmacokinetic (PK) population will include all patients who received at least one dose of study drug and had evaluable PK data.

Statistical analysis methods for primary and secondary endpoints

Analysis for Primary Endpoint

The primary endpoint OS is defined as the time (months) from the date of randomization to the date of death for patients who died in the study due to any cause, and the time to the last contact date known to be alive for those who survived as of the data cutoff date for the interim OS analysis or as of the date for the final database lock (censored cases). Patients lacking data beyond the date of randomization will have their survival time censored at the date of randomization. The targeted number of deaths for the final analysis is 104 and the analysis for OS is event-driven.

Treatment effect on OS will be primarily evaluated using a stratified log-rank test controlling for the stratification factors of region (US, Europe, or Asia), and ECOG performance status (0-1 versus 2). Unless otherwise specified, ECOG status information as entered in the Interactive Web Response System (IWRS) at the time of randomization will be used as the factor for this and all other stratified analyses. The magnitude of the treatment effect, HR (trilaciclib versus placebo), will be estimated using a Cox proportional hazard model with the same factors as included in the stratified log-rank test. Additionally, the Kaplan-Meier plots will be generated, and the median, 25% and 75% percentile of OS will be estimated using the Kaplan-Meier method with their corresponding 95% confidence interval calculated based on the method by [Brookmeyer and Crowley \(1982\)](#) for each treatment group. The analyses for OS will be performed on the ITT population.

Interim Analysis for OS

An interim analysis of OS will be conducted at the 70% information fraction, that is, when 73 deaths are observed. The timing of the interim analysis is estimated to be approximately 19 months after the first patient is randomized in the study. To perform the interim analysis, the database will be locked and the study will be unblinded. If the interim OS analysis result by the stratified log-rank test is positive as determined by the pre-specified statistical criterion, the study will be stopped for success and the results from the interim OS analyses are considered to be final. If the interim OS analysis result does not meet the criterion of success, the study will continue until a total of 104 deaths are observed. At that time, the study database will be locked to perform the final OS analysis. It is estimated that it will take approximately 30 months after the first patient is randomized in the study to reach the total targeted number of deaths in this study.

Analysis for secondary anti-tumor efficacy endpoints

PFS

PFS is defined as the time (months) from date of randomization until date of documented radiologic disease progression (PD) per RECIST v1.1 or death due to any cause, whichever comes first. For patients who do not experience PD or are alive at time of performing the analysis, PFS will be calculated per censoring rules detailed in the Statistical Analysis Plan (SAP).

Per literature, the expected median PFS for patients receiving docetaxel is 3 months ([Garon, 2014](#)). Assuming trilaciclib can achieve a treatment effect of HR of 0.60, it is estimated that at the time of performing the OS interim analysis, 86% of patients would have a radiographic-determined disease progression or died. Therefore, the analysis for PFS will be conducted at the time when the OS interim analysis is conducted since the PFS events are considered mature. Treatment effect on PFS will be evaluated using the stratified log-rank test controlling for the two stratification factors. A Cox proportional hazard model with the same terms as in the stratified log-rank test will be used to estimate the HR between the 2 treatment groups (trilaciclib versus placebo) for PFS along with its 95%

confidence interval. In addition, the Kaplan-Meier plots will be produced, and the median, 25% and 75% percentile of PFS will be estimated using the Kaplan-Meier method with their corresponding 95% confidence interval calculated based on the method by [Brookmeyer and Crowley \(1982\)](#) for each treatment group. PFS will be analyzed on the ITT population.

Tumor Response

Objective response is defined as achieving either complete response (CR) or partial response (PR) per RECIST v1.1. The ORR along with its exact 95% two-sided confidence interval using the Clopper-Pearson method will be computed for each treatment group. The treatment effect on ORR will be evaluated using a stratified Cochran-Mantel-Haenszel (CMH) method to account for the two stratification factors. The adjusted proportion difference (trilaciclib minus placebo) and its 95% confidence intervals will be calculated using CMH weight. ORR will be analyzed on the Response Evaluable patient population.

DOR is the time (months) between the date achieving first objective response (CR or PR), confirmed at the next tumor scan, and the date of documented disease progression per RECIST v1.1 or death, whichever comes first. Patients who do not experience objective CR or PR will not be included in the analysis. For patients with objective response who do not reach radiographically determined PD or die at the time of analysis, censored time will be calculated following the rules detailed in Section [12.4.6.2.2](#). The median, 25% and 75% percentile of DOR will be estimated using the Kaplan-Meier method with their corresponding 95% confidence interval calculated based on the method by [Brookmeyer and Crowley \(1982\)](#) for each treatment group.

Analysis for safety endpoints

Safety and tolerability will be assessed by AEs, dose modifications, laboratory tests, vital signs, and ECG. Safety data will be summarized using descriptive statistics by treatment group based on the safety population. AEs are defined as those events occurring or worsening after treatment has begun on this study. AE data will be coded to system organ class (SOC) and preferred term (PT) using the latest version of Medical Dictionary for Regulatory Activities (MedDRA). The severity (toxicity grades 1-5) will be summarized by SOC, PT and CTCAE grade, as appropriate. In the tabulation of severity and causality for an AE, if the same AE occurs on multiple occasions, the highest grade and strongest relationship to study drug will be used. Concomitant medications, as well as prior and subsequent anticancer therapies, will be coded to Anatomical Therapeutic Classification (ATC) using the World Health Organization-Drug Dictionary (WHO-DD) and summarized by treatment group.

For laboratory assessments, vital signs, and ECG intervals, observed values and changes from baseline will be summarized by treatment group. For serum chemistry AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 by Investigators. AEs overall, AEs related to each study drug, AEs leading to study drug discontinuation or dose modifications, and trilaciclib AEs of special interests (AESIs) will be summarized by SOC, PT and CTCAE grade, as appropriate. For laboratory assessments, vital signs, and ECG intervals, observed values and changes from baseline will be summarized by treatment group. For serum chemistry and hematology laboratory parameters, clinical labs will be characterized according to CTCAE toxicity grade from 1 to 5, v5.0 when possible, and the number and percentage of patients within each CTCAE grade will be summarized for the overall treatment period as well as for each cycle. Safety data collected through scheduled or unscheduled visits will all be included in the safety evaluation.

Pharmacokinetic/Pharmacodynamic Analyses

Analyses may be performed to examine the relationship(s) between exposure to trilaciclib and pharmacodynamic endpoints or other efficacy and safety endpoints.

2. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES

TABLE OF CONTENTS

PROTOCOL SIGNATURE PAGE	2
INVESTIGATOR'S AGREEMENT	3
1. SYNOPSIS	4
2. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES	9
3. LIST OF ABBREVIATIONS.....	15
4. INTRODUCTION	21
4.1. Lung Cancer.....	21
4.2. Study Rationale.....	22
4.2.1. Rationale for Improving Anti-tumor Efficacy with Trilaciclib	23
4.2.2. Rationale for Immunogenicity of NSCLC Tumor Type and Docetaxel Chemotherapy	25
4.2.3. Rationale for Immune Mechanism of Trilaciclib	26
4.2.4. Rationale for Trilaciclib following Progression on Immunotherapy	26
4.2.5. Rationale for Myelopreservation	27
4.2.6. Rationale for Combination with Docetaxel	27
4.2.7. Summary of Nonclinical Data	28
4.2.7.1. Pharmacology Studies	28
4.2.7.2. Pharmacokinetic Studies.....	30
4.2.8. Summary of Clinical Data	31
4.2.8.1. Trilaciclib.....	31
4.2.8.2. Trilaciclib.....	35
4.2.8.3. Docetaxel	37
4.3. Benefit/Risk Assessment	37
5. OBJECTIVES AND ENDPOINTS.....	39
6. INVESTIGATIONAL PLAN.....	42
6.1. Overall Study Design.....	42
6.2. Rationale for Primary and Secondary Endpoints.....	43
6.2.1. Anti-tumor Efficacy.....	43
6.2.2. Myelopreservation Efficacy.....	43
6.2.3. Patient-Reported Outcomes	43

6.2.4.	Safety	44
6.3.	Rationale for Dose and Schedule of Study Treatment.....	44
6.3.1.	Trilaciclib.....	44
6.3.2.	Docetaxel	45
6.4.	Rationale for Supportive Care Interventions	45
6.5.	Rationale for Patient Population	45
6.6.	Rationale for Stratification Factors.....	45
7.	STUDY POPULATION	47
7.1.	Inclusion Criteria	47
7.2.	Exclusion Criteria	48
8.	SCHEDULE OF ASSESSMENTS.....	50
9.	STUDY TREATMENT	54
9.1.	Study Drugs Administered	54
9.1.1.	Dose, Dosing Regimen, and Route.....	54
9.1.1.1.	Trilaciclib/Placebo	54
9.1.1.2.	Docetaxel	55
9.1.2.	Preparation, Handling, Storage, and Accountability	56
9.1.3.	Treatment Compliance.....	56
9.2.	Criteria for Starting Each Cycle	56
9.3.	Toxicity Management and Dose Modifications	57
9.3.1.	Dose reduction	57
9.3.2.	Safety Criteria for Adjustment or Stopping Doses	59
9.3.3.	Recommended Actions with Trilaciclib/Placebo for Adverse Events of Special Interest.....	61
9.3.4.	Hy's Law Management.....	62
9.4.	Supportive Care Interventions	63
9.4.1.	Colony Stimulating Factor Usage.....	63
9.4.2.	Erythropoiesis-Stimulating Agent Usage	64
9.4.3.	Transfusions.....	64
9.5.	Prior/Concomitant Medications and Procedures	64
9.6.	Measures to Minimize Bias: Randomization and Blinding.....	65
9.7.	Intervention after End of Study Treatment.....	66

10.	DISCONTINUATION OF STUDY INTERVENTION AND PATIENT DISCONTINUATION/WITHDRAWAL	67
10.1.	Discontinuation of Study Treatment.....	67
10.2.	Discontinuation/Withdrawal from the Study.....	67
10.3.	Lost to Follow-Up.....	68
10.4.	Study and Site Start and Closure	68
11.	STUDY ASSESSMENTS	70
11.1.	Screening Assessments	70
11.1.1.	Randomization	70
11.1.2.	Demographics	70
11.1.3.	Medical History and NSCLC Cancer Disease History	70
11.2.	Anti-tumor Efficacy Assessments	71
11.2.1.	Anti-tumor Efficacy Assessment.....	71
11.2.2.	Myelopreservation Assessments.....	72
11.3.	Safety Assessments.....	72
11.3.1.	Vital Signs	72
11.3.2.	Physical Examination	72
11.3.3.	ECOG Performance Status	72
11.3.4.	Electrocardiogram.....	73
11.3.5.	Clinical Safety Laboratory Assessments	73
11.3.6.	Adverse and Serious Adverse Events	74
11.3.6.1.	Time Period and Frequency for Collecting Adverse and Serious Adverse Event Information	74
11.3.6.2.	Method of Detecting Adverse and Serious Adverse Events.....	75
11.3.6.3.	Follow-up of Adverse and Serious Adverse Events	75
11.3.6.4.	Regulatory Reporting Requirements for Serious Adverse Events	75
11.3.6.5.	Pregnancy	75
11.4.	Patient-Reported Outcomes	76
11.4.1.	EORTC QLQ-C30 and EORTC QLQ-LC13	76
11.4.2.	FACIT-Fatigue	77
11.4.3.	Patient Global Impression of Change and Patient Global Impression of Severity	77
11.4.4.	5-Level EQ-5D	77

11.5.	Pharmacokinetics	77
11.6.	Biomarkers	78
11.6.1.	Rationale for Archival Tumor Collection	78
11.6.2.	Description of CDK4/6 Signature	78
11.7.	Immunologic and Hematologic Markers	79
11.8.	Data Monitoring Committee	79
11.10.	Survival Follow-up Phase	80
12.	STATISTICAL CONSIDERATIONS	81
12.1.	Sample Size Determination	81
12.2.	Analysis Population	81
12.3.	Timing of Planned Analysis	81
12.3.1.	First Planned Analysis – Interim Analysis for Overall Survival and Analyses for Progression Free Survival, Tumor Responses and Myelosuppression Endpoints	81
12.3.2.	Second Planed Analysis – Final Analysis for Overall Survival and Safety Data Analyses	82
12.4.	Statistical Analysis Methods	82
12.4.1.	General Considerations	82
12.4.2.	Patient Disposition	83
12.4.3.	Demographic and Baseline Characteristics	83
12.4.4.	Prior and Subsequent Anticancer Therapies	83
12.4.5.	Study Drug Exposure, Modification and Dose Intensity	83
12.4.6.	Efficacy Analyses	84
12.4.6.1.	Analyses of Primary Efficacy Endpoint – Overall Survival	84
12.4.6.2.	Analysis for Secondary Anti-tumor Efficacy Endpoints	85
12.4.6.3.	Analysis for Myelosuppression Endpoints	87
12.4.6.4.	Subgroup Analysis for Primary Efficacy Endpoint	88
12.4.7.	PRO Analyses	88
12.4.8.	Safety Analyses	88
12.4.8.1.	Adverse Events	88
12.4.8.2.	Other Safety Endpoints	89
12.4.9.	Exploratory Analyses	89
12.4.10.	Pharmacokinetic Analyses	89

12.4.11.	Pharmacokinetic/Pharmacodynamic Analyses	90
13.	ETHICS	91
13.1.	Ethics Review	91
13.2.	Ethical Conduct of the Study	91
13.3.	Written Informed Consent	91
14.	DATA HANDLING AND RECORDKEEPING	92
14.1.	Data Protection	92
14.2.	Data Quality Assurance	92
14.3.	Dissemination of Clinical Study Data	93
14.4.	Source Documents	93
14.5.	Audits and Inspections	93
15.	PUBLICATION POLICY	94
16.	REFERENCES	95
17.	APPENDICES	105
17.1.	Clinical Laboratory Tests	105
17.2.	Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting	106
17.2.1.	Definition of AE	106
17.2.2.	Definition of SAE	107
17.2.3.	Recording and Follow-Up of AE and/or SAE	109
17.2.4.	Reporting of SAEs	111
17.3.	Contraceptive Guidance and Collection of Pregnancy Information	112
17.4.	Definitions of Tumor Response and Disease Progression (per RECIST v1.1)	115

LIST OF TABLES

Table 1:	Abbreviations	15
Table 2:	Integrated Analysis for Myelopreservation Efficacy in SCLC (Studies G1T28-02, G1T28-03, and G1T28-05)	32
Table 3:	G1T28-04: Summary of Overall Survival and Progression-Free Survival (ITT Analysis Set)	33
Table 4:	G1T28-04: Tumor Response According to PD-L1 Status	34
Table 5:	Objectives and Endpoints	39
Table 6:	Schedule of Assessments	51

Table 7:	Study Drugs	54
Table 8:	Recommended Chemotherapy Dose Modifications	58
Table 9:	Recommended Dose Modification for Drug-Related Hematologic Toxicity.....	59
Table 10:	Recommended Actions with Trilaciclib/Placebo Following AESIs	61
Table 11:	Patient Risk Factors for Poor Clinical Outcomes Resulting from Febrile Neutropenia or Infection.....	64
Table 12:	ECOG Performance Status	73
Table 13:	Thresholds for Claiming Statistical Superiority (Trilaciclib versus Placebo) at Interim or Final Analysis for Overall Survival.....	85
Table 14:	Protocol-Specified Safety Laboratory Assessments	105

LIST OF FIGURES

Figure 1:	Trilaciclib Transiently Arrests Normal Cells to Prevent Chemotherapy-Induced Myelosuppression and Improve Anti-Tumor Efficacy	23
Figure 2:	G1T28-04: Overall Survival – Kaplan-Meier Curve (ITT Analysis Set).....	24
Figure 3:	The Addition of Trilaciclib to Chemotherapy/Immune Checkpoint Inhibitor Treatment Enhances Efficacy Through T Cell Activation	29
Figure 4:	Study Design.....	42

3. LIST OF ABBREVIATIONS

The following abbreviations and specialist terms are used in this study protocol.

Table 1: Abbreviations

Abbreviation	Definition
5-FU	5-fluorouracil
AE	adverse event
AESI	adverse event of special interest
ALK	anaplastic lymphoma kinase
ALT	alanine aminotransferase
ANC	absolute neutrophil count
ANCOVA	analysis of covariance
aPTT	activated partial thromboplastin time
aRR	adjusted relative risk
ASCO	American Society of Clinical Oncology
AST	aspartate aminotransferase
ATC	Anatomical Therapeutic Classification
AUC	area under the concentration-time curve
BCRP	breast cancer resistance protein
BED	biologically effective dose
β -hCG	beta human chorionic gonadotropin
BICR	blinded independent central review
BMI	body mass index
BOR	best overall response
BSA	body surface area
BSEP	bile salt export pump
CAP	College of American Pathologists
CBC	complete blood count
CD	cluster of differentiation
CDK	cyclin-dependent kinase
CFR	Code of Federal Regulations
CI	confidence interval
CIM	chemotherapy-induced myelosuppression

Abbreviation	Definition
CMH	Cochran-Mantel-Haenszel
CNS	central nervous system
CPS	combined positive score
CR	complete response
CT	computed tomography
CTCAE	Common Terminology Criteria for Adverse Events
CTLA-4	cytotoxic T-lymphocyte associated protein 4
CYP	cytochrome P450
D5W	dextrose 5% in water
DC	dendritic cell
DCAF	d-type cyclin activating features
DDI	drug-drug interaction
DMC	Data Monitoring Committee
DNA	deoxyribonucleic acid
DOR	duration of objective response
DSN	duration of severe neutropenia
ECG	electrocardiogram
ECOG	Eastern Cooperative Oncology Group
eCRF	electronic case report form
EDC	electronic data capture
EGFR	epidermal growth factor receptor
EMA	European Medicines Agency
EORTC QLQ-C30	European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire
EORTC QLQ-LC13	European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module
EOT	End of Treatment
E/P	etoposide plus carboplatin
E/P/A	cisplatin, etoposide and atezolizumab
ES-SCLC	extensive stage SCLC
EQ-5D-5L	5-level EQ-5D
EQ-VAS	EQ visual analogue scale

Abbreviation	Definition
ER	estrogen receptor
ESA	erythropoiesis stimulating agent
FACIT-Fatigue	Functional Assessment of Chronic Illness Therapy - Fatigue
FDA	Food and Drug Administration
FFPE	formalin-fixed paraffin-embedded
FN	febrile neutropenia
FSH	follicle stimulating hormone
G ₁	gap 1 phase of the cell cycle
G ₂	gap 2 phase of the cell cycle
G1T28	trilaciclib; formerly G1T28-1
GC	gemcitabine and carboplatin
GC therapy	gemcitabine and carboplatin on Days 1 and 8 of 21-day cycles
GCP	Good Clinical Practice
G-CSF	granulocyte colony-stimulating factor
GI	gastrointestinal
GM-CSF	granulocyte-macrophage colony-stimulating factor
HBV	hepatitis B virus
HCV	hepatitis C virus
HER2	human epidermal growth factor receptor 2
HIV	human immunodeficiency virus
HR	hazard ratio
HRT	hormone replacement therapy
HSPC	hematopoietic stem and progenitor cell
IB	Investigator's Brochure
IC	tumor-infiltrating immune cells
IC ₅₀	half maximal inhibitory concentration
ICF	informed consent form
ICH	International Council for Harmonisation
ICI	immune checkpoint inhibitors
IEC	independent ethics committee
IFN	interferon

Abbreviation	Definition
IHC	immunohistochemistry
ILD	interstitial lung disease
INR	International Normalized Ratio
IP	intraperitoneal
IRB	institutional review board
ISH	in situ hybridization
ITT	intent-to-treat
IV	intravenous
IWRS	Interactive Web Response System
Ki	inhibition constant
LFT	liver function test
M	mitosis
mAb	monoclonal antibody
MATE1 or 2-K	multidrug and toxin extrusion 1 or 2-K
MDR1	p-glycoprotein
MedDRA	Medical Dictionary for Regulatory Activities
MHC	major histocompatibility complex
MOA	mechanism of action
MRI	magnetic resonance imaging
MRP1 or 2	multidrug resistance protein 1 or 2
NCCN	National Comprehensive Cancer Network
NCI	National Cancer Institute
NE	not evaluable
NSCLC	non-small cell lung cancer
NYHA	New York Heart Association
OAT1 or 3	organic anion transporter 1 or 3
OATP1B1 or 1B3	organic anion transporting polypeptide 1B1 or 1B3
OCT1 or 2	organic cation transporter 1 or 2
ORR	objective response rate
OS	overall survival
PCS	potentially clinically significant

Abbreviation	Definition
PD	progressive disease
PD-1	programmed cell death protein 1
PD-L1	programmed death-ligand 1
PDX	patient derived xenografts
PFS	progression-free survival
PGIC	Patient Global Impression of Change
PGIS	Patient Global Impression of Severity
PK	pharmacokinetic(s)
PR	partial response
PRO	patient-reported outcome
PSA	prostate-specific antigen
PT	preferred term
PTFE	polytetrafluorethylene
PVG	pharmacovigilance
QTcF	QT corrected using Fridericia's formula
Rb	retinoblastoma protein
RB	retinoblastoma gene
RBC	red blood cell
RE	Response Evaluable
RECIST	Response Evaluation Criteria in Solid Tumors
ROS1	c-ROS oncogene 1
RP2D	recommended Phase 2 dose
S	synthesis phase of the cell cycle
SAE	serious adverse event
SAP	statistical analysis plan
SCLC	small cell lung cancer
SD	stable disease
SOC	system organ class
SN	severe neutropenia
SUSAR	suspected unexpected serious adverse reactions
TCR	T cell receptor

Abbreviation	Definition
TEAE	treatment-emergent adverse event
TIM3	T-cell immunoglobulin and mucin domain 3
TNBC	triple-negative breast cancer
T _{reg}	regulatory T cells
TTCD-fatigue	Time to confirmed deterioration of fatigue
ULN	upper limit of normal
US	United States
VAS	visual analog scale
WHO-DD	World Health Organization Drug Dictionary

4. INTRODUCTION

4.1. Lung Cancer

Worldwide, there were more than 2 million cases of lung cancer and 1.75 million lung cancer related deaths in 2018 (WHO, 2020). The American Cancer Society estimates that in 2020, ~135,000 of those lung cancer deaths will occur in the US alone (American Cancer Society, 2020). Approximately 84% of these patients will be diagnosed with non-small cell lung cancer (NSCLC) and almost 70% will present with locally advanced or metastatic disease (ASCO, 2020; Little, 2007). Historically, treatment in the metastatic setting has been driven almost exclusively by the use of systemic chemotherapy. However, in the last ten to twenty years, a greater understanding of the pathways that dictate tumor response and the advent of multiple targeted therapies has changed the landscape of treatment options significantly. Lung tumors are routinely tested for the presence of specific driver mutations (e.g., epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], BRAF, and cROS- oncogene 1 [ROS1]), that predict a favorable response to targeted tyrosine kinase inhibitors (Kalemkerian, 2018). As many as 50% to 64% of patients have been identified as having a targetable genetic alteration and those that receive treatment have better outcomes (Kris, 2014; Barlesi, 2016).

For those patients without a targetable genetic alteration, treatment options have also changed considerably. Though systemic therapy remains an important component of treatment in this context, the advent of immunotherapy has significantly improved outcomes for this patient population. Multiple randomized trials, in both squamous and non-squamous histologies, have established that overall survival (OS) is improved with the addition of programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitors (Spigel, 2019; Reck, 2016; Gandhi, 2018; Paz-Ares, 2018). Those with high levels of PD-L1 expression typically receive pembrolizumab or atezolizumab monotherapy in the first line followed by platinum-based chemotherapy in order to maximize treatment response and minimize toxicity. Those with a higher burden of disease requiring more aggressive initial treatment or with lower levels of PD-L1 expression typically receive immunotherapy in combination with a platinum-based chemotherapy doublet.

Despite these improvements in the therapy for metastatic NSCLC, the majority of patients ultimately progress during or after treatment with immunotherapy and platinum-based chemotherapy. Management of this pretreated patient population is challenging and treatment options are limited to single agent chemotherapies such as docetaxel, pemetrexed (for those with non-squamous histology), and gemcitabine (Shepherd, 2000; Fossella, 2010; Gridelli, 2004; Hanna, 2004; Anderson, 2000). The clinical trials that established these treatment options predated immunotherapies and robust data for individual agents is often lacking. The high-level evidence that does exist demonstrates a limited impact of 2nd line therapy on treatment outcomes. For example, in a study where 1,253 patients were treated with docetaxel plus or minus the VEGFR2 inhibitor ramucirumab following progression on platinum-based chemotherapy, survival was significantly improved with the addition of ramucirumab, but the clinical benefit was only 1.5 months (hazard ratio [HR] 0.86, p=0.023) (Garon, 2014).

In contrast, the large Phase 3 studies evaluating the addition of immunotherapy in the first line consistently demonstrated large treatment effects (HRs ~0.5-0.6) that were both statistically

significant and highly clinically meaningful (Spigel, 2019; Reck, 2016; Gandhi, 2018; Paz-Ares, 2018). In an effort to translate these early successes to later lines of therapy, numerous ongoing Phase 3 studies are evaluating the continuation of PD-1/PD-L1 inhibitors (following progression on the same) in combination with kinase inhibitors hypothesized to synergistically illicit an ongoing immune response. However, the mechanisms of immune checkpoint inhibitor (ICI) resistance are complex and include genetic, epigenetic, and cellular signaling alterations that dysregulate neoantigen presentation/processing and disrupt cytotoxic T cells activity as well as mechanisms in which non-cancerous stromal or immune cells promote growth and resistance to ICIs (Liu, 2019; Barrueto, 2020; Jenkins, 2018; Fares, 2019; Borchering, 2018; Gidel, 2018). Novel therapies, whose mechanisms broadly target these ICI mechanisms of resistance, including CDK4/6 inhibition, could be particularly valuable following disease progression on currently clinically available immunotherapies.

In addition to the need for therapies that more effectively extend overall survival, patients treated in the metastatic setting are particularly vulnerable to the chemotherapy-induced myelosuppression (CIM) and health-related quality of life impacts associated with extensive systemic therapy. CIM is a significant issue in cancer treatment; patients with myelosuppression are more likely to experience infections, sepsis, bleeding, and fatigue, often leading to the need for hospitalizations, hematopoietic growth factor support, transfusions (red blood cells [RBCs] and/or platelets) and even death (Caggiano, 2005; Gustinetti, 2016; Bodey, 1966; Li, 2016). Moreover, CIM commonly leads to dose reductions and delays, which limit therapeutic dose intensity and can compromise the anti-tumor efficacy benefits of chemotherapy. Furthermore, existing supportive care interventions for CIM are generally used after the onset of symptoms, only address the deficiency of a single blood cell lineage, and carry their own set of risks and limitations. Introducing a therapy that can protect the hematopoietic stem and progenitor cells (HSPCs) of the host from CIM has the potential to maximize the anti-tumor activity of the chemotherapy while minimizing the consequences to the patient of chemotherapy-induced cellular damage.


In summary, though immunotherapy has markedly improved the treatment of metastatic NSCLC, options following disease progression on these therapies remain limited. An alternative therapy that extends the duration of OS without significant additive toxicity, while concurrently decreasing myelosuppression and improving quality of life, would be a welcome addition in this heavily pretreated and often clinically fragile patient population. Therefore, further evaluation of trilaciclib in this area of high unmet medical need is warranted.

4.2. Study Rationale

Trilaciclib is a highly potent and selective, reversible, cyclin-dependent kinase (CDK) 4/6 inhibitor that preserves HSPCs as well as immune system function during chemotherapy (myelopreservation) in addition to directly enhancing anti-tumor immunity (anti-cancer efficacy) (Figure 1). Both HSPC and lymphocyte proliferation are dependent on CDK4/6 activity (Kozar, 2004; Malumbres, 2004; Ramsey, 2007; Horsley, 2008) and become arrested in the gap 1 (G₁) phase of the cell cycle upon exposure to trilaciclib (He, 2017). This trilaciclib-induced transient cell cycle arrest has been demonstrated to provide resistance to chemotherapy-induced cell damage by preventing HSPCs from proliferating in the presence of cytotoxic chemotherapy

and favorably altering the tumor immune microenvironment through transient T-cell inhibition when combined with chemotherapy and ICIs (He, 2017; Bisi, 2016; Lai, 2020).

Figure 1: Trilaciclib Transiently Arrests Normal Cells to Prevent Chemotherapy-Induced Myelosuppression and Improve Anti-Tumor Efficacy



4.2.1. Rationale for Improving Anti-tumor Efficacy with Trilaciclib


The use of trilaciclib for patients with triple-negative breast cancer (TNBC) was evaluated in Study G1T28-04, a global, multicenter, randomized, open-label, Phase 2 clinical trial to evaluate the safety, efficacy, and pharmacokinetics (PK) of trilaciclib administered prior to gemcitabine/carboplatin (GC) therapy for patients with locally advanced unresectable/metastatic TNBC who had previously been treated with 0 to 2 lines of therapy in the metastatic setting. Patients were randomized 1:1:1 to one of two different trilaciclib + GC treatment regimens or GC alone. Based on its mechanism of action (MOA), it was hypothesized that trilaciclib administered before chemotherapy could protect the bone marrow from the cytotoxic effects of chemotherapy, while also enhancing immune activity in patients with TNBC, thus potentially improving both safety and anti-tumor activity.

The G1T28-04 study was the first evaluation of trilaciclib in a tumor type other than small cell lung cancer (SCLC), where trilaciclib development has focused on myelopreservation benefits (Section 4.2.8.1). Three randomized, double-blind, Phase 2 clinical trials (G1T28-02, G1T28-03 and G1T28-05) evaluating trilaciclib/placebo administered prior to chemotherapy in patients with SCLC have demonstrated in a variety of clinical settings (first-, second-, third-line SCLC treated with several different classes of chemotherapy) that trilaciclib can prevent chemotherapy-induced myelosuppression as measured by multiple endpoints (Section 4.2.8.1;

Table 2; Weiss, 2019; Hart, 2019; Daniel, 2019). While the benefit in chemotherapy-induced myelosuppression in these studies was striking, these myelopreservation benefits were observed in the setting of only minor improvements in progression-free survival (PFS) and OS as evidenced by HRs <1.0 in almost all clinical settings for trilaciclib compared with placebo.

In contrast to the previously observed SCLC results, the addition of trilaciclib to chemotherapy for patients with TNBC in G1T28-04 did not result in statistically significant improvements in myelosuppression endpoints, but instead resulted in a substantial improvement in anti-tumor efficacy as measured by OS (median OS duration in control: 12.6 months versus not evaluable or 17.8 months in the two trilaciclib groups, HR: 0.31 [p=0.0016] and HR: 0.40 [p=0.0004], respectively; Figure 2) and by PFS (median PFS in control 5.7 months versus 9.4 months or 7.3 months in the two trilaciclib groups HR: 0.65 and 0.57, respectively; not statistically significant) (O’Shaughnessy, 2020; Tan, 2019). The clinically meaningful anti-tumor efficacy results observed in G1T28-04 were noted across both of the trilaciclib treatment groups and in the context of a control group with survival reflective of published literature.

Figure 2: G1T28-04: Overall Survival – Kaplan-Meier Curve (ITT Analysis Set)



CI=confidence interval; HR=hazard ratio; ITT=intent-to-treat; NR=not reached.

Group 1: GC administered on Days 1 and 8 of 21-day cycles; Group 2: Trilaciclib and GC administered on Days 1 and 8 of 21-day cycles; Group 3: Trilaciclib administered on Days 1, 2, 8, and 9 and GC administered on Days 2 and 9 of 21-day cycles

Note: The HR and its 95% CI comparing Group 1 and 2 and Group 1 and 3 were calculated using the Cox regression model with treatment and stratification factors of number of prior lines of therapy (0 versus 1 or 2) and liver involvement.

Note: P-values comparing Group 1 and 2 and Group 1 and 3 were calculated using the stratified log-rank test to account for the number of prior lines of therapy (0 versus 1 or 2) and liver involvement as the stratification factors.

Note: data generated from final database.

The impact on OS was consistent across subgroups, including predictors of immune response. Approximately 57.6% of the available tumor samples in G1T28-04 were considered PD-L1 positive (Ventana SP142 assay), and though larger in the PD-L1 positive population, the benefit of adding trilaciclib extended to both PD-L1 positive and negative cohorts (Table 4).

The translation of these anti-tumor efficacy findings to other tumor types is predicted to be primarily driven by the tumor type, chemotherapy type and host, i.e., (1) the tumor must be sufficiently immunogenic and sensitive to the host cytolytic efforts as to see improvement in anti-tumor endpoints like OS, (2) the chemotherapy should promote immune activation, and (3) the host must be able to mount an effective cytolytic response against the tumor. In the SCLC trials, the addition of trilaciclib to the standard of care therapies provided modest improvement, to neutral effects, on measures of anti-tumor efficacy including objective response rate (ORR), PFS and OS. These results are not surprising considering that SCLC is one of the most aggressive solid tumors and is not particularly immunogenic or sensitive to immune modulation (Wang, 2019).

In contrast, NSCLC has been extensively documented as sensitive to immune modulation with multiple established immunotherapy treatment options in the early lines of treatment for metastatic NSCLC (Spigel, 2019; Wang, 2019; Reck, 2016; Gandhi, 2018; Paz-Ares, 2018). This highly responsive NSCLC immune milieu and the novel trilaciclib immune activating effects described below provide a strong rationale to evaluate the efficacy of trilaciclib in patients with previously treated NSCLC.

4.2.2. Rationale for Immunogenicity of NSCLC Tumor Type and Docetaxel Chemotherapy

While NSCLC has been recognized as having an immunosuppressive tumor microenvironment through high numbers of regulatory T cells (T_{reg}) directly inhibiting T-cell proliferation (Woo, 2001; Woo, 2002), tumor-infiltrating cluster of differentiation (CD) 8^{+} T cells with increased PD-1 expression (Zhang, 2010), and downregulation of major histocompatibility complex (MHC) class I/tumor antigen expression (Korkolopoulou, 1996), results from numerous trials evaluating immunotherapeutic agents, including immune checkpoint inhibitors, have demonstrated the efficacy of this approach in NSCLC (Spigel, 2019; Reck, 2016; Gandhi, 2018; Paz-Ares, 2018).

A number of immune correlates of clinical outcome in patients with NSCLC have been identified providing clinical evidence for immune system involvement in NSCLC. High levels of infiltrating CD 8^{+} , CD 4^{+} , CD 3^{+} T cells as well as higher densities of mature dendritic cells (DCs) have been associated with improved survival (Wing, 2008; Chen, 2012). Conversely, the number of T_{reg} cells as well as PD-L1 expression in NSCLC tumors have been shown to be independent predictors of reduced survival or unfavorable prognosis in patients with NSCLC, respectively (Petersen, 2006; Shimizu, 2010; Mu, 2011).

In addition to the inherent immunogenicity associated with NSCLC, docetaxel has demonstrated an ability to enhance the sensitivity of tumors to immune-mediated cell death (Hodge, 2013). In particular, immune modulating effects on the tumor stroma have been noted (Opzomer, 2019). *In vivo*, docetaxel has been shown to induce selective cell death in myeloid-derived suppressor cells known to contribute to immune suppression while simultaneously promoting differentiation of this cell type towards a pro-inflammatory phenotype (Kodumudi, 2010). Lastly, docetaxel has

been shown to decrease T_{reg} cells in patients with non-small cell lung cancer (Li, 2014). Taken together, these data suggest docetaxel may lead to immune activation in NSCLC and further the potential benefit of trilaciclib.

4.2.3. Rationale for Immune Mechanism of Trilaciclib

In the G1T28-05 study evaluating trilaciclib prior to cisplatin, etoposide, and atezolizumab (E/P/A) in patients with extensive stage SCLC (ES-SCLC), flow cytometry and T cell receptor (TCR) immunosequencing data revealed that patients receiving trilaciclib had an increased ratio of total and activated CD8⁺ T cells to T_{regs}, and increased peripheral T-cell clonal expansion suggesting enhanced T-cell activation. Furthermore, there was significant enhancement in newly detected expanded clones among patients receiving trilaciclib compared with placebo, which was stronger among patients with an anti-tumor response to E/P/A, suggesting that trilaciclib may enhance tumor antigen presentation, a phenomenon that has been observed in preclinical studies with other CDK4/6 inhibitors (Daniel, 2020).

These observations are consistent with those from the G1T28-02 Phase 2 study of patients with ES-SCLC receiving trilaciclib prior to etoposide plus carboplatin (E/P). In G1T28-02, a higher proportion of activated or effector CD8⁺ and CD4⁺ T cells was observed in patients receiving trilaciclib compared with placebo. In addition, high levels of T-cell clonal expansion were associated with improved PFS and numerically longer median OS. Taken together, the data suggest that the addition of trilaciclib at least preserves, if not enhances, T-cell function during treatment with E/P or E/P/A (Lai 2020).

Lastly, to evaluate the effect of trilaciclib on T cell activation in G1T28-04, peripheral blood was collected and the TCR was evaluated. Simpson clonality decreased over time in patients that received trilaciclib in addition to GC when compared to GC alone. Furthermore, when patients were stratified above or below median Simpson clonality at baseline, there was an improvement among patients receiving trilaciclib. In addition to a decrease in Simpson clonality, responders receiving trilaciclib prior to GC had more newly detected expanded T-cell clones compared with responders receiving GC alone. These data suggest trilaciclib enhances anti-tumor immunity through T cell activation leading to an anti-tumor response (O'Shaughnessy, 2020).

Taken together these data from clinical trials evaluating trilaciclib in a variety of clinical contexts, suggest that trilaciclib has a consistent positive impact on anti-tumor immune modulation. Further, there appear to be several immune based mechanisms through which this effect can be mediated including neoantigen presentation and T cell activation and function.

4.2.4. Rationale for Trilaciclib following Progression on Immunotherapy

Interestingly, many of the mechanisms to overcome ICI-induced resistance have been associated with the immune activating effects of CDK4/6 inhibition, including increasing antigen presentation (MHC class I), enhancing T cell clonality and tumor infiltration, inhibiting regulatory T cell proliferation, decreasing T cell exhaustion markers (PD-1, cytotoxic T-lymphocyte associated protein 4 [CTLA-4], and T-cell immunoglobulin and mucin domain 3 [TIM3]), stabilizing expression of PD-L1 on tumor cells, promoting dendritic cell migration, and increasing T effector cell function through high interferon [IFN] gamma production (Chaikovsky and Sage, 2018; Deng, 2018; Goel, 2017; Schaer, 2018; Lai, 2020; Bonelli, 2019; Teh and Aplin, 2019).

Multiple ongoing trials in this setting, i.e., following disease progression on platinum-based chemotherapy and immunotherapy, are evaluating additional checkpoint inhibitor therapy, but in combination with a partner hypothesized to promote an ongoing immune response. However, as described above, multiple mechanisms of resistance can develop following treatment with immunotherapy and novel agents that exploit multiple or alternative pathways may be preferred. In addition to documented anti-tumor immune modulating effects alone and in combination with checkpoint inhibitors, trilaciclib has translated these effects to improved survival in the TNBC setting, and belongs to a class of agents with a diverse repertoire of immune-modulating effects. Overall, these data suggest that patients may benefit from trilaciclib after progressing on ICI treatment.

4.2.5. Rationale for Myelopreservation

Trilaciclib has shown well-documented improvement in myelosuppression outcomes that could provide a substantial benefit to patients receiving docetaxel. In the REVEL trial, 39% of patients receiving docetaxel alone experienced grade 3 or greater neutropenia with 10% experiencing febrile neutropenia (FN) (Garon, 2014). In addition, 6% of patients experienced Grade 3 or greater anemia. Patients treated for SCLC with trilaciclib had marked reductions in the occurrence of these endpoints, required less supportive care, and experienced enhanced quality of life (Table 2).

4.2.6. Rationale for Combination with Docetaxel

Following progression on chemotherapy and immunotherapy, single-agent chemotherapy is the most common standard of care. As there is limited high-quality data for any specific agent in the modern era, several options can be utilized. However, single-agent docetaxel, with activity in both squamous and non-squamous histologies, is commonly utilized in clinical practice and as the reference standard in metastatic NSCLC clinical trials.

Ramucirumab in combination with docetaxel is also approved for the treatment of metastatic NSCLC following disease progression on or after platinum-based chemotherapy. This approval was based on a Phase 3 study that revealed a 1.5 month improvement in survival with the addition of ramucirumab. However, the rate of grade 3 or greater treatment-emergent adverse events increased from 71% to 79%. Furthermore, this small benefit occurred prior to the widespread use of immunotherapy. It is unclear if the same benefit would be seen in patients treated with today's standard of care. As a result, National Comprehensive Cancer Network (NCCN) guidelines list both the combination and docetaxel alone as potential treatment options in this clinical setting and utilization is at the discretion of the individual provider. Because there are no mature data available evaluating the combination of trilaciclib and a taxane containing regimen, the risks of also incorporating ramucirumab were felt to outweigh the small associated benefits.

Trilaciclib has been successfully combined at the recommended Phase 2 dose with most major chemotherapy classes other than microtubule inhibitors. In three randomized, controlled, Phase 2 studies in SCLC patients, the combination resulted in consistent improvements in chemotherapy-induced myelosuppression across multiple lineages. Even in the TNBC trial where the addition of trilaciclib to gemcitabine/carboplatin did not improve neutropenia-based myelopreservation endpoints, rates of adverse events were comparable despite patients on trilaciclib receiving almost double the number of chemotherapy cycles. There is no evidence to suggest that a

different result would be expected from the combination of trilaciclib with taxane based chemotherapy.

Preclinical *in vivo* studies evaluating trilaciclib in combination with paclitaxel or docetaxel utilizing a clinically relevant dose administration schedule support the safety of this combination. In addition, there are at least 4 clinical studies combining chronically dosed oral CDK4/6 inhibitors (palbociclib, ribociclib) with taxane-based chemotherapy. Two of those studies have reported acceptable early safety results in combination with standard clinical doses of paclitaxel and docetaxel (Lewis, 2018; Clark, 2019). In both of these studies, patients received multiple doses of oral CDK4/6 inhibitors (known to cause neutropenia). In contrast, trilaciclib is an IV CDK4/6 inhibitor dosed only prior to chemotherapy. Finally, trilaciclib is being evaluated in an ongoing Phase 2 study in combination with paclitaxel in the neoadjuvant breast cancer setting.

4.2.7. Summary of Nonclinical Data

A summary of the trilaciclib nonclinical data is presented in the trilaciclib Investigator's Brochure (IB).

Nonclinical data related to docetaxel are provided in the local prescribing information.

4.2.7.1. Pharmacology Studies


Through a structure-based design approach to optimize potency, selectivity, and drug metabolism and PK properties, G1 Therapeutics, Inc. identified trilaciclib as a highly potent inhibitor of CDK4 and CDK6 (half maximal inhibitory concentration [IC₅₀] values of 1 nM and 4 nM, respectively) that is highly selective for CDK4/Cyclin D1 versus cyclin-dependent kinase 2 (CDK2)/Cyclin E (>2500-fold selectivity). Trilaciclib also demonstrated reversible inhibition of CDK4/Cyclin D1, with an inhibition constant (K_i) value of 0.78 nM.

The trilaciclib-induced G₁ arrest of HSPCs has been shown to be transient and readily reversible in both *in vitro* and *in vivo* models. *In vivo* analysis has demonstrated that trilaciclib administered prior to myelosuppressive chemotherapy leads to improved complete blood count (CBC) recovery of all blood lineages and increased survival. Specifically, in a model using the chemotherapy 5-fluorouracil (5-FU) that is highly myelosuppressive in mice, the extent and duration of nadir in CBCs worsened after each cycle of 5-FU administered alone. Trilaciclib administered prior to 5-FU ameliorated this worsening effect and the animals that received trilaciclib + 5-FU demonstrated a faster rate of recovery of CBCs compared with the 5-FU alone group following Cycle 4 (He, 2017).

Preclinical data has also shown that trilaciclib enhances immune activation and promotes anti-tumor immunity by differentially arresting cytotoxic and regulatory T-cell subsets followed by a faster recovery in cytotoxic T lymphocytes than in regulatory T cells in tumors. Specifically, the addition of trilaciclib to various chemotherapy/ICI treatment combinations resulted in enhanced tumor growth delay and durability of the antitumor response. Trilaciclib favorably modulated the proliferation of T-cell subsets in the tumor microenvironment, consistent with an enhanced cytotoxic T-cell response (Figure 3; Lai, 2020). This differential alteration of cell cycle kinetics between cytotoxic T lymphocytes and regulatory T cells results in a higher proportion of cytotoxic T lymphocytes than regulatory T cells, enhancement of T-cell activation, and a decrease in regulatory T cell-mediated immunosuppressive functions (Chaikovsky and Sage, 2018; Deng, 2018; Goel, 2017; Schaer, 2018). Together, these events

promote the cytotoxic T lymphocyte-mediated clearance of tumor cells. Therefore, these data support the hypothesis that trilaciclib-mediated transient proliferative arrest of T cells (protecting them from chemotherapy-induced damage), followed by activation of cytotoxic T lymphocytes in the context of fewer regulatory T cells led to the anti-tumor response observed.

Figure 3: The Addition of Trilaciclib to Chemotherapy/Immune Checkpoint Inhibitor Treatment Enhances Efficacy Through T Cell Activation



(Upper right and upper left) Addition of trilaciclib to oxaliplatin and αPD-L1/ αPD-1 combination therapy led to enhanced anti-tumor activity and durability of response in the MC38 tumor model (n=10–15 per treatment group). (Lower left) Transient G1 arrest led to changes in the proportion of intra-tumor T-cell subsets favoring effector T-cell function as measured by the ratio of CD8⁺ T cells to Tregs (% CD8⁺ T cells / % Tregs) in the CD45⁺ population (n=5–8 tumors analyzed per treatment group and time point). (Lower right) Trilaciclib in combination with chemotherapy and ICI enhanced the gene signature of cytotoxic anti-tumor response. T-cell repertoire analyses of MC38 tumors from OP- or TOP-treated mice (n=5 per treatment group) on day 17, presented as median clonality score and TIL fraction (right panel). Error bars denote standard error, and dotted lines represent the median value for TIL fraction and clonality score. *p<0.05.

However, as a consequence of trilaciclib's MOA, there is a hypothetical risk that administration of trilaciclib prior to chemotherapy could decrease chemotherapy efficacy by pausing CDK4/6-dependent tumor cells in G₁ in the presence of chemotherapy; nonclinical data suggest this risk is not clinically significant. To understand why trilaciclib should not antagonize chemotherapy treatment, the baseline proliferation rates of HSPCs, bone marrow, and patient derived xenografts (PDX) were examined using flow cytometric analysis of the cell cycle. A bar graph depicting mean percentage of cells in synthesis phase of the cell cycle (S)/gap 2 phase of the cell cycle (G₂)/mitosis (M) demonstrates that there are a higher proportion of cells cycling in tumor cells when compared to bone marrow/HSPCs. Specifically, <4% of human HSPCs are cycling, while in breast tumors an average of ~40% of cells were cycling (Sorrentino, 2018).

These results illustrate why tumor cells are more susceptible to chemotherapy-induced damage compared to HSPCs, since chemotherapy treatment is predominantly effective in the S/G₂/M phases of the cell cycle.

To evaluate the impact of trilaciclib on chemotherapy anti-tumor efficacy in CDK4/6 dependent tumors, two different models were treated with chemotherapy and trilaciclib. MCF7 tumor-bearing mice, a well-established estrogen receptor (ER)+ CDK4/6 dependent breast cancer model, were treated with docetaxel (IV, 5 mg/kg) ± trilaciclib once weekly for three doses. Although weekly trilaciclib treatment caused some tumor growth inhibition, administering trilaciclib with docetaxel did not alter the effects of chemotherapy. Next, MDA-MB231 tumor-bearing mice were treated with daily trilaciclib (intraperitoneal [IP], 100 mg/kg) for 28 days to confirm CDK4/6 dependence. Continuous treatment with trilaciclib caused stable disease in MDA-MB231 tumor-bearing mice. MDA-MB231 tumor-bearing mice were then treated with eribulin (IV, 0.5 mg/kg) ± trilaciclib once weekly for three doses. Similar to the MCF7 model, the addition of trilaciclib to eribulin treatment did not impact chemotherapy efficacy (Sorrentino, 2018). These experiments demonstrate that transient CDK4/6 inhibition prior to chemotherapy (eribulin, docetaxel) does not antagonize the intended anti-tumor effects of the chemotherapy in these CDK4/6-dependent tumor models.

While there is emerging preclinical data demonstrating the efficacy of CDK4/6 inhibitors in combination with targeted therapy in NSCLC subpopulations (Freed, 2019; Gopalan, 2018; Haines, 2018; Knudsen, 2017), single agent efficacy has shown minimal benefit in the clinic (Goldman, 2020; Edelman, 2019; Gopalan, 2018; Patnaik, 2016). Furthermore, the available nonclinical *in vivo* data indicate combining chemotherapy with trilaciclib does not diminish the antitumor intended effects of the chemotherapy (data not shown, internal G1 data) as loss of CDK4/6 pathway function is correlated with increased tumor proliferation and improved tumor response to chemotherapy in a variety of cancer types (Socinski, 2009; Herschkowitz, 2008; Ertel, 2010; Witkiewicz, 2012). Lastly, applying a DNA signature analysis algorithm to the cBioportal dataset to characterize NSCLC tumors as CDK4/6 dependent, independent or indeterminate, only 7.4% of EGFR WT NSCLC lung tumor would be classified as CDK4/6 dependent (Gao, 2013; Cerami, 2012). Overall, preclinical and clinical data suggest that there is minimal risk that trilaciclib administered prior to docetaxel will induce a G1 arrest in the tumor cell with resultant antagonism of the intended efficacy effect of the chemotherapy.

4.2.7.2. Pharmacokinetic Studies

In vitro analyses of direct and time-dependent inhibition suggest that drug interactions based on inhibition of cytochrome P450 (CYP)1A2-, 2B6-, 2C8-, 2C9-, 2C19-, and 2D6-mediated metabolic pathways are unlikely at clinical doses, however, the studies do suggest that drug interactions based on trilaciclib-mediated inhibition of CYP3A4-mediated metabolic pathways are possible (see Section 4.2.8.1.1). Additionally, *in vitro* induction studies of the 3 major inducible CYP enzymes (CYP1A2, CYP3A4, and CYP2B6) in human hepatocytes suggest that trilaciclib-mediated induction is unlikely.

In vitro inhibition studies with membrane transporter model systems also suggest trilaciclib is unlikely to cause a drug-drug interaction (DDI) based on inhibition of breast cancer resistance protein (BCRP)-, bile salt export pump (BSEP)-, organic anion transporter 1 (OAT1)-, organic anion transporter 3 (OAT3)-, organic anion transporting polypeptide 1B1 (OATP1B1)-, p

glycoprotein (MDR1)-, multidrug resistance protein 1 (MRP1)-, multidrug resistance protein 2 (MRP2)-, or organic anion transporting polypeptide 1B3 (OATP1B3)-mediated transport. However, in vitro, trilaciclib is a potent inhibitor of multidrug and toxin extrusion 1 (MATE1), multidrug and toxin extrusion 2-K (MATE2-K), organic cation transporter 1 (OCT1), and organic cation transporter 2 (OCT2). See Section 4.2.8.1.1 for clinical evaluation.

4.2.8. Summary of Clinical Data

4.2.8.1. Trilaciclib

A brief summary of the clinical data is provided in the following sections. Detailed information is presented in the trilaciclib IB.

The safety and efficacy of administering trilaciclib prior to chemotherapy was tested in one completed and one ongoing Phase 1b/2 study (G1T28-02 and G1T28-03) and one ongoing and one completed Phase 2 study (G1T28-05 and G1T28-04) in patients with SCLC or TNBC. The Phase 2 portions of Studies G1T28-02, G1T28-03, and Study G1T28-05 were randomized, double-blind, and placebo-controlled. Study G1T28-04 was randomized and included a control arm but was not double-blinded.

- Study G1T28-02 examined once-daily IV administration of either trilaciclib or placebo on Days 1 to 3 of each 21-day E/P chemotherapy cycle in patients with treatment naïve extensive-stage SCLC.
- Study G1T28-03 examined once-daily IV administration of trilaciclib or placebo on Days 1 to 5 of each 21-day topotecan chemotherapy cycle in patients with previously treated extensive-stage SCLC.
- Study G1T28-05 examined once-daily IV administration of trilaciclib or placebo on Days 1 to 3 for a maximum of four 21-day cycles of E/P and atezolizumab, followed by monotherapy atezolizumab, in patients with treatment naïve extensive-stage SCLC.
- Study G1T28-04 examined once-daily IV administration of trilaciclib prior to gemcitabine and carboplatin in patients with metastatic TNBC who had received 0 to 2 lines of previous therapy in the metastatic setting. Patients received 1) GC therapy only on Days 1 and 8 of a 21-day cycle, 2) trilaciclib and GC once daily on Days 1 and 8 of each 21-day cycle, OR 3) trilaciclib on Days 1, 2, 8 and 9 with GC on Days 2 and 9 of each 21-day cycle (further noted as Group 1, 2, or 3, respectively).

At the recommended phase 2 dose (RP2D) of 240 mg/m², across all three SCLC studies, trilaciclib administered prior to chemotherapy statistically significantly reduced the duration of severe neutropenia (DSN) in Cycle 1 and occurrence of severe neutropenia (SN) (primary endpoints) compared with placebo. An integrated data analysis of the three SCLC studies (G1T28-02, G1T28-03, and G1T28-05) for 8 of the most relevant myelosuppression endpoints (neutrophils, RBCs and platelets) demonstrated statistically significant, and clinically meaningful, improvements for trilaciclib over available therapies in 6 of 8 endpoints across multiple lineages. Importantly, these myelopreservation benefits come with an overall improved safety profile compared with available therapy, as evidenced by reduced high grade treatment-emergent AEs across all SCLC studies, and no detriment to anti-tumor efficacy results.

Table 2: Integrated Analysis for Myelopreservation Efficacy in SCLC (Studies G1T28-02, G1T28-03, and G1T28-05)

	Placebo +Chemo	Trilaciclib +Chemo	2-sided p-value
ITT Set	119	123	
Neutrophils			
DSN [days] in Cycle 1 – Mean (SD) ^a	4 (5.1)	0 (1.8)	<0.0001
Occurrence of SN (Yes, %) ^b	64 (52.9)	14 (11.4)	<0.0001
RBCs			
Occurrence of Grade 3/4 hemoglobin decreased (anemia) (Yes, %) ^b	38 (31.9)	25 (20.3)	0.0279
Occurrence of RBC transfusion on/after 5 weeks (Yes, %) ^b	31 (26.1)	18 (14.6)	0.0252
Cumulative incidence of RBC transfusion on/after 5 weeks - Event rate (per 100 weeks) ^c	3.1	1.5	0.0027
Platelets			
Occurrence of Grade 3/4 platelet count decreased (thrombocytopenia) (Yes, %) ^b	43 (36.1)	24 (19.5)	0.0067
Occurrence of platelet transfusion (Yes, %) ^b	11 (9.2)	10 (8.1)	0.9564
Cumulative incidence of platelet transfusion - Event rate (per 100 weeks) ^c	1.7	1.1	0.5169

ANC=absolute neutrophil count; Chemo=chemotherapy; DSN=duration of severe (Grade 4) neutropenia; ECOG=Eastern Cooperative Group; ITT=intent to treat; SN=severe (Grade 4) neutropenia which is defined as ANC < 500/mm³; RBC=red blood cells, SCLC=small cell lung cancer; SD=standard deviation.

Chemo=etoposide + platinum in G1T28-02, etoposide + platinum + atezolizumab in G1T28-05, and topotecan in G1T28-03. Standard supportive care interventions were allowed for all arms.

a. p-value was obtained from a nonparametric analysis of covariance (ANCOVA).

b. p-value was obtained from a modified Poisson model.

c. p-value was obtained from a negative binomial model. All three models contained fixed effect of treatment, ECOG performance status (0-1 versus 2), Presence of brain metastases (Y/N), and study (G1T28-02, G1T28-03, or G1T28-05). Corresponding baseline assessment was also included as a covariate.

Results from the TNBC Study G1T28-04 demonstrated that although the addition of trilaciclib to GC did not statistically significantly improve chemotherapy-induced myelosuppression as measured by the neutrophil-based endpoints of DSN in Cycle 1 and occurrence of SN, there were trends toward improvement in RBC and platelet-based measures. In addition, anti-tumor efficacy results demonstrated a clinically meaningful improvement in PFS and OS (Figure 2; Table 3). This meaningful anti-tumor efficacy was observed in both trilaciclib groups compared with the control group and was also consistent across subgroups, including predictors of immune response. Approximately 57.6% of the available tumor samples in G1T28-04 were considered PD-L1 positive (Ventana SP142 assay), and though larger in the PD-L1 positive population, the benefit of adding trilaciclib extended to both PD-L1 positive and negative cohorts (Table 4).

Table 3: G1T28-04: Summary of Overall Survival and Progression-Free Survival (ITT Analysis Set)

Category	Group 1 GC (Day 1+8) (N=34)	Group 2 GC + Trilaciclib (Day 1+8) (N=33)	Group 3 GC + Trilaciclib (Day 1/2+8/9) (N=35)	Groups 2+3 (N=68)
Overall survival (months) (95% CI)^{a, d}				
25%	5.8 (2.8, 9.7)	9.4 (3.4, 19.6)	8.8 (6.0, 15.3)	8.8 (6.0, 14.0)
Median	12.6 (6.3, 15.6)	NR (10.2, NR)	17.8 (12.9, 32.7)	19.8 (14.0, NR)
75%	17.8 (12.8, 25.0)	NR (NR, NR)	32.7 (19.8, NR)	NE (32.7, NR)
Comparison (treatment group versus Group 1)				
Adjusted HR (SE) ^b	NA	0.31 (0.111)	0.40 (0.125)	0.37 (0.101)
95% CI ^b	NA	0.15, 0.63	0.22, 0.74	0.21, 0.63
2-sided p-value ^c	NA	0.0016	0.0004	<0.0001
Progression-free survival (months) (95% CI)^{a, d}				
25%	2.2 (1.2, 5.4)	5.3 (1.2, 7.9)	6.2 (1.2, 7.1)	5.9 (2.1, 6.5)
Median	5.7 (3.3, 9.9)	9.4 (6.1, 11.9)	7.3 (6.2, 13.9)	9.0 (6.4, 11.3)
75%	9.9 (8.3, 18.8)	13.0 (9.7, 24.1)	13.9 (9.0, NR)	13.9 (10.9, 15.6)
Comparison (Treatment Group versus Group 1)				
Adjusted HR (SE) ^b	NA	0.62 (0.209)	0.63 (0.212)	0.62 (0.180)
95% CI ^b	NA	0.32-1.20	0.32, 1.22	0.36, 1.10
2-sided p-value ^c	NA	0.2099	0.1816	0.1291

CI=confidence interval; GC=gemcitabine and carboplatin; HR=hazard ratio; ITT=intent-to-treat; N=total number of patients in each treatment group; NA=not applicable; NR=not reached; SE=standard error.

^a Calculated using the Kaplan-Meier method

^b The HR and its 95% CI were calculated using the Cox regression model controlling for stratification factors of the number of prior lines of therapy (0 versus 1 or 2) and liver involvement.

^c P-value was calculated using the stratified log-rank test controlling for the two stratification factors.

^d OS reported from final database; PFS reported from earlier data cutoff on 15 May 2020.

Table 4: G1T28-04: Tumor Response According to PD-L1 Status

	PD-L1 Positive				PD-L1 Negative			
	Group 1	Group 2	Group 3	Group 2+3	Group 1	Group 2	Group 3	Group 2+3
Patients analyzed	17	16	16	32	10	10	16	26
Median PFS, months (95% CI) ^a	5.4 (3.3-NR)	7.9 (6.1-NR)	10.9 (6.2-NR)	9.7 (6.2-15.5)	9.2 (8.3-NR)	11.9 (8.8-NR)	9.0 (6.4-NR)	9.4 (6.5-14.6)
p-value	-	0.492	0.075	0.149	-	0.376	0.488	0.943
HR (95% CI)	-	0.74 (0.3-1.7)	0.41 (0.2-1.1)	0.57 (0.3-1.2)	-	0.60 (0.2-1.9)	1.47 (0.5-4.3)	0.97 (0.4-2.5)
Median OS, months (95% CI) ^a	10.5 (6.3-18.8)	20.1 (10.2-NR)	32.7 (15.3-NR)	32.7 (17.7-NR)	13.9 (12.6-NR)	NR (9.4-NR)	17.8 (12.9-NR)	17.8 (13.1-NR)
p-value	-	0.037	0.01	0.004	-	0.077	0.198	0.093
HR (95% CI)	-	0.38 (0.2-1.0)	0.30 (0.1-0.8)	0.34 (0.2-0.7)	-	0.35 (0.1-1.2)	0.55 (0.2-1.4)	0.48 (0.2-1.2)

HR=hazard ratio; NR=not reached; OS=overall survival; PD-L1=programmed death ligand-1; PFS=progression-free survival

Group 1: chemotherapy on Days 1 and 8; Group 2: trilaciclib and chemotherapy on Days 1 and 8; Group 3: trilaciclib along on Days 1 and 8 with chemotherapy on Days 2 and 9. HR and p-values are comparisons between Group 2 and Group 1, Group 3 and Group 1, and between combined Groups 2 and 3 and Group 1.

^aOS reported from final database; PFS reported from earlier data cutoff on 15 May 2020.

As mentioned in Section 4.2.7, there is a hypothetical risk that administration of trilaciclib prior to chemotherapy could decrease chemotherapy efficacy by pausing CDK4/6-dependent tumor cells in the G₁ phase of the cell cycle in the presence of chemotherapy. This hypothetical risk is countered by the results observed in Study G1T28-04 which suggested that the addition of trilaciclib improves the anti-tumor efficacy of GC regardless of the CDK4/6 status of the TNBC tumor. Although TNBC tumors are predominantly classified as CDK4/6 independent (i.e., their replication is not sensitive to CDK4/6 inhibition), there is a small subset of patients whose tumors are classified as either CDK4/6 indeterminate or CDK4/6 dependent. When the TNBC population enrolled in Study G1T28-04 is divided into these subsets, evaluation of the anti-tumor efficacy in patients whose tumors are classified as CDK4/6 indeterminate or CDK4/6 dependent suggests that trilaciclib does not antagonize the anti-tumor effects of GC. Specifically, PFS and OS did not decrease when trilaciclib was added to GC in the most CDK4/6-dependent population (see the trilaciclib IB).

4.2.8.1.1. Pharmacokinetics

A clinical DDI study using the index CYP3A substrate midazolam indicated that trilaciclib had no impact on CYP3A activity. Two clinical DDI studies using a strong CYP3A inhibitor itraconazole were also conducted. No clinically significant changes in exposure were observed for trilaciclib when coadministered with itraconazole.

Clinical data from the evaluation of trilaciclib administered prior to topotecan (Study G1T28-03) suggests that drugs that are substrates of MATE1 and MATE2 do not pose a clinically relevant

risk of DDIs when administered concomitantly with trilaciclib. In an additional clinical DDI assessment, trilaciclib increased metformin (MATE1, MATE2-K and OCT2 substrate) exposure by 65%, in healthy subjects, compared with administration of metformin alone. However, due to the intermittent schedule of trilaciclib administration and the observation that the effect of trilaciclib on metformin was similar to mild to moderate reductions in renal function, the clinical significance of the metformin plasma concentration increase is not expected to be high. OCT2 substrates with a narrow therapeutic index, such as dofetilide and dalfampridine, should be used with caution.

Docetaxel has not been reported to be a substrate for MATE1 or MATE2 (Nieuweboer, 2015), and is not believed to be a substrate for OCT2. As such, a clinically significant alteration of docetaxel PK due to trilaciclib inhibition of OCT2, MATE1, or MATE2-K is not expected.

Study G1T28-11 was a single ascending dose study, with both placebo and positive control groups, with the objective to evaluate potential effects of trilaciclib on ECG parameters, including concentration-QTc (C-QTc) analysis. Trilaciclib transiently increased heart rate by approximately 10 beats per minute. At the clinical dose of 240 mg/m², trilaciclib did not have a clinically relevant effect on QTc (i.e., >10 msec).

4.2.8.2. Trilaciclib

Reproductive/embryo-fetal effects are an important potential risk of trilaciclib. Both nonclinical toxicology studies with trilaciclib, and clinical studies with other compounds with a similar MOA, report effects on either the reproductive system or embryo/fetus. Since this clinical study will focus on trilaciclib administered prior to cytotoxic chemotherapy (which carries its own risk of reproductive/embryo-fetal toxicity), the risks specific to trilaciclib are consistent with those experienced with chemotherapy. In addition, female patients will be monitored for pregnancy and eligibility criteria describing specific birth control methods are incorporated. Dose discontinuation recommendations for female patients who become pregnant while receiving trilaciclib are also provided in the protocol (Section 11.3.6.5). Detailed information regarding all important identified and important potential risks of trilaciclib administration can be found in the trilaciclib IB.

Adverse events of special interest (AESIs) identified for trilaciclib are described below. Rates reported below reflect those observed in the integrated safety summary from the four Phase 2 oncology studies conducted with trilaciclib to date (G1T28-02 [database lock: 05 May 2019], G1T28-03 [data cutoff: 31 May 2019], G1T28-05 [data cutoff: 28 June 2019], and G1T28-04 [data cutoff: 28 June 2019]). Some AESIs have been infrequently reported (or not reported) in the trilaciclib clinical program to date but are considered to be potential class effects of CDK4/6 inhibitors. However, as trilaciclib is given IV and only when chemotherapy is administered, the safety profile of trilaciclib appears to be different from that of the oral, chronically-dosed members of its pharmacologic class. All patients will be monitored for these events and dose modification and discontinuation guidelines are provided in Section 9 and Section 10.

Trilaciclib AESIs:

1. **Injection Site Reaction/Phlebitis/Thrombophlebitis:** Infusion of trilaciclib may result in local irritation manifesting as erythema, pain, and swelling; and in a subset of patients, the irritation may cause phlebitis/thrombophlebitis. Injection site reactions have been

observed in approximately 15 to 20% of patients receiving trilaciclib and the events have been Grade 1 or 2. Phlebitis/thrombophlebitis has been noted in approximately 5 to 10% of patients receiving trilaciclib and the events were primarily Grade 1 or 2. Supportive care interventions such as slowing the infusion rate, flushing the infusion line with a minimum of 20 mL normal saline or 5% dextrose (D5W), rotating IV catheter sites, and removing the IV (when given peripherally) following each trilaciclib infusion can decrease the frequency and severity of these events. In addition, if symptoms are observed with normal saline as diluent/flush, use of D5W as an alternative may decrease the symptoms. Central access may also be considered.

2. **Acute Drug Hypersensitivity Reaction:** Trilaciclib administration may cause acute drug hypersensitivity reaction characterized by symptoms like angioedema, pruritis, and urticaria. These events have been reported in approximately 6% of patients receiving trilaciclib compared with approximately 3% in patients receiving placebo and were classified as Grade 1 and 2. Only one case of Grade 2 anaphylaxis was observed, which occurred 4 days after the preceding dose of trilaciclib, resolved on the same day, was not serious, and did not result in discontinuation of treatment.
3. **Pneumonitis/Interstitial Lung Disease:** A rare (1 to 3%) but serious class effect (<1% fatal) that is associated with the use of oral CDK4/6 inhibitors. Symptoms include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams in patients in whom infectious, neoplastic, or other causes have been excluded. The only case of pneumonitis reported in patients who received trilaciclib was observed in a patient in whom trilaciclib had been discontinued for two months and who had been receiving atezolizumab (known to cause pneumonitis) as monotherapy. The pneumonitis event was Grade 3 and considered by the Investigator to be related to atezolizumab.
4. **Hepatotoxicity:** Both nonclinical toxicology studies with trilaciclib, and clinical studies with other compounds with a similar MOA, report reversible elevations in transaminases with continuous dosing. There has been only 1 instance of Grade 4 alanine aminotransferase (ALT) increase in a patient receiving trilaciclib, no Grade 4 aspartate aminotransferase (AST) increases, and no cases of Hy's law reported in patients receiving trilaciclib. However, generally low grade and transient increases in AST, ALT, or bilirubin have been observed in a small number of patients (~ 5%) receiving trilaciclib prior to chemotherapy. Patients with mild hepatic impairment have been treated with trilaciclib without a clinically significant increase in exposure or the frequency/severity of AEs. Studies evaluating the PK of trilaciclib in patients with hepatic impairment are ongoing.
5. **Embolic and Thrombotic Events, Venous:** The CDK4/6 inhibitor abemaciclib has been associated with an increased risk for venous thromboembolism when combined with endocrine therapy in patients with breast cancer. This same risk has not been reported for the other approved oral CDK4/6 inhibitors (ribociclib and palbociclib); therefore, it is not clear if this is a class effect. Approximately 3% of cancer patients that received trilaciclib prior to chemotherapy experienced a venous thromboembolic event and half of those events (3/6) were Grade 3 or 4. No Grade 5 events were reported. Approximately 2% of patients receiving chemotherapy alone or with placebo reported an embolic or thrombotic event, 1 of 3 such events was Grade 3.

4.2.8.3. Docetaxel

Docetaxel is commonly used in the treatment of metastatic NSCLC (NCCN, 2020) and is approved by the US FDA and the European Medicines Agency for this indication (Taxotere®, 2020; Taxotere, 2005). Per Warnings and Precautions in the prescribing information for docetaxel, the following are important risks related to docetaxel use:

- Acute myeloid leukemia, myelodysplasia or other second primary malignancies
- Cutaneous reactions including erythema, edema and desquamation
- Neurologic reactions including paresthesia, dysesthesia, and pain
- Cystoid macular edema
- Asthenia
- Fetal harm
- Alcohol content (in a dose of Taxotere injection)
- Tumor lysis syndrome
- Neutropenia
- Serious gastrointestinal complications (ex. enterocolitis)
- Hypersensitivity reactions
- Fluid retention
- Respiratory disorders (ex. acute respiratory distress syndrome, interstitial lung disease, pulmonary fibrosis, respiratory failure)
- Severe adverse reactions in patients with liver impairment

4.3. Benefit/Risk Assessment

Trilaciclib (CDK4/6 inhibitor) is being evaluated for anti-tumor efficacy, specifically OS, following disease progression on both immunotherapy and platinum-based chemotherapy, a clinical setting where treatment options are limited and outcomes are suboptimal. In addition to facilitating host immune function, trilaciclib can also provide benefit by making chemotherapy safer and allowing patients to receive the standard of care doses and schedule. These effects have been shown in other trilaciclib clinical trials to improve the patient experience and are provided in the context of minimal toxicity (low grade injection site reactions/phlebitis/thrombophlebitis).

As stated in Section 4.2.8, the dose of 240 mg/m² trilaciclib established in the SCLC and TNBC studies (G1T28-04) will be administered prior to a commonly used chemotherapy regimen of docetaxel. The clinically meaningful anti-tumor efficacy results observed in G1T28-04 were noted across multiple endpoints, with OS, PFS, and ORR endpoints all showing numerical improvement with the addition of trilaciclib to GC compared with GC alone.

Studies to date with trilaciclib have demonstrated a manageable safety profile (see Section 4.2.8). Trilaciclib is not expected to have significant overlapping toxicity with docetaxel. In fact,

trilaciclib is expected to have a favorable impact on specific docetaxel complications such as myelosuppression and potentially on gastrointestinal (GI) related side effects.

As described in Section 4.2.9.1 and 4.2.8.1, there is a hypothetical risk that administration of trilaciclib prior to chemotherapy could decrease chemotherapy efficacy by pausing CDK4/6-dependent tumor cells in G1 in the presence of chemotherapy. However, at this time there is no nonclinical (Section 4.2.7) or clinical (Section 4.2.8) evidence to support this theoretical risk. In addition, since sensitivity to CDK4/6 inhibitors is a surrogate marker for CDK4/6 dependence, and the oral, chronically-dosed CDK4/6 inhibitors have shown minimal anti-tumor activity in solid tumors other than ER+ breast cancer (Baghdadi, 2019; Goldman, 2014; Goldman, 2018; Gopalan, 2014; Infante, 2016; Karasic, 2018; Rose, 2018), these results suggest that the majority of solid tumor cancers are not CDK4/6 dependent and not susceptible to this hypothetical risk.

Given the potential benefit to patients with previously treated metastatic NSCLC from the addition of trilaciclib to docetaxel and the limited potential for significant trilaciclib-related toxicity, the benefit/risk assessment is positive for this combination.

5. OBJECTIVES AND ENDPOINTS

The primary, secondary, safety, and exploratory objectives of this study and their associated endpoints, for patients with metastatic NSCLC receiving docetaxel in the 2nd or 3rd line, are presented in [Table 5](#).

Table 5: Objectives and Endpoints

Objectives	Endpoints
Primary Objective	
<ul style="list-style-type: none"> To assess the effect of trilaciclib on OS compared with placebo 	<ul style="list-style-type: none"> OS in the ITT population defined as time from randomization to death due to any cause for those who died; or time to last contact known as alive for those who survived in the study (censored cases).
Secondary Objectives: Other Anti-Tumor Efficacy	
<ul style="list-style-type: none"> To assess the effect of trilaciclib on PFS compared with placebo 	<ul style="list-style-type: none"> PFS in ITT population defined as time from randomization to disease progression using RECIST v1.1 or death due to any cause, whichever occurs first; for patients without disease progression or death, PFS will be calculated per censoring rules.
<ul style="list-style-type: none"> To assess the effect of trilaciclib on other anti-tumor endpoints compared with placebo 	<ul style="list-style-type: none"> ORR defined as percentage of patients with confirmed CR and PR per RECIST v1.1 DOR defined as duration of objective response
Secondary Objective: to evaluate the myelopreservation effect of trilaciclib compared with placebo	
<ul style="list-style-type: none"> To assess the effects of trilaciclib on the neutrophil lineage compared with placebo 	<ul style="list-style-type: none"> Duration of severe (Grade 4) neutropenia in Cycle 1 Occurrence of severe (Grade 4) neutropenia Occurrence of febrile neutropenia AEs Occurrence of G-CSF administration
<ul style="list-style-type: none"> To assess the effects of trilaciclib on the RBC lineage compared with placebo 	<ul style="list-style-type: none"> Occurrence of Grade 3 or 4 decreased hemoglobin laboratory values RBC transfusions on or after Week 5 (occurrence and number of transfusions) Occurrence of ESA administration
<ul style="list-style-type: none"> To assess the effects of trilaciclib on the platelet lineage compared with placebo 	<ul style="list-style-type: none"> Occurrence of Grade 3 or 4 decreased platelet count laboratory values Platelet transfusions (occurrence and number of transfusions)

Objectives	Endpoints
<ul style="list-style-type: none"> To assess the effects of trilaciclib on chemotherapy dosing compared with placebo 	<ul style="list-style-type: none"> All-cause dose reductions (occurrence and number of reductions) All-cause cycle delays (occurrence and number of delays)
<ul style="list-style-type: none"> To assess the effects of trilaciclib on hospitalizations due to chemotherapy-induced myelosuppression compared with placebo 	<ul style="list-style-type: none"> Occurrence and number of hospitalizations due to chemotherapy-induced myelosuppression
Secondary Objective: to evaluate the safety of trilaciclib compared with placebo	
<ul style="list-style-type: none"> To assess the safety and tolerability of trilaciclib compared with placebo 	<ul style="list-style-type: none"> Occurrence and severity of AEs by NCI-CTCAE v5 Study treatment discontinuation due to AEs Changes in laboratory parameters (hematology, chemistry), vital signs and ECG parameters Grade 3 or 4 abnormalities in laboratory parameters Trilaciclib AESIs Chemotherapy infusion interruptions Relative dose intensity for docetaxel
Exploratory Objectives	
<ul style="list-style-type: none"> To assess the anti-tumor efficacy of trilaciclib by CDK4/6-dependence status 	<ul style="list-style-type: none"> OS, PFS, and ORR (per RECIST v1.1) in patients with each of the following CDK4/6 dependence signatures: <ul style="list-style-type: none"> CDK4/6 dependent CDK4/6 independent CDK4/6 indeterminant
<ul style="list-style-type: none"> To assess the anti-tumor efficacy of trilaciclib by PD-L1 subgroups 	<ul style="list-style-type: none"> OS, PFS, ORR, and DOR in ITT population by PD-L1 subgroups (as measured by retrospective analysis)
<ul style="list-style-type: none"> To characterize the population PK of trilaciclib and identify important determinants of variability 	<ul style="list-style-type: none"> Exposure-response relationship between trilaciclib and response or safety endpoints
<ul style="list-style-type: none"> Estimate the PK parameters of docetaxel using a population PK model 	<ul style="list-style-type: none"> Clearance Volume of distribution

Objectives	Endpoints
<ul style="list-style-type: none"> To assess the effect of trilaciclib on CIM- and disease-related symptoms and functional limitations 	<p>Change from baseline and/or time to deterioration in:</p> <ul style="list-style-type: none"> EORTC QLQ-C30 domain scores EORTC QLQ-LC13 domain scores (including additional EORTC weight loss item) FACIT-Fatigue total score EQ-5D-5L <p>Percent of patients reporting deterioration and improvement using:</p> <ul style="list-style-type: none"> PGIC fatigue item PGIS fatigue item
<ul style="list-style-type: none"> To assess the pharmacodynamic effects, including immune based mechanism, of trilaciclib when added to docetaxel in peripheral blood 	<ul style="list-style-type: none"> Differences in pharmacodynamic parameters, including those relating to immune-based mechanisms, in peripheral blood

AE=adverse event; AESI=adverse event of special interest; BOR=best overall response; CDK=cyclin-dependent kinase; CIM=chemotherapy-induced myelosuppression; DOR=duration of response; ECG=electrocardiogram; EORTC QLQ-C30= European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire; EORTC QLQ-LC13= European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module; EQ-5D-5L=5-level EQ-5D; ESA=erythropoiesis stimulating agent; FACIT-Fatigue=Functional Assessment of Chronic Illness Therapy – Fatigue; G-CSF=granulocyte colony-stimulating factor; IV=intravenous; NCI=National Cancer Institute; NSCLC=non-small cell lung cancer; ORR=objective response rate; OS=overall survival; PFS=progression free survival; PGIC=Patient Global Impression of Change; PGIS=Patient Global Impression of Severity; PK=pharmacokinetic(s); PR=partial response; RBC=red blood cell; RECIST=Response Evaluation Criteria in Solid Tumors

6. INVESTIGATIONAL PLAN

6.1. Overall Study Design

This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib compared with placebo on OS in patients with metastatic NSCLC receiving docetaxel in the 2nd or 3rd line setting. Patients must have documented disease progression during or after 1 or 2 lines of systemic therapy for recurrent or metastatic NSCLC. Prior treatment must have included, either in the same line or as separate lines of therapy: 1) a maximum of 1 line of platinum-containing chemotherapy in the recurrent/metastatic setting and 2) a maximum of 1 line of a locally approved/authorized PD-1/PD-L1 monoclonal antibody (mAb) containing regimen in the recurrent/metastatic setting.


Approximately 146 patients will be randomly assigned (1:1) to receive trilaciclib or placebo by IV prior to docetaxel on Day 1 of each 21-day cycle. There will be 2 stratification factors for randomization: Country, and ECOG performance status (0-1 versus 2). Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2).

Study drugs administered are as follows:

- Trilaciclib (240 mg/m²) or placebo – administered as a 30-minute IV infusion no more than 4 hours prior to chemotherapy on each day chemotherapy is administered (Section 9.1.1).
- Docetaxel 75 mg/m² –IV, Day 1

The study will include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase (Figure 4). The Treatment Phase begins on the day of randomization for the first patient and completes at the Post-Treatment Visit for the last patient. The first Survival Follow-up assessment should occur approximately 2 months after the last dose of study drug.

Figure 4: Study Design



D=day; PD=progressive disease, WD=withdraw, DC=discontinue

Criteria which patients must meet in order to receive study drug on Day 1 are provided in Section 9.2. Treatment cycles will occur consecutively without interruption, except when necessary to manage toxicities or for administrative reasons. Study drug administration will continue until disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or clinical progression as determined by the Investigator, unacceptable toxicity, withdrawal of consent, discontinuation by Investigator, or the end of the trial, whichever occurs first.

A post-treatment visit will occur approximately 30 days (± 7 days) following the last dose of study drug. Upon discontinuation of study treatment, patients will be followed for survival, i.e., patients or their caregivers will be contacted approximately every 2 months until the end of the study (or death) to record their status (alive or dead) as well as details of any subsequent systemic anti-cancer therapy initiated. These survival follow-ups may be done via telephone, email, or clinic visit.

The duration of total follow-up relative to the first patient being randomized is approximately 30 months to collect the target number of deaths per sample size calculation. If assumptions vary in the study conduct, the study duration will be event-driven. That is, the study will continue until the targeted number of deaths is observed. There is an interim analysis for OS. If the interim results demonstrate a statistically significant effect of trilaciclib over placebo for OS based on pre-specified criterion, the study will be stopped early due to success. Otherwise, the study will be completed when the criteria outlined in Section 10.4 have been met, or upon sponsor termination of the study.

6.2. Rationale for Primary and Secondary Endpoints

6.2.1. Anti-tumor Efficacy

Measurements of anti-tumor response rates by RECIST, in addition to OS and PFS, are standard assessments used in oncology solid tumor studies to measure the effects of study treatment on the underlying malignant disease. Additionally, clinical benefit in oncology should be based on direct evidence, such as improvement in duration of overall survival, improvement in a patient's quality of life, improved physical functioning, or improved tumor-related symptoms, which may not be adequately measured by response rates alone. Therefore, improvement in survival is considered one of the most reliable measures providing direct evidence of clinical benefit to patients and is a preferred clinical endpoint. Survival is considered easy to measure via documentation of the date of death and is not prone to bias (FDA, 2008).

6.2.2. Myelopreservation Efficacy

Patients experiencing CIM often face severe clinical consequences (e.g., FN, bleeding, fatigue) leading to the need for hospitalizations, hematopoietic growth factor support, transfusions (RBCs and/or platelets) and even death (Caggiano, 2005; Gustinetti, 2016; Bodey, 1966; Li, 2016). Moreover, CIM commonly leads to dose reductions and delays, which limit therapeutic dose intensity and can compromise the anti-tumor efficacy benefits of chemotherapy. In 3 randomized, double-blind, placebo-controlled SCLC trials, the myelopreservation endpoints proposed in this clinical study were utilized to evaluate the efficacy of trilaciclib in reducing CIM. These endpoints proved to be robust measures of trilaciclib's myelopreservation efficacy and clinically meaningful improvements in multiple endpoints were observed across the 3 studies. This study will further investigate the impact of trilaciclib on CIM when used in combination with docetaxel.

6.2.3. Patient-Reported Outcomes

Throughout the trilaciclib clinical development program, patient-reported outcome (PRO) instruments have been evaluated in all randomized clinical trial settings. While exploratory endpoints in each of those studies, an integrated analysis of data collected in the 3 SCLC studies

suggests that trilaciclib added to chemotherapy can delay or prevent deterioration in multiple aspects of health-related quality of life. In these studies, trilaciclib generally maintained or reduced fatigue levels across cycles and prevented clinically meaningful increases in fatigue, which are commonly associated with myelosuppression. In G1T28-04 with TNBC patients, patients in the trilaciclib groups were less likely to have a deterioration in their symptoms, and in some cases had improvement in their symptoms, through the first 6 cycles of therapy (last time point evaluated). Trilaciclib delayed deterioration of patient functioning and symptoms measures over time compared with GC alone; suggesting that patients on trilaciclib (compared with GC alone) had a better experience receiving chemotherapy. This study will further investigate the patient experience and potential benefit to NSCLC patients receiving trilaciclib.

6.2.4. Safety

Assessment of AEs, changes in laboratory parameters, electrocardiogram (ECG) parameters, vital signs, and ECOG status are all standard assessments used in oncology trials to measure patient safety.

6.3. Rationale for Dose and Schedule of Study Treatment

6.3.1. Trilaciclib

Previous studies demonstrated the RP2D of trilaciclib was 240 mg/m². When trilaciclib was administered prior to chemotherapy to cancer patients, doses of 200 (rounded up from 192), 240, and 280 mg/m² were evaluated. Trilaciclib exposures in cancer patients were slightly lower compared with healthy subjects, such that the dose of 240 mg/m² (rather than 200 mg/m²) more closely matched the biologically effective dose (BED) of 192 mg/m². In addition, the dose of 240 mg/m² demonstrated maximal myelopreservation efficacy benefits (compared with 200 and 280 mg/m²) as measured by a variety of myelosuppression endpoints. The myelopreservation effect at 240 mg/m² was further evaluated and confirmed in three randomized controlled Phase 2 studies in SCLC patients. In addition, the planned dose was used in a previous TNBC study (G1T28-04) and demonstrated clinically meaningful benefits in OS duration. See the trilaciclib IB for details.

In addition, at the RP2D, trilaciclib has a limited toxicity profile and minimal overlapping toxicities are expected with docetaxel (Section 4.2.9). The primary AEs anticipated with trilaciclib are low grade injection site reactions including phlebitis/thrombophlebitis. These infusion reactions have generally been mild and occur in association with drug delivery through peripheral access. Central access is likely to reduce/eliminate these issues. The remainder of the trilaciclib AESIs to date have been uncommon and for most, the percentage of patients experiencing these AESIs is not clearly increased in patients receiving trilaciclib compared to placebo. Based on these results a dose-finding study is not needed.

In order to preserve hematopoietic stem and progenitor cells (HSPCs) as well as immune system function during chemotherapy, trilaciclib is always administered prior to systemic chemotherapy (docetaxel), on each day of chemotherapy administration. Trilaciclib will not be administered as monotherapy (i.e., on days that chemotherapy will be delayed).

6.3.2. Docetaxel

The dose and schedule of docetaxel is described in Section 9.1.1.2. This is consistent with standard of care as established in clinical trials (Shepherd, 2000; Garon, 2014), and the approved labeling for this product (NCCN, 2020; Taxotere, 2020; Taxotere, 2005).

6.4. Rationale for Supportive Care Interventions

Per NCCN guidelines docetaxel, as utilized in NSCLC, is considered an intermediate risk regimen with a risk of FN between 10 and 20%. At this level of risk, guidelines do not require routine prophylactic granulocyte colony-stimulating factor (G-CSF) in Cycle 1 (NCCN, 2020b). Therefore, in order to facilitate an unbiased evaluation of trilaciclib effects on the hematologic and pharmacodynamic endpoints, primary prophylactic G-CSF will be prohibited in Cycle 1; however therapeutic G-CSF (administered in response to a neutropenic event) in Cycle 1 and secondary prophylactic G-CSF beginning in Cycle 2 and for all subsequent cycles (i.e., after a precipitating event in a prior cycle of therapy) will be allowed per growth factor/neutropenia management guidelines in Section 9.4 and Investigator discretion (Aapro, 2010; Smith, 2015).

Erythropoiesis-stimulating agent (ESA) administration and RBC or platelet transfusions will be allowed per Investigator discretion based on guidelines detailed in Section 9.4.2 and Section 9.4.3. While these interventions may confound analysis of the myelosuppression endpoints, allowing physicians to provide appropriate supportive care to patients will facilitate patient safety.

6.5. Rationale for Patient Population

Though immunotherapy has markedly improved the treatment of metastatic NSCLC, options following disease progression remain limited. An alternative therapy that extends the duration of OS without significant additive toxicity, while concurrently decreasing myelosuppression and improving quality of life, would be a welcome addition in this heavily pretreated and often clinically fragile patient population. Therefore, further evaluation of trilaciclib in this area of high unmet medical need is warranted.

6.6. Rationale for Stratification Factors

As outlined in Section 6.1, randomization will be stratified by country and ECOG performance status. Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2). These factors were chosen because they are predicted to have an impact on the primary endpoint of overall survival, and in some cases the secondary myelopreservation endpoints, such that if there is an imbalance in these factors, interpretation of the results of the study could be compromised.

Country was chosen as a stratification factor to account for the geographic differences in patient populations, treatment practice patterns and access to supportive care and subsequent anti-cancer therapy; all of which could influence the primary and secondary endpoint outcomes.

Performance status is an established indicator of survival and treatment tolerance. Those with ECOG performance status of 2 typically have shorter survival times and greater toxicity with subsequent therapeutic interventions (Sweeney, 2001; Jang, 2014). However, this group in particular may derive benefit from the myelopreservation and limited toxicity seen with

trilaciclib and has few well-tolerated alternative options. As such, these patients will be eligible but stratified by ECOG performance status (0-1 versus 2) in order to minimize any impact on survival outcomes.

7. STUDY POPULATION

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as a protocol waiver or exemption, is not permitted.

7.1. Inclusion Criteria

Patient eligibility should be reviewed and documented by an appropriately qualified member of the investigator study team before patients are included in the study. Patients must meet *all* of the following inclusion criteria to be eligible for enrollment into the study:

1. Age ≥ 18 years of age at the time of signing the informed consent.
2. Histologically or cytologically confirmed metastatic NSCLC (squamous or nonsquamous) with no known actionable driver mutations (ex. EGFR, ROS1, ALK).
 - Patients must have had documented disease progression during or after 1 or 2 lines of systemic treatment for recurrent or metastatic disease.
 - Two components of treatment must have been received in the same line or as separate lines of therapy: (i) a maximum of 1 line of platinum-containing chemotherapy regimen for recurrent/metastatic disease, and (ii) a maximum of 1 line of a locally approved/authorized PD-1/PD-L1 mAb containing regimen for recurrent/metastatic disease.
 - Maintenance therapy following platinum doublet-based chemotherapy is not considered as a separate line of therapy. Maintenance therapy is defined as therapy given within 42 days after the last dose of platinum-based chemotherapy in patients with ongoing clinical benefit (complete response [CR], partial response [PR] or stable disease [SD]).
3. Measurable or non-measurable disease per RECIST v1.1
4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
5. A formalin-fixed paraffin-embedded (FFPE) tumor specimen (from archival or fresh biopsy) with an associated pathology report documenting NSCLC must be available to send to the Sponsor, within the specified timeframe, for planned retrospective biomarker analyses (see Section 11.6.1).
6. Adequate organ function defined by the following laboratory values:
 - a) Hemoglobin ≥ 9.0 g/dL in the absence of RBC transfusion or ESA administration within 14 days prior to first dose of trilaciclib/placebo
 - b) Absolute neutrophil count (ANC) $\geq 1.5 \times 10^9/\text{L}$
 - c) Platelet count $\geq 100 \times 10^9/\text{L}$
 - d) Total bilirubin \leq upper limit of normal (ULN)
 - e) AST/ALT $< 1.5 \times \text{ULN}$ if alkaline phosphatase $> 2.5 \times \text{ULN}$
 - f) If alkaline phosphatase $< 2.5 \times \text{ULN}$ then AST, ALT $< 2.5 \times \text{ULN}$ in the absence of liver metastasis or $< 5 \times \text{ULN}$ in the presence of liver metastasis

- g) Estimated glomerular filtration rate ≥ 30 mL/minute/1.73m²
- 7. Resolution of nonhematologic toxicities per National Cancer Institute Common Terminology Criteria Version 5.0 (NCI-CTCAE) from prior therapy or surgical procedures to \leq Grade 1 or baseline (except alopecia).
- 8. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Please see Section 17.3 for detailed instructions on methods of contraception requirements.
- 9. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

7.2. Exclusion Criteria

A patient will not be eligible for participation in this study if *any* of the following criteria apply:

1. Prior therapy with docetaxel.
2. Any contraindication to the administration of docetaxel at the discretion of the investigator.
3. Mixed NSCLC/SCLC, or lung tumors whose predominant histology is sarcomatoid, or neuroendocrine.
4. Any chemotherapy, immunotherapy, biologic, investigational, or hormonal therapy for cancer treatment (except for adjuvant hormonal therapy for breast cancer or prostate cancer defined as M0 disease or prostate-specific antigen (PSA) persistence/recurrence without metastatic disease) within 3 weeks prior to the first dose of trilaciclib/placebo.
5. Any radiotherapy within 2 weeks prior to the first dose of trilaciclib/placebo.
6. Presence of central nervous system (CNS) metastases requiring immediate treatment with radiation therapy or steroids (i.e., patient must be off steroids administered for brain metastases for at least 14 days prior to the first dose of trilaciclib/placebo).
7. Presence of leptomeningeal disease.
8. Significant third-space fluid retention (ex. ascites or pleural effusion) not amenable to required repeat drainage.
9. QT corrected using Fridericia's formula (QTcF) interval >480 msec at screening (confirmed on repeat). For patients with ventricular pacemakers, QTcF >500 msec.
10. Symptomatic peripheral neuropathy (\geq Grade 2 NCI-CTCAE v5.0)
11. History of interstitial lung disease (ILD)
12. Clinically significant (i.e., active) cardiovascular disease at the time of signing the informed consent; for example cerebrovascular accidents (≤ 6 months before the first dose of trilaciclib/placebo), myocardial infarction (≤ 6 months before the first dose of trilaciclib/placebo), unstable angina, serious cardiac arrhythmia requiring medication,

- or uncontrolled symptomatic congestive heart failure [Class II or higher as defined by the New York Heart Association [NYHA] functional classification system])
13. Known serious active infection (e.g., human immunodeficiency virus [HIV], hepatitis B or C, tuberculosis, etc.)
 14. Prior allogeneic or autologous hematopoietic stem cell or bone marrow transplantation
 15. Receipt of any low-dose systemic chemotherapeutic agent (e.g., low-dose methotrexate for rheumatoid arthritis) administered for a nononcologic purpose within 3 weeks prior to the first dose of trilaciclib/placebo.
 16. Receipt of any live attenuated vaccines within 4 weeks prior to first dose of study treatment or anticipation that such a vaccine will be required during the study treatment period.
 17. Known hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80 or any excipients of trilaciclib
 18. Pregnant or lactating women
 19. Legal incapacity or limited legal capacity
 20. Other uncontrolled serious chronic disease or psychiatric condition that in the Investigator's opinion could affect patient safety, compliance, or follow-up in the protocol
 21. Concurrent participation in any other interventional clinical trial.

8. SCHEDULE OF ASSESSMENTS

The procedures and assessments to be performed during the study are outlined in [Table 6](#). The timing and number of samples collected for biomarker testing may be altered based on emerging data without requiring an amendment if the blood volume per day or overall does not increase and the patient is not required to have additional clinic visits or prolongation of a clinic visit, i.e., the risk-benefit profile for the patient does not worsen.

When there are multiple procedures at the same or overlapping time points, order of events should be: patient reported outcome measures, ECGs, vitals, blood draw. Unscheduled assessments and visits to manage patient safety may occur at the Investigator's discretion. Study procedures performed at unscheduled visits should be recorded in the appropriate electronic case report form (eCRF).

Table 6: Schedule of Assessments

Assessment	Screening	Randomization	21 Day Treatment [Cycles]					Post-Treatment Visit	Survival Follow-Up	Details Provided in Section
			Cycle 1				Cycle 2 and beyond			
Day	-28 to -1	-3 to -1	1	5 (±1 day)	9 (±1 day)	13 (±1 day)	17 (±1 day)	1 ^a	30 ±7d post-last dose	Every 2 months
Informed Consent	X									Section 13.3
Demographics	X									Section 11.1.2
Medical History and NSCLC History	X									Section 11.1.3
Eligibility Evaluation and Randomization	X	X								Section 11.1.1, Section 7.1, and Section 7.2
Archived Tumor Sample	X									Section 11.6.1
ECOG Performance Status	X		X					X	X	Section 11.3.3
Complete physical exam, including height and weight	X									Section 11.3.2
Brief physical exam, including weight			X					X	X	Section 11.3.2
Vital Signs	X		X					X	X	Section 11.3.1
12-lead Electrocardiogram	X		X					X [C2 only]		Section 11.3.4

Assessment	Screening	Rand	21 Day Treatment [Cycles]					Post-Treatment Visit	Survival Follow-Up	Details Provided in Section
			Cycle 1				Cycle 2 and beyond			
Day	-28 to -1	-3 to -1	1	5 (±1 day)	9 (±1 day)	13 (±1 day)	17 (±1 day)	1 ^a	30 ±7d post-last dose	Every 2 months
Clinical Chemistry	X		X					X	X	Section 11.3.5
Hematology	X		X	X	X	X	X	X	X	Section 11.3.5
Pregnancy Test (WOCBP)		X	X					X	X	Section 11.3.5
Tumor Assessment by RECIST v1.1	X		X (every 6 weeks from C1D1)						X	Section 11.2.1
Trilaciclib or Placebo			X					X		Section 9.1.1.1
Docetaxel			X					X		Section 9.1.1.2
EORTC QLQ-C30, EORTC QLQ-LC13 (including weight loss item), FACIT-Fatigue, PGIS, and EQ-5D-5L			X			X		X	X	Section 11.4
PGIC						X		X	X	Section 11.4
Blood Sample for PK			X							Section 11.5
Blood Sample for Immunologic and Hematologic Markers			X		X			X [C2, C3, C5 only]		Section 11.7

Assessment	Screening	Rand	21 Day Treatment [Cycles]					Post-Treatment Visit	Survival Follow-Up	Details Provided in Section
			Cycle 1				Cycle 2 and beyond			
Day	-28 to -1	-3 to -1	1	5 (±1 day)	9 (±1 day)	13 (±1 day)	17 (±1 day)	1 ^a	30 ±7d post-last dose	Every 2 months
Survival Contact and Subsequent Anti-cancer Therapies									X	Section 11.10
AEs			X							Section 11.3.6
Concomitant Medications	X	X	X							Section 11.1.3

AE=adverse event; β-hCG=beta human chorionic gonadotropin; ECOG=Eastern Cooperative Oncology Group; EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire; EORTC QLQ-LC13=European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module; EQ-5D-5L=5-level EQ-5D; FACIT-Fatigue=Functional Assessment of Chronic Illness Therapy – Fatigue; NSCLC=non-small cell lung cancer; PGIC=Patient Global Impression of Change; PGIS=Patient Global Impression of Severity; PK=pharmacokinetic; Rand=randomization; RECIST=Response Evaluation Criteria in Solid Tumors; WOCBP=women of childbearing potential.

^a There should be no more than 5 weeks (for toxicity and/or administrative reasons) between doses of chemotherapy; however dosing delays >5 weeks may be permitted on a case by-case basis with the documented approval of the Investigator and Medical Monitor.

9. STUDY TREATMENT

9.1. Study Drugs Administered

Study drugs are defined as any investigational agent(s), marketed product(s), or placebo intended to be administered to a study patient according to the study protocol. Study drugs used in this protocol are described in [Table 7](#).

Table 7: Study Drugs

	Study Drugs		
Product Name:	Trilaciclib	Placebo	Docetaxel
Type	Investigational product	Placebo	Chemotherapy
Dosage Formulation:	Single-use, sterile powder to be reconstituted with 250 mL of dextrose 5% in water (D5W) or normal saline (sodium chloride solution 0.9%) per the Pharmacy Manual	250 mL of dextrose 5% in water (D5W) or normal saline (sodium chloride solution 0.9%)	Description of the formulation is provided in the current prescribing information (Taxotere, 2020 ; Taxotere, 2005)
Unit Dose Strength(s)	300 mg/20 mL	N/A	See current prescribing information
Dosage Level(s)	240 mg/m ²	N/A – administered on Day 1 to match trilaciclib	75 mg/m ²
Route of Administration	IV	IV	IV
Infusion Time	30 minutes	30 minutes	1 hour or per Institutional Standards

IV=intravenous; N/A=not applicable.

9.1.1. Dose, Dosing Regimen, and Route

9.1.1.1. Trilaciclib/Placebo

Trilaciclib for Injection, 300 mg/vial (also referred to as “Trilaciclib Sterile Powder for concentrate for solution for IV infusion, 300 mg/vial”) is supplied as a sterile, preservative-free, yellow, lyophilized cake in a single-dose vial (300 mg/20 mL).

Trilaciclib must be reconstituted and further diluted prior to IV infusion as outlined in the Pharmacy Manual. Aseptic technique must be used for reconstitution and dilution. Upon reconstitution, the solution must then be diluted to the calculated dose based on the body surface area (BSA) of the patient. BSA should be calculated as per institutional practice. Actual body weight (not “adjusted” body weight) should be utilized for dose calculations. If there is a change in body weight $\geq 10\%$ relative to the weight at the time of the last dose

calculation, dose should be recalculated. Recalculation of dose more frequently per local institutional guidelines is permitted. Dose recalculation to adjust for changes in body weight will not be considered a dose reduction and will be made at the discretion of the Investigator.

The placebo, either 250 mL of dextrose 5% in water (D5W) or sodium chloride solution 0.9%, will be administered by IV infusion over approximately 30 minutes by peripheral or central access.

9.1.1.1.1. Administration of Trilaciclib/Placebo

- Administer diluted trilaciclib solution or placebo as a 30-minute IV infusion completed within 4 hours prior to the start chemotherapy. Do not administer trilaciclib/placebo as a bolus.
- Trilaciclib/placebo is always administered first. Results from hematology labs should be reviewed prior to administration of trilaciclib/placebo. If administration of docetaxel therapy is delayed or discontinued, trilaciclib/placebo will also be delayed or discontinued.
- Diluted trilaciclib/placebo solution must be administered with an infusion set, including an in-line filter (0.2 or 0.22 micron). Compatible in-line filters include polyethylene sulfone, polyvinylidene fluoride, and cellulose acetate.
- Do not administer diluted trilaciclib/placebo solution with a polytetrafluorethylene (PTFE) in-line filter. PTFE in-line filters are not compatible with diluted trilaciclib/placebo solution.
- Do not co-administer other drugs through the same infusion line.
- Do not co-administer other drugs through a central access device unless the device supports co-administration of incompatible drugs.

Upon completion of infusion of diluted trilaciclib/placebo solution, the infusion line/cannula must be flushed with at least 20 mL sterile D5W or 0.9% normal saline.

The infusion rate may be decreased to manage an infusion-related AE; for example, if a patient experiences a burning sensation during infusion, the duration of infusion may be increased to 45 minutes (or longer if clinically indicated) to alleviate the symptoms. The actual start/stop time of infusion will be documented and entered in the eCRF.

9.1.1.2. Docetaxel

Docetaxel will be administered IV in accordance with the prescribing information/summary of product characteristics ([Taxotere, 2020](#); [Taxotere, 2005](#)) and according to the study site's standard practice. Protocol-specified doses of docetaxel will be administered IV in accordance with institutional guidelines and the recommended instructions below. Deviation from the recommendations provided in this protocol in order to follow institutional guidelines must receive prior approval from the Medical Monitor or Sponsor.

Actual body weight (not ideal body weight) should be utilized for dose calculations. At a minimum, if there is a change in body weight of >10% relative to the weight at the time of the last dose calculation, doses should be recalculated. Recalculation of the dose more frequently per local institutional guidelines is permitted. Dose recalculation to adjust for changes in body weight will not be considered a dose reduction.

Trilaciclib/placebo is always administered first, followed by docetaxel. Administer diluted trilaciclib solution or placebo as a 30-minute IV infusion to be completed within 4 hours prior to the start chemotherapy. Docetaxel may be administered immediately following trilaciclib/placebo, but not until the completion of the trilaciclib/placebo infusion. If administration of trilaciclib/placebo is delayed or discontinued, docetaxel will also be delayed or discontinued. Likewise, if docetaxel is delayed or discontinued, trilaciclib/placebo will also be delayed or discontinued.

9.1.2. Preparation, Handling, Storage, and Accountability

The Investigator or institution is responsible for study drug accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records). The Investigator/institution may assign some or all of the Investigator's/institution's duties for investigational product(s) accountability to an appropriate pharmacist or another appropriate individual who is under the supervision of the Investigator/institution.

Further guidance and information are provided in the Pharmacy Manual.

9.1.3. Treatment Compliance

The Investigator or designee will dispense the study drugs, via an unblinded Pharmacist/Designee, only for use by patients enrolled in the study as described in this protocol. The study drugs are not to be used for reasons other than those described in this protocol. The clinical study site will maintain records of study drugs' receipt, preparation, and dispensing, including the applicable lot numbers; patient's height, body weight, and body surface area; date and time of the start and end of each trilaciclib or placebo and docetaxel infusion; and total drug administered in milligrams. Any discrepancy between the calculated dose and dose administered and the reason for the discrepancy (e.g., interruption of infusion without restarting) will be recorded on eCRF and in the source documents.

9.2. Criteria for Starting Each Cycle

Please note the ANC for Cycle 1 Day 1 is required to be $\geq 1.5 \times 10^9/L$. Following completion of Cycle 1, patients must meet all the following criteria to receive study treatment on Day 1 for Cycle 2 and each subsequent cycle:

- $ANC \geq 1.0 \times 10^9/L$,
- Platelet count $\geq 50 \times 10^9/L$
- Total bilirubin \leq upper limit of normal (ULN)
- $AST/ALT \leq 1.5 \times ULN$ if alkaline phosphatase $> 2.5 \times ULN$
- Other nonhematologic drug-related toxicities (excluding alopecia) must be \leq Grade 1 or have returned to baseline.

For dose delays due to toxicity, the patient should be followed (at least) weekly, including CBCs if the AE is hematologic, to monitor the toxicity until treatment criteria are met or until they discontinue treatment (e.g., if more than 5 weeks elapse from the last chemotherapy dose). If the Day 1 dose is delayed, any assessments completed as part of the planned Day 1 visit will be captured in the eCRF as unscheduled visits. The PRO questionnaires should be

completed on both the planned Day 1 visit and on the actual Day 1 of the cycle (i.e., when criteria are met to proceed with Day 1 treatment).

There should be no more than 5 weeks (for toxicity and/or administrative reasons) between doses of chemotherapy; however dosing delays >5 weeks may be permitted on a case by-case basis with the documented approval of the Investigator and Medical Monitor.

In both the trilaciclib and placebo arms, study drug administration will continue until progressive disease per RECIST v1.1 or clinical progression as determined by the Investigator, unacceptable toxicity, withdrawal of consent, Investigator decision, or the end of the study.

9.3. Toxicity Management and Dose Modifications

The dose of trilaciclib will not be modified and will remain at 240 mg/m² throughout the study. If administration of docetaxel therapy is discontinued, trilaciclib will also be discontinued.

The dose of docetaxel can be reduced when necessary as described below. The recommended dose modification procedures for hematologic toxicities are described in [Table 9](#). If a subsequent cycle is delayed for toxicity, the patient should still complete the clinical laboratory assessments on the scheduled Day 1 (entered as an Unscheduled assessment in EDC) as well as on the actual first dosing day of that cycle. If the delay is secondary to hematologic toxicity, weekly repeat hematology assessments should continue until the finding meets criteria for resumption of dosing.

Non-hematologic toxicities should be managed as per standard of care for docetaxel. Recommendation for management of trilaciclib/placebo AESIs are provided in [Table 10](#). Recommendations for hepatobiliary toxicity management are in Section 9.3.4. All recommendations are intended as a minimum guideline for toxicity management and are not a replacement for independent medical judgement tailored to specific circumstances with an individual patient. Please also refer to the individual package insert/summary of product characteristics ([Taxotere, 2020](#); [Taxotere, 2005](#)) for additional information and recommendations.

9.3.1. Dose reduction

Recommended dose levels for reduction of docetaxel dose are described in [Table 8](#). Chemotherapy dose reductions for hematologic toxicities should be based on values obtained within 24 hours prior to Day 1 of a given cycle. All dose reductions for an individual patient are permanent; and the dose, which has been reduced for toxicity, must not be re-escalated. Up to a maximum of 2 dose reductions will be allowed per patient. If a third dose reduction is required per the modifications below, the patient should discontinue study treatment.

Table 8: Recommended Chemotherapy Dose Modifications

	Docetaxel
Starting Dose	75 mg/m ²
Dose Level -1	60 mg/m ²
Dose Level -2	50 mg/m ²

No dose modification is permitted for trilaciclib.

Note that dose modifications (specifically dose reductions/discontinuations) are recommended for those events considered related to drug (i.e., toxicities) such that decreasing the dose or stopping the drug will lead to improved patient safety. If an event is not thought to be related to study drug by the Investigator, dose reduction/discontinuation is not required since decreasing the dose or stopping the drug would not be expected to alter the risk of the event occurring again; rather the Investigator should consider if treatment should be delayed until the event recovers to ≤Grade 1 or baseline before resumption of treatment. Decreased neutrophil, platelet counts or hemoglobin values that occur in isolation (e.g., at nadir) that do not result in a dosing delay, FN, serious adverse event (SAE) or other consequence, do not require dose modification.

If drug-related toxicity requires discontinuation of docetaxel or trilaciclib then the patient must permanently discontinue all study drugs and should complete the Post-Treatment Visit and enter Survival Follow-up.

9.3.2. Safety Criteria for Adjustment or Stopping Doses

Table 9: Recommended Dose Modification for Drug-Related Hematologic Toxicity

		Action Taken		
Event, CTCAE Grade or Lab Value	Frequency	Trilaciclib	Docetaxel	Toxicity Management
ANC <1.0 x 10 ⁹ /L (≥Grade 3)	1 st occurrence	Hold drug until ANC criteria for dosing reached. No change in dose.	Hold drug until ANC criteria for dosing reached. No change in dose.	Administer prophylactic G-CSF with each subsequent cycle of chemotherapy.
	2 nd occurrence	Hold drug until ANC criteria for dosing reached. No change in dose.	Hold drug until ANC criteria for dosing reached. Reduce dose of docetaxel by one dose level and resume dosing.	
	3 rd occurrence	Hold drug until ANC criteria for dosing reached. No change in dose.	Hold drug until ANC criteria for dosing reached. Reduce dose of docetaxel by one more dose level and resume dosing.	
	4 th occurrence	Permanently discontinue		
Platelets <50 x 10 ⁹ /L (≥Grade 3) OR Symptomatic thrombocytopenia (severe or medically significant bleeding)	1 st occurrence	Hold drug until platelet criteria for dosing reached. No change in dose.	Hold drug until platelet criteria for dosing reached. Reduce dose of docetaxel by one dose level and resume dosing.	Monitor for signs and symptoms of bleeding. Consider treatment as clinically indicated
	2 nd occurrence	Hold drug until platelet criteria for dosing reached. No change in dose.	Hold drug until platelet criteria for dosing reached. Reduce dose of docetaxel by one more dose level and resume dosing.	
	3 rd occurrence	Permanently discontinue		
Febrile neutropenia (Grade 3 or 4) OR	1 st occurrence	Hold drug until ANC criteria for dosing reached. No change in dose.	Hold drug until ANC criteria for dosing reached. Reduce dose of docetaxel by one dose level and resume dosing.	Administer prophylactic G-CSF with each subsequent cycle of chemotherapy.

Event, CTCAE Grade or Lab Value	Frequency	Action Taken		
		Trilaciclib	Docetaxel	Toxicity Management
Grade 4 Neutropenia lasting >5 days	2 nd occurrence	Hold drug until ANC criteria for dosing reached. No change in dose.	Hold drug until ANC criteria for dosing reached. Reduce dose of docetaxel by one more dose level and resume dosing.	
	3 rd occurrence	Permanently discontinue		

ANC=absolute neutrophil count; CTCAE=Common Terminology Criteria for Adverse Events; G-CSF=granulocyte colony-stimulating factor.

9.3.3. Recommended Actions with Trilaciclib/Placebo for Adverse Events of Special Interest

Suggested actions to be taken with trilaciclib/placebo following AESI are provided in [Table 10](#).

Table 10: Recommended Actions with Trilaciclib/Placebo Following AESIs

AESI	Severity	Recommended Action
Injection site reactions including phlebitis and thrombophlebitis	Grade 1: Tenderness with or without symptoms (e.g. warmth, erythema, itching)	Interrupt or slow infusion of trilaciclib. If 0.9% normal saline is being used as a diluent/flush, consider changing to 5% dextrose as appropriate for subsequent infusions.
	Grade 2: Pain; lipodystrophy; edema; phlebitis	Interrupt infusion of trilaciclib. If pain not severe, follow instructions for Grade 1. Otherwise, stop infusion in extremity and rotate site of infusion to site in alternative extremity. If 0.9% normal saline is being used as a diluent/flush, consider changing to 5% dextrose as appropriate for subsequent infusions. Central access may also be considered.
	Grade 3: Ulceration or necrosis; severe tissue damage; operative intervention indicated. Grade 4: Life threatening consequences; urgent interventions indicated.	Stop infusion and permanently discontinue trilaciclib.
Acute drug hypersensitivity reactions	Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting Activities of Daily Living	Stop infusion and hold trilaciclib until recovery to Grade ≤ 1 or baseline, then consider resuming trilaciclib. If Grade 2 recurs, permanently discontinue trilaciclib.
	Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL OR Grade 4: Life-threatening consequences; urgent intervention indicated	Permanently discontinue trilaciclib.

AESI	Severity	Recommended Action
ILD/pneumonitis	Grade 2 (symptomatic)	Hold trilaciclib until recovery to Grade ≤ 1 or baseline, then consider resuming trilaciclib. If Grade 2 recurs, permanently discontinue trilaciclib.
	Grades 3: Severe symptoms; limiting self-care ADL; oxygen indicated OR Grade 4: Life-threatening respiratory compromise; urgent intervention indicated (e.g., tracheotomy or intubation)	Permanently discontinue trilaciclib.
Other toxicities	Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL.	Hold trilaciclib until recovery to Grade ≤ 1 or baseline, then consider resuming trilaciclib. If Grade 3 recurs, permanently discontinue trilaciclib.
	Grade 4: Life-threatening consequences; urgent intervention indicated.	Permanently discontinue trilaciclib

AESI=adverse event of special interest; ILD=interstitial lung disease

9.3.4. Hy's Law Management

Abnormal values in AST and/or ALT concurrent with abnormal elevations in total bilirubin that meet the criteria outlined below in the absence of other causes of liver injury are considered potential cases of drug-induced liver injury (potential Hy's Law cases) and should always be considered important medical events.

The threshold of laboratory abnormalities for a potential case of drug-induced liver injury depends on the patient's individual baseline values and underlying conditions. Patients who present with the following laboratory abnormalities should be evaluated further to determine the etiology of the abnormal laboratory values:

- Baseline AST or ALT and total bilirubin values are within the normal range and the patient subsequently presents with AST or ALT $\geq 3 \times$ ULN concurrent with a total bilirubin $\geq 2 \times$ ULN with no evidence of hemolysis and an alkaline phosphatase $\leq 2 \times$ ULN or not available.
- Preexisting ALT OR AST OR total bilirubin values above the upper limit of normal, and the patient subsequently presents with:
 - AST or ALT ≥ 2 times the baseline values and $\geq 3 \times$ ULN, or $\geq 8 \times$ ULN (whichever is smaller)

- Concurrent with total bilirubin increased by one time the baseline value OR $\geq 3 \times$ ULN (whichever is smaller).

The patient should return to the investigational site and be evaluated as soon as possible, preferably within 48 hours from awareness of the abnormal results. This evaluation should include laboratory tests, detailed history and physical assessment. In addition to repeating AST and ALT, laboratory tests should include albumin, creatine kinase, total bilirubin, direct and indirect bilirubin, gamma-glutamyl transferase, prothrombin time (PT)/International Normalized Ratio (INR), and alkaline phosphatase. A detailed history, including relevant information, such as review of ethanol, acetaminophen, recreational drug and supplement consumption, family history, occupational exposure, sexual history, travel history, history of contact with a jaundiced patient, surgery, blood transfusion, history of liver or allergic disease, and work exposure, should be collected. Further testing for acute hepatitis A, B, or C infection and liver imaging (e.g., biliary tract) may be warranted.

All cases confirmed on repeat testing as meeting the laboratory criteria defined above, with no other cause for liver function test (LFT) abnormalities identified at the time should be considered potential Hy's Law cases irrespective of availability of all the results of the investigations performed to determine etiology of the abnormal LFTs. Such potential Hy's Law cases should be promptly reported as SAE via the EDC.

9.4. Supportive Care Interventions

9.4.1. Colony Stimulating Factor Usage

Use of prophylactic colony stimulating factors (e.g., G-CSF; granulocyte-macrophage colony-stimulating factor [GM-CSF]) during Cycle 1 (i.e., prior to the actual Cycle 2 Day 1 dosing visit) is not allowed. In subsequent cycles (Cycle 2 and beyond), prophylactic colony-stimulating factors are allowed as outlined in regional guidelines or consensus (e.g., American Society of Clinical Oncology [ASCO], European Society for Medical Oncology [ESMO], Chinese Anti-Cancer Association) and package inserts/summary of product characteristics.

If in any cycle (including Cycle 1), a patient experiences severe neutropenia (Grade 4) or FN and is at high risk for infection-associated complications or has prognostic factors that are predictive of poor clinical outcomes (Table 11), therapeutic G-CSF/GM-CSF may be used to treat the severe neutropenia or FN event per regional guidelines and package inserts.

Short-acting G-CSF products (i.e., Neupogen or biosimilars) may be administered starting 24 to 48 hours after chemotherapy and must be stopped 48 hours prior to study drug administration in the next cycle. Similarly, Neulasta (or biosimilars) or other long half-life G-CSF products (ex. macapegfilgrastim) may be administered 24 to 48 hours after chemotherapy but due to its prolonged half-life should not be repeated within that cycle. Biosimilars must be approved for use by the national regulatory authority (ex. FDA, European Commission, or the China National Medical Products Administration (NMPA)).

Table 11: Patient Risk Factors for Poor Clinical Outcomes Resulting from Febrile Neutropenia or Infection

Risk Factor
Sepsis syndrome
Age >65 years
Profound neutropenia (absolute neutrophil count $<0.1 \times 10^9/L$)
Neutropenia expected to last >10 days
Pneumonia
Invasive fungal infection
Other clinically documented infections
Hospitalization at time of fever
Prior episode of febrile neutropenia

ASCO=American Society of Clinical Oncology

Source: Table recreated from Table 2 of the ASCO guidelines ([Smith, 2015](#); [Smith, 2006](#)).

9.4.2. Erythropoiesis-Stimulating Agent Usage

If a patient experiences a hemoglobin level <10.0 g/dL or symptomatic anemia during study treatment, ESAs may be used per the current prescribing information ([Bohlius, 2019](#)) ([Procrit[®], 2017](#); [Aranesp[®], 2011](#)).

9.4.3. Transfusions

Red Blood Cells

Based on the NCCN Clinical Practice Guidelines in Oncology for Hematopoietic Growth Factors Version 2.2020 and the AABB Clinical Practice Guidelines, the following RBC transfusion thresholds are recommended ([Carson, 2016](#); [Goel, 2018](#)); however, the patient's clinical situation should always be the primary guiding factor when deciding to transfuse.

- Transfusion is not indicated until the hemoglobin level is ≤ 7 g/dL for hospitalized adult patients who are hemodynamically stable.
- An RBC transfusion threshold of ≤ 8 g/dL is recommended for patients undergoing orthopedic surgery, cardiac surgery, and those with preexisting cardiovascular disease.
- Patients with symptomatic anemia should be transfused per the Investigator discretion regardless of hemoglobin levels.

Platelets

Platelet transfusion is recommended at a threshold of $\leq 10 \times 10^9/L$. Platelets should also be transfused in any patient who is bleeding with a platelet count $<50 \times 10^9/L$ ($100 \times 10^9/L$ for central nervous system or ocular bleeding) ([Kaufman, 2015](#); [Schiffer, 2017](#)).

9.5. Prior/Concomitant Medications and Procedures

All concomitant medications including prescription medications, over-the-counter preparations, growth factors, and blood products from informed consent through 30 days after the last dose of study treatment (Post-Treatment Visit) will be documented, where possible. During the study,

prescription and commercially available products, including traditional Chinese medications, with known or suspected immunomodulatory properties should be used with caution or avoided entirely.

Caution should be exercised with concomitant use of drugs that are substrates for OCT2 with a narrow therapeutic index (Section 4.2.8.1.1).

Any medication that is contraindicated when using docetaxel is not permitted, and special warnings and precautions for use of docetaxel should be observed.

Administration of other concomitant investigational agents for any indication or any live attenuated vaccines is not permitted while on this study. Necessary supportive care (antiemetics, antidiarrheals, chemotherapy premedication, etc.) per the standard of care at the study center will be permitted. See Section 9.4 for guidance on the use of growth factors (colony-stimulating factors and ESAs) during the study.

Administration of other systemic concomitant non-protocol anticancer therapies prior to progression is not permitted while on this study, with the exception of adjuvant endocrine therapy for breast cancer or prostate cancer defined as M0 disease or PSA persistence/recurrence without metastatic disease. This includes any low-dose systemic chemotherapeutic agent given for a nononcologic purpose (e.g., low-dose methotrexate for rheumatoid arthritis). Palliative treatment of a symptomatic lesion(s) is permitted to control disease symptoms but not to aid in the response of the tumor. If the lesion(s) treated is being followed for evaluation by RECIST (target or nontarget lesion), then “not evaluable” should be reported in electronic data capture (EDC) for this lesion at subsequent disease assessments following palliative treatment. Patients requiring palliative therapy may continue receiving study drug until documented disease progression (radiographic or clinical) if, in the Investigator’s opinion, the patient is continuing to receive clinical benefit and they meet the requirements described in Section 9.2. However, for patients who have not had disease progression at the time of the need for palliative radiation therapy or surgery, the requirement for intervention will be regarded as disease progression in the study’s analyses and will be entered as such in the EDC.

Any diagnostic, therapeutic, or surgical procedures performed during the study period will be documented. Documentation will include information regarding the date(s), indication(s), description of the procedure(s), and any clinical or pathological findings, if available.

9.6. Measures to Minimize Bias: Randomization and Blinding

The study will be randomized and double-blind. Patients meeting all inclusion and exclusion criteria will be randomized 1:1 by an Interactive Web Response System (IWRS) according to a randomization schedule generated by an unblinded external statistician. Each patient will be assigned a unique randomization number, which will not be reused. A patient who is randomized and discontinues from the study, even if no study drug was administered, will not be replaced. If a patient does not receive the correct study treatment for their allocated treatment arm, the reason must be clearly documented in the eCRF. The patient will remain on study and continue to receive the same study treatment, all data will be collected, and follow up will continue as described in the Schedule of Assessments.

There will be 2 stratification factors for randomization: country and ECOG performance status (0-1 versus 2). Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2).

Each site will have an unblinded Pharmacist/Designee, who will have access to the treatment assignment. Because the active drug product trilaciclib has a faint yellow color when reconstituted and diluted, additional procedures will be implemented to ensure the blind is maintained for the patient, Investigator, Research Nurse, Study Coordinator, and other blinded site personnel. Details regarding the preparation and administration of trilaciclib/placebo in a manner to maintain the blind will be included in the Pharmacy Manual.

The patients, Investigators, other site staff involved in the clinical care of the patients, and the Sponsor or Designees involved in the conduct of the study will not be aware of the treatment group to which a particular patient has been randomized. If an Investigator determines that a patient's assignment should be unblinded for reasons of safety, this should be discussed with the study Medical Monitor prior to unblinding, unless an urgent and immediate intervention is required that precludes this discussion. If unblinding of the treatment assignment is necessary, the Investigator or Designee will obtain the treatment assignment details from the IWRS. Unblinding of personnel should be limited to the minimum needed for mitigation of safety concern. Following unblinding, patient continuation on study will be determined on a case by case basis. Any unplanned unblinding must be communicated to the Project Manager, Study Statistician, and Sponsor for documentation in the study files and the clinical study report.

If the blinding code is broken, the date and reason for unblinding must be fully documented in source documents and entered on the eCRF. However, every effort should be made by the site staff to ensure that the treatment arm in which the unblinded patient is assigned is not communicated to any sponsor personnel or designee involved in the conduct of the trial.

9.7. Intervention after End of Study Treatment

Following completion of study treatment on the study, patients will receive treatment as determined by their healthcare provider. During Survival Follow-up, the patient (or legally authorized representative where allowed by local regulation) will be contacted to record their status (alive or dead) as well as details of any subsequent systemic anti-cancer therapy initiated (see Section 11.10).

10. DISCONTINUATION OF STUDY INTERVENTION AND PATIENT DISCONTINUATION/WITHDRAWAL

10.1. Discontinuation of Study Treatment

Study drugs will be discontinued if any of the following events occur during the study:

- A patient suffers an AE that, in the judgment of the Investigator, Sponsor, or Medical Monitor, presents an unacceptable risk to the patient
- General or specific changes in the patient's condition (e.g., a significant intercurrent illness or complication) that, in the judgment of the Investigator, are unacceptable for further administration of study drug
- Occurrence of pregnancy during the study
- Significant noncompliance with protocol requirements
- The Sponsor or legal representative of the Sponsor requests the patient to withdraw
- Patient has documented disease progression (radiographic or clinical progression). See Section 9.5 for details regarding palliative therapy.
- If total time between chemotherapy treatments exceeds a total of >5 weeks, unless agreed to by the treating Investigator and Medical Monitor.
- Where permanent discontinuation of all study drugs is indicated in the toxicity management recommendations

At the time of study drug discontinuation, a Post-Treatment Visit should be completed with assessments performed as shown in the Schedule of Assessments (Table 6). The Investigator or Designee will document the reason for study drug discontinuation on the applicable eCRF. When discontinuation is due to a SAE or a Grade 3 or 4 toxicity considered to be related to study medication, the Investigator should follow the event until resolution, return to baseline, or it is deemed that further recovery is unlikely. Data on these events should be collected on the AE eCRF. In the event a patient discontinues due to pregnancy, the Investigator or designee should notify the Medical Monitor by telephone within 24 hours of pregnancy confirmation (see Section 17.3).

For those patients who have not progressed clinically or radiologically at the time of study drug discontinuation, every effort should be made to continue radiological tumor assessments every 12 weeks (± 7 days) during survival follow-up, utilizing the same imaging modality as used at Screening as outlined in the Schedule of Assessments (Table 6), until progressive disease, initiation of subsequent anti-cancer therapy, withdrawal of consent, or study completion, whichever occurs first. Results of these scans should be assessed by RECIST v1.1 and data entered in EDC in the corresponding tumor assessment forms.

10.2. Discontinuation/Withdrawal from the Study

A patient may withdraw from the study at any time at his/her own request or may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons. At the time of discontinuing from the study, if patient has not already

discontinued study intervention, a Post-Treatment Visit should be completed with assessments performed as shown in the Schedule of Assessments (Table 6).

If the patient withdraws consent for disclosure of future information, the Sponsor may retain and continue to use any data collected before such a withdrawal of consent.

If a patient withdraws from the study, he/she may request destruction of any samples taken and not tested, and the Investigator or designee must document this in the site study records.

If a patient withdraws consent for further study procedures, the site should clarify if the patient (or legally authorized representative where allowed by local regulation) remains open to survival contact and associated data collection. Public records may be used to verify survival status if permitted by institutional or country guidelines.

10.3. Lost to Follow-Up

A patient will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site.

In general, a patient is considered lost to follow-up after there are at least 3 documented attempts to contact the patient. It is recommended that 1 attempt is via certified letter to the patient.

10.4. Study and Site Start and Closure

The overall study begins when the first patient signs the informed consent form. The overall study ends when the last patient completes the last study-related phone-call or visit, discontinues from the trial or is lost to follow-up (i.e., the subject is unable to be contacted by the investigator).

A study site is considered eligible to start participation in the study once all regulatory approvals are in place, site agreement contract is fully executed, and any other required documents are in place as required by Sponsor.

The end of study is event driven. That is, the study will continue until the targeted number of deaths is observed. There is an interim analysis for OS planned when approximately 73 patients have died. If the interim results demonstrate a statistically significant effect of trilaciclib over placebo for OS based on pre-specified criterion, the study will be stopped early due to success. Otherwise, the study will continue and be considered complete when the targeted number of deaths have occurred for the final OS analysis (approximately 104 deaths), or upon sponsor termination of the study.

The Sponsor's designee reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected, a study-site closure visit has been performed, and the site has closed all regulatory activities with the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).

The Investigator may be requested to initiate study-site closure at any time, provided there is reasonable cause and sufficient notice is given in advance of the intended termination. Should

this occur with patients receiving study drug, the patients will transition to receive standard of care treatment by their healthcare provider outside of this study.

Reasons for the early closure of a study site by the Sponsor or Investigator may include but are not limited to:

- Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the Sponsor's procedures, or Good Clinical Practice (GCP) guidelines
- Inadequate recruitment of patients by the Investigator
- Discontinuation of further development of trilaciclib

If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the Investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) used in the study of the reason for termination or suspension, as specified by the applicable regulatory requirements. The Investigator shall promptly inform the patient and should assure appropriate patient therapy and/or follow-up.

11. STUDY ASSESSMENTS

Study procedures and their timing are summarized in the Schedule of Assessments (Table 6). Adherence to the study design requirements, including those specified in the Schedule of Assessments, is essential and required for study conduct. Immediate safety concerns should be discussed with the study Medical Monitor upon occurrence or awareness to determine if the patient should continue or discontinue study intervention.

The Investigator or Designee will maintain a screening log to record details of all patients screened and to confirm eligibility or record reasons for screening failure, as applicable.

Procedures conducted as part of the patient's routine clinical management (e.g., hematology, clinical chemistry) and obtained before signing of the ICF may be utilized for screening or baseline purposes provided the procedures met the protocol-specified criteria and are performed within the permitted 28-day Screening period.

11.1. Screening Assessments

The following information for screening failures should be recorded into appropriate eCRFs: patient ID, demographic data, and reason for failing the screening process. Patients may only be rescreened one time at the discretion of the Investigator. For abnormal laboratory values, a second test to confirm the first is permitted.

11.1.1. Randomization

Eligibility should be determined prior to randomization and the start of study treatment. All eligible patients will be randomly allocated according to the randomization schedule and will receive a unique randomization number. Once a randomization number is assigned to a patient, it can never be re-assigned to another patient.

Eligible patients will be instructed on all protocol requirements, including any restrictions on concomitant medication usage.

Randomization will be performed via IWRS and can be completed up to 3 days prior to the first dose of trilaciclib or placebo + docetaxel therapy, following confirmation that the patient is eligible for the study. Patients can also be randomized and receive Cycle 1 Day 1 on the same day. When required by institutional procedures, randomization will be allowed up to 7 days prior to dosing without a protocol deviation. Screening procedures must be completed prior to randomization and the screening window remains 28 days.

11.1.2. Demographics

Age, gender, race, and ethnicity will be collected during the Screening period.

11.1.3. Medical History and NSCLC Cancer Disease History

Medical and surgical history, including past and current conditions, will be collected. Concomitant medications taken from informed consent through 30 days after the last dose of study treatment will be recorded. Prior medications (those taken within 14 days of informed consent will also be recorded.

Documentation of NSCLC history, including date of diagnosis and histologic type, as well as prior therapy (ex. surgery, radiation, systemic chemotherapy, immunotherapy) for NSCLC will also be recorded. PD-L1 status will be collected and recorded where available.

11.2. Anti-tumor Efficacy Assessments

11.2.1. Anti-tumor Efficacy Assessment

All sites of measurable and non-measurable disease must be documented at Screening and re-assessed at each subsequent tumor evaluation. Tumor assessment will be performed at the timepoints specified in the Schedule of Assessments ([Table 6](#)) relative to Cycle 1 Day 1, regardless of drug (cycle) delays.

Baseline imaging should include computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen, pelvis, and brain. IV contrast should be used unless contraindicated. Any CT or MRI obtained as standard of care prior to Screening visit will not need to be repeated as long as those imaging tests were obtained within 28 days prior to the date of randomization.

After baseline tumor assessments (Screening assessment within 28 days), evaluation of tumor response per RECIST v1.1 will be performed every 6 weeks following Cycle 1 Day 1 (± 7 days) during study drug administration (including imaging of the chest, abdomen, and pelvis [and brain if metastasis present at Screening or if symptoms develop]), with additional scans performed as clinically indicated. Post-baseline tumor assessments should use the same imaging modality as at Screening. IV contrast should be used unless contraindicated. Tumor assessments will continue until disease progression, withdrawal of consent, initiation of subsequent anti-cancer therapy, or the end of study, whichever occurs first.

For those patients who have not progressed clinically or radiologically at the time of study drug discontinuation, every effort should be made to continue radiological tumor assessments every 12 weeks (± 7 days) during survival follow-up, utilizing the same imaging modality as used at Screening, until the occurrence of progressive disease, withdrawal of consent, initiation of subsequent anticancer therapy, or study completion.

Tumor response criteria will be based on RECIST v1.1 ([Eisenhauer, 2009](#)) as cited in Section [17.4](#). A partial or complete response should be confirmed by a repeat scan at the next scheduled tumor assessment per RECIST v1.1.

During the course of this study, scans may be collected and sent/uploaded to the Sponsor or Designee for storage. Centralized storage is intended for possible blinded independent central review (BICR) of disease assessments. At the discretion of the Sponsor, BICR of all scans by RECIST v1.1 may be conducted retrospectively. The blinded review will include all patients with available images. However, the raw images for patients enrolled in China cannot be stored outside of China and therefore these images will be stored in the server in China for central imaging review if approved by the related authority. If needed, guidelines for imaging collection and storage will be provided in a separate document. The clinical management of patients will be based solely upon the results of the assessment conducted by the Investigator based on RECIST v1.1 per protocol.

11.2.2. Myelopreservation Assessments

The myelopreservation effects of trilaciclib administered prior to docetaxel compared with placebo administered prior to docetaxel will be evaluated based on the following: kinetics of changes in CBCs (including DSN in Cycle 1 and rate of SN); hematologic toxicities, including FN; RBC and platelet transfusions; hematopoietic growth factor utilization; infections and systemic antibiotic use. All of these variables will be assessed as described in the safety assessments (monitoring of AEs, clinical laboratory assessments, and concomitant medications).

11.3. Safety Assessments

Unless specified otherwise, safety assessments should be conducted prior to study drug administration.

11.3.1. Vital Signs

The following will be collected per the Schedule of Assessments (Table 6) 15 minutes (+/- 10 minutes) before and after the trilaciclib/placebo infusion:

- Body temperature, pulse rate, blood pressure (diastolic and systolic)

11.3.2. Physical Examination

Full physical examination at Screening should include general appearance, height in centimeters, body weight in kilograms, skin, neck, eyes, ears, nose, throat, lungs, heart, abdomen, lymph nodes, extremities, and neurological examinations. Subsequent physical exams should include body systems as determined by provider (e.g., brief physical exam) and weight.

Information about the physical examination must be present in the source documentation at the study site. Clinically relevant findings observed **prior** to the start of study drug, should be recorded as medical history. Clinically relevant findings observed **after** the start of study drug, which meet the definition of an AE, must be recorded on the AE eCRF.

Assessments may be performed by a physician, registered nurse, or other qualified health care provider.

11.3.3. ECOG Performance Status

The Investigator or qualified designee will assess ECOG performance status during the Screening Period to assess for eligibility according to the inclusion and exclusion criteria (Table 12) as well as to monitor performance throughout the study (Table 6).

Table 12: ECOG Performance Status

Grade	ECOG
0	Fully active, able to carry on all pre-disease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
2	Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours
3	Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4	Completely disabled. Cannot carry out any selfcare. Totally confined to bed or chair
5	Dead

ECOG=Eastern Cooperative Oncology Group

Source: [Oken, 1982](#).

11.3.4. Electrocardiogram

Single standard 12-lead ECGs will be performed as outlined in the Schedule of Assessments ([Table 6](#)) on Day 1 of Cycles 1 and 2 at the following timepoints: predose (any time prior to trilaciclib/placebo on the day of dosing) and at the end of trilaciclib/placebo infusion (within 30 minutes following the infusion but prior to initiation of docetaxel infusion). Additional ECGs may be performed as clinically indicated at any time during the study.

All 12-lead ECGs will be obtained after the patient has been resting for at least 5 minutes and shall be recorded at 25 mm/sec. All ECGs for an individual patient shall be recorded with the patient in the same physical position.

Any ECG with a QTc value of >500 msec shall have the QTc value confirmed via manual read. A repeat ECG in triplicate (over approximate 5 minute period) should also be obtained for confirmation. The Investigator or qualified designee should review the ECGs for any abnormalities as compared with the baseline ECG. Following confirmation, the Investigator should evaluate for any other potential causes of the prolongation (e.g., concomitant medications) and determine the appropriate clinical course.

11.3.5. Clinical Safety Laboratory Assessments

Hematology, clinical chemistry, and serum or urine pregnancy test will be performed at the site's local certified laboratory per the schedule outlined in the Schedule of Assessments ([Table 6](#)).

Any consideration for laboratory assessments to be performed at an alternate laboratory outside of the facilities identified for the conduct of the study may impact the integrity of the study data. As such, any such testing should be discussed with the study Medical Monitor and considered as a means to continue appropriate testing for the safety of the patient during COVID-19 restrictions. Clinical laboratory samples may be collected from patients at a different location than the Investigator's clinic following approval by the Medical Monitor. A list of clinical laboratory tests to be performed is provided in [Section 17.1](#). Hematology may be obtained up to 24 hours and serum chemistry may be obtained up to 72 hours prior to each time point on

Schedule of Assessments but must be reviewed before dosing. Laboratory toxicities will be assessed using the NCI-CTCAE, v5.0.

For women of childbearing potential, pregnancy tests will be performed as follows: serum beta human chorionic gonadotropin (β -hCG) at Screening (must be performed during window allowing randomization in IWRS and negative results should be available prior to randomization) and serum or urine β -hCG prior to the start of each cycle thereafter, as well at the post-treatment visit.

An abnormal laboratory value is not an AE unless it is considered to be clinically significant. Whether a clinically significant laboratory value is also an adverse event will be determined by the investigator. Laboratory parameters for which clinically significant values are noted will be re-measured on the appropriate clinical follow-up arranged by the Investigator. Any laboratory value that remains abnormal at the end of the study and that is considered clinically significant should be followed according to accepted medical standards for up to 30 days or until the values return to normal or baseline or are no longer considered clinically significant by the Investigator. If such values do not return to normal/baseline within a period of time judged reasonable by the Investigator, the etiology should be identified, and the Medical Monitor notified.

If a subsequent cycle is delayed for toxicity, the patient should still complete the clinical laboratory assessments on the scheduled Day 1 (entered as an Unscheduled assessment in EDC) as well as on the actual first dosing day of that cycle. If the delay is secondary to hematologic toxicity, weekly repeat hematology assessments should continue until the finding meets criteria for resumption of dosing (see Section 9.3.2; Table 9).

11.3.6. Adverse and Serious Adverse Events

The Investigator and any qualified designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE and remain responsible for following up, as applicable, AEs that are serious, considered related to the study drugs or study procedures, or that caused the patient to discontinue the study or study drugs (see Section 10.1). Patients should be encouraged to report AEs freely or in response to general, nondirected questioning. Adverse events (serious and non-serious) should be reported on the appropriate page of the eCRF. Toxicity will be assessed by Investigators using NCI-CTCAE v5.0.

11.3.6.1. Time Period and Frequency for Collecting Adverse and Serious Adverse Event Information

AEs will be collected starting from the first dose of study drug through the Post-Treatment Visit. Any SAE occurring between the date the patient signs informed consent and the first dose of any study drug, and which the Investigator feels is related to a study specific procedure (i.e., would not have occurred unless the patient was on the study), should also be reported. Any AEs that occur between the date of signing informed consent and the first dose of study drug should be recorded as Medical History.

All SAEs will be recorded and reported to G1 Therapeutics, Inc. Pharmacovigilance (PVG) or designee immediately and should not exceed 24 hours after becoming aware of the event, as indicated in Section 17.2.

Investigators are not obligated to actively seek AE or SAE information after 30 days following the last dose of study drugs on this study. However, if the Investigator learns of any SAE, including a death, at any time after a patient has been discharged from the study, and he/she considers the event to be reasonably related to the study intervention or study participation, the Investigator or designee must promptly notify G1 Therapeutics, Inc. PVG or designee.

11.3.6.2. Method of Detecting Adverse and Serious Adverse Events

The method of recording, evaluating, and assessing causality of AE and SAE and the procedures for completing and transmitting SAE reports are provided in Section [17.2](#).

Care should be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and nonleading verbal questioning of the patient is the preferred method to inquire about AE occurrences.

11.3.6.3. Follow-up of Adverse and Serious Adverse Events

After the initial AE/SAE report, the Investigator is required to proactively follow each patient at subsequent visits/contacts. All AEs (both serious and nonserious) will be followed in accordance with good medical practice until resolution, return to baseline, or it is deemed that further recovery is unlikely. All measures required for AE management and the ultimate outcome of the AE will be recorded in the source document and reported to G1 Therapeutics, Inc.

All SAEs will be followed until resolution, stabilization, the event is otherwise explained, or the patient is lost to follow-up (as defined in Section [10.3](#)). Further information on follow-up procedures is provided in Section [17.2](#).

11.3.6.4. Regulatory Reporting Requirements for Serious Adverse Events

Prompt notification of G1 Therapeutics, Inc. PVG or designee by the Investigator (or designee) of a SAE is essential so that legal obligations and ethical responsibilities towards the safety of patients and the safety of a study intervention under clinical investigation are met.

G1 Therapeutics, Inc. has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. G1 Therapeutics, Inc. will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, Central IRB/IEC, and Investigators. For all studies, except those utilizing medical devices, Investigator safety reports must be prepared for suspected unexpected serious adverse reactions (SUSAR) according to local regulatory requirements and G1 Therapeutics, Inc. policy and forwarded to Investigators, as necessary.

An Investigator who receives an Investigator safety report describing a SAE or other specific safety information (e.g., summary or listing of SAEs) from G1 Therapeutics, Inc. or designee will review and then file it along with the Investigator's Brochure and will notify the IRB/IEC, if appropriate according to local requirements.

11.3.6.5. Pregnancy

Details of all pregnancies in female patients and female partners of male patients will be collected after the start of study intervention and until 30 and 120 days respectively, after the last dose of study drug.

If a pregnancy is reported, the Investigator or designee should inform G1 Therapeutics, Inc. PVG or designee within 24 hours of learning of the pregnancy and should follow the procedures outlined in Section 17.3.

Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.

11.4. Patient-Reported Outcomes

The PRO items below will be self-administered by patients, overseen by a designated study site staff member. PRO questionnaires should be completed on Days 1 and 13 of Cycle 1 and Day 1 of each subsequent cycle and at the Post-Treatment Visit, except for the Patient Global Impression of Change (PGIC) which is not administered on Day 1 of Cycle 1, per the schedule outlined in the Schedule of Assessments (Table 6).

The PRO questionnaires should be completed on both the planned Day 1 visit and on the actual Day 1 of the cycle (i.e., when dosing is delayed and criteria are then met to proceed with Day 1 treatment). PRO questionnaires may be administered up to 1 calendar day prior to each dosing day and are to be completed on the same day a blood sample is collected for hematology assessment. Questionnaires administered on Cycle 1 Day 13 may be obtained ± 1 day of scheduled visit. Questionnaires should be completed before treatment administration, and where possible before any laboratory tests or other procedures that are performed that day.

11.4.1. EORTC QLQ-C30 and EORTC QLQ-LC13

The EORTC QLQ-C30 and QLQ-LC13 are validated instruments that will be administered on the days outlined in the Schedule of Assessments (Table 6).

The EORTC quality of life questionnaire (QLQ) is an integrated system for assessing the health-related quality of life (QoL) of cancer patients participating in international clinical trials (Aaronsen, 1993). The core questionnaire, the QLQ-C30, includes 30 items that address symptoms and functional impacts that are applicable across cancer populations. The QLQ-C30 yields 15 domains assessing global health status, symptoms (e.g., fatigue, nausea and vomiting), and function (e.g., physical functioning, emotional functioning). Each domain is scored on a 0-100 scale. The detailed scoring algorithm is included in the scoring manual (Fayers, 2001).

The EORTC QLQ-LC13 is a supplemental module that was designed for use among a wide range of lung cancer patients varying in disease stage and treatment modality (Bergman, 1994). The QLQ-LC13 incorporates one multi-item scale to assess dyspnea, and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. Domains are scored on a 0-100 scale. The open-ended item assessing location of pain and the item asking about the use and effect of pain medications will not be included in the QLQ-LC13 version to be administered in this trial, as it is not used in the scoring of the measure. A supplemental item from the EORTC Item Library addressing weight loss (“Has weight loss been a problem for you?”) will be added to the QLQ-LC13. The scoring algorithm is described in the scoring manual (Fayers, 2001).

11.4.2. FACIT-Fatigue

The FACIT-Fatigue (Yellen, 1997) is a 13-item measure that measures the severity of fatigue (e.g., “I feel fatigued,” “I feel tired”) and the impact of fatigue on functioning (e.g., “I have trouble starting things because I am tired,” “I need to sleep during the day”). Patients rate their experiences over the “past 7 days” using a 0-4 verbal rating scale (“Not at all” to “Very Much”). The FACIT-Fatigue is scored as a sum of all 13 of the item responses; the scale range is from 0-52. After appropriate reverse scoring of 11 items, lower scores on the FACIT-F indicate greater levels of fatigue.

11.4.3. Patient Global Impression of Change and Patient Global Impression of Severity

The PGIC and Patient Global Impression of Severity (PGIS) items will be self-administered on the days outlined in the Schedule of Assessments (Table 6). The PGIC item will ask the patient to rate the change in their fatigue since taking study drug on a 7-point scale ranging from -3 (very much worse) to 3 (very much better). The PGIS item, will ask the patient to rate the overall severity of their fatigue over the past week on a 5-point scale ranging from 0 (none) to 4 (severe).

11.4.4. 5-Level EQ-5D

The EQ-5D-5L will be provided to patients for self-administration on the days outlined in the Schedule of Assessments (Table 6). The 5-level EQ-5D (EQ-5D-5L) is a standardized instrument by which treatment effects can be assessed by measuring health status at different points in time, e.g., before and after treatment, and then investigating the gains (or losses) in reported health status. The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS). For the EQ-5D, respondents will rate their health on each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The patient will be asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient’s health state. The EQ-VAS records the patient’s self-rated health on a vertical visual analogue scale, where the endpoints are labelled “The best health you can imagine” and “The worst health you can imagine”. The VAS can be used as a quantitative measure of health outcome that reflect the patient’s own judgement.

11.5. Pharmacokinetics

Blood samples for PK analysis will be collected as indicated in the Schedule of Assessments (Table 6) from all patients. Three blood samples for PK analysis of trilaciclib will be collected: on Cycle 1 Day 1 at the end of trilaciclib/placebo infusion (sample can be taken up to 15 minutes prior to the end of infusion), at 30 minutes post the end of trilaciclib/placebo infusion (± 15 minutes) and at 4-6 hours post the end of the trilaciclib/placebo infusion.

Three samples will also be collected for PK analysis of docetaxel: on Cycle 1 Day 1 at the end of docetaxel infusion (sample can be taken up to 15 minutes prior to end of infusion), 2 hours after end of docetaxel infusion (± 30 minutes) and at 4-6 hours post the end of the docetaxel infusion.

The actual date and time of each blood sample collection, the scheduled timepoint of collection, and the time of dose administration prior to the pharmacokinetic sample will be recorded. Details of PK blood sample collection including volume to be collected, timing of samples, processing, storage, and shipping procedures are provided in the Laboratory Manual. Blood samples for PK analysis may be collected from patients at a different location than Investigator's clinic.

11.6. Biomarkers

11.6.1. Rationale for Archival Tumor Collection

Because trilaciclib maintains G1 arrest in CDK4/6 dependent cells, there is a hypothetical risk that trilaciclib could antagonize the anti-tumor efficacy of cytotoxic chemotherapy by maintaining a G1 cell cycle arrest of CDK4/6 dependent tumor cells during chemotherapy. While the currently available nonclinical and clinical data indicate that this risk remains hypothetical and does not influence the overall benefit/risk assessment for combining trilaciclib with chemotherapy, this study will evaluate in a retrospective fashion the relationship between CDK4/6 status and measures of anti-tumor efficacy; the planned statistical analyses are described in Section 12.4.9.

To support these analyses, prior to signing the informed consent, a FFPE archival tumor specimen with an associated pathology report documenting NSCLC (recurrent/metastatic preferred) for each patient must be confirmed to be available to send to a central storage facility for planned retrospective biomarker analyses collection. Tumor tissue must consist of a minimum of 15 slides (preferably 20) or a fixed paraffin block with a depth of at least 75 microns unless approved by the Medical Monitor. If archival tissue is not available, a fresh biopsy must be obtained. Acceptable samples include core needle biopsies, tumor tissue - excisional or incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions. Fine-needle aspiration, brushing, cell pellet from pleural effusion, bone metastases, and lavage samples are not acceptable. Additional guidance is provided in the Laboratory Manual.

In addition to CDK4/6 status as described below, tumor PD-L1 status (positive or negative) will be determined and anti-tumor efficacy endpoints by PD-L1 status will be evaluated. Any remaining tumor tissue following the described analyses will be banked and may be analyzed for relevant DNA, ribonucleic acid (RNA), or protein biomarkers and their role in cancer, including to better understand immune-related mechanisms.

Note: No tumor tissue will be archived for study centers in China.

11.6.2. Description of CDK4/6 Signature

In order to characterize this hypothetical risk in a tumor type without a clear CDK4/6 response phenotype, archival tumor tissue will be collected from patients' most recent biopsy (NSCLC primary or metastatic site) and subjected to a genetic signature analysis based on published literature in an effort to characterize patient tumors into one of the following three groups (Gong, 2017; Shapiro, 2017):

- CDK4/6 independent
- CDK4/6 dependent
- CDK4/6 indeterminate

The evaluation of the relationship between CDK4/6 status and anti-tumor outcomes may be performed when the final OS analysis is performed, that is, when the predicted death events are observed. The use of mature OS data, in addition to the ORR and PFS data, will allow for a more robust interpretation of the relationship between CDK4/6 status and anti-tumor outcomes without the complication of trying to draw conclusions with inadequate information (i.e., immature anti-tumor efficacy data).

This timing is considered to be appropriate since all currently available data indicate that if there is a risk, it is not clinically relevant; therefore, waiting until mature OS data does not pose a significant hazard to the enrolled patients, particularly since the percentage of patients at risk for a potential negative outcome (i.e., who have CDK4/6 dependent tumors) is predicted to be <10% (Section 4.2.7).

11.7. Immunologic and Hematologic Markers

Blood samples for biomarker analysis will be collected at the time points indicated in the Schedule of Assessments (Table 6) from all patients.

Chemotherapeutic agents may elicit part of their anti-tumor efficacy by modulating the immune system to enhance antigen presentation, uptake, and processing; prime the immune response through immunodepletion; inhibit regulatory cells; and stimulate immune effector cells (Zitvogel, 2008; McDonnell, 2011; Bracci, 2014). Conversely, immunosuppression from direct cytotoxicity to the bone marrow and immune system over repeated cycles of chemotherapy may counterbalance the positive immunostimulatory effects of chemotherapy. Therefore, therapeutic approaches to maintain bone marrow health and immune system function should enhance the immune-mediated anti-tumor activity.

Trilaciclib and other CDK4/6 inhibitors have been shown to augment anti-tumor responses in preclinical settings (Klein, 2018) by enhancing T-cell activation through modulation of nuclear factor of activated T-cell activity (Deng, 2018), as well as increasing antigen presentation through upregulation of MHC class I and II in CDK4/6-sensitive tumors and myeloid cells (Goel, 2017; Schaer, 2018). Additionally, CDK4/6 inhibition can upregulate and stabilize the protein expression of PD-L1 on tumor cells (Zhang, 2018).

To evaluate the impact of trilaciclib administration on chemotherapy-induced changes of the immune and hematopoietic system, immunophenotypic and hematologic changes will be compared (as data warrant) between trilaciclib and placebo on patients receiving docetaxel therapy. To assess these changes, peripheral blood will be collected per the timepoints in the Schedule of Assessments (Table 6). At each time point (Cycle 1 Day 1, Cycle 1 Day 9, Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 5 Day 1), collection should occur prior to trilaciclib dosing.

These blood samples will be banked and may be analyzed for relevant DNA, RNA, or protein biomarkers and their role in cancer. Samples may be stored for up to 10 years if patients sign the consent form and allow their samples to be stored for any future research. Note: No blood will be archived for study centers in China.

11.8. Data Monitoring Committee

An unblinded, independent Data Monitoring Committee will monitor accumulating safety and disposition data with the first meeting planned for when approximately 20 patients have enrolled

and completed at least 2 cycles of study treatment. The meetings will continue approximately every 4 months while patients are on study treatment depending upon the enrollment rate. Additional reviews may occur based on DMC requests.

A DMC charter will define the roles and responsibilities of the DMC and its members. Additional details regarding the committee's composition, scope, objectives, procedures and policies, including detailed data analysis plan and strategy for maintaining study blind for the Sponsor, Investigators and patients, are described in the DMC charter. The DMC will monitor accumulating safety and disposition data entirely independent of the conduct of the study.

11.9. Post-Treatment Visit

When a patient permanently discontinues study treatment, the patient should complete a Post-Treatment Visit 30 days (\pm 7 days) from last dose of study drug as outlined in [Table 6](#).

11.10. Survival Follow-up Phase

Starting from the last dose of study drug, the patient will be followed approximately every 2 months for survival. Survival Follow-up Visits can be via telephone, email, or clinic visits.

For those patients who have not progressed clinically or radiologically at the time of study drug discontinuation, every effort should be made to continue radiological tumor assessments every 12 weeks (\pm 7 days) during survival follow-up, utilizing the same imaging modality as used at Screening, as outlined in the Schedule of Assessments ([Table 6](#)), until progressive disease, initiation of subsequent anti-cancer therapy, withdrawal of consent, or study completion, whichever occurs first.

Information will be collected until the end of the study (or death) to record their status (alive or dead). In addition, details of any subsequent systemic anti-cancer therapy initiated, including name(s) of agent(s), dates (start/stop) administered, best response to the treatment, and date of progression should also be reported to the best of their ability.

If a patient withdraws consent for further study procedures, the site should clarify if the patient (or legally authorized representative where allowed by local regulation) remains open to survival contact and associated data collection. Provided that the patient has not withdrawn consent for follow up contact, information from medical records may be substituted for phone or other contact, provided that records are available as source documentation. Public records may be used to verify survival status if permitted by institutional or country guidances.

12. STATISTICAL CONSIDERATIONS

Full details on the statistical analyses to be performed will be provided in a separate statistical analysis plan (SAP).

12.1. Sample Size Determination

The sample size is determined to support the primary objective of the study. That is, to evaluate the effect of trilaciclib compared to placebo on the overall survival of patients with metastatic NSCLC receiving docetaxel in the 2nd/3rd line setting. A total of 104 deaths will be required to achieve 85% power to detect a hazard ratio (HR) of 0.55 in OS at a 2-sided significance level of 0.05. A HR of 0.55 corresponds to a median OS of 16.5 months for the trilaciclib group assuming a median OS of 9.1 months for the placebo group (Garon, 2014). With a 12-month enrollment period and a 30-month study duration (after the first patient is randomized), a total of 146 patients are required for randomization at a 1:1 ratio to trilaciclib or placebo. This sample size has taken into consideration an interim analysis for OS at the information fraction of 0.70 using the O'Brien-Fleming method for α -spending to ensure strong control of Type I error rate at 1-sided 0.025 between the interim and the final analysis for OS. In the sample size calculation, it is also assumed that about 5% of patients are lost-to-follow-up during the 30-month study duration. EAST[®] v6.5 is used for the power and sample size calculations.

12.2. Analysis Population

The intent-to-treat (ITT) population includes all randomized patients. Analyses for the ITT population will be conducted according to the randomly assigned treatment regardless of whether the patient received study treatment or was compliant with the protocol. Unless otherwise specified, the ITT population is the primary analysis population for all efficacy analyses.

The Response Evaluable (RE) population includes all patients who are in the ITT population and who have measurable (target) tumor lesion(s) at the baseline tumor assessment and either (i) have at least 1 post-baseline tumor assessment, or (ii) do not have post-dose tumor assessment but have clinical progression as noted by the Investigator, or (iii) died due to disease progression prior to their first post-baseline tumor scan. Analyses using this analysis population will be conducted according to the randomly assigned treatment. The RE population will be the primary analysis set for tumor response analyses.

The safety population includes all randomized patients who received at least 1 dose of study drug. Analyses using the safety population will be conducted according to the actual treatment received. All safety analyses will be evaluated using the safety population.

The pharmacokinetic (PK) population will include all patients who received at least one dose of study drug and had evaluable PK data.

12.3. Timing of Planned Analysis

12.3.1. First Planned Analysis – Interim Analysis for Overall Survival and Analyses for Progression Free Survival, Tumor Responses and Myelosuppression Endpoints

The first planned analysis will take place primarily to perform the interim analysis for OS. The timing of this analysis will be based on the timing when 73 deaths are observed. Following the

assumptions that are used in the sample size calculation (Section 12.1), this analysis might be conducted approximately 19 months after the first patient is randomized.

Per literature, the expected median PFS for patients receiving docetaxel is 3 months (Garon, 2014). Assuming trilaciclib can achieve a treatment effect of HR of 0.60, it is estimated that at the time of performing the OS interim analysis, 86% of patients would have had radiographic-determined disease progression or died. Therefore, the analysis for PFS will be conducted at the time when the OS interim analysis is conducted since the PFS events are considered mature. It is also anticipated that the treatment effect on tumor response will be mature at this time. The study database will be locked to perform the OS interim, PFS, tumor response, and myelopreservation analyses. The G1 study team will be unblinded to the results.

If the interim OS analysis result is positive as determined by the pre-specified statistical criterion, the study will be stopped for success and the OS analysis results are considered final. If the interim OS analysis result does not meet the criterion of success, the study will continue until a total of 104 deaths are observed.

12.3.2. Second Planned Analysis – Final Analysis for Overall Survival and Safety Data Analyses

At the time when 104 deaths are observed, the study database will be locked to perform the final analysis for OS. This will be the closure of the study. Safety data and anti-tumor efficacy evaluation by CDK 4/6 status and other exploratory analyses will be performed at this time. Under the assumptions used in sample size calculation (Section 12.1), this analysis could be performed approximately 30 months after the first patient is randomized.

It is expected that PFS data are mature at the time of performing the OS interim analysis (i.e., the first planned analysis). However, if the percentage of patients with a radiographic determined disease progression or death at the time of the first planned analysis is less than 80%, PFS will be analyzed again at this time and the results from this analysis will be considered as primary to interpret trilaciclib's effect on PFS in this study.

12.4. Statistical Analysis Methods

A SAP will be developed and finalized prior to the first database lock of the study and will include more details related to the statistical analysis of data collected in this study. This section is a summary of the key aspects of the planned statistical analyses.

12.4.1. General Considerations

Data will be summarized by treatment group. The descriptive summary for the categorical variables will include counts and percentages. The descriptive summary for the continuous variables will include means, medians, standard deviations, 25% and 75% percentiles, and minimum and maximum values.

There are two stratification factors for randomization: country and ECOG performance status (0-1 versus 2). A randomization schema will be in place to ensure the best possible balance of treatment assignment within each stratum produced by these stratification factors. Countries will be grouped into the factor of “region” with 3 components: US, Europe, and Asia. The factor “region” will be used instead of “country” in the statistical analysis models to account for

regional differences in clinical practice. Unless otherwise specified, ECOG status as entered in IWRS at the time of randomization will be used as the factor for all stratified analyses.

12.4.2. Patient Disposition

Patient disposition will be summarized for all patients by treatment group and overall. The summary will include number of all screened patients, and number and percentage of patients who were randomized, received study drug, discontinued from the study drug with the reasons, and discontinued from study with the reasons.

12.4.3. Demographic and Baseline Characteristics

Demographics and baseline characteristics will be summarized for the ITT population by treatment group and overall. The demographics to be summarized include age, age group (<65 versus ≥65 years old), gender, race, ethnicity, and region. The baseline characteristics to be summarized include ECOG status, NSCLC history (date of diagnosis, histologic type, and prior therapies by line (eg, surgery, radiation, systemic chemotherapy, or immunotherapy). In addition, the recorded PD-L1 status at the screening visit will also be summarized along with vital signs at the screening visit (body weight, body mass index [BMI], BSA).

12.4.4. Prior and Subsequent Anticancer Therapies

Prior and subsequent anticancer therapy verbatim terms will be coded to Anatomical Therapeutic Classification (ATC) and preferred term (PT) using the latest version of World Health Organization-Drug Dictionary (WHO-DD) for the ITT population. Summary statistics will be provided for prior systemic anti-cancer therapies given in different setting (1st line or 2nd line) by treatment group and overall. For the subsequent systemic anti-cancer therapies, the lines of therapy, response to each treatment regimen, and disease progression status will also be summarized by treatment group and overall.

12.4.5. Study Drug Exposure, Modification and Dose Intensity

The summary described below will be based on the safety population.

Duration of study drug exposure will be calculated for docetaxel and for trilaciclib/placebo by treatment group.

For each treatment group, the number of cycles that patients have received will be summarized by descriptive statistics as a continuous variable, while the number of cycles that are completed will be summarized as a categorical variable.

Study drug modifications will be summarized by treatment group in three categories: chemotherapy dose reductions, chemotherapy cycle delay, and infusion interruption. The number and percentage of patients who have at least one dose reduction for docetaxel will be summarized along with a summary of the number of dose reductions that have occurred; the number and percentage of patients who have at least one cycle delay will be summarized along with a summary of the number of cycles that have been delayed; the number and percentage of patients who have at least one infusion interruption for trilaciclib/placebo or docetaxel will be summarized along with a summary of the number of interruptions. Lastly, the primary reason for

each form of study drug modification (docetaxel dose reduction, cycle delay, and infusion interruption) will also be summarized by treatment group.

For trilaciclib/placebo and docetaxel, respectively, cumulative dose, dose intensity, relative dose, and relative dose intensity will be derived and summarized by treatment group.

12.4.6. Efficacy Analyses

Unless otherwise specified, all efficacy analyses will be performed on the ITT population.

12.4.6.1. Analyses of Primary Efficacy Endpoint – Overall Survival

The primary endpoint OS is defined as the time (months) from the date of randomization to the date of death for patients who died in the study due to any cause, and the time to the last contact date known to be alive for those who survived as of the data cutoff date for the interim OS analysis or as of the date when the study database is locked for the final analysis (censored cases). Patients lacking data beyond the date of randomization will have their survival time censored at the date of randomization.

The targeted number of deaths for the final analysis is 104 and the final analysis for OS is event-driven. The number and percentage of patients who died or censored will be summarized by treatment group along with the reason for death.

Treatment effect on OS will be primarily evaluated using a stratified log-rank test controlling for the stratification factors of region (US, Europe, or Asia) and ECOG performance status (0-1 versus 2). The magnitude of the treatment effect, HR (trilaciclib versus placebo), will be estimated using a Cox proportional hazard model with the same factors as included in the stratified log-rank test. At the final analysis, the $(1-\alpha)*100\%$ confidence interval (CI) will be generated for the HR, where the α is a 2-sided statistically significant level to be used for the final OS analysis determined by actual information fraction used at the interim and the O'Brien-Fleming α -spending function.

For each treatment group, the Kaplan-Meier plot will be generated, and the median, 25% and 75% percentile of OS will be estimated using the Kaplan-Meier method with their corresponding 95% confidence interval calculated using the method by [Brookmeyer and Crowley \(1982\)](#). Additionally, Kaplan-Meier estimates will be provided for the survival probability along with their two-sided 95% CIs ([Kalbfleisch, 1980](#)) at selected landmarks of 6, 12, 18, and 24 months.

12.4.6.1.1. Interim Analysis for Overall Survival

An interim analysis of OS will be conducted at the 70% information fraction, that is, when 73 deaths are observed. The timing of the interim analysis is estimated to be approximately 19 months after the first patient is randomized in the study. O'Brien-Fleming method for α -spending is applied to ensure strong control family-wise Type I error rate of 1-sided of 0.025 between the interim and the final analysis for OS. At the interim analysis, the significant treatment effect of trilaciclib compared with placebo for OS is established if the 1-sided p-value from the stratified log-rank test is less than or equal to 0.0075 ([Table 13](#)). If the final analysis is performed at 104 cumulative deaths as planned, a 1-sided significance level of 0.0227 will be used to evaluate treatment effect for OS at the final analysis. The actual significance level at the final analysis for

OS will be re-calculated if the actual information fraction for the interim OS analysis is different than the planned 0.70 using the O'Brien-Fleming α -spending function.

There will be no final OS analysis if the superiority of trilaciclib over placebo for OS is established at the interim analysis.

Table 13: Thresholds for Claiming Statistical Superiority (Trilaciclib versus Placebo) at Interim or Final Analysis for Overall Survival

Analysis	# of Deaths	Analysis Timing from FPI (month) ^a	Z-scale	HR-scale	P-value Scale (1-Sided)
Interim Analysis	73	19	2.434	0.562	0.0075
Final Analysis ^b	104	30	2.000	0.673	0.0227

FPI=first patient randomized; HR=hazard ratio.

^a Estimated based on the assumptions of accrual period and duration of follow up as used in the sample size calculation.

^b Statistical criteria judging the significance at the final analysis could be re-calculated if the interim analysis information fraction is different than 0.70.

The aforementioned analyses will be conducted on the ITT population.

12.4.6.2. Analysis for Secondary Anti-tumor Efficacy Endpoints

Secondary anti-tumor endpoints include the following:

- Progression free survival (PFS)
- Objective response rate (ORR)
- Duration of objective response (DOR)

Progressive disease (PD) and tumor response status are derived per RECIST v1.1 based on tumor assessment data entered into the EDC by Investigators.

12.4.6.2.1. Analysis for Progression Free Survival

Progression free survival is defined as the time (months) from date of randomization to the date of documented radiologic PD per RECIST v1.1 or date of death regardless the cause, whichever comes first. PFS will be determined using all available data up to the date of (i) radiographic disease progression per RECIST v1.1; (ii) withdrawal of consent to obtain additional scans on study; or (iii) initiation of subsequent anticancer therapy, whichever is earliest. Censoring rules for patients who do not experience PD or death at the data cutoff date or at the date for final database lock will be detailed in the study SAP.

The treatment effect on PFS will be evaluated by using a stratified log-rank test controlling for the two stratification factors. A Cox proportional hazard model with the same terms as in the stratified log-rank test will be used to estimate the HR (trilaciclib versus placebo) for PFS along with its 95% confidence interval. In addition, Kaplan-Meier plots will be generated and the median, 25% and 75% percentile of PFS will be estimated using the Kaplan-Meier method by

treatment group with their corresponding 95% confidence interval calculated using the method by [Brookmeyer and Crowley \(1982\)](#).

Per literature, the expected median PFS for patients receiving docetaxel is 3 months ([Garon, 2014](#)). Assuming trilaciclib can achieve a treatment effect of HR of 0.60, it is estimated that 86% of patients would have a radiographic disease progression or died at the time when OS interim analysis is performed. Therefore, the analysis for PFS will be conducted at the time of performing interim OS analysis. However, if the observed PD or deaths at the date of data cutoff for the OS interim analysis is less than 80%, the final PFS will be performed using the final database if the study is not stopped for success after the interim OS analysis. In that event, the treatment effect for PFS as observed at the final analysis will be considered to be primary.

PFS will be analyzed on the ITT population.

12.4.6.2.2. Analysis for Tumor Response Status and Duration of Objective Response

At each tumor assessment visit, an overall time point response per RECIST v1.1 will be determined programmatically using the measurements of target lesions, non-target lesions, and new lesions entered to the eCRF by the Investigators. Best overall response (BOR) will be determined per RECIST v1.1 using all timepoint responses prior to or on the date of (i) radiographic disease progression; (ii) withdrawal of consent to obtain tumor scans; (iii) death; (iv) lost to follow-up; or (v) initiation of subsequent anticancer therapy, whichever is earliest. The BOR status for patients will be summarized by the number and percentage of patients in each of the following categories: complete response (CR) (confirmed), partial response (PR) (confirmed), stable disease (SD) and Not Evaluable (NE).

ORR is defined as the proportion of patients with confirmed CR or confirmed PR as the BOR status. ORR along with its exact 95% two-sided confidence interval using the Clopper-Pearson method will be computed for each treatment group. The treatment group difference for ORR will be evaluated using a stratified Cochran–Mantel–Haenszel (CMH) test accounting for the two stratification factors. The adjusted proportion difference (trilaciclib minus placebo) and its 95% CI will be calculated using CMH weight ([Kim, 2013](#)).

DOR is the time (months) from the first date when CR or PR was achieved and confirmed in the next tumor scan to the date when the patient experienced disease progression or died in the absence of PD. For those who achieved objective response status and did not have disease progression or death at the time of data analysis, the earliest date of the following, if it exists, will be used to calculate censored time: (i) withdrew consent to obtain scans; (ii) last contact; (iii) initiated subsequent anticancer therapy; otherwise, the censored DOR will be calculated using the last date known with retained response status as of the data cutoff date for the analysis. DOR will be analyzed for the patients who have achieved objective response. The Kaplan-Meier method will be used to estimate the median, 25% and 75% percentile of DOR by treatment group, along with the 95% CI calculated using the method by [Brookmeyer and Crowley \(1982\)](#).

Analyses for ORR and DOR will be based on the Response Evaluable patient population.

12.4.6.3. Analysis for Myelosuppression Endpoints

Myelosuppression endpoints are grouped by lineage and consequence of CIM as follows.

- Neutrophils related (including DSN in Cycle 1, occurrence of SN, occurrence of FN, and occurrence of G-CSF administration)
- RBC related (including occurrence of Grade 3/4 decrease of hemoglobin, occurrence and number of RBC transfusions on/after Week 5, and occurrence of ESA administration)
- Platelet related (including occurrence of Grade 3 /4 decrease of platelets, occurrence and number of platelet transfusions)
- Endpoints related to trilaciclib's effect on chemotherapy dosing and hospitalization due to CIM (including occurrence and number of dose reductions or dose delay, and occurrence and number of hospitalization due to CIM)

12.4.6.3.1. Analysis for DSN in Cycle 1

For patients with at least one SN event (ANC value $<0.5 \times 10^9/L$) in Cycle 1, DSN (days) in Cycle 1 is defined as the number of days from the date of the first ANC value of $<0.5 \times 10^9/L$ observed at Cycle 1 to the date of the first ANC value $\geq 0.5 \times 10^9/L$ and no other ANC values $<0.5 \times 10^9/L$ occurred between this day and end of Cycle 1. DSN will be set to 0 for patients who do not experience SN in Cycle 1. Data from both scheduled and unscheduled assessments will be included in the calculation, and the actual assessment date will be used in the derivation of DSN in Cycle 1.

Treatment effect on DSN in Cycle 1 will be evaluated using a nonparametric analysis of covariance (ANCOVA) (Quade, 1967). In this analysis, the rank-transformed (within each stratum) DSN values are analyzed by an ANCOVA model with the terms of treatment, and the two stratification factors as fixed effects and the rank-transformed baseline ANC as a covariate. In addition, the mean difference (trilaciclib – placebo), the standard error and the 95% confidence interval for the difference generated from a Satterthwaite t-test will be presented.

12.4.6.3.2. Analysis for Binary Myelosuppression Endpoints

For the binary myelosuppression endpoints (e.g., the occurrence of SN and the occurrence of RBC transfusions on/after Week 5), the number and percentage of patients with at least one occurrence during the treatment period will be summarized by treatment group. The treatment effect will be evaluated using a Poisson regression model (Zou, 2004). The model will include the two stratification factors as the fixed effect with corresponding baseline value as a covariate when applicable (e.g., baseline ANC for occurrence of SN, and baseline hemoglobin for RBC transfusions on/after Week 5). The log-transformed duration of exposure either in week or in cycle will be used as the offset in the model to account for the variable duration for each patient (e.g., the number of cycles for occurrence of SN, and the number of weeks for RBC transfusions on/after Week 5). A 2-sided p-value, adjusted relative risk (aRR) (trilaciclib versus placebo) and its 95% CI will be generated from the statistical model as applied.

12.4.6.3.3. Analysis for Counting Myelosuppression Endpoints

For the counting myelosuppression endpoints (e.g., the number of RBC transfusions on/after Week 5, and the number of dose reductions during the treatment period), the total number of the event, the total number of exposure (either in the unit of week or cycle determined by the medical meaning), and event rate per 100 weeks or cycles will be summarized by treatment group. For example, the event rate for RBC transfusions on/after Week 5 will be reported by 100 weeks and that for dose reduction will be reported by 100 cycles. For a given event, patients without any of the event during the treatment period will be assigned a value 0 to be included in the analysis. The treatment group difference in the event rate will be assessed by a negative binomial model. The model will include the two stratification factors as the fixed effect with corresponding baseline value as a covariate when applicable (e.g., baseline hemoglobin for the analysis of number of RBC transfusions on/after Week 5). The log-transformed duration of exposure in week or in cycle will be used as the offset in the model to account for the variable duration for each patient (e.g., number of weeks for RBC transfusions on/after Week 5, and number of cycles for dose reduction). A 2-sided p-value, aRR (trilaciclib versus placebo) and its 95% CI will be generated from the statistical model as applied.

12.4.6.4. Subgroup Analysis for Primary Efficacy Endpoint

Treatment effect for the primary endpoint OS will be evaluated for each of the stratification factors: Region (US, Europe, or Asia) and ECOG status (0-1 versus 2). The treatment effects in each category of a factor will be evaluated by using a stratified log-rank test controlling for the other stratification factor. A Cox proportional hazard model with the same terms as used in the stratified log-rank test will be employed to estimate the HR and its 95% CIs within each category of the factor. A forest plot for the HR of OS and its 95% CI will be produced.

Subgroup analysis will be conducted for some baseline characteristics that might have impact on the treatment effect for OS and the details will be specified in the study SAP.

12.4.7. PRO Analyses

The EORTC QLQ-C30, EORTC QLQ-LC13 (with weight loss item), FACIT-Fatigue, EQ-5D-5L, PGIC, and PGIS instruments will be used to collect the quality-of-life data to assess the impact of trilaciclib on various quality of life measures compared with placebo. Analysis for the variables derived from these questionnaires will be based on the ITT population and detailed in the study SAP.

12.4.8. Safety Analyses

Safety and tolerability will be assessed by AEs, laboratory tests, vital signs and ECGs. All safety data will be summarized using descriptive statistics by treatment group on the safety population. Data collected through scheduled or non-scheduled visits will all be included in the safety analyses.

12.4.8.1. Adverse Events

AEs are defined as those events occurring or worsening after treatment has begun on this study. Adverse event data will be coded to system organ class (SOC) and PT using the latest version of MedDRA. The severity (toxicity grades 1-5) of AEs will be graded according to the

NCI-CTCAE v5.0 by Investigators. The number and percentage of patients experiencing any AEs will be summarized overall and tabulated by SOC, PT and CTCAE grade for each treatment group. AEs considered by the Investigator to be related to a study drug, AEs leading to study drug discontinuation or dose modifications, and trilaciclib AESIs will be summarized by SOC, PT and CTCAE grade, when appropriate. In the tabulation of severity and causality of an AE, if the same AE occurred on multiple occasions, the highest grade of toxicity and strongest relationship to the study drug will be used in a summary.

12.4.8.2. Other Safety Endpoints

Observed values and changes from baseline to each end of the cycle, the maximum and minimum values during the treatment period in vital signs, and ECG intervals, and laboratory assessments of hematology, serum chemistry, and liver function parameters will be summarized by treatment group.

Serum chemistry and hematology laboratory parameters will be characterized according to CTCAE toxicity grade from 1 to 5, when possible. The number and percentage of patients within each CTCAE grade will be summarized for the overall treatment period as well as for each cycle. If a patient has multiple laboratory assessments in an interval of interest, the maximum grade will be reported.

For vital signs and ECG parameters, potentially clinically significant (PCS) findings will be summarized by treatment group. The potentially clinically significant vital signs and ECG parameters are defined either by post-baseline assessments or by change from baseline with respect to the pre-specified thresholds. The criteria defining PCS for vital signs and ECG parameters will be detailed in the study SAP, respectively.

12.4.9. Exploratory Analyses

The number and percentage of patients in different CDK4/6 signature status (i.e., CDK4/6 independent, CDK4/6 dependent, and CDK4/6 indeterminate) will be summarized by treatment group. Anti-tumor efficacy endpoints (OS, PFS, and ORR) will be evaluated for the subgroup of patients with different CDK 4/6 signature status. Within each type of signature, the analysis for OS will follow the statistical methods as outlined in Section 12.4.6.1, and the analysis for PFS and ORR will use the similar statistical approaches as outlined in Section 12.4.6.2.

In addition, anti-tumor efficacy endpoints (OS, PFS, and ORR) will be evaluated by PD-L1 status determined using archived tumor tissues and applying similar statistical approaches as used for the analyses of anti-tumor efficacy endpoints by CDK4/6 signature status.

Treatment group differences in pharmacodynamic parameters obtained from peripheral blood including those relating to immune-based mechanisms will be evaluated.

12.4.10. Pharmacokinetic Analyses

The pharmacokinetics of trilaciclib will be determined using a non-linear mixed effects modeling approach. Relevant population pharmacokinetic parameters will be estimated and reported. Details of population pharmacokinetic analyses will be described in the population pharmacokinetic/pharmacodynamic analysis plan.

The pharmacokinetics of docetaxel will also be determined using a non-linear mixed effects modeling approach. Relevant population pharmacokinetic parameters will be estimated and reported. Details of population pharmacokinetic analyses will be described in the population pharmacokinetic/pharmacodynamic analysis plan.

12.4.11. Pharmacokinetic/Pharmacodynamic Analyses

If data warrant, exploratory analyses may be performed to examine the relationship(s) between exposure to trilaciclib and pharmacodynamic endpoints or other efficacy and safety endpoints. Details of population PK/pharmacodynamic analyses will be described in a separate population PK/pharmacodynamic analysis plan.

13. ETHICS

13.1. Ethics Review

The protocol, protocol amendments, ICF, IB, and other relevant documents (e.g., advertisements) must be submitted to an IRB/IEC by the Investigator and reviewed and approved by the IRB/IEC before the study is initiated.

Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study patients.

The Investigator will be responsible for the following:

- Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC
- Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC procedures
- Providing oversight of the conduct of the study at the site and adherence to requirements of 21 Code of Federal Regulations (CFR), International Council for Harmonisation (ICH) guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations

13.2. Ethical Conduct of the Study

This study will be conducted in accordance with the protocol and with the following:

- Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines
- Applicable ICH GCP Guidelines
- Applicable laws and regulations

13.3. Written Informed Consent

The Principal Investigator(s) at each center will ensure that the patient is given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study. Patients must also be notified that they are free to discontinue from the study at any time. The patient should be given the opportunity to ask questions and allowed time to consider the information provided.

The patient's signed and dated informed consent must be obtained before conducting any study procedures.

The Principal Investigator(s) must maintain the original, signed ICF. A copy of the signed ICF must be given to the patient or the patient's legally authorized representative where allowed by local regulation.

14. DATA HANDLING AND RECORDKEEPING

14.1. Data Protection

Patients will be assigned a unique identifier by the Sponsor. Any patient records or datasets that are transferred to the Sponsor will contain the identifier only; patient names or any information which would make the patient identifiable will not be transferred.

The patient must be informed that his/her personal study-related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the patient who will be required to give consent for their data to be used as described in the informed consent.

The patient must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.

14.2. Data Quality Assurance

- All patient data relating to the study will be recorded on eCRF unless transmitted to the Sponsor or Designee electronically. The Investigator is responsible for verifying that data entries are accurate and correct by physically or electronically signing the eCRF.
- The Investigator must maintain accurate documentation (source data) that supports the information entered in the eCRF.
- The Investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents.
- Monitoring details describing strategy (e.g., risk-based initiatives in operations and quality such as Risk Management and Mitigation Strategies and Analytical Risk Based Monitoring), methods, responsibilities, and requirements, including handling of noncompliance issues and monitoring techniques (central, remote, or on-site monitoring) are provided in the Monitoring Plan.
- The Sponsor or Designee is responsible for the data management of this study including quality checking of the data.
- Study Monitors will perform ongoing source data verification (SDV) at the frequencies and SDV extent as outlined in the Monitoring Plan to confirm that data entered into the eCRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of patients are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.
- The Investigator must maintain all documentation relating to the study for a period of 2 years after the last marketing application approval, or if not approved 2 years following the discontinuance of the investigation of trilaciclib. If it becomes necessary for the Sponsor or the Regulatory Authority to review any documentation

relating to the study, the Investigator must permit access to such records. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor. The Investigator must ensure that the records continue to be stored securely for as long as they are maintained. It is the responsibility of the Sponsor to inform the investigator when these documents no longer need to be retained. However, if required by local regulation that these documents should be retained for a longer period, then Retention of Documentation will abide by local regulation.

A study-specific COVID-19 Assessment Plan will be utilized for any necessary modifications and/or mitigation to the data collection, monitoring or other associated activities during this study due to the COVID-19 pandemic.

14.3. Dissemination of Clinical Study Data

The Sponsor fulfills its commitment to publicly disclose clinical study results through posting the results of studies on www.clinicaltrials.gov, the EudraCT, and other public registries in accordance with applicable local laws/regulations.

Data results are posted in an objective, accurate, balanced, and complete manner. Results are posted regardless of outcome of the study.

14.4. Source Documents

Source documents provide evidence for the existence of the patient and substantiate the integrity of the data collected. Source documents are filed at the Investigator's site. All data reported in the eCRF should be supported by source documents; direct entry of data into the eCRF is not permitted in this study.

Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

14.5. Audits and Inspections

Authorized representatives of G1 Therapeutics, Inc., a regulatory authority, an IEC, or IRB may visit the site to perform audits or inspections, including source data verification. The purpose of an audit or inspection is to systematically and independently examine all study-related activities and documents to determine whether these activities were conducted, and data were recorded, analyzed, and accurately reported according to the protocol, GCP guidelines of the ICH, and any applicable regulatory requirements. The Investigator should contact G1 Therapeutics, Inc. immediately if contacted by a regulatory agency about an inspection.

15. PUBLICATION POLICY

By signing the study protocol, the Investigator and his or her institution agree that the results of the study may be used by G1 Therapeutics, Inc. for the purposes of national and international registration, publication, and information for medical and pharmaceutical professionals. If necessary, the authorities will be notified of the Investigator's name, address, qualifications, and extent of involvement.

Initial publication of the results of this study will be of a cooperative nature that may include authors representing the Sponsor, Investigator(s), and collaborating scientists. Independent publications by involved individuals may follow. Investigators and their institutions agree not to publish or publicly present any interim results of studies without the prior written consent of G1 Therapeutics, Inc. G1 Therapeutics Inc. reserves the right to request modification of any publication, presentation or use by the Investigator if such activity may jeopardize a patent application, an existing patent, or other proprietary rights. G1 Therapeutics, Inc. shall determine order of authorship of any publication combining all clinical results of this study.

16. REFERENCES

Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. *Eur J Cancer*. 2011;47:8-32.

Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. *Journal of the National Cancer Institute* 1993;85:365-76.

American Cancer Society. Key Statistics for Lung Cancer. Accessed 03 Dec 2020: <https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html>

Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. *Non-Small Cell Lung Cancer*. *Br J Cancer*. 2000;83(4):447-53.

Aranesp® (darbepoetin alpha) Prescribing Information. Amgen. 2011. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103951Orig1s5173_103951Orig1s52581bl.pdf

ASCO. Cancer.Net. Lung Cancer – Non-Small Cell: Statistics. Accessed 03 Dec 2020: <https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics>

Baghdadi TA, Halabi S, Garrett-Mayer E, et al. Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. *JCO Precision Oncology*. 2019;3:1-8.

Barlesi F, Mazieres J, Merlio J-P, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). *Lancet*. 2016;387(10026):1415-26.

Barrueto L, Caminero F, Cash L. Resistance to checkpoint inhibition in cancer immunotherapy. *Transl Onc*. 2020;13:100738.

Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. *European Journal of Cancer*. 1994;30A:635-42.

Bisi JE, Sorrentino JA, Roberts PJ, et al. Preclinical characterization of G1T28: A novel CDk4/6 inhibitor for reduction of chemotherapy-induced myelosuppression. *Mol Cancer Ther*. 2016;15:783–93.

Blackhall FH, O'brien M, Schmid P, et al. A phase I study of vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. *J Thorac Oncol*. 2010;5:1285-1288.

Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. *Ann Intern Med*. 1966;64(2):328-40.

Bohlius J, Bohlke K, Castelli R, et al. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. 2019; 37.

- Bonelli M, La Monica S, Fumarola C, et al. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation. *Biochem Pharmacol*. 2019;170:113676.
- Borcherding N, Kolb R, Gullicksrud J, et al. Keeping tumors in check: A mechanistic review of clinical response and resistance to immune checkpoint blockade in cancer. *J Mol Biol*. 2018;430:2014-29.
- Bracci L, Schiavoni G, Sistigu A, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. *Cell Death Differ*. 2014 Jan;21(1):15-25.
- Brody R, Zhang Y, Ballas M, et al. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. *Lung Cancer*. 2017;112:200-15.
- Brookmeyer R., and Crowley J. (1982). A confidence interval for the median survival time. *Biometrics*. 29-41.
- Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. *Cancer*. 2005;103(9):1916-24.
- Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature*. 2012;490(7418):61-70.
- Carson JL, Guyatt G, Heddle NM, et al. Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. *JAMA*. 2016;316(19):2025-35.
- Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov*. 2012;2:401-4.
- Chaikovsky AC, Sage J. Beyond the cell cycle: enhancing the immune surveillance of tumors via CDK4/6 inhibition. *Mol Cancer Res*. 2018;16:1454-57.
- Chen WS, Alshalalfa M, Zhao SG, et al. Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. *Clin Cancer Res*. 2019;25(14):4290-9.
- Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. *Tumori*. 2012;98(6):751-5.
- Clark A, McAndrew NP, Troxel A, et al. Combination paclitaxel and Palbociclib: Results of a Phase 1 trial in advanced breast cancer. *Clin Cancer Res*. 2019;25(7):2072-9.
- Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial [published online ahead of print, 2020 Dec 21]. *Int J Cancer*. 2020;10.1002/ijc.33453.
- Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib decreases myelosuppression in extensive-stage small cell lung cancer patients receiving first-line chemotherapy plus atezolizumab. *ESMO Annual Meeting 2019; Barcelona, Spain; Sep 2019 (abstr 1742PD)*.

- Deng J, Wang ES, Jenkins RW, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. *Cancer Discov*. 2018;8:216-33.
- Edelman MJ, Redman MW, Albain KS, et al. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). *J Thorac Oncol*. 2019;14(10):1853-9.
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45:228-247.
- Ertel A, Dean JL, Rui H, et al. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. *Cell Cycle*. 2010;9(20):4153-63.
- Fares CM, Van Allen EM, Drake CG, et al. Mechanisms of resistance to immune checkpoint blockade: Why does checkpoint inhibitor immunotherapy not work for all patients? 2019 ASCO Educational Book.
- Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). Published by: European Organisation for Research and Treatment of Cancer, Brussels 2001.
- Finn RS, Liu Y, Zhu Z, et al. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. *Clin Cancer Res*. 2020;26(1):110-21.
- Food and Drug Administration (FDA) Guidance for Industry, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2008.
- Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. *J Clin Oncol*. 2000;18(12):2354.
- Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. *N Engl J Med*. 2010 Nov 11;363(20):1938-48.
- Freed DM, Hall CR, Strum JC. CDK4/6 inhibition with lerociclib (G1T38) delays acquired resistance to targeted therapies in preclinical models of non-small cell lung cancer. American Association for Cancer Research Annual Meeting 2019; Chicago, IL, 201 (abstr 4415).
- Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal*. 2013;6:pl1. doi: 10.1126/scisignal.2004088.
- Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *NEJM*. 2018;378:2078-92.
- Garon EB, Ciuleanu T, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomized phase 3 trial. *Lancet*. 2014;384:665-73.

- Gidel TN, Wilmott JS, Scolyer RA, et al. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. *Clin Cancer Res*. 2018;24(6).
- Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumor immunity. *Nature* 2017; 548(7668): 471-5.
- Goldman JW, Gandhi L, Patnaik A, et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer. *J Clin Oncol*. 2014;32(15_Suppl.):8026.
- Goldman JW, Mazieres J, Barlesi F, et al. A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER. *Journal of Clinical Oncology*. 2018 36:15_suppl, 9025.
- Goldman JW, Mazieres J, Barlesi F, et al. A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable *KRAS* Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. *Front Oncol*. 2020;10:578756.
- Gong X, Litchfield LM, Webster Y, et al. Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib. *Cancer Cell*. 2017;32(6):761-776.e6.
- Gopalan PK, Villegas AG, Cao C, et al. CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition. *Oncotarget*. 2018;9(100):37352-66.
- Gopalan PK, Pinder MC, Chiappori A, et al. A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A. *J Clin Oncol*. 2014;32(5_Suppl.):8077.
- Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. *Br J Cancer*. 2004;91(12):1996.
- Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: A practical update. *Virulence*. 2016;7(3):280-97.
- Haines E, Chen T, Kommajosyula N, et al. Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in *KRAS*-mutant non-small cell lung cancer. *Oncotarget*. 2018;9(60):31572-31589.
- Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. *J Clin Oncol*. 2004;22(9):1589.
- Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. *Adv Ther*. 2020. doi: 10.1007/s12325-020-01538-0.
- He S, Roberts PJ, Sorrentino JA, et al. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. *Sci Transl Med*. 2017;9.

He Y, Rozeboom L, Rivard CJ, et al. MHC class II expression in lung cancer. *Lung Cancer*. 2017 Oct;112:75-80.

Herschkowitz JI, He X, Fan C, et al. The functional loss of the retinoblastoma tumor suppressor is a common event in basal-like and luminal B breast carcinomas. *Breast Cancer Res*. 2008;10(5):R75.

Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Practice Guideline Update. *J Clin Oncol*. 2020;38.

Hodge JW, Garnett CT, Farsaci B, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. *Int J Cancer*. 2013;133(3):624-36.

Horsley V, Aliprantis AO, Polak L, et al. NFATc1 balances quiescence and proliferation of skin stem cells. *Cell*. 2008;132(2):299-310.

Infante JR, Cassier PA, Gerecitano JF, et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. *Clin Cancer Res*. 2016;22:5696–705.

Jang RW, Caraiscos VB, Swami N, et al. Simple prognostic model for patients with advanced cancer based on performance status. *J Oncol Pract*. 2014;10(5):e335-41.

Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. *Brit J Cancer*. 2018;118:9-16.

Kalbfleisch, J.D, and Prentice, R.L. 1980. *The Statistical Analysis of Failure Time Data*. New York: John Wiley & Sons.

Kalemkerian GP, Narula N, Kennedy EB. Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors: America Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for Molecular Pathology Clinical Practice Guideline Update. *ASCO*. 2018;14(5):323-7.

Karasic TB, O'Hara MH, Teitelbaum UR, et al. Phase II trial of palbociclib in patients with advanced esophageal or gastric cancer. *J Clin Oncol*. 2018;36(4_Suppl.):68.

Kaufman RM, Djulbegovic BD, Gernsheimer T, et al. Platelet Transfusion: A Clinical Practice Guideline From the AABB. *Ann Intern Med*. 2015; 162:205-213.

Kim Y, Won S. (2013) Adjusted proportion difference and confidence interval in stratified randomized trials. *PharmaSUG*; Paper SP-04.

Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. *Cancer Cell*. 2018;34(1):9-20.

Knudsen ES, Witkiewicz AK. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. *Trends Cancer*. 2017;3(1):39-55.

Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. *Clin Cancer Res*. 2010;16(18):4583-94.

- Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. *Br J Cancer*. 1996;73(2):148-53.
- Kozar K, Ciemerych MA, Rebel VI, et al. Mouse development and cell proliferation in the absence of D-cyclins. *Cell*. 2004;118(4):477-91.
- Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancer to select targeted drugs. *JAMA*. 2014;311(19):1998-2006.
- Lai AY, Sorrentino JA, Dragnev KH, et al. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. *J Immunother Cancer*. 2020; 8.
- Lewis C, Smith DC, Carneiro BA, et al. A Phase 1b study of the oral CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration resistant prostate cancer (mCRPC) – A prostate cancer clinical trials consortium study. 2018;36(15):e17028.
- Li CH, Karantza V, Aktan G, et al. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. *Breast Cancer Res*. 2019;21:143.
- Li H, Xu Y, Wan B, et al. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. *Transl Lung Cancer Res*. 2019;8(4):429-49.
- Li Y, Kippel Z, Shih X, et al. Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies. *Support Care Cancer* 2016;24(10):4377-83.
- Li JY, Duan XF, Wang LP, et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. *J Immunol Res*. 2014;2014:286170.
- Little AG, Gay EGG, Gaspar LE, et al. National survey of non-small cell lung cancer in the United States: Epidemiology pathology and patterns of care. *Lung Cancer*. 2007;57:253-60.
- Liu D, Jenkins R, Sullivan RJ. Mechanisms of resistance to immune checkpoint blockade. *Am J Clin Dermatol*. 2019;20(1):41-54.
- Lyman 2006
- Malumbres M, Sotillo R, Santamaria D, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. *Cell*. 2004;118(4):493-504.
- Maroulakou IG, Anver M, Garrett L, et al. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. *Proc Natl Acad Sci USA* 1994;91:11236-11240.
- McDonnell AM, Nowak AK, Lake RA. Contribution of the immune system to the chemotherapeutic response. *Semin Immunopathol*. 2011;33(4):353-67.
- Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. *Med Oncol*. 2011;28(3):682-8.

- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer. Version 1.2021. 2020. NCCN, Fort Washington, PA.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Hematopoietic Growth Factors. Version 2. 2020b. NCCN, Fort Washington, PA.
- Nieuweboer AJ, de Morree ES, de Graan AJ, Sparreboom A, de Wit R, Mathijssen RH. Inter-patient variability in docetaxel pharmacokinetics: A review. *Cancer Treat Rev.* 2015;41(7):605-13.
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol.* 1982;5(6):649-55.
- Opzoomer JW, Sosnowska D, Anstee JE, Spicer JF, Arnold JN. Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer. *Front Immunol.* 2019;10:1654.
- O'Shaughnessy J, Wright GS, Thummala AR, et al. Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized Phase 2 trial. San Antonio Breast Cancer Symposium. Dec 8-11 2020. Poster #PD1-06
- Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. *Cancer Discov.* 2016;6(7):740-53.
- Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *NEJM.* 2018;379:2040-51.
- Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. *Cancer.* 2006;107(12):2866-72.
- Procrit® (epoetin alpha) Prescribing Information. Janssen Products LP. 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5363s5366lbl.pdf
- Quade, D. (1967). Rank analysis of covariance. *Journal of the American Statistical Association* 1967; 62:1187-1200.
- Ramsey MR, Krishnamurthy J, Pei XH, et al. Expression of p16Ink4a Compensates for p16Ink4a Loss in Cyclin-Dependent Kinase 4/6-Dependent Tumors and Tissues. *Cancer Res* 2007;67:4732-41.
- Reck M, Rodriguez-Abreu D, Robinson EG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *NEJM.* 2016;375(19):1823-33.
- Rose TL, Chism DD, Shivaram Alva A, et al. Phase II trial of Palbociclib (pd-0332991) in patients with metastatic urothelial cancer (UC) after failure of first-line chemotherapy. *Journal of Clinical Oncology.* 2018;36:500.
- Schaer DA, Beckmann RP, Dempsey JA, et al. The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. *Cell Rep.* 2018;22:2978-94.

Shapiro GI. Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search. *Cancer Cell*. 2017;32(6):721-3.

Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. *J Clin Oncol*. 2001;19(5):1519-38.

Shen R, Wang X, Drissi H, et al. Cyclin D1-cdk4 induce runx2 ubiquitination and degradation. *J Biol Chem*. 2006;281:16347-53.

Shepherd FA, Dancey J, Ramlau, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *J Clin Oncol*. 2000;18(10):2095-103.

Sherr CJ, McCormick F. The RB and p53 pathways in cancer. *Cancer Cell*. 2002;2(2):103-12.

Shimizu K, Nakata M, Hiram Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. *J Thorac Oncol*. 2010;5(5):585-90.

Smith RE. Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors. *J Natl Compr Canc Netw*. 2006;4:649–58.

Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2015;33:3199-212.

Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naïve patients with extensive-stage small-cell lung cancer. *J Clin Oncol*. 2009;27:4787-4792.

Sorrentino JA, Bisi JE, Thompson D, et al. Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models. 30th EORTC-NCI-AACR Symposium. 13-16 November 2018. Dublin, Ireland.

Spigel D, de Marinis F, Giaccone G, et al. Impower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC. EMSO 2019 Congress. 27 Sep 2019.

Stefansson OA, Jonasson JG, Olafsdottir K, et al. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. *Epigenetics* 2011; 6(5):638-49.

Subhawong AP, Subhawong T, Nassar H, Kouprina N, Begum S, Vang R, et al. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. *Am J Surg Pathol*. 2009; 33:163-75.

Sweeney CJ, Zhu J, Sandler AB, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic non-small cell lung carcinoma. *Cancer*. 2001;92(10):2639-47.

Tan AR, Wright GS, Thummala AR, et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomized, open-label, Phase 2 trial. *Lancet Oncol*. 2019;20:1587-601.

Taxotere® (docetaxel) Prescribing Information. Sanofi-Aventis U.S. LLC. 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020449s084lbl.pdf

Taxotere® (docetaxel) Summary of Product Characteristics. Sanofi Mature IP. France. 2005. Available at: https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf.

Teh JLF, Aplin AE. Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment. *Clin Cancer Res*. 2019;25(3).

Treré D, Brighenti E, Donati G, et al. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. *Ann Oncol*. 2009 Nov;20(11):1818-23.

Turner NC, Liu Y, Zhu Z, et al. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer [published correction appears in *J Clin Oncol*. 2019 Nov 1;37(31):2956]. *J Clin Oncol*. 2019;37(14):1169-78.

Wang S, He Z, Wang X, Li H, Liu XS. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. *Elife*. 2019;8:e49020.

Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. *Ann Oncol*. 2019;30:1613-21.

Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. *Science*. 2008;322(5899):271-5.

Witkiewicz AK, Ertel A, McFalls J, Valsecchi ME, Schwartz G., Knudsen ES. RB-Pathway Disruption Is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer. *Clin Cancer Res*. 2012;18:5110-22.

Woo EY, Yeh H, Chu CS, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. *J Immunol*. 2002;168(9):4272-76.

Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. *Cancer Res*. 2001;61(12):4766-72.

World Health Organization (WHO). Cancer: Key facts. Accessed 03 Dec 2020: [https://www.who.int/news-room/fact-sheets/detail/cancer#:~:text=Cancer%20is%20a%20leading%20cause,Lung%20\(2.09%20million%20cases\)](https://www.who.int/news-room/fact-sheets/detail/cancer#:~:text=Cancer%20is%20a%20leading%20cause,Lung%20(2.09%20million%20cases)).

Yellen SB, Cella OF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) Measurement System. *J Pain Symptom Manage*. 1997;13(2):63-74.

Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance [published correction appears in Nature. 2019 Jul;571(7766):E10]. *Nature*. 2018;553(7686):91-5.

Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. *Cell Mol Immunol*. 2010;7(5):389-95.

Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. *Nat Rev Immunol*. 2008;8:59-73.

Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol*. 2004;159(7):702-6.

17. APPENDICES

17.1. Clinical Laboratory Tests

- The timing and laboratory tests detailed in Schedule of Assessments ([Table 6](#)) will be performed by a local laboratory.
- Protocol-specific requirements for inclusion or exclusion of patients are detailed in Section 7 of the protocol.
- Additional tests may be performed at any time during the study as determined necessary by the Investigator or required by local regulations.

Table 14: Protocol-Specified Safety Laboratory Assessments

Laboratory Assessment	Parameters		
Hematology	WBC	Hemoglobin	Absolute neutrophil count
	Platelets	Lymphocytes	Hematocrit
Serum Chemistry	Blood Urea Nitrogen (BUN) or Urea	Serum Creatinine	Bicarbonate
	Aspartate Aminotransferase (AST)	Alanine Aminotransferase (ALT)	Calcium
	Potassium	Sodium	Chloride
	Glucose	Total Protein	Albumin
	Alkaline phosphatase	Total Bilirubin	
Other Tests	Serum or urine human chorionic gonadotropin (hCG) pregnancy test (for WOCBP only)		

hCG=human chorionic gonadotropin; RBC=red blood cell; WBC=white blood cell; WOCBP=woman of childbearing potential

17.2. Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting

17.2.1. Definition of AE

AE Definition
<ul style="list-style-type: none"> • An AE is any untoward medical occurrence in a patient or clinical study patient, temporally associated with the use of study intervention, whether or not considered related to the study intervention. • NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.
Events <u>Meeting</u> the AE Definition
<ul style="list-style-type: none"> • Any abnormal laboratory test results (hematology, serum chemistry) or other safety assessments (e.g., ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinically significant and require clinical intervention or further investigation (beyond ordering a repeat [confirmatory] test) in the medical and scientific judgment of the Investigator (i.e., not related to progression of underlying disease) unless they are associated with an already reported clinical event, e.g. elevated liver enzymes in a patient with jaundice. • Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition. • New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study. • Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.

AE Definition
Events <u>NOT</u> Meeting the AE Definition
<ul style="list-style-type: none"> Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are associated with the underlying disease, unless judged by the Investigator to be more severe than expected for the patient's condition. The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the patient's condition. Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the procedure is the AE. Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital). Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen.

17.2.2. Definition of SAE

If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met (e.g., hospitalization for signs/symptoms of the disease under study, death due to progression of disease).

A SAE is defined as any untoward medical occurrence that, at any dose:
1. Results in death
2. Is life-threatening The term 'life-threatening' in the definition of 'serious' refers to an event in which the patient was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.
3. Requires inpatient hospitalization or prolongation of existing hospitalization In general, hospitalization signifies that the patient has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician's office or outpatient setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline is not considered an AE.
4. Results in persistent disability/incapacity <ul style="list-style-type: none"> The term disability means a substantial disruption of a person's ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.
5. Is a congenital anomaly/birth defect
6. Other situations:

A SAE is defined as any untoward medical occurrence that, at any dose:

- Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious.
- Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

17.2.3. Recording and Follow-Up of AE and/or SAE

AE and SAE Recording
<ul style="list-style-type: none"> • When an AE/SAE occurs, it is the responsibility of the Investigator to review all documentation (e.g., hospital progress notes, laboratory reports, and diagnostics reports) related to the event. • The Investigator will then record all relevant AE/SAE information in the eCRF. • It is not acceptable for the Investigator to send photocopies of the patient's medical records to G1 Therapeutics, Inc. (or designee) in lieu of completion of the AE/SAE eCRF page. • There may be instances when copies of medical records for certain cases are requested by G1 Therapeutics, Inc. (or designee). In this case, all patient identifiers, with the exception of the patient number, will be redacted on the copies of the medical records before submission to G1 Therapeutics, Inc. (or designee). • The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE. • All SAEs should be reported to G1 Therapeutics, Inc. PVG (or designee) within 24 hours of notification on an SAE Form in the eCRF. Any relevant source data related to the SAE that cannot be entered in the EDC should be emailed or faxed to G1 Therapeutics, Inc. PVG (or designee): G1 Therapeutics, Inc. Pharmacovigilance Email: safetyreporting@g1therapeutics.com Fax: +1-984-285-7131
Assessment of Intensity
<p>Intensity will be assessed using NCI-CTCAE v5.0 criteria, as follows:</p> <ul style="list-style-type: none"> • Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. • Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. • Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. • Grade 4: Life-threatening consequences; urgent intervention indicated. • Grade 5: Death related to AE.

AE and SAE Recording
Assessment of Causality
<ul style="list-style-type: none"> • The Investigator is obligated to assess the relationship between study intervention and each occurrence of each AE/SAE (Related or Not Related); i.e., is there a “reasonable possibility” the study intervention caused the event (yes/no). • A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. • The Investigator will use clinical judgment to determine the relationship. • Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study intervention administration will be considered and investigated. • The Investigator will also consult the IB and/or Product Information, for marketed products, in his/her assessment. • For each AE/SAE, the Investigator must document in the medical notes that he/she has reviewed the AE/SAE and has provided an assessment of causality. • There may be situations in which an SAE has occurred and the Investigator has minimal information to include in the initial report to G1 Therapeutics, Inc. PVG (or designee). However, it is very important that the Investigator always make an assessment of causality (Not Related or Related) for every event before the initial transmission of the SAE data to G1 Therapeutics, Inc. PVG (or designee). • The Investigator may change his/her opinion of causality in light of follow-up information and send a SAE follow-up report with the updated causality assessment. • The causality assessment is one of the criteria used when determining regulatory reporting requirements.
Follow-up of SAEs
<ul style="list-style-type: none"> • The Investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by G1 Therapeutics, Inc. PVG (or designee) to elucidate the nature and/or causality of the SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals. • New or updated information will be recorded in the originally completed eCRF. • The Investigator will submit any new or updated SAE data to G1 Therapeutics, Inc. PVG (or designee) within 24 hours of receipt of the information: <p>G1 Therapeutics, Inc. Pharmacovigilance Email: safetyreporting@g1therapeutics.com Fax: +1-984-285-7131</p>

17.2.4. Reporting of SAEs**SAE Reporting to G1 Therapeutics, Inc. (or designee) via an Electronic Data Collection Tool**

- The primary mechanism for reporting an SAE to G1 Therapeutics, Inc. (or designee) will be the EDC.
- If the electronic system is unavailable, then the site will use the paper SAE Report Form in order to report the event within 24 hours via email or fax (see below for SAE reporting contact information).
- The site will enter the SAE data into the electronic system as soon as it becomes available.
- After the study is completed at a given site, the electronic data collection tool will be taken off-line to prevent the entry of new data or changes to existing data.
- If a site receives a report of a new SAE from a study patient or receives updated data on a previously reported SAE after the electronic data collection tool has been taken off-line, then the site should report this information on a paper SAE Report form or notify the Medical Monitor by telephone.
- Contact for SAE reporting:
G1 Therapeutics, Inc. Pharmacovigilance
Email: safetyreporting@g1therapeutics.com
Fax: +1-984-285-7131

17.3. Contraceptive Guidance and Collection of Pregnancy Information

WOCBP Definition

Woman of Childbearing Potential

A woman is considered fertile following menarche and until becoming post-menopausal unless permanently sterile (see below).

If fertility is unclear (e.g., amenorrhea in adolescents or athletes), additional evaluation should be considered.

Women in the following categories are not considered Woman of Childbearing Potential

1. Premenarchal

Note: Documentation can come from the site personnel's review of the patient's medical records, medical examination, or medical history interview.

2. Premenopausal female with 1 of the following acceptable surgical sterilization techniques: complete or partial hysterectomy, bilateral tubal ligation, or occlusion with surgery at least 6 months prior to dosing, or bilateral oophorectomy with surgery at least 2 months prior to dosing.
3. Postmenopausal female: defined as spontaneous amenorrhea for >12 months prior to Screening without alternative cause (e.g., implantable contraceptive, side effect of medication, etc.) and a serum follicle stimulating hormone (FSH) within the laboratory's reference range for postmenopausal females.
 - Women taking hormone replacement therapy (HRT) must discontinue HRT at least 2-4 weeks prior to Screening for accurate assessment of FSH (though exact interval will depend on the type and dosage of HRT and should be determined by the principal Investigator).

Contraception Guidance

Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

- Male patients: Males must be surgically sterile prior to Screening with appropriate documentation (absence of sperm in ejaculate 6 months after procedure) or have a female partner(s) who is either postmenopausal, surgically sterile, or using 2 forms of concurrent contraception as defined below. In addition, males must also refrain from sperm donation during the study and utilize a barrier method with intercourse during and for 6 months following discontinuation of treatment.
- Female patients: All females of childbearing potential must have a negative serum β -hCG test result at Screening, and negative serum or urine pregnancy test at each cycle during treatment and at the Post Treatment Visit (see Section 11.3.5 and Table 6).
- Females must be either postmenopausal, surgically sterile, or agree to use 2 concurrent forms of contraception during the study and for 6 months following last dose of study drug. Acceptable forms of contraception include:

- Established use of oral, injected or implanted hormonal methods of contraception (stable dose at least 3 months prior to dosing)
- Intrauterine device or intrauterine system
- Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. Barrier methods alone (without spermicide) are not acceptable methods. Likewise, spermicide alone is not an acceptable method
- Male sterilization prior to Screening with the appropriate post-vasectomy documentation (absence of sperm in the ejaculate 6 months after procedure). For female patients on the study, the vasectomized male partner should be the sole partner for that patient
- True abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
- For patients who are exclusively in same-sex relationships, contraceptive requirements do not apply. If a patient who is in a same-sex relationship at the time of signing the ICF becomes engaged in a heterosexual relationship, they must agree to use contraception as described previously. If a patient who is abstinent at the time of signing the ICF becomes sexually active, they must agree to use contraception as described above.

Collection of Pregnancy Information

Male participants with partners who become pregnant

- The Investigator or designee will attempt to collect pregnancy information on any male patient's female partner who becomes pregnant while the male patient is in this study. This applies only to males who receive study intervention.
- After obtaining the necessary signed informed consent from the pregnant female partner directly, the Investigator or designee will record pregnancy information on the Pregnancy – Initial Report Form and submitted to G1 Therapeutics, Inc. PVG or designee within 24 hours of learning of the partner's pregnancy. The female partner will also be followed to determine the outcome of the pregnancy. The Pregnancy – Follow-up Report Form should be used to report information on the status of the mother and child and will be forwarded to G1 Therapeutics, Inc. PVG or designee. Generally, the follow-up will be no longer than 12 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.
- Contact for Pregnancy reporting:
G1 Therapeutics Pharmacovigilance
Email: safetyreporting@g1therapeutics.com
Fax: +1-984-285-7131

Female Patients who become pregnant

- The Investigator or designee will collect pregnancy information on any female patient who becomes pregnant while participating in this study. The initial information will be recorded on the Pregnancy Reporting and Outcome Form (Pregnancy – Initial Report Form) and submitted to G1 PVG or designee within 24 hours of learning of a patient's pregnancy within 24 hours of learning of a patient's pregnancy.
- The patient will be followed to determine the outcome of the pregnancy. The Investigator or designee will collect follow-up information on the patient and the neonate and the information will be collected on the Pregnancy – Follow-up Report Form and forwarded to G1 Therapeutics, Inc. PVG or designee. Generally, follow-up will not be required for longer than 12 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.
- While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy for medical reasons will be reported as an AE or SAE. A spontaneous abortion (occurring at <22 weeks gestational age) or still birth (occurring at >22 weeks gestational age) is always considered to be an SAE and will be reported as such. Any post-study pregnancy related SAE considered reasonably related to the study intervention by the Investigator will be reported to G1 Therapeutics, Inc. PVG or designee. While the Investigator is not obligated to actively seek this information in former study patients, he or she may learn of an SAE through spontaneous reporting.
- Any female patient who becomes pregnant while participating in the study will discontinue study intervention.
- Contact for Pregnancy reporting:
G1 Therapeutics Pharmacovigilance
Email: safetyreporting@g1therapeutics.com
Fax: +1-984-285-7131

17.4. Definitions of Tumor Response and Disease Progression (per RECIST v1.1)

The determination of tumor response and progression will be based on the RECIST v1.1 ([Eisenhauer, 2009](#)). Disease progression may also be determined clinically by the Investigator. Tumor lesions will be categorized as follows:

Measurable lesions: tumor lesions with a longest diameter (measured in at least 1 dimension) with a minimum size as follows:

- 10 mm by CT or MRI (with a scan slice thickness of no greater than 5 mm)
- Measurable lymph nodes must be ≥ 15 mm on the short axis by CT or MRI (with a scan slice thickness of no greater than 5 mm); only the short axis is to be measured at baseline and follow-up.
- Lytic bone lesions or mixed lytic-blastic lesions with a soft tissue component meeting the definition of measurability above can be considered measurable lesions.
- Cystic lesions representing cystic metastases that meet the definition of measurability described above can be considered measurable lesions. If present, noncystic lesions should be selected as target lesions for this study.
- A tumor lesion that has been previously irradiated may be considered measurable if unequivocal growth of the lesion has been demonstrated.

Target lesions: At baseline, up to 5 measurable tumor lesions/lymph nodes (with a maximum of 2 lesions per organ) should be identified as target lesions. Lesions with the longest diameter, that are representative of all involved organs, and for which reproducible repeated measurements can be obtained should be selected as the target lesions. Malignant lymph node is considered an organ in this study, therefore only 2 malignant lymph nodes (regardless of location) may be selected as target lesions and all others should be entered as nontarget lesions.

Non-measurable Lesions: tumor lesions with a longest diameter < 10 mm, lymph nodes with ≥ 10 to < 15 mm short axis, or non-measurable lesions such as leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, or abdominal masses/abdominal organomegaly identified by physical exam that is not measurable by CT scan or MRI.

Nontarget lesions: All other lesions (or sites of disease) identified at baseline should be identified as nontarget lesions and recorded in the eCRF. Measurements of these lesions are not required, but the presence, absence, or unequivocal progression of each nontarget lesion should be recorded in the eCRF at each follow up time point. Multiple nontarget lesions in the same organ may be noted as a single item on the eCRF.

Evaluation of Target Lesions

The definitions for tumor response for the target lesion per RECIST v1.1 are as follows:

Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm (< 1 cm).

Partial Response: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Progressive Disease: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm (0.5 cm). (Note: the appearance of one or more new lesions is also considered progression).

Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Evaluation of Non-Target Lesions

Complete Response: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (<10 mm [<1 cm] short axis).

Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.

Progressive Disease: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. ‘Unequivocal progression’ represents a substantial increase in overall tumor burden such that treatment should be discontinued even in the setting of SD or PR in the target disease. Although a clear progression of “non-target” lesions only is rare, the opinion of the treating physician should prevail in such circumstances.

Appearance of New Lesions

The appearance of new lesion(s) is considered PD according to RECIST v1.1.

Timepoint Response

Patients with Measurable Disease (i.e., Target ± Non-Target Disease)

Target Lesions	Non-Target Lesions	New Lesions	Overall Response
CR	CR	No	CR
CR	Non-CR/Non-PD	No	PR
CR	NE	No	PR
PR	Non-CR/Non-PD/NE	No	PR
SD	Non-CR/Non-PD/NE	No	SD
NE	Non-PD	No	NE
PD	Any	Yes or No	PD
Any	PD ^a	Yes or No	PD
Any	Any	Yes	PD

CR=complete response; NE=not evaluable; PD: progressive disease; PR=partial response; SD=stable disease.

Note: Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “*symptomatic deterioration*.” Every effort should be made to document the objective progression even after discontinuation of treatment.

^a Unequivocal progression in non-target lesions may be accepted as disease progression.

Patients with Evaluable or Non-Measurable Disease Only (i.e., Non-Target Disease)

Non-Target Lesions	New Lesions	Overall Response
CR	No	CR
Non-CR/non-PD	No	Non-CR/non-PD ^a
Not all evaluated	No	NE
Unequivocal PD	Yes or No	PD
Any	Yes	PD

CR=complete response; NE=not evaluable; PD: progressive disease; SD=stable disease.

^a 'Non-CR/non-PD' is preferred over 'stable disease' for non-target disease since SD is increasingly used as an endpoint for assessment of efficacy in some studies so to assign this category when no lesions can be measured is not advised.



Protocol Title: A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)

Protocol Number: G1T28-210

Compound: Trilaciclib for Injection, 300 mg/vial

Study Phase: 2

Study Name: PRESERVE 4

Sponsor Name: G1 Therapeutics, Inc.

Legal Registered Address: G1 Therapeutics, Inc.
700 Park Offices Dr. Suite 200
PO Box 110341
Research Triangle Park, NC 27709

Regulatory Agency Identifier Numbers: IND: 154630
EudraCT: 2021-000186-32

Approval Date: 20 May 2021 (Version 2.0)

Original Protocol: 01 Feb 2021 (Version 1.0)

This document contains confidential and/or trade secret information that is disclosed only in connection with the licensing and/or registration of products for G1 Therapeutics, Inc. This document should not be disclosed or used, in whole or in part, for any other purpose without the prior written consent of G1 Therapeutics, Inc.

PROTOCOL SIGNATURE PAGE

Sponsor's Approval

I have read and understand the contents of this clinical protocol, Version 2.0 for Study G1T28-210 dated 20 May 2021 and I agree to meet all obligations of the Sponsor as detailed in all applicable regulations and guidelines. In addition, I will inform the Principal Investigator and all other investigators of all relevant information that becomes available during the conduct of the study.

Janet Horton, MD, MHSc
Director, Clinical Development
Physician Sponsor Representative
G1 Therapeutics, Inc.

Date

INVESTIGATOR'S AGREEMENT

Clinical Study Protocol G1T28-210: A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)

Protocol Amendment 1 (Version 2.0) Issue Date: 20 May 2021

Original Protocol (Version 1.0) Issue Date: 01 Feb 2021

I have read the G1T28-210 protocol and agree to conduct the study as outlined. I agree to maintain the confidentiality of all information received or developed in connection with this protocol.

Principal Investigator Signature

Date

Principal Investigator Name

Institution

1. SYNOPSIS

Name of Sponsor/Company: G1 Therapeutics, Inc.		
Name of Investigational Product: Trilaciclib for Injection, 300 mg/vial		
Name of Active Ingredient: Trilaciclib dihydrochloride (hereafter referred to as trilaciclib) (G1T28)		
Protocol Number: G1T28-210	Phase: 2	Country: Worldwide
Title of Study: A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2 nd /3 rd Line Setting (PRESERVE 4)		
Study center(s): Approximately 60 centers		
Study period: Estimated date first patient enrolled: 2Q2021 Estimated date last patient completed: 1Q2024		
Objectives: Primary: To assess the effect of trilaciclib administered prior to docetaxel compared with placebo administered prior to docetaxel on overall survival (OS) in patients with metastatic NSCLC receiving docetaxel in the 2 nd or 3 rd line. Study Design: This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib compared with placebo on OS in metastatic NSCLC patients receiving docetaxel in the 2 nd or 3 rd line setting. Patients must have documented disease progression during or after one or two lines of systemic therapy for recurrent or metastatic NSCLC. Prior treatment must have included, either in the same line or as separate lines of therapy: 1) a maximum of 1 line of platinum-containing chemotherapy for recurrent/metastatic disease and 2) a maximum of 1 line of a locally approved/authorized programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) containing regimen for recurrent/metastatic disease. Patients will be randomly assigned (1:1) to receive trilaciclib or placebo intravenously (IV) prior to docetaxel on Day 1 of each 21-day cycle. There will be 2 stratification factors for randomization: Country and Eastern Cooperative Oncology Group (ECOG) performance status (0-1 versus 2). Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2). Study drugs will be administered as follows: <ul style="list-style-type: none"> Trilaciclib (240 mg/m²) or placebo – administered as a 30-minute IV infusion no more than 4 hours prior to chemotherapy on each day chemotherapy is administered. Docetaxel 75 mg/m² – IV, Day 1 The study will include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of randomization for the first patient and completes at the Post-Treatment visit for the last patient. The first Survival Follow-up assessment should occur ~2 months after the last dose of study drug. The patient may continue to receive treatment on study until disease progression, unacceptable toxicity, withdrawal of consent, discontinuation by Investigator, or the end of the trial, whichever		

occurs first. Treatment cycles will occur consecutively without interruption, except when necessary to manage toxicities or for administrative reasons.

Upon discontinuation of study treatment, patients will be followed for survival, i.e., patients or their caregivers will be contacted approximately every 2 months until the end of the study (or death) to record their status (alive or dead) as well as details of any subsequent systemic anti-cancer therapy initiated.

Methodology:

Sample Size Justification:

The sample size is determined to support the primary objective of the study. That is, to evaluate the effect of trilaciclib compared to placebo on the OS of patients with metastatic NSCLC receiving docetaxel in the 2nd/3rd line setting. A total of 104 deaths will be required to achieve 85% power to detect a hazard ratio (HR) of 0.55 in OS at a 2-sided significance level of 0.05. A HR of 0.55 corresponds to a median OS of 16.5 months for the trilaciclib group assuming a median OS of 9.1 months for the placebo group (Garon, 2014). With a 12-month enrollment period and a 30-month study duration (after the first patient is randomized), a total of 146 patients are required for randomization at a 1:1 ratio to trilaciclib or placebo. This sample size has taken into consideration an interim analysis for OS at the information fraction of 0.70 using the O'Brien-Fleming method for α -spending to ensure strong control of Type I error rate at 1-sided 0.025 between the interim and the final analysis for OS. In the sample size calculation, it is also assumed that about 5% of patients are lost-to-follow-up during the 30-month study duration.

Number of patients (planned):

Approximately 146 patients with NSCLC are planned in this study.

Diagnosis and main criteria for inclusion:

Patients ≥ 18 years of age at the time of signing the informed consent with histologically or cytologically-confirmed metastatic NSCLC. Patients of any histology appropriate for treatment with docetaxel in the 2nd/3rd line will be eligible. Patients must have documented disease progression during or after treatment with platinum-based chemotherapy and a locally approved/authorized PD-1/PD-L1 inhibitor. Patients should not have been previously treated with docetaxel or with therapy targeted to driver mutations. Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is permitted as is ECOG performance status of 0 to 2. At the time of providing informed consent, a formalin-fixed paraffin-embedded (FFPE) tumor specimen (from archival or fresh biopsy) with an associated pathology report documenting NSCLC must be available to send to Sponsor, within the timeframe specified, for planned retrospective biomarker analyses.

Investigational product, dosage and mode of administration:

On Day 1 of each 21-day cycle, a dose of trilaciclib 240 mg/m² diluted in 250 mL of dextrose 5% in water or sodium chloride solution 0.9% will be administered as a 30-minute IV infusion no more than 4 hours prior to docetaxel administration.

Duration of treatment:

Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, discontinuation by Investigator, or the end of the trial, whichever occurs first.

Reference therapy, dosage and mode of administration:

On Day 1 of each 21-day cycle, a dose of placebo (250 mL of dextrose 5% in water or sodium chloride solution 0.9%) will be administered by IV infusion over approximately 30 minutes no more than 4 hours prior to docetaxel administration.

On Day 1 of each 21-day cycle, docetaxel will be administered IV in accordance with the prescribing information and institutional guidelines.

Criteria for evaluation:

Efficacy:

Antitumor efficacy will be assessed by OS, PFS, objective response rate (ORR), and duration of objective response (DOR). Tumor response criteria will be based on RECIST v1.1.

Myelopreservation efficacy will be assessed based on hematology assessments, myelosuppression-related adverse event (AE) details, dose reductions/delays and supportive care interventions (including transfusions).

Safety:

Safety will be evaluated by monitoring AEs, clinical laboratory test results (hematology, clinical chemistry), vital sign measurements (blood pressure, heart rate, and body temperature), 12-lead safety electrocardiogram (ECG) results, dose intensity, and physical examination findings.

PROs:

Patient-reported outcomes (PROs) will be assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-LC13 with supplemental weight loss item (EORTC IL118), Functional Assessment of Chronic Illness Therapy – Fatigue Scale (FACIT-Fatigue), Patient Global Impression of Change (PGIC), Patient Global Impression of Severity (PGIS), and 5-level EQ-5D (EQ-5D-5L).

Pharmacodynamics:

Pharmacodynamics will be assessed using peripheral blood to evaluate potential markers of response and resistance, including immune effects.

Statistical methods:

Data will be summarized by treatment group. The descriptive summary for the categorical variables will include counts and percentages. The descriptive summary for the continuous variables will include means, standard deviations, medians, 25% and 75% percentiles, and minimum and maximum values.

Stratification factors and factors used in statistical models:

There are two stratification factors for randomization: country and ECOG performance status (0-1 versus 2). Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2). A randomization schema will be in place to ensure the best possible balance of treatment assignment within each stratum produced by these stratification factors. Countries will be grouped into the factor of “region” with 3 components: United States (US), Europe, and Asia. The factor “region” will be used instead of “country” in the statistical analysis models to account for regional differences in clinical practice.

Analysis population

The intent-to-treat (ITT) population includes all randomized patients. Analyses for the ITT population will be conducted based on the randomly assigned treatment regardless of whether the patient received study treatment or was compliant with the protocol. Unless otherwise specified, the ITT population is the primary population for all efficacy analyses.

The **response evaluable (RE) population** will include patients in the ITT population who have a measurable lesion (target lesions) at the baseline tumor assessment, and either (i) have at least 1 post-dose tumor assessment, or (ii) do not have post-dose tumor assessment but have clinical progression as noted by the Investigator, or (iii) have died due to disease progression before their first post-dose tumor scan. RE population will be the primary analysis set to evaluate tumor response and the data will be analyzed based on the randomly assigned treatment.

The safety population includes all randomized patients who received at least one dose of study drug. Analyses conducted on the safety population will be based on the actual treatment received. All safety analyses will be conducted using the safety population.

The pharmacokinetic (PK) population will include all patients who received at least one dose of study drug and had evaluable PK data.

Statistical analysis methods for primary and secondary endpoints

Analysis for Primary Endpoint

The primary endpoint OS is defined as the time (months) from the date of randomization to the date of death for patients who died in the study due to any cause, and the time to the last contact date known to be alive for those who survived as of the data cutoff date for the interim OS analysis or as of the date for the final database lock (censored cases). Patients lacking data beyond the date of randomization will have their survival time censored at the date of randomization. The targeted number of deaths for the final analysis is 104 and the analysis for OS is event-driven.

Treatment effect on OS will be primarily evaluated using a stratified log-rank test controlling for the stratification factors of region (US, Europe, or Asia), and ECOG performance status (0-1 versus 2). Unless otherwise specified, ECOG status information as entered in the Interactive Web Response System (IWRS) at the time of randomization will be used as the factor for this and all other stratified analyses. The magnitude of the treatment effect, HR (trilaciclib versus placebo), will be estimated using a Cox proportional hazard model with the same factors as included in the stratified log-rank test. Additionally, the Kaplan-Meier plots will be generated, and the median, 25% and 75% percentile of OS will be estimated using the Kaplan-Meier method with their corresponding 95% confidence interval calculated based on the method by [Brookmeyer and Crowley \(1982\)](#) for each treatment group. The analyses for OS will be performed on the ITT population.

Interim Analysis for OS

An interim analysis of OS will be conducted at the 70% information fraction, that is, when 73 deaths are observed. The timing of the interim analysis is estimated to be approximately **19 months** after the first patient is randomized in the study. To perform the interim analysis, the database will be locked. If the interim OS analysis result by the stratified log-rank test is positive as determined by the pre-specified statistical criterion, the study will be stopped for success and the results from the interim OS analyses are considered to be final. If the interim OS analysis result does not meet the criterion of success, the study will continue until a total of 104 deaths are observed. At that time, the study database will be locked to perform the final OS analysis. It is estimated that it will take approximately 30 months after the first patient is randomized in the study to reach the total targeted number of deaths in this study.

Analysis for secondary anti-tumor efficacy endpoints

PFS

PFS is defined as the time (months) from date of randomization until date of documented radiologic disease progression (PD) per RECIST v1.1 or death due to any cause, whichever comes first. For patients who do not experience PD or are alive at time of performing the analysis, PFS will be calculated per censoring rules detailed in the Statistical Analysis Plan (SAP).

Per literature, the expected median PFS for patients receiving docetaxel is 3 months ([Garon, 2014](#)). Assuming trilaciclib can achieve a treatment effect of HR of 0.60, it is estimated that at the time of performing the OS interim analysis, 86% of patients would have a radiographic-determined disease progression or died. Therefore, the analysis for PFS will be conducted at the time when the OS interim analysis is conducted since the PFS events are considered mature. Treatment effect on PFS will be evaluated using the stratified log-rank test controlling for the two stratification factors. A Cox proportional hazard model with the same terms as in the stratified log-rank test will be used to estimate the HR between the 2 treatment groups (trilaciclib versus placebo) for PFS along with its 95%

confidence interval. In addition, the Kaplan-Meier plots will be produced, and the median, 25% and 75% percentile of PFS will be estimated using the Kaplan-Meier method with their corresponding 95% confidence interval calculated based on the method by [Brookmeyer and Crowley \(1982\)](#) for each treatment group. PFS will be analyzed on the ITT population.

Tumor Response

Objective response is defined as achieving either complete response (CR) or partial response (PR) per RECIST v1.1. The ORR along with its exact 95% two-sided confidence interval using the Clopper-Pearson method will be computed for each treatment group. The treatment effect on ORR will be evaluated using a stratified Cochran-Mantel-Haenszel (CMH) method to account for the two stratification factors. The adjusted proportion difference (trilaciclib minus placebo) and its 95% confidence intervals will be calculated using CMH weight. ORR will be analyzed on the Response Evaluable patient population.

DOR is the time (months) between the date achieving first objective response (CR or PR), confirmed at the next tumor scan, and the date of documented disease progression per RECIST v1.1 or death, whichever comes first. Patients who do not experience objective CR or PR will not be included in the analysis. For patients with objective response who do not reach radiographically determined PD or die at the time of analysis, censored time will be calculated following the rules detailed in Section [12.4.6.2.2](#). The median, 25% and 75% percentile of DOR will be estimated using the Kaplan-Meier method with their corresponding 95% confidence interval calculated based on the method by [Brookmeyer and Crowley \(1982\)](#) for each treatment group.

Analysis for safety endpoints

Safety and tolerability will be assessed by AEs, dose modifications, laboratory tests, vital signs, and ECG. Safety data will be summarized using descriptive statistics by treatment group based on the safety population. AEs are defined as those events occurring or worsening after treatment has begun on this study. AE data will be coded to system organ class (SOC) and preferred term (PT) using the latest version of Medical Dictionary for Regulatory Activities (MedDRA). The severity (toxicity grades 1-5) will be summarized by SOC, PT and CTCAE grade, as appropriate. In the tabulation of severity and causality for an AE, if the same AE occurs on multiple occasions, the highest grade and strongest relationship to study drug will be used. Concomitant medications, as well as prior and subsequent anticancer therapies, will be coded to Anatomical Therapeutic Classification (ATC) using the World Health Organization-Drug Dictionary (WHO-DD) and summarized by treatment group.

For laboratory assessments, vital signs, and ECG intervals, observed values and changes from baseline will be summarized by treatment group. For serum chemistry AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 by Investigators. AEs overall, AEs related to each study drug, AEs leading to study drug discontinuation or dose modifications, and trilaciclib AEs of special interests (AESIs) will be summarized by SOC, PT and CTCAE grade, as appropriate. For laboratory assessments, vital signs, and ECG intervals, observed values and changes from baseline will be summarized by treatment group. For serum chemistry and hematology laboratory parameters, clinical labs will be characterized according to CTCAE toxicity grade from 1 to 5, v5.0 when possible, and the number and percentage of patients within each CTCAE grade will be summarized for the overall treatment period as well as for each cycle. Safety data collected through scheduled or unscheduled visits will all be included in the safety evaluation.

Pharmacokinetic/Pharmacodynamic Analyses

Analyses may be performed to examine the relationship(s) between exposure to trilaciclib and pharmacodynamic endpoints or other efficacy and safety endpoints.

2. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES

TABLE OF CONTENTS

PROTOCOL SIGNATURE PAGE	2
INVESTIGATOR'S AGREEMENT	3
1. SYNOPSIS	4
2. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES	9
3. LIST OF ABBREVIATIONS.....	15
4. INTRODUCTION	21
4.1. Lung Cancer.....	21
4.2. Study Rationale.....	22
4.2.1. Rationale for Improving Anti-tumor Efficacy with Trilaciclib	23
4.2.2. Rationale for Immunogenicity of NSCLC Tumor Type and Docetaxel Chemotherapy	25
4.2.3. Rationale for Immune Mechanism of Trilaciclib	26
4.2.4. Rationale for Trilaciclib following Progression on Immunotherapy	26
4.2.5. Rationale for Myelopreservation	27
4.2.6. Rationale for Combination with Docetaxel	27
4.2.7. Summary of Nonclinical Data	28
4.2.7.1. Pharmacology Studies	28
4.2.7.2. Pharmacokinetic Studies.....	30
4.2.8. Summary of Clinical Data	31
4.2.8.1. Trilaciclib.....	31
4.2.8.2. Trilaciclib Risks.....	35
4.2.8.3. Docetaxel	37
4.3. Benefit/Risk Assessment	37
5. OBJECTIVES AND ENDPOINTS.....	39
6. INVESTIGATIONAL PLAN.....	42
6.1. Overall Study Design.....	42
6.2. Rationale for Primary and Secondary Endpoints.....	43
6.2.1. Anti-tumor Efficacy.....	43
6.2.2. Myelopreservation Efficacy.....	43
6.2.3. Patient-Reported Outcomes	43

6.2.4.	Safety	44
6.3.	Rationale for Dose and Schedule of Study Treatment.....	44
6.3.1.	Trilaciclib.....	44
6.3.2.	Docetaxel	45
6.4.	Rationale for Supportive Care Interventions	45
6.5.	Rationale for Patient Population	45
6.6.	Rationale for Stratification Factors.....	45
7.	STUDY POPULATION	47
7.1.	Inclusion Criteria	47
7.2.	Exclusion Criteria	48
8.	SCHEDULE OF ASSESSMENTS.....	50
9.	STUDY TREATMENT	54
9.1.	Study Drugs Administered	54
9.1.1.	Dose, Dosing Regimen, and Route.....	54
9.1.1.1.	Trilaciclib/Placebo	54
9.1.1.2.	Docetaxel	55
9.1.2.	Preparation, Handling, Storage, and Accountability	56
9.1.3.	Treatment Compliance.....	56
9.2.	Criteria for Starting Each Cycle	56
9.3.	Toxicity Management and Dose Modifications	57
9.3.1.	Dose reduction	57
9.3.2.	Safety Criteria for Adjustment or Stopping Doses	59
9.3.3.	Recommended Actions with Trilaciclib/Placebo for Adverse Events of Special Interest.....	61
9.3.4.	Hy's Law Management.....	62
9.4.	Supportive Care Interventions	63
9.4.1.	Colony Stimulating Factor Usage.....	63
9.4.2.	Erythropoiesis-Stimulating Agent Usage	64
9.4.3.	Transfusions.....	64
9.5.	Prior/Concomitant Medications and Procedures	64
9.6.	Measures to Minimize Bias: Randomization and Blinding.....	65
9.7.	Intervention after End of Study Treatment.....	66

10.	DISCONTINUATION OF STUDY INTERVENTION AND PATIENT DISCONTINUATION/WITHDRAWAL	67
10.1.	Discontinuation of Study Treatment.....	67
10.2.	Discontinuation/Withdrawal from the Study	67
10.3.	Lost to Follow-Up.....	68
10.4.	Study and Site Start and Closure	68
11.	STUDY ASSESSMENTS	70
11.1.	Screening Assessments	70
11.1.1.	Randomization	70
11.1.2.	Demographics	70
11.1.3.	Medical History and NSCLC Cancer Disease History	70
11.2.	Anti-tumor Efficacy Assessments	71
11.2.1.	Anti-tumor Efficacy Assessment	71
11.2.2.	Myelopreservation Assessments.....	72
11.3.	Safety Assessments.....	72
11.3.1.	Vital Signs	72
11.3.2.	Physical Examination	72
11.3.3.	ECOG Performance Status	72
11.3.4.	Electrocardiogram.....	73
11.3.5.	Clinical Safety Laboratory Assessments	73
11.3.6.	Adverse and Serious Adverse Events	74
11.3.6.1.	Time Period and Frequency for Collecting Adverse and Serious Adverse Event Information	74
11.3.6.2.	Method of Detecting Adverse and Serious Adverse Events.....	75
11.3.6.3.	Follow-up of Adverse and Serious Adverse Events	75
11.3.6.4.	Regulatory Reporting Requirements for Serious Adverse Events	75
11.3.6.5.	Pregnancy	75
11.4.	Patient-Reported Outcomes	76
11.4.1.	EORTC QLQ-C30 and EORTC QLQ-LC13	76
11.4.2.	FACIT-Fatigue	76
11.4.3.	Patient Global Impression of Change and Patient Global Impression of Severity	77
11.4.4.	5-Level EQ-5D	77

11.5.	Pharmacokinetics	77
11.6.	Biomarkers	78
11.6.1.	Rationale for Archival Tumor Collection	78
11.6.2.	Description of CDK4/6 Signature	78
11.7.	Immunologic and Hematologic Markers	79
11.8.	Data Monitoring Committee	79
11.10.	Survival Follow-up Phase	80
12.	STATISTICAL CONSIDERATIONS	81
12.1.	Sample Size Determination	81
12.2.	Analysis Population	81
12.3.	Timing of Planned Analysis	81
12.3.1.	First Planned Analysis – Interim Analysis for Overall Survival and Analyses for Progression Free Survival, Tumor Responses and Myelosuppression Endpoints	81
12.3.2.	Second Planed Analysis – Final Analysis for Overall Survival and Safety Data Analyses	82
12.4.	Statistical Analysis Methods	82
12.4.1.	General Considerations	82
12.4.2.	Patient Disposition	83
12.4.3.	Demographic and Baseline Characteristics	83
12.4.4.	Prior and Subsequent Anticancer Therapies	83
12.4.5.	Study Drug Exposure, Modification and Dose Intensity	83
12.4.6.	Efficacy Analyses	84
12.4.6.1.	Analyses of Primary Efficacy Endpoint – Overall Survival	84
12.4.6.2.	Analysis for Secondary Anti-tumor Efficacy Endpoints	85
12.4.6.3.	Analysis for Myelosuppression Endpoints	87
12.4.6.4.	Subgroup Analysis for Primary Efficacy Endpoint	88
12.4.7.	PRO Analyses	88
12.4.8.	Safety Analyses	88
12.4.8.1.	Adverse Events	88
12.4.8.2.	Other Safety Endpoints	89
12.4.9.	Exploratory Analyses	89
12.4.10.	Pharmacokinetic Analyses	89

12.4.11.	Pharmacokinetic/Pharmacodynamic Analyses	90
13.	ETHICS	91
13.1.	Ethics Review	91
13.2.	Ethical Conduct of the Study	91
13.3.	Written Informed Consent	91
14.	DATA HANDLING AND RECORDKEEPING	92
14.1.	Data Protection	92
14.2.	Data Quality Assurance	92
14.3.	Dissemination of Clinical Study Data	93
14.4.	Source Documents	93
14.5.	Audits and Inspections	93
15.	PUBLICATION POLICY	94
16.	REFERENCES	95
17.	APPENDICES	105
17.1.	Clinical Laboratory Tests	105
17.2.	Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting	106
17.2.1.	Definition of AE	106
17.2.2.	Definition of SAE	107
17.2.3.	Recording and Follow-Up of AE and/or SAE	109
17.2.4.	Reporting of SAEs	111
17.3.	Contraceptive Guidance and Collection of Pregnancy Information	112
17.4.	Definitions of Tumor Response and Disease Progression (per RECIST v1.1)	115

LIST OF TABLES

Table 1:	Abbreviations	15
Table 2:	Integrated Analysis for Myelopreservation Efficacy in SCLC (Studies G1T28-02, G1T28-03, and G1T28-05)	32
Table 3:	G1T28-04: Summary of Overall Survival and Progression-Free Survival (ITT Analysis Set)	33
Table 4:	G1T28-04: Tumor Response According to PD-L1 Status	34
Table 5:	Objectives and Endpoints	39
Table 6:	Schedule of Assessments	51

Table 7:	Study Drugs	54
Table 8:	Recommended Chemotherapy Dose Modifications	57
Table 9:	Recommended Dose Modification for Drug-Related Hematologic Toxicity.....	59
Table 10:	Recommended Actions with Trilaciclib/Placebo Following AESIs	61
Table 11:	Patient Risk Factors for Poor Clinical Outcomes Resulting from Febrile Neutropenia or Infection.....	64
Table 12:	ECOG Performance Status	73
Table 13:	Thresholds for Claiming Statistical Superiority (Trilaciclib versus Placebo) at Interim or Final Analysis for Overall Survival.....	85
Table 14:	Protocol-Specified Safety Laboratory Assessments	105

LIST OF FIGURES

Figure 1:	Trilaciclib Transiently Arrests Normal Cells to Prevent Chemotherapy-Induced Myelosuppression and Improve Anti-Tumor Efficacy	23
Figure 2:	G1T28-04: Overall Survival – Kaplan-Meier Curve (ITT Analysis Set).....	24
Figure 3:	The Addition of Trilaciclib to Chemotherapy/Immune Checkpoint Inhibitor Treatment Enhances Efficacy Through T Cell Activation	29
Figure 4:	Study Design.....	42

3. LIST OF ABBREVIATIONS

The following abbreviations and specialist terms are used in this study protocol.

Table 1: Abbreviations

Abbreviation	Definition
5-FU	5-fluorouracil
AE	adverse event
AESI	adverse event of special interest
ALK	anaplastic lymphoma kinase
ALT	alanine aminotransferase
ANC	absolute neutrophil count
ANCOVA	analysis of covariance
aPTT	activated partial thromboplastin time
aRR	adjusted relative risk
ASCO	American Society of Clinical Oncology
AST	aspartate aminotransferase
ATC	Anatomical Therapeutic Classification
AUC	area under the concentration-time curve
BCRP	breast cancer resistance protein
BED	biologically effective dose
β-hCG	beta human chorionic gonadotropin
BICR	blinded independent central review
BMI	body mass index
BOR	best overall response
BSA	body surface area
BSEP	bile salt export pump
CAP	College of American Pathologists
CBC	complete blood count
CD	cluster of differentiation
CDK	cyclin-dependent kinase
CFR	Code of Federal Regulations
CI	confidence interval
CIM	chemotherapy-induced myelosuppression

Abbreviation	Definition
CMH	Cochran-Mantel-Haenszel
CNS	central nervous system
CPS	combined positive score
CR	complete response
CT	computed tomography
CTCAE	Common Terminology Criteria for Adverse Events
CTLA-4	cytotoxic T-lymphocyte associated protein 4
CYP	cytochrome P450
D5W	dextrose 5% in water
DC	dendritic cell
DCAF	d-type cyclin activating features
DDI	drug-drug interaction
DMC	Data Monitoring Committee
DNA	deoxyribonucleic acid
DOR	duration of objective response
DSN	duration of severe neutropenia
ECG	electrocardiogram
ECOG	Eastern Cooperative Oncology Group
eCRF	electronic case report form
EDC	electronic data capture
EGFR	epidermal growth factor receptor
EMA	European Medicines Agency
EORTC QLQ-C30	European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire
EORTC QLQ-LC13	European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module
EORTC IL118	European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module with supplemental weight loss item
EOT	End of Treatment
E/P	etoposide plus carboplatin
E/P/A	cisplatin, etoposide and atezolizumab
ES-SCLC	extensive stage SCLC
EQ-5D-5L	5-level EQ-5D

Abbreviation	Definition
EQ-VAS	EQ visual analogue scale
ER	estrogen receptor
ESA	erythropoiesis stimulating agent
FACIT-Fatigue	Functional Assessment of Chronic Illness Therapy - Fatigue
FDA	Food and Drug Administration
FFPE	formalin-fixed paraffin-embedded
FN	febrile neutropenia
FSH	follicle stimulating hormone
G ₁	gap 1 phase of the cell cycle
G ₂	gap 2 phase of the cell cycle
G1T28	trilaciclib; formerly G1T28-1
GC	gemcitabine and carboplatin
GC therapy	gemcitabine and carboplatin on Days 1 and 8 of 21-day cycles
GCP	Good Clinical Practice
G-CSF	granulocyte colony-stimulating factor
GI	gastrointestinal
GM-CSF	granulocyte-macrophage colony-stimulating factor
HBV	hepatitis B virus
HCV	hepatitis C virus
HER2	human epidermal growth factor receptor 2
HIV	human immunodeficiency virus
HR	hazard ratio
HRT	hormone replacement therapy
HSPC	hematopoietic stem and progenitor cell
IB	Investigator's Brochure
IC	tumor-infiltrating immune cells
IC ₅₀	half maximal inhibitory concentration
ICF	informed consent form
ICH	International Council for Harmonisation
ICI	immune checkpoint inhibitors
IEC	independent ethics committee

Abbreviation	Definition
IFN	interferon
IHC	immunohistochemistry
ILD	interstitial lung disease
INR	International Normalized Ratio
IP	intraperitoneal
IRB	institutional review board
ISH	in situ hybridization
ITT	intent-to-treat
IV	intravenous
IWRS	Interactive Web Response System
Ki	inhibition constant
LFT	liver function test
M	mitosis
mAb	monoclonal antibody
MATE1 or 2-K	multidrug and toxin extrusion 1 or 2-K
MDR1	p-glycoprotein
MedDRA	Medical Dictionary for Regulatory Activities
MHC	major histocompatibility complex
MOA	mechanism of action
MRI	magnetic resonance imaging
MRP1 or 2	multidrug resistance protein 1 or 2
NCCN	National Comprehensive Cancer Network
NCI	National Cancer Institute
NE	not evaluable
NSCLC	non-small cell lung cancer
NYHA	New York Heart Association
OAT1 or 3	organic anion transporter 1 or 3
OATP1B1 or 1B3	organic anion transporting polypeptide 1B1 or 1B3
OCT1 or 2	organic cation transporter 1 or 2
ORR	objective response rate
OS	overall survival

Abbreviation	Definition
PCS	potentially clinically significant
PD	progressive disease
PD-1	programmed cell death protein 1
PD-L1	programmed death-ligand 1
PDX	patient derived xenografts
PFS	progression-free survival
PGIC	Patient Global Impression of Change
PGIS	Patient Global Impression of Severity
PK	pharmacokinetic(s)
PR	partial response
PRO	patient-reported outcome
PSA	prostate-specific antigen
PT	preferred term
PTFE	polytetrafluoroethylene
PVG	pharmacovigilance
QTcF	QT corrected using Fridericia's formula
Rb	retinoblastoma protein
RB	retinoblastoma gene
RBC	red blood cell
RE	Response Evaluable
RECIST	Response Evaluation Criteria in Solid Tumors
ROS1	c-ROS oncogene 1
RP2D	recommended Phase 2 dose
S	synthesis phase of the cell cycle
SAE	serious adverse event
SAP	statistical analysis plan
SCLC	small cell lung cancer
SD	stable disease
SOC	system organ class
SN	severe neutropenia
SUSAR	suspected unexpected serious adverse reactions

Abbreviation	Definition
TCR	T cell receptor
TEAE	treatment-emergent adverse event
TIM3	T-cell immunoglobulin and mucin domain 3
TNBC	triple-negative breast cancer
T _{reg}	regulatory T cells
TTCD-fatigue	Time to confirmed deterioration of fatigue
ULN	upper limit of normal
US	United States
VAS	visual analog scale
WHO-DD	World Health Organization Drug Dictionary

4. INTRODUCTION

4.1. Lung Cancer

Worldwide, there were more than 2 million cases of lung cancer and 1.75 million lung cancer related deaths in 2018 (WHO, 2020). The American Cancer Society estimates that in 2020, ~135,000 of those lung cancer deaths will occur in the US alone (American Cancer Society, 2020). Approximately 84% of these patients will be diagnosed with non-small cell lung cancer (NSCLC) and almost 70% will present with locally advanced or metastatic disease (ASCO, 2020; Little, 2007). Historically, treatment in the metastatic setting has been driven almost exclusively by the use of systemic chemotherapy. However, in the last ten to twenty years, a greater understanding of the pathways that dictate tumor response and the advent of multiple targeted therapies has changed the landscape of treatment options significantly. Lung tumors are routinely tested for the presence of specific driver mutations (e.g., epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], BRAF, and cROS- oncogene 1 [ROS1]), that predict a favorable response to targeted tyrosine kinase inhibitors (Kalemkerian, 2018). As many as 50% to 64% of patients have been identified as having a targetable genetic alteration and those that receive treatment have better outcomes (Kris, 2014; Barlesi, 2016).

For those patients without a targetable genetic alteration, treatment options have also changed considerably. Though systemic therapy remains an important component of treatment in this context, the advent of immunotherapy has significantly improved outcomes for this patient population. Multiple randomized trials, in both squamous and non-squamous histologies, have established that overall survival (OS) is improved with the addition of programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitors (Spigel, 2019; Reck, 2016; Gandhi, 2018; Paz-Ares, 2018). Those with high levels of PD-L1 expression typically receive pembrolizumab or atezolizumab monotherapy in the first line followed by platinum-based chemotherapy in order to maximize treatment response and minimize toxicity. Those with a higher burden of disease requiring more aggressive initial treatment or with lower levels of PD-L1 expression typically receive immunotherapy in combination with a platinum-based chemotherapy doublet.

Despite these improvements in the therapy for metastatic NSCLC, the majority of patients ultimately progress during or after treatment with immunotherapy and platinum-based chemotherapy. Management of this pretreated patient population is challenging and treatment options are limited to single agent chemotherapies such as docetaxel, pemetrexed (for those with non-squamous histology), and gemcitabine (Shepherd, 2000; Fossella, 2010; Gridelli, 2004; Hanna, 2004; Anderson, 2000). The clinical trials that established these treatment options predated immunotherapies and robust data for individual agents is often lacking. The high-level evidence that does exist demonstrates a limited impact of 2nd line therapy on treatment outcomes. For example, in a study where 1,253 patients were treated with docetaxel plus or minus the VEGFR2 inhibitor ramucirumab following progression on platinum-based- chemotherapy, survival was significantly improved with the addition of ramucirumab, but the clinical benefit was only 1.5 months (hazard ratio [HR] 0.86, p=0.023) (Garon, 2014).

In contrast, the large Phase 3 studies evaluating the addition of immunotherapy in the first line consistently demonstrated large treatment effects (HRs ~0.5-0.6) that were both statistically

significant and highly clinically meaningful (Spigel, 2019; Reck, 2016; Gandhi, 2018; Paz-Ares, 2018). In an effort to translate these early successes to later lines of therapy, numerous ongoing Phase 3 studies are evaluating the continuation of PD-1/PD-L1 inhibitors (following progression on the same) in combination with kinase inhibitors hypothesized to synergistically illicit an ongoing immune response. However, the mechanisms of immune checkpoint inhibitor (ICI) resistance are complex and include genetic, epigenetic, and cellular signaling alterations that dysregulate neoantigen presentation/processing and disrupt cytotoxic T cells activity as well as mechanisms in which non-cancerous stromal or immune cells promote growth and resistance to ICIs (Liu, 2019; Barrueto, 2020; Jenkins, 2018; Fares, 2019; Borchering, 2018; Gidel, 2018). Novel therapies, whose mechanisms broadly target these ICI mechanisms of resistance, including CDK4/6 inhibition, could be particularly valuable following disease progression on currently clinically available immunotherapies.

In addition to the need for therapies that more effectively extend overall survival, patients treated in the metastatic setting are particularly vulnerable to the chemotherapy-induced myelosuppression (CIM) and health-related quality of life impacts associated with extensive systemic therapy. CIM is a significant issue in cancer treatment; patients with myelosuppression are more likely to experience infections, sepsis, bleeding, and fatigue, often leading to the need for hospitalizations, hematopoietic growth factor support, transfusions (red blood cells [RBCs] and/or platelets) and even death (Caggiano, 2005; Gustinetti, 2016; Bodey, 1966; Li, 2016). Moreover, CIM commonly leads to dose reductions and delays, which limit therapeutic dose intensity and can compromise the anti-tumor efficacy benefits of chemotherapy. Furthermore, existing supportive care interventions for CIM are generally used after the onset of symptoms, only address the deficiency of a single blood cell lineage and carry their own set of risks and limitations. Introducing a therapy that can protect the hematopoietic stem and progenitor cells (HSPCs) of the host from CIM has the potential to maximize the anti-tumor activity of the chemotherapy while minimizing the consequences to the patient of chemotherapy-induced cellular damage.


In summary, though immunotherapy has markedly improved the treatment of metastatic NSCLC, options following disease progression on these therapies remain limited. An alternative therapy that extends the duration of OS without significant additive toxicity, while concurrently decreasing myelosuppression and improving quality of life, would be a welcome addition in this heavily pretreated and often clinically fragile patient population. Therefore, further evaluation of trilaciclib in this area of high unmet medical need is warranted.

4.2. Study Rationale

Trilaciclib is a highly potent and selective, reversible, cyclin-dependent kinase (CDK) 4/6 inhibitor that preserves HSPCs as well as immune system function during chemotherapy (myelopreservation) in addition to directly enhancing anti-tumor immunity (anti-cancer efficacy) (Figure 1). Both HSPC and lymphocyte proliferation are dependent on CDK4/6 activity (Kozar, 2004; Malumbres, 2004; Ramsey, 2007; Horsley, 2008) and become arrested in the gap 1 (G₁) phase of the cell cycle upon exposure to trilaciclib (He, 2017). This trilaciclib-induced transient cell cycle arrest has been demonstrated to provide resistance to chemotherapy-induced cell damage by preventing HSPCs from proliferating in the presence of cytotoxic chemotherapy and favorably altering the tumor immune microenvironment through transient T-cell inhibition

when combined with chemotherapy and ICIs (He, 2017; Bisi, 2016; Lai, 2020). In February 2021, the FDA approved trilaciclib (COSELA™) as a treatment to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

Figure 1: Trilaciclib Transiently Arrests Normal Cells to Prevent Chemotherapy-Induced Myelosuppression and Improve Anti-Tumor Efficacy



4.2.1. Rationale for Improving Anti-tumor Efficacy with Trilaciclib


The use of trilaciclib for patients with triple-negative breast cancer (TNBC) was evaluated in Study G1T28-04, a global, multicenter, randomized, open-label, Phase 2 clinical trial to evaluate the safety, efficacy, and pharmacokinetics (PK) of trilaciclib administered prior to gemcitabine/carboplatin (GC) therapy for patients with locally advanced unresectable/metastatic TNBC who had previously been treated with 0 to 2 lines of therapy in the metastatic setting. Patients were randomized 1:1:1 to one of two different trilaciclib + GC treatment regimens or GC alone. Based on its mechanism of action (MOA), it was hypothesized that trilaciclib administered before chemotherapy could protect the bone marrow from the cytotoxic effects of chemotherapy, while also enhancing immune activity in patients with TNBC, thus potentially improving both safety and anti-tumor activity.

The G1T28-04 study was the first evaluation of trilaciclib in a tumor type other than small cell lung cancer (SCLC), where trilaciclib development has focused on myelopreservation benefits (Section 4.2.8.1). Three randomized, double-blind, Phase 2 clinical trials (G1T28-02, G1T28-03 and G1T28-05) evaluating trilaciclib/placebo administered prior to chemotherapy in patients

with SCLC have demonstrated in a variety of clinical settings (first-, second-, third-line SCLC treated with several different classes of chemotherapy) that trilaciclib can prevent chemotherapy -induced myelosuppression as measured by multiple endpoints (Section 4.2.8.1; Table 2; Weiss, 2019; Hart, 2019; Daniel, 2019). While the benefit in chemotherapy-induced myelosuppression in these studies was striking, these myelopreservation benefits were observed in the setting of only minor improvements in progression-free survival (PFS) and OS as evidenced by HRs <1.0 in almost all clinical settings for trilaciclib compared with placebo.

In contrast to the previously observed SCLC results, the addition of trilaciclib to chemotherapy for patients with TNBC in G1T28-04 did not result in statistically significant improvements in myelosuppression endpoints, but instead resulted in a substantial improvement in anti-tumor efficacy as measured by OS (median OS duration in control: 12.6 months versus not evaluable or 17.8 months in the two trilaciclib groups, HR: 0.31 [p=0.0016] and HR: 0.40 [p=0.0004], respectively; Figure 2) and by PFS (median PFS in control 5.7 months versus 9.4 months or 7.3 months in the two trilaciclib groups HR: 0.65 and 0.57, respectively; not statistically significant) (O'Shaughnessy, 2020; Tan, 2019). The clinically meaningful anti-tumor efficacy results observed in G1T28-04 were noted across both of the trilaciclib treatment groups and in the context of a control group with survival reflective of published literature.

Figure 2: G1T28-04: Overall Survival – Kaplan-Meier Curve (ITT Analysis Set)



CI=confidence interval; HR=hazard ratio; ITT=intent-to-treat; NR=not reached.

Group 1: GC administered on Days 1 and 8 of 21-day cycles; Group 2: Trilaciclib and GC administered on Days 1 and 8 of 21-day cycles; Group 3: Trilaciclib administered on Days 1, 2, 8, and 9 and GC administered on Days 2 and 9 of 21-day cycles

Note: The HR and its 95% CI comparing Group 1 and 2 and Group 1 and 3 were calculated using the Cox regression model with treatment and stratification factors of number of prior lines of therapy (0 versus 1 or 2) and liver involvement.

Note: P-values comparing Group 1 and 2 and Group 1 and 3 were calculated using the stratified log-rank test to account for the number of prior lines of therapy (0 versus 1 or 2) and liver involvement as the stratification factors.

Note: data generated from final database.

The impact on OS was consistent across subgroups, including predictors of immune response. Approximately 57.6% of the available tumor samples in G1T28-04 were considered PD-L1 positive (Ventana SP142 assay), and though larger in the PD-L1 positive population, the benefit of adding trilaciclib extended to both PD-L1 positive and negative cohorts (Table 4).

The translation of these anti-tumor efficacy findings to other tumor types is predicted to be primarily driven by the tumor type, chemotherapy type and host, i.e., (1) the tumor must be sufficiently immunogenic and sensitive to the host cytolytic efforts as to see improvement in anti-tumor endpoints like OS, (2) the chemotherapy should promote immune activation, and (3) the host must be able to mount an effective cytolytic response against the tumor. In the SCLC trials, the addition of trilaciclib to the standard of care therapies provided modest improvement, to neutral effects, on measures of anti-tumor efficacy including objective response rate (ORR), PFS and OS. These results are not surprising considering that SCLC is one of the most aggressive solid tumors and is not particularly immunogenic or sensitive to immune modulation (Wang, 2019).

In contrast, NSCLC has been extensively documented as sensitive to immune modulation with multiple established immunotherapy treatment options in the early lines of treatment for metastatic NSCLC (Spigel, 2019; Wang, 2019; Reck, 2016; Gandhi, 2018; Paz-Ares, 2018). This highly responsive NSCLC immune milieu and the novel trilaciclib immune activating effects described below provide a strong rationale to evaluate the efficacy of trilaciclib in patients with previously treated NSCLC.

4.2.2. Rationale for Immunogenicity of NSCLC Tumor Type and Docetaxel Chemotherapy

While NSCLC has been recognized as having an immunosuppressive tumor microenvironment through high numbers of regulatory T cells (T_{reg}) directly inhibiting T-cell proliferation (Woo, 2001; Woo, 2002), tumor-infiltrating cluster of differentiation (CD) 8^{+} T cells with increased PD-1 expression (Zhang, 2010), and downregulation of major histocompatibility complex (MHC) class I/tumor antigen expression (Korkolopoulou, 1996), results from numerous trials evaluating immunotherapeutic agents, including immune checkpoint inhibitors, have demonstrated the efficacy of this approach in NSCLC (Spigel, 2019; Reck, 2016; Gandhi, 2018; Paz-Ares, 2018).

A number of immune correlates of clinical outcome in patients with NSCLC have been identified providing clinical evidence for immune system involvement in NSCLC. High levels of infiltrating CD 8^{+} , CD 4^{+} , CD 3^{+} T cells as well as higher densities of mature dendritic cells (DCs) have been associated with improved survival (Wing, 2008; Chen, 2012). Conversely, the number of T_{reg} cells as well as PD-L1 expression in NSCLC tumors have been shown to be independent predictors of reduced survival or unfavorable prognosis in patients with NSCLC, respectively (Petersen, 2006; Shimizu, 2010; Mu, 2011).

In addition to the inherent immunogenicity associated with NSCLC, docetaxel has demonstrated an ability to enhance the sensitivity of tumors to immune-mediated cell death (Hodge, 2013). In particular, immune modulating effects on the tumor stroma have been noted (Opzomer, 2019). *In vivo*, docetaxel has been shown to induce selective cell death in myeloid-derived suppressor cells known to contribute to immune suppression while simultaneously promoting differentiation of this cell type towards a pro-inflammatory phenotype (Kodumudi, 2010). Lastly, docetaxel has

been shown to decrease T_{reg} cells in patients with non-small cell lung cancer (Li, 2014). Taken together, these data suggest docetaxel may lead to immune activation in NSCLC and further the potential benefit of trilaciclib.

4.2.3. Rationale for Immune Mechanism of Trilaciclib

In the G1T28-05 study evaluating trilaciclib prior to cisplatin, etoposide, and atezolizumab (E/P/A) in patients with ES-SCLC, flow cytometry and T cell receptor (TCR) immunosequencing data revealed that patients receiving trilaciclib had an increased ratio of total and activated CD8⁺ T cells to Tregs and increased peripheral T-cell clonal expansion suggesting enhanced T-cell activation. Furthermore, there was significant enhancement in newly detected expanded clones among patients receiving trilaciclib compared with placebo, which was stronger among patients with an anti-tumor response to E/P/A, suggesting that trilaciclib may enhance tumor antigen presentation, a phenomenon that has been observed in preclinical studies with other CDK4/6 inhibitors (Daniel, 2020).

These observations are consistent with those from the G1T28-02 Phase 2 study of patients with ES-SCLC receiving trilaciclib prior to etoposide plus carboplatin (E/P). In G1T28-02, a higher proportion of activated or effector CD8⁺ and CD4⁺ T cells was observed in patients receiving trilaciclib compared with placebo. In addition, high levels of T-cell clonal expansion were associated with improved PFS and numerically longer median OS. Taken together, the data suggest that the addition of trilaciclib at least preserves, if not enhances, T-cell function during treatment with E/P or E/P/A (Lai 2020).

Lastly, to evaluate the effect of trilaciclib on T cell activation in G1T28-04, peripheral blood was collected and the TCR was evaluated. Simpson clonality decreased over time in patients that received trilaciclib in addition to GC when compared to GC alone. Furthermore, when patients were stratified above or below median Simpson clonality at baseline, there was an improvement among patients receiving trilaciclib. In addition to a decrease in Simpson clonality, responders receiving trilaciclib prior to GC had more newly detected expanded T-cell clones compared with responders receiving GC alone. These data suggest trilaciclib enhances anti-tumor immunity through T cell activation leading to an anti-tumor response (O'Shaughnessy, 2020).

Taken together these data from clinical trials evaluating trilaciclib in a variety of clinical contexts, suggest that trilaciclib has a consistent positive impact on anti-tumor immune modulation. Further, there appear to be several immune based mechanisms through which this effect can be mediated including neoantigen presentation and T cell activation and function.

4.2.4. Rationale for Trilaciclib following Progression on Immunotherapy

Interestingly, many of the mechanisms to overcome ICI-induced resistance have been associated with the immune activating effects of CDK4/6 inhibition, including increasing antigen presentation (MHC class I), enhancing T cell clonality and tumor infiltration, inhibiting regulatory T cell proliferation, decreasing T cell exhaustion markers (PD-1, cytotoxic T-lymphocyte associated protein 4 [CTLA-4], and T-cell immunoglobulin and mucin domain 3 [TIM3]), stabilizing expression of PD-L1 on tumor cells, promoting dendritic cell migration, and increasing T effector cell function through high interferon [IFN] gamma production (Chaikovsky and Sage, 2018; Deng, 2018; Goel, 2017; Schaer, 2018; Lai, 2020; Bonelli, 2019; Teh and Aplin, 2019).

Multiple ongoing trials in this setting, i.e., following disease progression on platinum-based chemotherapy and immunotherapy, are evaluating additional checkpoint inhibitor therapy, but in combination with a partner hypothesized to promote an ongoing immune response. However, as described above, multiple mechanisms of resistance can develop following treatment with immunotherapy and novel agents that exploit multiple or alternative pathways may be preferred. In addition to documented anti-tumor immune modulating effects alone and in combination with checkpoint inhibitors, trilaciclib has translated these effects to improved survival in the TNBC setting and belongs to a class of agents with a diverse repertoire of immune-modulating effects. Overall, these data suggest that patients may benefit from trilaciclib after progressing on ICI treatment.

4.2.5. Rationale for Myelopreservation

Trilaciclib has shown well-documented improvement in myelosuppression outcomes that could provide a substantial benefit to patients receiving docetaxel. In the REVEL trial, 39% of patients receiving docetaxel alone experienced grade 3 or greater neutropenia with 10% experiencing febrile neutropenia (FN) (Garon, 2014). In addition, 6% of patients experienced Grade 3 or greater anemia. Patients treated for SCLC with trilaciclib had marked reductions in the occurrence of these endpoints, required less supportive care, and experienced enhanced quality of life (Table 2).

4.2.6. Rationale for Combination with Docetaxel

Following progression on chemotherapy and immunotherapy, single-agent chemotherapy is the most common standard of care. As there is limited high-quality data for any specific agent in the modern era, several options can be utilized. However, single-agent docetaxel, with activity in both squamous and non-squamous histologies, is commonly utilized in clinical practice and as the reference standard in metastatic NSCLC clinical trials.

Ramucirumab in combination with docetaxel is also approved for the treatment of metastatic NSCLC following disease progression on or after platinum-based chemotherapy. This approval was based on a Phase 3 study that revealed a 1.5-month improvement in survival with the addition of ramucirumab. However, the rate of grade 3 or greater treatment-emergent adverse events increased from 71% to 79%. Furthermore, this small benefit occurred prior to the widespread use of immunotherapy. It is unclear if the same benefit would be seen in patients treated with today's standard of care. As a result, National Comprehensive Cancer Network (NCCN) guidelines list both the combination and docetaxel alone as potential treatment options in this clinical setting and utilization is at the discretion of the individual provider. Because there are no mature data available evaluating the combination of trilaciclib and a taxane containing regimen, the risks of also incorporating ramucirumab were felt to outweigh the small associated benefits.

Trilaciclib has been successfully combined at the recommended Phase 2 dose with most major chemotherapy classes other than microtubule inhibitors. In three randomized, controlled, Phase 2 studies in SCLC patients, the combination resulted in consistent improvements in chemotherapy-induced myelosuppression across multiple lineages. Even in the TNBC trial where the addition of trilaciclib to gemcitabine/carboplatin did not improve neutropenia-based myelopreservation endpoints, rates of adverse events were comparable despite patients on trilaciclib receiving almost double the number of chemotherapy cycles. There is no evidence to suggest that a

different result would be expected from the combination of trilaciclib with taxane based chemotherapy.

Preclinical *in vivo* studies evaluating trilaciclib in combination with paclitaxel or docetaxel utilizing a clinically relevant dose administration schedule support the safety of this combination. In addition, there are at least 4 clinical studies combining chronically dosed oral CDK4/6 inhibitors (palbociclib, ribociclib) with taxane-based chemotherapy. Two of those studies have reported acceptable early safety results in combination with standard clinical doses of paclitaxel and docetaxel (Lewis, 2018; Clark, 2019). In both of these studies, patients received multiple doses of oral CDK4/6 inhibitors (known to cause neutropenia). In contrast, trilaciclib is an IV CDK4/6 inhibitor dosed only prior to chemotherapy. Finally, trilaciclib is being evaluated in an ongoing Phase 2 study in combination with paclitaxel in the neoadjuvant breast cancer setting.

4.2.7. Summary of Nonclinical Data

A summary of the trilaciclib nonclinical data is presented in the trilaciclib Investigator's Brochure (IB).

Nonclinical data related to docetaxel are provided in the local prescribing information.

4.2.7.1. Pharmacology Studies


Through a structure-based design approach to optimize potency, selectivity, and drug metabolism and PK properties, G1 Therapeutics, Inc. identified trilaciclib as a highly potent inhibitor of CDK4 and CDK6 (half maximal inhibitory concentration [IC₅₀] values of 1 nM and 4 nM, respectively) that is highly selective for CDK4/Cyclin D1 versus cyclin-dependent kinase 2 (CDK2)/Cyclin E (>2500-fold selectivity). Trilaciclib also demonstrated reversible inhibition of CDK4/Cyclin D1, with an inhibition constant (K_i) value of 0.78 nM.

The trilaciclib-induced G₁ arrest of HSPCs has been shown to be transient and readily reversible in both *in vitro* and *in vivo* models. *In vivo* analysis has demonstrated that trilaciclib administered prior to myelosuppressive chemotherapy leads to improved complete blood count (CBC) recovery of all blood lineages and increased survival. Specifically, in a model using the chemotherapy 5-fluorouracil (5-FU) that is highly myelosuppressive in mice, the extent and duration of nadir in CBCs worsened after each cycle of 5-FU administered alone. Trilaciclib administered prior to 5-FU ameliorated this worsening effect and the animals that received trilaciclib + 5-FU demonstrated a faster rate of recovery of CBCs compared with the 5-FU alone group following Cycle 4 (He, 2017).

Preclinical data has also shown that trilaciclib enhances immune activation and promotes anti-tumor immunity by differentially arresting cytotoxic and regulatory T-cell subsets followed by a faster recovery in cytotoxic T lymphocytes than in regulatory T cells in tumors. Specifically, the addition of trilaciclib to various chemotherapy/ICI treatment combinations resulted in enhanced tumor growth delay and durability of the antitumor response. Trilaciclib favorably modulated the proliferation of T-cell subsets in the tumor microenvironment, consistent with an enhanced cytotoxic T-cell response (Figure 3; Lai, 2020). This differential alteration of cell cycle kinetics between cytotoxic T lymphocytes and regulatory T cells results in a higher proportion of cytotoxic T lymphocytes than regulatory T cells, enhancement of T-cell activation, and a decrease in regulatory T cell-mediated immunosuppressive functions (Chaikovsky and Sage, 2018; Deng, 2018; Goel, 2017; Schaer, 2018). Together, these events

promote the cytotoxic T lymphocyte-mediated clearance of tumor cells. Therefore, these data support the hypothesis that trilaciclib-mediated transient proliferative arrest of T cells (protecting them from chemotherapy-induced damage), followed by activation of cytotoxic T lymphocytes in the context of fewer regulatory T cells led to the anti-tumor response observed.

Figure 3: The Addition of Trilaciclib to Chemotherapy/Immune Checkpoint Inhibitor Treatment Enhances Efficacy Through T Cell Activation



(Upper right and upper left) Addition of trilaciclib to oxaliplatin and αPD-L1/ αPD-1 combination therapy led to enhanced anti-tumor activity and durability of response in the MC38 tumor model (n=10–15 per treatment group). (Lower left) Transient G1 arrest led to changes in the proportion of intra-tumor T-cell subsets favoring effector T-cell function as measured by the ratio of CD8⁺ T cells to Tregs (% CD8⁺ T cells / % Tregs) in the CD45⁺ population (n=5–8 tumors analyzed per treatment group and time point). (Lower right) Trilaciclib in combination with chemotherapy and ICI enhanced the gene signature of cytotoxic anti-tumor response. T-cell repertoire analyses of MC38 tumors from OP- or TOP-treated mice (n=5 per treatment group) on day 17, presented as median clonality score and TIL fraction (right panel). Error bars denote standard error, and dotted lines represent the median value for TIL fraction and clonality score. *p<0.05.

However, as a consequence of trilaciclib's MOA, there is a hypothetical risk that administration of trilaciclib prior to chemotherapy could decrease chemotherapy efficacy by pausing CDK4/6-dependent tumor cells in G₁ in the presence of chemotherapy; nonclinical data suggest this risk is not clinically significant. To understand why trilaciclib should not antagonize chemotherapy treatment, the baseline proliferation rates of HSPCs, bone marrow, and patient derived xenografts (PDX) were examined using flow cytometric analysis of the cell cycle. A bar graph depicting mean percentage of cells in synthesis phase of the cell cycle (S)/gap 2 phase of the cell cycle (G₂)/mitosis (M) demonstrates that there are a higher proportion of cells cycling in tumor cells when compared to bone marrow/HSPCs. Specifically, <4% of human HSPCs are cycling, while in breast tumors an average of ~40% of cells were cycling (Sorrentino, 2018).

These results illustrate why tumor cells are more susceptible to chemotherapy-induced damage compared to HSPCs, since chemotherapy treatment is predominantly effective in the S/G₂/M phases of the cell cycle.

To evaluate the impact of trilaciclib on chemotherapy anti-tumor efficacy in CDK4/6 dependent tumors, two different models were treated with chemotherapy and trilaciclib. MCF7 tumor-bearing mice, a well-established estrogen receptor (ER)+ CDK4/6 dependent breast cancer model, were treated with docetaxel (IV, 5 mg/kg) ± trilaciclib once weekly for three doses. Although weekly trilaciclib treatment caused some tumor growth inhibition, administering trilaciclib with docetaxel did not alter the effects of chemotherapy. Next, MDA-MB231 tumor-bearing mice were treated with daily trilaciclib (intraperitoneal [IP], 100 mg/kg) for 28 days to confirm CDK4/6 dependence. Continuous treatment with trilaciclib caused stable disease in MDA-MB231 tumor-bearing mice. MDA-MB231 tumor-bearing mice were then treated with eribulin (IV, 0.5 mg/kg) ± trilaciclib once weekly for three doses. Similar to the MCF7 model, the addition of trilaciclib to eribulin treatment did not impact chemotherapy efficacy (Sorrentino, 2018). These experiments demonstrate that transient CDK4/6 inhibition prior to chemotherapy (eribulin, docetaxel) does not antagonize the intended anti-tumor effects of the chemotherapy in these CDK4/6-dependent tumor models.

While there is emerging preclinical data demonstrating the efficacy of CDK4/6 inhibitors in combination with targeted therapy in NSCLC subpopulations (Freed, 2019; Gopalan, 2018; Haines, 2018; Knudsen, 2017), single agent efficacy has shown minimal benefit in the clinic (Goldman, 2020; Edelman, 2019; Gopalan, 2018; Patnaik, 2016). Furthermore, the available nonclinical *in vivo* data indicate combining chemotherapy with trilaciclib does not diminish the antitumor intended effects of the chemotherapy (data not shown, internal G1 data) as loss of CDK4/6 pathway function is correlated with increased tumor proliferation and improved tumor response to chemotherapy in a variety of cancer types (Socinski, 2009; Herschkowitz, 2008; Ertel, 2010; Witkiewicz, 2012). Lastly, applying a DNA signature analysis algorithm to the cBioportal dataset to characterize NSCLC tumors as CDK4/6 dependent, independent or indeterminate, only 7.4% of EGFR WT NSCLC lung tumor would be classified as CDK4/6 dependent (Gao, 2013; Cerami, 2012). Overall, preclinical and clinical data suggest that there is minimal risk that trilaciclib administered prior to docetaxel will induce a G1 arrest in the tumor cell with resultant antagonism of the intended efficacy effect of the chemotherapy.

4.2.7.2. Pharmacokinetic Studies

In vitro analyses of direct and time-dependent inhibition suggest that drug interactions based on inhibition of cytochrome P450 (CYP)1A2-, 2B6-, 2C8-, 2C9-, 2C19-, and 2D6-mediated metabolic pathways are unlikely at clinical doses, however, the studies do suggest that drug interactions based on trilaciclib-mediated inhibition of CYP3A4-mediated metabolic pathways are possible (see Section 4.2.8.1.1). Additionally, *in vitro* induction studies of the 3 major inducible CYP enzymes (CYP1A2, CYP3A4, and CYP2B6) in human hepatocytes suggest that trilaciclib-mediated induction is unlikely.

In vitro inhibition studies with membrane transporter model systems also suggest trilaciclib is unlikely to cause a drug-drug interaction (DDI) based on inhibition of breast cancer resistance protein (BCRP)-, bile salt export pump (BSEP)-, organic anion transporter 1 (OAT1)-, organic anion transporter 3 (OAT3)-, organic anion transporting polypeptide 1B1 (OATP1B1)-, p

glycoprotein (MDR1)-, multidrug resistance protein 1 (MRP1)-, multidrug resistance protein 2 (MRP2)-, or organic anion transporting polypeptide 1B3 (OATP1B3)-mediated transport. However, in vitro, trilaciclib is a potent inhibitor of multidrug and toxin extrusion 1 (MATE1), multidrug and toxin extrusion 2-K (MATE2-K), organic cation transporter 1 (OCT1), and organic cation transporter 2 (OCT2). See Section 4.2.8.1.1 for clinical evaluation.

4.2.8. Summary of Clinical Data

4.2.8.1. Trilaciclib

A brief summary of the clinical data is provided in the following sections. Detailed information is presented in the trilaciclib IB.

The safety and efficacy of administering trilaciclib prior to chemotherapy was tested in one completed and one ongoing Phase 1b/2 study (G1T28-02 and G1T28-03) and one ongoing and one completed Phase 2 study (G1T28-05 and G1T28-04) in patients with SCLC or TNBC. The Phase 2 portions of Studies G1T28-02, G1T28-03, and Study G1T28-05 were randomized, double-blind, and placebo-controlled. Study G1T28-04 was randomized and included a control arm but was not double-blinded.

- Study G1T28-02 examined once-daily IV administration of either trilaciclib or placebo on Days 1 to 3 of each 21-day E/P chemotherapy cycle in patients with treatment naïve extensive-stage SCLC.
- Study G1T28-03 examined once-daily IV administration of trilaciclib or placebo on Days 1 to 5 of each 21-day topotecan chemotherapy cycle in patients with previously treated extensive-stage SCLC.
- Study G1T28-05 examined once-daily IV administration of trilaciclib or placebo on Days 1 to 3 for a maximum of four 21-day cycles of E/P and atezolizumab, followed by monotherapy atezolizumab, in patients with treatment naïve extensive-stage SCLC.
- Study G1T28-04 examined once-daily IV administration of trilaciclib prior to gemcitabine and carboplatin in patients with metastatic TNBC who had received 0 to 2 lines of previous therapy in the metastatic setting. Patients received 1) GC therapy only on Days 1 and 8 of a 21-day cycle, 2) trilaciclib and GC once daily on Days 1 and 8 of each 21-day cycle, OR 3) trilaciclib on Days 1, 2, 8 and 9 with GC on Days 2 and 9 of each 21-day cycle (further noted as Group 1, 2, or 3, respectively).

At the recommended phase 2 dose (RP2D) of 240 mg/m², across all three SCLC studies, trilaciclib administered prior to chemotherapy statistically significantly reduced the duration of severe neutropenia (DSN) in Cycle 1 and occurrence of severe neutropenia (SN) (primary endpoints) compared with placebo. An integrated data analysis of the three SCLC studies (G1T28-02, G1T28-03, and G1T28-05) for 8 of the most relevant myelosuppression endpoints (neutrophils, RBCs and platelets) demonstrated statistically significant, and clinically meaningful, improvements for trilaciclib over available therapies in 6 of 8 endpoints across multiple lineages. Importantly, these myelopreservation benefits come with an overall improved safety profile compared with available therapy, as evidenced by reduced high grade treatment-emergent AEs across all SCLC studies, and no detriment to anti-tumor efficacy results.

Table 2: Integrated Analysis for Myelopreservation Efficacy in SCLC (Studies G1T28-02, G1T28-03, and G1T28-05)

	Placebo +Chemo	Trilaciclib +Chemo	2-sided p-value
ITT Set	119	123	
Neutrophils			
DSN [days] in Cycle 1 – Mean (SD) ^a	4 (5.1)	0 (1.8)	<0.0001
Occurrence of SN (Yes, %) ^b	64 (52.9)	14 (11.4)	<0.0001
RBCs			
Occurrence of Grade 3/4 hemoglobin decreased (anemia) (Yes, %) ^b	38 (31.9)	25 (20.3)	0.0279
Occurrence of RBC transfusion on/after 5 weeks (Yes, %) ^b	31 (26.1)	18 (14.6)	0.0252
Cumulative incidence of RBC transfusion on/after 5 weeks - Event rate (per 100 weeks) ^c	3.1	1.5	0.0027
Platelets			
Occurrence of Grade 3/4 platelet count decreased (thrombocytopenia) (Yes, %) ^b	43 (36.1)	24 (19.5)	0.0067
Occurrence of platelet transfusion (Yes, %) ^b	11 (9.2)	10 (8.1)	0.9564
Cumulative incidence of platelet transfusion - Event rate (per 100 weeks) ^c	1.7	1.1	0.5169

ANC=absolute neutrophil count; Chemo=chemotherapy; DSN=duration of severe (Grade 4) neutropenia; ECOG=Eastern Cooperative Group; ITT=intent to treat; SN=severe (Grade 4) neutropenia which is defined as ANC < 500/mm³; RBC=red blood cells, SCLC=small cell lung cancer; SD=standard deviation.

Chemo=etoposide + platinum in G1T28-02, etoposide + platinum + atezolizumab in G1T28-05, and topotecan in G1T28-03. Standard supportive care interventions were allowed for all arms.

a. p-value was obtained from a nonparametric analysis of covariance (ANCOVA).

b. p-value was obtained from a modified Poisson model.

c. p-value was obtained from a negative binomial model. All three models contained fixed effect of treatment, ECOG performance status (0-1 versus 2), Presence of brain metastases (Y/N), and study (G1T28-02, G1T28-03, or G1T28-05). Corresponding baseline assessment was also included as a covariate.

Results from the TNBC Study G1T28-04 demonstrated that although the addition of trilaciclib to GC did not statistically significantly improve chemotherapy-induced myelosuppression as measured by the neutrophil-based endpoints of DSN in Cycle 1 and occurrence of SN, there were trends toward improvement in RBC and platelet-based measures. In addition, antitumor efficacy results demonstrated- a clinically meaningful improvement in PFS and OS (Figure 2; Table 3). This meaningful antitumor efficacy was observed in both trilaciclib- groups compared with the control group and was also consistent across subgroups, including predictors of immune response. Approximately 57.6% of the available tumor samples in G1T28-04 were considered PD-L1 positive (Ventana SP142 assay), and though larger in the PD-L1 positive population, the benefit of adding trilaciclib extended to both PD-L1 positive and negative cohorts (Table 4).

Table 3: G1T28-04: Summary of Overall Survival and Progression-Free Survival (ITT Analysis Set)

Category	Group 1 GC (Day 1+8) (N=34)	Group 2 GC + Trilaciclib (Day 1+8) (N=33)	Group 3 GC + Trilaciclib (Day 1/2+8/9) (N=35)	Groups 2+3 (N=68)
Overall survival (months) (95% CI)^{a, d}				
25%	5.8 (2.8, 9.7)	9.4 (3.4, 19.6)	8.8 (6.0, 15.3)	8.8 (6.0, 14.0)
Median	12.6 (6.3, 15.6)	NR (10.2, NR)	17.8 (12.9, 32.7)	19.8 (14.0, NR)
75%	17.8 (12.8, 25.0)	NR (NR, NR)	32.7 (19.8, NR)	NE (32.7, NR)
Comparison (treatment group versus Group 1)				
Adjusted HR (SE) ^b	NA	0.31 (0.111)	0.40 (0.125)	0.37 (0.101)
95% CI ^b	NA	0.15, 0.63	0.22, 0.74	0.21, 0.63
2-sided p-value ^c	NA	0.0016	0.0004	<0.0001
Progression-free survival (months) (95% CI)^{a, d}				
25%	2.2 (1.2, 5.4)	5.3 (1.2, 7.9)	6.2 (1.2, 7.1)	5.9 (2.1, 6.5)
Median	5.7 (3.3, 9.9)	9.4 (6.1, 11.9)	7.3 (6.2, 13.9)	9.0 (6.4, 11.3)
75%	9.9 (8.3, 18.8)	13.0 (9.7, 24.1)	13.9 (9.0, NR)	13.9 (10.9, 15.6)
Comparison (Treatment Group versus Group 1)				
Adjusted HR (SE) ^b	NA	0.62 (0.209)	0.63 (0.212)	0.62 (0.180)
95% CI ^b	NA	0.32-1.20	0.32, 1.22	0.36, 1.10
2-sided p-value ^c	NA	0.2099	0.1816	0.1291

CI=confidence interval; GC=gemcitabine and carboplatin; HR=hazard ratio; ITT=intent-to-treat; N=total number of patients in each treatment group; NA=not applicable; NR=not reached; SE=standard error.

^a Calculated using the Kaplan-Meier method

^b The HR and its 95% CI were calculated using the Cox regression model controlling for stratification factors of the number of prior lines of therapy (0 versus 1 or 2) and liver involvement.

^c P-value was calculated using the stratified log-rank test controlling for the two stratification factors.

^d OS reported from final database; PFS reported from earlier data cutoff on 15 May 2020.

Table 4: G1T28-04: Tumor Response According to PD-L1 Status

	PD-L1 Positive				PD-L1 Negative			
	Group 1	Group 2	Group 3	Group 2+3	Group 1	Group 2	Group 3	Group 2+3
Patients analyzed	17	16	16	32	10	10	16	26
Median PFS, months (95% CI) ^a	5.4 (3.3-NR)	7.9 (6.1-NR)	10.9 (6.2-NR)	9.7 (6.2-15.5)	9.2 (8.3-NR)	11.9 (8.8-NR)	9.0 (6.4-NR)	9.4 (6.5-14.6)
p-value	-	0.492	0.075	0.149	-	0.376	0.488	0.943
HR (95% CI)	-	0.74 (0.3-1.7)	0.41 (0.2-1.1)	0.57 (0.3-1.2)	-	0.60 (0.2-1.9)	1.47 (0.5-4.3)	0.97 (0.4-2.5)
Median OS, months (95% CI) ^a	10.5 (6.3-18.8)	20.1 (10.2-NR)	32.7 (15.3-NR)	32.7 (17.7-NR)	13.9 (12.6-NR)	NR (9.4-NR)	17.8 (12.9-NR)	17.8 (13.1-NR)
p-value	-	0.037	0.01	0.004	-	0.077	0.198	0.093
HR (95% CI)	-	0.38 (0.2-1.0)	0.30 (0.1-0.8)	0.34 (0.2-0.7)	-	0.35 (0.1-1.2)	0.55 (0.2-1.4)	0.48 (0.2-1.2)

HR=hazard ratio; NR=not reached; OS=overall survival; PD-L1=programmed death ligand-1; PFS=progression-free survival

Group 1: chemotherapy on Days 1 and 8; Group 2: trilaciclib and chemotherapy on Days 1 and 8; Group 3: trilaciclib along on Days 1 and 8 with chemotherapy on Days 2 and 9. HR and p-values are comparisons between Group 2 and Group 1, Group 3 and Group 1, and between combined Groups 2 and 3 and Group 1.

^aOS reported from final database; PFS reported from earlier data cutoff on 15 May 2020.

As mentioned in Section 4.2.7, there is a hypothetical risk that administration of trilaciclib prior to chemotherapy could decrease chemotherapy efficacy by pausing CDK4/6-dependent tumor cells in the G₁ phase of the cell cycle in the presence of chemotherapy. This hypothetical risk is countered by the results observed in Study G1T28-04 which suggested that the addition of trilaciclib improves the anti-tumor efficacy of GC regardless of the CDK4/6 status of the TNBC tumor. Although TNBC tumors are predominantly classified as CDK4/6 independent (i.e., their replication is not sensitive to CDK4/6 inhibition), there is a small subset of patients whose tumors are classified as either CDK4/6 indeterminate or CDK4/6 dependent. When the TNBC population enrolled in Study G1T28-04 is divided into these subsets, evaluation of the anti-tumor efficacy in patients whose tumors are classified as CDK4/6 indeterminate or CDK4/6 dependent suggests that trilaciclib does not antagonize the anti-tumor effects of GC. Specifically, PFS and OS did not decrease when trilaciclib was added to GC in the most CDK4/6-dependent population (see the trilaciclib IB).

4.2.8.1.1. Pharmacokinetics

A clinical DDI study using the index CYP3A substrate midazolam indicated that trilaciclib had no impact on CYP3A activity. Two clinical DDI studies using a strong CYP3A inhibitor itraconazole were also conducted. No clinically significant changes in exposure were observed for trilaciclib when co-administered with itraconazole.

Clinical data from the evaluation of trilaciclib administered prior to topotecan (Study G1T28-03) suggests that drugs that are substrates of MATE1 and MATE2 do not pose a clinically relevant

risk of DDIs when administered concomitantly with trilaciclib. In an additional clinical DDI assessment, trilaciclib increased metformin (MATE1, MATE-2K and OCT2 substrate) exposure by 65%, in healthy subjects, compared with administration of metformin alone.

Avoid concomitant use of trilaciclib with certain OCT2, MATE1, and MATE-2K substrates (e.g., dofetilide, dalfampridine) where minimal concentration changes may lead to serious or life-threatening toxicities. Refer to the prescribing information for these concomitant medications for assessing the benefit and risk of concomitant use with trilaciclib.

Docetaxel has not been reported to be a substrate for MATE1 or MATE2 (Nieuweboer, 2015), and is not believed to be a substrate for OCT2. As such, a clinically significant alteration of docetaxel PK due to trilaciclib inhibition of OCT2, MATE1, or MATE2-K is not expected.

Study G1T28-11 was a single ascending dose study, with both placebo and positive control groups, with the objective to evaluate potential effects of trilaciclib on ECG parameters, including concentration-QTc (C-QTc) analysis. Trilaciclib transiently increased heart rate by approximately 10 beats per minute. At the clinical dose of 240 mg/m², trilaciclib did not have a clinically relevant effect on QTc (i.e., >10 msec).

4.2.8.2. Trilaciclib Risks

Reproductive/embryo-fetal effects are an important potential risk of trilaciclib. Both nonclinical toxicology studies with trilaciclib, and clinical studies with other compounds with a similar MOA, report effects on either the reproductive system or embryo/fetus. Since this clinical study will focus on trilaciclib administered prior to cytotoxic chemotherapy (which carries its own risk of reproductive/embryo-fetal toxicity), the risks specific to trilaciclib are consistent with those experienced with chemotherapy. In addition, female patients will be monitored for pregnancy and eligibility criteria describing specific birth control methods are incorporated. Dose discontinuation recommendations for female patients who become pregnant while receiving trilaciclib are also provided in the protocol (Section 11.3.6.5). Detailed information regarding all important identified and important potential risks of trilaciclib administration can be found in the trilaciclib IB.

Adverse events of special interest (AESIs) identified for trilaciclib are described below. Rates reported below reflect those observed in the integrated safety summary from the four Phase 2 oncology studies conducted with trilaciclib to date (G1T28-02 [database lock: 05 May 2019], G1T28-03 [data cutoff: 31 May 2019], G1T28-05 [data cutoff: 28 June 2019], and G1T28-04 [data cutoff: 28 June 2019]). Some AESIs have been infrequently reported (or not reported) in the trilaciclib clinical program to date but are considered to be potential class effects of CDK4/6 inhibitors. However, as trilaciclib is given IV and only when chemotherapy is administered, the safety profile of trilaciclib appears to be different from that of the oral, chronically dosed members of its pharmacologic class. All patients will be monitored for these events and dose modification and discontinuation guidelines are provided in Section 9 and Section 10.

Trilaciclib AESIs:

1. **Injection Site Reaction/Phlebitis/Thrombophlebitis:** Infusion of trilaciclib may result in local irritation manifesting as erythema, pain, and swelling; and in a subset of patients, the irritation may cause phlebitis/thrombophlebitis. Injection site reactions have been observed in approximately 15 to 20% of patients receiving trilaciclib and the events have

been Grade 1 or 2. Phlebitis/thrombophlebitis has been noted in approximately 5 to 10% of patients receiving trilaciclib and the events were primarily Grade 1 or 2. Supportive care interventions such as slowing the infusion rate, flushing the infusion line with a minimum of 20 mL normal saline or 5% dextrose (D5W), rotating IV catheter sites, and removing the IV (when given peripherally) following each trilaciclib infusion can decrease the frequency and severity of these events. In addition, if symptoms are observed with normal saline as diluent/flush, use of D5W as an alternative may decrease the symptoms. Central access may also be considered.

2. **Acute Drug Hypersensitivity Reaction:** Trilaciclib administration may cause acute drug hypersensitivity reaction characterized by symptoms like angioedema, pruritis, and urticaria. These events have been reported in approximately 6% of patients receiving trilaciclib compared with approximately 3% in patients receiving placebo and were classified as Grade 1 and 2. Only one case of Grade 2 anaphylaxis was observed, which occurred 4 days after the preceding dose of trilaciclib, resolved on the same day, was not serious, and did not result in discontinuation of treatment.
3. **Pneumonitis/Interstitial Lung Disease:** A rare (1 to 3%) but serious class effect (<1% fatal) that is associated with the use of oral CDK4/6 inhibitors. Symptoms include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams in patients in whom infectious, neoplastic, or other causes have been excluded. The only case of pneumonitis reported in patients who received trilaciclib was observed in a patient in whom trilaciclib had been discontinued for two months and who had been receiving atezolizumab (known to cause pneumonitis) as monotherapy. The pneumonitis event was Grade 3 and considered by the Investigator to be related to atezolizumab.
4. **Hepatotoxicity:** Both nonclinical toxicology studies with trilaciclib, and clinical studies with other compounds with a similar MOA, report reversible elevations in transaminases with continuous dosing. There has been only 1 instance of Grade 4 alanine aminotransferase (ALT) increase in a patient receiving trilaciclib, no Grade 4 aspartate aminotransferase (AST) increases, and no cases of Hy's law reported in patients receiving trilaciclib. However, generally low grade and transient increases in AST, ALT, or bilirubin have been observed in a small number of patients (~ 5%) receiving trilaciclib prior to chemotherapy. Patients with mild hepatic impairment have been treated with trilaciclib without a clinically significant increase in exposure or the frequency/severity of AEs. Studies evaluating the PK of trilaciclib in patients with hepatic impairment are ongoing.
5. **Embolism and Thrombotic Events, Venous:** The CDK4/6 inhibitor abemaciclib has been associated with an increased risk for venous thromboembolism when combined with endocrine therapy in patients with breast cancer. This same risk has not been reported for the other approved oral CDK4/6 inhibitors (ribociclib and palbociclib); therefore, it is not clear if this is a class effect. Approximately 3% of cancer patients that received trilaciclib prior to chemotherapy experienced a venous thromboembolic event and half of those events (3/6) were Grade 3 or 4. No Grade 5 events were reported. Approximately 2% of patients receiving chemotherapy alone or with placebo reported an embolic or thrombotic event, 1 of 3 such events was Grade 3.

4.2.8.3. Docetaxel

Docetaxel is commonly used in the treatment of metastatic NSCLC ([NCCN, 2020](#)) and is approved by the US FDA and the European Medicines Agency for this indication ([Taxotere®, 2020](#); [Taxotere, 2005](#)). Per Warnings and Precautions in the prescribing information for docetaxel, the following are important risks related to docetaxel use:

- Acute myeloid leukemia, myelodysplasia or other second primary malignancies
- Cutaneous reactions including erythema, edema and desquamation
- Neurologic reactions including paresthesia, dysesthesia, and pain
- Cystoid macular edema
- Asthenia
- Fetal harm
- Alcohol content (in a dose of Taxotere injection)
- Tumor lysis syndrome
- Neutropenia
- Serious gastrointestinal complications (ex. enterocolitis)
- Hypersensitivity reactions
- Fluid retention
- Respiratory disorders (ex. acute respiratory distress syndrome, interstitial lung disease, pulmonary fibrosis, respiratory failure)
- Severe adverse reactions in patients with liver impairment

4.3. Benefit/Risk Assessment

Trilaciclib (CDK4/6 inhibitor) is being evaluated for anti-tumor efficacy, specifically OS, following disease progression on both immunotherapy and platinum-based chemotherapy, a clinical setting where treatment options are limited and outcomes are suboptimal. In addition to facilitating host immune function, trilaciclib can also provide benefit by making chemotherapy safer and allowing patients to receive the standard of care doses and schedule. These effects have been shown in other trilaciclib clinical trials to improve the patient experience and are provided in the context of minimal toxicity (low grade injection site reactions/phlebitis/thrombophlebitis).

As stated in Section [4.2.8](#), the dose of 240 mg/m² trilaciclib established in the SCLC and TNBC studies (G1T28-04) will be administered prior to a commonly used chemotherapy regimen of docetaxel. The clinically meaningful anti-tumor efficacy results observed in G1T28-04 were noted across multiple endpoints, with OS, PFS, and ORR endpoints all showing numerical improvement with the addition of trilaciclib to GC compared with GC alone.

Studies to date with trilaciclib have demonstrated a manageable safety profile (see Section [4.2.8](#)). Trilaciclib is not expected to have significant overlapping toxicity with docetaxel. In fact,

trilaciclib is expected to have a favorable impact on specific docetaxel complications such as myelosuppression and potentially on gastrointestinal (GI) related side effects.

As described in Section 4.2.9.1 and 4.2.8.1, there is a hypothetical risk that administration of trilaciclib prior to chemotherapy could decrease chemotherapy efficacy by pausing CDK4/6-dependent tumor cells in G1 in the presence of chemotherapy. However, at this time there is no nonclinical (Section 4.2.7) or clinical (Section 4.2.8) evidence to support this theoretical risk. In addition, since sensitivity to CDK4/6 inhibitors is a surrogate marker for CDK4/6 dependence, and the oral, chronically-dosed CDK4/6 inhibitors have shown minimal anti-tumor activity in solid tumors other than ER+ breast cancer (Baghdadi, 2019; Goldman, 2014; Goldman, 2018; Gopalan, 2014; Infante, 2016; Karasic, 2018; Rose, 2018), these results suggest that the majority of solid tumor cancers are not CDK4/6 dependent and not susceptible to this hypothetical risk.

Given the potential benefit to patients with previously treated metastatic NSCLC from the addition of trilaciclib to docetaxel and the limited potential for significant trilaciclib-related toxicity, the benefit/risk assessment is positive for this combination.

A COVID-19 risk assessment has been performed, documented, and will be provided as a separate document.

5. OBJECTIVES AND ENDPOINTS

The primary, secondary, safety, and exploratory objectives of this study and their associated endpoints, for patients with metastatic NSCLC receiving docetaxel in the 2nd or 3rd line, are presented in [Table 5](#).

Table 5: Objectives and Endpoints

Objectives	Endpoints
Primary Objective	
<ul style="list-style-type: none"> To assess the effect of trilaciclib on OS compared with placebo 	<ul style="list-style-type: none"> OS in the ITT population defined as time from randomization to death due to any cause for those who died; or time to last contact known as alive for those who survived in the study (censored cases).
Secondary Objectives: Other Anti-Tumor Efficacy	
<ul style="list-style-type: none"> To assess the effect of trilaciclib on PFS compared with placebo 	<ul style="list-style-type: none"> PFS in ITT population defined as time from randomization to disease progression using RECIST v1.1 or death due to any cause, whichever occurs first; for patients without disease progression or death, PFS will be calculated per censoring rules.
<ul style="list-style-type: none"> To assess the effect of trilaciclib on other anti-tumor endpoints compared with placebo 	<ul style="list-style-type: none"> ORR defined as percentage of patients with confirmed CR and PR per RECIST v1.1 DOR defined as duration of objective response
Secondary Objective: to evaluate the myelopreservation effect of trilaciclib compared with placebo	
<ul style="list-style-type: none"> To assess the effects of trilaciclib on the neutrophil lineage compared with placebo 	<ul style="list-style-type: none"> Duration of severe (Grade 4) neutropenia in Cycle 1 Occurrence of severe (Grade 4) neutropenia Occurrence of febrile neutropenia AEs Occurrence of G-CSF administration
<ul style="list-style-type: none"> To assess the effects of trilaciclib on the RBC lineage compared with placebo 	<ul style="list-style-type: none"> Occurrence of Grade 3 or 4 decreased hemoglobin laboratory values RBC transfusions on or after Week 5 (occurrence and number of transfusions) Occurrence of ESA administration
<ul style="list-style-type: none"> To assess the effects of trilaciclib on the platelet lineage compared with placebo 	<ul style="list-style-type: none"> Occurrence of Grade 3 or 4 decreased platelet count laboratory values Platelet transfusions (occurrence and number of transfusions)

Objectives	Endpoints
<ul style="list-style-type: none"> To assess the effects of trilaciclib on chemotherapy dosing compared with placebo 	<ul style="list-style-type: none"> All-cause dose reductions (occurrence and number of reductions) All-cause cycle delays (occurrence and number of delays)
<ul style="list-style-type: none"> To assess the effects of trilaciclib on hospitalizations due to chemotherapy-induced myelosuppression compared with placebo 	<ul style="list-style-type: none"> Occurrence and number of hospitalizations due to chemotherapy-induced myelosuppression
Secondary Objective: to evaluate the safety of trilaciclib compared with placebo	
<ul style="list-style-type: none"> To assess the safety and tolerability of trilaciclib compared with placebo 	<ul style="list-style-type: none"> Occurrence and severity of AEs by NCI-CTCAE v5 Study treatment discontinuation due to AEs Changes in laboratory parameters (hematology, chemistry), vital signs and ECG parameters Grade 3 or 4 abnormalities in laboratory parameters Trilaciclib AESIs Chemotherapy infusion interruptions Relative dose intensity for docetaxel
Exploratory Objectives	
<ul style="list-style-type: none"> To assess the anti-tumor efficacy of trilaciclib by CDK4/6-dependence status 	<ul style="list-style-type: none"> OS, PFS, and ORR (per RECIST v1.1) in patients with each of the following CDK4/6 dependence signatures: <ul style="list-style-type: none"> CDK4/6 dependent CDK4/6 independent CDK4/6 indeterminant
<ul style="list-style-type: none"> To assess the anti-tumor efficacy of trilaciclib by PD-L1 subgroups 	<ul style="list-style-type: none"> OS, PFS, ORR, and DOR in ITT population by PD-L1 subgroups (as measured by retrospective analysis)
<ul style="list-style-type: none"> To characterize the population PK of trilaciclib and identify important determinants of variability 	<ul style="list-style-type: none"> Exposure-response relationship between trilaciclib and response or safety endpoints
<ul style="list-style-type: none"> Estimate the PK parameters of docetaxel using a population PK model 	<ul style="list-style-type: none"> Clearance Volume of distribution

Objectives	Endpoints
<ul style="list-style-type: none"> To assess the effect of trilaciclib on CIM- and disease-related symptoms and functional limitations 	<p>Change from baseline and/or time to deterioration in:</p> <ul style="list-style-type: none"> EORTC QLQ-C30 domain scores EORTC QLQ-LC13 with supplemental weight loss item (EORTC IL118) domain scores FACIT-Fatigue total score EQ-5D-5L <p>Percent of patients reporting deterioration and improvement using:</p> <ul style="list-style-type: none"> PGIC fatigue item PGIS fatigue item
<ul style="list-style-type: none"> To assess the pharmacodynamic effects, including immune based mechanism, of trilaciclib when added to docetaxel in peripheral blood 	<ul style="list-style-type: none"> Differences in pharmacodynamic parameters, including those relating to immune-based mechanisms, in peripheral blood

AE=adverse event; AESI=adverse event of special interest; BOR=best overall response; CDK=cyclin-dependent kinase; CIM=chemotherapy-induced myelosuppression; DOR=duration of response; ECG=electrocardiogram; EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire; EORTC QLQ-LC13=European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module; EORTC IL118= European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module with supplemental weight loss item; EQ-5D-5L=5-level EQ-5D; ESA=erythropoiesis stimulating agent; FACIT-Fatigue=Functional Assessment of Chronic Illness Therapy – Fatigue; G-CSF=granulocyte colony-stimulating factor; IV=intravenous; NCI=National Cancer Institute; NSCLC=non-small cell lung cancer; ORR=objective response rate; OS=overall survival; PFS=progression free survival; PGIC=Patient Global Impression of Change; PGIS=Patient Global Impression of Severity; PK=pharmacokinetic(s); PR=partial response; RBC=red blood cell; RECIST=Response Evaluation Criteria in Solid Tumors

6. INVESTIGATIONAL PLAN

6.1. Overall Study Design

This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib compared with placebo on OS in patients with metastatic NSCLC receiving docetaxel in the 2nd or 3rd line setting. Patients must have documented disease progression during or after 1 or 2 lines of systemic therapy for recurrent or metastatic NSCLC. Prior treatment must have included, either in the same line or as separate lines of therapy: 1) a maximum of 1 line of platinum-containing chemotherapy in the recurrent/metastatic setting and 2) a maximum of 1 line of a locally approved/authorized PD-1/PD-L1 monoclonal antibody (mAb) containing regimen in the recurrent/metastatic setting.


Approximately 146 patients will be randomly assigned (1:1) to receive trilaciclib or placebo by IV prior to docetaxel on Day 1 of each 21-day cycle. There will be 2 stratification factors for randomization: Country, and ECOG performance status (0-1 versus 2). Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2).

Study drugs administered are as follows:

- Trilaciclib (240 mg/m²) or placebo – administered as a 30-minute IV infusion no more than 4 hours prior to chemotherapy on each day chemotherapy is administered (Section 9.1.1).
- Docetaxel 75 mg/m² –IV, Day 1

The study will include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase (Figure 4). The Treatment Phase begins on the day of randomization for the first patient and completes at the Post-Treatment Visit for the last patient. The first Survival Follow-up assessment should occur approximately 2 months after the last dose of study drug.

Figure 4: Study Design



D=day; PD=progressive disease, WD=withdraw, DC=discontinue

Criteria which patients must meet in order to receive study drug on Day 1 are provided in Section 9.2. Treatment cycles will occur consecutively without interruption, except when necessary to manage toxicities or for administrative reasons. Study drug administration will continue until disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or clinical progression as determined by the Investigator, unacceptable toxicity, withdrawal of consent, discontinuation by Investigator, or the end of the trial, whichever occurs first.

A post-treatment visit will occur approximately 30 days (± 7 days) following the last dose of study drug. Upon discontinuation of study treatment, patients will be followed for survival, i.e., patients or their caregivers will be contacted approximately every 2 months until the end of the study (or death) to record their status (alive or dead) as well as details of any subsequent systemic anti-cancer therapy initiated. These survival follow-ups may be done via telephone, email, or clinic visit.

The duration of total follow-up relative to the first patient being randomized is approximately 30 months to collect the target number of deaths per sample size calculation. If assumptions vary in the study conduct, the study duration will be event-driven. That is, the study will continue until the targeted number of deaths is observed. There is an interim analysis for OS. If the interim results demonstrate a statistically significant effect of trilaciclib over placebo for OS based on pre-specified criterion, the study will be stopped early due to success. Otherwise, the study will be completed when the criteria outlined in Section 10.4 have been met, or upon sponsor termination of the study.

6.2. Rationale for Primary and Secondary Endpoints

6.2.1. Anti-tumor Efficacy

Measurements of anti-tumor response rates by RECIST, in addition to OS and PFS, are standard assessments used in oncology solid tumor studies to measure the effects of study treatment on the underlying malignant disease. Additionally, clinical benefit in oncology should be based on direct evidence, such as improvement in duration of overall survival, improvement in a patient's quality of life, improved physical functioning, or improved tumor related symptoms, which may not be adequately measured by response rates alone. Therefore, improvement in survival is considered one of the most reliable measures providing- direct evidence of clinical benefit to patients and is a preferred clinical endpoint. Survival is considered easy to measure via documentation of the date of death and is not prone to bias ([FDA, 2008](#)).

6.2.2. Myelopreservation Efficacy

Patients experiencing CIM often face severe clinical consequences (e.g., FN, bleeding, fatigue) leading to the need for hospitalizations, hematopoietic growth factor support, transfusions (RBCs and/or platelets) and even death ([Caggiano, 2005](#); [Gustinetti, 2016](#); [Bodey, 1966](#); [Li, 2016](#)). Moreover, CIM commonly leads to dose reductions and delays, which limit therapeutic dose intensity and can compromise the anti-tumor efficacy benefits of chemotherapy. In 3 randomized, double-blind, placebo-controlled SCLC trials, the myelopreservation endpoints proposed in this clinical study were utilized to evaluate the efficacy of trilaciclib in reducing CIM. These endpoints proved to be robust measures of trilaciclib's myelopreservation efficacy and clinically meaningful improvements in multiple endpoints were observed across the 3 studies. This study will further investigate the impact of trilaciclib on CIM when used in combination with docetaxel.

6.2.3. Patient-Reported Outcomes

Throughout the trilaciclib clinical development program, patient-reported outcome (PRO) instruments have been evaluated in all randomized clinical trial settings. While exploratory endpoints in each of those studies, an integrated analysis of data collected in the 3 SCLC studies

suggests that trilaciclib added to chemotherapy can delay or prevent deterioration in multiple aspects of health-related quality of life. In these studies, trilaciclib generally maintained or reduced fatigue levels across cycles and prevented clinically meaningful increases in fatigue, which are commonly associated with myelosuppression. In G1T28-04 with TNBC patients, patients in the trilaciclib groups were less likely to have a deterioration in their symptoms, and in some cases had improvement in their symptoms, through the first 6 cycles of therapy (last time point evaluated). Trilaciclib delayed deterioration of patient functioning and symptoms measures over time compared with GC alone; suggesting that patients on trilaciclib (compared with GC alone) had a better experience receiving chemotherapy. This study will further investigate the patient experience and potential benefit to NSCLC patients receiving trilaciclib.

6.2.4. Safety

Assessment of AEs, changes in laboratory parameters, electrocardiogram (ECG) parameters, vital signs, and ECOG status are all standard assessments used in oncology trials to measure patient safety.

6.3. Rationale for Dose and Schedule of Study Treatment

6.3.1. Trilaciclib

Previous studies demonstrated the RP2D of trilaciclib was 240 mg/m². When trilaciclib was administered prior to chemotherapy to cancer patients, doses of 200 (rounded up from 192), 240, and 280 mg/m² were evaluated. Trilaciclib exposures in cancer patients were slightly lower compared with healthy subjects, such that the dose of 240 mg/m² (rather than 200 mg/m²) more closely matched the biologically effective dose (BED) of 192 mg/m². In addition, the dose of 240 mg/m² demonstrated maximal myelopreservation efficacy benefits (compared with 200 and 280 mg/m²) as measured by a variety of myelosuppression endpoints. The myelopreservation effect at 240 mg/m² was further evaluated and confirmed in three randomized controlled Phase 2 studies in SCLC patients. In addition, the planned dose was used in a previous TNBC study (G1T28-04) and demonstrated clinically meaningful benefits in OS duration. See the trilaciclib IB for details.

In addition, at the RP2D, trilaciclib has a limited toxicity profile and minimal overlapping toxicities are expected with docetaxel (Section 4.2.9). The primary AEs anticipated with trilaciclib are low grade injection site reactions including phlebitis/thrombophlebitis. These infusion reactions have generally been mild and occur in association with drug delivery through peripheral access. Central access is likely to reduce/eliminate these issues. The remainder of the trilaciclib AESIs to date have been uncommon and for most, the percentage of patients experiencing these AESIs is not clearly increased in patients receiving trilaciclib compared to placebo. Based on these results a dose-finding study is not needed.

In order to preserve hematopoietic stem and progenitor cells (HSPCs) as well as immune system function during chemotherapy, trilaciclib is always administered prior to systemic chemotherapy (docetaxel), on each day of chemotherapy administration. Trilaciclib will not be administered as monotherapy (i.e., on days that chemotherapy will be delayed).

6.3.2. Docetaxel

The dose and schedule of docetaxel is described in Section 9.1.1.2. This is consistent with standard of care as established in clinical trials (Shepherd, 2000; Garon, 2014), and the approved labeling for this product (NCCN, 2020; Taxotere, 2020; Taxotere, 2005).

6.4. Rationale for Supportive Care Interventions

Per NCCN guidelines docetaxel, as utilized in NSCLC, is considered an intermediate risk regimen with a risk of FN between 10 and 20%. At this level of risk, guidelines do not require routine prophylactic granulocyte colony-stimulating factor (G-CSF) in Cycle 1 (NCCN, 2020b). Therefore, in order to facilitate an unbiased evaluation of trilaciclib effects on the hematologic and pharmacodynamic endpoints, primary prophylactic G-CSF will be prohibited in Cycle 1; however therapeutic G-CSF (administered in response to a neutropenic event) in Cycle 1 and secondary prophylactic G-CSF beginning in Cycle 2 and for all subsequent cycles (i.e., after a precipitating event in a prior cycle of therapy) will be allowed per growth factor/neutropenia management guidelines in Section 9.4 and Investigator discretion (Aapro, 2010; Smith, 2015).

Erythropoiesis-stimulating agent (ESA) administration and RBC or platelet transfusions will be allowed per Investigator discretion based on guidelines detailed in Section 9.4.2 and Section 9.4.3. While these interventions may confound analysis of the myelosuppression endpoints, allowing physicians to provide appropriate supportive care to patients will facilitate patient safety.

6.5. Rationale for Patient Population

Though immunotherapy has markedly improved the treatment of metastatic NSCLC, options following disease progression remain limited. An alternative therapy that extends the duration of OS without significant additive toxicity, while concurrently decreasing myelosuppression and improving quality of life, would be a welcome addition in this heavily pretreated and often clinically fragile patient population. Therefore, further evaluation of trilaciclib in this area of high unmet medical need is warranted.

6.6. Rationale for Stratification Factors

As outlined in Section 6.1, randomization will be stratified by country and ECOG performance status. Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2). These factors were chosen because they are predicted to have an impact on the primary endpoint of overall survival, and in some cases the secondary myelopreservation endpoints, such that if there is an imbalance in these factors, interpretation of the results of the study could be compromised.

Country was chosen as a stratification factor to account for the geographic differences in patient populations, treatment practice patterns and access to supportive care and subsequent anti-cancer therapy; all of which could influence the primary and secondary endpoint outcomes.

Performance status is an established indicator of survival and treatment tolerance. Those with ECOG performance status of 2 typically have shorter survival times and greater toxicity with subsequent therapeutic interventions (Sweeney, 2001; Jang, 2014). However, this group in particular may derive benefit from the myelopreservation and limited toxicity seen with

trilaciclib and has few well-tolerated alternative options. As such, these patients will be eligible but stratified by ECOG performance status (0-1 versus 2) in order to minimize any impact on survival outcomes.

7. STUDY POPULATION

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as a protocol waiver or exemption, is not permitted.

7.1. Inclusion Criteria

Patient eligibility should be reviewed and documented by an appropriately qualified member of the investigator study team before patients are included in the study. Patients must meet *all* of the following inclusion criteria to be eligible for enrollment into the study:

1. Age ≥ 18 years of age at the time of signing the informed consent.
2. Histologically or cytologically confirmed metastatic NSCLC (squamous or nonsquamous) with no known actionable driver mutations (ex. EGFR, ROS1, ALK).
 - Patients must have had documented disease progression during or after 1 or 2 lines of systemic treatment for recurrent or metastatic disease.
 - Two components of treatment must have been received in the same line or as separate lines of therapy: (i) a maximum of 1 line of platinum-containing chemotherapy regimen for recurrent/metastatic disease, and (ii) a maximum of 1 line of a locally approved/authorized PD-1/PD-L1 mAb containing regimen for recurrent/metastatic disease.
 - Maintenance therapy following platinum doublet-based chemotherapy is not considered as a separate line of therapy. Maintenance therapy is defined as therapy given within 42 days after the last dose of platinum-based chemotherapy in patients with ongoing clinical benefit (complete response [CR], partial response [PR] or stable disease [SD]).
3. Measurable or non-measurable disease per RECIST v1.1
4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
5. A formalin-fixed paraffin-embedded (FFPE) tumor specimen (from archival or fresh biopsy) with an associated pathology report documenting NSCLC must be available to send to the Sponsor, within the specified timeframe, for planned retrospective biomarker analyses (see Section 11.6.1).
6. Adequate organ function defined by the following laboratory values:
 - a) Hemoglobin ≥ 9.0 g/dL in the absence of RBC transfusion or ESA administration within 14 days prior to first dose of trilaciclib/placebo
 - b) Absolute neutrophil count (ANC) $\geq 1.5 \times 10^9/\text{L}$
 - c) Platelet count $\geq 100 \times 10^9/\text{L}$
 - d) Total bilirubin \leq upper limit of normal (ULN)
 - e) AST/ALT $< 1.5 \times \text{ULN}$ if alkaline phosphatase $> 2.5 \times \text{ULN}$
 - f) If alkaline phosphatase $< 2.5 \times \text{ULN}$ then AST, ALT $< 2.5 \times \text{ULN}$ in the absence of liver metastasis or $< 5 \times \text{ULN}$ in the presence of liver metastasis

- g) Estimated glomerular filtration rate ≥ 30 mL/minute/1.73m²
7. Resolution of nonhematologic toxicities per National Cancer Institute Common Terminology Criteria Version 5.0 (NCI-CTCAE) from prior therapy or surgical procedures to \leq Grade 1 or baseline (except alopecia).
 8. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Please see Section 17.3 for detailed instructions on methods of contraception requirements.
 9. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

7.2. Exclusion Criteria

A patient will not be eligible for participation in this study if *any* of the following criteria apply:

1. Prior therapy with docetaxel.
2. Any contraindication to the administration of docetaxel at the discretion of the investigator.
3. Mixed NSCLC/SCLC, or lung tumors whose predominant histology is sarcomatoid, or neuroendocrine.
4. Any chemotherapy, immunotherapy, biologic, investigational, or hormonal therapy for cancer treatment (except for adjuvant hormonal therapy for breast cancer or prostate cancer defined as M0 disease or prostate-specific antigen (PSA) persistence/recurrence without metastatic disease) within 3 weeks prior to the first dose of trilaciclib/placebo.
5. Any radiotherapy within 2 weeks prior to the first dose of trilaciclib/placebo.
6. Presence of central nervous system (CNS) metastases requiring immediate treatment with radiation therapy or steroids (i.e., patient must be off steroids administered for brain metastases for at least 14 days prior to the first dose of trilaciclib/placebo).
7. Presence of leptomeningeal disease.
8. Significant third-space fluid retention (ex. ascites or pleural effusion) not amenable to required repeat drainage.
9. QT corrected using Fridericia's formula (QTcF) interval >480 msec at screening (confirmed on repeat). For patients with ventricular pacemakers, QTcF >500 msec.
10. Symptomatic peripheral neuropathy (\geq Grade 2 NCI-CTCAE v5.0)
11. History of interstitial lung disease (ILD)
12. Clinically significant (i.e., active) cardiovascular disease at the time of signing the informed consent; for example cerebrovascular accidents (≤ 6 months before the first dose of trilaciclib/placebo), myocardial infarction (≤ 6 months before the first dose of trilaciclib/placebo), unstable angina, serious cardiac arrhythmia requiring medication,

- or uncontrolled symptomatic congestive heart failure [Class II or higher as defined by the New York Heart Association [NYHA] functional classification system])
13. Known serious active infection including but not limited to human immunodeficiency virus (HIV) (e.g., viral load indicative of HIV, HIV 1/2 antibodies), Hepatitis B (e.g., HBsAg reactive or HBV DNA detected), Hepatitis C (e.g., HCV RNA [quantitative] is detected) or tuberculosis
 14. Prior allogeneic or autologous hematopoietic stem cell or bone marrow transplantation
 15. Receipt of any low-dose systemic chemotherapeutic agent (e.g., low-dose methotrexate for rheumatoid arthritis) administered for a nononcologic purpose within 3 weeks prior to the first dose of trilaciclib/placebo.
 16. Receipt of any live attenuated vaccines within 4 weeks prior to first dose of study treatment or anticipation that such a vaccine will be required during the study treatment period.
 17. Known hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80 or any excipients of trilaciclib
 18. Pregnant or lactating women
 19. Legal incapacity or limited legal capacity
 20. Other uncontrolled serious chronic disease or psychiatric condition that in the Investigator's opinion could affect patient safety, compliance, or follow-up in the protocol
 21. Concurrent participation in any other interventional clinical trial.

8. SCHEDULE OF ASSESSMENTS

The procedures and assessments to be performed during the study are outlined in [Table 6](#). The timing and number of samples collected for biomarker testing may be altered based on emerging data without requiring an amendment if the blood volume per day or overall does not increase and the patient is not required to have additional clinic visits or prolongation of a clinic visit, i.e., the risk-benefit profile for the patient does not worsen.

When there are multiple procedures at the same or overlapping time points, order of events should be: patient reported outcome measures, ECGs, vitals, blood draw. Unscheduled assessments and visits to manage patient safety may occur at the Investigator's discretion. Study procedures performed at unscheduled visits should be recorded in the appropriate electronic case report form (eCRF).

Table 6: Schedule of Assessments

Assessment	Screening	Rand	21 Day Treatment [Cycles]						Post-Treatment Visit	Survival Follow-Up	Details Provided in Section
			Cycle 1					Cycle 2 and beyond			
Day	-28 to -1	-3 to -1	1	5 (±1 day)	9 (±1 day)	13 (±1 day)	17 (±1 day)	1 ^a	30 ±7d post-last dose	Every 2 months	
Informed Consent	X										Section 13.3
Demographics	X										Section 11.1.2
Medical History and NSCLC History	X										Section 11.1.3
Eligibility Evaluation and Randomization	X	X									Section 11.1.1, Section 7.1, and Section 7.2
Archived Tumor Sample	X										Section 11.6.1
ECOG Performance Status	X		X					X	X		Section 11.3.3
Complete physical exam, including height and weight	X										Section 11.3.2
Brief physical exam, including weight			X					X	X		Section 11.3.2
Vital Signs	X		X					X	X		Section 11.3.1
12-lead Electrocardiogram	X		X					X [C2 only]			Section 11.3.4

Assessment	Screening	Rand	21 Day Treatment [Cycles]						Post-Treatment Visit	Survival Follow-Up	Details Provided in Section
			Cycle 1					Cycle 2 and beyond			
Day	-28 to -1	-3 to -1	1	5 (±1 day)	9 (±1 day)	13 (±1 day)	17 (±1 day)	1 ^a	30 ±7d post-last dose	Every 2 months	
Clinical Chemistry	X		X					X	X		Section 11.3.5
Hematology	X		X	X	X	X	X	X	X		Section 11.3.5
Pregnancy Test (WOCBP)		X	X					X	X		Section 11.3.5
Tumor Assessment by RECIST v1.1	X		X (every 6 weeks from C1D1)							X	Section 11.2.1
Trilaciclib or Placebo			X					X			Section 9.1.1.1
Docetaxel			X					X			Section 9.1.1.2
EORTC QLQ-C30, EORTC QLQ-LC13 with supplemental weight loss item (EORTC IL118), FACIT-Fatigue, PGIS, and EQ-5D-5L			X			X		X	X		Section 11.4
PGIC						X		X	X		Section 11.4
Blood Sample for PK			X								Section 11.5

Assessment	Screening	Rand	21 Day Treatment [Cycles]						Post-Treatment Visit	Survival Follow-Up	Details Provided in Section
			Cycle 1					Cycle 2 and beyond			
Day	-28 to -1	-3 to -1	1	5 (±1 day)	9 (±1 day)	13 (±1 day)	17 (±1 day)	1 ^a	30 ±7d post-last dose	Every 2 months	
Blood Sample for Immunologic and Hematologic Markers			X		X			X [C2, C3, C5 only]			Section 11.7
Survival Contact and Subsequent Anti-cancer Therapies										X	Section 11.10
AEs			X								Section 11.3.6
Concomitant Medications	X	X	X								Section 11.1.3

AE=adverse event; β-hCG=beta human chorionic gonadotropin; ECOG=Eastern Cooperative Oncology Group; EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire; EORTC QLQ-LC13=European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module; EORTC IL118=European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module with supplemental weight loss item; EQ-5D-5L=5-level EQ-5D; FACIT-Fatigue=Functional Assessment of Chronic Illness Therapy – Fatigue; NSCLC=non-small cell lung cancer; PGIC=Patient Global Impression of Change; PGIS=Patient Global Impression of Severity; PK=pharmacokinetic; Rand=randomization; RECIST=Response Evaluation Criteria in Solid Tumors; WOCBP=women of childbearing potential.

^a There should be no more than 5 weeks (for toxicity and/or administrative reasons) between doses of chemotherapy; however dosing delays >5 weeks may be permitted on a case by-case basis with the documented approval of the Investigator and Medical Monitor.

9. STUDY TREATMENT

9.1. Study Drugs Administered

Study drugs are defined as any investigational agent(s), marketed product(s), or placebo intended to be administered to a study patient according to the study protocol. Study drugs used in this protocol are described in [Table 7](#).

Table 7: Study Drugs

	Study Drugs		
Product Name:	Trilaciclib	Placebo	Docetaxel
Type	Investigational product	Placebo	Chemotherapy
Dosage Formulation:	Single-use, sterile powder to be reconstituted with 250 mL of dextrose 5% in water (D5W) or normal saline (sodium chloride solution 0.9%) per the Pharmacy Manual	250 mL of dextrose 5% in water (D5W) or normal saline (sodium chloride solution 0.9%)	Description of the formulation is provided in the current prescribing information (Taxotere, 2020 ; Taxotere, 2005)
Unit Dose Strength(s)	300 mg/20 mL	N/A	See current prescribing information
Dosage Level(s)	240 mg/m ²	N/A – administered on Day 1 to match trilaciclib	75 mg/m ²
Route of Administration	IV	IV	IV
Infusion Time	30 minutes	30 minutes	1 hour or per Institutional Standards

IV=intravenous; N/A=not applicable.

9.1.1. Dose, Dosing Regimen, and Route

9.1.1.1. Trilaciclib/Placebo

Trilaciclib for Injection, 300 mg/vial (also referred to as “Trilaciclib Sterile Powder for concentrate for solution for IV infusion, 300 mg/vial”) is supplied as a sterile, preservative-free, yellow, lyophilized cake in a single-dose vial (300 mg/20 mL).

Trilaciclib must be reconstituted and further diluted prior to IV infusion as outlined in the Pharmacy Manual. Aseptic technique must be used for reconstitution and dilution. BSA should be calculated as per institutional practice. Actual body weight (not “adjusted” body weight) should be utilized for dose calculations. If there is a change in body weight $\geq 10\%$ relative to the weight at the time of the last dose calculation, dose should be recalculated. Recalculation of dose more frequently per local institutional guidelines is permitted. Dose

recalculation to adjust for changes in body weight will not be considered a dose reduction and will be made at the discretion of the Investigator.

The placebo, either 250 mL of dextrose 5% in water (D5W) or sodium chloride solution 0.9%, will be administered by IV infusion over approximately 30 minutes by peripheral or central access.

9.1.1.1.1. Administration of Trilaciclib/Placebo

- Administer diluted trilaciclib solution or placebo as a 30-minute IV infusion completed within 4 hours prior to the start chemotherapy. Do not administer trilaciclib/placebo as a bolus.
- Trilaciclib/placebo is always administered first. Results from hematology labs should be reviewed prior to administration of trilaciclib/placebo. If administration of docetaxel therapy is delayed or discontinued, trilaciclib/placebo will also be delayed or discontinued.
- Diluted trilaciclib/placebo solution must be administered with an infusion set, including an in-line filter (0.2 or 0.22 micron). Compatible in-line filters include polyethylene sulfone, polyvinylidene fluoride, and cellulose acetate.
- Do not administer diluted trilaciclib/placebo solution with a polytetrafluorethylene (PTFE) in-line filter. PTFE in-line filters are not compatible with diluted trilaciclib/placebo solution.
- Do not co-administer other drugs through the same infusion line.
- Do not co-administer other drugs through a central access device unless the device supports co-administration of incompatible drugs.

Upon completion of infusion of diluted trilaciclib/placebo solution, the infusion line/cannula must be flushed with at least 20 mL sterile D5W or 0.9% normal saline.

The infusion rate may be decreased to manage an infusion-related AE; for example, if a patient experiences a burning sensation during infusion, the duration of infusion may be increased to 45 minutes (or longer if clinically indicated) to alleviate the symptoms.

9.1.1.2. Docetaxel

Docetaxel will be administered IV in accordance with the prescribing information/summary of product characteristics ([Taxotere, 2020](#); [Taxotere, 2005](#)) and according to the study site's standard practice. Protocol-specified doses of docetaxel will be administered IV in accordance with institutional guidelines and the recommended instructions below. Deviation from the recommendations provided in this protocol in order to follow institutional guidelines must receive prior approval from the Medical Monitor or Sponsor.

Actual body weight (not ideal body weight) should be utilized for dose calculations. At a minimum, if there is a change in body weight of >10% relative to the weight at the time of the last dose calculation, doses should be recalculated. Recalculation of the dose more frequently per local institutional guidelines is permitted. Dose recalculation to adjust for changes in body weight will not be considered a dose reduction.

Trilaciclib/placebo is always administered first, followed by docetaxel. Administer diluted trilaciclib solution or placebo as a 30-minute IV infusion to be completed within 4 hours prior to the start chemotherapy. Docetaxel may be administered immediately following trilaciclib/placebo, but not until the completion of the trilaciclib/placebo infusion. If administration of trilaciclib/placebo is delayed or discontinued, docetaxel will also be delayed or discontinued. Likewise, if docetaxel is delayed or discontinued, trilaciclib/placebo will also be delayed or discontinued.

9.1.2. Preparation, Handling, Storage, and Accountability

The Investigator or institution is responsible for study drug accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records). The Investigator/institution may assign some or all of the Investigator's/institution's duties for investigational product(s) accountability to an appropriate pharmacist or another appropriate individual who is under the supervision of the Investigator/institution.

Further guidance and information are provided in the Pharmacy Manual.

9.1.3. Treatment Compliance

The Investigator or designee will dispense the study drugs, via an unblinded Pharmacist/Designee, only for use by patients enrolled in the study as described in this protocol. The study drugs are not to be used for reasons other than those described in this protocol. The clinical study site will maintain records of study drugs' receipt, preparation, and dispensing, including the applicable lot numbers; patient's height, body weight, and body surface area; date and time of the start and end of each trilaciclib or placebo and docetaxel infusion; and total drug administered in milligrams. Any discrepancy between the calculated dose and dose administered and the reason for the discrepancy (e.g., interruption of infusion without restarting) will be recorded on eCRF and in the source documents.

9.2. Criteria for Starting Each Cycle

Patients must meet all the following minimum criteria to receive study treatment on Day 1 for Cycle 1 and each subsequent cycle:

- $ANC \geq 1.5 \times 10^9/L$,
- Platelet count $\geq 100 \times 10^9/L$
- Total bilirubin \leq upper limit of normal (ULN)
- $AST/ALT \leq 1.5 \times ULN$ if alkaline phosphatase $> 2.5 \times ULN$
- Other nonhematologic drug-related toxicities (excluding alopecia) must be \leq Grade 1 or have returned to baseline.

For dose delays due to toxicity, the patient should be followed (at least) weekly, including CBCs if the AE is hematologic, to monitor the toxicity until treatment criteria described above are met or until they discontinue treatment (e.g., if more than 5 weeks elapse from the last chemotherapy dose). If the Day 1 dose is delayed, any assessments completed as part of the planned Day 1 visit will be captured in the eCRF as unscheduled visits. The PRO questionnaires should be completed on both the planned Day 1 visit and on the actual Day 1 of the cycle (i.e., when criteria are met to proceed with Day 1 treatment).

There should be no more than 5 weeks (for toxicity and/or administrative reasons) between doses of chemotherapy; however dosing delays >5 weeks may be permitted on a case by-case basis with the documented approval of the Investigator and Medical Monitor.

In both the trilaciclib and placebo arms, study drug administration will continue until progressive disease per RECIST v1.1 or clinical progression as determined by the Investigator, unacceptable toxicity, withdrawal of consent, Investigator decision, or the end of the study.

9.3. Toxicity Management and Dose Modifications

The dose of trilaciclib will not be modified and will remain at 240 mg/m² throughout the study. If administration of docetaxel therapy is discontinued, trilaciclib will also be discontinued.

The dose of docetaxel can be reduced when necessary as described below. The recommended dose modification procedures for hematologic toxicities are described in [Table 9](#). If a subsequent cycle is delayed for toxicity, the patient should still complete the clinical laboratory assessments on the scheduled Day 1 (entered as an Unscheduled assessment in EDC) as well as on the actual first dosing day of that cycle. If the delay is secondary to hematologic toxicity, weekly repeat hematology assessments should continue until the finding meets criteria for resumption of dosing.

Non-hematologic toxicities should be managed as per standard of care for docetaxel. Recommendation for management of trilaciclib/placebo AEs are provided in [Table 10](#). Recommendations for hepatobiliary toxicity management are in [Section 9.3.4](#). All recommendations are intended as a minimum guideline for toxicity management and are not a replacement for independent medical judgement tailored to specific circumstances with an individual patient. Please also refer to the individual package insert/summary of product characteristics ([Taxotere, 2020](#); [Taxotere, 2005](#)) for additional information and recommendations.

9.3.1. Dose reduction

Recommended dose levels for reduction of docetaxel dose are described in [Table 8](#). Chemotherapy dose reductions for hematologic toxicities should be based on values obtained within 24 hours prior to Day 1 of a given cycle. All dose reductions for an individual patient are permanent; and the dose, which has been reduced for toxicity, must not be re-escalated. Up to a maximum of 2 dose reductions will be allowed per patient. If a third dose reduction is required per the modifications below, the patient should discontinue study treatment.

Table 8: Recommended Chemotherapy Dose Modifications

	Docetaxel
Starting Dose	75 mg/m ²
Dose Level -1	60 mg/m ²
Dose Level -2	50 mg/m ²

No dose modification is permitted for trilaciclib.

Note that dose modifications (specifically dose reductions/discontinuations) are recommended for those events considered related to drug (i.e., toxicities) such that

decreasing the dose or stopping the drug will lead to improved patient safety. If an event is not thought to be related to study drug by the Investigator, dose reduction/discontinuation is not required since decreasing the dose or stopping the drug would not be expected to alter the risk of the event occurring again; rather the Investigator should consider if treatment should be delayed until the event recovers to \leq Grade 1 or baseline before resumption of treatment. Decreased neutrophil, platelet counts or hemoglobin values that occur in isolation (e.g., at nadir) that do not result in a dosing delay, FN, serious adverse event (SAE) or other consequence, do not require dose modification.

If drug-related toxicity requires discontinuation of docetaxel or trilaciclib then the patient must permanently discontinue all study drugs and should complete the Post-Treatment Visit and enter Survival Follow-up.

9.3.2. Safety Criteria for Adjustment or Stopping Doses

Table 9: Recommended Dose Modification for Drug-Related Hematologic Toxicity

		Action Taken		
Event, CTCAE Grade or Lab Value	Frequency	Trilaciclib	Docetaxel	Toxicity Management
ANC <1.5 x 10 ⁹ /L (≥Grade 2)	1 st occurrence	Hold drug until ANC criteria for dosing reached. No change in dose.	Hold drug until ANC criteria for dosing reached. No change in dose.	Administer prophylactic G-CSF with each subsequent cycle of chemotherapy.
	2 nd occurrence	Hold drug until ANC criteria for dosing reached. No change in dose.	Hold drug until ANC criteria for dosing reached. Reduce dose of docetaxel by one dose level and resume dosing.	
	3 rd occurrence	Hold drug until ANC criteria for dosing reached. No change in dose.	Hold drug until ANC criteria for dosing reached. Reduce dose of docetaxel by one more dose level and resume dosing.	
	4 th occurrence	Permanently discontinue		
Febrile neutropenia (Grade 3 or 4) OR Grade 4 Neutropenia lasting >7 days	1 st occurrence	Hold drug until ANC criteria for dosing reached. No change in dose.	Hold drug until ANC criteria for dosing reached. Reduce dose of docetaxel by one dose level and resume dosing.	Administer prophylactic G-CSF with each subsequent cycle of chemotherapy.
	2 nd occurrence	Hold drug until ANC criteria for dosing reached. No change in dose.	Hold drug until ANC criteria for dosing reached. Reduce dose of docetaxel by one more dose level and resume dosing.	
	3 rd occurrence	Permanently discontinue		
Platelets <100 - 75 x 10 ⁹ /L (Grade 1)	Any occurrence	Hold drug until platelet criteria for dosing reached. No change in dose.	Hold drug until platelet criteria for dosing reached. No change in dose.	Monitor for signs and symptoms of bleeding. Consider treatment as clinically indicated

		Action Taken		
Event, CTCAE Grade or Lab Value	Frequency	Trilaciclib	Docetaxel	Toxicity Management
Platelets <75 - 50 x10 ⁹ /L (Grade 2)	1 st Occurrence	Hold drug until platelet criteria for dosing reached. No change in dose.	Hold drug until platelet criteria for dosing reached. No change in dose.	Monitor for signs and symptoms of bleeding. Consider treatment as clinically indicated
	2 nd Occurrence	Hold drug until platelet criteria for dosing reached. No change in dose.	Hold drug until platelet criteria for dosing reached. Reduce dose of docetaxel by one dose level and resume dosing.	
	3 rd Occurrence	Hold drug until platelet criteria for dosing reached. No change in dose.	Hold drug until platelet criteria for dosing reached. Reduce dose of docetaxel by one dose level and resume dosing.	
	4 th Occurrence	Permanently discontinue		
Platelets <50 x 10 ⁹ /L (≥Grade 3) OR Symptomatic thrombocytopenia (severe or medically significant bleeding)	1 st occurrence	Hold drug until platelet criteria for dosing reached. No change in dose.	Hold drug until platelet criteria for dosing reached. Reduce dose of docetaxel by one dose level and resume dosing.	Monitor for signs and symptoms of bleeding. Consider treatment as clinically indicated
	2 nd occurrence	Hold drug until platelet criteria for dosing reached. No change in dose.	Hold drug until platelet criteria for dosing reached. Reduce dose of docetaxel by one more dose level and resume dosing.	
	3 rd occurrence	Permanently discontinue		

ANC=absolute neutrophil count; CTCAE=Common Terminology Criteria for Adverse Events; G-CSF=granulocyte colony-stimulating factor.

9.3.3. Recommended Actions with Trilaciclib/Placebo for Adverse Events of Special Interest

Suggested actions to be taken with trilaciclib/placebo following AESI are provided in [Table 10](#).

Table 10: Recommended Actions with Trilaciclib/Placebo Following AESIs

AESI	Severity	Recommended Action
Injection site reactions including phlebitis and thrombophlebitis	Grade 1: Tenderness with or without symptoms (e.g. warmth, erythema, itching)	Interrupt or slow infusion of trilaciclib. If 0.9% normal saline is being used as a diluent/flush, consider changing to 5% dextrose as appropriate for subsequent infusions.
	Grade 2: Pain; lipodystrophy; edema; phlebitis	Interrupt infusion of trilaciclib. If pain not severe, follow instructions for Grade 1. Otherwise, stop infusion in extremity and rotate site of infusion to site in alternative extremity. If 0.9% normal saline is being used as a diluent/flush, consider changing to 5% dextrose as appropriate for subsequent infusions. Central access may also be considered.
	Grade 3: Ulceration or necrosis; severe tissue damage; operative intervention indicated. Grade 4: Life threatening consequences; urgent interventions indicated.	Stop infusion and permanently discontinue trilaciclib.
Acute drug hypersensitivity reactions	Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting Activities of Daily Living	Stop infusion and hold trilaciclib until recovery to Grade ≤ 1 or baseline, then consider resuming trilaciclib. If Grade 2 recurs, permanently discontinue trilaciclib.
	Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL OR Grade 4: Life-threatening consequences; urgent intervention indicated	Permanently discontinue trilaciclib.

AESI	Severity	Recommended Action
ILD/pneumonitis	Grade 2 (symptomatic)	Hold trilaciclib until recovery to Grade ≤ 1 or baseline, then consider resuming trilaciclib. If Grade 2 recurs, permanently discontinue trilaciclib.
	Grades 3: Severe symptoms; limiting self-care ADL; oxygen indicated OR Grade 4: Life-threatening respiratory compromise; urgent intervention indicated (e.g., tracheotomy or intubation)	Permanently discontinue trilaciclib.
Other toxicities	Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL.	Hold trilaciclib until recovery to Grade ≤ 1 or baseline, then consider resuming trilaciclib. If Grade 3 recurs, permanently discontinue trilaciclib.
	Grade 4: Life-threatening consequences; urgent intervention indicated.	Permanently discontinue trilaciclib

AESI=adverse event of special interest; ILD=interstitial lung disease

9.3.4. Hy's Law Management

Abnormal values in AST and/or ALT concurrent with abnormal elevations in total bilirubin that meet the criteria outlined below in the absence of other causes of liver injury are considered potential cases of drug-induced liver injury (potential Hy's Law cases) and should always be considered important medical events.

The threshold of laboratory abnormalities for a potential case of drug-induced liver injury depends on the patient's individual baseline values and underlying conditions. Patients who present with the following laboratory abnormalities should be evaluated further to determine the etiology of the abnormal laboratory values:

- Baseline AST or ALT and total bilirubin values are within the normal range and the patient subsequently presents with AST or ALT $\geq 3 \times$ ULN concurrent with a total bilirubin $\geq 2 \times$ ULN with no evidence of hemolysis and an alkaline phosphatase $\leq 2 \times$ ULN or not available.
- Preexisting ALT OR AST OR total bilirubin values above the upper limit of normal, and the patient subsequently presents with:
 - AST or ALT ≥ 2 times the baseline values and $\geq 3 \times$ ULN, or $\geq 8 \times$ ULN (whichever is smaller)

- Concurrent with total bilirubin increased by one time the baseline value OR $\geq 3 \times$ ULN (whichever is smaller).

The patient should return to the investigational site and be evaluated as soon as possible, preferably within 48 hours from awareness of the abnormal results. This evaluation should include laboratory tests, detailed history and physical assessment. In addition to repeating AST and ALT, laboratory tests should include albumin, creatine kinase, total bilirubin, direct and indirect bilirubin, gamma-glutamyl transferase, prothrombin time (PT)/International Normalized Ratio (INR), and alkaline phosphatase. A detailed history, including relevant information, such as review of ethanol, acetaminophen, recreational drug and supplement consumption, family history, occupational exposure, sexual history, travel history, history of contact with a jaundiced patient, surgery, blood transfusion, history of liver or allergic disease, and work exposure, should be collected. Further testing for acute hepatitis A, B, or C infection and liver imaging (e.g., biliary tract) may be warranted.

All cases confirmed on repeat testing as meeting the laboratory criteria defined above, with no other cause for liver function test (LFT) abnormalities identified at the time should be considered potential Hy's Law cases irrespective of availability of all the results of the investigations performed to determine etiology of the abnormal LFTs. Such potential Hy's Law cases should be promptly reported as SAE via the EDC.

9.4. Supportive Care Interventions

9.4.1. Colony Stimulating Factor Usage

Use of prophylactic colony stimulating factors (e.g., G-CSF; granulocyte-macrophage colony-stimulating factor [GM-CSF]) during Cycle 1 (i.e., prior to the actual Cycle 2 Day 1 dosing visit) is not allowed. In subsequent cycles (Cycle 2 and beyond), prophylactic colony-stimulating factors are allowed as outlined in regional guidelines or consensus (e.g., American Society of Clinical Oncology [ASCO], European Society for Medical Oncology [ESMO], Chinese Anti-Cancer Association) and package inserts/summary of product characteristics.

If in any cycle (including Cycle 1), a patient experiences severe neutropenia (Grade 4) or FN and is at high risk for infection associated- complications or has prognostic factors that are predictive of poor clinical outcomes ([Table 11](#)), therapeutic G-CSF/GM-CSF may be used to treat the severe neutropenia or FN event per regional guidelines and package inserts.

Short-acting G-CSF products (i.e., Neupogen or biosimilars) may be administered starting 24 to 48 hours after chemotherapy and must be stopped 48 hours prior to study drug administration in the next cycle. Similarly, Neulasta (or biosimilars) or other long half-life G-CSF products (ex. macapegfilgrastim) may be administered 24 to 48 hours after chemotherapy but due to its prolonged half-life should not be repeated within that cycle. Biosimilars must be approved for use by the national regulatory authority (ex. FDA, European Commission, or the China National Medical Products Administration [NMPA]).

Table 11: Patient Risk Factors for Poor Clinical Outcomes Resulting from Febrile Neutropenia or Infection

Risk Factor
Sepsis syndrome
Age >65 years
Profound neutropenia (absolute neutrophil count $<0.1 \times 10^9/L$)
Neutropenia expected to last >10 days
Pneumonia
Invasive fungal infection
Other clinically documented infections
Hospitalization at time of fever
Prior episode of febrile neutropenia

ASCO=American Society of Clinical Oncology

Source: Table recreated from Table 2 of the ASCO guidelines ([Smith, 2015](#); [Smith, 2006](#)).

9.4.2. Erythropoiesis-Stimulating Agent Usage

If a patient experiences a hemoglobin level <10.0 g/dL or symptomatic anemia during study treatment, ESAs may be used per the current prescribing information ([Bohlius, 2019](#)) ([Procrit[®], 2017](#); [Aranesp[®], 2011](#)).

9.4.3. Transfusions

Red Blood Cells

Based on the NCCN Clinical Practice Guidelines in Oncology for Hematopoietic Growth Factors Version 2.2020 and the AABB Clinical Practice Guidelines, the following RBC transfusion thresholds are recommended ([Carson, 2016](#); [Goel, 2018](#)); however, the patient's clinical situation should always be the primary guiding factor when deciding to transfuse.

- Transfusion is not indicated until the hemoglobin level is ≤ 7 g/dL for hospitalized adult patients who are hemodynamically stable.
- An RBC transfusion threshold of ≤ 8 g/dL is recommended for patients undergoing orthopedic surgery, cardiac surgery, and those with preexisting cardiovascular disease.
- Patients with symptomatic anemia should be transfused per the Investigator discretion regardless of hemoglobin levels.

Platelets

Platelet transfusion is recommended at a threshold of $\leq 10 \times 10^9/L$. Platelets should also be transfused in any patient who is bleeding with a platelet count $<50 \times 10^9/L$ ($100 \times 10^9/L$ for central nervous system or ocular bleeding) ([Kaufman, 2015](#); [Schiffer, 2017](#)).

9.5. Prior/Concomitant Medications and Procedures

All concomitant medications including prescription medications, over-the-counter preparations, growth factors, and blood products from informed consent through 30 days after the last dose of study treatment (Post-Treatment Visit) will be documented, where possible. During the study,

prescription, and commercially available products, including traditional Chinese medications, with known or suspected immunomodulatory properties should be used with caution or avoided entirely.

Avoid concomitant use of trilaciclib with certain OCT2, MATE1, and MATE-2K substrates (e.g., dofetilide, dalfampridine) where minimal concentration changes may lead to serious or life-threatening toxicities. Refer to the prescribing information for these concomitant medications for assessing the benefit and risk of concomitant use of trilaciclib (Section 4.2.8.1.1).

Docetaxel is a CYP3A4 substrate. Concomitant use of docetaxel and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. In patients receiving treatment with docetaxel, close monitoring for toxicity and a docetaxel dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided.

Any medication that is contraindicated when using docetaxel is not permitted, and special warnings and precautions for use of docetaxel should be observed.

Administration of other concomitant investigational agents for any indication or any live attenuated vaccines is not permitted while on this study. Necessary supportive care (antiemetics, antidiarrheals, chemotherapy premedication, etc.) per the standard of care at the study center will be permitted. See Section 9.4 for guidance on the use of growth factors (colony-stimulating factors and ESAs) during the study.

Administration of other systemic concomitant non-protocol anticancer therapies prior to progression is not permitted while on this study, with the exception of adjuvant endocrine therapy for breast cancer or prostate cancer defined as M0 disease or PSA persistence/recurrence without metastatic disease. This includes any low-dose systemic chemotherapeutic agent given for a nononcologic purpose (e.g., low-dose methotrexate for rheumatoid arthritis). Palliative treatment of a symptomatic lesion(s) is permitted to control disease symptoms but not to aid in the response of the tumor. If the lesion(s) treated is being followed for evaluation by RECIST (target or nontarget lesion), then “not evaluable” should be reported in electronic data capture (EDC) for this lesion at subsequent disease assessments following palliative treatment. Patients requiring palliative therapy may continue receiving study drug until documented disease progression (radiographic or clinical) if, in the Investigator’s opinion, the patient is continuing to receive clinical benefit and they meet the requirements described in Section 9.2. However, for patients who have not had disease progression at the time of the need for palliative radiation therapy or surgery, the requirement for intervention will be regarded as disease progression in the study’s analyses and will be entered as such in the EDC.

Any diagnostic, therapeutic, or surgical procedures performed during the study period will be documented. Documentation will include information regarding the date(s), indication(s), description of the procedure(s), and any clinical or pathological findings, if available.

9.6. Measures to Minimize Bias: Randomization and Blinding

The study will be randomized and double-blind. Patients meeting all inclusion and exclusion criteria will be randomized 1:1 by an Interactive Web Response System (IWRS) according to a randomization schedule generated by an unblinded external statistician. Each patient will be assigned a unique randomization number, which will not be reused. A patient who is randomized and discontinues from the study, even if no study drug was administered, will not be replaced. If

a patient does not receive the correct study treatment for their allocated treatment arm, the reason must be clearly documented in the eCRF. The patient will remain on study and continue to receive the same study treatment, all data will be collected, and follow up will continue as described in the Schedule of Assessments.

There will be 2 stratification factors for randomization: country and ECOG performance status (0-1 versus 2). Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2).

Each site will have an unblinded Pharmacist/Designee, who will have access to the treatment assignment. Because the active drug product trilaciclib has a faint yellow color when reconstituted and diluted, additional procedures will be implemented to ensure the blind is maintained for the patient, Investigator, Research Nurse, Study Coordinator, and other blinded site personnel. Details regarding the preparation and administration of trilaciclib/placebo in a manner to maintain the blind will be included in the Pharmacy Manual.

The patients, Investigators, other site staff involved in the clinical care of the patients, and the Sponsor or Designees involved in the conduct of the study will not be aware of the treatment group to which a particular patient has been randomized. If an Investigator determines that a patient's assignment should be unblinded for reasons of safety, this should be discussed with the study Medical Monitor prior to unblinding, unless an urgent and immediate intervention is required that precludes this discussion. If unblinding of the treatment assignment is necessary, the Investigator or Designee will obtain the treatment assignment details from the IWRS. Unblinding of personnel should be limited to the minimum needed for mitigation of safety concern. Following unblinding, patient continuation on study will be determined on a case by case basis. Any unplanned unblinding must be communicated to the Project Manager, Study Statistician, and Sponsor for documentation in the study files and the clinical study report.

If the blinding code is broken, the date and reason for unblinding must be fully documented in source documents and entered on the eCRF. However, every effort should be made by the site staff to ensure that the treatment arm in which the unblinded patient is assigned is not communicated to any sponsor personnel or designee involved in the conduct of the trial.

9.7. Intervention after End of Study Treatment

Following completion of study treatment on the study, patients will receive treatment as determined by their healthcare provider. During Survival Follow-up, the patient (or legally authorized representative where allowed by local regulation) will be contacted to record their status (alive or dead) as well as details of any subsequent systemic anti-cancer therapy initiated (see Section [11.10](#)).

10. DISCONTINUATION OF STUDY INTERVENTION AND PATIENT DISCONTINUATION/WITHDRAWAL

10.1. Discontinuation of Study Treatment

Study drugs will be discontinued if any of the following events occur during the study:

- A patient suffers an AE that, in the judgment of the Investigator, Sponsor, or Medical Monitor, presents an unacceptable risk to the patient
- General or specific changes in the patient's condition (e.g., a significant intercurrent illness or complication) that, in the judgment of the Investigator, are unacceptable for further administration of study drug
- Occurrence of pregnancy during the study
- Significant noncompliance with protocol requirements
- The Sponsor or legal representative of the Sponsor requests the patient to withdraw
- Patient has documented disease progression (radiographic or clinical progression). See Section 9.5 for details regarding palliative therapy.
- If total time between chemotherapy treatments exceeds a total of >5 weeks, unless agreed to by the treating Investigator and Medical Monitor.
- Where permanent discontinuation of all study drugs is indicated in the toxicity management recommendations

At the time of study drug discontinuation, a Post-Treatment Visit should be completed with assessments performed as shown in the Schedule of Assessments (Table 6). The Investigator or Designee will document the reason for study drug discontinuation on the applicable eCRF. When discontinuation is due to a SAE or a Grade 3 or 4 toxicity considered to be related to study medication, the Investigator should follow the event until resolution, return to baseline, or it is deemed that further recovery is unlikely. Data on these events should be collected on the AE eCRF. In the event a patient discontinues due to pregnancy, the Investigator or designee should notify the Medical Monitor by telephone within 24 hours of pregnancy confirmation (see Section 17.3).

For those patients who have not progressed clinically or radiologically at the time of study drug discontinuation, every effort should be made to continue radiological tumor assessments every 12 weeks (± 7 days) during survival follow-up, utilizing the same imaging modality as used at Screening as outlined in the Schedule of Assessments (Table 6), until progressive disease, initiation of subsequent anti-cancer therapy, withdrawal of consent, or study completion, whichever occurs first. Results of these scans should be assessed by RECIST v1.1 and data entered in EDC in the corresponding tumor assessment forms.

10.2. Discontinuation/Withdrawal from the Study

A patient may withdraw from the study at any time at his/her own request or may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons. At the time of discontinuing from the study, if patient has not already

discontinued study intervention, a Post-Treatment Visit should be completed with assessments performed as shown in the Schedule of Assessments (Table 6).

If the patient withdraws consent for disclosure of future information, the Sponsor may retain and continue to use any data collected before such a withdrawal of consent.

If a patient withdraws from the study, he/she may request destruction of any samples taken and not tested, and the Investigator or designee must document this in the site study records.

If a patient withdraws consent for further study procedures, the site should clarify if the patient (or legally authorized representative where allowed by local regulation) remains open to survival contact and associated data collection. Public records may be used to verify survival status if permitted by institutional or country guidelines.

10.3. Lost to Follow-Up

A patient will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site.

In general, a patient is considered lost to follow-up after there are at least 3 documented attempts to contact the patient. It is recommended that 1 attempt is via certified letter to the patient.

10.4. Study and Site Start and Closure

The overall study begins when the first patient signs the informed consent form. The overall study ends when the last patient completes the last study-related phone-call or visit, discontinues from the trial or is lost to follow-up (i.e., the subject is unable to be contacted by the investigator).

A study site is considered eligible to start participation in the study once all regulatory approvals are in place, site agreement contract is fully executed, and any other required documents are in place as required by Sponsor.

The end of study is event driven. That is, the study will continue until the targeted number of deaths is observed. There is an interim analysis for OS planned when approximately 73 patients have died. If the interim results demonstrate a statistically significant effect of trilaciclib over placebo for OS based on pre-specified criterion, the study will be stopped early due to success. Otherwise, the study will continue and be considered complete when the targeted number of deaths have occurred for the final OS analysis (approximately 104 deaths), or upon sponsor termination of the study.

The Sponsor's designee reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected, a study-site closure visit has been performed, and the site has closed all regulatory activities with the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).

The Investigator may be requested to initiate study-site closure at any time, provided there is reasonable cause and sufficient notice is given in advance of the intended termination. Should

this occur with patients receiving study drug, the patients will transition to receive standard of care treatment by their healthcare provider outside of this study.

Reasons for the early closure of a study site by the Sponsor or Investigator may include but are not limited to:

- Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the Sponsor's procedures, or Good Clinical Practice (GCP) guidelines
- Inadequate recruitment of patients by the Investigator
- Discontinuation of further development of trilaciclib

If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the Investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) used in the study of the reason for termination or suspension, as specified by the applicable regulatory requirements. The Investigator shall promptly inform the patient and should assure appropriate patient therapy and/or follow-up.

11. STUDY ASSESSMENTS

Study procedures and their timing are summarized in the Schedule of Assessments (Table 6). Adherence to the study design requirements, including those specified in the Schedule of Assessments, is essential and required for study conduct. Immediate safety concerns should be discussed with the study Medical Monitor upon occurrence or awareness to determine if the patient should continue or discontinue study intervention.

The Investigator or Designee will maintain a screening log to record details of all patients screened and to confirm eligibility or record reasons for screening failure, as applicable.

Procedures conducted as part of the patient's routine clinical management (e.g., hematology, clinical chemistry) and obtained before signing of the ICF may be utilized for screening or baseline purposes provided the procedures met the protocol-specified criteria and are performed within 28 days prior to Cycle 1 Day 1.

11.1. Screening Assessments

The following information for screening failures should be recorded into appropriate eCRFs: patient ID, demographic data, and reason for failing the screening process. Patients may only be rescreened one time at the discretion of the Investigator. For abnormal laboratory values, a second test to confirm the first is permitted.

11.1.1. Randomization

Eligibility should be determined prior to randomization and the start of study treatment. All eligible patients will be randomly allocated according to the randomization schedule and will receive a unique randomization number. Once a randomization number is assigned to a patient, it can never be re-assigned to another patient.

Eligible patients will be instructed on all protocol requirements, including any restrictions on concomitant medication usage.

Randomization will be performed via IWRS and can be completed up to 3 days prior to the first dose of trilaciclib or placebo + docetaxel therapy, following confirmation that the patient is eligible for the study. Patients can also be randomized and receive Cycle 1 Day 1 on the same day. When required by institutional procedures, randomization will be allowed up to 7 days prior to dosing without a protocol deviation. Screening procedures must be completed prior to randomization and the screening window remains 28 days.

11.1.2. Demographics

Age, gender, race, and ethnicity will be collected during the Screening period.

11.1.3. Medical History and NSCLC Cancer Disease History

Medical and surgical history, including past and current conditions, will be collected. Concomitant medications taken from informed consent through 30 days after the last dose of study treatment will be recorded. Prior medications (those taken within 14 days of informed consent will also be recorded.

Documentation of NSCLC history, including date of diagnosis and histologic type, as well as prior therapy (ex. surgery, radiation, systemic chemotherapy, immunotherapy) for NSCLC will also be recorded. PD-L1 status will be collected and recorded where available.

11.2. Anti-tumor Efficacy Assessments

11.2.1. Anti-tumor Efficacy Assessment

Tumor assessment will be performed at the timepoints specified in the Schedule of Assessments ([Table 6](#)) relative to Cycle 1 Day 1, regardless of drug (cycle) delays.

Baseline imaging should include computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen, pelvis, and brain. IV contrast should be used unless contraindicated. Any CT or MRI obtained as standard of care prior to signing the informed consent will not need to be repeated as long as those imaging tests were obtained within 28 days prior to Cycle 1 Day 1.

After baseline tumor assessments (Screening assessment within 28 days prior to Cycle 1 Day 1), evaluation of tumor response per RECIST v1.1 will be performed every 6 weeks following Cycle 1 Day 1 (± 7 days) during study drug administration (including imaging of the chest, abdomen, and pelvis [and brain if metastasis present at Screening or if symptoms develop]), with additional scans performed as clinically indicated. Post-baseline tumor assessments should use the same imaging modality as at Screening. IV contrast should be used unless contraindicated. Tumor assessments will continue until disease progression, withdrawal of consent, initiation of subsequent anti-cancer therapy, or the end of study, whichever occurs first.

For those patients who have not progressed clinically or radiologically at the time of study drug discontinuation, every effort should be made to continue radiological tumor assessments every 12 weeks (± 7 days) during survival follow-up, utilizing the same imaging modality as used at Screening, until the occurrence of progressive disease, withdrawal of consent, initiation of subsequent anticancer therapy, or study completion.

Tumor response criteria will be based on RECIST v1.1 ([Eisenhauer, 2009](#)) as cited in Section 17.4. A partial or complete response should be confirmed by a repeat scan at the next scheduled tumor assessment per RECIST v1.1.

During the course of this study, scans may be collected and sent/uploaded to the Sponsor or Designee for storage. Centralized storage is intended for possible blinded independent central review (BICR) of disease assessments. At the discretion of the Sponsor, BICR of all scans by RECIST v1.1 may be conducted retrospectively. The blinded review will include all patients with available images. However, the raw images for patients enrolled in China cannot be stored outside of China and therefore these images will be stored in the server in China for central imaging review if approved by the related authority. If needed, guidelines for imaging collection and storage will be provided in a separate document. The clinical management of patients will be based solely upon the results of the assessment conducted by the Investigator based on RECIST v1.1 per protocol.

11.2.2. Myelopreservation Assessments

The myelopreservation effects of trilaciclib administered prior to docetaxel compared with placebo administered prior to docetaxel will be evaluated based on the following: kinetics of changes in CBCs (including DSN in Cycle 1 and rate of SN); hematologic toxicities, including FN; RBC and platelet transfusions; hematopoietic growth factor utilization; infections and systemic antibiotic use. All of these variables will be assessed as described in the safety assessments (monitoring of AEs, clinical laboratory assessments, and concomitant medications).

11.3. Safety Assessments

Unless specified otherwise, safety assessments should be conducted prior to study drug administration.

11.3.1. Vital Signs

The following will be collected per the Schedule of Assessments ([Table 6](#)) 15 minutes (+/- 10 minutes) before and after the trilaciclib/placebo infusion:

- Body temperature, pulse rate, blood pressure (diastolic and systolic)

11.3.2. Physical Examination

Full physical examination at Screening should include general appearance, height in centimeters, body weight in kilograms, skin, neck, eyes, ears, nose, throat, lungs, heart, abdomen, lymph nodes, extremities, and neurological examinations. Subsequent physical exams should include body systems as determined by provider (e.g., brief physical exam) and weight.

Information about the physical examination must be present in the source documentation at the study site. Clinically relevant findings observed **prior** to the start of study drug, should be recorded as medical history. Clinically relevant findings observed **after** the start of study drug, which meet the definition of an AE, must be recorded on the AE eCRF.

Assessments may be performed by a physician, registered nurse, or other qualified health care provider.

11.3.3. ECOG Performance Status

The Investigator or qualified designee will assess ECOG performance status during the Screening Period to assess for eligibility according to the inclusion and exclusion criteria ([Table 12](#)) as well as to monitor performance throughout the study ([Table 6](#)).

Table 12: ECOG Performance Status

Grade	ECOG
0	Fully active, able to carry on all pre-disease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work
2	Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours
3	Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4	Completely disabled. Cannot carry out any selfcare. Totally confined to bed or chair
5	Dead

ECOG=Eastern Cooperative Oncology Group
Source: [Oken, 1982](#).

11.3.4. Electrocardiogram

Single standard 12-lead ECGs will be performed as outlined in the Schedule of Assessments ([Table 6](#)) on Day 1 of Cycles 1 and 2 at the following timepoints: predose (any time prior to trilaciclib/placebo on the day of dosing) and at the end of trilaciclib/placebo infusion (within 30 minutes following the infusion but prior to initiation of docetaxel infusion). Additional ECGs may be performed as clinically indicated at any time during the study.

All 12-lead ECGs will be obtained after the patient has been resting for at least 5 minutes and shall be recorded at 25 mm/sec. All ECGs for an individual patient shall be recorded with the patient in the same physical position.

Any ECG with a QTc value of >500 msec shall have the QTc value confirmed via manual read. A repeat ECG in triplicate (over approximate 5-minute period) should also be obtained for confirmation. The Investigator or qualified designee should review the ECGs for any abnormalities as compared with the baseline ECG. Following confirmation, the Investigator should evaluate for any other potential causes of the prolongation (e.g., concomitant medications) and determine the appropriate clinical course.

11.3.5. Clinical Safety Laboratory Assessments

Hematology, clinical chemistry, and serum or urine pregnancy test will be performed at the site's local certified laboratory per the schedule outlined in the Schedule of Assessments ([Table 6](#)). Clinical laboratory samples may be collected from patients at a different location than the Investigator's clinic following approval by the Medical Monitor. A list of clinical laboratory tests to be performed is provided in Section 17.1. Hematology may be obtained up to 24 hours and serum chemistry may be obtained up to 72 hours prior to each time point on Schedule of Assessments but must be reviewed before dosing. Laboratory toxicities will be assessed using the NCI-CTCAE, v5.0.

For women of childbearing potential, pregnancy tests will be performed as follows: serum beta human chorionic gonadotropin (β -hCG) at Screening (must be performed during window allowing randomization in IWRS and negative results should be available prior to

randomization) and serum or urine β -hCG prior to the start of each cycle thereafter, as well at the post-treatment visit.

An abnormal laboratory value is not an AE unless it is considered to be clinically significant. Whether a clinically significant laboratory value is also an adverse event will be determined by the investigator. Laboratory parameters for which clinically significant values are noted will be re-measured on the appropriate clinical follow-up arranged by the Investigator. Any laboratory value that remains abnormal at the end of the study and that is considered clinically significant should be followed according to accepted medical standards for up to 30 days or until the values return to normal or baseline or are no longer considered clinically significant by the Investigator. If such values do not return to normal/baseline within a period of time judged reasonable by the Investigator, the etiology should be identified, and the Medical Monitor notified.

If a subsequent cycle is delayed for toxicity, the patient should still complete the clinical laboratory assessments on the scheduled Day 1 (entered as an Unscheduled assessment in EDC) as well as on the actual first dosing day of that cycle. If the delay is secondary to hematologic toxicity, weekly repeat hematology assessments should continue until the finding meets criteria for resumption of dosing (see Section 9.3.2; Table 9).

11.3.6. Adverse and Serious Adverse Events

The Investigator and any qualified designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE and remain responsible for following up, as applicable, AEs that are serious, considered related to the study drugs or study procedures, or that caused the patient to discontinue the study or study drugs (see Section 10.1). Patients should be encouraged to report AEs freely or in response to general, nondirected questioning. Adverse events (serious and non-serious) should be reported on the appropriate page of the eCRF. Toxicity will be assessed by Investigators using NCI-CTCAE v5.0.

11.3.6.1. Time Period and Frequency for Collecting Adverse and Serious Adverse Event Information

AEs will be collected starting from the first dose of study drug through the Post-Treatment Visit. Any SAE occurring between the date the patient signs informed consent and the first dose of any study drug, and which the Investigator feels is related to a study specific procedure (i.e., would not have occurred unless the patient was on the study), should also be reported. Any AEs that occur between the date of signing informed consent and the first dose of study drug should be recorded as Medical History.

All SAEs will be recorded and reported to G1 Therapeutics, Inc. Pharmacovigilance (PVG) or designee immediately and should not exceed 24 hours after becoming aware of the event, as indicated in Section 17.2.

Investigators are not obligated to actively seek AE or SAE information after 30 days following the last dose of study drugs on this study. However, if the Investigator learns of any SAE, including a death, at any time after a patient has been discharged from the study, and he/she considers the event to be reasonably related to the study intervention or study participation, the Investigator or designee must promptly notify G1 Therapeutics, Inc. PVG or designee.

11.3.6.2. Method of Detecting Adverse and Serious Adverse Events

The method of recording, evaluating, and assessing causality of AE and SAE and the procedures for completing and transmitting SAE reports are provided in Section 17.2.

Care should be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and nonleading verbal questioning of the patient is the preferred method to inquire about AE occurrences.

11.3.6.3. Follow-up of Adverse and Serious Adverse Events

After the initial AE/SAE report, the Investigator is required to proactively follow each patient at subsequent visits/contacts. All AEs (both serious and nonserious) will be followed in accordance with good medical practice until resolution, return to baseline, or it is deemed that further recovery is unlikely. All measures required for AE management and the ultimate outcome of the AE will be recorded in the source document and reported to G1 Therapeutics, Inc.

All SAEs will be followed until resolution, stabilization, the event is otherwise explained, or the patient is lost to follow-up (as defined in Section 10.3). Further information on follow-up procedures is provided in Section 17.2.

11.3.6.4. Regulatory Reporting Requirements for Serious Adverse Events

Prompt notification of G1 Therapeutics, Inc. PVG or designee by the Investigator (or designee) of a SAE is essential so that legal obligations and ethical responsibilities towards the safety of patients and the safety of a study intervention under clinical investigation are met.

G1 Therapeutics, Inc. has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. G1 Therapeutics, Inc. will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, Central IRB/IEC, and Investigators. For all studies, except those utilizing medical devices, Investigator safety reports must be prepared for suspected unexpected serious adverse reactions (SUSAR) according to local regulatory requirements and G1 Therapeutics, Inc. policy and forwarded to Investigators, as necessary.

An Investigator who receives an Investigator safety report describing a SAE or other specific safety information (e.g., summary or listing of SAEs) from G1 Therapeutics, Inc. or designee will review and then file it along with the Investigator's Brochure and will notify the IRB/IEC, if appropriate according to local requirements.

11.3.6.5. Pregnancy

Details of all pregnancies in female patients and female partners of male patients will be collected after the start of study intervention and until 30 and 120 days respectively, after the last dose of study drug.

If a pregnancy is reported, the Investigator or designee should inform G1 Therapeutics, Inc. PVG or designee within 24 hours of learning of the pregnancy and should follow the procedures outlined in Section 17.3.

Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.

11.4. Patient-Reported Outcomes

The PRO items below will be self-administered by patients, overseen by a designated study site staff member. PRO questionnaires should be completed on Days 1 and 13 of Cycle 1 and Day 1 of each subsequent cycle and at the Post-Treatment Visit, except for the Patient Global Impression of Change (PGIC) which is not administered on Day 1 of Cycle 1, per the schedule outlined in the Schedule of Assessments (Table 6).

The PRO questionnaires should be completed on both the planned Day 1 visit and on the actual Day 1 of the cycle (i.e., when dosing is delayed and criteria are then met to proceed with Day 1 treatment). PRO questionnaires may be administered up to 1 calendar day prior to each dosing day and are to be completed on the same day a blood sample is collected for hematology assessment. Questionnaires administered on Cycle 1 Day 13 may be obtained ± 1 day of scheduled visit. Questionnaires should be completed before treatment administration, and where possible before any laboratory tests or other procedures that are performed that day.

11.4.1. EORTC QLQ-C30 and EORTC QLQ-LC13

The EORTC QLQ-C30 and QLQ-LC13 are validated instruments that will be administered on the days outlined in the Schedule of Assessments (Table 6).

The EORTC quality of life questionnaire (QLQ) is an integrated system for assessing the health-related quality of life (QoL) of cancer patients participating in international clinical trials (Aronson, 1993). The core questionnaire, the QLQ-C30, includes 30 items that address symptoms and functional impacts that are applicable across cancer populations. The QLQ-C30 yields 15 domains assessing global health status, symptoms (e.g., fatigue, nausea and vomiting), and function (e.g., physical functioning, emotional functioning). Each domain is scored on a 0-100 scale. The detailed scoring algorithm is included in the scoring manual (Fayers, 2001).

The EORTC QLQ-LC13 is a supplemental module that was designed for use among a wide range of lung cancer patients varying in disease stage and treatment modality (Bergman, 1994). The QLQ-LC13 incorporates one multi-item scale to assess dyspnea, and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. Domains are scored on a 0-100 scale. The open-ended item assessing location of pain and the item asking about the use and effect of pain medications will not be included in the QLQ-LC13 version to be administered in this trial, as it is not used in the scoring of the measure. A supplemental item from the EORTC Item Library addressing weight loss (“Has weight loss been a problem for you?”) will be added to the QLQ-LC13. This version of the QLQ-LC13 has been titled the EORTC IL118 by the EORTC. The scoring algorithm is described in the scoring manual (Fayers, 2001).

11.4.2. FACIT-Fatigue

The FACIT-Fatigue (Yellen, 1997) is a 13-item measure that measures the severity of fatigue (e.g., “I feel fatigued,” “I feel tired”) and the impact of fatigue on functioning (e.g., “I have trouble starting things because I am tired,” “I need to sleep during the day”). Patients rate their experiences over the “past 7 days” using a 0-4 verbal rating scale (“Not at all” to “Very Much”). The FACIT-Fatigue is scored as a sum of all 13 of the item responses; the scale range is from 0-

52. After appropriate reverse scoring of 11 items, lower scores on the FACIT-F indicate greater levels of fatigue.

11.4.3. Patient Global Impression of Change and Patient Global Impression of Severity

The PGIC and Patient Global Impression of Severity (PGIS) items will be self-administered on the days outlined in the Schedule of Assessments (Table 6). The PGIC item will ask the patient to rate the change in their fatigue since taking study drug on a 7-point scale ranging from -3 (very much worse) to 3 (very much better). The PGIS item, will ask the patient to rate the overall severity of their fatigue over the past week on a 5-point scale ranging from 0 (none) to 4 (severe).

11.4.4. 5-Level EQ-5D

The EQ-5D-5L will be provided to patients for self-administration on the days outlined in the Schedule of Assessments (Table 6). The 5-level EQ-5D (EQ-5D-5L) is a standardized instrument by which treatment effects can be assessed by measuring health status at different points in time, e.g., before and after treatment, and then investigating the gains (or losses) in reported health status. The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS). For the EQ-5D, respondents will rate their health on each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The patient will be asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ-VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled "The best health you can imagine" and "The worst health you can imagine". The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

11.5. Pharmacokinetics

Blood samples for PK analysis will be collected as indicated in the Schedule of Assessments (Table 6) from all patients. Three blood samples for PK analysis of trilaciclib will be collected: on Cycle 1 Day 1 at the end of trilaciclib/placebo infusion (sample can be taken up to 15 minutes prior to the end of infusion), at 30 minutes post the end of trilaciclib/placebo infusion (± 15 minutes) and at 4-6 hours post the end of the trilaciclib/placebo infusion.

Three samples will also be collected for PK analysis of docetaxel: on Cycle 1 Day 1 at the end of docetaxel infusion (sample can be taken up to 15 minutes prior to end of infusion), 2 hours after end of docetaxel infusion (± 30 minutes) and at 4-6 hours post the end of the docetaxel infusion.

The actual date and time of each blood sample collection, the scheduled timepoint of collection, and the time of dose administration prior to the pharmacokinetic sample will be recorded. Details of PK blood sample collection including volume to be collected, timing of samples, processing, storage, and shipping procedures are provided in the Laboratory Manual. Blood samples for PK analysis may be collected from patients at a different location than Investigator's clinic.

11.6. Biomarkers

11.6.1. Rationale for Archival Tumor Collection

Because trilaciclib maintains G1 arrest in CDK4/6 dependent cells, there is a hypothetical risk that trilaciclib could antagonize the anti-tumor efficacy of cytotoxic chemotherapy by maintaining a G1 cell cycle arrest of CDK4/6 dependent tumor cells during chemotherapy. While the currently available nonclinical and clinical data indicate that this risk remains hypothetical and does not influence the overall benefit/risk assessment for combining trilaciclib with chemotherapy, this study will evaluate in a retrospective fashion the relationship between CDK4/6 status and measures of anti-tumor efficacy; the planned statistical analyses are described in Section [12.4.9](#).

To support these analyses, prior to signing the informed consent, a FFPE archival tumor specimen with an associated pathology report documenting NSCLC (recurrent/metastatic preferred) for each patient must be confirmed to be available to send to a central storage facility for planned retrospective biomarker analyses. Tumor tissue must consist of a fixed paraffin-embedded block (100 microns preferred; 75 microns (minimum) unless otherwise approved by the Medical Monitor. If a block is not available, 20 or more (15 minimum) freshly cut unstained slides are an acceptable alternative. If archival tissue is not available, a fresh biopsy must be obtained. Acceptable samples include core needle biopsies, tumor tissue - excisional or incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions. Fine-needle aspiration, brushing, cell pellet from pleural effusion, bone metastases, and lavage samples are not acceptable. Additional guidance is provided in the Laboratory Manual.

In addition to CDK4/6 status as described below, tumor PD-L1 status (positive or negative) will be determined and anti-tumor efficacy endpoints by PD-L1 status will be evaluated. Any remaining tumor tissue following the described analyses will be banked and may be analyzed for relevant DNA, ribonucleic acid (RNA), or protein biomarkers and their role in cancer, including to better understand immune-related mechanisms.

Note: No tumor tissue will be archived for study centers in China.

11.6.2. Description of CDK4/6 Signature

In order to characterize this hypothetical risk in a tumor type without a clear CDK4/6 response phenotype, archival tumor tissue will be collected from patients' most recent biopsy (NSCLC primary or metastatic site) and subjected to a genetic signature analysis based on published literature in an effort to characterize patient tumors into one of the following three groups ([Gong, 2017](#); [Shapiro, 2017](#)):

- CDK4/6 independent
- CDK4/6 dependent
- CDK4/6 indeterminate

The evaluation of the relationship between CDK4/6 status and anti-tumor outcomes may be performed when the final OS analysis is performed, that is, when the predicted death events are observed. The use of mature OS data, in addition to the ORR and PFS data, will allow for a more robust interpretation of the relationship between CDK4/6 status and anti-tumor outcomes without

the complication of trying to draw conclusions with inadequate information (i.e., immature anti-tumor efficacy data).

This timing is considered to be appropriate since all currently available data indicate that if there is a risk, it is not clinically relevant; therefore, waiting until mature OS data does not pose a significant hazard to the enrolled patients, particularly since the percentage of patients at risk for a potential negative outcome (i.e., who have CDK4/6 dependent tumors) is predicted to be <10% (Section 4.2.7).

11.7. Immunologic and Hematologic Markers

Blood samples for biomarker analysis will be collected at the time points indicated in the Schedule of Assessments (Table 6) from all patients.

Chemotherapeutic agents may elicit part of their anti-tumor efficacy by modulating the immune system to enhance antigen presentation, uptake, and processing; prime the immune response through immunodepletion; inhibit regulatory cells; and stimulate immune effector cells (Zitvogel, 2008; McDonnell, 2011; Bracci, 2014). Conversely, immunosuppression from direct cytotoxicity to the bone marrow and immune system over repeated cycles of chemotherapy may counterbalance the positive immunostimulatory effects of chemotherapy. Therefore, therapeutic approaches to maintain bone marrow health and immune system function should enhance the immune-mediated anti-tumor activity.

Trilaciclib and other CDK4/6 inhibitors have been shown to augment anti-tumor responses in preclinical settings (Klein, 2018) by enhancing T-cell activation through modulation of nuclear factor of activated T-cell activity (Deng, 2018), as well as increasing antigen presentation through upregulation of MHC class I and II in CDK4/6-sensitive tumors and myeloid cells (Goel, 2017; Schaer, 2018). Additionally, CDK4/6 inhibition can upregulate and stabilize the protein expression of PD-L1 on tumor cells (Zhang, 2018).

To evaluate the impact of trilaciclib administration on chemotherapy-induced changes of the immune and hematopoietic system, immunophenotypic and hematologic changes will be compared (as data warrant) between trilaciclib and placebo on patients receiving docetaxel therapy. To assess these changes, peripheral blood will be collected per the timepoints in the Schedule of Assessments (Table 6). At each time point (Cycle 1 Day 1, Cycle 1 Day 9, Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 5 Day 1), collection should occur prior to trilaciclib dosing.

These blood samples will be banked and may be analyzed for relevant DNA, RNA, or protein biomarkers and their role in cancer. Samples may be stored for up to 10 years if patients sign the consent form and allow their samples to be stored for any future research. Note: No blood will be archived for study centers in China.

11.8. Data Monitoring Committee

An unblinded, independent Data Monitoring Committee will monitor accumulating safety and disposition data with the first meeting planned for when approximately 20 patients have enrolled and completed at least 2 cycles of study treatment. The meetings will continue approximately every 4 months while patients are on study treatment depending upon the enrollment rate. Additional reviews may occur based on DMC requests.

A DMC charter will define the roles and responsibilities of the DMC and its members. Additional details regarding the committee's composition, scope, objectives, procedures and policies, including detailed data analysis plan and strategy for maintaining study blind for the Sponsor, Investigators and patients, are described in the DMC charter. The DMC will monitor accumulating safety and disposition data entirely independent of the conduct of the study.

11.9. Post-Treatment Visit

When a patient permanently discontinues study treatment, the patient should complete a Post-Treatment Visit 30 days (\pm 7 days) from last dose of study drug as outlined in [Table 6](#).

11.10. Survival Follow-up Phase

Starting from the last dose of study drug, the patient will be followed approximately every 2 months for survival. Survival Follow-up Visits can be via telephone, email, or clinic visits.

For those patients who have not progressed clinically or radiologically at the time of study drug discontinuation, every effort should be made to continue radiological tumor assessments every 12 weeks (\pm 7 days) during survival follow-up, utilizing the same imaging modality as used at Screening, as outlined in the Schedule of Assessments ([Table 6](#)), until progressive disease, initiation of subsequent anti-cancer therapy, withdrawal of consent, or study completion, whichever occurs first.

Information will be collected until the end of the study (or death) to record their status (alive or dead). In addition, details of any subsequent systemic anti-cancer therapy initiated, including name(s) of agent(s), dates (start/stop) administered, best response to the treatment, and date of progression should also be reported to the best of their ability.

If a patient withdraws consent for further study procedures, the site should clarify if the patient (or legally authorized representative where allowed by local regulation) remains open to survival contact and associated data collection. Provided that the patient has not withdrawn consent for follow up contact, information from medical records may be substituted for phone or other contact, provided that records are available as source documentation. Public records may be used to verify survival status if permitted by institutional or country guidance.

12. STATISTICAL CONSIDERATIONS

Full details on the statistical analyses to be performed will be provided in a separate statistical analysis plan (SAP).

12.1. Sample Size Determination

The sample size is determined to support the primary objective of the study. That is, to evaluate the effect of trilaciclib compared to placebo on the overall survival of patients with metastatic NSCLC receiving docetaxel in the 2nd/3rd line setting. A total of 104 deaths will be required to achieve 85% power to detect a hazard ratio (HR) of 0.55 in OS at a 2-sided significance level of 0.05. A HR of 0.55 corresponds to a median OS of 16.5 months for the trilaciclib group assuming a median OS of 9.1 months for the placebo group (Garon, 2014). With a 12-month enrollment period and a 30-month study duration (after the first patient is randomized), a total of 146 patients are required for randomization at a 1:1 ratio to trilaciclib or placebo. This sample size has taken into consideration an interim analysis for OS at the information fraction of 0.70 using the O'Brien-Fleming method for α -spending to ensure strong control of Type I error rate at 1-sided 0.025 between the interim and the final analysis for OS. In the sample size calculation, it is also assumed that about 5% of patients are lost-to-follow-up during the 30-month study duration. EAST[®] v6.5 is used for the power and sample size calculations.

12.2. Analysis Population

The intent-to-treat (ITT) population includes all randomized patients. Analyses for the ITT population will be conducted according to the randomly assigned treatment regardless of whether the patient received study treatment or was compliant with the protocol. Unless otherwise specified, the ITT population is the primary analysis population for all efficacy analyses.

The Response Evaluable (RE) population includes all patients who are in the ITT population and who have measurable (target) tumor lesion(s) at the baseline tumor assessment and either (i) have at least 1 post-baseline tumor assessment, or (ii) do not have post-dose tumor assessment but have clinical progression as noted by the Investigator, or (iii) died due to disease progression prior to their first post-baseline tumor scan. Analyses using this analysis population will be conducted according to the randomly assigned treatment. The RE population will be the primary analysis set for tumor response analyses.

The safety population includes all randomized patients who received at least 1 dose of study drug. Analyses using the safety population will be conducted according to the actual treatment received. All safety analyses will be evaluated using the safety population.

The pharmacokinetic (PK) population will include all patients who received at least one dose of study drug and had evaluable PK data.

12.3. Timing of Planned Analysis

12.3.1. First Planned Analysis – Interim Analysis for Overall Survival and Analyses for Progression Free Survival, Tumor Responses and Myelosuppression Endpoints

The first planned analysis will take place primarily to perform the interim analysis for OS. The timing of this analysis will be based on the timing when 73 deaths are observed. Following the

assumptions that are used in the sample size calculation (Section 12.1), this analysis might be conducted approximately 19 months after the first patient is randomized.

Per literature, the expected median PFS for patients receiving docetaxel is 3 months (Garon, 2014). Assuming trilaciclib can achieve a treatment effect of HR of 0.60, it is estimated that at the time of performing the OS interim analysis, 86% of patients would have had radiographic-determined disease progression or died. Therefore, the analysis for PFS will be conducted at the time when the OS interim analysis is conducted since the PFS events are considered mature. It is also anticipated that the treatment effect on tumor response will be mature at this time, thus, ORR and DOR will also be analyzed at this time. In addition, analyses for myelosuppression and PRO endpoints will be performed at this time.

The study database will be locked to perform these planned analyses.

If the interim OS analysis result is positive as determined by the pre-specified statistical criterion, the study will be stopped for success and the OS analysis results are considered final. If the interim OS analysis result does not meet the criterion of success, the study will continue until a total of 104 deaths are observed.

12.3.2. Second Planned Analysis – Final Analysis for Overall Survival and Safety Data Analyses

At the time when 104 deaths are observed, the study database will be locked to perform the final analysis for OS. This will be the closure of the study. Safety data and anti-tumor efficacy evaluation by CDK 4/6 status and other exploratory analyses will be performed at this time. Under the assumptions used in sample size calculation (Section 12.1), this analysis could be performed approximately 30 months after the first patient is randomized.

It is expected that PFS data are mature at the time of performing the OS interim analysis (i.e., the first planned analysis). However, if the percentage of patients with a radiographic determined disease progression or death at the time of the first planned analysis is less than 80%, PFS will be analyzed again at this time and the results from this analysis will be considered as primary to interpret trilaciclib's effect on PFS in this study.

At this time, other SAP specified analyses that are not mentioned in Section 12.3.1 will all be conducted.

12.4. Statistical Analysis Methods

A SAP will be developed and finalized prior to the first database lock of the study and will include more details related to the statistical analysis of data collected in this study. This section is a summary of the key aspects of the planned statistical analyses.

12.4.1. General Considerations

Data will be summarized by treatment group. The descriptive summary for the categorical variables will include counts and percentages. The descriptive summary for the continuous variables will include means, medians, standard deviations, 25% and 75% percentiles, and minimum and maximum values.

There are two stratification factors for randomization: country and ECOG performance status (0-1 versus 2). A randomization schema will be in place to ensure the best possible balance of treatment assignment within each stratum produced by these stratification factors. Countries will be grouped into the factor of “region” with 3 components: US, Europe, and Asia. The factor “region” will be used instead of “country” in the statistical analysis models to account for regional differences in clinical practice. Unless otherwise specified, ECOG status as entered in IWRS at the time of randomization will be used as the factor for all stratified analyses.

12.4.2. Patient Disposition

Patient disposition will be summarized for all patients by treatment group and overall. The summary will include number of all screened patients, and number and percentage of patients who were randomized, received study drug, discontinued from the study drug with the reasons, and discontinued from study with the reasons.

12.4.3. Demographic and Baseline Characteristics

Demographics and baseline characteristics will be summarized for the ITT population by treatment group and overall. The demographics to be summarized include age, age group (<65 versus ≥65 years old), gender, race, ethnicity, and region. The baseline characteristics to be summarized include ECOG status, NSCLC history (date of diagnosis, histologic type, and prior therapies by line (eg, surgery, radiation, systemic chemotherapy, or immunotherapy). In addition, the recorded PD-L1 status at the screening visit will also be summarized along with vital signs at the screening visit (body weight, body mass index [BMI], BSA).

12.4.4. Prior and Subsequent Anticancer Therapies

Prior and subsequent anticancer therapy verbatim terms will be coded to Anatomical Therapeutic Classification (ATC) and preferred term (PT) using the latest version of World Health Organization-Drug Dictionary (WHO-DD) for the ITT population. Summary statistics will be provided for prior systemic anti-cancer therapies given in different setting (1st line or 2nd line) by treatment group and overall. For the subsequent systemic anti-cancer therapies, the lines of therapy, response to each treatment regimen, and disease progression status will also be summarized by treatment group and overall.

12.4.5. Study Drug Exposure, Modification and Dose Intensity

The summary described below will be based on the safety population.

Duration of study drug exposure will be calculated for docetaxel and for trilaciclib/placebo by treatment group.

For each treatment group, the number of cycles that patients have received will be summarized by descriptive statistics as a continuous variable, while the number of cycles that are completed will be summarized as a categorical variable.

Study drug modifications will be summarized by treatment group in three categories: chemotherapy dose reductions, chemotherapy cycle delay, and infusion interruption. The number and percentage of patients who have at least one dose reduction for docetaxel will be summarized along with a summary of the number of dose reductions that have occurred; the number and percentage of patients who have at least one cycle delay will be summarized along

with a summary of the number of cycles that have been delayed; the number and percentage of patients who have at least one infusion interruption for trilaciclib/placebo or docetaxel will be summarized along with a summary of the number of interruptions. Lastly, the primary reason for each form of study drug modification (docetaxel dose reduction, cycle delay, and infusion interruption) will also be summarized by treatment group.

For trilaciclib/placebo and docetaxel, respectively, cumulative dose, dose intensity, relative dose, and relative dose intensity will be derived and summarized by treatment group.

12.4.6. Efficacy Analyses

Unless otherwise specified, all efficacy analyses will be performed on the ITT population.

12.4.6.1. Analyses of Primary Efficacy Endpoint – Overall Survival

The primary endpoint OS is defined as the time (months) from the date of randomization to the date of death for patients who died in the study due to any cause, and the time to the last contact date known to be alive for those who survived as of the data cutoff date for the interim OS analysis or as of the date when the study database is locked for the final analysis (censored cases). Patients lacking data beyond the date of randomization will have their survival time censored at the date of randomization.

The targeted number of deaths for the final analysis is 104 and the final analysis for OS is event-driven. The number and percentage of patients who died or censored will be summarized by treatment group along with the reason for death.

Treatment effect on OS will be primarily evaluated using a stratified log-rank test controlling for the stratification factors of region (US, Europe, or Asia) and ECOG performance status (0-1 versus 2). The magnitude of the treatment effect, HR (trilaciclib versus placebo), will be estimated using a Cox proportional hazard model with the same factors as included in the stratified log-rank test. At the final analysis, the $(1-\alpha)*100\%$ confidence interval (CI) will be generated for the HR, where the α is a 2-sided statistically significant level to be used for the final OS analysis determined by actual information fraction used at the interim and the O'Brien-Fleming α -spending function.

For each treatment group, the Kaplan-Meier plot will be generated, and the median, 25% and 75% percentile of OS will be estimated using the Kaplan-Meier method with their corresponding 95% confidence interval calculated using the method by [Brookmeyer and Crowley \(1982\)](#). Additionally, Kaplan-Meier estimates will be provided for the survival probability along with their two-sided 95% CIs ([Kalbfleisch, 1980](#)) at selected landmarks of 6, 12, 18, and 24 months.

12.4.6.1.1. Interim Analysis for Overall Survival

An interim analysis of OS will be conducted at the 70% information fraction, that is, when 73 deaths are observed. The timing of the interim analysis is estimated to be approximately 19 months after the first patient is randomized in the study. O'Brien-Fleming method for α -spending is applied to ensure strong control family-wise Type I error rate of 1-sided of 0.025 between the interim and the final analysis for OS. At the interim analysis, the significant treatment effect of trilaciclib compared with placebo for OS is established if the 1-sided p-value from the stratified log-rank test is less than or equal to 0.0075 ([Table 13](#)). If the final analysis is performed at 104

cumulative deaths as planned, a 1-sided significance level of 0.0227 will be used to evaluate treatment effect for OS at the final analysis. The actual significance level at the final analysis for OS will be re-calculated if the actual information fraction for the interim OS analysis is different than the planned 0.70 using the O'Brien-Fleming α -spending function.

There will be no final OS analysis if the superiority of trilaciclib over placebo for OS is established at the interim analysis.

Table 13: Thresholds for Claiming Statistical Superiority (Trilaciclib versus Placebo) at Interim or Final Analysis for Overall Survival

Analysis	# of Deaths	Analysis Timing from FPI (month) ^a	Z-scale	HR-scale	P-value Scale (1-Sided)
Interim Analysis	73	19	2.434	0.562	0.0075
Final Analysis ^b	104	30	2.000	0.673	0.0227

FPI=first patient randomized; HR=hazard ratio.

^a Estimated based on the assumptions of accrual period and duration of follow up as used in the sample size calculation.

^bStatistical criteria judging the significance at the final analysis could be re-calculated if the interim analysis information fraction is different than 0.70.

The aforementioned analyses will be conducted on the ITT population.

12.4.6.2. Analysis for Secondary Anti-tumor Efficacy Endpoints

Secondary anti-tumor endpoints include the following:

- Progression free survival (PFS)
- Objective response rate (ORR)
- Duration of objective response (DOR)

Progressive disease (PD) and tumor response status are derived per RECIST v1.1 based on tumor assessment data entered into the EDC by Investigators.

12.4.6.2.1. Analysis for Progression Free Survival

Progression free survival is defined as the time (months) from date of randomization to the date of documented radiologic PD per RECIST v1.1 or date of death regardless the cause, whichever comes first. PFS will be determined using all available data up to the date of (i) radiographic disease progression per RECIST v1.1; (ii) withdrawal of consent to obtain additional scans on study; or (iii) initiation of subsequent anticancer therapy, whichever is earliest. Censoring rules for patients who do not experience PD or death at the data cutoff date or at the date for final database lock will be detailed in the study SAP.

The treatment effect on PFS will be evaluated by using a stratified log-rank test controlling for the two stratification factors. A Cox proportional hazard model with the same terms as in the stratified log-rank test will be used to estimate the HR (trilaciclib versus placebo) for PFS along with its 95% confidence interval. In addition, Kaplan-Meier plots will be generated and the

median, 25% and 75% percentile of PFS will be estimated using the Kaplan-Meier method by treatment group with their corresponding 95% confidence interval calculated using the method by [Brookmeyer and Crowley \(1982\)](#).

Per literature, the expected median PFS for patients receiving docetaxel is 3 months ([Garon, 2014](#)). Assuming trilaciclib can achieve a treatment effect of HR of 0.60, it is estimated that 86% of patients would have a radiographic disease progression or died at the time when OS interim analysis is performed. Therefore, the analysis for PFS will be conducted at the time of performing interim OS analysis. However, if the observed PD or deaths at the date of data cutoff for the OS interim analysis is less than 80%, the final PFS will be performed using the final database if the study is not stopped for success after the interim OS analysis. In that event, the treatment effect for PFS as observed at the final analysis will be considered to be primary.

PFS will be analyzed on the ITT population.

12.4.6.2.2. Analysis for Tumor Response Status and Duration of Objective Response

At each tumor assessment visit, an overall time point response per RECIST v1.1 will be determined programmatically using the measurements of target lesions, non-target lesions, and new lesions entered to the eCRF by the Investigators. Best overall response (BOR) will be determined per RECIST v1.1 using all timepoint responses prior to or on the date of (i) radiographic disease progression; (ii) withdrawal of consent to obtain tumor scans; (iii) death; (iv) lost to follow-up; or (v) initiation of subsequent anticancer therapy, whichever is earliest. The BOR status for patients will be summarized by the number and percentage of patients in each of the following categories: complete response (CR) (confirmed), partial response (PR) (confirmed), stable disease (SD) and Not Evaluable (NE).

ORR is defined as the proportion of patients with confirmed CR or confirmed PR as the BOR status. ORR along with its exact 95% two-sided confidence interval using the Clopper-Pearson method will be computed for each treatment group. The treatment group difference for ORR will be evaluated using a stratified Cochran–Mantel–Haenszel (CMH) test accounting for the two stratification factors. The adjusted proportion difference (trilaciclib minus placebo) and its 95% CI will be calculated using CMH weight ([Kim, 2013](#)).

DOR is the time (months) from the first date when CR or PR was achieved and confirmed in the next tumor scan to the date when the patient experienced disease progression or died in the absence of PD. For those who achieved objective response status and did not have disease progression or death at the time of data analysis, the earliest date of the following, if it exists, will be used to calculate censored time: (i) withdrew consent to obtain scans; (ii) last contact; (iii) initiated subsequent anticancer therapy; otherwise, the censored DOR will be calculated using the last date known with retained response status as of the data cutoff date for the analysis. DOR will be analyzed for the patients who have achieved objective response. The Kaplan-Meier method will be used to estimate the median, 25% and 75% percentile of DOR by treatment group, along with the 95% CI calculated using the method by [Brookmeyer and Crowley \(1982\)](#).

Analyses for ORR and DOR will be based on the Response Evaluable patient population.

12.4.6.3. Analysis for Myelosuppression Endpoints

Myelosuppression endpoints are grouped by lineage and consequence of CIM as follows.

- Neutrophils related (including DSN in Cycle 1, occurrence of SN, occurrence of FN, and occurrence of G-CSF administration)
- RBC related (including occurrence of Grade 3/4 decrease of hemoglobin, occurrence and number of RBC transfusions on/after Week 5, and occurrence of ESA administration)
- Platelet related (including occurrence of Grade 3 /4 decrease of platelets, occurrence and number of platelet transfusions)
- Endpoints related to trilaciclib's effect on chemotherapy dosing and hospitalization due to CIM (including occurrence and number of dose reductions or dose delay, and occurrence and number of hospitalization due to CIM)

12.4.6.3.1. Analysis for DSN in Cycle 1

For patients with at least one SN event (ANC value $<0.5 \times 10^9/L$) in Cycle 1, DSN (days) in Cycle 1 is defined as the number of days from the date of the first ANC value of $<0.5 \times 10^9/L$ observed at Cycle 1 to the date of the first ANC value $\geq 0.5 \times 10^9/L$ and no other ANC values $<0.5 \times 10^9/L$ occurred between this day and end of Cycle 1. DSN will be set to 0 for patients who do not experience SN in Cycle 1. Data from both scheduled and unscheduled assessments will be included in the calculation, and the actual assessment date will be used in the derivation of DSN in Cycle 1.

Treatment effect on DSN in Cycle 1 will be evaluated using a nonparametric analysis of covariance (ANCOVA) (Quade, 1967). In this analysis, the rank-transformed (within each stratum) DSN values are analyzed by an ANCOVA model with the terms of treatment, and the two stratification factors as fixed effects and the rank-transformed baseline ANC as a covariate. In addition, the mean difference (trilaciclib – placebo), the standard error and the 95% confidence interval for the difference generated from a Satterthwaite t-test will be presented.

12.4.6.3.2. Analysis for Binary Myelosuppression Endpoints

For the binary myelosuppression endpoints (e.g., the occurrence of SN and the occurrence of RBC transfusions on/after Week 5), the number and percentage of patients with at least one occurrence during the treatment period will be summarized by treatment group. The treatment effect will be evaluated using a Poisson regression model (Zou, 2004). The model will include the two stratification factors as the fixed effect with corresponding baseline value as a covariate when applicable (e.g., baseline ANC for occurrence of SN, and baseline hemoglobin for RBC transfusions on/after Week 5). The log transformed- duration of exposure either in week or in cycle will be used as the offset in the model to account for the variable duration for each patient (e.g., the number of cycles for occurrence of SN, and the number of weeks for RBC transfusions on/after Week 5). A 2-sided p-value, adjusted relative risk (aRR) (trilaciclib versus placebo) and its 95% CI will be generated from the statistical model as applied.

12.4.6.3.3. Analysis for Counting Myelosuppression Endpoints

For the counting myelosuppression endpoints (e.g., the number of RBC transfusions on/after Week 5, and the number of dose reductions during the treatment period), the total number of the event, the total number of exposure (either in the unit of week or cycle determined by the medical meaning), and event rate per 100 weeks or cycles will be summarized by treatment group. For example, the event rate for RBC transfusions on/after Week 5 will be reported by 100 weeks and that for dose reduction will be reported by 100 cycles. For a given event, patients without any of the event during the treatment period will be assigned a value 0 to be included in the analysis. The treatment group difference in the event rate will be assessed by a negative binomial model. The model will include the two stratification factors as the fixed effect with corresponding baseline value as a covariate when applicable (e.g., baseline hemoglobin for the analysis of number of RBC transfusions on/after Week 5). The log-transformed duration of exposure in week or in cycle will be used as the offset in the model to account for the variable duration for each patient (e.g., number of weeks for RBC transfusions on/after Week 5, and number of cycles for dose reduction). A 2-sided p-value, aRR (trilaciclib versus placebo) and its 95% CI will be generated from the statistical model as applied.

12.4.6.4. Subgroup Analysis for Primary Efficacy Endpoint

Treatment effect for the primary endpoint OS will be evaluated for each of the stratification factors: Region (US, Europe, or Asia) and ECOG status (0-1 versus 2). The treatment effects in each category of a factor will be evaluated by using a stratified log-rank test controlling for the other stratification factor. A Cox proportional hazard model with the same terms as used in the stratified log-rank test will be employed to estimate the HR and its 95% CIs within each category of the factor. A forest plot for the HR of OS and its 95% CI will be produced.

Subgroup analysis will be conducted for some baseline characteristics that might have impact on the treatment effect for OS and the details will be specified in the study SAP.

12.4.7. PRO Analyses

The EORTC QLQ-C30, EORTC QLQ-LC13 with supplemental weight loss item (EORTC IL118), FACIT-Fatigue, EQ-5D-5L, PGIC, and PGIS instruments will be used to collect the quality-of-life data to assess the impact of trilaciclib on various quality of life measures compared with placebo. Analysis for the variables derived from these questionnaires will be based on the ITT population and detailed in the study SAP.

12.4.8. Safety Analyses

Safety and tolerability will be assessed by AEs, laboratory tests, vital signs and ECGs. All safety data will be summarized using descriptive statistics by treatment group on the safety population. Data collected through scheduled or non-scheduled visits will all be included in the safety analyses.

12.4.8.1. Adverse Events

AEs are defined as those events occurring or worsening after treatment has begun on this study. Adverse event data will be coded to system organ class (SOC) and PT using the latest version of MedDRA. The severity (toxicity grades 1-5) of AEs will be graded according to the

NCI-CTCAE v5.0 by Investigators. The number and percentage of patients experiencing any AEs will be summarized overall and tabulated by SOC, PT and CTCAE grade for each treatment group. AEs considered by the Investigator to be related to a study drug, AEs leading to study drug discontinuation or dose modifications, and trilaciclib AESIs will be summarized by SOC, PT and CTCAE grade, when appropriate. In the tabulation of severity and causality of an AE, if the same AE occurred on multiple occasions, the highest grade of toxicity and strongest relationship to the study drug will be used in a summary.

12.4.8.2. Other Safety Endpoints

Observed values and changes from baseline to each end of the cycle, the maximum and minimum values during the treatment period in vital signs, and ECG intervals, and laboratory assessments of hematology, serum chemistry, and liver function parameters will be summarized by treatment group.

Serum chemistry and hematology laboratory parameters will be characterized according to CTCAE toxicity grade from 1 to 5, when possible. The number and percentage of patients within each CTCAE grade will be summarized for the overall treatment period as well as for each cycle. If a patient has multiple laboratory assessments in an interval of interest, the maximum grade will be reported.

For vital signs and ECG parameters, potentially clinically significant (PCS) findings will be summarized by treatment group. The potentially clinically significant vital signs and ECG parameters are defined either by post-baseline assessments or by change from baseline with respect to the pre-specified thresholds. The criteria defining PCS for vital signs and ECG parameters will be detailed in the study SAP, respectively.

12.4.9. Exploratory Analyses

The number and percentage of patients in different CDK4/6 signature status (i.e., CDK4/6 independent, CDK4/6 dependent, and CDK4/6 indeterminate) will be summarized by treatment group. Anti-tumor efficacy endpoints (OS, PFS, and ORR) will be evaluated for the subgroup of patients with different CDK 4/6 signature status. Within each type of signature, the analysis for OS will follow the statistical methods as outlined in Section 12.4.6.1, and the analysis for PFS and ORR will use the similar statistical approaches as outlined in Section 12.4.6.2.

In addition, anti-tumor efficacy endpoints (OS, PFS, and ORR) will be evaluated by PD-L1 status determined using archived tumor tissues and applying similar statistical approaches as used for the analyses of anti-tumor efficacy endpoints by CDK4/6 signature status.

Treatment group differences in pharmacodynamic parameters obtained from peripheral blood including those relating to immune-based mechanisms will be evaluated.

12.4.10. Pharmacokinetic Analyses

The pharmacokinetics of trilaciclib will be determined using a non-linear mixed effects modeling approach. Relevant population pharmacokinetic parameters will be estimated and reported. Details of population pharmacokinetic analyses will be described in the population pharmacokinetic/pharmacodynamic analysis plan.

The pharmacokinetics of docetaxel will also be determined using a non-linear mixed effects modeling approach. Relevant population pharmacokinetic parameters will be estimated and reported. Details of population pharmacokinetic analyses will be described in the population pharmacokinetic/pharmacodynamic analysis plan.

12.4.11. Pharmacokinetic/Pharmacodynamic Analyses

If data warrant, exploratory analyses may be performed to examine the relationship(s) between exposure to trilaciclib and pharmacodynamic endpoints or other efficacy and safety endpoints. Details of population PK/pharmacodynamic analyses will be described in a separate population PK/pharmacodynamic analysis plan.

13. ETHICS

13.1. Ethics Review

The protocol, protocol amendments, ICF, IB, and other relevant documents (e.g., advertisements) must be submitted to an IRB/IEC by the Investigator and reviewed and approved by the IRB/IEC before the study is initiated.

Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study patients.

The Investigator will be responsible for the following:

- Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC
- Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC procedures
- Providing oversight of the conduct of the study at the site and adherence to requirements of 21 Code of Federal Regulations (CFR), International Council for Harmonisation (ICH) guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations

13.2. Ethical Conduct of the Study

This study will be conducted in accordance with the protocol and with the following:

- Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines
- Applicable ICH GCP Guidelines
- Applicable laws and regulations

13.3. Written Informed Consent

The Principal Investigator(s) at each center will ensure that the patient is given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study. Patients must also be notified that they are free to discontinue from the study at any time. The patient should be given the opportunity to ask questions and allowed time to consider the information provided.

The patient's signed and dated informed consent must be obtained before conducting any study procedures.

The Principal Investigator(s) must maintain the original, signed ICF. A copy of the signed ICF must be given to the patient or the patient's legally authorized representative where allowed by local regulation.

14. DATA HANDLING AND RECORDKEEPING

14.1. Data Protection

Patients will be assigned a unique identifier by the Sponsor. Any patient records or datasets that are transferred to the Sponsor will contain the identifier only; patient names or any information which would make the patient identifiable will not be transferred.

The patient must be informed that his/her personal study-related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the patient who will be required to give consent for their data to be used as described in the informed consent.

The patient must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.

14.2. Data Quality Assurance

- All patient data relating to the study will be recorded on eCRF unless transmitted to the Sponsor or Designee electronically. The Investigator is responsible for verifying that data entries are accurate and correct by physically or electronically signing the eCRF.
- The Investigator must maintain accurate documentation (source data) that supports the information entered in the eCRF.
- The Investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents.
- Monitoring details describing strategy (e.g., risk-based initiatives in operations and quality such as Risk Management and Mitigation Strategies and Analytical Risk Based Monitoring), methods, responsibilities, and requirements, including handling of noncompliance issues and monitoring techniques (central, remote, or on-site monitoring) are provided in the Monitoring Plan.
- The Sponsor or Designee is responsible for the data management of this study including quality checking of the data.
- Study Monitors will perform ongoing source data verification (SDV) at the frequencies and SDV extent as outlined in the Monitoring Plan to confirm that data entered into the eCRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of patients are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.
- The Investigator must maintain all documentation relating to the study for a period of 2 years after the last marketing application approval, or if not approved 2 years following the discontinuance of the investigation of trilaciclib. If it becomes necessary for the Sponsor or the Regulatory Authority to review any documentation

relating to the study, the Investigator must permit access to such records. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor. The Investigator must ensure that the records continue to be stored securely for as long as they are maintained. It is the responsibility of the Sponsor to inform the investigator when these documents no longer need to be retained. However, if required by local regulation that these documents should be retained for a longer period, then Retention of Documentation will abide by local regulation.

A study-specific COVID-19 Assessment Plan will be utilized for any necessary modifications and/or mitigation to the data collection, monitoring or other associated activities during this study due to the COVID-19 pandemic.

14.3. Dissemination of Clinical Study Data

The Sponsor fulfills its commitment to publicly disclose clinical study results through posting the results of studies on www.clinicaltrials.gov, the EudraCT, and other public registries in accordance with applicable local laws/regulations.

Data results are posted in an objective, accurate, balanced, and complete manner. Results are posted regardless of outcome of the study.

14.4. Source Documents

Source documents provide evidence for the existence of the patient and substantiate the integrity of the data collected. Source documents are filed at the Investigator's site. All data reported in the eCRF should be supported by source documents; direct entry of data into the eCRF is not permitted in this study.

Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

14.5. Audits and Inspections

Authorized representatives of G1 Therapeutics, Inc., a regulatory authority, an IEC, or IRB may visit the site to perform audits or inspections, including source data verification. The purpose of an audit or inspection is to systematically and independently examine all study-related activities and documents to determine whether these activities were conducted, and data were recorded, analyzed, and accurately reported according to the protocol, GCP guidelines of the ICH, and any applicable regulatory requirements. The Investigator should contact G1 Therapeutics, Inc. immediately if contacted by a regulatory agency about an inspection.

15. PUBLICATION POLICY

By signing the study protocol, the Investigator and his or her institution agree that the results of the study may be used by G1 Therapeutics, Inc. for the purposes of national and international registration, publication, and information for medical and pharmaceutical professionals. If necessary, the authorities will be notified of the Investigator's name, address, qualifications, and extent of involvement.

Initial publication of the results of this study will be of a cooperative nature that may include authors representing the Sponsor, Investigator(s), and collaborating scientists. Independent publications by involved individuals may follow. Investigators and their institutions agree not to publish or publicly present any interim results of studies without the prior written consent of G1 Therapeutics, Inc. G1 Therapeutics Inc. reserves the right to request modification of any publication, presentation or use by the Investigator if such activity may jeopardize a patent application, an existing patent, or other proprietary rights. G1 Therapeutics, Inc. shall determine order of authorship of any publication combining all clinical results of this study.

16. REFERENCES

Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. *Eur J Cancer*. 2011;47:8-32.

Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. *Journal of the National Cancer Institute* 1993;85:365-76.

American Cancer Society. Key Statistics for Lung Cancer. Accessed 03 Dec 2020: <https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html>

Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. *Non-Small Cell Lung Cancer*. *Br J Cancer*. 2000;83(4):447-53.

Aranesp® (darbepoetin alpha) Prescribing Information. Amgen. 2011. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103951Orig1s5173_103951Orig1s52581bl.pdf

ASCO. Cancer.Net. Lung Cancer – Non-Small Cell: Statistics. Accessed 03 Dec 2020: <https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics>

Baghdadi TA, Halabi S, Garrett-Mayer E, et al. Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. *JCO Precision Oncology*. 2019;3:1-8.

Barlesi F, Mazieres J, Merlio J-P, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). *Lancet*. 2016;387(10026):1415-26.

Barrueto L, Caminero F, Cash L. Resistance to checkpoint inhibition in cancer immunotherapy. *Transl Onc*. 2020;13:100738.

Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. *European Journal of Cancer*. 1994;30A:635-42.

Bisi JE, Sorrentino JA, Roberts PJ, et al. Preclinical characterization of G1T28: A novel CDk4/6 inhibitor for reduction of chemotherapy-induced myelosuppression. *Mol Cancer Ther*. 2016;15:783–93.

Blackhall FH, O'brien M, Schmid P, et al. A phase I study of vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. *J Thorac Oncol*. 2010;5:1285-1288.

Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. *Ann Intern Med*. 1966;64(2):328-40.

Bohlius J, Bohlke K, Castelli R, et al. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. 2019; 37.

- Bonelli M, La Monica S, Fumarola C, et al. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation. *Biochem Pharmacol*. 2019;170:113676.
- Borcherding N, Kolb R, Gullicksrud J, et al. Keeping tumors in check: A mechanistic review of clinical response and resistance to immune checkpoint blockade in cancer. *J Mol Biol*. 2018;430:2014-29.
- Bracci L, Schiavoni G, Sistigu A, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. *Cell Death Differ*. 2014 Jan;21(1):15-25.
- Brody R, Zhang Y, Ballas M, et al. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. *Lung Cancer*. 2017;112:200-15.
- Brookmeyer R., and Crowley J. (1982). A confidence interval for the median survival time. *Biometrics*. 29-41.
- Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. *Cancer*. 2005;103(9):1916-24.
- Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature*. 2012;490(7418):61-70.
- Carson JL, Guyatt G, Heddle NM, et al. Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. *JAMA*. 2016;316(19):2025-35.
- Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov*. 2012;2:401-4.
- Chaikovsky AC, Sage J. Beyond the cell cycle: enhancing the immune surveillance of tumors via CDK4/6 inhibition. *Mol Cancer Res*. 2018;16:1454-57.
- Chen WS, Alshalalfa M, Zhao SG, et al. Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. *Clin Cancer Res*. 2019;25(14):4290-9.
- Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. *Tumori*. 2012;98(6):751-5.
- Clark A, McAndrew NP, Troxel A, et al. Combination paclitaxel and Palbociclib: Results of a Phase 1 trial in advanced breast cancer. *Clin Cancer Res*. 2019;25(7):2072-9.
- Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial [published online ahead of print, 2020 Dec 21]. *Int J Cancer*. 2020;10.1002/ijc.33453.
- Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib decreases myelosuppression in extensive-stage small cell lung cancer patients receiving first-line chemotherapy plus atezolizumab. *ESMO Annual Meeting 2019; Barcelona, Spain; Sep 2019 (abstr 1742PD)*.

- Deng J, Wang ES, Jenkins RW, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. *Cancer Discov*. 2018;8:216-33.
- Edelman MJ, Redman MW, Albain KS, et al. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). *J Thorac Oncol*. 2019;14(10):1853-9.
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45:228-247.
- Ertel A, Dean JL, Rui H, et al. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. *Cell Cycle*. 2010;9(20):4153-63.
- Fares CM, Van Allen EM, Drake CG, et al. Mechanisms of resistance to immune checkpoint blockade: Why does checkpoint inhibitor immunotherapy not work for all patients? 2019 ASCO Educational Book.
- Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). Published by: European Organisation for Research and Treatment of Cancer, Brussels 2001.
- Finn RS, Liu Y, Zhu Z, et al. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. *Clin Cancer Res*. 2020;26(1):110-21.
- Food and Drug Administration (FDA) Guidance for Industry, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2008.
- Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. *J Clin Oncol*. 2000;18(12):2354.
- Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. *N Engl J Med*. 2010 Nov 11;363(20):1938-48.
- Freed DM, Hall CR, Strum JC. CDK4/6 inhibition with lerociclib (G1T38) delays acquired resistance to targeted therapies in preclinical models of non-small cell lung cancer. American Association for Cancer Research Annual Meeting 2019; Chicago, IL, 201 (abstr 4415).
- Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal*. 2013;6:pl1. doi: 10.1126/scisignal.2004088.
- Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *NEJM*. 2018;378:2078-92.
- Garon EB, Ciuleanu T, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomized phase 3 trial. *Lancet*. 2014;384:665-73.

- Gidel TN, Wilmott JS, Scolyer RA, et al. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. *Clin Cancer Res*. 2018;24(6).
- Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumor immunity. *Nature* 2017; 548(7668): 471-5.
- Goldman JW, Gandhi L, Patnaik A, et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer. *J Clin Oncol*. 2014;32(15_Suppl.):8026.
- Goldman JW, Mazieres J, Barlesi F, et al. A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER. *Journal of Clinical Oncology*. 2018 36:15_suppl, 9025.
- Goldman JW, Mazieres J, Barlesi F, et al. A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable *KRAS* Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. *Front Oncol*. 2020;10:578756.
- Gong X, Litchfield LM, Webster Y, et al. Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib. *Cancer Cell*. 2017;32(6):761-776.e6.
- Gopalan PK, Villegas AG, Cao C, et al. CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition. *Oncotarget*. 2018;9(100):37352-66.
- Gopalan PK, Pinder MC, Chiappori A, et al. A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A. *J Clin Oncol*. 2014;32(5_Suppl.):8077.
- Gridelli C, Gallo C, Di Maio M, et al A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. *Br J Cancer*. 2004;91(12):1996.
- Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: A practical update. *Virulence*. 2016;7(3):280-97.
- Haines E, Chen T, Kommajosyula N, et al. Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in *KRAS*-mutant non-small cell lung cancer. *Oncotarget*. 2018;9(60):31572-31589.
- Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. *J Clin Oncol*. 2004;22(9):1589.
- Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. *Adv Ther*. 2020. doi: 10.1007/s12325-020-01538-0.
- He S, Roberts PJ, Sorrentino JA, et al. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. *Sci Transl Med*. 2017;9.

He Y, Rozeboom L, Rivard CJ, et al. MHC class II expression in lung cancer. *Lung Cancer*. 2017 Oct;112:75-80.

Herschkowitz JI, He X, Fan C, et al. The functional loss of the retinoblastoma tumor suppressor is a common event in basal-like and luminal B breast carcinomas. *Breast Cancer Res*. 2008;10(5):R75.

Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Practice Guideline Update. *J Clin Oncol*. 2020;38.

Hodge JW, Garnett CT, Farsaci B, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. *Int J Cancer*. 2013;133(3):624-36.

Horsley V, Aliprantis AO, Polak L, et al. NFATc1 balances quiescence and proliferation of skin stem cells. *Cell*. 2008;132(2):299-310.

Infante JR, Cassier PA, Gerecitano JF, et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. *Clin Cancer Res*. 2016;22:5696–705.

Jang RW, Caraiscos VB, Swami N, et al. Simple prognostic model for patients with advanced cancer based on performance status. *J Oncol Pract*. 2014;10(5):e335-41.

Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. *Brit J Cancer*. 2018;118:9-16.

Kalbfleisch, J.D, and Prentice, R.L. 1980. *The Statistical Analysis of Failure Time Data*. New York: John Wiley & Sons.

Kalemkerian GP, Narula N, Kennedy EB. Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors: America Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for Molecular Pathology Clinical Practice Guideline Update. *ASCO*. 2018;14(5):323-7.

Karasic TB, O'Hara MH, Teitelbaum UR, et al. Phase II trial of palbociclib in patients with advanced esophageal or gastric cancer. *J Clin Oncol*. 2018;36(4_Suppl.):68.

Kaufman RM, Djulbegovic BD, Gernsheimer T, et al. Platelet Transfusion: A Clinical Practice Guideline From the AABB. *Ann Intern Med*. 2015; 162:205-213.

Kim Y, Won S. (2013) Adjusted proportion difference and confidence interval in stratified randomized trials. *PharmaSUG*; Paper SP-04.

Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. *Cancer Cell*. 2018;34(1):9-20.

Knudsen ES, Witkiewicz AK. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. *Trends Cancer*. 2017;3(1):39-55.

Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. *Clin Cancer Res*. 2010;16(18):4583-94.

- Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. *Br J Cancer*. 1996;73(2):148-53.
- Kozar K, Ciemerych MA, Rebel VI, et al. Mouse development and cell proliferation in the absence of D-cyclins. *Cell*. 2004;118(4):477-91.
- Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancer to select targeted drugs. *JAMA*. 2014;311(19):1998-2006.
- Lai AY, Sorrentino JA, Dragnev KH, et al. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. *J Immunother Cancer*. 2020; 8.
- Lewis C, Smith DC, Carneiro BA, et al. A Phase 1b study of the oral CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration resistant prostate cancer (mCRPC) – A prostate cancer clinical trials consortium study. 2018;36(15):e17028.
- Li CH, Karantza V, Aktan G, et al. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. *Breast Cancer Res*. 2019;21:143.
- Li H, Xu Y, Wan B, et al. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. *Transl Lung Cancer Res*. 2019;8(4):429-49.
- Li Y, Kippel Z, Shih X, et al. Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies. *Support Care Cancer* 2016;24(10):4377-83.
- Li JY, Duan XF, Wang LP, et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. *J Immunol Res*. 2014;2014:286170.
- Little AG, Gay EGG, Gaspar LE, et al. National survey of non-small cell lung cancer in the United States: Epidemiology pathology and patterns of care. *Lung Cancer*. 2007;57:253-60.
- Liu D, Jenkins R, Sullivan RJ. Mechanisms of resistance to immune checkpoint blockade. *Am J Clin Dermatol*. 2019;20(1):41-54.
- Lyman 2006
- Malumbres M, Sotillo R, Santamaria D, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. *Cell*. 2004;118(4):493-504.
- Maroulakou IG, Anver M, Garrett L, et al. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. *Proc Natl Acad Sci USA* 1994;91:11236-11240.
- McDonnell AM, Nowak AK, Lake RA. Contribution of the immune system to the chemotherapeutic response. *Semin Immunopathol*. 2011;33(4):353-67.
- Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. *Med Oncol*. 2011;28(3):682-8.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer. Version 1.2021. 2020. NCCN, Fort Washington, PA.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Hematopoietic Growth Factors. Version 2. 2020b. NCCN, Fort Washington, PA.

Nieuweboer AJ, de Morree ES, de Graan AJ, Sparreboom A, de Wit R, Mathijssen RH. Inter-patient variability in docetaxel pharmacokinetics: A review. *Cancer Treat Rev.* 2015;41(7):605-13.

Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol.* 1982;5(6):649-55.

Opzoomer JW, Sosnowska D, Anstee JE, Spicer JF, Arnold JN. Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer. *Front Immunol.* 2019;10:1654.

O'Shaughnessy J, Wright GS, Thummala AR, et al. Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized Phase 2 trial. *San Antonio Breast Cancer Symposium.* Dec 8-11 2020. Poster #PD1-06

Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. *Cancer Discov.* 2016;6(7):740-53.

Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *NEJM.* 2018;379:2040-51.

Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. *Cancer.* 2006;107(12):2866-72.

Procrit® (epoetin alpha) Prescribing Information. Janssen Products LP. 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5363s5366lbl.pdf

Quade, D. (1967). Rank analysis of covariance. *Journal of the American Statistical Association* 1967; 62:1187-1200.

Ramsey MR, Krishnamurthy J, Pei XH, et al. Expression of p16Ink4a Compensates for p16Ink4a Loss in Cyclin-Dependent Kinase 4/6–Dependent Tumors and Tissues. *Cancer Res* 2007;67:4732-41.

Reck M, Rodriguez-Abreu D, Robinson EG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *NEJM.* 2016;375(19):1823-33.

Rose TL, Chism DD, Shivaram Alva A, et al. Phase II trial of Palbociclib (pd-0332991) in patients with metastatic urothelial cancer (UC) after failure of first-line chemotherapy. *Journal of Clinical Oncology.* 2018;36:500.

Schaer DA, Beckmann RP, Dempsey JA, et al. The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. *Cell Rep.* 2018;22:2978-94.

Shapiro GI. Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search. *Cancer Cell*. 2017;32(6):721-3.

Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. *J Clin Oncol*. 2001;19(5):1519-38.

Shen R, Wang X, Drissi H, et al. Cyclin D1-cdk4 induce runx2 ubiquitination and degradation. *J Biol Chem*. 2006;281:16347-53.

Shepherd FA, Dancey J, Ramlau, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *J Clin Oncol*. 2000;18(10):2095-103.

Sherr CJ, McCormick F. The RB and p53 pathways in cancer. *Cancer Cell*. 2002;2(2):103-12.

Shimizu K, Nakata M, Hiram Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. *J Thorac Oncol*. 2010;5(5):585-90.

Smith RE. Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors. *J Natl Compr Canc Netw*. 2006;4:649–58.

Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2015;33:3199-212.

Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naïve patients with extensive-stage small-cell lung cancer. *J Clin Oncol*. 2009;27:4787-4792.

Sorrentino JA, Bisi JE, Thompson D, et al. Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models. 30th EORTC-NCI-AACR Symposium. 13-16 November 2018. Dublin, Ireland.

Spigel D, de Marinis F, Giaccone G, et al. Impower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC. *EMSO 2019 Congress*. 27 Sep 2019.

Stefansson OA, Jonasson JG, Olafsdottir K, et al. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. *Epigenetics* 2011; 6(5):638-49.

Subhawong AP, Subhawong T, Nassar H, Kouprina N, Begum S, Vang R, et al. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. *Am J Surg Pathol*. 2009; 33:163-75.

Sweeney CJ, Zhu J, Sandler AB, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic non-small cell lung carcinoma. *Cancer*. 2001;92(10):2639-47.

Tan AR, Wright GS, Thummala AR, et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomized, open-label, Phase 2 trial. *Lancet Oncol*. 2019;20:1587-601.

Taxotere® (docetaxel) Prescribing Information. Sanofi-Aventis U.S. LLC. 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020449s084lbl.pdf

Taxotere® (docetaxel) Summary of Product Characteristics. Sanofi Mature IP. France. 2005. Available at: https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf.

Teh JLF, Aplin AE. Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment. *Clin Cancer Res*. 2019;25(3).

Treré D, Brighenti E, Donati G, et al. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. *Ann Oncol*. 2009 Nov;20(11):1818-23.

Turner NC, Liu Y, Zhu Z, et al. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer [published correction appears in *J Clin Oncol*. 2019 Nov 1;37(31):2956]. *J Clin Oncol*. 2019;37(14):1169-78.

Wang S, He Z, Wang X, Li H, Liu XS. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. *Elife*. 2019;8:e49020.

Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. *Ann Oncol*. 2019;30:1613-21.

Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. *Science*. 2008;322(5899):271-5.

Witkiewicz AK, Ertel A, McFalls J, Valsecchi ME, Schwartz G., Knudsen ES. RB-Pathway Disruption Is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer. *Clin Cancer Res*. 2012;18:5110-22.

Woo EY, Yeh H, Chu CS, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. *J Immunol*. 2002;168(9):4272-76.

Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. *Cancer Res*. 2001;61(12):4766-72.

World Health Organization (WHO). Cancer: Key facts. Accessed 03 Dec 2020: [https://www.who.int/news-room/fact-sheets/detail/cancer#:~:text=Cancer%20is%20a%20leading%20cause,Lung%20\(2.09%20million%20cases\)](https://www.who.int/news-room/fact-sheets/detail/cancer#:~:text=Cancer%20is%20a%20leading%20cause,Lung%20(2.09%20million%20cases)).

Yellen SB, Cella OF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) Measurement System. *J Pain Symptom Manage*. 1997;13(2):63-74.

Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance [published correction appears in Nature. 2019 Jul;571(7766):E10]. *Nature*. 2018;553(7686):91-5.

Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. *Cell Mol Immunol*. 2010;7(5):389-95.

Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. *Nat Rev Immunol*. 2008;8:59-73.

Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol*. 2004;159(7):702-6.

17. APPENDICES

17.1. Clinical Laboratory Tests

- The timing and laboratory tests detailed in Schedule of Assessments (Table 6) will be performed by a local laboratory.
- Protocol-specific requirements for inclusion or exclusion of patients are detailed in Section 7 of the protocol.
- Additional tests may be performed at any time during the study as determined necessary by the Investigator or required by local regulations.

Table 14: Protocol-Specified Safety Laboratory Assessments

Laboratory Assessment	Parameters		
Hematology	WBC	Hemoglobin	Absolute neutrophil count
	Platelets	Lymphocytes	Hematocrit
Serum Chemistry	Blood Urea Nitrogen (BUN) or Urea	Serum Creatinine	Bicarbonate
	Aspartate Aminotransferase (AST)	Alanine Aminotransferase (ALT)	Calcium
	Potassium	Sodium	Chloride
	Glucose	Total Protein	Albumin
	Alkaline phosphatase	Total Bilirubin	
Other Tests	Serum or urine human chorionic gonadotropin (hCG) pregnancy test (for WOCBP only)		

hCG=human chorionic gonadotropin; RBC=red blood cell; WBC=white blood cell; WOCBP=woman of childbearing potential

17.2. Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting

17.2.1. Definition of AE

AE Definition
<ul style="list-style-type: none"> • An AE is any untoward medical occurrence in a patient or clinical study patient, temporally associated with the use of study intervention, whether or not considered related to the study intervention. • NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.
Events <u>Meeting</u> the AE Definition
<ul style="list-style-type: none"> • Any abnormal laboratory test results (hematology, serum chemistry) or other safety assessments (e.g., ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinically significant and require clinical intervention or further investigation (beyond ordering a repeat [confirmatory] test) in the medical and scientific judgment of the Investigator (i.e., not related to progression of underlying disease) unless they are associated with an already reported clinical event, e.g. elevated liver enzymes in a patient with jaundice. • Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition. • New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study. • Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.

AE Definition
Events <u>NOT</u> Meeting the AE Definition
<ul style="list-style-type: none"> Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are associated with the underlying disease, unless judged by the Investigator to be more severe than expected for the patient's condition. The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the patient's condition. Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the procedure is the AE. Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital). Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen.

17.2.2. Definition of SAE

If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met (e.g., hospitalization for signs/symptoms of the disease under study, death due to progression of disease).

A SAE is defined as any untoward medical occurrence that, at any dose:
1. Results in death
2. Is life-threatening The term 'life-threatening' in the definition of 'serious' refers to an event in which the patient was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.
3. Requires inpatient hospitalization or prolongation of existing hospitalization In general, hospitalization signifies that the patient has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician's office or outpatient setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline is not considered an AE.
4. Results in persistent disability/incapacity <ul style="list-style-type: none"> The term disability means a substantial disruption of a person's ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.
5. Is a congenital anomaly/birth defect
6. Other situations:

A SAE is defined as any untoward medical occurrence that, at any dose:

- Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious.
- Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

17.2.3. Recording and Follow-Up of AE and/or SAE

<p>AE and SAE Recording</p> <ul style="list-style-type: none"> • When an AE/SAE occurs, it is the responsibility of the Investigator to review all documentation (e.g., hospital progress notes, laboratory reports, and diagnostics reports) related to the event. • The Investigator will then record all relevant AE/SAE information in the eCRF. • It is not acceptable for the Investigator to send photocopies of the patient's medical records to G1 Therapeutics, Inc. (or designee) in lieu of completion of the AE/SAE eCRF page. • There may be instances when copies of medical records for certain cases are requested by G1 Therapeutics, Inc. (or designee). In this case, all patient identifiers, with the exception of the patient number, will be redacted on the copies of the medical records before submission to G1 Therapeutics, Inc. (or designee). • The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE. • All SAEs should be reported to G1 Therapeutics, Inc. PVG (or designee) within 24 hours of notification on an SAE Form in the eCRF. Any relevant source data related to the SAE that cannot be entered in the EDC should be emailed or faxed to G1 Therapeutics, Inc. PVG (or designee): <p>G1 Therapeutics, Inc. Pharmacovigilance Email: safetyreporting@g1therapeutics.com Fax: +1-984-285-7131</p>
<p>Assessment of Intensity</p> <p>Intensity will be assessed using NCI-CTCAE v5.0 criteria, as follows:</p> <ul style="list-style-type: none"> • Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. • Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. • Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. • Grade 4: Life-threatening consequences; urgent intervention indicated. • Grade 5: Death related to AE.

AE and SAE Recording
Assessment of Causality
<ul style="list-style-type: none"> • The Investigator is obligated to assess the relationship between study intervention and each occurrence of each AE/SAE (Related or Not Related); i.e., is there a “reasonable possibility” the study intervention caused the event (yes/no). • A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. • The Investigator will use clinical judgment to determine the relationship. • Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study intervention administration will be considered and investigated. • The Investigator will also consult the IB and/or Product Information, for marketed products, in his/her assessment. • For each AE/SAE, the Investigator must document in the medical notes that he/she has reviewed the AE/SAE and has provided an assessment of causality. • There may be situations in which an SAE has occurred and the Investigator has minimal information to include in the initial report to G1 Therapeutics, Inc. PVG (or designee). However, it is very important that the Investigator always make an assessment of causality (Not Related or Related) for every event before the initial transmission of the SAE data to G1 Therapeutics, Inc. PVG (or designee). • The Investigator may change his/her opinion of causality in light of follow-up information and send a SAE follow-up report with the updated causality assessment. • The causality assessment is one of the criteria used when determining regulatory reporting requirements.
Follow-up of SAEs
<ul style="list-style-type: none"> • The Investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by G1 Therapeutics, Inc. PVG (or designee) to elucidate the nature and/or causality of the SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals. • New or updated information will be recorded in the originally completed eCRF. • The Investigator will submit any new or updated SAE data to G1 Therapeutics, Inc. PVG (or designee) within 24 hours of receipt of the information: <p>G1 Therapeutics, Inc. Pharmacovigilance Email: safetyreporting@g1therapeutics.com Fax: +1-984-285-7131</p>

17.2.4. Reporting of SAEs

SAE Reporting to G1 Therapeutics, Inc. (or designee) via an Electronic Data Collection Tool
--

- | |
|---|
| <ul style="list-style-type: none">• The primary mechanism for reporting an SAE to G1 Therapeutics, Inc. (or designee) will be the EDC.• If the electronic system is unavailable, then the site will use the paper SAE Report Form in order to report the event within 24 hours via email or fax (see below for SAE reporting contact information).• The site will enter the SAE data into the electronic system as soon as it becomes available.• After the study is completed at a given site, the electronic data collection tool will be taken off-line to prevent the entry of new data or changes to existing data.• If a site receives a report of a new SAE from a study patient or receives updated data on a previously reported SAE after the electronic data collection tool has been taken off-line, then the site should report this information on a paper SAE Report form or notify the Medical Monitor by telephone.• Contact for SAE reporting:
G1 Therapeutics, Inc. Pharmacovigilance
Email: safetyreporting@g1therapeutics.com
Fax: +1-984-285-7131 |
|---|

17.3. Contraceptive Guidance and Collection of Pregnancy Information

WOCBP Definition

Woman of Childbearing Potential

A woman is considered fertile following menarche and until becoming post-menopausal unless permanently sterile (see below).

If fertility is unclear (e.g., amenorrhea in adolescents or athletes), additional evaluation should be considered.

Women in the following categories are not considered Woman of Childbearing Potential

1. Premenarchal

Note: Documentation can come from the site personnel's review of the patient's medical records, medical examination, or medical history interview.

2. Premenopausal female with 1 of the following acceptable surgical sterilization techniques: complete or partial hysterectomy, bilateral tubal ligation, or occlusion with surgery at least 6 months prior to dosing, or bilateral oophorectomy with surgery at least 2 months prior to dosing.

3. Postmenopausal female: defined as spontaneous amenorrhea for >12 months prior to Screening without alternative cause (e.g., implantable contraceptive, side effect of medication, etc.) and a serum follicle stimulating hormone (FSH) within the laboratory's reference range for postmenopausal females.

- Women taking hormone replacement therapy (HRT) must discontinue HRT at least 2-4 weeks prior to Screening for accurate assessment of FSH (though exact interval will depend on the type and dosage of HRT and should be determined by the principal Investigator).

Contraception Guidance

Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

- Male patients: Males must be surgically sterile prior to Screening with appropriate documentation (absence of sperm in ejaculate 6 months after procedure) or have a female partner(s) who is either postmenopausal, surgically sterile, or using 2 forms of concurrent contraception as defined below. In addition, males must also refrain from sperm donation during the study and utilize a barrier method with intercourse during and for 6 months following discontinuation of treatment.
- Female patients: All females of childbearing potential must have a negative serum β -hCG test result at Screening, and negative serum or urine pregnancy test at each cycle during treatment and at the Post Treatment Visit (see Section 11.3.5 and Table 6).
- Females must be either postmenopausal, surgically sterile, or agree to use 2 concurrent forms of contraception during the study and for 6 months following last dose of study drug. Acceptable forms of contraception include:

- Established use of oral, injected or implanted hormonal methods of contraception (stable dose at least 3 months prior to dosing)
- Intrauterine device or intrauterine system
- Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. Barrier methods alone (without spermicide) are not acceptable methods. Likewise, spermicide alone is not an acceptable method
- Male sterilization prior to Screening with the appropriate post-vasectomy documentation (absence of sperm in the ejaculate 6 months after procedure). For female patients on the study, the vasectomized male partner should be the sole partner for that patient
- True abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
- For patients who are exclusively in same-sex relationships, contraceptive requirements do not apply. If a patient who is in a same-sex relationship at the time of signing the ICF becomes engaged in a heterosexual relationship, they must agree to use contraception as described previously. If a patient who is abstinent at the time of signing the ICF becomes sexually active, they must agree to use contraception as described above.

Collection of Pregnancy Information

Male participants with partners who become pregnant

- The Investigator or designee will attempt to collect pregnancy information on any male patient's female partner who becomes pregnant while the male patient is in this study. This applies only to males who receive study intervention.
- After obtaining the necessary signed informed consent from the pregnant female partner directly, the Investigator or designee will record pregnancy information on the Pregnancy – Initial Report Form and submitted to G1 Therapeutics, Inc. PVG or designee within 24 hours of learning of the partner's pregnancy. The female partner will also be followed to determine the outcome of the pregnancy. The Pregnancy – Follow-up Report Form should be used to report information on the status of the mother and child and will be forwarded to G1 Therapeutics, Inc. PVG or designee. Generally, the follow-up will be no longer than 12 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.
- Contact for Pregnancy reporting:
G1 Therapeutics Pharmacovigilance
Email: safetyreporting@g1therapeutics.com
Fax: +1-984-285-7131

Female Patients who become pregnant

- The Investigator or designee will collect pregnancy information on any female patient who becomes pregnant while participating in this study. The initial Information will be recorded on the Pregnancy Reporting and Outcome Form (Pregnancy – Initial Report Form) and submitted to G1 PVG or designee within 24 hours of learning of a patient's pregnancy within 24 hours of learning of a patient's pregnancy.
- The patient will be followed to determine the outcome of the pregnancy. The Investigator or designee will collect follow-up information on the patient and the neonate and the information will be collected on the Pregnancy – Follow-up Report Form and forwarded to G1 Therapeutics, Inc. PVG or designee. Generally, follow-up will not be required for longer than 12 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.
- While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy for medical reasons will be reported as an AE or SAE. A spontaneous abortion (occurring at <22 weeks gestational age) or still birth (occurring at >22 weeks gestational age) is always considered to be an SAE and will be reported as such. Any post-study pregnancy related SAE considered reasonably related to the study intervention by the Investigator will be reported to G1 Therapeutics, Inc. PVG or designee. While the Investigator is not obligated to actively seek this information in former study patients, he or she may learn of an SAE through spontaneous reporting.
- Any female patient who becomes pregnant while participating in the study will discontinue study intervention.
- Contact for Pregnancy reporting:
G1 Therapeutics Pharmacovigilance
Email: safetyreporting@g1therapeutics.com
Fax: +1-984-285-7131

17.4. Definitions of Tumor Response and Disease Progression (per RECIST v1.1)

The determination of tumor response and progression will be based on the RECIST v1.1 ([Eisenhauer, 2009](#)). Disease progression may also be determined clinically by the Investigator. Tumor lesions will be categorized as follows:

Measurable lesions: tumor lesions with a longest diameter (measured in at least 1 dimension) with a minimum size as follows:

- 10 mm by CT or MRI (with a scan slice thickness of no greater than 5 mm)
- Measurable lymph nodes must be ≥ 15 mm on the short axis by CT or MRI (with a scan slice thickness of no greater than 5 mm); only the short axis is to be measured at baseline and follow-up.
- Lytic bone lesions or mixed lytic-blastic lesions with a soft tissue component meeting the definition of measurability above can be considered measurable lesions.
- Cystic lesions representing cystic metastases that meet the definition of measurability described above can be considered measurable lesions. If present, noncystic lesions should be selected as target lesions for this study.
- A tumor lesion that has been previously irradiated may be considered measurable if unequivocal growth of the lesion has been demonstrated.

Target lesions: At baseline, up to 5 measurable tumor lesions/lymph nodes (with a maximum of 2 lesions per organ) should be identified as target lesions. Lesions with the longest diameter, that are representative of all involved organs, and for which reproducible repeated measurements can be obtained should be selected as the target lesions. Malignant lymph node is considered an organ in this study, therefore only 2 malignant lymph nodes (regardless of location) may be selected as target lesions and all others should be entered as nontarget lesions.

Non-measurable Lesions: tumor lesions with a longest diameter < 10 mm, lymph nodes with ≥ 10 to < 15 mm short axis, or non-measurable lesions such as leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, or abdominal masses/abdominal organomegaly identified by physical exam that is not measurable by CT scan or MRI.

Nontarget lesions: All other lesions (or sites of disease) identified at baseline should be identified as nontarget lesions and recorded in the eCRF. Measurements of these lesions are not required, but the presence, absence, or unequivocal progression of each nontarget lesion should be recorded in the eCRF at each follow up time point. Multiple nontarget lesions in the same organ may be noted as a single item on the eCRF.

Evaluation of Target Lesions

The definitions for tumor response for the target lesion per RECIST v1.1 are as follows:

Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm (< 1 cm).

Partial Response: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Progressive Disease: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm (0.5 cm). (Note: the appearance of one or more new lesions is also considered progression).

Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Evaluation of Non-Target Lesions

Complete Response: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (<10 mm [<1 cm] short axis).

Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.

Progressive Disease: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. ‘Unequivocal progression’ represents a substantial increase in overall tumor burden such that treatment should be discontinued even in the setting of SD or PR in the target disease. Although a clear progression of “non-target” lesions only is rare, the opinion of the treating physician should prevail in such circumstances.

Appearance of New Lesions

The appearance of new lesion(s) is considered PD according to RECIST v1.1.

Timepoint Response

Patients with Measurable Disease (i.e., Target ± Non-Target Disease)

Target Lesions	Non-Target Lesions	New Lesions	Overall Response
CR	CR	No	CR
CR	Non-CR/Non-PD	No	PR
CR	NE	No	PR
PR	Non-CR/Non-PD/NE	No	PR
SD	Non-CR/Non-PD/NE	No	SD
NE	Non-PD	No	NE
PD	Any	Yes or No	PD
Any	PD ^a	Yes or No	PD
Any	Any	Yes	PD

CR=complete response; NE=not evaluable; PD: progressive disease; PR=partial response; SD=stable disease.

Note: Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “*symptomatic deterioration*.” Every effort should be made to document the objective progression even after discontinuation of treatment.

^a Unequivocal progression in non-target lesions may be accepted as disease progression.

Patients with Evaluable or Non-Measurable Disease Only (i.e., Non-Target Disease)

Non-Target Lesions	New Lesions	Overall Response
CR	No	CR
Non-CR/non-PD	No	Non-CR/non-PD ^a
Not all evaluated	No	NE
Unequivocal PD	Yes or No	PD
Any	Yes	PD

CR=complete response; NE=not evaluable; PD: progressive disease; SD=stable disease.

^a 'Non-CR/non-PD' is preferred over 'stable disease' for non-target disease since SD is increasingly used as an endpoint for assessment of efficacy in some studies so to assign this category when no lesions can be measured is not advised.



Protocol Title: A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)

Protocol Number: G1T28-210

Compound: Trilaciclib for Injection, 300 mg/vial

Study Phase: 2

Study Name: PRESERVE 4

Sponsor Name: G1 Therapeutics, Inc.

Legal Registered Address: G1 Therapeutics, Inc.
700 Park Offices Dr. Suite 200
PO Box 110341
Research Triangle Park, NC 27709

Regulatory Agency Identifier Numbers: IND: 154630
EudraCT: 2021-000186-32

Approval Date: [20 May 2021 \(Version 2.0\)](#)

Original Protocol: 01 Feb 2021 (Version 1.0)

This document contains confidential and/or trade secret information that is disclosed only in connection with the licensing and/or registration of products for G1 Therapeutics, Inc. This document should not be disclosed or used, in whole or in part, for any other purpose without the prior written consent of G1 Therapeutics, Inc.

PROTOCOL SIGNATURE PAGE

Sponsor's Approval

I have read and understand the contents of this clinical protocol, Version ~~1.0~~ 2.0 for Study G1T28-210 dated ~~01 Feb 2021~~ 20 May 2021 and I agree to meet all obligations of the Sponsor as detailed in all applicable regulations and guidelines. In addition, I will inform the Principal Investigator and all other investigators of all relevant information that becomes available during the conduct of the study.

Janet Horton, MD, MHSc
Director, Clinical Development
Physician Sponsor Representative
G1 Therapeutics, Inc.

Date

INVESTIGATOR'S AGREEMENT

Clinical Study Protocol G1T28-210: A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)

Protocol Amendment 1 (Version 2.0) Issue Date: 20 May 2021

Original Protocol (Version 1.0) Issue Date: 01 Feb 2021

I have read the G1T28-210 protocol and agree to conduct the study as outlined. I agree to maintain the confidentiality of all information received or developed in connection with this protocol.

Principal Investigator Signature

Date

Principal Investigator Name

Institution

1 SYNOPSIS

Name of Sponsor/Company: G1 Therapeutics, Inc.		
Name of Investigational Product: Trilaciclib for Injection, 300 mg/vial		
Name of Active Ingredient: Trilaciclib dihydrochloride (hereafter referred to as trilaciclib) (G1T28)		
Protocol Number: G1T28-210	Phase: 2	Country: Worldwide
Title of Study: A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2 nd /3 rd Line Setting (PRESERVE 4)		
Study center(s): Approximately 60 centers		
Study period: Estimated date first patient enrolled: 2Q2021 Estimated date last patient completed: 1Q2024		
Objectives: Primary: To assess the effect of trilaciclib administered prior to docetaxel compared with placebo administered prior to docetaxel on overall survival (OS) in patients with metastatic NSCLC receiving docetaxel in the 2 nd or 3 rd line. Study Design: This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib compared with placebo on OS in metastatic NSCLC patients receiving docetaxel in the 2 nd or 3 rd line setting. Patients must have documented disease progression during or after one or two lines of systemic therapy for recurrent or metastatic NSCLC. Prior treatment must have included, either in the same line or as separate lines of therapy: 1) a maximum of 1 line of platinum-containing chemotherapy for recurrent/metastatic disease and 2) a maximum of 1 line of a locally approved/authorized programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) containing regimen for recurrent/metastatic disease. Patients will be		

randomly assigned (1:1) to receive trilaciclib or placebo intravenously (IV) prior to docetaxel on Day 1 of each 21-day cycle. There will be 2 stratification factors for randomization: Country and Eastern Cooperative Oncology Group (ECOG) performance status (0-1 versus 2). Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2).

Study drugs will be administered as follows:

- Trilaciclib (240 mg/m²) or placebo – administered as a 30-minute IV infusion no more than 4 hours prior to chemotherapy on each day chemotherapy is administered.
- Docetaxel 75 mg/m² – IV, Day 1

The study will include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of randomization for the first patient and completes at the Post-Treatment visit for the last patient. The first Survival Follow-up assessment should occur ~2 months after the last dose of study drug.

The patient may continue to receive treatment on study until disease progression, unacceptable toxicity, withdrawal of consent, discontinuation by Investigator, or the end of the trial, whichever occurs first. Treatment cycles will occur consecutively without interruption, except when necessary to manage toxicities or for administrative reasons.

Upon discontinuation of study treatment, patients will be followed for survival, i.e., patients or their caregivers will be contacted approximately every 2 months until the end of the study (or death) to record their status (alive or dead) as well as details of any subsequent systemic anti-cancer therapy initiated.

Methodology:

Sample Size Justification:

The sample size is determined to support the primary objective of the study. That is, to evaluate the effect of trilaciclib compared to placebo on the OS of patients with metastatic NSCLC receiving docetaxel in the 2nd/3rd line setting. A total of 104 deaths will be required to achieve 85% power to detect a hazard ratio (HR) of 0.55 in OS at a 2-sided significance level of 0.05. A HR of 0.55 corresponds to a median OS of 16.5 months for the trilaciclib group assuming a median OS of 9.1 months for the placebo group (Garon, 2014). With a 12-month enrollment period and a 30-month study duration (after the first patient is randomized), a total of 146 patients are required for randomization at a 1:1 ratio to trilaciclib or placebo. This sample size has taken into consideration an interim analysis for OS at the information fraction of 0.70 using the O'Brien-Fleming method for α -spending to ensure strong control of Type I error rate at 1-sided 0.025 between the interim and the final analysis for OS. In the sample size calculation, it is also assumed that about 5% of patients are lost-to-follow-up during the 30-month study duration.

Number of patients (planned):

Approximately 146 patients with NSCLC are planned in this study.

Diagnosis and main criteria for inclusion:

Patients ≥ 18 years of age at the time of signing the informed consent with histologically or cytologically-confirmed metastatic NSCLC. Patients of any histology appropriate for treatment with docetaxel in the 2nd/3rd line will be eligible. Patients must have documented disease progression during or after treatment with platinum-based chemotherapy and a locally approved/authorized PD-1/PD-L1 inhibitor. Patients should not have been previously treated with docetaxel or with therapy targeted to driver mutations. Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is permitted as is ECOG performance status of 0 to 2. At the time of providing informed consent, a formalin-fixed paraffin-embedded (FFPE) tumor specimen (from archival or fresh

<p>biopsy) with an associated pathology report documenting NSCLC must be available to send to Sponsor, within the timeframe specified, for planned retrospective biomarker analyses.</p>
<p>Investigational product, dosage and mode of administration:</p> <p>On Day 1 of each 21-day cycle, a dose of trilaciclib 240 mg/m² diluted in 250 mL of dextrose 5% in water or sodium chloride solution 0.9% will be administered as a 30-minute IV infusion no more than 4 hours prior to docetaxel administration.</p>
<p>Duration of treatment:</p> <p>Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, discontinuation by Investigator, or the end of the trial, whichever occurs first.</p>
<p>Reference therapy, dosage and mode of administration:</p> <p>On Day 1 of each 21-day cycle, a dose of placebo (250 mL of dextrose 5% in water or sodium chloride solution 0.9%) will be administered by IV infusion over approximately 30 minutes no more than 4 hours prior to docetaxel administration.</p> <p>On Day 1 of each 21-day cycle, docetaxel will be administered IV in accordance with the prescribing information and institutional guidelines.</p>
<p>Criteria for evaluation:</p> <p>Efficacy:</p> <p>Antitumor efficacy will be assessed by OS, PFS, objective response rate (ORR), and duration of objective response (DOR). Tumor response criteria will be based on RECIST v1.1.</p> <p>Myelopreservation efficacy will be assessed based on hematology assessments, myelosuppression-related adverse event (AE) details, dose reductions/delays and supportive care interventions (including transfusions).</p> <p>Safety:</p> <p>Safety will be evaluated by monitoring AEs, clinical laboratory test results (hematology, clinical chemistry), vital sign measurements (blood pressure, heart rate, and body temperature), 12-lead safety electrocardiogram (ECG) results, dose intensity, and physical examination findings.</p> <p>PROs:</p> <p>Patient-reported outcomes (PROs) will be assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-LC13 with supplemental weight loss item, (EORTC IL118), Functional Assessment of Chronic Illness Therapy – Fatigue Scale (FACIT-Fatigue), Patient Global Impression of Change (PGIC), Patient Global Impression of Severity (PGIS), and 5-level EQ-5D (EQ-5D-5L).</p> <p>Pharmacodynamics:</p> <p>Pharmacodynamics will be assessed using peripheral blood to evaluate potential markers of response and resistance, including immune effects.</p>
<p>Statistical methods:</p> <p>Data will be summarized by treatment group. The descriptive summary for the categorical variables will include counts and percentages. The descriptive summary for the continuous variables will include means, standard deviations, medians, 25% and 75% percentiles, and minimum and maximum values.</p> <p>Stratification factors and factors used in statistical models:</p> <p>There are two stratification factors for randomization: country and ECOG performance status (0-1 versus 2). Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2). A randomization schema will be in place to ensure the best possible balance of treatment assignment within each stratum produced by these stratification factors. Countries will be</p>

grouped into the factor of “region” with 3 components: United States (US), Europe, and Asia. The factor “region” will be used instead of “country” in the statistical analysis models to account for regional differences in clinical practice.

Analysis population

The intent-to-treat (ITT) population includes all randomized patients. Analyses for the ITT population will be conducted based on the randomly assigned treatment regardless of whether the patient received study treatment or was compliant with the protocol. Unless otherwise specified, the ITT population is the primary population for all efficacy analyses.

The response evaluable (RE) population will include patients in the ITT population who have a measurable lesion (target lesions) at the baseline tumor assessment, and either (i) have at least 1 post-dose tumor assessment, or (ii) do not have post-dose tumor assessment but have clinical progression as noted by the Investigator, or (iii) have died due to disease progression before their first post-dose tumor scan. RE population will be the primary analysis set to evaluate tumor response and the data will be analyzed based on the randomly assigned treatment.

The safety population includes all randomized patients who received at least one dose of study drug. Analyses conducted on the safety population will be based on the actual treatment received. All safety analyses will be conducted using the safety population.

The pharmacokinetic (PK) population will include all patients who received at least one dose of study drug and had evaluable PK data.

Statistical analysis methods for primary and secondary endpoints

Analysis for Primary Endpoint

The primary endpoint OS is defined as the time (months) from the date of randomization to the date of death for patients who died in the study due to any cause, and the time to the last contact date known to be alive for those who survived as of the data cutoff date for the interim OS analysis or as of the date for the final database lock (censored cases). Patients lacking data beyond the date of randomization will have their survival time censored at the date of randomization. The targeted number of deaths for the final analysis is 104 and the analysis for OS is event-driven.

Treatment effect on OS will be primarily evaluated using a stratified log-rank test controlling for the stratification factors of region (US, Europe, or Asia), and ECOG performance status (0-1 versus 2). Unless otherwise specified, ECOG status information as entered in the Interactive Web Response System (IWRS) at the time of randomization will be used as the factor for this and all other stratified analyses. The magnitude of the treatment effect, HR (trilaciclib versus placebo), will be estimated using a Cox proportional hazard model with the same factors as included in the stratified log-rank test. Additionally, the Kaplan-Meier plots will be generated, and the median, 25% and 75% percentile of OS will be estimated using the Kaplan-Meier method with their corresponding 95% confidence interval calculated based on the method by [Brookmeyer and Crowley \(1982\)](#) for each treatment group. The analyses for OS will be performed on the ITT population.

Interim Analysis for OS

An interim analysis of OS will be conducted at the 70% information fraction, that is, when 73 deaths are observed. The timing of the interim analysis is estimated to be approximately 19 months after the first patient is randomized in the study. To perform the interim analysis, the database will be locked ~~and the study will be unblinded.~~ If the interim OS analysis result by the stratified log-rank test is positive as determined by the pre-specified statistical criterion, the study will be stopped for success and the results from the interim OS analyses are considered to be final. If the interim OS analysis result does not meet the criterion of success, the study will continue until a total of 104 deaths are observed. At that time, the study database will be locked to perform the final OS analysis. It is estimated that it will take approximately 30 months after the first patient is randomized in the study to reach the total targeted number of deaths in this study.

Analysis for secondary anti-tumor efficacy endpoints

PFS

PFS is defined as the time (months) from date of randomization until date of documented radiologic disease progression (PD) per RECIST v1.1 or death due to any cause, whichever comes first. For patients who do not experience PD or are alive at time of performing the analysis, PFS will be calculated per censoring rules detailed in the Statistical Analysis Plan (SAP).

Per literature, the expected median PFS for patients receiving docetaxel is 3 months ([Garon, 2014](#)). Assuming trilaciclib can achieve a treatment effect of HR of 0.60, it is estimated that at the time of performing the OS interim analysis, 86% of patients would have a radiographic-determined disease progression or died. Therefore, the analysis for PFS will be conducted at the time when the OS interim analysis is conducted since the PFS events are considered mature. Treatment effect on PFS will be evaluated using the stratified log-rank test controlling for the two stratification factors. A Cox proportional hazard model with the same terms as in the stratified log-rank test will be used to estimate the HR between the 2 treatment groups (trilaciclib versus placebo) for PFS along with its 95% confidence interval. In addition, the Kaplan-Meier plots will be produced, and the median, 25% and 75% percentile of PFS will be estimated using the Kaplan-Meier method with their corresponding 95% confidence interval calculated based on the method by [Brookmeyer and Crowley \(1982\)](#) for each treatment group. PFS will be analyzed on the ITT population.

Tumor Response

Objective response is defined as achieving either complete response (CR) or partial response (PR) per RECIST v1.1. The ORR along with its exact 95% two-sided confidence interval using the Clopper-Pearson method will be computed for each treatment group. The treatment effect on ORR will be evaluated using a stratified Cochran-Mantel-Haenszel (CMH) method to account for the two stratification factors. The adjusted proportion difference (trilaciclib minus placebo) and its 95% confidence intervals will be calculated using CMH weight. ORR will be analyzed on the Response Evaluable patient population.

DOR is the time (months) between the date achieving first objective response (CR or PR), confirmed at the next tumor scan, and the date of documented disease progression per RECIST v1.1 or death, whichever comes first. Patients who do not experience objective CR or PR will not be included in the analysis. For patients with objective response who do not reach radiographically determined PD or die at the time of analysis, censored time will be calculated following the rules detailed in Section [12.4.6.2.2](#). The median, 25% and 75% percentile of DOR will be estimated using the Kaplan-Meier method with their corresponding 95% confidence interval calculated based on the method by [Brookmeyer and Crowley \(1982\)](#) for each treatment group.

Analysis for safety endpoints

Safety and tolerability will be assessed by AEs, dose modifications, laboratory tests, vital signs, and ECG. Safety data will be summarized using descriptive statistics by treatment group based on the safety population. AEs are defined as those events occurring or worsening after treatment has begun on this study. AE data will be coded to system organ class (SOC) and preferred term (PT) using the latest version of Medical Dictionary for Regulatory Activities (MedDRA). The severity (toxicity grades 1-5) will be summarized by SOC, PT and CTCAE grade, as appropriate. In the tabulation of severity and causality for an AE, if the same AE occurs on multiple occasions, the highest grade and strongest relationship to study drug will be used. Concomitant medications, as well as prior and subsequent anticancer therapies, will be coded to Anatomical Therapeutic Classification (ATC) using the World Health Organization-Drug Dictionary (WHO-DD) and summarized by treatment group.

For laboratory assessments, vital signs, and ECG intervals, observed values and changes from baseline will be summarized by treatment group. For serum chemistry AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 by Investigators. AEs overall, AEs related to each study drug, AEs leading to study drug discontinuation

or dose modifications, and trilaciclib AEs of special interests (AESIs) will be summarized by SOC, PT and CTCAE grade, as appropriate. For laboratory assessments, vital signs, and ECG intervals, observed values and changes from baseline will be summarized by treatment group. For serum chemistry and hematology laboratory parameters, clinical labs will be characterized according to CTCAE toxicity grade from 1 to 5, v5.0 when possible, and the number and percentage of patients within each CTCAE grade will be summarized for the overall treatment period as well as for each cycle. Safety data collected through scheduled or unscheduled visits will all be included in the safety evaluation.

Pharmacokinetic/Pharmacodynamic Analyses

Analyses may be performed to examine the relationship(s) between exposure to trilaciclib and pharmacodynamic endpoints or other efficacy and safety endpoints.

2 TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES

TABLE OF CONTENTS

PROTOCOL SIGNATURE PAGE	2
INVESTIGATOR'S AGREEMENT	2
1. SYNOPSIS	3
2. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES	8
3. LIST OF ABBREVIATIONS	17
4. INTRODUCTION	23
4.1. Lung Cancer	23
4.2. Study Rationale	24
4.2.1. Rationale for Improving Anti-tumor Efficacy with Trilaciclib	25
4.2.2. Rationale for Immunogenicity of NSCLC Tumor Type and Docetaxel Chemotherapy	28
4.2.3. Rationale for Immune Mechanism of Trilaciclib	29
4.2.4. Rationale for Trilaciclib following Progression on Immunotherapy	29
4.2.5. Rationale for Myelopreservation	30
4.2.6. Rationale for Combination with Docetaxel	30
4.2.7. Summary of Nonclinical Data	31
4.2.7.1. Pharmacology Studies	31
4.2.7.2. Pharmacokinetic Studies	35
4.2.8. Summary of Clinical Data	35
4.2.8.1. Trilaciclib	35
4.2.8.2. Trilaciclib	40
4.2.8.3. Docetaxel	42
4.3. Benefit/Risk Assessment	42
5. OBJECTIVES AND ENDPOINTS	43
6. INVESTIGATIONAL PLAN	46
6.1. Overall Study Design	46

6.2. Rationale for Primary and Secondary Endpoints	48
6.2.1. Anti-tumor Efficacy	48
6.2.2. Myelopreservation Efficacy	48
6.2.3. Patient Reported Outcomes	48
6.2.4. Safety	48
6.3. Rationale for Dose and Schedule of Study Treatment	49
6.3.1. Trilaciclib	49
6.3.2. Docetaxel	49
6.4. Rationale for Supportive Care Interventions	49
6.5. Rationale for Patient Population	50
6.6. Rationale for Stratification Factors	50
7. STUDY POPULATION	50
7.1. Inclusion Criteria	50
7.2. Exclusion Criteria	51
8. SCHEDULE OF ASSESSMENTS	53
9. STUDY TREATMENT	57
9.1. Study Drugs Administered	57
9.1.1. Dose, Dosing Regimen, and Route	57
9.1.1.1. Trilaciclib/Placebo	57
9.1.1.2. Docetaxel	58
9.1.2. Preparation, Handling, Storage, and Accountability	59
9.1.3. Treatment Compliance	59
9.2. Criteria for Starting Each Cycle	59
9.3. Toxicity Management and Dose Modifications	60
9.3.1. Dose reduction	60
9.3.2. Safety Criteria for Adjustment or Stopping Doses	62
9.3.3. Recommended Actions with Trilaciclib/Placebo for Adverse Events of Special Interest	65
9.3.4. Hy's Law Management	66
9.4. Supportive Care Interventions	67
9.4.1. Colony Stimulating Factor Usage	67
9.4.2. Erythropoiesis Stimulating Agent Usage	68
9.4.3. Transfusions	68
9.5. Prior/Concomitant Medications and Procedures	68
9.6. Measures to Minimize Bias: Randomization and Blinding	69
9.7. Intervention after End of Study Treatment	70
10. DISCONTINUATION OF STUDY INTERVENTION AND PATIENT DISCONTINUATION/WITHDRAWAL	70
10.1. Discontinuation of Study Treatment	70

10.2. Discontinuation/Withdrawal from the Study	71
10.3. Lost to Follow Up	72
10.4. Study and Site Start and Closure	72
11. STUDY ASSESSMENTS	73
11.1. Screening Assessments	73
11.1.1. Randomization	73
11.1.2. Demographics	73
11.1.3. Medical History and NSCLC Cancer Disease History	73
11.2. Anti tumor Efficacy Assessments	74
11.2.1. Anti tumor Efficacy Assessment	74
11.2.2. Myelopreservation Assessments	75
11.3. Safety Assessments	75
11.3.1. Vital Signs	75
11.3.2. Physical Examination	75
11.3.3. ECOG Performance Status	75
11.3.4. Electrocardiogram	76
11.3.5. Clinical Safety Laboratory Assessments	76
11.3.6. Adverse and Serious Adverse Events	77
11.3.6.1. Time Period and Frequency for Collecting Adverse and Serious Adverse Event Information	77
11.3.6.2. Method of Detecting Adverse and Serious Adverse Events	78
11.3.6.3. Follow-up of Adverse and Serious Adverse Events	78
11.3.6.4. Regulatory Reporting Requirements for Serious Adverse Events	78
11.3.6.5. Pregnancy	78
11.4. Patient Reported Outcomes	79
11.4.1. EORTC QLQ-C30 and EORTC QLQ-LC13	79
11.4.2. FACIT-Fatigue	79
11.4.3. Patient Global Impression of Change and Patient Global Impression of Severity	80
11.4.4. 5-Level EQ-5D	80
11.5. Pharmacokinetics	80
11.6. Biomarkers	81
11.6.1. Rationale for Archival Tumor Collection	81
11.6.2. Description of CDK4/6 Signature	81
11.7. Immunologic and Hematologic Markers	82
11.8. Data Monitoring Committee	82
11.10. Survival Follow-up Phase	83
12. STATISTICAL CONSIDERATIONS	83
12.1. Sample Size Determination	83

12.2.	Analysis Population	84
12.3.	Timing of Planned Analysis	84
12.3.1.	First Planned Analysis—Interim Analysis for Overall Survival and Analyses for Progression Free Survival, Tumor Responses and Myelosuppression Endpoints	84
12.3.2.	Second Planned Analysis—Final Analysis for Overall Survival and Safety Data Analyses	85
12.4.	Statistical Analysis Methods	85
12.4.1.	General Considerations	85
12.4.2.	Patient Disposition	85
12.4.3.	Demographic and Baseline Characteristics	86
12.4.4.	Prior and Subsequent Anticancer Therapies	86
12.4.5.	Study Drug Exposure, Modification and Dose Intensity	86
12.4.6.	Efficacy Analyses	86
12.4.6.1.	Analyses of Primary Efficacy Endpoint—Overall Survival	86
12.4.6.2.	Analysis for Secondary Anti-tumor Efficacy Endpoints	88
12.4.6.3.	Analysis for Myelosuppression Endpoints	90
12.4.6.4.	Subgroup Analysis for Primary Efficacy Endpoint	91
12.4.7.	PRO Analyses	91
12.4.8.	Safety Analyses	91
12.4.8.1.	Adverse Events	91
12.4.8.2.	Other Safety Endpoints	92
12.4.9.	Exploratory Analyses	92
12.4.10.	Pharmacokinetic Analyses	92
12.4.11.	Pharmacokinetic/Pharmacodynamic Analyses	93
13.	ETHICS	93
13.1.	Ethics Review	93
13.2.	Ethical Conduct of the Study	93
13.3.	Written Informed Consent	93
14.	DATA HANDLING AND RECORDKEEPING	94
14.1.	Data Protection	94
14.2.	Data Quality Assurance	94
14.3.	Dissemination of Clinical Study Data	95
14.4.	Source Documents	95
14.5.	Audits and Inspections	95
15.	PUBLICATION POLICY	95
16.	REFERENCES	96
17.	APPENDICES	105
17.1.	Clinical Laboratory Tests	105

17.2. Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting.....	107
17.2.1. Definition of AE.....	107
17.2.2. Definition of SAE.....	108
17.2.3. Recording and Follow-Up of AE and/or SAE.....	110
17.2.4. Reporting of SAEs.....	112
17.3. Contraceptive Guidance and Collection of Pregnancy Information.....	113
17.4. Definitions of Tumor Response and Disease Progression (per RECIST v1.1).....	116
PROTOCOL SIGNATURE PAGE	2
INVESTIGATOR'S AGREEMENT	2
1. SYNOPSIS.....	3
2. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES	8
3. LIST OF ABBREVIATIONS.....	17
4. INTRODUCTION	23
4.1. Lung Cancer.....	23
4.2. Study Rationale.....	24
4.2.1. Rationale for Improving Anti-tumor Efficacy with Trilaciclib	25
4.2.2. Rationale for Immunogenicity of NSCLC Tumor Type and Docetaxel Chemotherapy.....	28
4.2.3. Rationale for Immune Mechanism of Trilaciclib	29
4.2.4. Rationale for Trilaciclib following Progression on Immunotherapy.....	29
4.2.5. Rationale for Myelopreservation	30
4.2.6. Rationale for Combination with Docetaxel	30
4.2.7. Summary of Nonclinical Data	31
4.2.7.1. Pharmacology Studies	31
4.2.7.2. Pharmacokinetic Studies	35
4.2.8. Summary of Clinical Data	35
4.2.8.1. Trilaciclib	35
4.2.8.2. Trilaciclib Risks	40
4.2.8.3. Docetaxel.....	42
4.3. Benefit/Risk Assessment	42
5. OBJECTIVES AND ENDPOINTS	43
6. INVESTIGATIONAL PLAN.....	46
6.1. Overall Study Design.....	46
6.2. Rationale for Primary and Secondary Endpoints.....	48
6.2.1. Anti-tumor Efficacy.....	48
6.2.2. Myelopreservation Efficacy.....	48
6.2.3. Patient-Reported Outcomes	48
6.2.4. Safety	48

6.3.	Rationale for Dose and Schedule of Study Treatment.....	49
6.3.1.	Trilaciclib.....	49
6.3.2.	Docetaxel	49
6.4.	Rationale for Supportive Care Interventions	49
6.5.	Rationale for Patient Population	50
6.6.	Rationale for Stratification Factors	50
7.	STUDY POPULATION	50
7.1.	Inclusion Criteria	50
7.2.	Exclusion Criteria	51
8.	SCHEDULE OF ASSESSMENTS.....	53
9.	STUDY TREATMENT	57
9.1.	Study Drugs Administered.....	57
9.1.1.	Dose, Dosing Regimen, and Route.....	57
9.1.1.1.	Trilaciclib/Placebo.....	57
9.1.1.2.	Docetaxel.....	58
9.1.2.	Preparation, Handling, Storage, and Accountability	59
9.1.3.	Treatment Compliance.....	59
9.2.	Criteria for Starting Each Cycle.....	59
9.3.	Toxicity Management and Dose Modifications.....	60
9.3.1.	Dose reduction	60
9.3.2.	Safety Criteria for Adjustment or Stopping Doses	62
9.3.3.	Recommended Actions with Trilaciclib/Placebo for Adverse Events of Special Interest	65
9.3.4.	Hy's Law Management.....	66
9.4.	Supportive Care Interventions	67
9.4.1.	Colony Stimulating Factor Usage.....	67
9.4.2.	Erythropoiesis-Stimulating Agent Usage	68
9.4.3.	Transfusions.....	68
9.5.	Prior/Concomitant Medications and Procedures	68
9.6.	Measures to Minimize Bias: Randomization and Blinding	69
9.7.	Intervention after End of Study Treatment	70
10.	DISCONTINUATION OF STUDY INTERVENTION AND PATIENT DISCONTINUATION/WITHDRAWAL.....	70
10.1.	Discontinuation of Study Treatment.....	70
10.2.	Discontinuation/Withdrawal from the Study.....	71
10.3.	Lost to Follow-Up.....	72
10.4.	Study and Site Start and Closure	72
11.	STUDY ASSESSMENTS	73
11.1.	Screening Assessments	73

11.1.1.	Randomization	73
11.1.2.	Demographics	73
11.1.3.	Medical History and NSCLC Cancer Disease History	73
11.2.	Anti-tumor Efficacy Assessments	74
11.2.1.	Anti-tumor Efficacy Assessment	74
11.2.2.	Myelopreservation Assessments	75
11.3.	Safety Assessments	75
11.3.1.	Vital Signs	75
11.3.2.	Physical Examination	75
11.3.3.	ECOG Performance Status	75
11.3.4.	Electrocardiogram	76
11.3.5.	Clinical Safety Laboratory Assessments	76
11.3.6.	Adverse and Serious Adverse Events	77
11.3.6.1.	Time Period and Frequency for Collecting Adverse and Serious Adverse Event Information	77
11.3.6.2.	Method of Detecting Adverse and Serious Adverse Events	78
11.3.6.3.	Follow-up of Adverse and Serious Adverse Events	78
11.3.6.4.	Regulatory Reporting Requirements for Serious Adverse Events	78
11.3.6.5.	Pregnancy	78
11.4.	Patient-Reported Outcomes	79
11.4.1.	EORTC QLQ-C30 and EORTC QLQ-LC13	79
11.4.2.	FACIT-Fatigue	79
11.4.3.	Patient Global Impression of Change and Patient Global Impression of Severity	80
11.4.4.	5-Level EQ-5D	80
11.5.	Pharmacokinetics	80
11.6.	Biomarkers	81
11.6.1.	Rationale for Archival Tumor Collection	81
11.6.2.	Description of CDK4/6 Signature	81
11.7.	Immunologic and Hematologic Markers	82
11.8.	Data Monitoring Committee	82
11.10.	Survival Follow-up Phase	83
12.	STATISTICAL CONSIDERATIONS	83
12.1.	Sample Size Determination	83
12.2.	Analysis Population	84
12.3.	Timing of Planned Analysis	84
12.3.1.	First Planned Analysis – Interim Analysis for Overall Survival and Analyses for Progression Free Survival, Tumor Responses and Myelosuppression Endpoints	84
12.3.2.	Second Planned Analysis – Final Analysis for Overall Survival and Safety Data Analyses	85

12.4. Statistical Analysis Methods.....	85
12.4.1. General Considerations.....	85
12.4.2. Patient Disposition.....	85
12.4.3. Demographic and Baseline Characteristics	86
12.4.4. Prior and Subsequent Anticancer Therapies.....	86
12.4.5. Study Drug Exposure, Modification and Dose Intensity.....	86
12.4.6. Efficacy Analyses	86
12.4.6.1. Analyses of Primary Efficacy Endpoint – Overall Survival	86
12.4.6.2. Analysis for Secondary Anti-tumor Efficacy Endpoints.....	88
12.4.6.3. Analysis for Myelosuppression Endpoints.....	90
12.4.6.4. Subgroup Analysis for Primary Efficacy Endpoint.....	91
12.4.7. PRO Analyses.....	91
12.4.8. Safety Analyses	91
12.4.8.1. Adverse Events.....	91
12.4.8.2. Other Safety Endpoints	92
12.4.9. Exploratory Analyses.....	92
12.4.10. Pharmacokinetic Analyses.....	92
12.4.11. Pharmacokinetic/Pharmacodynamic Analyses	93
13. ETHICS.....	93
13.1. Ethics Review	93
13.2. Ethical Conduct of the Study	93
13.3. Written Informed Consent	93
14. DATA HANDLING AND RECORDKEEPING	94
14.1. Data Protection.....	94
14.2. Data Quality Assurance	94
14.3. Dissemination of Clinical Study Data.....	95
14.4. Source Documents	95
14.5. Audits and Inspections.....	95
15. PUBLICATION POLICY	95
16. REFERENCES	96
17. APPENDICES	105
17.1. Clinical Laboratory Tests.....	105
17.2. Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting.....	107
17.2.1. Definition of AE	107
17.2.2. Definition of SAE.....	108
17.2.3. Recording and Follow-Up of AE and/or SAE.....	110
17.2.4. Reporting of SAEs.....	112

17.3. Contraceptive Guidance and Collection of Pregnancy Information	113
17.4. Definitions of Tumor Response and Disease Progression (per RECIST v1.1)	116

LIST OF TABLES

Table 1: Abbreviations	17
Table 2: Integrated Analysis for Myelopreservation Efficacy in SCLC (Studies G1T28-02, G1T28-03, and G1T28-05)	36
Table 3: G1T28-04: Summary of Overall Survival and Progression-Free Survival (ITT Analysis Set)	37
Table 4: G1T28-04: Tumor Response According to PD-L1 Status	39
Table 5: Objectives and Endpoints	43
Table 6: Schedule of Assessments	54
Table 7: Study Drugs	57
Table 8: Recommended Chemotherapy Dose Modifications	60
Table 9: Recommended Dose Modification for Drug-Related Hematologic Toxicity	62
Table 10: Recommended Actions with Trilaciclib/Placebo Following AESIs	65
Table 11: Patient Risk Factors for Poor Clinical Outcomes Resulting from Febrile Neutropenia or Infection	68
Table 12: ECOG Performance Status	76
Table 13: Thresholds for Claiming Statistical Superiority (Trilaciclib versus Placebo) at Interim or Final Analysis for Overall Survival	87
Table 14: Protocol-Specified Safety Laboratory Assessments	105
Table 1: Abbreviations	17
Table 2: Integrated Analysis for Myelopreservation Efficacy in SCLC (Studies G1T28-02, G1T28-03, and G1T28-05)	36
Table 3: G1T28-04: Summary of Overall Survival and Progression-Free Survival (ITT Analysis Set)	37
Table 4: G1T28-04: Tumor Response According to PD-L1 Status	39
Table 5: Objectives and Endpoints	43
Table 6: Schedule of Assessments	54
Table 7: Study Drugs	57
Table 8: Recommended Chemotherapy Dose Modifications	60
Table 9: Recommended Dose Modification for Drug-Related Hematologic Toxicity	62

Table 10:	Recommended Actions with Trilaciclib/Placebo Following AESIs.....	65
Table 11:	Patient Risk Factors for Poor Clinical Outcomes Resulting from Febrile Neutropenia or Infection.....	68
Table 12:	ECOG Performance Status	76
Table 13:	Thresholds for Claiming Statistical Superiority (Trilaciclib versus Placebo) at Interim or Final Analysis for Overall Survival	87
Table 14:	Protocol-Specified Safety Laboratory Assessments	105

LIST OF FIGURES

Figure 1:	Trilaciclib Transiently Arrests Normal Cells to Prevent Chemotherapy-Induced Myelosuppression and Improve Anti-Tumor Efficacy.....	25
Figure 2:	G1T28-04: Overall Survival – Kaplan-Meier Curve (ITT Analysis Set).....	26
Figure 3:	The Addition of Trilaciclib to Chemotherapy/Immune Checkpoint Inhibitor Treatment Enhances Efficacy Through T Cell Activation	33
Figure 4:	Study Design.....	47
Figure 1:	Trilaciclib Transiently Arrests Normal Cells to Prevent Chemotherapy-Induced Myelosuppression and Improve Anti-Tumor Efficacy.....	25
Figure 2:	G1T28-04: Overall Survival – Kaplan-Meier Curve (ITT Analysis Set).....	26
Figure 3:	The Addition of Trilaciclib to Chemotherapy/Immune Checkpoint Inhibitor Treatment Enhances Efficacy Through T Cell Activation	33
Figure 4:	Study Design.....	47

3 LIST OF ABBREVIATIONS

The following abbreviations and specialist terms are used in this study protocol.

Table 1: Abbreviations

Abbreviation	Definition
5-FU	5-fluorouracil
AE	adverse event
AESI	adverse event of special interest
ALK	anaplastic lymphoma kinase
ALT	alanine aminotransferase

Abbreviation	Definition
ANC	absolute neutrophil count
ANCOVA	analysis of covariance
aPTT	activated partial thromboplastin time
aRR	adjusted relative risk
ASCO	American Society of Clinical Oncology
AST	aspartate aminotransferase
ATC	Anatomical Therapeutic Classification
AUC	area under the concentration-time curve
BCRP	breast cancer resistance protein
BED	biologically effective dose
β-hCG	beta human chorionic gonadotropin
BICR	blinded independent central review
BMI	body mass index
BOR	best overall response
BSA	body surface area
BSEP	bile salt export pump
CAP	College of American Pathologists
CBC	complete blood count
CD	cluster of differentiation
CDK	cyclin-dependent kinase
CFR	Code of Federal Regulations
CI	confidence interval
CIM	chemotherapy-induced myelosuppression
CMH	Cochran-Mantel-Haenszel
CNS	central nervous system
CPS	combined positive score
CR	complete response
CT	computed tomography
CTCAE	Common Terminology Criteria for Adverse Events
CTLA-4	cytotoxic T-lymphocyte associated protein 4
CYP	cytochrome P450

Abbreviation	Definition
D5W	dextrose 5% in water
DC	dendritic cell
DCAF	d-type cyclin activating features
DDI	drug-drug interaction
DMC	Data Monitoring Committee
DNA	deoxyribonucleic acid
DOR	duration of objective response
DSN	duration of severe neutropenia
ECG	electrocardiogram
ECOG	Eastern Cooperative Oncology Group
eCRF	electronic case report form
EDC	electronic data capture
EGFR	epidermal growth factor receptor
EMA	European Medicines Agency
EORTC QLQ-C30	European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire
EORTC QLQ-LC13	European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module
EORTC IL118	European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module with supplemental weight loss item
EOT	End of Treatment
E/P	etoposide plus carboplatin
E/P/A	cisplatin, etoposide and atezolizumab
ES-SCLC	extensive stage SCLC
EQ-5D-5L	5-level EQ-5D
EQ-VAS	EQ visual analogue scale
ER	estrogen receptor
ESA	erythropoiesis stimulating agent
FACIT-Fatigue	Functional Assessment of Chronic Illness Therapy - Fatigue
FDA	Food and Drug Administration
FFPE	formalin-fixed paraffin-embedded
FN	febrile neutropenia
FSH	follicle stimulating hormone

Abbreviation	Definition
G ₁	gap 1 phase of the cell cycle
G ₂	gap 2 phase of the cell cycle
G1T28	trilaciclib; formerly G1T28-1
GC	gemcitabine and carboplatin
GC therapy	gemcitabine and carboplatin on Days 1 and 8 of 21-day cycles
GCP	Good Clinical Practice
G-CSF	granulocyte colony-stimulating factor
GI	gastrointestinal
GM-CSF	granulocyte-macrophage colony-stimulating factor
HBV	hepatitis B virus
HCV	hepatitis C virus
HER2	human epidermal growth factor receptor 2
HIV	human immunodeficiency virus
HR	hazard ratio
HRT	hormone replacement therapy
HSPC	hematopoietic stem and progenitor cell
IB	Investigator's Brochure
IC	tumor-infiltrating immune cells
IC ₅₀	half maximal inhibitory concentration
ICF	informed consent form
ICH	International Council for Harmonisation
ICI	immune checkpoint inhibitors
IEC	independent ethics committee
IFN	interferon
IHC	immunohistochemistry
ILD	interstitial lung disease
INR	International Normalized Ratio
IP	intraperitoneal
IRB	institutional review board
ISH	in situ hybridization
ITT	intent-to-treat

Abbreviation	Definition
IV	intravenous
IWRS	Interactive Web Response System
Ki	inhibition constant
LFT	liver function test
M	mitosis
mAb	monoclonal antibody
MATE1 or 2-K	multidrug and toxin extrusion 1 or 2-K
MDR1	p-glycoprotein
MedDRA	Medical Dictionary for Regulatory Activities
MHC	major histocompatibility complex
MOA	mechanism of action
MRI	magnetic resonance imaging
MRP1 or 2	multidrug resistance protein 1 or 2
NCCN	National Comprehensive Cancer Network
NCI	National Cancer Institute
NE	not evaluable
NSCLC	non-small cell lung cancer
NYHA	New York Heart Association
OAT1 or 3	organic anion transporter 1 or 3
OATP1B1 or 1B3	organic anion transporting polypeptide 1B1 or 1B3
OCT1 or 2	organic cation transporter 1 or 2
ORR	objective response rate
OS	overall survival
PCS	potentially clinically significant
PD	progressive disease
PD-1	programmed cell death protein 1
PD-L1	programmed death-ligand 1
PDX	patient derived xenografts
PFS	progression-free survival
PGIC	Patient Global Impression of Change
PGIS	Patient Global Impression of Severity

Abbreviation	Definition
PK	pharmacokinetic(s)
PR	partial response
PRO	patient-reported outcome
PSA	prostate-specific antigen
PT	preferred term
PTFE	polytetrafluorethylene
PVG	pharmacovigilance
QTcF	QT corrected using Fridericia's formula
Rb	retinoblastoma protein
RB	retinoblastoma gene
RBC	red blood cell
RE	Response Evaluable
RECIST	Response Evaluation Criteria in Solid Tumors
ROS1	c-ROS oncogene 1
RP2D	recommended Phase 2 dose
S	synthesis phase of the cell cycle
SAE	serious adverse event
SAP	statistical analysis plan
SCLC	small cell lung cancer
SD	stable disease
SOC	system organ class
SN	severe neutropenia
SUSAR	suspected unexpected serious adverse reactions
TCR	T cell receptor
TEAE	treatment-emergent adverse event
TIM3	T-cell immunoglobulin and mucin domain 3
TNBC	triple-negative breast cancer
T _{reg}	regulatory T cells
TTCD-fatigue	Time to confirmed deterioration of fatigue
ULN	upper limit of normal
US	United States

Abbreviation	Definition
VAS	visual analog scale
WHO-DD	World Health Organization Drug Dictionary

4 INTRODUCTION

4.1 Lung Cancer

Worldwide, there were more than 2 million cases of lung cancer and 1.75 million lung cancer related deaths in 2018 (WHO, 2020). The American Cancer Society estimates that in 2020, ~135,000 of those lung cancer deaths will occur in the US alone (American Cancer Society, 2020). Approximately 84% of these patients will be diagnosed with non-small cell lung cancer (NSCLC) and almost 70% will present with locally advanced or metastatic disease (ASCO, 2020; Little, 2007). Historically, treatment in the metastatic setting has been driven almost exclusively by the use of systemic chemotherapy. However, in the last ten to twenty years, a greater understanding of the pathways that dictate tumor response and the advent of multiple targeted therapies has changed the landscape of treatment options significantly. Lung tumors are routinely tested for the presence of specific driver mutations (e.g., epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], BRAF, and cROS- oncogene 1 [ROS1]), that predict a favorable response to targeted tyrosine kinase inhibitors (Kalemkerian, 2018). As many as 50% to 64% of patients have been identified as having a targetable genetic alteration and those that receive treatment have better outcomes (Kris, 2014; Barlesi, 2016).

For those patients without a targetable genetic alteration, treatment options have also changed considerably. Though systemic therapy remains an important component of treatment in this context, the advent of immunotherapy has significantly improved outcomes for this patient population. Multiple randomized trials, in both squamous and non-squamous histologies, have established that overall survival (OS) is improved with the addition of programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitors (Spigel, 2019; Reck, 2016; Gandhi, 2018; Paz-Ares, 2018). Those with high levels of PD-L1 expression typically receive pembrolizumab or atezolizumab monotherapy in the first line followed by platinum-based chemotherapy in order to maximize treatment response and minimize toxicity. Those with a higher burden of disease requiring more aggressive initial treatment or with lower levels of PD-L1 expression typically receive immunotherapy in combination with a platinum-based chemotherapy doublet.

Despite these improvements in the therapy for metastatic NSCLC, the majority of patients ultimately progress during or after treatment with immunotherapy and platinum-based chemotherapy. Management of this pretreated patient population is challenging and treatment options are limited to single agent chemotherapies such as docetaxel, pemetrexed (for those with non-squamous histology), and gemcitabine (Shepherd, 2000; Fossella, 2010; Gridelli, 2004; Hanna, 2004; Anderson, 2000). The clinical trials that established these treatment options predated immunotherapies and robust data for individual agents is often lacking. The high-level evidence that does exist demonstrates a limited impact of 2nd line therapy on treatment outcomes. For example, in a study where 1,253 patients were treated with docetaxel plus or minus the VEGFR2 inhibitor ramucirumab following progression on platinum-based chemotherapy,

survival was significantly improved with the addition of ramucirumab, but the clinical benefit was only 1.5 months (hazard ratio [HR] 0.86, $p=0.023$) (Garon, 2014).

In contrast, the large Phase 3 studies evaluating the addition of immunotherapy in the first line consistently demonstrated large treatment effects (HRs ~0.5-0.6) that were both statistically significant and highly clinically meaningful (Spigel, 2019; Reck, 2016; Gandhi, 2018; Paz-Ares, 2018). In an effort to translate these early successes to later lines of therapy, numerous ongoing Phase 3 studies are evaluating the continuation of PD-1/PD-L1 inhibitors (following progression on the same) in combination with kinase inhibitors hypothesized to synergistically illicit an ongoing immune response. However, the mechanisms of immune checkpoint inhibitor (ICI) resistance are complex and include genetic, epigenetic, and cellular signaling alterations that dysregulate neoantigen presentation/processing and disrupt cytotoxic T cells activity as well as mechanisms in which non-cancerous stromal or immune cells promote growth and resistance to ICIs (Liu, 2019; Barrueto, 2020; Jenkins, 2018; Fares, 2019; Borchering, 2018; Gidel, 2018). Novel therapies, whose mechanisms broadly target these ICI mechanisms of resistance, including CDK4/6 inhibition, could be particularly valuable following disease progression on currently clinically available immunotherapies.

In addition to the need for therapies that more effectively extend overall survival, patients treated in the metastatic setting are particularly vulnerable to the chemotherapy-induced myelosuppression (CIM) and health-related quality of life impacts associated with extensive systemic therapy. CIM is a significant issue in cancer treatment; patients with myelosuppression are more likely to experience infections, sepsis, bleeding, and fatigue, often leading to the need for hospitalizations, hematopoietic growth factor support, transfusions (red blood cells [RBCs] and/or platelets) and even death (Caggiano, 2005; Gustinetti, 2016; Bodey, 1966; Li, 2016). Moreover, CIM commonly leads to dose reductions and delays, which limit therapeutic dose intensity and can compromise the anti-tumor efficacy benefits of chemotherapy. Furthermore, existing supportive care interventions for CIM are generally used after the onset of symptoms, only address the deficiency of a single blood cell lineage, and carry their own set of risks and limitations. Introducing a therapy that can protect the hematopoietic stem and progenitor cells (HSPCs) of the host from CIM has the potential to maximize the anti-tumor activity of the chemotherapy while minimizing the consequences to the patient of chemotherapy-induced cellular damage.


In summary, though immunotherapy has markedly improved the treatment of metastatic NSCLC, options following disease progression on these therapies remain limited. An alternative therapy that extends the duration of OS without significant additive toxicity, while concurrently decreasing myelosuppression and improving quality of life, would be a welcome addition in this heavily pretreated and often clinically fragile patient population. Therefore, further evaluation of trilaciclib in this area of high unmet medical need is warranted.

4.2 Study Rationale

Trilaciclib is a highly potent and selective, reversible, cyclin-dependent kinase (CDK) 4/6 inhibitor that preserves HSPCs as well as immune system function during chemotherapy (myelopreservation) in addition to directly enhancing anti-tumor immunity (anti-cancer efficacy) (Figure 1). Both HSPC and lymphocyte proliferation are dependent on CDK4/6 activity (Kozar, 2004; Malumbres, 2004; Ramsey, 2007; Horsley, 2008) and become arrested in the gap 1 (G_1) phase of the cell cycle upon exposure to trilaciclib (He, 2017). This trilaciclib-induced

transient cell cycle arrest has been demonstrated to provide resistance to chemotherapy-induced cell damage by preventing HSPCs from proliferating in the presence of cytotoxic chemotherapy and favorably altering the tumor immune microenvironment through transient T-cell inhibition when combined with chemotherapy and ICIs ([He, 2017](#); [Bisi, 2016](#); [Lai, 2020](#)). [In February 2021, the FDA approved trilaciclib \(COSELA™\) as a treatment to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer \(ES-SCLC\).](#)

Figure 1: Trilaciclib Transiently Arrests Normal Cells to Prevent Chemotherapy-Induced Myelosuppression and Improve Anti-Tumor Efficacy




4.2.1 Rationale for Improving Anti-tumor Efficacy with Trilaciclib

The use of trilaciclib for patients with triple-negative breast cancer (TNBC) was evaluated in Study G1T28-04, a global, multicenter, randomized, open-label, Phase 2 clinical trial to evaluate the safety, efficacy, and pharmacokinetics (PK) of trilaciclib administered prior to gemcitabine/carboplatin (GC) therapy for patients with locally advanced unresectable/metastatic TNBC who had previously been treated with 0 to 2 lines of therapy in the metastatic setting. Patients were randomized 1:1:1 to one of two different trilaciclib + GC treatment regimens or GC alone. Based on its mechanism of action (MOA), it was hypothesized that trilaciclib administered before chemotherapy could protect the bone marrow from the cytotoxic effects of chemotherapy, while also enhancing immune activity in patients with TNBC, thus potentially improving both safety and anti-tumor activity.

The G1T28-04 study was the first evaluation of trilaciclib in a tumor type other than small cell lung cancer (SCLC), where trilaciclib development has focused on myelopreservation benefits (Section 4.2.8.1). Three randomized, double-blind, Phase 2 clinical trials (G1T28-02, G1T28-03 and G1T28-05) evaluating trilaciclib/placebo administered prior to chemotherapy in patients with SCLC have demonstrated in a variety of clinical settings (first-, second-, third-line SCLC treated with several different classes of chemotherapy) that trilaciclib can prevent chemotherapy-induced myelosuppression as measured by multiple endpoints (Section 4.2.8.1; Table 2; Weiss, 2019; Hart, 2019; Daniel, 2019). While the benefit in chemotherapy-induced myelosuppression in these studies was striking, these myelopreservation benefits were observed in the setting of only minor improvements in progression-free survival (PFS) and OS as evidenced by HRs <1.0 in almost all clinical settings for trilaciclib compared with placebo.

In contrast to the previously observed SCLC results, the addition of trilaciclib to chemotherapy for patients with TNBC in G1T28-04 did not result in statistically significant improvements in myelosuppression endpoints, but instead resulted in a substantial improvement in anti-tumor efficacy as measured by OS (median OS duration in control: 12.6 months versus not evaluable or 17.8 months in the two trilaciclib groups, HR: 0.31 [p=0.0016] and HR: 0.40 [p=0.0004], respectively; Figure 2) and by PFS (median PFS in control 5.7 months versus 9.4 months or 7.3 months in the two trilaciclib groups HR: 0.65 and 0.57, respectively; not statistically significant) (O'Shaughnessy, 2020; Tan, 2019). The clinically meaningful anti-tumor efficacy results observed in G1T28-04 were noted across both of the trilaciclib treatment groups and in the context of a control group with survival reflective of published literature.

Figure 2: G1T28-04: Overall Survival – Kaplan-Meier Curve (ITT Analysis Set)



CI=confidence interval; HR=hazard ratio; ITT=intent-to-treat; NR=not reached.

Group 1: GC administered on Days 1 and 8 of 21-day cycles; Group 2: Trilaciclib and GC administered on Days 1 and 8 of 21-day cycles; Group 3: Trilaciclib administered on Days 1, 2, 8, and 9 and GC administered on Days 2 and 9 of 21-day cycles

Note: The HR and its 95% CI comparing Group 1 and 2 and Group 1 and 3 were calculated using the Cox regression model with treatment and stratification factors of number of prior lines of therapy (0 versus 1 or 2) and liver involvement.

Note: P-values comparing Group 1 and 2 and Group 1 and 3 were calculated using the stratified log-rank test to account for the number of prior lines of therapy (0 versus 1 or 2) and liver involvement as the stratification factors.

Note: data generated from final database.

The impact on OS was consistent across subgroups, including predictors of immune response. Approximately 57.6% of the available tumor samples in G1T28-04 were considered PD-L1 positive (Ventana SP142 assay), and though larger in the PD-L1 positive population, the benefit of adding trilaciclib extended to both PD-L1 positive and negative cohorts (Table 4).

The translation of these anti-tumor efficacy findings to other tumor types is predicted to be primarily driven by the tumor type, chemotherapy type and host, i.e., (1) the tumor must be sufficiently immunogenic and sensitive to the host cytolytic efforts as to see improvement in anti-tumor endpoints like OS, (2) the chemotherapy should promote immune activation, and (3) the host must be able to mount an effective cytolytic response against the tumor. In the SCLC trials, the addition of trilaciclib to the standard of care therapies provided modest improvement, to neutral effects, on measures of anti-tumor efficacy including objective response rate (ORR), PFS and OS. These results are not surprising considering that SCLC is one of the most aggressive solid tumors and is not particularly immunogenic or sensitive to immune modulation (Wang, 2019).

In contrast, NSCLC has been extensively documented as sensitive to immune modulation with multiple established immunotherapy treatment options in the early lines of treatment for metastatic NSCLC (Spigel, 2019; Wang, 2019; Reck, 2016; Gandhi, 2018; Paz-Ares, 2018). This highly responsive NSCLC immune milieu and the novel trilaciclib immune activating effects described below provide a strong rationale to evaluate the efficacy of trilaciclib in patients with previously treated NSCLC.

4.2.2 Rationale for Immunogenicity of NSCLC Tumor Type and Docetaxel Chemotherapy

While NSCLC has been recognized as having an immunosuppressive tumor microenvironment through high numbers of regulatory T cells (T_{reg}) directly inhibiting T-cell proliferation (Woo, 2001; Woo, 2002), tumor-infiltrating cluster of differentiation (CD) 8^{+} T cells with increased PD-1 expression (Zhang, 2010), and downregulation of major histocompatibility complex (MHC) class I/tumor antigen expression (Korkolopoulou, 1996), results from numerous trials evaluating immunotherapeutic agents, including immune checkpoint inhibitors, have demonstrated the efficacy of this approach in NSCLC (Spigel, 2019; Reck, 2016; Gandhi, 2018; Paz-Ares, 2018).

A number of immune correlates of clinical outcome in patients with NSCLC have been identified providing clinical evidence for immune system involvement in NSCLC. High levels of infiltrating CD 8^{+} , CD 4^{+} , CD 3^{+} T cells as well as higher densities of mature dendritic cells (DCs) have been associated with improved survival (Wing, 2008; Chen, 2012). Conversely, the number of T_{reg} cells as well as PD-L1 expression in NSCLC tumors have been shown to be independent predictors of reduced survival or unfavorable prognosis in patients with NSCLC, respectively (Petersen, 2006; Shimizu, 2010; Mu, 2011).

In addition to the inherent immunogenicity associated with NSCLC, docetaxel has demonstrated an ability to enhance the sensitivity of tumors to immune-mediated cell death (Hodge, 2013). In particular, immune modulating effects on the tumor stroma have been noted (Opzomer, 2019). *In vivo*, docetaxel has been shown to induce selective cell death in myeloid-derived suppressor cells known to contribute to immune suppression while simultaneously promoting differentiation of this cell type towards a pro-inflammatory phenotype (Kodumudi, 2010). Lastly, docetaxel has

been shown to decrease T_{reg} cells in patients with non-small cell lung cancer (Li, 2014). Taken together, these data suggest docetaxel may lead to immune activation in NSCLC and further the potential benefit of trilaciclib.

4.2.3 Rationale for Immune Mechanism of Trilaciclib

In the G1T28-05 study evaluating trilaciclib prior to cisplatin, etoposide, and atezolizumab (E/P/A) in patients with ~~extensive-stage SCLC~~ (ES-SCLC), flow cytometry and T cell receptor (TCR) immunosequencing data revealed that patients receiving trilaciclib had an increased ratio of total and activated CD8⁺ T cells to Tregs, and increased peripheral T-cell clonal expansion suggesting enhanced T-cell activation. Furthermore, there was significant enhancement in newly detected expanded clones among patients receiving trilaciclib compared with placebo, which was stronger among patients with an anti-tumor response to E/P/A, suggesting that trilaciclib may enhance tumor antigen presentation, a phenomenon that has been observed in preclinical studies with other CDK4/6 inhibitors (Daniel, 2020).

These observations are consistent with those from the G1T28-02 Phase 2 study of patients with ES-SCLC receiving trilaciclib prior to etoposide plus carboplatin (E/P). In G1T28-02, a higher proportion of activated or effector CD8⁺ and CD4⁺ T cells was observed in patients receiving trilaciclib compared with placebo. In addition, high levels of T-cell clonal expansion were associated with improved PFS and numerically longer median OS. Taken together, the data suggest that the addition of trilaciclib at least preserves, if not enhances, T-cell function during treatment with E/P or E/P/A (Lai 2020).

Lastly, to evaluate the effect of trilaciclib on T cell activation in G1T28-04, peripheral blood was collected and the TCR was evaluated. Simpson clonality decreased over time in patients that received trilaciclib in addition to GC when compared to GC alone. Furthermore, when patients were stratified above or below median Simpson clonality at baseline, there was an improvement among patients receiving trilaciclib. In addition to a decrease in Simpson clonality, responders receiving trilaciclib prior to GC had more newly detected expanded T-cell clones compared with responders receiving GC alone. These data suggest trilaciclib enhances anti-tumor immunity through T cell activation leading to an anti-tumor response (O'Shaughnessy, 2020).

Taken together these data from clinical trials evaluating trilaciclib in a variety of clinical contexts, suggest that trilaciclib has a consistent positive impact on anti-tumor immune modulation. Further, there appear to be several immune based mechanisms through which this effect can be mediated including neoantigen presentation and T cell activation and function.

4.2.4 Rationale for Trilaciclib following Progression on Immunotherapy

Interestingly, many of the mechanisms to overcome ICI-induced resistance have been associated with the immune activating effects of CDK4/6 inhibition, including increasing antigen presentation (MHC class I), enhancing T cell clonality and tumor infiltration, inhibiting regulatory T cell proliferation, decreasing T cell exhaustion markers (PD-1, cytotoxic T-lymphocyte associated protein 4 [CTLA-4], and T-cell immunoglobulin and mucin domain 3 [TIM3]), stabilizing expression of PD-L1 on tumor cells, promoting dendritic cell migration, and increasing T effector cell function through high interferon [IFN] gamma production (Chaikovsky and Sage, 2018; Deng, 2018; Goel, 2017; Schaer, 2018; Lai, 2020; Bonelli, 2019; Teh and Aplin, 2019).

Multiple ongoing trials in this setting, i.e., following disease progression on platinum-based chemotherapy and immunotherapy, are evaluating additional checkpoint inhibitor therapy, but in combination with a partner hypothesized to promote an ongoing immune response. However, as described above, multiple mechanisms of resistance can develop following treatment with immunotherapy and novel agents that exploit multiple or alternative pathways may be preferred. In addition to documented anti-tumor immune modulating effects alone and in combination with checkpoint inhibitors, trilaciclib has translated these effects to improved survival in the TNBC setting, and belongs to a class of agents with a diverse repertoire of immune-modulating effects. Overall, these data suggest that patients may benefit from trilaciclib after progressing on ICI treatment.

4.2.5 Rationale for Myelopreservation

Trilaciclib has shown well-documented improvement in myelosuppression outcomes that could provide a substantial benefit to patients receiving docetaxel. In the REVEL trial, 39% of patients receiving docetaxel alone experienced grade 3 or greater neutropenia with 10% experiencing febrile neutropenia (FN) (Garon, 2014). In addition, 6% of patients experienced Grade 3 or greater anemia. Patients treated for SCLC with trilaciclib had marked reductions in the occurrence of these endpoints, required less supportive care, and experienced enhanced quality of life (Table 2).

4.2.6 Rationale for Combination with Docetaxel

Following progression on chemotherapy and immunotherapy, single-agent chemotherapy is the most common standard of care. As there is limited high-quality data for any specific agent in the modern era, several options can be utilized. However, single-agent docetaxel, with activity in both squamous and non-squamous histologies, is commonly utilized in clinical practice and as the reference standard in metastatic NSCLC clinical trials.

Ramucirumab in combination with docetaxel is also approved for the treatment of metastatic NSCLC following disease progression on or after platinum-based chemotherapy. This approval was based on a Phase 3 study that revealed a 1.5-month improvement in survival with the addition of ramucirumab. However, the rate of grade 3 or greater treatment-emergent adverse events increased from 71% to 79%. Furthermore, this small benefit occurred prior to the widespread use of immunotherapy. It is unclear if the same benefit would be seen in patients treated with today's standard of care. As a result, National Comprehensive Cancer Network (NCCN) guidelines list both the combination and docetaxel alone as potential treatment options in this clinical setting and utilization is at the discretion of the individual provider. Because there are no mature data available evaluating the combination of trilaciclib and a taxane containing regimen, the risks of also incorporating ramucirumab were felt to outweigh the small associated benefits.

Trilaciclib has been successfully combined at the recommended Phase 2 dose with most major chemotherapy classes other than microtubule inhibitors. In three randomized, controlled, Phase 2 studies in SCLC patients, the combination resulted in consistent improvements in chemotherapy-induced myelosuppression across multiple lineages. Even in the TNBC trial where the addition of trilaciclib to gemcitabine/carboplatin did not improve neutropenia-based myelopreservation endpoints, rates of adverse events were comparable despite patients on trilaciclib receiving almost double the number of chemotherapy cycles. There is no evidence to suggest that a

different result would be expected from the combination of trilaciclib with taxane based chemotherapy.

Preclinical *in vivo* studies evaluating trilaciclib in combination with paclitaxel or docetaxel utilizing a clinically relevant dose administration schedule support the safety of this combination. In addition, there are at least 4 clinical studies combining chronically dosed oral CDK4/6 inhibitors (palbociclib, ribociclib) with taxane-based chemotherapy. Two of those studies have reported acceptable early safety results in combination with standard clinical doses of paclitaxel and docetaxel (Lewis, 2018; Clark, 2019). In both of these studies, patients received multiple doses of oral CDK4/6 inhibitors (known to cause neutropenia). In contrast, trilaciclib is an IV CDK4/6 inhibitor dosed only prior to chemotherapy. Finally, trilaciclib is being evaluated in an ongoing Phase 2 study in combination with paclitaxel in the neoadjuvant breast cancer setting.

4.2.7 Summary of Nonclinical Data

A summary of the trilaciclib nonclinical data is presented in the trilaciclib Investigator's Brochure (IB).

Nonclinical data related to docetaxel are provided in the local prescribing information.

4.2.7.1 Pharmacology Studies


Through a structure-based design approach to optimize potency, selectivity, and drug metabolism and PK properties, G1 Therapeutics, Inc. identified trilaciclib as a highly potent inhibitor of CDK4 and CDK6 (half maximal inhibitory concentration [IC₅₀] values of 1 nM and 4 nM, respectively) that is highly selective for CDK4/Cyclin D1 versus cyclin-dependent kinase 2 (CDK2)/Cyclin E (>2500-fold selectivity). Trilaciclib also demonstrated reversible inhibition of CDK4/Cyclin D1, with an inhibition constant (K_i) value of 0.78 nM.

The trilaciclib-induced G₁ arrest of HSPCs has been shown to be transient and readily reversible in both *in vitro* and *in vivo* models. *In vivo* analysis has demonstrated that trilaciclib administered prior to myelosuppressive chemotherapy leads to improved complete blood count (CBC) recovery of all blood lineages and increased survival. Specifically, in a model using the chemotherapy 5-fluorouracil (5-FU) that is highly myelosuppressive in mice, the extent and duration of nadir in CBCs worsened after each cycle of 5-FU administered alone. Trilaciclib administered prior to 5-FU ameliorated this worsening effect and the animals that received trilaciclib + 5-FU demonstrated a faster rate of recovery of CBCs compared with the 5-FU alone group following Cycle 4 (He, 2017).

Preclinical data has also shown that trilaciclib enhances immune activation and promotes anti-tumor immunity by differentially arresting cytotoxic and regulatory T-cell subsets followed by a faster recovery in cytotoxic T lymphocytes than in regulatory T cells in tumors. Specifically, the addition of trilaciclib to various chemotherapy/ICI treatment combinations resulted in enhanced tumor growth delay and durability of the antitumor response. Trilaciclib favorably modulated the proliferation of T-cell subsets in the tumor microenvironment, consistent with an enhanced cytotoxic T-cell response (Figure 3; Lai, 2020). This differential alteration of cell cycle kinetics between cytotoxic T lymphocytes and regulatory T cells results in a higher proportion of cytotoxic T lymphocytes than regulatory T cells, enhancement of T-cell activation, and a decrease in regulatory T cell-mediated immunosuppressive functions (Chaikovsky and Sage, 2018; Deng, 2018; Goel, 2017; Schaer, 2018). Together, these events

promote the cytotoxic T lymphocyte-mediated clearance of tumor cells. Therefore, these data support the hypothesis that trilaciclib-mediated transient proliferative arrest of T cells (protecting them from chemotherapy-induced damage), followed by activation of cytotoxic T lymphocytes in the context of fewer regulatory T cells led to the anti-tumor response observed.

Figure 3: The Addition of Trilaciclib to Chemotherapy/Immune Checkpoint Inhibitor Treatment Enhances Efficacy Through T Cell Activation



(Upper right and upper left) Addition of trilaciclib to oxaliplatin and αPD-L1/ αPD-1 combination therapy led to enhanced anti-tumor activity and durability of response in the MC38 tumor model (n=10–15 per treatment group). (Lower left) Transient G1 arrest led to changes in the proportion of intra-tumor T-cell subsets favoring effector T-cell function as measured by the ratio of CD8⁺ T cells to Tregs (% CD8⁺ T cells / % Tregs) in the CD45⁺ population

(n=5–8 tumors analyzed per treatment group and time point). (Lower right) Trilaciclib in combination with chemotherapy and ICI enhanced the gene signature of cytotoxic anti-tumor response. T-cell repertoire analyses of MC38 tumors from OP- or TOP-treated mice (n=5 per treatment group) on day 17, presented as median clonality score and TIL fraction (right panel). Error bars denote standard error, and dotted lines represent the median value for TIL fraction and clonality score. *p<0.05.

However, as a consequence of trilaciclib's MOA, there is a hypothetical risk that administration of trilaciclib prior to chemotherapy could decrease chemotherapy efficacy by pausing CDK4/6-dependent tumor cells in G₁ in the presence of chemotherapy; nonclinical data suggest this risk is not clinically significant. To understand why trilaciclib should not antagonize chemotherapy treatment, the baseline proliferation rates of HSPCs, bone marrow, and patient derived xenografts (PDX) were examined using flow cytometric analysis of the cell cycle. A bar graph depicting mean percentage of cells in synthesis phase of the cell cycle (S)/gap 2 phase of the cell cycle (G₂)/mitosis (M) demonstrates that there are a higher proportion of cells cycling in tumor cells when compared to bone marrow/HSPCs. Specifically, <4% of human HSPCs are cycling, while in breast tumors an average of ~40% of cells were cycling ([Sorrentino, 2018](#)). These results illustrate why tumor cells are more susceptible to chemotherapy-induced damage compared to HSPCs, since chemotherapy treatment is predominantly effective in the S/G₂/M phases of the cell cycle.

To evaluate the impact of trilaciclib on chemotherapy anti-tumor efficacy in CDK4/6 dependent tumors, two different models were treated with chemotherapy and trilaciclib. MCF7 tumor-bearing mice, a well-established estrogen receptor (ER)+ CDK4/6 dependent breast cancer model, were treated with docetaxel (IV, 5 mg/kg) ± trilaciclib once weekly for three doses. Although weekly trilaciclib treatment caused some tumor growth inhibition, administering trilaciclib with docetaxel did not alter the effects of chemotherapy. Next, MDA-MB231 tumor-bearing mice were treated with daily trilaciclib (intraperitoneal [IP], 100 mg/kg) for 28 days to confirm CDK4/6 dependence. Continuous treatment with trilaciclib caused stable disease in MDA-MB231 tumor-bearing mice. MDA-MB231 tumor-bearing mice were then treated with eribulin (IV, 0.5 mg/kg) ± trilaciclib once weekly for three doses. Similar to the MCF7 model, the addition of trilaciclib to eribulin treatment did not impact chemotherapy efficacy ([Sorrentino, 2018](#)). These experiments demonstrate that transient CDK4/6 inhibition prior to chemotherapy (eribulin, docetaxel) does not antagonize the intended anti-tumor effects of the chemotherapy in these CDK4/6-dependent tumor models.

While there is emerging preclinical data demonstrating the efficacy of CDK4/6 inhibitors in combination with targeted therapy in NSCLC subpopulations ([Freed, 2019](#); [Gopalan, 2018](#); [Haines, 2018](#); [Knudsen, 2017](#)), single agent efficacy has shown minimal benefit in the clinic ([Goldman, 2020](#); [Edelman, 2019](#); [Gopalan, 2018](#); [Patnaik, 2016](#)). Furthermore, the available nonclinical *in vivo* data indicate combining chemotherapy with trilaciclib does not diminish the antitumor intended effects of the chemotherapy (data not shown, internal G1 data) as loss of CDK4/6 pathway function is correlated with increased tumor proliferation and improved tumor response to chemotherapy in a variety of cancer types ([Socinski, 2009](#); [Herschkowitz, 2008](#); [Ertel, 2010](#); [Witkiewicz, 2012](#)). Lastly, applying a DNA signature analysis algorithm to the cBioportal dataset to characterize NSCLC tumors as CDK4/6 dependent, independent or indeterminate, only 7.4% of EGFR WT NSCLC lung tumor would be classified as CDK4/6 dependent ([Gao, 2013](#); [Cerami, 2012](#)). Overall, preclinical and clinical data suggest that there is

minimal risk that trilaciclib administered prior to docetaxel will induce a G1 arrest in the tumor cell with resultant antagonism of the intended efficacy effect of the chemotherapy.

4.2.7.2 Pharmacokinetic Studies

In vitro analyses of direct and time-dependent inhibition suggest that drug interactions based on inhibition of cytochrome P450 (CYP)1A2-, 2B6-, 2C8-, 2C9-, 2C19-, and 2D6-mediated metabolic pathways are unlikely at clinical doses, however, the studies do suggest that drug interactions based on trilaciclib-mediated inhibition of CYP3A4-mediated metabolic pathways are possible (see Section 4.2.8.1.1). Additionally, *in vitro* induction studies of the 3 major inducible CYP enzymes (CYP1A2, CYP3A4, and CYP2B6) in human hepatocytes suggest that trilaciclib-mediated induction is unlikely.

In vitro inhibition studies with membrane transporter model systems also suggest trilaciclib is unlikely to cause a drug-drug interaction (DDI) based on inhibition of breast cancer resistance protein (BCRP)-, bile salt export pump (BSEP)-, organic anion transporter 1 (OAT1)-, organic anion transporter 3 (OAT3)-, organic anion transporting polypeptide 1B1 (OATP1B1)-, p glycoprotein (MDR1)-, multidrug resistance protein 1 (MRP1)-, multidrug resistance protein 2 (MRP2)-, or organic anion transporting polypeptide 1B3 (OATP1B3)-mediated transport. However, *in vitro*, trilaciclib is a potent inhibitor of multidrug and toxin extrusion 1 (MATE1), multidrug and toxin extrusion 2-K (MATE2-K), organic cation transporter 1 (OCT1), and organic cation transporter 2 (OCT2). See Section 4.2.8.1.1 for clinical evaluation.

4.2.8 Summary of Clinical Data

4.2.8.1 Trilaciclib

A brief summary of the clinical data is provided in the following sections. Detailed information is presented in the trilaciclib IB.

The safety and efficacy of administering trilaciclib prior to chemotherapy was tested in one completed and one ongoing Phase 1b/2 study (G1T28-02 and G1T28-03) and one ongoing and one completed Phase 2 study (G1T28-05 and G1T28-04) in patients with SCLC or TNBC. The Phase 2 portions of Studies G1T28-02, G1T28-03, and Study G1T28-05 were randomized, double-blind, and placebo-controlled. Study G1T28-04 was randomized and included a control arm but was not double-blinded.

- Study G1T28-02 examined once-daily IV administration of either trilaciclib or placebo on Days 1 to 3 of each 21-day E/P chemotherapy cycle in patients with treatment naïve extensive-stage SCLC.
- Study G1T28-03 examined once-daily IV administration of trilaciclib or placebo on Days 1 to 5 of each 21-day topotecan chemotherapy cycle in patients with previously treated extensive-stage SCLC.
- Study G1T28-05 examined once-daily IV administration of trilaciclib or placebo on Days 1 to 3 for a maximum of four 21-day cycles of E/P and atezolizumab, followed by monotherapy atezolizumab, in patients with treatment naïve extensive-stage SCLC.
- Study G1T28-04 examined once-daily IV administration of trilaciclib prior to gemcitabine and carboplatin in patients with metastatic TNBC who had received 0 to 2 lines of previous therapy in the metastatic setting. Patients received 1) GC therapy only on Days 1 and 8 of a

21-day cycle, 2) trilaciclib and GC once daily on Days 1 and 8 of each 21-day cycle, OR 3) trilaciclib on Days 1, 2, 8 and 9 with GC on Days 2 and 9 of each 21-day cycle (further noted as Group 1, 2, or 3, respectively).

At the recommended phase 2 dose (RP2D) of 240 mg/m², across all three SCLC studies, trilaciclib administered prior to chemotherapy statistically significantly reduced the duration of severe neutropenia (DSN) in Cycle 1 and occurrence of severe neutropenia (SN) (primary endpoints) compared with placebo. An integrated data analysis of the three SCLC studies (G1T28-02, G1T28-03, and G1T28-05) for 8 of the most relevant myelosuppression endpoints (neutrophils, RBCs and platelets) demonstrated statistically significant, and clinically meaningful, improvements for trilaciclib over available therapies in 6 of 8 endpoints across multiple lineages. Importantly, these myelopreservation benefits come with an overall improved safety profile compared with available therapy, as evidenced by reduced high grade treatment-emergent AEs across all SCLC studies, and no detriment to anti-tumor efficacy results.

Table 2: Integrated Analysis for Myelopreservation Efficacy in SCLC (Studies G1T28-02, G1T28-03, and G1T28-05)

	Placebo +Chemo	Trilaciclib +Chemo	2-sided p-value
ITT Set	119	123	
Neutrophils			
DSN [days] in Cycle 1 – Mean (SD) ^a	4 (5.1)	0 (1.8)	<0.0001
Occurrence of SN (Yes, %) ^b	64 (52.9)	14 (11.4)	<0.0001
RBCs			
Occurrence of Grade 3/4 hemoglobin decreased (anemia) (Yes, %) ^b	38 (31.9)	25 (20.3)	0.0279
Occurrence of RBC transfusion on/after 5 weeks (Yes, %) ^b	31 (26.1)	18 (14.6)	0.0252
Cumulative incidence of RBC transfusion on/after 5 weeks - Event rate (per 100 weeks) ^c	3.1	1.5	0.0027
Platelets			
Occurrence of Grade 3/4 platelet count decreased (thrombocytopenia) (Yes, %) ^b	43 (36.1)	24 (19.5)	0.0067
Occurrence of platelet transfusion (Yes, %) ^b	11 (9.2)	10 (8.1)	0.9564
Cumulative incidence of platelet transfusion - Event rate (per 100 weeks) ^c	1.7	1.1	0.5169

ANC=absolute neutrophil count; Chemo=chemotherapy; DSN=duration of severe (Grade 4) neutropenia; ECOG=Eastern Cooperative Group; ITT=intent to treat; SN=severe (Grade 4) neutropenia which is defined as ANC < 500/mm³; RBC=red blood cells, SCLC=small cell lung cancer; SD=standard deviation.

Chemo=etoposide + platinum in G1T28-02, etoposide + platinum + atezolizumab in G1T28-05, and topotecan in G1T28-03. Standard supportive care interventions were allowed for all arms.

a. p-value was obtained from a nonparametric analysis of covariance (ANCOVA).

b. p-value was obtained from a modified Poisson model.

c. p-value was obtained from a negative binomial model. All three models contained fixed effect of treatment, ECOG performance status (0-1 versus 2), Presence of brain metastases (Y/N), and study (G1T28-02, G1T28-03, or G1T28-05). Corresponding baseline assessment was also included as a covariate.

Results from the TNBC Study G1T28-04 demonstrated that although the addition of trilaciclib to GC did not statistically significantly improve chemotherapy-induced myelosuppression as measured by the neutrophil-based endpoints of DSN in Cycle 1 and occurrence of SN, there were trends toward improvement in RBC and platelet-based measures. In addition, ~~anti-tumor~~ ~~antitumor~~ efficacy results demonstrated a clinically meaningful improvement in PFS and OS (Figure 2; Table 3). This meaningful ~~anti-tumor~~ ~~antitumor~~ efficacy was observed in both trilaciclib groups compared with the control group and was also consistent across subgroups, including predictors of immune response. Approximately 57.6% of the available tumor samples in G1T28-04 were considered PD-L1 positive (Ventana SP142 assay), and though larger in the PD-L1 positive population, the benefit of adding trilaciclib extended to both PD-L1 positive and negative cohorts (Table 4).

Table 3: G1T28-04: Summary of Overall Survival and Progression-Free Survival (ITT Analysis Set)

Category	Group 1 GC (Day 1+8) (N=34)	Group 2 GC + Trilaciclib (Day 1+8) (N=33)	Group 3 GC + Trilaciclib (Day 1/2+8/9) (N=35)	Groups 2+3 (N=68)
Overall survival (months) (95% CI)^{a, d}				
25%	5.8 (2.8, 9.7)	9.4 (3.4, 19.6)	8.8 (6.0, 15.3)	8.8 (6.0, 14.0)
Median	12.6 (6.3, 15.6)	NR (10.2, NR)	17.8 (12.9, 32.7)	19.8 (14.0, NR)
75%	17.8 (12.8, 25.0)	NR (NR, NR)	32.7 (19.8, NR)	NE (32.7, NR)
Comparison (treatment group versus Group 1)				
Adjusted HR (SE) ^b	NA	0.31 (0.111)	0.40 (0.125)	0.37 (0.101)
95% CI ^b	NA	0.15, 0.63	0.22, 0.74	0.21, 0.63
2-sided p-value ^c	NA	0.0016	0.0004	<0.0001
Progression-free survival (months) (95% CI)^{a, d}				
25%	2.2 (1.2, 5.4)	5.3 (1.2, 7.9)	6.2 (1.2, 7.1)	5.9 (2.1, 6.5)
Median	5.7 (3.3, 9.9)	9.4 (6.1, 11.9)	7.3 (6.2, 13.9)	9.0 (6.4, 11.3)
75%	9.9 (8.3, 18.8)	13.0 (9.7, 24.1)	13.9 (9.0, NR)	13.9 (10.9, 15.6)
Comparison (Treatment Group versus Group 1)				
Adjusted HR (SE) ^b	NA	0.62 (0.209)	0.63 (0.212)	0.62 (0.180)
95% CI ^b	NA	0.32-1.20	0.32, 1.22	0.36, 1.10
2-sided p-value ^c	NA	0.2099	0.1816	0.1291

CI=confidence interval; GC=gemcitabine and carboplatin; HR=hazard ratio; ITT=intent-to-treat; N=total number of patients in each treatment group; NA=not applicable; NR=not reached; SE=standard error.

^a Calculated using the Kaplan-Meier method

^b The HR and its 95% CI were calculated using the Cox regression model controlling for stratification factors of the number of prior lines of therapy (0 versus 1 or 2) and liver involvement.

^c P-value was calculated using the stratified log-rank test controlling for the two stratification factors.

^d OS reported from final database; PFS reported from earlier data cutoff on 15 May 2020.

Table 4: G1T28-04: Tumor Response According to PD-L1 Status

	PD-L1 Positive				PD-L1 Negative			
	Group 1	Group 2	Group 3	Group 2+3	Group 1	Group 2	Group 3	Group 2+3
Patients analyzed	17	16	16	32	10	10	16	26
Median PFS, months (95% CI) ^a	5.4 (3.3-NR)	7.9 (6.1-NR)	10.9 (6.2-NR)	9.7 (6.2-15.5)	9.2 (8.3-NR)	11.9 (8.8-NR)	9.0 (6.4-NR)	9.4 (6.5-14.6)
p-value	-	0.492	0.075	0.149	-	0.376	0.488	0.943
HR (95% CI)	-	0.74 (0.3-1.7)	0.41 (0.2-1.1)	0.57 (0.3-1.2)	-	0.60 (0.2-1.9)	1.47 (0.5-4.3)	0.97 (0.4-2.5)
Median OS, months (95% CI) ^a	10.5 (6.3-18.8)	20.1 (10.2-NR)	32.7 (15.3-NR)	32.7 (17.7-NR)	13.9 (12.6-NR)	NR (9.4-NR)	17.8 (12.9-NR)	17.8 (13.1-NR)
p-value	-	0.037	0.01	0.004	-	0.077	0.198	0.093
HR (95% CI)	-	0.38 (0.2-1.0)	0.30 (0.1-0.8)	0.34 (0.2-0.7)	-	0.35 (0.1-1.2)	0.55 (0.2-1.4)	0.48 (0.2-1.2)

HR=hazard ratio; NR=not reached; OS=overall survival; PD-L1=programmed death ligand-1; PFS=progression-free survival

Group 1: chemotherapy on Days 1 and 8; Group 2: trilaciclib and chemotherapy on Days 1 and 8; Group 3: trilaciclib along on Days 1 and 8 with chemotherapy on Days 2 and 9. HR and p-values are comparisons between Group 2 and Group 1, Group 3 and Group 1, and between combined Groups 2 and 3 and Group 1.

^a OS reported from final database; PFS reported from earlier data cutoff on 15 May 2020.

As mentioned in Section 4.2.7, there is a hypothetical risk that administration of trilaciclib prior to chemotherapy could decrease chemotherapy efficacy by pausing CDK4/6-dependent tumor cells in the G₁ phase of the cell cycle in the presence of chemotherapy. This hypothetical risk is countered by the results observed in Study G1T28-04 which suggested that the addition of trilaciclib improves the anti-tumor efficacy of GC regardless of the CDK4/6 status of the TNBC tumor. Although TNBC tumors are predominantly classified as CDK4/6 independent (i.e., their replication is not sensitive to CDK4/6 inhibition), there is a small subset of patients whose tumors are classified as either CDK4/6 indeterminate or CDK4/6 dependent. When the TNBC population enrolled in Study G1T28-04 is divided into these subsets, evaluation of the anti-tumor efficacy in patients whose tumors are classified as CDK4/6 indeterminate or CDK4/6 dependent suggests that trilaciclib does not antagonize the anti-tumor effects of GC. Specifically, PFS and OS did not decrease when trilaciclib was added to GC in the most CDK4/6-dependent population (see the trilaciclib IB).

4.2.8.1.1 Pharmacokinetics

A clinical DDI study using the index CYP3A substrate midazolam indicated that trilaciclib had no impact on CYP3A activity. Two clinical DDI studies using a strong CYP3A inhibitor itraconazole were also conducted. No clinically significant changes in exposure were observed for trilaciclib when ~~co-administered~~co-administered with itraconazole.

Clinical data from the evaluation of trilaciclib administered prior to topotecan (Study G1T28-03) suggests that drugs that are substrates of MATE1 and MATE2 do not pose a clinically relevant

risk of DDIs when administered concomitantly with trilaciclib. In an additional clinical DDI assessment, trilaciclib increased metformin (MATE1, ~~MATE2-K~~ MATE-2K and OCT2 substrate) exposure by 65%, in healthy subjects, compared with administration of metformin alone. ~~However, due to the intermittent schedule of trilaciclib administration and the observation that the effect of trilaciclib on metformin was similar to mild to moderate reductions in renal function, the clinical significance of the metformin plasma concentration increase is not expected to be high. OCT2 substrates with a narrow therapeutic index, such as dofetilide and dalfampridine, should be used with caution.~~

Avoid concomitant use of trilaciclib with certain OCT2, MATE1, and MATE-2K substrates (e.g., dofetilide, dalfampridine) where minimal concentration changes may lead to serious or life-threatening toxicities. Refer to the prescribing information for these concomitant medications for assessing the benefit and risk of concomitant use with trilaciclib.

Docetaxel has not been reported to be a substrate for MATE1 or MATE2 ([Nieuweboer, 2015](#)), and is not believed to be a substrate for OCT2. As such, a clinically significant alteration of docetaxel PK due to trilaciclib inhibition of OCT2, MATE1, or MATE2-K is not expected.

Study G1T28-11 was a single ascending dose study, with both placebo and positive control groups, with the objective to evaluate potential effects of trilaciclib on ECG parameters, including concentration-QTc (C-QTc) analysis. Trilaciclib transiently increased heart rate by approximately 10 beats per minute. At the clinical dose of 240 mg/m², trilaciclib did not have a clinically relevant effect on QTc (i.e., >10 msec).

4.2.8.2 Trilaciclib Risks

Reproductive/embryo-fetal effects are an important potential risk of trilaciclib. Both nonclinical toxicology studies with trilaciclib, and clinical studies with other compounds with a similar MOA, report effects on either the reproductive system or embryo/fetus. Since this clinical study will focus on trilaciclib administered prior to cytotoxic chemotherapy (which carries its own risk of reproductive/embryo-fetal toxicity), the risks specific to trilaciclib are consistent with those experienced with chemotherapy. In addition, female patients will be monitored for pregnancy and eligibility criteria describing specific birth control methods are incorporated. Dose discontinuation recommendations for female patients who become pregnant while receiving trilaciclib are also provided in the protocol (Section [11.3.6.5](#)). Detailed information regarding all important identified and important potential risks of trilaciclib administration can be found in the trilaciclib IB.

Adverse events of special interest (AESIs) identified for trilaciclib are described below. Rates reported below reflect those observed in the integrated safety summary from the four Phase 2 oncology studies conducted with trilaciclib to date (G1T28-02 [database lock: 05 May 2019], G1T28-03 [data cutoff: 31 May 2019], G1T28-05 [data cutoff: 28 June 2019], and G1T28-04 [data cutoff: 28 June 2019]). Some AESIs have been infrequently reported (or not reported) in the trilaciclib clinical program to date but are considered to be potential class effects of CDK4/6 inhibitors. However, as trilaciclib is given IV and only when chemotherapy is administered, the safety profile of trilaciclib appears to be different from that of the oral, chronically-dosed members of its pharmacologic class. All patients will be monitored for these events and dose modification and discontinuation guidelines are provided in Section [9](#) and Section [10](#).

Trilaciclib AESIs:

1. **Injection Site Reaction/Phlebitis/Thrombophlebitis:** Infusion of trilaciclib may result in local irritation manifesting as erythema, pain, and swelling; and in a subset of patients, the irritation may cause phlebitis/thrombophlebitis. Injection site reactions have been observed in approximately 15 to 20% of patients receiving trilaciclib and the events have been Grade 1 or 2. Phlebitis/thrombophlebitis has been noted in approximately 5 to 10% of patients receiving trilaciclib and the events were primarily Grade 1 or 2. Supportive care interventions such as slowing the infusion rate, flushing the infusion line with a minimum of 20 mL normal saline or 5% dextrose (D5W), rotating IV catheter sites, and removing the IV (when given peripherally) following each trilaciclib infusion can decrease the frequency and severity of these events. In addition, if symptoms are observed with normal saline as diluent/flush, use of D5W as an alternative may decrease the symptoms. Central access may also be considered.
2. **Acute Drug Hypersensitivity Reaction:** Trilaciclib administration may cause acute drug hypersensitivity reaction characterized by symptoms like angioedema, pruritis, and urticaria. These events have been reported in approximately 6% of patients receiving trilaciclib compared with approximately 3% in patients receiving placebo and were classified as Grade 1 and 2. Only one case of Grade 2 anaphylaxis was observed, which occurred 4 days after the preceding dose of trilaciclib, resolved on the same day, was not serious, and did not result in discontinuation of treatment.
3. **Pneumonitis/Interstitial Lung Disease:** A rare (1 to 3%) but serious class effect (<1% fatal) that is associated with the use of oral CDK4/6 inhibitors. Symptoms include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams in patients in whom infectious, neoplastic, or other causes have been excluded. The only case of pneumonitis reported in patients who received trilaciclib was observed in a patient in whom trilaciclib had been discontinued for two months and who had been receiving atezolizumab (known to cause pneumonitis) as monotherapy. The pneumonitis event was Grade 3 and considered by the Investigator to be related to atezolizumab.
4. **Hepatotoxicity:** Both nonclinical toxicology studies with trilaciclib, and clinical studies with other compounds with a similar MOA, report reversible elevations in transaminases with continuous dosing. There has been only 1 instance of Grade 4 alanine aminotransferase (ALT) increase in a patient receiving trilaciclib, no Grade 4 aspartate aminotransferase (AST) increases, and no cases of Hy's law reported in patients receiving trilaciclib. However, generally low grade and transient increases in AST, ALT, or bilirubin have been observed in a small number of patients (~ 5%) receiving trilaciclib prior to chemotherapy. Patients with mild hepatic impairment have been treated with trilaciclib without a clinically significant increase in exposure or the frequency/severity of AEs. Studies evaluating the PK of trilaciclib in patients with hepatic impairment are ongoing.
5. **Embolic and Thrombotic Events, Venous:** The CDK4/6 inhibitor abemaciclib has been associated with an increased risk for venous thromboembolism when combined with endocrine therapy in patients with breast cancer. This same risk has not been reported for the other approved oral CDK4/6 inhibitors (ribociclib and palbociclib); therefore, it is not clear if this is a class effect. Approximately 3% of cancer patients that received trilaciclib prior to chemotherapy experienced a venous thromboembolic event and half of those events (3/6)

were Grade 3 or 4. No Grade 5 events were reported. Approximately 2% of patients receiving chemotherapy alone or with placebo reported an embolic or thrombotic event, 1 of 3 such events was Grade 3.

4.2.8.3 Docetaxel

Docetaxel is commonly used in the treatment of metastatic NSCLC (NCCN, 2020) and is approved by the US FDA and the European Medicines Agency for this indication (Taxotere®, 2020; Taxotere, 2005). Per Warnings and Precautions in the prescribing information for docetaxel, the following are important risks related to docetaxel use:

- Acute myeloid leukemia, myelodysplasia or other second primary malignancies
- Cutaneous reactions including erythema, edema and desquamation
- Neurologic reactions including paresthesia, dysesthesia, and pain
- Cystoid macular edema
- Asthenia
- Fetal harm
- Alcohol content (in a dose of Taxotere injection)
- Tumor lysis syndrome
- Neutropenia
- Serious gastrointestinal complications (ex. enterocolitis)
- Hypersensitivity reactions
- Fluid retention
- Respiratory disorders (ex. acute respiratory distress syndrome, interstitial lung disease, pulmonary fibrosis, respiratory failure)
- Severe adverse reactions in patients with liver impairment

4.3 Benefit/Risk Assessment

Trilaciclib (CDK4/6 inhibitor) is being evaluated for anti-tumor efficacy, specifically OS, following disease progression on both immunotherapy and platinum-based chemotherapy, a clinical setting where treatment options are limited and outcomes are suboptimal. In addition to facilitating host immune function, trilaciclib can also provide benefit by making chemotherapy safer and allowing patients to receive the standard of care doses and schedule. These effects have been shown in other trilaciclib clinical trials to improve the patient experience and are provided in the context of minimal toxicity (low grade injection site reactions/phlebitis/thrombophlebitis).

As stated in Section 4.2.8, the dose of 240 mg/m² trilaciclib established in the SCLC and TNBC studies (G1T28-04) will be administered prior to a commonly used chemotherapy regimen of docetaxel. The clinically meaningful anti-tumor efficacy results observed in G1T28-04 were noted across multiple endpoints, with OS, PFS, and ORR endpoints all showing numerical improvement with the addition of trilaciclib to GC compared with GC alone.

Studies to date with trilaciclib have demonstrated a manageable safety profile (see Section 4.2.8). Trilaciclib is not expected to have significant overlapping toxicity with docetaxel. In fact, trilaciclib is expected to have a favorable impact on specific docetaxel complications such as myelosuppression and potentially on gastrointestinal (GI) related side effects.

As described in Section 4.2.9.1 and 4.2.8.1, there is a hypothetical risk that administration of trilaciclib prior to chemotherapy could decrease chemotherapy efficacy by pausing CDK4/6-dependent tumor cells in G1 in the presence of chemotherapy. However, at this time there is no nonclinical (Section 4.2.7) or clinical (Section 4.2.8) evidence to support this theoretical risk. In addition, since sensitivity to CDK4/6 inhibitors is a surrogate marker for CDK4/6 dependence, and the oral, chronically-dosed CDK4/6 inhibitors have shown minimal anti-tumor activity in solid tumors other than ER+ breast cancer (Baghdadi, 2019; Goldman, 2014; Goldman, 2018; Gopalan, 2014; Infante, 2016; Karasic, 2018; Rose, 2018), these results suggest that the majority of solid tumor cancers are not CDK4/6 dependent and not susceptible to this hypothetical risk.

Given the potential benefit to patients with previously treated metastatic NSCLC from the addition of trilaciclib to docetaxel and the limited potential for significant trilaciclib-related toxicity, the benefit/risk assessment is positive for this combination.

[A COVID-19 risk assessment has been performed, documented, and will be provided as a separate document.](#)

5 OBJECTIVES AND ENDPOINTS

The primary, secondary, safety, and exploratory objectives of this study and their associated endpoints, for patients with metastatic NSCLC receiving docetaxel in the 2nd or 3rd line, are presented in Table 5.

Table 5: Objectives and Endpoints

Objectives	Endpoints
Primary Objective	
<ul style="list-style-type: none"> To assess the effect of trilaciclib on OS compared with placebo 	<ul style="list-style-type: none"> OS in the ITT population defined as time from randomization to death due to any cause for those who died; or time to last contact known as alive for those who survived in the study (censored cases).
Secondary Objectives: Other Anti-Tumor Efficacy	
<ul style="list-style-type: none"> To assess the effect of trilaciclib on PFS compared with placebo 	<ul style="list-style-type: none"> PFS in ITT population defined as time from randomization to disease progression using RECIST v1.1 or death due to any cause, whichever occurs first; for patients without disease progression or death, PFS will be calculated per censoring rules.

Objectives	Endpoints
<ul style="list-style-type: none"> To assess the effect of trilaciclib on other anti-tumor endpoints compared with placebo 	<ul style="list-style-type: none"> ORR defined as percentage of patients with confirmed CR and PR per RECIST v1.1 DOR defined as duration of objective response
Secondary Objective: to evaluate the myelopreservation effect of trilaciclib compared with placebo	
<ul style="list-style-type: none"> To assess the effects of trilaciclib on the neutrophil lineage compared with placebo 	<ul style="list-style-type: none"> Duration of severe (Grade 4) neutropenia in Cycle 1 Occurrence of severe (Grade 4) neutropenia Occurrence of febrile neutropenia AEs Occurrence of G-CSF administration
<ul style="list-style-type: none"> To assess the effects of trilaciclib on the RBC lineage compared with placebo 	<ul style="list-style-type: none"> Occurrence of Grade 3 or 4 decreased hemoglobin laboratory values RBC transfusions on or after Week 5 (occurrence and number of transfusions) Occurrence of ESA administration
<ul style="list-style-type: none"> To assess the effects of trilaciclib on the platelet lineage compared with placebo 	<ul style="list-style-type: none"> Occurrence of Grade 3 or 4 decreased platelet count laboratory values Platelet transfusions (occurrence and number of transfusions)
<ul style="list-style-type: none"> To assess the effects of trilaciclib on chemotherapy dosing compared with placebo 	<ul style="list-style-type: none"> All-cause dose reductions (occurrence and number of reductions) All-cause cycle delays (occurrence and number of delays)
<ul style="list-style-type: none"> To assess the effects of trilaciclib on hospitalizations due to chemotherapy-induced myelosuppression compared with placebo 	<ul style="list-style-type: none"> Occurrence and number of hospitalizations due to chemotherapy-induced myelosuppression
Secondary Objective: to evaluate the safety of trilaciclib compared with placebo	
<ul style="list-style-type: none"> To assess the safety and tolerability of trilaciclib compared with placebo 	<ul style="list-style-type: none"> Occurrence and severity of AEs by NCI-CTCAE v5 Study treatment discontinuation due to AEs Changes in laboratory parameters (hematology, chemistry), vital signs and ECG parameters Grade 3 or 4 abnormalities in laboratory parameters Trilaciclib AESIs Chemotherapy infusion interruptions Relative dose intensity for docetaxel

Objectives	Endpoints
Exploratory Objectives	
<ul style="list-style-type: none"> To assess the anti-tumor efficacy of trilaciclib by CDK4/6-dependence status 	<ul style="list-style-type: none"> OS, PFS, and ORR (per RECIST v1.1) in patients with each of the following CDK4/6 dependence signatures: <ul style="list-style-type: none"> CDK4/6 dependent CDK4/6 independent CDK4/6 indeterminant
<ul style="list-style-type: none"> To assess the anti-tumor efficacy of trilaciclib by PD-L1 subgroups 	<ul style="list-style-type: none"> OS, PFS, ORR, and DOR in ITT population by PD-L1 subgroups (as measured by retrospective analysis)
<ul style="list-style-type: none"> To characterize the population PK of trilaciclib and identify important determinants of variability 	<ul style="list-style-type: none"> Exposure-response relationship between trilaciclib and response or safety endpoints
<ul style="list-style-type: none"> Estimate the PK parameters of docetaxel using a population PK model 	<ul style="list-style-type: none"> Clearance Volume of distribution

Objectives	Endpoints
<ul style="list-style-type: none"> To assess the effect of trilaciclib on CIM- and disease-related symptoms and functional limitations 	<p>Change from baseline and/or time to deterioration in:</p> <ul style="list-style-type: none"> EORTC QLQ-C30 domain scores EORTC QLQ-LC13 domain scores <u>(including additional EORTC with supplemental weight loss item) (EORTC IL118) domain scores</u> FACIT-Fatigue total score EQ-5D-5L <p>Percent of patients reporting deterioration and improvement using:</p> <ul style="list-style-type: none"> PGIC fatigue item PGIS fatigue item
<ul style="list-style-type: none"> To assess the pharmacodynamic effects, including immune based mechanism, of trilaciclib when added to docetaxel in peripheral blood 	<ul style="list-style-type: none"> Differences in pharmacodynamic parameters, including those relating to immune-based mechanisms, in peripheral blood

AE=adverse event; AESI=adverse event of special interest; BOR=best overall response; CDK=cyclin-dependent kinase; CIM=chemotherapy-induced myelosuppression; DOR=duration of response; ECG=electrocardiogram; EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire; EORTC QLQ-LC13=European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module; EORTC IL118= European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module with supplemental weight loss item; EQ-5D-5L=5-level EQ-5D; ESA=erythropoiesis stimulating agent; FACIT-Fatigue=Functional Assessment of Chronic Illness Therapy – Fatigue; G-CSF=granulocyte colony-stimulating factor; IV=intravenous; NCI=National Cancer Institute; NSCLC=non-small cell lung cancer; ORR=objective response rate; OS=overall survival; PFS=progression free survival; PGIC=Patient Global Impression of Change; PGIS=Patient Global Impression of Severity; PK=pharmacokinetic(s); PR=partial response; RBC=red blood cell; RECIST=Response Evaluation Criteria in Solid Tumors

6 INVESTIGATIONAL PLAN

6.1 Overall Study Design

This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib compared with placebo on OS in patients with metastatic NSCLC receiving docetaxel in the 2nd or 3rd line setting. Patients must have documented disease progression during or after 1 or 2 lines of systemic therapy for recurrent or metastatic NSCLC. Prior treatment must have included, either in the same line or as separate lines of therapy: 1) a maximum of 1 line of platinum-containing chemotherapy in the recurrent/metastatic setting and 2) a maximum of 1 line of a locally approved/authorized PD-1/PD-L1 monoclonal antibody (mAb) containing regimen in the recurrent/metastatic setting.


Approximately 146 patients will be randomly assigned (1:1) to receive trilaciclib or placebo by IV prior to docetaxel on Day 1 of each 21-day cycle. There will be 2 stratification factors for randomization: Country, and ECOG performance status (0-1 versus 2). Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2).

Study drugs administered are as follows:

- Trilaciclib (240 mg/m²) or placebo – administered as a 30-minute IV infusion no more than 4 hours prior to chemotherapy on each day chemotherapy is administered (Section 9.1.1).
- Docetaxel 75 mg/m² –IV, Day 1

The study will include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase (Figure 4). The Treatment Phase begins on the day of randomization for the first patient and completes at the Post-Treatment Visit for the last patient. The first Survival Follow-up assessment should occur approximately 2 months after the last dose of study drug.

Figure 4: Study Design



D=day; PD=progressive disease, WD=withdraw, DC=discontinue

Criteria which patients must meet in order to receive study drug on Day 1 are provided in Section 9.2. Treatment cycles will occur consecutively without interruption, except when necessary to manage toxicities or for administrative reasons. Study drug administration will continue until disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or clinical progression as determined by the Investigator, unacceptable toxicity, withdrawal of consent, discontinuation by Investigator, or the end of the trial, whichever occurs first.

A post-treatment visit will occur approximately 30 days (± 7 days) following the last dose of study drug. Upon discontinuation of study treatment, patients will be followed for survival, i.e., patients or their caregivers will be contacted approximately every 2 months until the end of the study (or death) to record their status (alive or dead) as well as details of any subsequent systemic anti-cancer therapy initiated. These survival follow-ups may be done via telephone, email, or clinic visit.

The duration of total follow-up relative to the first patient being randomized is approximately 30 months to collect the target number of deaths per sample size calculation. If assumptions vary in the study conduct, the study duration will be event-driven. That is, the study will continue until the targeted number of deaths is observed. There is an interim analysis for OS. If the interim results demonstrate a statistically significant effect of trilaciclib over placebo for OS based on pre-specified criterion, the study will be stopped early due to success. Otherwise, the study will be completed when the criteria outlined in Section 10.4 have been met, or upon sponsor termination of the study.

6.2 Rationale for Primary and Secondary Endpoints

6.2.1 Anti-tumor Efficacy

Measurements of anti-tumor response rates by RECIST, in addition to OS and PFS, are standard assessments used in oncology solid tumor studies to measure the effects of study treatment on the underlying malignant disease. Additionally, clinical benefit in oncology should be based on direct evidence, such as improvement in duration of overall survival, improvement in a patient's quality of life, improved physical functioning, or improved tumor-related symptoms, which may not be adequately measured by response rates alone. Therefore, improvement in survival is considered one of the most reliable measures providing direct evidence of clinical benefit to patients and is a preferred clinical endpoint. Survival is considered easy to measure via documentation of the date of death and is not prone to bias (FDA, 2008).

6.2.2 Myelopreservation Efficacy

Patients experiencing CIM often face severe clinical consequences (e.g., FN, bleeding, fatigue) leading to the need for hospitalizations, hematopoietic growth factor support, transfusions (RBCs and/or platelets) and even death (Caggiano, 2005; Gustinetti, 2016; Bodey, 1966; Li, 2016). Moreover, CIM commonly leads to dose reductions and delays, which limit therapeutic dose intensity and can compromise the anti-tumor efficacy benefits of chemotherapy. In 3 randomized, double-blind, placebo-controlled SCLC trials, the myelopreservation endpoints proposed in this clinical study were utilized to evaluate the efficacy of trilaciclib in reducing CIM. These endpoints proved to be robust measures of trilaciclib's myelopreservation efficacy and clinically meaningful improvements in multiple endpoints were observed across the 3 studies. This study will further investigate the impact of trilaciclib on CIM when used in combination with docetaxel.

6.2.3 Patient-Reported Outcomes

Throughout the trilaciclib clinical development program, patient-reported outcome (PRO) instruments have been evaluated in all randomized clinical trial settings. While exploratory endpoints in each of those studies, an integrated analysis of data collected in the 3 SCLC studies suggests that trilaciclib added to chemotherapy can delay or prevent deterioration in multiple aspects of health-related quality of life. In these studies, trilaciclib generally maintained or reduced fatigue levels across cycles and prevented clinically meaningful increases in fatigue, which are commonly associated with myelosuppression. In G1T28-04 with TNBC patients, patients in the trilaciclib groups were less likely to have a deterioration in their symptoms, and in some cases had improvement in their symptoms, through the first 6 cycles of therapy (last time point evaluated). Trilaciclib delayed deterioration of patient functioning and symptoms measures over time compared with GC alone; suggesting that patients on trilaciclib (compared with GC alone) had a better experience receiving chemotherapy. This study will further investigate the patient experience and potential benefit to NSCLC patients receiving trilaciclib.

6.2.4 Safety

Assessment of AEs, changes in laboratory parameters, electrocardiogram (ECG) parameters, vital signs, and ECOG status are all standard assessments used in oncology trials to measure patient safety.

6.3 Rationale for Dose and Schedule of Study Treatment

6.3.1 Trilaciclib

Previous studies demonstrated the RP2D of trilaciclib was 240 mg/m². When trilaciclib was administered prior to chemotherapy to cancer patients, doses of 200 (rounded up from 192), 240, and 280 mg/m² were evaluated. Trilaciclib exposures in cancer patients were slightly lower compared with healthy subjects, such that the dose of 240 mg/m² (rather than 200 mg/m²) more closely matched the biologically effective dose (BED) of 192 mg/m². In addition, the dose of 240 mg/m² demonstrated maximal myelopreservation efficacy benefits (compared with 200 and 280 mg/m²) as measured by a variety of myelosuppression endpoints. The myelopreservation effect at 240 mg/m² was further evaluated and confirmed in three randomized controlled Phase 2 studies in SCLC patients. In addition, the planned dose was used in a previous TNBC study (G1T28-04) and demonstrated clinically meaningful benefits in OS duration. See the trilaciclib IB for details.

In addition, at the RP2D, trilaciclib has a limited toxicity profile and minimal overlapping toxicities are expected with docetaxel (Section 4.2.9). The primary AEs anticipated with trilaciclib are low grade injection site reactions including phlebitis/thrombophlebitis. These infusion reactions have generally been mild and occur in association with drug delivery through peripheral access. Central access is likely to reduce/eliminate these issues. The remainder of the trilaciclib AESIs to date have been uncommon and for most, the percentage of patients experiencing these AESIs is not clearly increased in patients receiving trilaciclib compared to placebo. Based on these results a dose-finding study is not needed.

In order to preserve hematopoietic stem and progenitor cells (HSPCs) as well as immune system function during chemotherapy, trilaciclib is always administered prior to systemic chemotherapy (docetaxel), on each day of chemotherapy administration. Trilaciclib will not be administered as monotherapy (i.e., on days that chemotherapy will be delayed).

6.3.2 Docetaxel

The dose and schedule of docetaxel is described in Section 9.1.1.2. This is consistent with standard of care as established in clinical trials (Shepherd, 2000; Garon, 2014), and the approved labeling for this product (NCCN, 2020; Taxotere, 2020; Taxotere, 2005).

6.4 Rationale for Supportive Care Interventions

Per NCCN guidelines docetaxel, as utilized in NSCLC, is considered an intermediate risk regimen with a risk of FN between 10 and 20%. At this level of risk, guidelines do not require routine prophylactic granulocyte colony-stimulating factor (G-CSF) in Cycle 1 (NCCN, 2020b). Therefore, in order to facilitate an unbiased evaluation of trilaciclib effects on the hematologic and pharmacodynamic endpoints, primary prophylactic G-CSF will be prohibited in Cycle 1; however therapeutic G-CSF (administered in response to a neutropenic event) in Cycle 1 and secondary prophylactic G-CSF beginning in Cycle 2 and for all subsequent cycles (i.e., after a precipitating event in a prior cycle of therapy) will be allowed per growth factor/neutropenia management guidelines in Section 9.4 and Investigator discretion (Aapro, 2010; Smith, 2015).

Erythropoiesis-stimulating agent (ESA) administration and RBC or platelet transfusions will be allowed per Investigator discretion based on guidelines detailed in Section 9.4.2 and Section 9.4.3. While these interventions may confound analysis of the myelosuppression

endpoints, allowing physicians to provide appropriate supportive care to patients will facilitate patient safety.

6.5 Rationale for Patient Population

Though immunotherapy has markedly improved the treatment of metastatic NSCLC, options following disease progression remain limited. An alternative therapy that extends the duration of OS without significant additive toxicity, while concurrently decreasing myelosuppression and improving quality of life, would be a welcome addition in this heavily pretreated and often clinically fragile patient population. Therefore, further evaluation of trilaciclib in this area of high unmet medical need is warranted.

6.6 Rationale for Stratification Factors

As outlined in Section 6.1, randomization will be stratified by country and ECOG performance status. Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2). These factors were chosen because they are predicted to have an impact on the primary endpoint of overall survival, and in some cases the secondary myelopreservation endpoints, such that if there is an imbalance in these factors, interpretation of the results of the study could be compromised.

Country was chosen as a stratification factor to account for the geographic differences in patient populations, treatment practice patterns and access to supportive care and subsequent anti-cancer therapy; all of which could influence the primary and secondary endpoint outcomes.

Performance status is an established indicator of survival and treatment tolerance. Those with ECOG performance status of 2 typically have shorter survival times and greater toxicity with subsequent therapeutic interventions (Sweeney, 2001; Jang, 2014). However, this group in particular may derive benefit from the myelopreservation and limited toxicity seen with trilaciclib and has few well-tolerated alternative options. As such, these patients will be eligible but stratified by ECOG performance status (0-1 versus 2) in order to minimize any impact on survival outcomes.

7 STUDY POPULATION

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as a protocol waiver or exemption, is not permitted.

7.1 Inclusion Criteria

Patient eligibility should be reviewed and documented by an appropriately qualified member of the investigator study team before patients are included in the study. Patients must meet *all* of the following inclusion criteria to be eligible for enrollment into the study:

1. Age ≥ 18 years of age at the time of signing the informed consent.
2. Histologically or cytologically confirmed metastatic NSCLC (squamous or nonsquamous) with no known actionable driver mutations (ex. EGFR, ROS1, ALK).
 - Patients must have had documented disease progression during or after 1 or 2 lines of systemic treatment for recurrent or metastatic disease.

- Two components of treatment must have been received in the same line or as separate lines of therapy: (i) a maximum of 1 line of platinum-containing chemotherapy regimen for recurrent/metastatic disease, and (ii) a maximum of 1 line of a locally approved/authorized PD-1/PD-L1 mAb containing regimen for recurrent/metastatic disease.
 - Maintenance therapy following platinum doublet-based chemotherapy is not considered as a separate line of therapy. Maintenance therapy is defined as therapy given within 42 days after the last dose of platinum-based chemotherapy in patients with ongoing clinical benefit (complete response [CR], partial response [PR] or stable disease [SD]).
3. Measurable or non-measurable disease per RECIST v1.1
 4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
 5. A formalin-fixed paraffin-embedded (FFPE) tumor specimen (from archival or fresh biopsy) with an associated pathology report documenting NSCLC must be available to send to the Sponsor, within the specified timeframe, for planned retrospective biomarker analyses (see Section 11.6.1).
 6. Adequate organ function defined by the following laboratory values:
 - a) Hemoglobin ≥ 9.0 g/dL in the absence of RBC transfusion or ESA administration within 14 days prior to first dose of trilaciclib/placebo
 - b) Absolute neutrophil count (ANC) $\geq 1.5 \times 10^9/\text{L}$
 - c) Platelet count $\geq 100 \times 10^9/\text{L}$
 - d) Total bilirubin \leq upper limit of normal (ULN)
 - e) AST/ALT $< 1.5 \times \text{ULN}$ if alkaline phosphatase $> 2.5 \times \text{ULN}$
 - f) If alkaline phosphatase $< 2.5 \times \text{ULN}$ then AST, ALT $< 2.5 \times \text{ULN}$ in the absence of liver metastasis or $< 5 \times \text{ULN}$ in the presence of liver metastasis
 - g) Estimated glomerular filtration rate ≥ 30 mL/minute/ 1.73m^2
 7. Resolution of nonhematologic toxicities per National Cancer Institute Common Terminology Criteria Version 5.0 (NCI-CTCAE) from prior therapy or surgical procedures to \leq Grade 1 or baseline (except alopecia).
 8. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Please see Section 17.3 for detailed instructions on methods of contraception requirements.
 9. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

7.2 Exclusion Criteria

A patient will not be eligible for participation in this study if *any* of the following criteria apply:

1. Prior therapy with docetaxel.

2. Any contraindication to the administration of docetaxel at the discretion of the investigator.
3. Mixed NSCLC/SCLC, or lung tumors whose predominant histology is sarcomatoid, or neuroendocrine.
4. Any chemotherapy, immunotherapy, biologic, investigational, or hormonal therapy for cancer treatment (except for adjuvant hormonal therapy for breast cancer or prostate cancer defined as M0 disease or prostate-specific antigen (PSA) persistence/recurrence without metastatic disease) within 3 weeks prior to the first dose of trilaciclib/placebo.
5. Any radiotherapy within 2 weeks prior to the first dose of trilaciclib/placebo.
6. Presence of central nervous system (CNS) metastases requiring immediate treatment with radiation therapy or steroids (i.e., patient must be off steroids administered for brain metastases for at least 14 days prior to the first dose of trilaciclib/placebo).
7. Presence of leptomeningeal disease.
8. Significant third-space fluid retention (ex. ascites or pleural effusion) not amenable to required repeat drainage.
9. QT corrected using Fridericia's formula (QTcF) interval >480 msec at screening (confirmed on repeat). For patients with ventricular pacemakers, QTcF >500 msec.
10. Symptomatic peripheral neuropathy (\geq Grade 2 NCI-CTCAE v5.0)
11. History of interstitial lung disease (ILD)
12. Clinically significant (i.e., active) cardiovascular disease at the time of signing the informed consent; for example cerebrovascular accidents (\leq 6 months before the first dose of trilaciclib/placebo), myocardial infarction (\leq 6 months before the first dose of trilaciclib/placebo), unstable angina, serious cardiac arrhythmia requiring medication, or uncontrolled symptomatic congestive heart failure [Class II or higher as defined by the New York Heart Association [NYHA] functional classification system])
13. Known serious active infection ~~(e.g., including but not limited to~~ human immunodeficiency virus ~~[(HIV), hepatitis] (e.g., viral load indicative of HIV, HIV 1/2 antibodies), Hepatitis B (e.g., HBsAg reactive or HBV DNA detected), Hepatitis C, (e.g., HCV RNA [quantitative] is detected) or tuberculosis, etc.)~~
14. Prior allogeneic or autologous hematopoietic stem cell or bone marrow transplantation
15. Receipt of any low-dose systemic chemotherapeutic agent (e.g., low-dose methotrexate for rheumatoid arthritis) administered for a nononcologic purpose within 3 weeks prior to the first dose of trilaciclib/placebo.
16. Receipt of any live attenuated vaccines within 4 weeks prior to first dose of study treatment or anticipation that such a vaccine will be required during the study treatment period.

17. Known hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80 or any excipients of trilaciclib
18. Pregnant or lactating women
19. Legal incapacity or limited legal capacity
20. Other uncontrolled serious chronic disease or psychiatric condition that in the Investigator's opinion could affect patient safety, compliance, or follow-up in the protocol
21. Concurrent participation in any other interventional clinical trial.

8 SCHEDULE OF ASSESSMENTS

The procedures and assessments to be performed during the study are outlined in [Table 6](#). The timing and number of samples collected for biomarker testing may be altered based on emerging data without requiring an amendment if the blood volume per day or overall does not increase and the patient is not required to have additional clinic visits or prolongation of a clinic visit, i.e., the risk-benefit profile for the patient does not worsen.

When there are multiple procedures at the same or overlapping time points, order of events should be: patient reported outcome measures, ECGs, vitals, blood draw. Unscheduled assessments and visits to manage patient safety may occur at the Investigator's discretion. Study procedures performed at unscheduled visits should be recorded in the appropriate electronic case report form (eCRF).

Table 6: Schedule of Assessments

Assessment	Screening	Rand	21 Day Treatment [Cycles]						Post-Treatment Visit	Survival Follow-Up	Details Provided in Section
			Cycle 1					Cycle 2 and beyond			
Day	-28 to -1	-3 to -1	1	5 (±1 day)	9 (±1 day)	13 (±1 day)	17 (±1 day)	1 ^a	30 ±7d post-last dose	Every 2 months	
Informed Consent	X										Section 13.3
Demographics	X										Section 11.1.2
Medical History and NSCLC History	X										Section 11.1.3
Eligibility Evaluation and Randomization	X	X									Section 11.1.1, Section 7.1, and Section 7.2
Archived Tumor Sample	X										Section 11.6.1
ECOG Performance Status	X		X					X	X		Section 11.3.3
Complete physical exam, including height and weight	X										Section 11.3.2
Brief physical exam, including weight			X					X	X		Section 11.3.2
Vital Signs	X		X					X	X		Section 11.3.1
12-lead Electrocardiogram	X		X					X [C2 only]			Section 11.3.4

Assessment	Screening	Rand	21 Day Treatment [Cycles]						Post-Treatment Visit	Survival Follow-Up	Details Provided in Section
			Cycle 1					Cycle 2 and beyond			
Day	-28 to -1	-3 to -1	1	5 (±1 day)	9 (±1 day)	13 (±1 day)	17 (±1 day)	1 ^a	30 ±7d post-last dose	Every 2 months	
Clinical Chemistry	X		X					X	X		Section 11.3.5
Hematology	X		X	X	X	X	X	X	X		Section 11.3.5
Pregnancy Test (WOCBP)		X	X					X	X		Section 11.3.5
Tumor Assessment by RECIST v1.1	X		X (every 6 weeks from C1D1)							X	Section 11.2.1
Trilaciclib or Placebo			X					X			Section 9.1.1.1
Docetaxel			X					X			Section 9.1.1.2
EORTC QLQ-C30, EORTC QLQ-LC13 (including with supplemental weight loss item (EORTC IL118)) , FACIT-Fatigue, PGIS, and EQ-5D-5L			X			X		X	X		Section 11.4
PGIC						X		X	X		Section 11.4
Blood Sample for PK			X								Section 11.5

Assessment	Screening	Rand	21 Day Treatment [Cycles]						Post-Treatment Visit	Survival Follow-Up	Details Provided in Section
			Cycle 1					Cycle 2 and beyond			
Day	-28 to -1	-3 to -1	1	5 (±1 day)	9 (±1 day)	13 (±1 day)	17 (±1 day)	1 ^a	30 ±7d post-last dose	Every 2 months	
Blood Sample for Immunologic and Hematologic Markers			X		X			X [C2, C3, C5 only]			Section 11.7
Survival Contact and Subsequent Anti-cancer Therapies										X	Section 11.10
AEs			X								Section 11.3.6
Concomitant Medications	X	X	X								Section 11.1.3

AE=adverse event; β-hCG=beta human chorionic gonadotropin; ECOG=Eastern Cooperative Oncology Group; EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire; EORTC QLQ-LC13=European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module; [EORTC IL118=European Organisation for Research and Treatment of Cancer Quality of Life Lung Cancer Module with supplemental weight loss item](#); EQ-5D-5L=5-level EQ-5D; FACIT-Fatigue=Functional Assessment of Chronic Illness Therapy – Fatigue; NSCLC=non-small cell lung cancer; PGIC=Patient Global Impression of Change; PGIS=Patient Global Impression of Severity; PK=pharmacokinetic; Rand=randomization; RECIST=Response Evaluation Criteria in Solid Tumors; WOCBP=women of childbearing potential.

^a There should be no more than 5 weeks (for toxicity and/or administrative reasons) between doses of chemotherapy; however dosing delays >5 weeks may be permitted on a case by-case basis with the documented approval of the Investigator and Medical Monitor.

9 STUDY TREATMENT

9.1 Study Drugs Administered

Study drugs are defined as any investigational agent(s), marketed product(s), or placebo intended to be administered to a study patient according to the study protocol. Study drugs used in this protocol are described in [Table 7](#).

Table 7: Study Drugs

	Study Drugs		
Product Name:	Trilaciclib	Placebo	Docetaxel
Type	Investigational product	Placebo	Chemotherapy
Dosage Formulation:	Single-use, sterile powder to be reconstituted with 250 mL of dextrose 5% in water (D5W) or normal saline (sodium chloride solution 0.9%) per the Pharmacy Manual	250 mL of dextrose 5% in water (D5W) or normal saline (sodium chloride solution 0.9%)	Description of the formulation is provided in the current prescribing information (Taxotere, 2020 ; Taxotere, 2005)
Unit Dose Strength(s)	300 mg/20 mL	N/A	See current prescribing information
Dosage Level(s)	240 mg/m ²	N/A – administered on Day 1 to match trilaciclib	75 mg/m ²
Route of Administration	IV	IV	IV
Infusion Time	30 minutes	30 minutes	1 hour or per Institutional Standards

IV=intravenous; N/A=not applicable.

9.1.1 Dose, Dosing Regimen, and Route

9.1.1.1 Trilaciclib/Placebo

Trilaciclib for Injection, 300 mg/vial (also referred to as “Trilaciclib Sterile Powder for concentrate for solution for IV infusion, 300 mg/vial”) is supplied as a sterile, preservative-free, yellow, lyophilized cake in a single-dose vial (300 mg/20 mL).

Trilaciclib must be reconstituted and further diluted prior to IV infusion as outlined in the Pharmacy Manual. Aseptic technique must be used for reconstitution and dilution. ~~Upon reconstitution, the solution must then be diluted to the calculated dose based on the body surface area (BSA) of the patient.~~ BSA should be calculated as per institutional practice. Actual body weight (not “adjusted” body weight) should be utilized for dose calculations. If there is a change in body weight $\geq 10\%$ relative to the weight at the time of the last dose calculation, dose should be recalculated. Recalculation of dose more frequently per local institutional guidelines is permitted. Dose recalculation to adjust for changes in body weight will not be considered a dose reduction and will be made at the discretion of the Investigator.

The placebo, either 250 mL of dextrose 5% in water (D5W) or sodium chloride solution 0.9%, will be administered by IV infusion over approximately 30 minutes by peripheral or central access.

9.1.1.1.1 Administration of Trilaciclib/Placebo

- Administer diluted trilaciclib solution or placebo as a 30-minute IV infusion completed within 4 hours prior to the start chemotherapy. Do not administer trilaciclib/placebo as a bolus.
- Trilaciclib/placebo is always administered first. Results from hematology labs should be reviewed prior to administration of trilaciclib/placebo. If administration of docetaxel therapy is delayed or discontinued, trilaciclib/placebo will also be delayed or discontinued.
- Diluted trilaciclib/placebo solution must be administered with an infusion set, including an in-line filter (0.2 or 0.22 micron). Compatible in-line filters include polyethylene sulfone, polyvinylidene fluoride, and cellulose acetate.
- Do not administer diluted trilaciclib/placebo solution with a polytetrafluorethylene (PTFE) in-line filter. PTFE in-line filters are not compatible with diluted trilaciclib/placebo solution.
- Do not co-administer other drugs through the same infusion line.
- Do not co-administer other drugs through a central access device unless the device supports co-administration of incompatible drugs.

Upon completion of infusion of diluted trilaciclib/placebo solution, the infusion line/cannula must be flushed with at least 20 mL sterile D5W or 0.9% normal saline.

The infusion rate may be decreased to manage an infusion-related AE; for example, if a patient experiences a burning sensation during infusion, the duration of infusion may be increased to 45 minutes (or longer if clinically indicated) to alleviate the symptoms. ~~The actual start/stop time of infusion will be documented and entered in the eCRF.~~

9.1.1.2 Docetaxel

Docetaxel will be administered IV in accordance with the prescribing information/summary of product characteristics ([Taxotere, 2020](#); [Taxotere, 2005](#)) and according to the study site's standard practice. Protocol-specified doses of docetaxel will be administered IV in accordance with institutional guidelines and the recommended instructions below. Deviation from the recommendations provided in this protocol in order to follow institutional guidelines must receive prior approval from the Medical Monitor or Sponsor.

Actual body weight (not ideal body weight) should be utilized for dose calculations. At a minimum, if there is a change in body weight of >10% relative to the weight at the time of the last dose calculation, doses should be recalculated. Recalculation of the dose more frequently per local institutional guidelines is permitted. Dose recalculation to adjust for changes in body weight will not be considered a dose reduction.

Trilaciclib/placebo is always administered first, followed by docetaxel. Administer diluted trilaciclib solution or placebo as a 30-minute IV infusion to be completed within 4 hours prior to the start chemotherapy. Docetaxel may be administered immediately following trilaciclib/placebo, but not until the completion of the trilaciclib/placebo infusion. If

administration of trilaciclib/placebo is delayed or discontinued, docetaxel will also be delayed or discontinued. Likewise, if docetaxel is delayed or discontinued, trilaciclib/placebo will also be delayed or discontinued.

9.1.2 Preparation, Handling, Storage, and Accountability

The Investigator or institution is responsible for study drug accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records). The Investigator/institution may assign some or all of the Investigator's/institution's duties for investigational product(s) accountability to an appropriate pharmacist or another appropriate individual who is under the supervision of the Investigator/institution.

Further guidance and information are provided in the Pharmacy Manual.

9.1.3 Treatment Compliance

The Investigator or designee will dispense the study drugs, via an unblinded Pharmacist/Designee, only for use by patients enrolled in the study as described in this protocol. The study drugs are not to be used for reasons other than those described in this protocol. The clinical study site will maintain records of study drugs' receipt, preparation, and dispensing, including the applicable lot numbers; patient's height, body weight, and body surface area; date and time of the start and end of each trilaciclib or placebo and docetaxel infusion; and total drug administered in milligrams. Any discrepancy between the calculated dose and dose administered and the reason for the discrepancy (e.g., interruption of infusion without restarting) will be recorded on eCRF and in the source documents.

9.2 Criteria for Starting Each Cycle

~~Please note the ANC for Cycle 1 Day 1 is required to be $\geq 1.5 \times 10^9/L$. Following completion of Cycle 1, patients~~ Patients must meet all the following minimum criteria to receive study treatment on Day 1 for Cycle ~~2~~1 and each subsequent cycle:

- $ANC \geq 1.05 \times 10^9/L$,
- Platelet count $\geq 50100 \times 10^9/L$
- Total bilirubin \leq upper limit of normal (ULN)
- $AST/ALT \leq 1.5 \times ULN$ if alkaline phosphatase $> 2.5 \times ULN$
- Other nonhematologic drug-related toxicities (excluding alopecia) must be \leq Grade 1 or have returned to baseline.

For dose delays due to toxicity, the patient should be followed (at least) weekly, including CBCs if the AE is hematologic, to monitor the toxicity until treatment criteria described above are met or until they discontinue treatment (e.g., if more than 5 weeks elapse from the last chemotherapy dose). If the Day 1 dose is delayed, any assessments completed as part of the planned Day 1 visit will be captured in the eCRF as unscheduled visits. The PRO questionnaires should be completed on both the planned Day 1 visit and on the actual Day 1 of the cycle (i.e., when criteria are met to proceed with Day 1 treatment).

There should be no more than 5 weeks (for toxicity and/or administrative reasons) between doses of chemotherapy; however dosing delays > 5 weeks may be permitted on a case by-case basis with the documented approval of the Investigator and Medical Monitor.

In both the trilaciclib and placebo arms, study drug administration will continue until progressive disease per RECIST v1.1 or clinical progression as determined by the Investigator, unacceptable toxicity, withdrawal of consent, Investigator decision, or the end of the study.

9.3 Toxicity Management and Dose Modifications

The dose of trilaciclib will not be modified and will remain at 240 mg/m² throughout the study. If administration of docetaxel therapy is discontinued, trilaciclib will also be discontinued.

The dose of docetaxel can be reduced when necessary as described below. The recommended dose modification procedures for hematologic toxicities are described in [Table 9](#). If a subsequent cycle is delayed for toxicity, the patient should still complete the clinical laboratory assessments on the scheduled Day 1 (entered as an Unscheduled assessment in EDC) as well as on the actual first dosing day of that cycle. If the delay is secondary to hematologic toxicity, weekly repeat hematology assessments should continue until the finding meets criteria for resumption of dosing.

Non-hematologic toxicities should be managed as per standard of care for docetaxel. Recommendation for management of trilaciclib/placebo AEs are provided in [Table 10](#). Recommendations for hepatobiliary toxicity management are in [Section 9.3.4](#). All recommendations are intended as a minimum guideline for toxicity management and are not a replacement for independent medical judgement tailored to specific circumstances with an individual patient. Please also refer to the individual package insert/summary of product characteristics ([Taxotere, 2020](#); [Taxotere, 2005](#)) for additional information and recommendations.

9.3.1 Dose reduction

Recommended dose levels for reduction of docetaxel dose are described in [Table 8](#). Chemotherapy dose reductions for hematologic toxicities should be based on values obtained within 24 hours prior to Day 1 of a given cycle. All dose reductions for an individual patient are permanent; and the dose, which has been reduced for toxicity, must not be re-escalated. Up to a maximum of 2 dose reductions will be allowed per patient. If a third dose reduction is required per the modifications below, the patient should discontinue study treatment.

Table 8: Recommended Chemotherapy Dose Modifications

	Docetaxel
Starting Dose	75 mg/m ²
Dose Level -1	60 mg/m ²
Dose Level -2	50 mg/m ²

No dose modification is permitted for trilaciclib.

Note that dose modifications (specifically dose reductions/discontinuations) are recommended for those events considered related to drug (i.e., toxicities) such that decreasing the dose or stopping the drug will lead to improved patient safety. If an event is not thought to be related to study drug by the Investigator, dose reduction/discontinuation is not required since decreasing the dose or stopping the drug would not be expected to alter the risk of the event occurring again; rather the Investigator should consider if treatment should be delayed until the event recovers to ≤Grade 1 or baseline before resumption of treatment.

Decreased neutrophil, platelet counts or hemoglobin values that occur in isolation (e.g., at nadir) that do not result in a dosing delay, FN, serious adverse event (SAE) or other consequence, do not require dose modification.

If drug-related toxicity requires discontinuation of docetaxel or trilaciclib then the patient must permanently discontinue all study drugs and should complete the Post-Treatment Visit and enter Survival Follow-up.

9.3.2 Safety Criteria for Adjustment or Stopping Doses

Table 9: Recommended Dose Modification for Drug-Related Hematologic Toxicity

Event, CTCAE Grade or Lab Value	Frequency	Action Taken		
		Trilaciclib	Docetaxel	Toxicity Management
ANC <1.05 x 10 ⁹ /L (≥Grade 32)	1 st occurrence	Hold drug until ANC criteria for dosing reached. No change in dose.	Hold drug until ANC criteria for dosing reached. No change in dose.	Administer prophylactic G-CSF with each subsequent cycle of chemotherapy.
	2 nd occurrence	Hold drug until ANC criteria for dosing reached. No change in dose.	Hold drug until ANC criteria for dosing reached. Reduce dose of docetaxel by one dose level and resume dosing.	
	3 rd occurrence	Hold drug until ANC criteria for dosing reached. No change in dose.	Hold drug until ANC criteria for dosing reached. Reduce dose of docetaxel by one more dose level and resume dosing.	
	4 th occurrence	Permanently discontinue		
<u>Febrile neutropenia (Grade 3 or 4)</u> <u>OR</u> <u>Grade 4 Neutropenia lasting >7 days</u>	<u>1st occurrence</u>	<u>Hold drug until ANC criteria for dosing reached. No change in dose.</u>	<u>Hold drug until ANC criteria for dosing reached. Reduce dose of docetaxel by one dose level and resume dosing.</u>	<u>Administer prophylactic G-CSF with each subsequent cycle of chemotherapy.</u>
	<u>2nd occurrence</u>	<u>Hold drug until ANC criteria for dosing reached. No change in dose.</u>	<u>Hold drug until ANC criteria for dosing reached. Reduce dose of docetaxel by one more dose level and resume dosing.</u>	
	<u>3rd occurrence</u>	<u>Permanently discontinue</u>		
<u>Platelets <100 - 75 x 10⁹/L (Grade 1)</u>	<u>Any occurrence</u>	<u>Hold drug until platelet criteria for dosing reached. No change in dose.</u>	<u>Hold drug until platelet criteria for dosing reached. No change in dose.</u>	<u>Monitor for signs and symptoms of bleeding. Consider treatment as clinically indicated</u>

Event, CTCAE Grade or Lab Value	Frequency	Action Taken		
		Trilaciclib	Docetaxel	Toxicity Management
<u>Platelets</u> <u><75 - 50 x10⁹/L</u> <u>(Grade 2)</u>	<u>1st Occurrence</u>	<u>Hold drug until platelet criteria for dosing reached. No change in dose.</u>	<u>Hold drug until platelet criteria for dosing reached. No change in dose.</u>	<u>Monitor for signs and symptoms of bleeding. Consider treatment as clinically indicated</u>
	<u>2nd Occurrence</u>	<u>Hold drug until platelet criteria for dosing reached. No change in dose.</u>	<u>Hold drug until platelet criteria for dosing reached. Reduce dose of docetaxel by one dose level and resume dosing.</u>	
	<u>3rd Occurrence</u>	<u>Hold drug until platelet criteria for dosing reached. No change in dose.</u>	<u>Hold drug until platelet criteria for dosing reached. Reduce dose of docetaxel by one dose level and resume dosing.</u>	
	<u>4th Occurrence</u>	<u>Permanently discontinue</u>		
Platelets <50 x 10 ⁹ /L (≥Grade 3) OR Symptomatic thrombocytopenia (severe or medically significant bleeding)	1 st occurrence	Hold drug until platelet criteria for dosing reached. No change in dose.	Hold drug until platelet criteria for dosing reached. Reduce dose of docetaxel by one dose level and resume dosing.	Monitor for signs and symptoms of bleeding. Consider treatment as clinically indicated
	2 nd occurrence	Hold drug until platelet criteria for dosing reached. No change in dose.	Hold drug until platelet criteria for dosing reached. Reduce dose of docetaxel by one more dose level and resume dosing.	
	3 rd occurrence	Permanently discontinue		
<u>Febrile neutropenia</u> <u>(Grade 3 or 4)</u> OR <u>Grade 4 Neutropenia</u> <u>lasting >5 days</u>	<u>1st occurrence</u>	<u>Hold drug until ANC criteria for dosing reached. No change in dose.</u>	<u>Hold drug until ANC criteria for dosing reached. Reduce dose of docetaxel by one dose level and resume dosing.</u>	<u>Administer prophylactic G-CSF with each subsequent cycle of chemotherapy.</u>
	<u>2nd occurrence</u>	<u>Hold drug until ANC criteria for dosing reached. No change in dose.</u>	<u>Hold drug until ANC criteria for dosing reached. Reduce dose of docetaxel by one more dose level and resume dosing.</u>	
	<u>3rd occurrence</u>	<u>Permanently discontinue</u>		

ANC=absolute neutrophil count; CTCAE=Common Terminology Criteria for Adverse Events; G-CSF=granulocyte colony-stimulating factor.

9.3.3 Recommended Actions with Trilaciclib/Placebo for Adverse Events of Special Interest

Suggested actions to be taken with trilaciclib/placebo following AESI are provided in [Table 10](#).

Table 10: Recommended Actions with Trilaciclib/Placebo Following AESIs

AESI	Severity	Recommended Action
Injection site reactions including phlebitis and thrombophlebitis	Grade 1: Tenderness with or without symptoms (e.g. warmth, erythema, itching)	Interrupt or slow infusion of trilaciclib. If 0.9% normal saline is being used as a diluent/flush, consider changing to 5% dextrose as appropriate for subsequent infusions.
	Grade 2: Pain; lipodystrophy; edema; phlebitis	Interrupt infusion of trilaciclib. If pain not severe, follow instructions for Grade 1. Otherwise, stop infusion in extremity and rotate site of infusion to site in alternative extremity. If 0.9% normal saline is being used as a diluent/flush, consider changing to 5% dextrose as appropriate for subsequent infusions. Central access may also be considered.
	Grade 3: Ulceration or necrosis; severe tissue damage; operative intervention indicated. Grade 4: Life threatening consequences; urgent interventions indicated.	Stop infusion and permanently discontinue trilaciclib.
Acute drug hypersensitivity reactions	Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting Activities of Daily Living	Stop infusion and hold trilaciclib until recovery to Grade ≤ 1 or baseline, then consider resuming trilaciclib. If Grade 2 recurs, permanently discontinue trilaciclib.
	Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL OR Grade 4: Life-threatening consequences; urgent intervention indicated	Permanently discontinue trilaciclib.

AESI	Severity	Recommended Action
ILD/pneumonitis	Grade 2 (symptomatic)	Hold trilaciclib until recovery to Grade ≤ 1 or baseline, then consider resuming trilaciclib. If Grade 2 recurs, permanently discontinue trilaciclib.
	Grades 3: Severe symptoms; limiting self-care ADL; oxygen indicated OR Grade 4: Life-threatening respiratory compromise; urgent intervention indicated (e.g., tracheotomy or intubation)	Permanently discontinue trilaciclib.
Other toxicities	Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL.	Hold trilaciclib until recovery to Grade ≤ 1 or baseline, then consider resuming trilaciclib. If Grade 3 recurs, permanently discontinue trilaciclib.
	Grade 4: Life-threatening consequences; urgent intervention indicated.	Permanently discontinue trilaciclib

AESI=adverse event of special interest; ILD=interstitial lung disease

9.3.4 Hy's Law Management

Abnormal values in AST and/or ALT concurrent with abnormal elevations in total bilirubin that meet the criteria outlined below in the absence of other causes of liver injury are considered potential cases of drug-induced liver injury (potential Hy's Law cases) and should always be considered important medical events.

The threshold of laboratory abnormalities for a potential case of drug-induced liver injury depends on the patient's individual baseline values and underlying conditions. Patients who present with the following laboratory abnormalities should be evaluated further to determine the etiology of the abnormal laboratory values:

- Baseline AST or ALT and total bilirubin values are within the normal range and the patient subsequently presents with AST or ALT $\geq 3 \times$ ULN concurrent with a total bilirubin $\geq 2 \times$ ULN with no evidence of hemolysis and an alkaline phosphatase $\leq 2 \times$ ULN or not available.
- Preexisting ALT OR AST OR total bilirubin values above the upper limit of normal, and the patient subsequently presents with:
 - AST or ALT ≥ 2 times the baseline values and $\geq 3 \times$ ULN, or $\geq 8 \times$ ULN (whichever is smaller)
 - Concurrent with total bilirubin increased by one time the baseline value OR $\geq 3 \times$ ULN (whichever is smaller).

The patient should return to the investigational site and be evaluated as soon as possible, preferably within 48 hours from awareness of the abnormal results. This evaluation should include laboratory tests, detailed history and physical assessment. In addition to repeating AST and ALT, laboratory tests should include albumin, creatine kinase, total bilirubin, direct and indirect bilirubin, gamma-glutamyl transferase, prothrombin time (PT)/International Normalized Ratio (INR), and alkaline phosphatase. A detailed history, including relevant information, such as review of ethanol, acetaminophen, recreational drug and supplement consumption, family history, occupational exposure, sexual history, travel history, history of contact with a jaundiced patient, surgery, blood transfusion, history of liver or allergic disease, and work exposure, should be collected. Further testing for acute hepatitis A, B, or C infection and liver imaging (e.g., biliary tract) may be warranted.

All cases confirmed on repeat testing as meeting the laboratory criteria defined above, with no other cause for liver function test (LFT) abnormalities identified at the time should be considered potential Hy's Law cases irrespective of availability of all the results of the investigations performed to determine etiology of the abnormal LFTs. Such potential Hy's Law cases should be promptly reported as SAE via the EDC.

9.4 Supportive Care Interventions

9.4.1 Colony Stimulating Factor Usage

Use of prophylactic colony stimulating factors (e.g., G-CSF; granulocyte-macrophage colony-stimulating factor [GM-CSF]) during Cycle 1 (i.e., prior to the actual Cycle 2 Day 1 dosing visit) is not allowed. In subsequent cycles (Cycle 2 and beyond), prophylactic colony-stimulating factors are allowed as outlined in regional guidelines or consensus (e.g., American Society of Clinical Oncology [ASCO], European Society for Medical Oncology [ESMO], Chinese Anti-Cancer Association) and package inserts/summary of product characteristics.

If in any cycle (including Cycle 1), a patient experiences severe neutropenia (Grade 4) or FN and is at high risk for infection-associated complications or has prognostic factors that are predictive of poor clinical outcomes (Table 11), therapeutic G-CSF/GM-CSF may be used to treat the severe neutropenia or FN event per regional guidelines and package inserts.

Short-acting G-CSF products (i.e., Neupogen or biosimilars) may be administered starting 24 to 48 hours after chemotherapy and must be stopped 48 hours prior to study drug administration in the next cycle. Similarly, Neulasta (or biosimilars) or other long half-life G-CSF products (ex. macappegfilgrastim) may be administered 24 to 48 hours after chemotherapy but due to its prolonged half-life should not be repeated within that cycle. Biosimilars must be approved for use by the national regulatory authority (ex. FDA, European Commission, or the China National Medical Products Administration (NMPA)).

Table 11: Patient Risk Factors for Poor Clinical Outcomes Resulting from Febrile Neutropenia or Infection

Risk Factor
Sepsis syndrome
Age >65 years
Profound neutropenia (absolute neutrophil count $<0.1 \times 10^9/L$)
Neutropenia expected to last >10 days
Pneumonia
Invasive fungal infection
Other clinically documented infections
Hospitalization at time of fever
Prior episode of febrile neutropenia

ASCO=American Society of Clinical Oncology

Source: Table recreated from Table 2 of the ASCO guidelines (Smith, 2015; Smith, 2006).

9.4.2 Erythropoiesis-Stimulating Agent Usage

If a patient experiences a hemoglobin level <10.0 g/dL or symptomatic anemia during study treatment, ESAs may be used per the current prescribing information (Bohlius, 2019) (Procrit®, 2017; Aranesp®, 2011).

9.4.3 Transfusions

Red Blood Cells

Based on the NCCN Clinical Practice Guidelines in Oncology for Hematopoietic Growth Factors Version 2.2020 and the AABB Clinical Practice Guidelines, the following RBC transfusion thresholds are recommended (Carson, 2016; Goel, 2018); however, the patient's clinical situation should always be the primary guiding factor when deciding to transfuse.

- Transfusion is not indicated until the hemoglobin level is ≤ 7 g/dL for hospitalized adult patients who are hemodynamically stable.
- An RBC transfusion threshold of ≤ 8 g/dL is recommended for patients undergoing orthopedic surgery, cardiac surgery, and those with preexisting cardiovascular disease.
- Patients with symptomatic anemia should be transfused per the Investigator discretion regardless of hemoglobin levels.

Platelets

Platelet transfusion is recommended at a threshold of $\leq 10 \times 10^9/L$. Platelets should also be transfused in any patient who is bleeding with a platelet count $<50 \times 10^9/L$ ($100 \times 10^9/L$ for central nervous system or ocular bleeding) (Kaufman, 2015; Schiffer, 2017).

9.5 Prior/Concomitant Medications and Procedures

All concomitant medications including prescription medications, over-the-counter preparations, growth factors, and blood products from informed consent through 30 days after the last dose of study treatment (Post-Treatment Visit) will be documented, where possible. During the study, prescription, and commercially available products, including traditional Chinese medications,

with known or suspected immunomodulatory properties should be used with caution or avoided entirely.

~~Caution should be exercised with concomitant use of drugs that are substrates for OCT2 with a narrow therapeutic index (Section 4.2.8.1.1). Avoid concomitant use of trilaciclib with certain OCT2, MATE1, and MATE-2K substrates (e.g., dofetilide, dalfampridine) where minimal concentration changes may lead to serious or life-threatening toxicities. Refer to the prescribing information for these concomitant medications for assessing the benefit and risk of concomitant use of trilaciclib (Section 4.2.8.1.1).~~

Docetaxel is a CYP3A4 substrate. Concomitant use of docetaxel and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. In patients receiving treatment with docetaxel, close monitoring for toxicity and a docetaxel dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided.

Any medication that is contraindicated when using docetaxel is not permitted, and special warnings and precautions for use of docetaxel should be observed.

Administration of other concomitant investigational agents for any indication or any live attenuated vaccines is not permitted while on this study. Necessary supportive care (antiemetics, antidiarrheals, chemotherapy premedication, etc.) per the standard of care at the study center will be permitted. See Section 9.4 for guidance on the use of growth factors (colony-stimulating factors and ESAs) during the study.

Administration of other systemic concomitant non-protocol anticancer therapies prior to progression is not permitted while on this study, with the exception of adjuvant endocrine therapy for breast cancer or prostate cancer defined as M0 disease or PSA persistence/recurrence without metastatic disease. This includes any low-dose systemic chemotherapeutic agent given for a nononcologic purpose (e.g., low-dose methotrexate for rheumatoid arthritis). Palliative treatment of a symptomatic lesion(s) is permitted to control disease symptoms but not to aid in the response of the tumor. If the lesion(s) treated is being followed for evaluation by RECIST (target or nontarget lesion), then “not evaluable” should be reported in electronic data capture (EDC) for this lesion at subsequent disease assessments following palliative treatment. Patients requiring palliative therapy may continue receiving study drug until documented disease progression (radiographic or clinical) if, in the Investigator’s opinion, the patient is continuing to receive clinical benefit and they meet the requirements described in Section 9.2. However, for patients who have not had disease progression at the time of the need for palliative radiation therapy or surgery, the requirement for intervention will be regarded as disease progression in the study’s analyses and will be entered as such in the EDC.

Any diagnostic, therapeutic, or surgical procedures performed during the study period will be documented. Documentation will include information regarding the date(s), indication(s), description of the procedure(s), and any clinical or pathological findings, if available.

9.6 Measures to Minimize Bias: Randomization and Blinding

The study will be randomized and double-blind. Patients meeting all inclusion and exclusion criteria will be randomized 1:1 by an Interactive Web Response System (IWRS) according to a randomization schedule generated by an unblinded external statistician. Each patient will be assigned a unique randomization number, which will not be reused. A patient who is randomized

and discontinues from the study, even if no study drug was administered, will not be replaced. If a patient does not receive the correct study treatment for their allocated treatment arm, the reason must be clearly documented in the eCRF. The patient will remain on study and continue to receive the same study treatment, all data will be collected, and follow up will continue as described in the Schedule of Assessments.

There will be 2 stratification factors for randomization: country and ECOG performance status (0-1 versus 2). Within each country, patient randomization will be stratified by ECOG performance status (0-1 versus 2).

Each site will have an unblinded Pharmacist/Designee, who will have access to the treatment assignment. Because the active drug product trilaciclib has a faint yellow color when reconstituted and diluted, additional procedures will be implemented to ensure the blind is maintained for the patient, Investigator, Research Nurse, Study Coordinator, and other blinded site personnel. Details regarding the preparation and administration of trilaciclib/placebo in a manner to maintain the blind will be included in the Pharmacy Manual.

The patients, Investigators, other site staff involved in the clinical care of the patients, and the Sponsor or Designees involved in the conduct of the study will not be aware of the treatment group to which a particular patient has been randomized. If an Investigator determines that a patient's assignment should be unblinded for reasons of safety, this should be discussed with the study Medical Monitor prior to unblinding, unless an urgent and immediate intervention is required that precludes this discussion. If unblinding of the treatment assignment is necessary, the Investigator or Designee will obtain the treatment assignment details from the IWRS. Unblinding of personnel should be limited to the minimum needed for mitigation of safety concern. Following unblinding, patient continuation on study will be determined on a case by case basis. Any unplanned unblinding must be communicated to the Project Manager, Study Statistician, and Sponsor for documentation in the study files and the clinical study report.

If the blinding code is broken, the date and reason for unblinding must be fully documented in source documents and entered on the eCRF. However, every effort should be made by the site staff to ensure that the treatment arm in which the unblinded patient is assigned is not communicated to any sponsor personnel or designee involved in the conduct of the trial.

9.7 Intervention after End of Study Treatment

Following completion of study treatment on the study, patients will receive treatment as determined by their healthcare provider. During Survival Follow-up, the patient (or legally authorized representative where allowed by local regulation) will be contacted to record their status (alive or dead) as well as details of any subsequent systemic anti-cancer therapy initiated (see Section 11.10).

10 DISCONTINUATION OF STUDY INTERVENTION AND PATIENT DISCONTINUATION/WITHDRAWAL

10.1 Discontinuation of Study Treatment

Study drugs will be discontinued if any of the following events occur during the study:

- A patient suffers an AE that, in the judgment of the Investigator, Sponsor, or Medical Monitor, presents an unacceptable risk to the patient

- General or specific changes in the patient's condition (e.g., a significant intercurrent illness or complication) that, in the judgment of the Investigator, are unacceptable for further administration of study drug
- Occurrence of pregnancy during the study
- Significant noncompliance with protocol requirements
- The Sponsor or legal representative of the Sponsor requests the patient to withdraw
- Patient has documented disease progression (radiographic or clinical progression). See Section 9.5 for details regarding palliative therapy.
- If total time between chemotherapy treatments exceeds a total of >5 weeks, unless agreed to by the treating Investigator and Medical Monitor.
- Where permanent discontinuation of all study drugs is indicated in the toxicity management recommendations

At the time of study drug discontinuation, a Post-Treatment Visit should be completed with assessments performed as shown in the Schedule of Assessments (Table 6). The Investigator or Designee will document the reason for study drug discontinuation on the applicable eCRF. When discontinuation is due to a SAE or a Grade 3 or 4 toxicity considered to be related to study medication, the Investigator should follow the event until resolution, return to baseline, or it is deemed that further recovery is unlikely. Data on these events should be collected on the AE eCRF. In the event a patient discontinues due to pregnancy, the Investigator or designee should notify the Medical Monitor by telephone within 24 hours of pregnancy confirmation (see Section 17.3).

For those patients who have not progressed clinically or radiologically at the time of study drug discontinuation, every effort should be made to continue radiological tumor assessments every 12 weeks (± 7 days) during survival follow-up, utilizing the same imaging modality as used at Screening as outlined in the Schedule of Assessments (Table 6), until progressive disease, initiation of subsequent anti-cancer therapy, withdrawal of consent, or study completion, whichever occurs first. Results of these scans should be assessed by RECIST v1.1 and data entered in EDC in the corresponding tumor assessment forms.

10.2 Discontinuation/Withdrawal from the Study

A patient may withdraw from the study at any time at his/her own request or may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons. At the time of discontinuing from the study, if patient has not already discontinued study intervention, a Post-Treatment Visit should be completed with assessments performed as shown in the Schedule of Assessments (Table 6).

If the patient withdraws consent for disclosure of future information, the Sponsor may retain and continue to use any data collected before such a withdrawal of consent.

If a patient withdraws from the study, he/she may request destruction of any samples taken and not tested, and the Investigator or designee must document this in the site study records.

If a patient withdraws consent for further study procedures, the site should clarify if the patient (or legally authorized representative where allowed by local regulation) remains open to survival

contact and associated data collection. Public records may be used to verify survival status if permitted by institutional or country guidelines.

10.3 Lost to Follow-Up

A patient will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site.

In general, a patient is considered lost to follow-up after there are at least 3 documented attempts to contact the patient. It is recommended that 1 attempt is via certified letter to the patient.

10.4 Study and Site Start and Closure

The overall study begins when the first patient signs the informed consent form. The overall study ends when the last patient completes the last study-related phone-call or visit, discontinues from the trial or is lost to follow-up (i.e., the subject is unable to be contacted by the investigator).

A study site is considered eligible to start participation in the study once all regulatory approvals are in place, site agreement contract is fully executed, and any other required documents are in place as required by Sponsor.

The end of study is event driven. That is, the study will continue until the targeted number of deaths is observed. There is an interim analysis for OS planned when approximately 73 patients have died. If the interim results demonstrate a statistically significant effect of trilaciclib over placebo for OS based on pre-specified criterion, the study will be stopped early due to success. Otherwise, the study will continue and be considered complete when the targeted number of deaths have occurred for the final OS analysis (approximately 104 deaths), or upon sponsor termination of the study.

The Sponsor's designee reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected, a study-site closure visit has been performed, and the site has closed all regulatory activities with the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).

The Investigator may be requested to initiate study-site closure at any time, provided there is reasonable cause and sufficient notice is given in advance of the intended termination. Should this occur with patients receiving study drug, the patients will transition to receive standard of care treatment by their healthcare provider outside of this study.

Reasons for the early closure of a study site by the Sponsor or Investigator may include but are not limited to:

- Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the Sponsor's procedures, or Good Clinical Practice (GCP) guidelines
- Inadequate recruitment of patients by the Investigator
- Discontinuation of further development of trilaciclib

If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the Investigators, the IECs/IRBs, the regulatory authorities, and any contract research

organization(s) used in the study of the reason for termination or suspension, as specified by the applicable regulatory requirements. The Investigator shall promptly inform the patient and should assure appropriate patient therapy and/or follow-up.

11 STUDY ASSESSMENTS

Study procedures and their timing are summarized in the Schedule of Assessments (Table 6). Adherence to the study design requirements, including those specified in the Schedule of Assessments, is essential and required for study conduct. Immediate safety concerns should be discussed with the study Medical Monitor upon occurrence or awareness to determine if the patient should continue or discontinue study intervention.

The Investigator or Designee will maintain a screening log to record details of all patients screened and to confirm eligibility or record reasons for screening failure, as applicable.

Procedures conducted as part of the patient's routine clinical management (e.g., hematology, clinical chemistry) and obtained before signing of the ICF may be utilized for screening or baseline purposes provided the procedures met the protocol-specified criteria and are performed within ~~the permitted 28-day Screening period~~ 28 days prior to Cycle 1 Day 1.

11.1 Screening Assessments

The following information for screening failures should be recorded into appropriate eCRFs: patient ID, demographic data, and reason for failing the screening process. Patients may only be rescreened one time at the discretion of the Investigator. For abnormal laboratory values, a second test to confirm the first is permitted.

11.1.1 Randomization

Eligibility should be determined prior to randomization and the start of study treatment. All eligible patients will be randomly allocated according to the randomization schedule and will receive a unique randomization number. Once a randomization number is assigned to a patient, it can never be re-assigned to another patient.

Eligible patients will be instructed on all protocol requirements, including any restrictions on concomitant medication usage.

Randomization will be performed via IWRS and can be completed up to 3 days prior to the first dose of trilaciclib or placebo + docetaxel therapy, following confirmation that the patient is eligible for the study. Patients can also be randomized and receive Cycle 1 Day 1 on the same day. When required by institutional procedures, randomization will be allowed up to 7 days prior to dosing without a protocol deviation. Screening procedures must be completed prior to randomization and the screening window remains 28 days.

11.1.2 Demographics

Age, gender, race, and ethnicity will be collected during the Screening period.

11.1.3 Medical History and NSCLC Cancer Disease History

Medical and surgical history, including past and current conditions, will be collected. Concomitant medications taken from informed consent through 30 days after the last dose of study treatment will be recorded. Prior medications (those taken within 14 days of informed consent will also be recorded.

Documentation of NSCLC history, including date of diagnosis and histologic type, as well as prior therapy (ex. surgery, radiation, systemic chemotherapy, immunotherapy) for NSCLC will also be recorded. PD-L1 status will be collected and recorded where available.

11.2 Anti-tumor Efficacy Assessments

11.2.1 Anti-tumor Efficacy Assessment

~~All sites of measurable and non-measurable disease must be documented at Screening and re-assessed at each subsequent tumor evaluation.~~ Tumor assessment will be performed at the timepoints specified in the Schedule of Assessments ([Table 6](#)) relative to Cycle 1 Day 1, regardless of drug (cycle) delays.

Baseline imaging should include computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen, pelvis, and brain. IV contrast should be used unless contraindicated. Any CT or MRI obtained as standard of care prior to [Screening visitsigning the informed consent](#) will not need to be repeated as long as those imaging tests were obtained within 28 days prior to ~~the date of randomization~~[Cycle 1 Day 1](#).

After baseline tumor assessments (Screening assessment within 28 days [prior to Cycle 1 Day 1](#)), evaluation of tumor response per RECIST v1.1 will be performed every 6 weeks following Cycle 1 Day 1 (± 7 days) during study drug administration (including imaging of the chest, abdomen, and pelvis [and brain if metastasis present at Screening or if symptoms develop]), with additional scans performed as clinically indicated. Post-baseline tumor assessments should use the same imaging modality as at Screening. IV contrast should be used unless contraindicated. Tumor assessments will continue until disease progression, withdrawal of consent, initiation of subsequent anti-cancer therapy, or the end of study, whichever occurs first.

For those patients who have not progressed clinically or radiologically at the time of study drug discontinuation, every effort should be made to continue radiological tumor assessments every 12 weeks (± 7 days) during survival follow-up, utilizing the same imaging modality as used at Screening, until the occurrence of progressive disease, withdrawal of consent, initiation of subsequent anticancer therapy, or study completion.

Tumor response criteria will be based on RECIST v1.1 ([Eisenhauer, 2009](#)) as cited in Section [17.4](#). A partial or complete response should be confirmed by a repeat scan at the next scheduled tumor assessment per RECIST v1.1.

During the course of this study, scans may be collected and sent/uploaded to the Sponsor or Designee for storage. Centralized storage is intended for possible blinded independent central review (BICR) of disease assessments. At the discretion of the Sponsor, BICR of all scans by RECIST v1.1 may be conducted retrospectively. The blinded review will include all patients with available images. However, the raw images for patients enrolled in China cannot be stored outside of China and therefore these images will be stored in the server in China for central imaging review if approved by the related authority. If needed, guidelines for imaging collection and storage will be provided in a separate document. The clinical management of patients will be based solely upon the results of the assessment conducted by the Investigator based on RECIST v1.1 per protocol.

11.2.2 Myelopreservation Assessments

The myelopreservation effects of trilaciclib administered prior to docetaxel compared with placebo administered prior to docetaxel will be evaluated based on the following: kinetics of changes in CBCs (including DSN in Cycle 1 and rate of SN); hematologic toxicities, including FN; RBC and platelet transfusions; hematopoietic growth factor utilization; infections and systemic antibiotic use. All of these variables will be assessed as described in the safety assessments (monitoring of AEs, clinical laboratory assessments, and concomitant medications).

11.3 Safety Assessments

Unless specified otherwise, safety assessments should be conducted prior to study drug administration.

11.3.1 Vital Signs

The following will be collected per the Schedule of Assessments (Table 6) 15 minutes (+/- 10 minutes) before and after the trilaciclib/placebo infusion:

- Body temperature, pulse rate, blood pressure (diastolic and systolic)

11.3.2 Physical Examination

Full physical examination at Screening should include general appearance, height in centimeters, body weight in kilograms, skin, neck, eyes, ears, nose, throat, lungs, heart, abdomen, lymph nodes, extremities, and neurological examinations. Subsequent physical exams should include body systems as determined by provider (e.g., brief physical exam) and weight.

Information about the physical examination must be present in the source documentation at the study site. Clinically relevant findings observed **prior** to the start of study drug, should be recorded as medical history. Clinically relevant findings observed **after** the start of study drug, which meet the definition of an AE, must be recorded on the AE eCRF.

Assessments may be performed by a physician, registered nurse, or other qualified health care provider.

11.3.3 ECOG Performance Status

The Investigator or qualified designee will assess ECOG performance status during the Screening Period to assess for eligibility according to the inclusion and exclusion criteria (Table 12) as well as to monitor performance throughout the study (Table 6).

Table 12: ECOG Performance Status

Grade	ECOG
0	Fully active, able to carry on all pre-disease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work housework, office work
2	Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours
3	Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4	Completely disabled. Cannot carry out any selfcare. Totally confined to bed or chair
5	Dead

ECOG=Eastern Cooperative Oncology Group
Source: [Oken, 1982](#).

11.3.4 Electrocardiogram

Single standard 12-lead ECGs will be performed as outlined in the Schedule of Assessments ([Table 6](#)) on Day 1 of Cycles 1 and 2 at the following timepoints: predose (any time prior to trilaciclib/placebo on the day of dosing) and at the end of trilaciclib/placebo infusion (within 30 minutes following the infusion but prior to initiation of docetaxel infusion). Additional ECGs may be performed as clinically indicated at any time during the study.

All 12-lead ECGs will be obtained after the patient has been resting for at least 5 minutes and shall be recorded at 25 mm/sec. All ECGs for an individual patient shall be recorded with the patient in the same physical position.

Any ECG with a QTc value of >500 msec shall have the QTc value confirmed via manual read. A repeat ECG in triplicate (over approximate 5-minute period) should also be obtained for confirmation. The Investigator or qualified designee should review the ECGs for any abnormalities as compared with the baseline ECG. Following confirmation, the Investigator should evaluate for any other potential causes of the prolongation (e.g., concomitant medications) and determine the appropriate clinical course.

11.3.5 Clinical Safety Laboratory Assessments

Hematology, clinical chemistry, and serum or urine pregnancy test will be performed at the site's local certified laboratory per the schedule outlined in the Schedule of Assessments ([Table 6](#)).

~~Any consideration for laboratory assessments to be performed at an alternate laboratory outside of the facilities identified for the conduct of the study may impact the integrity of the study data. As such, any such testing should be discussed with the study Medical Monitor and considered as a means to continue appropriate testing for the safety of the patient during COVID-19 restrictions.~~ Clinical laboratory samples may be collected from patients at a different location than the Investigator's clinic following approval by the Medical Monitor. A list of clinical laboratory tests to be performed is provided in Section 17.1. Hematology may be obtained up to 24 hours and serum chemistry may be obtained up to 72 hours prior to each time point on Schedule of Assessments but must be reviewed before dosing. Laboratory toxicities will be assessed using the NCI-CTCAE, v5.0.

For women of childbearing potential, pregnancy tests will be performed as follows: serum beta human chorionic gonadotropin (β -hCG) at Screening (must be performed during window allowing randomization in IWRS and negative results should be available prior to randomization) and serum or urine β -hCG prior to the start of each cycle thereafter, as well at the post-treatment visit.

An abnormal laboratory value is not an AE unless it is considered to be clinically significant. Whether a clinically significant laboratory value is also an adverse event will be determined by the investigator. Laboratory parameters for which clinically significant values are noted will be re-measured on the appropriate clinical follow-up arranged by the Investigator. Any laboratory value that remains abnormal at the end of the study and that is considered clinically significant should be followed according to accepted medical standards for up to 30 days or until the values return to normal or baseline or are no longer considered clinically significant by the Investigator. If such values do not return to normal/baseline within a period of time judged reasonable by the Investigator, the etiology should be identified, and the Medical Monitor notified.

If a subsequent cycle is delayed for toxicity, the patient should still complete the clinical laboratory assessments on the scheduled Day 1 (entered as an Unscheduled assessment in EDC) as well as on the actual first dosing day of that cycle. If the delay is secondary to hematologic toxicity, weekly repeat hematology assessments should continue until the finding meets criteria for resumption of dosing (see Section 9.3.2; Table 9).

11.3.6 Adverse and Serious Adverse Events

The Investigator and any qualified designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE and remain responsible for following up, as applicable, AEs that are serious, considered related to the study drugs or study procedures, or that caused the patient to discontinue the study or study drugs (see Section 10.1). Patients should be encouraged to report AEs freely or in response to general, nondirected questioning. Adverse events (serious and non-serious) should be reported on the appropriate page of the eCRF. Toxicity will be assessed by Investigators using NCI-CTCAE v5.0.

11.3.6.1 Time Period and Frequency for Collecting Adverse and Serious Adverse Event Information

AEs will be collected starting from the first dose of study drug through the Post-Treatment Visit. Any SAE occurring between the date the patient signs informed consent and the first dose of any study drug, and which the Investigator feels is related to a study specific procedure (i.e., would not have occurred unless the patient was on the study), should also be reported. Any AEs that occur between the date of signing informed consent and the first dose of study drug should be recorded as Medical History.

All SAEs will be recorded and reported to G1 Therapeutics, Inc. Pharmacovigilance (PVG) or designee immediately and should not exceed 24 hours after becoming aware of the event, as indicated in Section 17.2.

Investigators are not obligated to actively seek AE or SAE information after 30 days following the last dose of study drugs on this study. However, if the Investigator learns of any SAE, including a death, at any time after a patient has been discharged from the study, and he/she

considers the event to be reasonably related to the study intervention or study participation, the Investigator or designee must promptly notify G1 Therapeutics, Inc. PVG or designee.

11.3.6.2 Method of Detecting Adverse and Serious Adverse Events

The method of recording, evaluating, and assessing causality of AE and SAE and the procedures for completing and transmitting SAE reports are provided in Section 17.2.

Care should be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and nonleading verbal questioning of the patient is the preferred method to inquire about AE occurrences.

11.3.6.3 Follow-up of Adverse and Serious Adverse Events

After the initial AE/SAE report, the Investigator is required to proactively follow each patient at subsequent visits/contacts. All AEs (both serious and nonserious) will be followed in accordance with good medical practice until resolution, return to baseline, or it is deemed that further recovery is unlikely. All measures required for AE management and the ultimate outcome of the AE will be recorded in the source document and reported to G1 Therapeutics, Inc.

All SAEs will be followed until resolution, stabilization, the event is otherwise explained, or the patient is lost to follow-up (as defined in Section 10.3). Further information on follow-up procedures is provided in Section 17.2.

11.3.6.4 Regulatory Reporting Requirements for Serious Adverse Events

Prompt notification of G1 Therapeutics, Inc. PVG or designee by the Investigator (or designee) of a SAE is essential so that legal obligations and ethical responsibilities towards the safety of patients and the safety of a study intervention under clinical investigation are met.

G1 Therapeutics, Inc. has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. G1 Therapeutics, Inc. will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, Central IRB/IEC, and Investigators. For all studies, except those utilizing medical devices, Investigator safety reports must be prepared for suspected unexpected serious adverse reactions (SUSAR) according to local regulatory requirements and G1 Therapeutics, Inc. policy and forwarded to Investigators, as necessary.

An Investigator who receives an Investigator safety report describing a SAE or other specific safety information (e.g., summary or listing of SAEs) from G1 Therapeutics, Inc. or designee will review and then file it along with the Investigator's Brochure and will notify the IRB/IEC, if appropriate according to local requirements.

11.3.6.5 Pregnancy

Details of all pregnancies in female patients and female partners of male patients will be collected after the start of study intervention and until 30 and 120 days respectively, after the last dose of study drug.

If a pregnancy is reported, the Investigator or designee should inform G1 Therapeutics, Inc. PVG or designee within 24 hours of learning of the pregnancy and should follow the procedures outlined in Section 17.3.

Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.

11.4 Patient-Reported Outcomes

The PRO items below will be self-administered by patients, overseen by a designated study site staff member. PRO questionnaires should be completed on Days 1 and 13 of Cycle 1 and Day 1 of each subsequent cycle and at the Post-Treatment Visit, except for the Patient Global Impression of Change (PGIC) which is not administered on Day 1 of Cycle 1, per the schedule outlined in the Schedule of Assessments ([Table 6](#)).

The PRO questionnaires should be completed on both the planned Day 1 visit and on the actual Day 1 of the cycle (i.e., when dosing is delayed and criteria are then met to proceed with Day 1 treatment). PRO questionnaires may be administered up to 1 calendar day prior to each dosing day and are to be completed on the same day a blood sample is collected for hematology assessment. Questionnaires administered on Cycle 1 Day 13 may be obtained ± 1 day of scheduled visit. Questionnaires should be completed before treatment administration, and where possible before any laboratory tests or other procedures that are performed that day.

11.4.1 EORTC QLQ-C30 and EORTC QLQ-LC13

The EORTC QLQ-C30 and QLQ-LC13 are validated instruments that will be administered on the days outlined in the Schedule of Assessments ([Table 6](#)).

The EORTC quality of life questionnaire (QLQ) is an integrated system for assessing the health-related quality of life (QoL) of cancer patients participating in international clinical trials ([Aaronsen, 1993](#)). The core questionnaire, the QLQ-C30, includes 30 items that address symptoms and functional impacts that are applicable across cancer populations. The QLQ-C30 yields 15 domains assessing global health status, symptoms (e.g., fatigue, nausea and vomiting), and function (e.g., physical functioning, emotional functioning). Each domain is scored on a 0-100 scale. The detailed scoring algorithm is included in the scoring manual ([Fayers, 2001](#)).

The EORTC QLQ-LC13 is a supplemental module that was designed for use among a wide range of lung cancer patients varying in disease stage and treatment modality ([Bergman, 1994](#)). The QLQ-LC13 incorporates one multi-item scale to assess dyspnea, and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. Domains are scored on a 0-100 scale. The open-ended item assessing location of pain and the item asking about the use and effect of pain medications will not be included in the QLQ-LC13 version to be administered in this trial, as it is not used in the scoring of the measure. A supplemental item from the EORTC Item Library addressing weight loss (“Has weight loss been a problem for you?”) will be added to the QLQ-LC13. [This version of the QLQ-LC13 has been titled the EORTC IL118 by the EORTC.](#) The scoring algorithm is described in the scoring manual ([Fayers, 2001](#)).

11.4.2 FACIT-Fatigue

The is FACIT-Fatigue ([Yellen, 1997](#)) is a 13-item measure that measures the severity of fatigue (e.g., “I feel fatigued,” “I feel tired”) and the impact of fatigue on functioning (e.g., “I have trouble starting things because I am tired,” “I need to sleep during the day”). Patients rate their experiences over the “past 7 days” using a 0-4 verbal rating scale (“Not at all” to “Very Much”). The FACIT-Fatigue is scored as a sum of all 13 of the item responses; the scale range is from 0-

52. After appropriate reverse scoring of 11 items, lower scores on the FACIT-F indicate greater levels of fatigue.

11.4.3 Patient Global Impression of Change and Patient Global Impression of Severity

The PGIC and Patient Global Impression of Severity (PGIS) items will be self-administered on the days outlined in the Schedule of Assessments (Table 6). The PGIC item will ask the patient to rate the change in their fatigue since taking study drug on a 7-point scale ranging from -3 (very much worse) to 3 (very much better). The PGIS item, will ask the patient to rate the overall severity of their fatigue over the past week on a 5-point scale ranging from 0 (none) to 4 (severe).

11.4.4 5-Level EQ-5D

The EQ-5D-5L will be provided to patients for self-administration on the days outlined in the Schedule of Assessments (Table 6). The 5-level EQ-5D (EQ-5D-5L) is a standardized instrument by which treatment effects can be assessed by measuring health status at different points in time, e.g., before and after treatment, and then investigating the gains (or losses) in reported health status. The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS). For the EQ-5D, respondents will rate their health on each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The patient will be asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ-VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled "The best health you can imagine" and "The worst health you can imagine". The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

11.5 Pharmacokinetics

Blood samples for PK analysis will be collected as indicated in the Schedule of Assessments (Table 6) from all patients. Three blood samples for PK analysis of trilaciclib will be collected: on Cycle 1 Day 1 at the end of trilaciclib/placebo infusion (sample can be taken up to 15 minutes prior to the end of infusion), at 30 minutes post the end of trilaciclib/placebo infusion (± 15 minutes) and at 4-6 hours post the end of the trilaciclib/placebo infusion.

Three samples will also be collected for PK analysis of docetaxel: on Cycle 1 Day 1 at the end of docetaxel infusion (sample can be taken up to 15 minutes prior to end of infusion), 2 hours after end of docetaxel infusion (± 30 minutes) and at 4-6 hours post the end of the docetaxel infusion.

The actual date and time of each blood sample collection, the scheduled timepoint of collection, and the time of dose administration prior to the pharmacokinetic sample will be recorded. Details of PK blood sample collection including volume to be collected, timing of samples, processing, storage, and shipping procedures are provided in the Laboratory Manual. Blood samples for PK analysis may be collected from patients at a different location than Investigator's clinic.

11.6 Biomarkers

11.6.1 Rationale for Archival Tumor Collection

Because trilaciclib maintains G1 arrest in CDK4/6 dependent cells, there is a hypothetical risk that trilaciclib could antagonize the anti-tumor efficacy of cytotoxic chemotherapy by maintaining a G1 cell cycle arrest of CDK4/6 dependent tumor cells during chemotherapy. While the currently available nonclinical and clinical data indicate that this risk remains hypothetical and does not influence the overall benefit/risk assessment for combining trilaciclib with chemotherapy, this study will evaluate in a retrospective fashion the relationship between CDK4/6 status and measures of anti-tumor efficacy; the planned statistical analyses are described in Section 12.4.9.

To support these analyses, prior to signing the informed consent, a FFPE archival tumor specimen with an associated pathology report documenting NSCLC (recurrent/metastatic preferred) for each patient must be confirmed to be available to send to a central storage facility for planned retrospective biomarker analyses ~~collection~~. Tumor tissue must consist of a ~~minimum of 15 slides (preferably 20) or a fixed paraffin-embedded block with a depth of at least 100 microns preferred; 75 microns (minimum) unless otherwise approved by the Medical Monitor. If a block is not available, 20 or more (15 minimum) freshly cut unstained slides are an acceptable alternative.~~ If archival tissue is not available, a fresh biopsy must be obtained. Acceptable samples include core needle biopsies, tumor tissue - excisional or incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions. Fine-needle aspiration, brushing, cell pellet from pleural effusion, bone metastases, and lavage samples are not acceptable. Additional guidance is provided in the Laboratory Manual.

In addition to CDK4/6 status as described below, tumor PD-L1 status (positive or negative) will be determined and anti-tumor efficacy endpoints by PD-L1 status will be evaluated. Any remaining tumor tissue following the described analyses will be banked and may be analyzed for relevant DNA, ribonucleic acid (RNA), or protein biomarkers and their role in cancer, including to better understand immune-related mechanisms.

Note: No tumor tissue will be archived for study centers in China.

11.6.2 Description of CDK4/6 Signature

In order to characterize this hypothetical risk in a tumor type without a clear CDK4/6 response phenotype, archival tumor tissue will be collected from patients' most recent biopsy (NSCLC primary or metastatic site) and subjected to a genetic signature analysis based on published literature in an effort to characterize patient tumors into one of the following three groups (Gong, 2017; Shapiro, 2017):

- CDK4/6 independent
- CDK4/6 dependent
- CDK4/6 indeterminate

The evaluation of the relationship between CDK4/6 status and anti-tumor outcomes may be performed when the final OS analysis is performed, that is, when the predicted death events are observed. The use of mature OS data, in addition to the ORR and PFS data, will allow for a more robust interpretation of the relationship between CDK4/6 status and anti-tumor outcomes without

the complication of trying to draw conclusions with inadequate information (i.e., immature anti-tumor efficacy data).

This timing is considered to be appropriate since all currently available data indicate that if there is a risk, it is not clinically relevant; therefore, waiting until mature OS data does not pose a significant hazard to the enrolled patients, particularly since the percentage of patients at risk for a potential negative outcome (i.e., who have CDK4/6 dependent tumors) is predicted to be <10% (Section 4.2.7).

11.7 Immunologic and Hematologic Markers

Blood samples for biomarker analysis will be collected at the time points indicated in the Schedule of Assessments (Table 6) from all patients.

Chemotherapeutic agents may elicit part of their anti-tumor efficacy by modulating the immune system to enhance antigen presentation, uptake, and processing; prime the immune response through immunodepletion; inhibit regulatory cells; and stimulate immune effector cells (Zitvogel, 2008; McDonnell, 2011; Bracci, 2014). Conversely, immunosuppression from direct cytotoxicity to the bone marrow and immune system over repeated cycles of chemotherapy may counterbalance the positive immunostimulatory effects of chemotherapy. Therefore, therapeutic approaches to maintain bone marrow health and immune system function should enhance the immune-mediated anti-tumor activity.

Trilaciclib and other CDK4/6 inhibitors have been shown to augment anti-tumor responses in preclinical settings (Klein, 2018) by enhancing T-cell activation through modulation of nuclear factor of activated T-cell activity (Deng, 2018), as well as increasing antigen presentation through upregulation of MHC class I and II in CDK4/6-sensitive tumors and myeloid cells (Goel, 2017; Schaer, 2018). Additionally, CDK4/6 inhibition can upregulate and stabilize the protein expression of PD-L1 on tumor cells (Zhang, 2018).

To evaluate the impact of trilaciclib administration on chemotherapy-induced changes of the immune and hematopoietic system, immunophenotypic and hematologic changes will be compared (as data warrant) between trilaciclib and placebo on patients receiving docetaxel therapy. To assess these changes, peripheral blood will be collected per the timepoints in the Schedule of Assessments (Table 6). At each time point (Cycle 1 Day 1, Cycle 1 Day 9, Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 5 Day 1), collection should occur prior to trilaciclib dosing.

These blood samples will be banked and may be analyzed for relevant DNA, RNA, or protein biomarkers and their role in cancer. Samples may be stored for up to 10 years if patients sign the consent form and allow their samples to be stored for any future research. Note: No blood will be archived for study centers in China.

11.8 Data Monitoring Committee

An unblinded, independent Data Monitoring Committee will monitor accumulating safety and disposition data with the first meeting planned for when approximately 20 patients have enrolled and completed at least 2 cycles of study treatment. The meetings will continue approximately every 4 months while patients are on study treatment depending upon the enrollment rate. Additional reviews may occur based on DMC requests.

A DMC charter will define the roles and responsibilities of the DMC and its members. Additional details regarding the committee's composition, scope, objectives, procedures and policies, including detailed data analysis plan and strategy for maintaining study blind for the Sponsor, Investigators and patients, are described in the DMC charter. The DMC will monitor accumulating safety and disposition data entirely independent of the conduct of the study.

1.1. Post-Treatment Visit

When a patient permanently discontinues study treatment, the patient should complete a Post-Treatment Visit 30 days (\pm 7 days) from last dose of study drug as outlined in [Table 6](#).

11.9 Survival Follow-up Phase

Starting from the last dose of study drug, the patient will be followed approximately every 2 months for survival. Survival Follow-up Visits can be via telephone, email, or clinic visits.

For those patients who have not progressed clinically or radiologically at the time of study drug discontinuation, every effort should be made to continue radiological tumor assessments every 12 weeks (\pm 7 days) during survival follow-up, utilizing the same imaging modality as used at Screening, as outlined in the Schedule of Assessments ([Table 6](#)), until progressive disease, initiation of subsequent anti-cancer therapy, withdrawal of consent, or study completion, whichever occurs first.

Information will be collected until the end of the study (or death) to record their status (alive or dead). In addition, details of any subsequent systemic anti-cancer therapy initiated, including name(s) of agent(s), dates (start/stop) administered, best response to the treatment, and date of progression should also be reported to the best of their ability.

If a patient withdraws consent for further study procedures, the site should clarify if the patient (or legally authorized representative where allowed by local regulation) remains open to survival contact and associated data collection. Provided that the patient has not withdrawn consent for follow up contact, information from medical records may be substituted for phone or other contact, provided that records are available as source documentation. Public records may be used to verify survival status if permitted by institutional or country [guidanceguidance](#).

12 STATISTICAL CONSIDERATIONS

Full details on the statistical analyses to be performed will be provided in a separate statistical analysis plan (SAP).

12.1 Sample Size Determination

The sample size is determined to support the primary objective of the study. That is, to evaluate the effect of trilaciclib compared to placebo on the overall survival of patients with metastatic NSCLC receiving docetaxel in the 2nd/3rd line setting. A total of 104 deaths will be required to achieve 85% power to detect a hazard ratio (HR) of 0.55 in OS at a 2-sided significance level of 0.05. A HR of 0.55 corresponds to a median OS of 16.5 months for the trilaciclib group assuming a median OS of 9.1 months for the placebo group ([Garon, 2014](#)). With a 12-month enrollment period and a 30-month study duration (after the first patient is randomized), a total of 146 patients are required for randomization at a 1:1 ratio to trilaciclib or placebo. This sample size has taken into consideration an interim analysis for OS at the information fraction of 0.70

using the O'Brien-Fleming method for α -spending to ensure strong control of Type I error rate at 1-sided 0.025 between the interim and the final analysis for OS. In the sample size calculation, it is also assumed that about 5% of patients are lost-to-follow-up during the 30-month study duration. EAST® v6.5 is used for the power and sample size calculations.

12.2 Analysis Population

The intent-to-treat (ITT) population includes all randomized patients. Analyses for the ITT population will be conducted according to the randomly assigned treatment regardless of whether the patient received study treatment or was compliant with the protocol. Unless otherwise specified, the ITT population is the primary analysis population for all efficacy analyses.

The Response Evaluable (RE) population includes all patients who are in the ITT population and who have measurable (target) tumor lesion(s) at the baseline tumor assessment and either (i) have at least 1 post-baseline tumor assessment, or (ii) do not have post-dose tumor assessment but have clinical progression as noted by the Investigator, or (iii) died due to disease progression prior to their first post-baseline tumor scan. Analyses using this analysis population will be conducted according to the randomly assigned treatment. The RE population will be the primary analysis set for tumor response analyses.

The safety population includes all randomized patients who received at least 1 dose of study drug. Analyses using the safety population will be conducted according to the actual treatment received. All safety analyses will be evaluated using the safety population.

The pharmacokinetic (PK) population will include all patients who received at least one dose of study drug and had evaluable PK data.

12.3 Timing of Planned Analysis

12.3.1 First Planned Analysis – Interim Analysis for Overall Survival and Analyses for Progression Free Survival, Tumor Responses and Myelosuppression Endpoints

The first planned analysis will take place primarily to perform the interim analysis for OS. The timing of this analysis will be based on the timing when 73 deaths are observed. Following the assumptions that are used in the sample size calculation (Section 12.1), this analysis might be conducted approximately 19 months after the first patient is randomized.

Per literature, the expected median PFS for patients receiving docetaxel is 3 months (Garon, 2014). Assuming trilaciclib can achieve a treatment effect of HR of 0.60, it is estimated that at the time of performing the OS interim analysis, 86% of patients would have had radiographic-determined disease progression or died. Therefore, the analysis for PFS will be conducted at the time when the OS interim analysis is conducted since the PFS events are considered mature. It is also anticipated that the treatment effect on tumor response will be mature at this time. The study database, thus, ORR and DOR will also be locked to perform the OS interim, PFS, tumor response, and myelosuppression analyzed at this time. In addition, analyses. The G1 study team for myelosuppression and PRO endpoints will be unblinded to the results performed at this time.

The study database will be locked to perform these planned analyses.

If the interim OS analysis result is positive as determined by the pre-specified statistical criterion, the study will be stopped for success and the OS analysis results are considered final. If the interim OS analysis result does not meet the criterion of success, the study will continue until a total of 104 deaths are observed.

12.3.2 Second Planned Analysis – Final Analysis for Overall Survival and Safety Data Analyses

At the time when 104 deaths are observed, the study database will be locked to perform the final analysis for OS. This will be the closure of the study. Safety data and anti-tumor efficacy evaluation by CDK 4/6 status and other exploratory analyses will be performed at this time. Under the assumptions used in sample size calculation (Section 12.1), this analysis could be performed approximately 30 months after the first patient is randomized.

It is expected that PFS data are mature at the time of performing the OS interim analysis (i.e., the first planned analysis). However, if the percentage of patients with a radiographic determined disease progression or death at the time of the first planned analysis is less than 80%, PFS will be analyzed again at this time and the results from this analysis will be considered as primary to interpret trilaciclib's effect on PFS in this study.

At this time, other SAP specified analyses that are not mentioned in Section 12.3.1 will all be conducted.

12.4 Statistical Analysis Methods

A SAP will be developed and finalized prior to the first database lock of the study and will include more details related to the statistical analysis of data collected in this study. This section is a summary of the key aspects of the planned statistical analyses.

12.4.1 General Considerations

Data will be summarized by treatment group. The descriptive summary for the categorical variables will include counts and percentages. The descriptive summary for the continuous variables will include means, medians, standard deviations, 25% and 75% percentiles, and minimum and maximum values.

There are two stratification factors for randomization: country and ECOG performance status (0-1 versus 2). A randomization schema will be in place to ensure the best possible balance of treatment assignment within each stratum produced by these stratification factors. Countries will be grouped into the factor of "region" with 3 components: US, Europe, and Asia. The factor "region" will be used instead of "country" in the statistical analysis models to account for regional differences in clinical practice. Unless otherwise specified, ECOG status as entered in IWRS at the time of randomization will be used as the factor for all stratified analyses.

12.4.2 Patient Disposition

Patient disposition will be summarized for all patients by treatment group and overall. The summary will include number of all screened patients, and number and percentage of patients who were randomized, received study drug, discontinued from the study drug with the reasons, and discontinued from study with the reasons.

12.4.3 Demographic and Baseline Characteristics

Demographics and baseline characteristics will be summarized for the ITT population by treatment group and overall. The demographics to be summarized include age, age group (<65 versus ≥65 years old), gender, race, ethnicity, and region. The baseline characteristics to be summarized include ECOG status, NSCLC history (date of diagnosis, histologic type, and prior therapies by line (eg, surgery, radiation, systemic chemotherapy, or immunotherapy). In addition, the recorded PD-L1 status at the screening visit will also be summarized along with vital signs at the screening visit (body weight, body mass index [BMI], BSA).

12.4.4 Prior and Subsequent Anticancer Therapies

Prior and subsequent anticancer therapy verbatim terms will be coded to Anatomical Therapeutic Classification (ATC) and preferred term (PT) using the latest version of World Health Organization-Drug Dictionary (WHO-DD) for the ITT population. Summary statistics will be provided for prior systemic anti-cancer therapies given in different setting (1st line or 2nd line) by treatment group and overall. For the subsequent systemic anti-cancer therapies, the lines of therapy, response to each treatment regimen, and disease progression status will also be summarized by treatment group and overall.

12.4.5 Study Drug Exposure, Modification and Dose Intensity

The summary described below will be based on the safety population.

Duration of study drug exposure will be calculated for docetaxel and for trilaciclib/placebo by treatment group.

For each treatment group, the number of cycles that patients have received will be summarized by descriptive statistics as a continuous variable, while the number of cycles that are completed will be summarized as a categorical variable.

Study drug modifications will be summarized by treatment group in three categories: chemotherapy dose reductions, chemotherapy cycle delay, and infusion interruption. The number and percentage of patients who have at least one dose reduction for docetaxel will be summarized along with a summary of the number of dose reductions that have occurred; the number and percentage of patients who have at least one cycle delay will be summarized along with a summary of the number of cycles that have been delayed; the number and percentage of patients who have at least one infusion interruption for trilaciclib/placebo or docetaxel will be summarized along with a summary of the number of interruptions. Lastly, the primary reason for each form of study drug modification (docetaxel dose reduction, cycle delay, and infusion interruption) will also be summarized by treatment group.

For trilaciclib/placebo and docetaxel, respectively, cumulative dose, dose intensity, relative dose, and relative dose intensity will be derived and summarized by treatment group.

1.1.6. Efficacy Analyses

Unless otherwise specified, all efficacy analyses will be performed on the ITT population.

12.4.5.1 Analyses of Primary Efficacy Endpoint – Overall Survival

The primary endpoint OS is defined as the time (months) from the date of randomization to the date of death for patients who died in the study due to any cause, and the time to the last contact

date known to be alive for those who survived as of the data cutoff date for the interim OS analysis or as of the date when the study database is locked for the final analysis (censored cases). Patients lacking data beyond the date of randomization will have their survival time censored at the date of randomization.

The targeted number of deaths for the final analysis is 104 and the final analysis for OS is event-driven. The number and percentage of patients who died or censored will be summarized by treatment group along with the reason for death.

Treatment effect on OS will be primarily evaluated using a stratified log-rank test controlling for the stratification factors of region (US, Europe, or Asia) and ECOG performance status (0-1 versus 2). The magnitude of the treatment effect, HR (trilaciclib versus placebo), will be estimated using a Cox proportional hazard model with the same factors as included in the stratified log-rank test. At the final analysis, the $(1-\alpha)*100\%$ confidence interval (CI) will be generated for the HR, where the α is a 2-sided statistically significant level to be used for the final OS analysis determined by actual information fraction used at the interim and the O'Brien-Fleming α -spending function.

For each treatment group, the Kaplan-Meier plot will be generated, and the median, 25% and 75% percentile of OS will be estimated using the Kaplan-Meier method with their corresponding 95% confidence interval calculated using the method by Brookmeyer and Crowley (1982). Additionally, Kaplan-Meier estimates will be provided for the survival probability along with their two-sided 95% CIs (Kalbfleisch, 1980) at selected landmarks of 6, 12, 18, and 24 months.

12.4.5.1.1 Interim Analysis for Overall Survival

An interim analysis of OS will be conducted at the 70% information fraction, that is, when 73 deaths are observed. The timing of the interim analysis is estimated to be approximately 19 months after the first patient is randomized in the study. O'Brien-Fleming method for α -spending is applied to ensure strong control family-wise Type I error rate of 1-sided of 0.025 between the interim and the final analysis for OS. At the interim analysis, the significant treatment effect of trilaciclib compared with placebo for OS is established if the 1-sided p-value from the stratified log-rank test is less than or equal to 0.0075 (Table 13). If the final analysis is performed at 104 cumulative deaths as planned, a 1-sided significance level of 0.0227 will be used to evaluate treatment effect for OS at the final analysis. The actual significance level at the final analysis for OS will be re-calculated if the actual information fraction for the interim OS analysis is different than the planned 0.70 using the O'Brien-Fleming α -spending function.

There will be no final OS analysis if the superiority of trilaciclib over placebo for OS is established at the interim analysis.

Table 13: Thresholds for Claiming Statistical Superiority (Trilaciclib versus Placebo) at Interim or Final Analysis for Overall Survival

Analysis	# of Deaths	Analysis Timing from FPI (month) ^a	Z-scale	HR-scale	P-value Scale (1-Sided)
Interim Analysis	73	19	2.434	0.562	0.0075

Analysis	# of Deaths	Analysis Timing from FPI (month) ^a	Z-scale	HR-scale	P-value Scale (1-Sided)
Final Analysis ^b	104	30	2.000	0.673	0.0227

FPI=first patient randomized; HR=hazard ratio.

^a Estimated based on the assumptions of accrual period and duration of follow up as used in the sample size calculation.

^b Statistical criteria judging the significance at the final analysis could be re-calculated if the interim analysis information fraction is different than 0.70.

The aforementioned analyses will be conducted on the ITT population.

12.4.5.2 Analysis for Secondary Anti-tumor Efficacy Endpoints

Secondary anti-tumor endpoints include the following:

- Progression free survival (PFS)
- Objective response rate (ORR)
- Duration of objective response (DOR)

Progressive disease (PD) and tumor response status are derived per RECIST v1.1 based on tumor assessment data entered into the EDC by Investigators.

12.4.5.2.1 Analysis for Progression Free Survival

Progression free survival is defined as the time (months) from date of randomization to the date of documented radiologic PD per RECIST v1.1 or date of death regardless the cause, whichever comes first. PFS will be determined using all available data up to the date of (i) radiographic disease progression per RECIST v1.1; (ii) withdrawal of consent to obtain additional scans on study; or (iii) initiation of subsequent anticancer therapy, whichever is earliest. Censoring rules for patients who do not experience PD or death at the data cutoff date or at the date for final database lock will be detailed in the study SAP.

The treatment effect on PFS will be evaluated by using a stratified log-rank test controlling for the two stratification factors. A Cox proportional hazard model with the same terms as in the stratified log-rank test will be used to estimate the HR (trilaciclib versus placebo) for PFS along with its 95% confidence interval. In addition, Kaplan-Meier plots will be generated and the median, 25% and 75% percentile of PFS will be estimated using the Kaplan-Meier method by treatment group with their corresponding 95% confidence interval calculated using the method by Brookmeyer and Crowley (1982).

Per literature, the expected median PFS for patients receiving docetaxel is 3 months (Garon, 2014). Assuming trilaciclib can achieve a treatment effect of HR of 0.60, it is estimated that 86% of patients would have a radiographic disease progression or died at the time when OS interim analysis is performed. Therefore, the analysis for PFS will be conducted at the time of performing interim OS analysis. However, if the observed PD or deaths at the date of data cutoff for the OS interim analysis is less than 80%, the final PFS will be performed using the final database if the study is not stopped for success after the interim OS analysis. In that event, the treatment effect for PFS as observed at the final analysis will be considered to be primary.

PFS will be analyzed on the ITT population.

12.4.5.2.2 Analysis for Tumor Response Status and Duration of Objective Response

At each tumor assessment visit, an overall time point response per RECIST v1.1 will be determined programmatically using the measurements of target lesions, non-target lesions, and new lesions entered to the eCRF by the Investigators. Best overall response (BOR) will be determined per RECIST v1.1 using all timepoint responses prior to or on the date of (i) radiographic disease progression; (ii) withdrawal of consent to obtain tumor scans; (iii) death; (iv) lost to follow-up; or (v) initiation of subsequent anticancer therapy, whichever is earliest. The BOR status for patients will be summarized by the number and percentage of patients in each of the following categories: complete response (CR) (confirmed), partial response (PR) (confirmed), stable disease (SD) and Not Evaluable (NE).

ORR is defined as the proportion of patients with confirmed CR or confirmed PR as the BOR status. ORR along with its exact 95% two-sided confidence interval using the Clopper-Pearson method will be computed for each treatment group. The treatment group difference for ORR will be evaluated using a stratified Cochran–Mantel–Haenszel (CMH) test accounting for the two stratification factors. The adjusted proportion difference (trilaciclib minus placebo) and its 95% CI will be calculated using CMH weight (Kim, 2013).

DOR is the time (months) from the first date when CR or PR was achieved and confirmed in the next tumor scan to the date when the patient experienced disease progression or died in the absence of PD. For those who achieved objective response status and did not have disease progression or death at the time of data analysis, the earliest date of the following, if it exists, will be used to calculate censored time: (i) withdrew consent to obtain scans; (ii) last contact; (iii) initiated subsequent anticancer therapy; otherwise, the censored DOR will be calculated using the last date known with retained response status as of the data cutoff date for the analysis. DOR will be analyzed for the patients who have achieved objective response. The Kaplan-Meier method will be used to estimate the median, 25% and 75% percentile of DOR by treatment group, along with the 95% CI calculated using the method by Brookmeyer and Crowley (1982).

Analyses for ORR and DOR will be based on the Response Evaluable patient population.

12.4.5.3 Analysis for Myelosuppression Endpoints

Myelosuppression endpoints are grouped by lineage and consequence of CIM as follows.

- Neutrophils related (including DSN in Cycle 1, occurrence of SN, occurrence of FN, and occurrence of G-CSF administration)
- RBC related (including occurrence of Grade 3/4 decrease of hemoglobin, occurrence and number of RBC transfusions on/after Week 5, and occurrence of ESA administration)
- Platelet related (including occurrence of Grade 3 /4 decrease of platelets, occurrence and number of platelet transfusions)
- Endpoints related to trilaciclib's effect on chemotherapy dosing and hospitalization due to CIM (including occurrence and number of dose reductions or dose delay, and occurrence and number of hospitalization due to CIM)

12.4.5.3.1 Analysis for DSN in Cycle 1

For patients with at least one SN event (ANC value $<0.5 \times 10^9/L$) in Cycle 1, DSN (days) in Cycle 1 is defined as the number of days from the date of the first ANC value of $<0.5 \times 10^9/L$ observed at Cycle 1 to the date of the first ANC value $\geq 0.5 \times 10^9/L$ and no other ANC values $<0.5 \times 10^9/L$ occurred between this day and end of Cycle 1. DSN will be set to 0 for patients who do not experience SN in Cycle 1. Data from both scheduled and unscheduled assessments will be included in the calculation, and the actual assessment date will be used in the derivation of DSN in Cycle 1.

Treatment effect on DSN in Cycle 1 will be evaluated using a nonparametric analysis of covariance (ANCOVA) (Quade, 1967). In this analysis, the rank-transformed (within each stratum) DSN values are analyzed by an ANCOVA model with the terms of treatment, and the two stratification factors as fixed effects and the rank-transformed baseline ANC as a covariate. In addition, the mean difference (trilaciclib – placebo), the standard error and the 95% confidence interval for the difference generated from a Satterthwaite t-test will be presented.

12.4.5.3.2 Analysis for Binary Myelosuppression Endpoints

For the binary myelosuppression endpoints (e.g., the occurrence of SN and the occurrence of RBC transfusions on/after Week 5), the number and percentage of patients with at least one occurrence during the treatment period will be summarized by treatment group. The treatment effect will be evaluated using a Poisson regression model (Zou, 2004). The model will include the two stratification factors as the fixed effect with corresponding baseline value as a covariate when applicable (e.g., baseline ANC for occurrence of SN, and baseline hemoglobin for RBC transfusions on/after Week 5). The log-transformed duration of exposure either in week or in cycle will be used as the offset in the model to account for the variable duration for each patient (e.g., the number of cycles for occurrence of SN, and the number of weeks for RBC transfusions on/after Week 5). A 2-sided p-value, adjusted relative risk (aRR) (trilaciclib versus placebo) and its 95% CI will be generated from the statistical model as applied.

12.4.5.3.3 Analysis for Counting Myelosuppression Endpoints

For the counting myelosuppression endpoints (e.g., the number of RBC transfusions on/after Week 5, and the number of dose reductions during the treatment period), the total number of the event, the total number of exposure (either in the unit of week or cycle determined by the

medical meaning), and event rate per 100 weeks or cycles will be summarized by treatment group. For example, the event rate for RBC transfusions on/after Week 5 will be reported by 100 weeks and that for dose reduction will be reported by 100 cycles. For a given event, patients without any of the event during the treatment period will be assigned a value 0 to be included in the analysis. The treatment group difference in the event rate will be assessed by a negative binomial model. The model will include the two stratification factors as the fixed effect with corresponding baseline value as a covariate when applicable (e.g., baseline hemoglobin for the analysis of number of RBC transfusions on/after Week 5). The log-transformed duration of exposure in week or in cycle will be used as the offset in the model to account for the variable duration for each patient (e.g., number of weeks for RBC transfusions on/after Week 5, and number of cycles for dose reduction). A 2-sided p-value, aRR (trilaciclib versus placebo) and its 95% CI will be generated from the statistical model as applied.

12.4.5.4 Subgroup Analysis for Primary Efficacy Endpoint

Treatment effect for the primary endpoint OS will be evaluated for each of the stratification factors: Region (US, Europe, or Asia) and ECOG status (0-1 versus 2). The treatment effects in each category of a factor will be evaluated by using a stratified log-rank test controlling for the other stratification factor. A Cox proportional hazard model with the same terms as used in the stratified log-rank test will be employed to estimate the HR and its 95% CIs within each category of the factor. A forest plot for the HR of OS and its 95% CI will be produced.

Subgroup analysis will be conducted for some baseline characteristics that might have impact on the treatment effect for OS and the details will be specified in the study SAP.

12.4.6 PRO Analyses

The EORTC QLQ-C30, EORTC QLQ-LC13 (with [supplemental](#) weight loss item [\(EORTC IL118\)](#)), FACIT-Fatigue, EQ-5D-5L, PGIC, and PGIS instruments will be used to collect the quality-of-life data to assess the impact of trilaciclib on various quality of life measures compared with placebo. Analysis for the variables derived from these questionnaires will be based on the ITT population and detailed in the study SAP.

12.4.7 Safety Analyses

Safety and tolerability will be assessed by AEs, laboratory tests, vital signs and ECGs. All safety data will be summarized using descriptive statistics by treatment group on the safety population. Data collected through scheduled or non-scheduled visits will all be included in the safety analyses.

12.4.7.1 Adverse Events

AEs are defined as those events occurring or worsening after treatment has begun on this study. Adverse event data will be coded to system organ class (SOC) and PT using the latest version of MedDRA. The severity (toxicity grades 1-5) of AEs will be graded according to the NCI-CTCAE v5.0 by Investigators. The number and percentage of patients experiencing any AEs will be summarized overall and tabulated by SOC, PT and CTCAE grade for each treatment group. AEs considered by the Investigator to be related to a study drug, AEs leading to study drug discontinuation or dose modifications, and trilaciclib AESIs will be summarized by SOC, PT and CTCAE grade, when appropriate. In the tabulation of severity and causality of an AE, if

the same AE occurred on multiple occasions, the highest grade of toxicity and strongest relationship to the study drug will be used in a summary.

12.4.7.2 Other Safety Endpoints

Observed values and changes from baseline to each end of the cycle, the maximum and minimum values during the treatment period in vital signs, and ECG intervals, and laboratory assessments of hematology, serum chemistry, and liver function parameters will be summarized by treatment group.

Serum chemistry and hematology laboratory parameters will be characterized according to CTCAE toxicity grade from 1 to 5, when possible. The number and percentage of patients within each CTCAE grade will be summarized for the overall treatment period as well as for each cycle. If a patient has multiple laboratory assessments in an interval of interest, the maximum grade will be reported.

For vital signs and ECG parameters, potentially clinically significant (PCS) findings will be summarized by treatment group. The potentially clinically significant vital signs and ECG parameters are defined either by post-baseline assessments or by change from baseline with respect to the pre-specified thresholds. The criteria defining PCS for vital signs and ECG parameters will be detailed in the study SAP, respectively.

12.4.8 Exploratory Analyses

The number and percentage of patients in different CDK4/6 signature status (i.e., CDK4/6 independent, CDK4/6 dependent, and CDK4/6 indeterminate) will be summarized by treatment group. Anti-tumor efficacy endpoints (OS, PFS, and ORR) will be evaluated for the subgroup of patients with different CDK 4/6 signature status. Within each type of signature, the analysis for OS will follow the statistical methods as outlined in Section 12.4.6.1, and the analysis for PFS and ORR will use the similar statistical approaches as outlined in Section 12.4.6.2.

In addition, anti-tumor efficacy endpoints (OS, PFS, and ORR) will be evaluated by PD-L1 status determined using archived tumor tissues and applying similar statistical approaches as used for the analyses of anti-tumor efficacy endpoints by CDK4/6 signature status.

Treatment group differences in pharmacodynamic parameters obtained from peripheral blood including those relating to immune-based mechanisms will be evaluated.

12.4.9 Pharmacokinetic Analyses

The pharmacokinetics of trilaciclib will be determined using a non-linear mixed effects modeling approach. Relevant population pharmacokinetic parameters will be estimated and reported. Details of population pharmacokinetic analyses will be described in the population pharmacokinetic/pharmacodynamic analysis plan.

The pharmacokinetics of docetaxel will also be determined using a non-linear mixed effects modeling approach. Relevant population pharmacokinetic parameters will be estimated and reported. Details of population pharmacokinetic analyses will be described in the population pharmacokinetic/pharmacodynamic analysis plan.

12.4.10 Pharmacokinetic/Pharmacodynamic Analyses

If data warrant, exploratory analyses may be performed to examine the relationship(s) between exposure to trilaciclib and pharmacodynamic endpoints or other efficacy and safety endpoints. Details of population PK/pharmacodynamic analyses will be described in a separate population PK/pharmacodynamic analysis plan.

13 ETHICS

13.1 Ethics Review

The protocol, protocol amendments, ICF, IB, and other relevant documents (e.g., advertisements) must be submitted to an IRB/IEC by the Investigator and reviewed and approved by the IRB/IEC before the study is initiated.

Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study patients.

The Investigator will be responsible for the following:

- Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC
- Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC procedures
- Providing oversight of the conduct of the study at the site and adherence to requirements of 21 Code of Federal Regulations (CFR), International Council for Harmonisation (ICH) guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations

13.2 Ethical Conduct of the Study

This study will be conducted in accordance with the protocol and with the following:

- Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines
- Applicable ICH GCP Guidelines
- Applicable laws and regulations

13.3 Written Informed Consent

The Principal Investigator(s) at each center will ensure that the patient is given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study. Patients must also be notified that they are free to discontinue from the study at any time. The patient should be given the opportunity to ask questions and allowed time to consider the information provided.

The patient's signed and dated informed consent must be obtained before conducting any study procedures.

The Principal Investigator(s) must maintain the original, signed ICF. A copy of the signed ICF must be given to the patient or the patient's legally authorized representative where allowed by local regulation.

14 DATA HANDLING AND RECORDKEEPING

14.1 Data Protection

Patients will be assigned a unique identifier by the Sponsor. Any patient records or datasets that are transferred to the Sponsor will contain the identifier only; patient names or any information which would make the patient identifiable will not be transferred.

The patient must be informed that his/her personal study-related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the patient who will be required to give consent for their data to be used as described in the informed consent.

The patient must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.

14.2 Data Quality Assurance

- All patient data relating to the study will be recorded on eCRF unless transmitted to the Sponsor or Designee electronically. The Investigator is responsible for verifying that data entries are accurate and correct by physically or electronically signing the eCRF.
- The Investigator must maintain accurate documentation (source data) that supports the information entered in the eCRF.
- The Investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents.
- Monitoring details describing strategy (e.g., risk-based initiatives in operations and quality such as Risk Management and Mitigation Strategies and Analytical Risk Based Monitoring), methods, responsibilities, and requirements, including handling of noncompliance issues and monitoring techniques (central, remote, or on-site monitoring) are provided in the Monitoring Plan.
- The Sponsor or Designee is responsible for the data management of this study including quality checking of the data.
- Study Monitors will perform ongoing source data verification (SDV) at the frequencies and SDV extent as outlined in the Monitoring Plan to confirm that data entered into the eCRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of patients are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.
- The Investigator must maintain all documentation relating to the study for a period of 2 years after the last marketing application approval, or if not approved 2 years following the discontinuance of the investigation of trilaciclib. If it becomes necessary for the Sponsor or the Regulatory Authority to review any documentation relating to the study, the Investigator

must permit access to such records. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor. The Investigator must ensure that the records continue to be stored securely for as long as they are maintained. It is the responsibility of the Sponsor to inform the investigator when these documents no longer need to be retained. However, if required by local regulation that these documents should be retained for a longer period, then Retention of Documentation will abide by local regulation.

A study-specific COVID-19 Assessment Plan will be utilized for any necessary modifications and/or mitigation to the data collection, monitoring or other associated activities during this study due to the COVID-19 pandemic.

14.3 Dissemination of Clinical Study Data

The Sponsor fulfills its commitment to publicly disclose clinical study results through posting the results of studies on www.clinicaltrials.gov, the EudraCT, and other public registries in accordance with applicable local laws/regulations.

Data results are posted in an objective, accurate, balanced, and complete manner. Results are posted regardless of outcome of the study.

14.4 Source Documents

Source documents provide evidence for the existence of the patient and substantiate the integrity of the data collected. Source documents are filed at the Investigator's site. All data reported in the eCRF should be supported by source documents; direct entry of data into the eCRF is not permitted in this study.

Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

14.5 Audits and Inspections

Authorized representatives of G1 Therapeutics, Inc., a regulatory authority, an IEC, or IRB may visit the site to perform audits or inspections, including source data verification. The purpose of an audit or inspection is to systematically and independently examine all study-related activities and documents to determine whether these activities were conducted, and data were recorded, analyzed, and accurately reported according to the protocol, GCP guidelines of the ICH, and any applicable regulatory requirements. The Investigator should contact G1 Therapeutics, Inc. immediately if contacted by a regulatory agency about an inspection.

15 PUBLICATION POLICY

By signing the study protocol, the Investigator and his or her institution agree that the results of the study may be used by G1 Therapeutics, Inc. for the purposes of national and international registration, publication, and information for medical and pharmaceutical professionals. If necessary, the authorities will be notified of the Investigator's name, address, qualifications, and extent of involvement.

Initial publication of the results of this study will be of a cooperative nature that may include authors representing the Sponsor, Investigator(s), and collaborating scientists. Independent publications by involved individuals may follow. Investigators and their institutions agree not to publish or publicly present any interim results of studies without the prior written consent of G1 Therapeutics, Inc. G1 Therapeutics Inc. reserves the right to request modification of any publication, presentation or use by the Investigator if such activity may jeopardize a patent application, an existing patent, or other proprietary rights. G1 Therapeutics, Inc. shall determine order of authorship of any publication combining all clinical results of this study.

16 REFERENCES

Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. *Eur J Cancer*. 2011;47:8-32.

Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. *Journal of the National Cancer Institute* 1993;85:365-76.

American Cancer Society. Key Statistics for Lung Cancer. Accessed 03 Dec 2020:
<https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html>

Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. *Non-Small Cell Lung Cancer*. *Br J Cancer*. 2000;83(4):447-53.

Aranesp® (darbepoetin alpha) Prescribing Information. Amgen. 2011. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103951Orig1s5173_103951Orig1s52581bl.pdf

ASCO. Cancer.Net. Lung Cancer – Non-Small Cell: Statistics. Accessed 03 Dec 2020:
<https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics>

Baghdadi TA, Halabi S, Garrett-Mayer E, et al. Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. *JCO Precision Oncology*. 2019;3:1-8.

Barlesi F, Mazieres J, Merlio J-P, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). *Lancet*. 2016;387(10026):1415-26.

Barrueto L, Caminero F, Cash L. Resistance to checkpoint inhibition in cancer immunotherapy. *Transl Onc*. 2020;13:100738.

Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. *European Journal of Cancer*. 1994;30A:635-42.

- Bisi JE, Sorrentino JA, Roberts PJ, et al. Preclinical characterization of G1T28: A novel CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression. *Mol Cancer Ther*. 2016;15:783–93.
- Blackhall FH, O'Brien M, Schmid P, et al. A phase I study of vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. *J Thorac Oncol*. 2010;5:1285-1288.
- Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. *Ann Intern Med*. 1966;64(2):328-40.
- Bohlius J, Bohlke K, Castelli R, et al. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. 2019; 37.
- Bonelli M, La Monica S, Fumarola C, et al. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation. *Biochem Pharmacol*. 2019;170:113676.
- Borcherding N, Kolb R, Gullicksrud J, et al. Keeping tumors in check: A mechanistic review of clinical response and resistance to immune checkpoint blockade in cancer. *J Mol Biol*. 2018;430:2014-29.
- Bracci L, Schiavoni G, Sistigu A, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. *Cell Death Differ*. 2014 Jan;21(1):15-25.
- Brody R, Zhang Y, Ballas M, et al. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. *Lung Cancer*. 2017;112:200-15.
- Brookmeyer R., and Crowley J. (1982). A confidence interval for the median survival time. *Biometrics*. 29-41.
- Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. *Cancer*. 2005;103(9):1916-24.
- Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature*. 2012;490(7418):61-70.
- Carson JL, Guyatt G, Heddle NM, et al. Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. *JAMA*. 2016;316(19):2025-35.
- Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov*. 2012;2:401-4.
- Chaikovsky AC, Sage J. Beyond the cell cycle: enhancing the immune surveillance of tumors via CDK4/6 inhibition. *Mol Cancer Res*. 2018;16:1454-57.
- Chen WS, Alshalalfa M, Zhao SG, et al. Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. *Clin Cancer Res*. 2019;25(14):4290-9.
- Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. *Tumori*. 2012;98(6):751-5.

Clark A, McAndrew NP, Troxel A, et al. Combination paclitaxel and Palbociclib: Results of a Phase 1 trial in advanced breast cancer. *Clin Cancer Res.* 2019;25(7):2072-9.

Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial [published online ahead of print, 2020 Dec 21]. *Int J Cancer.* 2020;10.1002/ijc.33453.

Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib decreases myelosuppression in extensive-stage small cell lung cancer patients receiving first-line chemotherapy plus atezolizumab. *ESMO Annual Meeting 2019; Barcelona, Spain; Sep 2019 (abstr 1742PD).*

Deng J, Wang ES, Jenkins RW, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. *Cancer Discov.* 2018;8:216-33.

Edelman MJ, Redman MW, Albain KS, et al. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). *J Thorac Oncol.* 2019;14(10):1853-9.

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). *Eur J Cancer.* 2009;45:228-247.

Ertel A, Dean JL, Rui H, et al. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. *Cell Cycle.* 2010; 9(20):4153-63.

Fares CM, Van Allen EM, Drake CG, et al. Mechanisms of resistance to immune checkpoint blockade: Why does checkpoint inhibitor immunotherapy not work for all patients? 2019 ASCO Educational Book.

Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). Published by: European Organisation for Research and Treatment of Cancer, Brussels 2001.

Finn RS, Liu Y, Zhu Z, et al. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. *Clin Cancer Res.* 2020;26(1):110-21.

Food and Drug Administration (FDA) Guidance for Industry, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2008.

Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. *J Clin Oncol.* 2000;18(12):2354.

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. *N Engl J Med.* 2010 Nov 11;363(20):1938-48.

Freed DM, Hall CR, Strum JC. CDK4/6 inhibition with lerociclib (G1T38) delays acquired resistance to targeted therapies in preclinical models of non-small cell lung cancer. *American Association for Cancer Research Annual Meeting 2019; Chicago, IL, 201 (abstr 4415).*

- Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal*. 2013;6:pl1. doi: 10.1126/scisignal.2004088.
- Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *NEJM*. 2018;378:2078-92.
- Garon EB, Ciuleanu T, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomized phase 3 trial. *Lancet*. 2014;384:665-73.
- Gidel TN, Wilmott JS, Scolyer RA, et al. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. *Clin Cancer Res*. 2018;24(6).
- Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumor immunity. *Nature* 2017; 548(7668): 471-5.
- Goldman JW, Gandhi L, Patnaik A, et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer. *J Clin Oncol*. 2014;32(15_Suppl.):8026.
- Goldman JW, Mazieres J, Barlesi F, et al. A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER. *Journal of Clinical Oncology*. 2018 36:15_suppl, 9025.
- Goldman JW, Mazieres J, Barlesi F, et al. A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable *KRAS* Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. *Front Oncol*. 2020;10:578756.
- Gong X, Litchfield LM, Webster Y, et al. Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib. *Cancer Cell*. 2017;32(6):761-776.e6.
- Gopalan PK, Villegas AG, Cao C, et al. CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition. *Oncotarget*. 2018;9(100):37352-66.
- Gopalan PK, Pinder MC, Chiappori A, et al. A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A. *J Clin Oncol*. 2014;32(5_Suppl.):8077.
- Gridelli C, Gallo C, Di Maio M, et al A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. *Br J Cancer*. 2004;91(12):1996.
- Gustineti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: A practical update. *Virulence*. 2016;7(3):280-97.
- Haines E, Chen T, Kommajosyula N, et al. Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in *KRAS*-mutant non-small cell lung cancer. *Oncotarget*. 2018;9(60):31572-31589.

- Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. *J Clin Oncol*. 2004;22(9):1589.
- Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. *Adv Ther*. 2020. doi: 10.1007/s12325-020-01538-0.
- He S, Roberts PJ, Sorrentino JA, et al. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. *Sci Transl Med*. 2017;9.
- He Y, Rozeboom L, Rivard CJ, et al. MHC class II expression in lung cancer. *Lung Cancer*. 2017 Oct;112:75-80.
- Herschkowitz JI, He X, Fan C, et al. The functional loss of the retinoblastoma tumor suppressor is a common event in basal-like and luminal B breast carcinomas. *Breast Cancer Res*. 2008;10(5):R75.
- Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Practice Guideline Update. *J Clin Oncol*. 2020;38.
- Hodge JW, Garnett CT, Farsaci B, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. *Int J Cancer*. 2013;133(3):624-36.
- Horsley V, Aliprantis AO, Polak L, et al. NFATc1 balances quiescence and proliferation of skin stem cells. *Cell*. 2008;132(2):299-310.
- Infante JR, Cassier PA, Gerecitano JF, et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. *Clin Cancer Res*. 2016;22:5696–705.
- Jang RW, Caraiscos VB, Swami N, et al. Simple prognostic model for patients with advanced cancer based on performance status. *J Oncol Pract*. 2014;10(5):e335-41.
- Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. *Brit J Cancer*. 2018;118:9-16.
- Kalbfleisch, J.D, and Prentice, R.L. 1980. *The Statistical Analysis of Failure Time Data*. New York: John Wiley & Sons.
- Kalemkerian GP, Narula N, Kennedy EB. Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors: America Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for Molecular Pathology Clinical Practice Guideline Update. *ASCO*. 2018;14(5):323-7.
- Karasic TB, O'Hara MH, Teitelbaum UR, et al. Phase II trial of palbociclib in patients with advanced esophageal or gastric cancer. *J Clin Oncol*. 2018;36(4_Suppl.):68.
- Kaufman RM, Djulbegovic BD, Gernsheimer T, et al. Platelet Transfusion: A Clinical Practice Guideline From the AABB. *Ann Intern Med*. 2015; 162:205-213.
- Kim Y, Won S. (2013) Adjusted proportion difference and confidence interval in stratified randomized trials. *PharmaSUG; Paper SP-04*.

- Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. *Cancer Cell*. 2018;34(1):9-20.
- Knudsen ES, Witkiewicz AK. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. *Trends Cancer*. 2017;3(1):39-55.
- Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. *Clin Cancer Res*. 2010;16(18):4583-94.
- Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. *Br J Cancer*. 1996;73(2):148-53.
- Kozar K, Ciemerych MA, Rebel VI, et al. Mouse development and cell proliferation in the absence of D-cyclins. *Cell*. 2004;118(4):477-91.
- Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancer to select targeted drugs. *JAMA*. 2014;311(19):1998-2006.
- Lai AY, Sorrentino JA, Dragnev KH, et al. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. *J Immunother Cancer*. 2020; 8.
- Lewis C, Smith DC, Carneiro BA, et al. A Phase 1b study of the oral CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration resistant prostate cancer (mCRPC) – A prostate cancer clinical trials consortium study. 2018;36(15):e17028.
- Li CH, Karantza V, Aktan G, et al. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. *Breast Cancer Res*. 2019;21:143.
- Li H, Xu Y, Wan B, et al. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. *Transl Lung Cancer Res*. 2019;8(4):429-49.
- Li Y, Kippel Z, Shih X, et al. Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies. *Support Care Cancer* 2016;24(10):4377-83.
- Li JY, Duan XF, Wang LP, et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. *J Immunol Res*. 2014;2014:286170.
- Little AG, Gay EGG, Gaspar LE, et al. National survey of non-small cell lung cancer in the United States: Epidemiology pathology and patterns of care. *Lung Cancer*. 2007;57:253-60.
- Liu D, Jenkins R, Sullivan RJ. Mechanisms of resistance to immune checkpoint blockade. *Am J Clin Dermatol*. 2019;20(1):41-54.
- Lyman 2006
- Malumbres M, Sotillo R, Santamaria D, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. *Cell*. 2004;118(4):493-504.

- Maroulakou IG, Anver M, Garrett L, et al. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. *Proc Natl Acad Sci USA* 1994;91:11236-11240.
- McDonnell AM, Nowak AK, Lake RA. Contribution of the immune system to the chemotherapeutic response. *Semin Immunopathol*. 2011;33(4):353-67.
- Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. *Med Oncol*. 2011;28(3):682-8.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer. Version 1.2021. 2020. NCCN, Fort Washington, PA.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Hematopoietic Growth Factors. Version 2. 2020b. NCCN, Fort Washington, PA.
- Nieuweboer AJ, de Morree ES, de Graan AJ, Sparreboom A, de Wit R, Mathijssen RH. Inter-patient variability in docetaxel pharmacokinetics: A review. *Cancer Treat Rev*. 2015;41(7):605-13.
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol*. 1982;5(6):649-55.
- Opzomer JW, Sosnowska D, Anstee JE, Spicer JF, Arnold JN. Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer. *Front Immunol*. 2019;10:1654.
- O'Shaughnessy J, Wright GS, Thummala AR, et al. Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized Phase 2 trial. San Antonio Breast Cancer Symposium. Dec 8-11 2020. Poster #PD1-06
- Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. *Cancer Discov*. 2016;6(7):740-53.
- Paz-Ares L, Luft A, Vincente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *NEJM*. 2018;379:2040-51.
- Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. *Cancer*. 2006;107(12):2866-72.
- Procrit® (epoetin alpha) Prescribing Information. Janssen Products LP. 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5363s5366lbl.pdf
- Quade, D. (1967). Rank analysis of covariance. *Journal of the American Statistical Association* 1967; 62:1187-1200.
- Ramsey MR, Krishnamurthy J, Pei XH, et al. Expression of p16Ink4a Compensates for p16Ink4a Loss in Cyclin-Dependent Kinase 4/6-Dependent Tumors and Tissues. *Cancer Res* 2007;67:4732-41.

- Reck M, Rodriguez-Abreu D, Robinson EG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *NEJM*. 2016;375(19):1823-33.
- Rose TL, Chism DD, Shivaram Alva A, et al. Phase II trial of Palbociclib (pd-0332991) in patients with metastatic urothelial cancer (UC) after failure of first-line chemotherapy. *Journal of Clinical Oncology*. 2018;36:500.
- Schaer DA, Beckmann RP, Dempsey JA, et al. The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. *Cell Rep*. 2018;22:2978-94.
- Shapiro GI. Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search. *Cancer Cell*. 2017;32(6):721-3.
- Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. *J Clin Oncol*. 2001;19(5):1519-38.
- Shen R, Wang X, Drissi H, et al. Cyclin D1-cdk4 induce runx2 ubiquitination and degradation. *J Biol Chem*. 2006;281:16347-53.
- Shepherd FA, Dancey J, Ramlau, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *J Clin Oncol*. 2000;18(10):2095-103.
- Sherr CJ, McCormick F. The RB and p53 pathways in cancer. *Cancer Cell*. 2002;2(2):103-12.
- Shimizu K, Nakata M, Hiram Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. *J Thorac Oncol*. 2010;5(5):585-90.
- Smith RE. Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors. *J Natl Compr Canc Netw*. 2006;4:649-58.
- Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2015;33:3199-212.
- Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naïve patients with extensive-stage small-cell lung cancer. *J Clin Oncol*. 2009;27:4787-4792.
- Sorrentino JA, Bisi JE, Thompson D, et al. Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models. 30th EORTC-NCI-AACR Symposium. 13-16 November 2018. Dublin, Ireland.
- Spigel D, de Marinis F, Giaccone G, et al. Impower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC. EMSO 2019 Congress. 27 Sep 2019.
- Stefansson OA, Jonasson JG, Olafsdottir K, et al. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. *Epigenetics* 2011; 6(5):638-49.

Subhawong AP, Subhawong T, Nassar H, Kouprina N, Begum S, Vang R, et al. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. *Am J Surg Pathol*. 2009; 33:163-75.

Sweeney CJ, Zhu J, Sandler AB, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic non-small cell lung carcinoma. *Cancer*. 2001;92(10):2639-47.

Tan AR, Wright GS, Thummala AR, et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomized, open-label, Phase 2 trial. *Lancet Oncol*. 2019;20:1587-601.

Taxotere® (docetaxel) Prescribing Information. Sanofi-Aventis U.S. LLC. 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020449s0841b1.pdf

Taxotere® (docetaxel) Summary of Product Characteristics. Sanofi Mature IP. France. 2005. Available at: https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf.

Teh JLF, Aplin AE. Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment. *Clin Cancer Res*. 2019;25(3).

Treré D, Brighenti E, Donati G, et al. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. *Ann Oncol*. 2009 Nov;20(11):1818-23.

Turner NC, Liu Y, Zhu Z, et al. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer [published correction appears in *J Clin Oncol*. 2019 Nov 1;37(31):2956]. *J Clin Oncol*. 2019;37(14):1169-78.

Wang S, He Z, Wang X, Li H, Liu XS. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. *Elife*. 2019;8:e49020.

Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. *Ann Oncol*. 2019;30:1613-21.

Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. *Science*. 2008;322(5899):271-5.

Witkiewicz AK, Ertel A, McFalls J, Valsecchi ME, Schwartz G., Knudsen ES. RB-Pathway Disruption Is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer. *Clin Cancer Res*. 2012;18:5110-22.

Woo EY, Yeh H, Chu CS, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. *J Immunol*. 2002;168(9):4272-76.

Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. *Cancer Res*. 2001;61(12):4766-72.

World Health Organization (WHO). Cancer: Key facts. Accessed 03 Dec 2020: <https://www.who.int/news-room/fact->

sheets/detail/cancer#:~:text=Cancer%20is%20a%20leading%20cause,Lung%20(2.09%20million%20cases).

Yellen SB, Cella OF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) Measurement System. J Pain Symptom Manage. 1997;13(2):63-74.

Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance [published correction appears in Nature. 2019 Jul;571(7766):E10]. Nature. 2018;553(7686):91-5.

Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol. 2010;7(5):389-95.

Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59-73.

Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702-6.

17 APPENDICES

17.1 Clinical Laboratory Tests

- The timing and laboratory tests detailed in Schedule of Assessments (Table 6) will be performed by a local laboratory.
- Protocol-specific requirements for inclusion or exclusion of patients are detailed in Section 7 of the protocol.
- Additional tests may be performed at any time during the study as determined necessary by the Investigator or required by local regulations.

Table 14: Protocol-Specified Safety Laboratory Assessments

Laboratory Assessment	Parameters		
Hematology	WBC	Hemoglobin	Absolute neutrophil count
	Platelets	Lymphocytes	Hematocrit
Serum Chemistry	Blood Urea Nitrogen (BUN) or Urea	Serum Creatinine	Bicarbonate
	Aspartate Aminotransferase (AST)	Alanine Aminotransferase (ALT)	Calcium
	Potassium	Sodium	Chloride
	Glucose	Total Protein	Albumin
	Alkaline phosphatase	Total Bilirubin	

Laboratory Assessment	Parameters
Other Tests	Serum or urine human chorionic gonadotropin (hCG) pregnancy test (for WOCBP only)

hCG=human chorionic gonadotropin; RBC=red blood cell; WBC=white blood cell; WOCBP=woman of childbearing potential

17.2 Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting

17.2.1 Definition of AE

AE Definition
<ul style="list-style-type: none"> • An AE is any untoward medical occurrence in a patient or clinical study patient, temporally associated with the use of study intervention, whether or not considered related to the study intervention. • NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.
Events <u>Meeting</u> the AE Definition
<ul style="list-style-type: none"> • Any abnormal laboratory test results (hematology, serum chemistry) or other safety assessments (e.g., ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinically significant and require clinical intervention or further investigation (beyond ordering a repeat [confirmatory] test) in the medical and scientific judgment of the Investigator (i.e., not related to progression of underlying disease) unless they are associated with an already reported clinical event, e.g. elevated liver enzymes in a patient with jaundice. • Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition. • New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study. • Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.

AE Definition
Events <u>NOT</u> Meeting the AE Definition
<ul style="list-style-type: none"> Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are associated with the underlying disease, unless judged by the Investigator to be more severe than expected for the patient's condition. The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the patient's condition. Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the procedure is the AE. Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital). Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen.

17.2.2 Definition of SAE

If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met (e.g., hospitalization for signs/symptoms of the disease under study, death due to progression of disease).

A SAE is defined as any untoward medical occurrence that, at any dose:
1. Results in death
2. Is life-threatening The term 'life-threatening' in the definition of 'serious' refers to an event in which the patient was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.
3. Requires inpatient hospitalization or prolongation of existing hospitalization In general, hospitalization signifies that the patient has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician's office or outpatient setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline is not considered an AE.
4. Results in persistent disability/incapacity <ul style="list-style-type: none"> The term disability means a substantial disruption of a person's ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.
5. Is a congenital anomaly/birth defect
6. Other situations:

A SAE is defined as any untoward medical occurrence that, at any dose:

- Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious.
- Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

17.2.3 Recording and Follow-Up of AE and/or SAE

<p>AE and SAE Recording</p> <ul style="list-style-type: none"> • When an AE/SAE occurs, it is the responsibility of the Investigator to review all documentation (e.g., hospital progress notes, laboratory reports, and diagnostics reports) related to the event. • The Investigator will then record all relevant AE/SAE information in the eCRF. • It is not acceptable for the Investigator to send photocopies of the patient's medical records to G1 Therapeutics, Inc. (or designee) in lieu of completion of the AE/SAE eCRF page. • There may be instances when copies of medical records for certain cases are requested by G1 Therapeutics, Inc. (or designee). In this case, all patient identifiers, with the exception of the patient number, will be redacted on the copies of the medical records before submission to G1 Therapeutics, Inc. (or designee). • The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE. • All SAEs should be reported to G1 Therapeutics, Inc. PVG (or designee) within 24 hours of notification on an SAE Form in the eCRF. Any relevant source data related to the SAE that cannot be entered in the EDC should be emailed or faxed to G1 Therapeutics, Inc. PVG (or designee): <p>G1 Therapeutics, Inc. Pharmacovigilance Email: safetyreporting@g1therapeutics.com Fax: +1-984-285-7131</p>
<p>Assessment of Intensity</p> <p>Intensity will be assessed using NCI-CTCAE v5.0 criteria, as follows:</p> <ul style="list-style-type: none"> • Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. • Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. • Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. • Grade 4: Life-threatening consequences; urgent intervention indicated. • Grade 5: Death related to AE.

AE and SAE Recording
Assessment of Causality
<ul style="list-style-type: none"> • The Investigator is obligated to assess the relationship between study intervention and each occurrence of each AE/SAE (Related or Not Related); i.e., is there a “reasonable possibility” the study intervention caused the event (yes/no). • A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. • The Investigator will use clinical judgment to determine the relationship. • Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study intervention administration will be considered and investigated. • The Investigator will also consult the IB and/or Product Information, for marketed products, in his/her assessment. • For each AE/SAE, the Investigator must document in the medical notes that he/she has reviewed the AE/SAE and has provided an assessment of causality. • There may be situations in which an SAE has occurred and the Investigator has minimal information to include in the initial report to G1 Therapeutics, Inc. PVG (or designee). However, it is very important that the Investigator always make an assessment of causality (Not Related or Related) for every event before the initial transmission of the SAE data to G1 Therapeutics, Inc. PVG (or designee). • The Investigator may change his/her opinion of causality in light of follow-up information and send a SAE follow-up report with the updated causality assessment. • The causality assessment is one of the criteria used when determining regulatory reporting requirements.
Follow-up of SAEs
<ul style="list-style-type: none"> • The Investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by G1 Therapeutics, Inc. PVG (or designee) to elucidate the nature and/or causality of the SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals. • New or updated information will be recorded in the originally completed eCRF. • The Investigator will submit any new or updated SAE data to G1 Therapeutics, Inc. PVG (or designee) within 24 hours of receipt of the information: <p>G1 Therapeutics, Inc. Pharmacovigilance Email: safetyreporting@g1therapeutics.com Fax: +1-984-285-7131</p>

17.2.4 Reporting of SAEs

SAE Reporting to G1 Therapeutics, Inc. (or designee) via an Electronic Data Collection Tool

- The primary mechanism for reporting an SAE to G1 Therapeutics, Inc. (or designee) will be the EDC.
- If the electronic system is unavailable, then the site will use the paper SAE Report Form in order to report the event within 24 hours via email or fax (see below for SAE reporting contact information).
- The site will enter the SAE data into the electronic system as soon as it becomes available.
- After the study is completed at a given site, the electronic data collection tool will be taken off-line to prevent the entry of new data or changes to existing data.
- If a site receives a report of a new SAE from a study patient or receives updated data on a previously reported SAE after the electronic data collection tool has been taken off-line, then the site should report this information on a paper SAE Report form or notify the Medical Monitor by telephone.
- Contact for SAE reporting:
G1 Therapeutics, Inc. Pharmacovigilance
Email: safetyreporting@g1therapeutics.com
Fax: +1-984-285-7131

17.3 Contraceptive Guidance and Collection of Pregnancy Information

WOCBP Definition

Woman of Childbearing Potential

A woman is considered fertile following menarche and until becoming post-menopausal unless permanently sterile (see below).

If fertility is unclear (e.g., amenorrhea in adolescents or athletes), additional evaluation should be considered.

Women in the following categories are not considered Woman of Childbearing Potential

1. Premenarchal

Note: Documentation can come from the site personnel's review of the patient's medical records, medical examination, or medical history interview.

6. Premenopausal female with 1 of the following acceptable surgical sterilization techniques: complete or partial hysterectomy, bilateral tubal ligation, or occlusion with surgery at least 6 months prior to dosing, or bilateral oophorectomy with surgery at least 2 months prior to dosing.
7. Postmenopausal female: defined as spontaneous amenorrhea for >12 months prior to Screening without alternative cause (e.g., implantable contraceptive, side effect of medication, etc.) and a serum follicle stimulating hormone (FSH) within the laboratory's reference range for postmenopausal females.
- Women taking hormone replacement therapy (HRT) must discontinue HRT at least 2-4 weeks prior to Screening for accurate assessment of FSH (though exact interval will depend on the type and dosage of HRT and should be determined by the principal Investigator).

Contraception Guidance

Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

- Male patients: Males must be surgically sterile prior to Screening with appropriate documentation (absence of sperm in ejaculate 6 months after procedure) or have a female partner(s) who is either postmenopausal, surgically sterile, or using 2 forms of concurrent contraception as defined below. In addition, males must also refrain from sperm donation during the study and utilize a barrier method with intercourse during and for 6 months following discontinuation of treatment.
- Female patients: All females of childbearing potential must have a negative serum β -hCG test result at Screening, and negative serum or urine pregnancy test at each cycle during treatment and at the Post Treatment Visit (see Section 11.3.5 and Table 6).
- Females must be either postmenopausal, surgically sterile, or agree to use 2 concurrent forms of contraception during the study and for 6 months following last dose of study drug. Acceptable forms of contraception include:

- Established use of oral, injected or implanted hormonal methods of contraception (stable dose at least 3 months prior to dosing)
 - Intrauterine device or intrauterine system
 - Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. Barrier methods alone (without spermicide) are not acceptable methods. Likewise, spermicide alone is not an acceptable method
 - Male sterilization prior to Screening with the appropriate post-vasectomy documentation (absence of sperm in the ejaculate 6 months after procedure). For female patients on the study, the vasectomized male partner should be the sole partner for that patient
 - True abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
- For patients who are exclusively in same-sex relationships, contraceptive requirements do not apply. If a patient who is in a same-sex relationship at the time of signing the ICF becomes engaged in a heterosexual relationship, they must agree to use contraception as described previously. If a patient who is abstinent at the time of signing the ICF becomes sexually active, they must agree to use contraception as described above.

Collection of Pregnancy Information

Male participants with partners who become pregnant

- The Investigator or designee will attempt to collect pregnancy information on any male patient's female partner who becomes pregnant while the male patient is in this study. This applies only to males who receive study intervention.
- After obtaining the necessary signed informed consent from the pregnant female partner directly, the Investigator or designee will record pregnancy information on the Pregnancy – Initial Report Form and submitted to G1 Therapeutics, Inc. PVG or designee within 24 hours of learning of the partner's pregnancy. The female partner will also be followed to determine the outcome of the pregnancy. The Pregnancy – Follow-up Report Form should be used to report information on the status of the mother and child and will be forwarded to G1 Therapeutics, Inc. PVG or designee. Generally, the follow-up will be no longer than 12 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.
- Contact for Pregnancy reporting:
G1 Therapeutics Pharmacovigilance
Email: safetyreporting@g1therapeutics.com
Fax: +1-984-285-7131

Female Patients who become pregnant

- The Investigator or designee will collect pregnancy information on any female patient who becomes pregnant while participating in this study. The initial Information will be recorded

on the Pregnancy Reporting and Outcome Form (Pregnancy – Initial Report Form) and submitted to G1 PVG or designee within 24 hours of learning of a patient's pregnancy within 24 hours of learning of a patient's pregnancy.

- The patient will be followed to determine the outcome of the pregnancy. The Investigator or designee will collect follow-up information on the patient and the neonate and the information will be collected on the Pregnancy – Follow-up Report Form and forwarded to G1 Therapeutics, Inc. PVG or designee. Generally, follow-up will not be required for longer than 12 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.
- While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy for medical reasons will be reported as an AE or SAE. A spontaneous abortion (occurring at <22 weeks gestational age) or still birth (occurring at >22 weeks gestational age) is always considered to be an SAE and will be reported as such. Any post-study pregnancy related SAE considered reasonably related to the study intervention by the Investigator will be reported to G1 Therapeutics, Inc. PVG or designee. While the Investigator is not obligated to actively seek this information in former study patients, he or she may learn of an SAE through spontaneous reporting.
- Any female patient who becomes pregnant while participating in the study will discontinue study intervention.
- Contact for Pregnancy reporting:

G1 Therapeutics Pharmacovigilance

Email: safetyreporting@g1therapeutics.com

Fax: +1-984-285-7131

17.4 Definitions of Tumor Response and Disease Progression (per RECIST v1.1)

The determination of tumor response and progression will be based on the RECIST v1.1 (Eisenhauer, 2009). Disease progression may also be determined clinically by the Investigator. Tumor lesions will be categorized as follows:

Measurable lesions: tumor lesions with a longest diameter (measured in at least 1 dimension) with a minimum size as follows:

- 10 mm by CT or MRI (with a scan slice thickness of no greater than 5 mm)
- Measurable lymph nodes must be ≥ 15 mm on the short axis by CT or MRI (with a scan slice thickness of no greater than 5 mm); only the short axis is to be measured at baseline and follow-up.
- Lytic bone lesions or mixed lytic-blastic lesions with a soft tissue component meeting the definition of measurability above can be considered measurable lesions.
- Cystic lesions representing cystic metastases that meet the definition of measurability described above can be considered measurable lesions. If present, noncystic lesions should be selected as target lesions for this study.
- A tumor lesion that has been previously irradiated may be considered measurable if unequivocal growth of the lesion has been demonstrated.

Target lesions: At baseline, up to 5 measurable tumor lesions/lymph nodes (with a maximum of 2 lesions per organ) should be identified as target lesions. Lesions with the longest diameter, that are representative of all involved organs, and for which reproducible repeated measurements can be obtained should be selected as the target lesions. Malignant lymph node is considered an organ in this study, therefore only 2 malignant lymph nodes (regardless of location) may be selected as target lesions and all others should be entered as nontarget lesions.

Non-measurable Lesions: tumor lesions with a longest diameter < 10 mm, lymph nodes with ≥ 10 to < 15 mm short axis, or non-measurable lesions such as leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, or abdominal masses/abdominal organomegaly identified by physical exam that is not measurable by CT scan or MRI.

Nontarget lesions: All other lesions (or sites of disease) identified at baseline should be identified as nontarget lesions and recorded in the eCRF. Measurements of these lesions are not required, but the presence, absence, or unequivocal progression of each nontarget lesion should be recorded in the eCRF at each follow up time point. Multiple nontarget lesions in the same organ may be noted as a single item on the eCRF.

Evaluation of Target Lesions

The definitions for tumor response for the target lesion per RECIST v1.1 are as follows:

Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm (< 1 cm).

Partial Response: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Progressive Disease: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm (0.5 cm). (Note: the appearance of one or more new lesions is also considered progression).

Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Evaluation of Non-Target Lesions

Complete Response: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (<10 mm [<1 cm] short axis).

Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.

Progressive Disease: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. ‘Unequivocal progression’ represents a substantial increase in overall tumor burden such that treatment should be discontinued even in the setting of SD or PR in the target disease. Although a clear progression of “non-target” lesions only is rare, the opinion of the treating physician should prevail in such circumstances.

Appearance of New Lesions

The appearance of new lesion(s) is considered PD according to RECIST v1.1.

Timepoint Response

Patients with Measurable Disease (i.e., Target \pm Non-Target Disease)

Target Lesions	Non-Target Lesions	New Lesions	Overall Response
CR	CR	No	CR
CR	Non-CR/Non-PD	No	PR
CR	NE	No	PR
PR	Non-CR/Non-PD/NE	No	PR
SD	Non-CR/Non-PD/NE	No	SD
NE	Non-PD	No	NE
PD	Any	Yes or No	PD
Any	PD ^a	Yes or No	PD
Any	Any	Yes	PD

CR=complete response; NE=not evaluable; PD: progressive disease; PR=partial response; SD=stable disease.

Note: Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “*symptomatic deterioration*.” Every effort should be made to document the objective progression even after discontinuation of treatment.

^a Unequivocal progression in non-target lesions may be accepted as disease progression.

Patients with Evaluable or Non-Measurable Disease Only (i.e., Non-Target Disease)

Non-Target Lesions	New Lesions	Overall Response
CR	No	CR
Non-CR/non-PD	No	Non-CR/non-PD ^a
Not all evaluated	No	NE
Unequivocal PD	Yes or No	PD
Any	Yes	PD

CR=complete response; NE=not evaluable; PD: progressive disease; SD=stable disease.

^a 'Non-CR/non-PD' is preferred over 'stable disease' for non-target disease since SD is increasingly used as an endpoint for assessment of efficacy in some studies so to assign this category when no lesions can be measured is not advised.

TABLE OF CONTENTS

6.2 Patient Data Listings	1
Listing: 16.2.1.1 Patient Disposition All Randomized Patients	2
Listing: 16.2.1.2 Protocol Deviations All Enrolled Patients	5
Listing: 16.2.2 Demographic and Patient Characteristics All Enrolled Patients	9
Listing: 16.2.13.1 Timepoint and Best Overall Response All Randomized Patients	12
Listing: 16.2.13.2 New and Target Lesions - Investigator Assessments All Randomized Patients	14
Listing: 16.2.13.3 Non-Target Lesions - Investigator Assessments All Randomized Patients	18
Listing: 16.2.6.1 Adverse Events Safety Population	19
Listing: 16.2.7.1 Laboratory Values - Chemistry All Randomized Patients	51

Listing: 16.2.1.1
Patient Disposition
All Randomized Patients

Treatment: Placebo

Subject Number	Drug	Study Drug Disposition			Study Discontinuation			
		Date of First Drug Dose/Date Decided to Discontinue (Study Day)	Reason for Drug Discont.	Survival Follow- up?	Date of Study Discont./ Date of Last Contact	Reason for Study Discont.	Date of Death (Study Day)/ Primary Cause of Death	Cancer Treatment Since Last Contact?
3145-2004	PLACEBO	2021-08-11/ 2021-11-12 (94)	STUDY TERMINATED BY SPONSOR	No	2021-11-12/ 2021-11-12	STUDY TERMINATED BY SPONSOR		
	DOCETAXEL	2021-08-11/ 2021-11-12 (94)	STUDY TERMINATED BY SPONSOR					
3145-2007	PLACEBO	2021-08-25/ 2021-09-05 (12)	DEATH	No	2021-09-05/ 2021-09-05	DEATH	2021-09-05 (12)/ Adverse Event	
	DOCETAXEL	2021-08-25/ 2021-09-05 (12)	DEATH				2021-09-05 (12)/ Adverse Event	
3145-2501	PLACEBO	2021-06-03/ 2021-09-29 (119)	WITHDRAWAL BY SUBJECT	No	2021-09-29/ 2021-09-29	WITHDRAWAL BY SUBJECT		
	DOCETAXEL	2021-06-03/ 2021-09-29 (119)	WITHDRAWAL BY SUBJECT					

Listing: 16.2.1.1
Patient Disposition
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Drug	Study Drug Disposition			Study Discontinuation			
		Date of First Drug Dose/Date Decided to Discontinue (Study Day)	Reason for Drug Discont.	Survival Follow- up?	Date of Study Discont./ Date of Last Contact	Reason for Study Discont.	Date of Death (Study Day)/ Primary Cause of Death	Cancer Treatment Since Last Contact?
2011-2001	TRILACICLIB	2021-09-09/ 2021-11-10 (63)	STUDY TERMINATED BY SPONSOR	No	2021-11-17/ 2021-11-17	STUDY TERMINATED BY SPONSOR		
	DOCETAXEL	2021-09-09/ 2021-11-10 (63)	STUDY TERMINATED BY SPONSOR					
3145-2005	TRILACICLIB	2021-08-05/ 2021-11-17 (105)	STUDY TERMINATED BY SPONSOR	Yes	2021-11-17/ 2021-11-17	STUDY TERMINATED BY SPONSOR		
	DOCETAXEL	2021-08-05/ 2021-11-17 (105)	STUDY TERMINATED BY SPONSOR					
3145-2006	TRILACICLIB	2021-08-11/ 2021-11-11 (93)	WITHDRAWAL BY SUBJECT	No	2021-11-11/ 2021-11-11	STUDY TERMINATED BY SPONSOR		
	DOCETAXEL	2021-08-11/ 2021-11-11 (93)	WITHDRAWAL BY SUBJECT					

Listing: 16.2.1.1
 Patient Disposition
 All Randomized Patients

 Treatment: Trilaciclib

Subject Number	Drug	Study Drug Disposition			Study Discontinuation			
		Date of First Drug Dose/Date Decided to Discontinue (Study Day)	Reason for Drug Discont.	Survival Follow- up?	Date of Study Discont./ Date of Last Contact	Reason for Study Discont.	Date of Death (Study Day)/ Primary Cause of Death	Cancer Treatment Since Last Contact?
3145-2008	TRILACICLIB	2021-10-07/	STUDY	No	2022-02-02/	STUDY		
		2022-02-02 (119)	TERMINATED BY SPONSOR		2022-02-02	TERMINATED BY SPONSOR		
	DOCETAXEL	2021-10-07/	STUDY					
		2022-02-02 (119)	TERMINATED BY SPONSOR					

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.1.2
Protocol Deviations
All Enrolled Patients

Treatment: Placebo

Subject Number	Date of Deviation (Study Day)	Category	Classification	Deviation Comment	Analysis Action
3145-2007	2021-08-21 (-4)	INFORMED CONSENT	SUSPECTED QI REPORTABLE IN EQMS	ON 20OCT2021 CRA WAS NOTIFIED BY GCOL THAT THE SITE HAS SUBMITTED A LAB REQUISITION & PATH REPORT FOR TUMOR TISSUE WITH SUBJECT 3145-2007'S PHI UNREDACTED. CRA HAS INFORMED SITE OF THE FOLLOWING: 1) RECORD THIS AS A MAJOR PROTOCOL DEVIATION RELATED TO ICF/HIPAA; 2) REPORT TO THE ADVARRA AS PER IRB REPORTING GUIDELINES REQUIRE; A. PROVIDE A COPY OF IRB ACKNOWLEDGMENT TO CRA ONCE RECEIVED. 3) SITE STAFF TO BE RETRAINED ON PROPER SUBMISSION OF SUBJECT RECORDS WITH PHI REDACTED IN ALL CASES; A. THIS MUST BE DOCUMENTED ON THE SCS' (ZAW AND OKINO) TRAINING LOGS-TRAINER SHOULD BE EITHER PI OR CRA; CRA'S EMAIL WITH SITE CONFIRMATION OF UNDERSTANDING & COMPLETION OF THESE RELATED TASKS CAN SERVE AS 'RETRAINING' OR THE PI CAN OPT TO CREATE A GENERAL UPDATE FOR THE SITE	CRA TO FOLLOW UP WITH SITE BY 08NOV2021 IF NOT RESOLVED BY THEN. 09NOV2021 RY: THESE ITEMS ARE NOT YET FILED IN THE SITE'S ELECTRONIC REG, AND THEREFORE WERE REQUESTED FROM THE SC. PI IS AWARE. CRA TO FOLLOW UP WITHIN THE FOLLOWING WEEK IF NOT RECEIVED BY 12NOV. 21DEC2021 RY:SITE HAS REPORTED TO THE IRB, AND ACKNOWLEDGEMENT RECEIVED. SITE STATED THEY HAVE COMPLETED AN UPDATED HIPAA TRAINING WITH CITI, AND CREATED A CAPA THAT THEY WILL PROVIDE AT TODAY'S VISIT. WILL CLOSE ISSUE WHEN PROVIDED. 24DEC2021 RY: SITE PROVIDED CAPA & TRAINING DOC REQUIRED. 25APR2022 RY: UPDATE 07MAR2022: DURING THE SPONSOR REVIEW MEETING ON 07MAR2022, THIS PD WAS ASSESSED AND CONCLUDED BY SPONSOR AS MAJOR PD, IN LINE WITH THE QI SEVERITY - MAJOR QI# 243664.

Program: l-dv.sas

2022-05-24 10:07

Page 1 of 4

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.1.2
Protocol Deviations
All Enrolled Patients

Treatment: Placebo

Subject Number	Date of Deviation (Study Day)	Category	Classification	Deviation Comment	Analysis Action
3145-2007 (continued)	2021-08-21 (-4) (continued)	INFORMED CONSENT	SUSPECTED QI REPORTABLE IN EQMS	STUDY TEAM FOR ALL STAFF; B. PROVIDE THE UPDATED TRAINING LOGS TO THE CRA ONCE COMPLETE (EMAIL OR FORWARD LINKS TO THEM). 4) SITE TO CREATE A CAPA TO IDENTIFY ROOT CAUSE-I.E., SC INATTENTION TO DETAIL, MISUNDERSTANDING ON HIPAA COVERAGE-WHATEVER THE CASE MAY BE; A. PROVIDE A COPY OF THE CAPA ONCE COMPLETED.	

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.1.2
Protocol Deviations
All Enrolled Patients

Treatment: Placebo

Subject Number	Date of Deviation (Study Day)	Category	Classification	Deviation Comment	Analysis Action
3145-2007 (continued)	2021-08-25 (1)	PROCEDURES/ TESTS	ADMIN	AT THIS MV, IT WAS NOTED THAT SUBJECT 3145-2007 IS DOCUMENTED TO BE A WOCBP AT SCREENING, HOWEVER NO PREGNANCY TEST WAS NOTED PRIOR TO DOSING AT C1D1.	ISSUE WAS BROUGHT UP TO THE SITE, AND SC STATED HE WOULD REVIEW. CRA ASKS THAT THIS BE NOTED AS A PD, WITH BRIEF EXPLANATION OF WHY MISSED, IF KNOWN, AND REPORT TO IRB IF APPLICABLE PER IRB REPORTING GUIDELINES. 21DEC2021 RY: NO IRB REPORT NOR SITE NOTES NOTED DURING THIS VISIT. SITE HAS BEEN REMINDED. 15FEB2022 RY: SCREEN 06AUG; HCG 18AUG, RAND 26AUG--HCG FALLS WITHIN THE PERIOD FOR RANDOMIZATION. NO REPORTING NECESSARY. UPDATE 07MAR2022: BASED ON THE EDC DATA ENTERED, THE PREGNANCY TEST WAS DONE AND TESTED NEGATIVE, HOWEVER OUT OF THE WINDOW REQUIRED PER THE PROTOCOL. DURING THE SPONSOR REVIEW MEETING ON 07MAR2022, THIS PD WAS CONCLUDED AS MINOR PD

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.1.2
Protocol Deviations
All Enrolled Patients

Treatment: Trilaciclib

Subject Number	Date of Deviation (Study Day)	Category	Classification	Deviation Comment	Analysis Action
2011-2001	2021-09-14 (6)	IP ADMIN/STUDY TREAT	ADMIN	UNBLINDING DEVIATION: AN UNBLINDING DEVIATION RELATED TO IP PREPARATION OCCURRED AND WAS ESCALATED BY UCRA TO THE UNBLINDED COL ON 14SEP2021. THE UNBLINDED COL ESCALATED TO THE UNBLINDED SPONSOR REPRESENTATIVE ON 14SEP2021.	THE UCRA RETRAINED UNBLINDED SITE STAFF. UPDATE 07MAR2022: DURING THE SPONSOR REVIEW MEETING ON 07MAR2022, THIS PD WAS ASSESSED AND CONCLUDE BY SPONSOR AS MINOR PD.

Listing: 16.2.2
Demographic and Patient Characteristics
All Enrolled Patients

Treatment: Screen Failure

Subject Number	Age (Yr.)	Race/ Gender/ Ethnicity	Childbearing Potential	Height (cm) / Weight (kg) / BSA (m ²)	Date of Initial Diagnosis/ Stage at Diagnosis	Date of Metastatic Diagnosis/ Stage at Screening	Histopathologic Type
3145-2001	60	BLACK OR AFRICAN AMERICAN/ MALE/ NOT HISPANIC OR LATINO					
3145-2002	63	WHITE/ MALE/ NOT HISPANIC OR LATINO					
3145-2003	63	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER/ FEMALE/ NOT HISPANIC OR LATINO	POST-MENOPAUSAL				

BSA = body surface area
Height, weight, and BSA are values at Screening.

Listing: 16.2.2
Demographic and Patient Characteristics
All Enrolled Patients

Treatment: Placebo

Subject Number	Age (Yr.)	Race/ Gender/ Ethnicity	Childbearing Potential	Height (cm) / Weight (kg) / BSA (m ²)	Date of Initial Diagnosis/ Stage at Diagnosis	Date of Metastatic Diagnosis/ Stage at Screening	Histopathologic Type
3145-2004	63	WHITE/ MALE/ HISPANIC OR LATINO		165.1/ 73/ 1.8	2021-04-22/ Stage IV	2021-06-06/ Stage IV	ADENOCARCINOMA
3145-2007	65	WHITE/ FEMALE/ NOT HISPANIC OR LATINO	POTENTIALLY ABLE TO BEAR CHILDREN	170.2/ 74.2/ 1.86	2019-10-02/ Stage IV	2021-08-18/ Stage IV	SQUAMOUS CELL CARCINOMA
3145-2501	60	BLACK OR AFRICAN AMERICAN/ MALE/ NOT HISPANIC OR LATINO		187/ 112/ 2.33	2017-02-10/ Stage IV	2017-02-10/ Stage IV	ADENOCARCINOMA

BSA = body surface area
Height, weight, and BSA are values at Screening.

Listing: 16.2.2
Demographic and Patient Characteristics
All Enrolled Patients

Treatment: Trilaciclib

Subject Number	Age (Yr.)	Race/ Gender/ Ethnicity	Childbearing Potential	Height (cm) / Weight (kg) / BSA (m ²)	Date of Initial Diagnosis/ Stage at Diagnosis	Date of Metastatic Diagnosis/ Stage at Screening	Histopathologic Type
2011-2001	58	WHITE/ MALE/ NOT HISPANIC OR LATINO		168.9/ 46.7/ 1.52	2020-12-09/ Stage IV	2021-04-20/ Stage IV	SQUAMOUS CELL CARCINOMA
3145-2005	73	WHITE/ MALE/ HISPANIC OR LATINO		167.6/ 65.3/ 1.74	2020-10-19/ Stage IV	2020-10-19/ Stage IV	ADENOCARCINOMA
3145-2006	45	BLACK OR AFRICAN AMERICAN/ FEMALE/ NOT HISPANIC OR LATINO	POTENTIALLY ABLE TO BEAR CHILDREN	156.2/ 68/ 1.68	2015-09-30/ Stage IV	2015-09-30/ Stage IV	ADENOCARCINOMA
3145-2008	57	BLACK OR AFRICAN AMERICAN/ FEMALE/ NOT HISPANIC OR LATINO	POTENTIALLY ABLE TO BEAR CHILDREN	170.2/ 68.9/ 1.8	2019-09/ Stage IV	2019-09/ Stage IV	ADENOCARCINOMA

BSA = body surface area

Height, weight, and BSA are values at Screening.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.13.1
Timepoint and Best Overall Response
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date of Assessment (Study Day)	Target Lesion Response	Non-Target Lesion Response	New Lesions?	Overall Response
3145-2004	Visit 1	2021-09-22 (43)	SD	NA	No	SD
	Visit 2	2021-11-01 (83)	NE	NA	No	NE
3145-2501	Visit 1	2021-07-14 (42)	SD	NA	No	SD
	Visit 2	2021-08-31 (90)	SD	NA	No	SD

CR = Complete Response; NA = Not Applicable, non-target lesions not identified at Screening; NE = Not Evaluable; PD = Progressive Disease; PR = Partial Response; SD = Stable Disease

Program: 1-rs-bor.sas

2022-05-24 10:11

Page 1 of 2

Listing: 16.2.13.1
Timepoint and Best Overall Response
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date of Assessment (Study Day)	Target Lesion Response	Non-Target Lesion Response	New Lesions?	Overall Response
2011-2001	Visit 1	2021-10-22 (44)	PR	NON-CR/NON-PD	No	PR
3145-2006	Visit 1	2021-09-20 (41)	PR	NA	No	PR
	Visit 2	2021-11-03 (85)	PR	NA	No	PR
3145-2008	Visit 1	2021-11-16 (41)	SD	NA	No	SD
	Visit 2	2021-12-29 (84)	SD	NA	No	SD

CR = Complete Response; NA = Not Applicable, non-target lesions not identified at Screening; NE = Not Evaluable; PD = Progressive Disease; PR = Partial Response; SD = Stable Disease

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.13.2
New and Target Lesions - Investigator Assessments
All Randomized Patients

Treatment: Placebo

Subject Number	Visit/ Date of Scan (Study Day)	Tumor Link ID	Method of Identification	Location/ Description	Tumor Length (mm)	Lesion Status
3145-2004	Screening/ 2021-07-28 (-14)	T1	CT SCAN	LUNG/ PRECARINAL LYMPH NODE	16	PRESENT
		T2	CT SCAN	LUNG/ RIGHT HILAR NODE	16	PRESENT
		T3	CT SCAN	LUNG/ LINGULAR LESION	20	PRESENT
	Visit 1/ 2021-09-22 (43)	T1	CT SCAN		13	PRESENT
		T2	CT SCAN		12	PRESENT
		T3	CT SCAN		21	PRESENT
	Visit 2/ 2021-11-01 (83)	T1	CT SCAN		7	PRESENT
		T2			Not Done	Not Done: NOT MEASURED
		T3	CT SCAN		21	PRESENT

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.13.2
New and Target Lesions - Investigator Assessments
All Randomized Patients

Treatment: Placebo

Subject Number	Visit/ Date of Scan (Study Day)	Tumor Link ID	Method of Identification	Location/ Description	Tumor Length (mm)	Lesion Status
3145-2007	Screening/ 2021-08-18 (-7)	T1	CT SCAN	LUNG/ LEFT LUNG APEX LESION	62	PRESENT
3145-2501	Screening/ 2021-05-28 (-6)	T1	CT SCAN	LUNG/ LEFT LOWER LOBE MASS	31	PRESENT
	Visit 1/ 2021-07-14 (42)	T1	CT SCAN		31	PRESENT
	Visit 2/ 2021-08-31 (90)	T1	CT SCAN		31	PRESENT

Listing: 16.2.13.2
 New and Target Lesions - Investigator Assessments
 All Randomized Patients

 Treatment: Trilaciclib

Subject Number	Visit/ Date of Scan (Study Day)	Tumor Link ID	Method of Identification	Location/ Description	Tumor Length (mm)	Lesion Status
2011-2001	Screening/ 2021-08-24 (-16)	T1	CT SCAN	LUNG/ RIGHT LUNG APEX	83	PRESENT
		T2	CT SCAN	LIVER/ LEFT LIVER MASS	16	PRESENT
		T3	CT SCAN	ADRENAL GLAND/ LEFT ADRENAL MASS	35	PRESENT
	Visit 1/ 2021-10-22 (44)	T1	CT SCAN		11	PRESENT
		T2	CT SCAN		8	PRESENT
		T3	CT SCAN		35	PRESENT
3145-2005	Screening/ 2021-07-28 (-8)	T1	CT SCAN	LUNG/ RIGHT LOWER LOBE LESION	41	PRESENT
		T2	CT SCAN	LUNG/ LEFT LUNG APEX LESION	18	PRESENT

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.13.2
New and Target Lesions - Investigator Assessments
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit/ Date of Scan (Study Day)	Tumor Link ID	Method of Identification	Location/ Description	Tumor Length (mm)	Lesion Status
3145-2006	Screening/ 2021-08-04 (-7)	T1	CT SCAN	LUNG/ LEFT UPPER LOBE	25	PRESENT
	Visit 1/ 2021-09-20 (41)	T1	CT SCAN		13	PRESENT
	Visit 2/ 2021-11-03 (85)	T1	CT SCAN		14	PRESENT
3145-2008	Screening/ 2021-09-24 (-13)	T1	CT SCAN	LUNG/ RIGHT UPPER LOBE MASS	45	PRESENT
	Visit 1/ 2021-11-16 (41)	T1	CT SCAN		45	PRESENT
	Visit 2/ 2021-12-29 (84)	T1	CT SCAN		49	PRESENT

Program: l-tr-target.sas

2022-05-24 10:12

Page 4 of 4

Listing: 16.2.13.3
Non-Target Lesions - Investigator Assessments
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit/ Date of Scan (Study Day)	Tumor Link ID	Method of Identification	Location/ Description	Lesion Status
2011-2001	Screening/ 2021-08-24 (-16)	NT1	CT SCAN	SMALL INTESTINE/ LEFT ILIAC BONE	PRESENT
		NT2	CT SCAN	SPINAL CORD/ T11 THORACIC SPINE	PRESENT
		NT3	CT SCAN	LUNG/ LEFT UPPER LUNG	PRESENT
	Visit 1/ 2021-10-22 (44)	NT1	CT SCAN		PRESENT
		NT2	CT SCAN		PRESENT
		NT3	CT SCAN		PRESENT

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2004	Blood and lymphatic system disorders/ Leukopenia/ LEUKOCYTOPENIA (3)	2021-08-16 (6) / 2021-08-19 (9)	No/ 3	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Lymphopenia/ LYMPHOCYTOPENIA (5)	2021-08-16 (6) / 2021-08-19 (9)	No/ 2	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Monocytopenia/ MONOCYTOPENIA (6)	2021-08-16 (6) / 2021-08-19 (9)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Neutropenia/ NEUTROPENIA (4)	2021-08-16 (6) / 2021-08-19 (9)	No/ 3	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event

Note: AEs are coded using MedDRA version 24.0.

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2004 (continued)	Investigations/ Blood bilirubin increased/ BILIRUBIN INCREASED (2)	2021-08-16 (6) / 2021-08-19 (9)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Anaemia/ ANEMIA (10)	2021-08-19 (9) / 2021-08-24 (14)	No/ 2	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Leukopenia/ LEUKOCYTOPENIA (7)	2021-08-19 (9) / 2021-08-24 (14)	No/ 4	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Neutropenia/ NEUTROPENIA (8)	2021-08-19 (9) / 2021-08-27 (17)	No/ 4	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event

Note: AEs are coded using MedDRA version 24.0.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2004 (continued)	Blood and lymphatic system disorders/ Lymphopenia/ LYMPHOCYTOPENIA (9)	2021-08-19 (9) / 2021-08-31 (21)	No/ 3	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Eosinopenia/ EOSINOPENIA (11)	2021-08-19 (9) / 2021-09-10 (31)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Monocytosis/ MONOCYTOPHILLA (12)	2021-08-31 (21) / 2021-09-10 (31)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Infections and infestations/ Staphylococcal sepsis/ MSSA SEPSIS (1)	2021-09-01 (22) / 2021-09-08 (29)	Yes/ 3	RECOVERED/ RESOLVED	RELATED/ CYCLE DELAYED	RELATED/ CYCLE DELAYED	Other: OTHER

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-all.sas

2022-06-08 10:00

Page 3 of 32

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2004 (continued)	Blood and lymphatic system disorders/ Lymphopenia/ LYMPHOCYTOPENIA (14)	2021-09-10 (31)/ 2021-09-14 (35)	No/ 2	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Anaemia/ ANEMIA (13)	2021-09-10 (31)/ 2021-10-26 (77)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Eosinopenia/ EOSINOPENIA (18)	2021-11-12 (94)/	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Leukopenia/ LEUKOCYTOPENIA (15)	2021-11-12 (94)/	No/ 2	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2004 (continued)	Blood and lymphatic system disorders/ Monocytosis/ MONOCYTOPHILLIA (17)	2021-11-12 (94)/	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Neutropenia/ NEUTROPENIA (16)	2021-11-12 (94)/	No/ 3	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
3145-2007	Blood and lymphatic system disorders/ Leukopenia/ LEUKOCYTOPENIA (3)	2021-08-30 (6)/ 2021-09-04 (11)	No/ 3	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Neutropenia/ NEUTROPENIA (5)	2021-08-30 (6)/ 2021-09-04 (11)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2007 (continued)	Investigations/ Blood alkaline phosphatase increased/ ELEVATED ALKALINE PHOSPHATASE (8)	2021-08-30 (6) / 2021-09-04 (11)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Investigations/ Metamyelocyte count increased/ ELEVATED METAMYELOCYTES (4)	2021-08-30 (6) / 2021-09-04 (11)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Investigations/ Protein total decreased/ DECREASED TOTAL PROTEIN (9)	2021-08-30 (6) / 2021-09-04 (11)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event

Note: AEs are coded using MedDRA version 24.0.

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2007 (continued)	Metabolism and nutrition disorders/ Hypoalbuminaemia/ HYPOALBUMINEMIA (7)	2021-08-30 (6) / 2021-09-04 (11)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Metabolism and nutrition disorders/ Hypocalcaemia/ HYPOCALCEMIA (6)	2021-08-30 (6) / 2021-09-04 (11)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Renal and urinary disorders/ Acute kidney injury/ ACUTE RENAL FAILURE (1)	2021-09-01 (8) / 2021-09-04 (11)	Yes/ 3	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	Other: OTHER
	Infections and infestations/ Urosepsis/ UROSEPSIS (2)	2021-09-05 (12) / 2021-09-05 (12)	Yes/ 5	FATAL	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	Other: CONCOMITANT MEDICATIONS

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event

Note: AEs are coded using MedDRA version 24.0.

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2501	Gastrointestinal disorders/ Diarrhoea/ DIARRHEA (5)	2021-06-03 (1) / 2021-06-04 (2)	No/ 2	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Gastrointestinal disorders/ Nausea/ NAUSEA (2)	2021-06-03 (1) / 2021-06-04 (2)	No/ 2	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	Other: CONCOMITANT MEDICATIONS
	Gastrointestinal disorders/ Vomiting/ VOMITING (3)	2021-06-03 (1) / 2021-06-04 (2)	No/ 2	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Metabolism and nutrition disorders/ Dehydration/ DEHYDRATION (4)	2021-06-03 (1) / 2021-06-04 (2)	No/ 2	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2501 (continued)	Blood and lymphatic system disorders/ Neutropenia/ NEUTROPENIA (7)	2021-06-11 (9) / 2021-06-15 (13)	No/ 3	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Leukopenia/ LEUKOCYTOPENIA (6)	2021-06-11 (9) / 2021-06-18 (16)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Lymphopenia/ LYMPHOCYTOPENIA (8)	2021-06-11 (9) / 2021-06-18 (16)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Eosinopenia/ EOSINOPENIA (12)	2021-06-15 (13) / 2021-06-15 (13)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2501 (continued)	Blood and lymphatic system disorders/ Neutropenia/ NEUTROPENIA (11)	2021-06-15 (13) / 2021-06-18 (16)	No/ 4	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Investigations/ Metamyelocyte count increased/ ELEVATED METAMYELOCYTES (9)	2021-06-15 (13) / 2021-06-18 (16)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Investigations/ Myelocyte count increased/ ELEVATED MYELOCYTES (10)	2021-06-15 (13) / 2021-06-18 (16)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-all.sas

2022-06-08 10:00

Page 10 of 32

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2501 (continued)	Blood and lymphatic system disorders/ Monocytosis/ MONOCYTOSIS (13)	2021-06-23 (21)/ 2021-09-17 (107)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Leukocytosis/ LEUKOCYTOSIS (14)	2021-07-15 (43)/ 2021-08-18 (77)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Neutrophilia/ NEUTROPHILLIA (15)	2021-07-15 (43)/ 2021-08-18 (77)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Metabolism and nutrition disorders/ Hyperglycaemia/ HYPERGLYCEMIA (16)	2021-08-18 (77)/ 2021-09-07 (97)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event

Note: AEs are coded using MedDRA version 24.0.

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2501 (continued)	Metabolism and nutrition disorders/ Dehydration/ DEHYDRATION (20)	2021-08-26 (85)/	No/ 2	NOT RECOVERED/ NOT RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	Other: CONCOMITANT MEDICATIONS
	Renal and urinary disorders/ Renal failure/ RENAL FAILURE (1)	2021-08-26 (85)/ 2021-08-30 (89)	Yes/ 3	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	Other: CONCOMITANT MEDICATIONS, OTHER
	Gastrointestinal disorders/ Diarrhoea/ DIARRHEA (19)	2021-08-26 (85)/ 2021-09-10 (100)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Nervous system disorders/ Dizziness/ DIZZINESS (18)	2021-08-26 (85)/ 2021-09-22 (112)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2501 (continued)	Blood and lymphatic system disorders/ Leukopenia/ LEUKOCYTOPENIA (25)	2021-09-17 (107) / 2021-09-28 (118)	No/ 2	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Neutropenia/ NEUTROPENIA (26)	2021-09-17 (107) / 2021-09-28 (118)	No/ 4	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Investigations/ Blood urea increased/ ELEVATED BUN (21)	2021-09-17 (107) / 2021-09-28 (118)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Investigations/ Cortisol increased/ ELEVATED TOTAL CORTISOL (27)	2021-09-17 (107) / 2021-09-28 (118)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2501 (continued)	Investigations/ Protein total decreased/ DECREASED TOTAL PROTEIN (23)	2021-09-17 (107)/ 2021-09-28 (118)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Metabolism and nutrition disorders/ Hypoalbuminaemia/ HYPOALBUMINEMIA (24)	2021-09-17 (107)/ 2021-09-28 (118)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Metabolism and nutrition disorders/ Hypocalcaemia/ HYPOCALCEMIA (22)	2021-09-17 (107)/ 2021-09-28 (118)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-all.sas

2022-06-08 10:00

Page 14 of 32

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2501 (continued)	General disorders and administration site conditions/ Fatigue/ FATIGUE (28)	2021-09-22 (112)/	No/ 1	NOT RECOVERED/ NOT RESOLVED	NOT RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Eosinopenia/ EOSINOPENIA (31)	2021-09-28 (118)/	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Monocytosis/ MONOCYTOSIS (30)	2021-09-28 (118)/	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2501 (continued)	Investigations/ Myelocyte count increased/ ELEVATED MYELOCYTES (29)	2021-09-28 (118)/	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-all.sas

2022-06-08 10:00

Page 16 of 32

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
2011-2001	Gastrointestinal disorders/ Nausea/ NAUSEA (1)	2021-09-09 (1) / 2021-09-16 (8)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	Other: CONCOMITANT MEDICATIONS
	Gastrointestinal disorders/ Gastroesophageal reflux disease/ GERD (4)	2021-09-09 (1) / 2021-09-27 (19)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	General disorders and administration site conditions/ Mucosal inflammation/ MUCOSITIS (2)	2021-09-13 (5) / 2021-10-06 (28)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	Other: CONCOMITANT MEDICATIONS

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
2011-2001 (continued)	Investigations/ Weight decreased/ WEIGHT LOSS (3)	2021-11-16 (69) / 2021-12-03 (86)	No/ 2	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
3145-2005	Gastrointestinal disorders/ Diarrhoea/ DIARRHEA (7)	2021-08 () / 2021-08 ()	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Monocytopenia/ MONOCYTOPENIA (2)	2021-08-09 (5) / 2021-08-13 (9)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Leukopenia/ LEUKOCYTOPENIA (3)	2021-08-13 (9) / 2021-08-20 (16)	No/ 2	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2005 (continued)	Blood and lymphatic system disorders/ Neutropenia/ NEUTROPENIA (4)	2021-08-13 (9) / 2021-08-20 (16)	No/ 3	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Gastrointestinal disorders/ Abdominal pain lower/ LOWER ABDOMINAL PAIN (5)	2021-08-26 (22) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Gastrointestinal disorders/ Nausea/ NAUSEA (6)	2021-08-28 (24) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	NOT RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-all.sas

2022-06-08 10:00

Page 19 of 32

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2005 (continued)	Respiratory, thoracic and mediastinal disorders/ Hypoxia/ HYPOXIA (8)	2021-09 () /	No/ 3	NOT RECOVERED/ NOT RESOLVED	NOT RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Infections and infestations/ Pneumonia/ PNEUMONIA (1)	2021-09-10 (37) / 2021-11-17 (105)	Yes/ 3	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	Other: CONCOMITANT MEDICATIONS, CONCOMITANT PROCEDURES, OTHER
	Metabolism and nutrition disorders/ Hypoalbuminaemia/ HYPOALBUMINEMIA (9)	2021-11-17 (105) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2006	Blood and lymphatic system disorders/ Monocytopenia/ MONOCYTOPENIA (14)	2021-08-17 (7) / 2021-08-20 (10)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Anaemia/ ANEMIA (13)	2021-08-17 (7) / 2021-08-27 (17)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Neutropenia/ NEUTROPENIA (15)	2021-08-20 (10) / 2021-08-24 (14)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Monocytosis/ MONOCYTOSIS (16)	2021-08-24 (14) / 2021-08-27 (17)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event

Note: AEs are coded using MedDRA version 24.0.

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2006 (continued)	Gastrointestinal disorders/ Gastroesophageal reflux disease/ GERD (4)	2021-08-27 (17) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	General disorders and administration site conditions/ Impaired healing/ DIMINISHED WOUND HEALING (1)	2021-08-27 (17) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Metabolism and nutrition disorders/ Decreased appetite/ ANOREXIA (3)	2021-08-27 (17) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2006 (continued)	Nervous system disorders/ Dysgeusia/ DYSGEUSIA (5)	2021-08-27 (17) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Psychiatric disorders/ Hallucination, visual/ VISUAL HALLUCINATION (6)	2021-08-27 (17) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Skin and subcutaneous tissue disorders/ Alopecia/ ALOPECIA (2)	2021-08-27 (17) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-all.sas

2022-06-08 10:00

Page 23 of 32

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2006 (continued)	Gastrointestinal disorders/ Diarrhoea/ DIARRHEA (8)	2021-09-08 (29) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Gastrointestinal disorders/ Stomatitis/ ORAL MUCOSITIS (9)	2021-09-08 (29) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Infections and infestations/ Conjunctivitis/ CONJUNCTIVITIS (7)	2021-09-08 (29) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Monocytosis/ MONOCYTOSIS (17)	2021-09-22 (43) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2006 (continued)	General disorders and administration site conditions/ Early satiety/ EARLY SATIETY (10)	2021-09-22 (43) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	NOT RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Musculoskeletal and connective tissue disorders/ Myalgia/ MYALGIA (11)	2021-10-13 (64) / 2021-11-02 (84)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE REDUCED	
	Blood and lymphatic system disorders/ Anaemia/ ANEMIA (18)	2021-11-03 (85) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Program: 1-ae-all.sas

2022-06-08 10:00

Page 25 of 32

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2006 (continued)	Musculoskeletal and connective tissue disorders/ Myalgia/ MYALGIA (12)	2021-11-03 (85) /	No/ 2	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
3145-2008	Blood and lymphatic system disorders/ Monocytopenia/ MONOCYTOPENIA (2)	2021-10-12 (6) / 2021-10-15 (9)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Hepatobiliary disorders/ Hyperbilirubinaemia/ HYPERBILIRUBINEMIA (1)	2021-10-12 (6) / 2021-10-15 (9)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2008 (continued)	Blood and lymphatic system disorders/ Eosinopenia/ EOSINOPENIA (3)	2021-10-15 (9) / 2021-10-27 (21)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Skin and subcutaneous tissue disorders/ Rash/ SKIN RASH (4)	2021-10-15 (9) / 2021-12-10 (65)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	Other: CONCOMITANT MEDICATIONS
	Blood and lymphatic system disorders/ Monocytosis/ MONOCYTOSIS (5)	2021-10-19 (13) / 2021-12-29 (84)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Leukocytosis/ LEUKOCYTOSIS (6)	2021-10-22 (16) / 2021-12-29 (84)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event

Note: AEs are coded using MedDRA version 24.0.

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2008 (continued)	Blood and lymphatic system disorders/ Neutrophilia/ NEUTROPHILIA (7)	2021-10-27 (21)/ 2021-11-17 (42)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Injury, poisoning and procedural complications/ Contusion/ SKIN BRUISES (10)	2021-10-28 (22)/	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Vascular disorders/ Phlebitis/ PHLEBITIS (8)	2021-10-28 (22)/	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	Other: CONCOMITANT MEDICATIONS
	Skin and subcutaneous tissue disorders/ Alopecia/ ALOPECIA (9)	2021-10-28 (22)/ 2021-12-10 (65)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2008 (continued)	Metabolism and nutrition disorders/ Hyperchloraemia/ HYPERCHLOREMIA (11)	2021-11-18 (43) / 2021-12-29 (84)	No/ 1	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Neutrophilia/ NEUTROPHILIA (12)	2021-12-09 (64) / 2021-12-29 (84)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	General disorders and administration site conditions/ Fatigue/ FATIGUE (13)	2021-12-10 (65) /	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-all.sas

2022-06-08 10:00

Page 29 of 32

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2008 (continued)	Skin and subcutaneous tissue disorders/ Alopecia/ ALOPECIA (14)	2021-12-10 (65)/	No/ 2	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Nervous system disorders/ Headache/ CEPHALALGIA (15)	2021-12-30 (85)/ 2022-02-02 (119)	No/ 1	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Leukocytosis/ LEUKOCYTOSIS (16)	2022-01-19 (105)/	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Lymphocytosis/ LYMPHOCYTOSIS (19)	2022-01-19 (105)/	No/ 2	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-all.sas

2022-06-08 10:00

Page 30 of 32

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.1
Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2008 (continued)	Blood and lymphatic system disorders/ Monocytosis/ MONOCYTOSIS (18)	2022-01-19 (105)/	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Blood and lymphatic system disorders/ Neutrophilia/ NEUTROPHILIA (17)	2022-01-19 (105)/	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	
	Skin and subcutaneous tissue disorders/ Pruritus/ PRURITIS (20)	2022-02-02 (119)/	No/ 2	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	Other: CONCOMITANT MEDICATIONS

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-all.sas

2022-06-08 10:00

Page 31 of 32

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.1

Adverse Events

Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trilaciclib/ Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2008 (continued)	Skin and subcutaneous tissue disorders/ Xeroderma/ XERODERMIA (21)	2022-02-02 (119)/	No/ 3	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	Other: CONCOMITANT MEDICATIONS

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event

Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-all.sas

2022-06-08 10:00

Page 32 of 32

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2004	Screening	2021-08-10/12:12 (-1)	Sodium (mmol/L)	139*	135 - 146	0	
			Potassium (mmol/L)	4.1*	3.5 - 5.3	0	
			Chloride (mmol/L)	100*	98 - 110		
			Urea Nitrogen (mg/dL)	14*	7 - 25		
			Creatinine (mg/dL)	0.89*	0.7 - 1.25	0	
			Glucose (mg/dL)	82*	65 - 99	0	
			Calcium (mg/dL)	9.1*	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	25*	10 - 35	0	
			Alanine Aminotransferase (U/L)	25*	9 - 60	0	
			Bilirubin (mg/dL)	1.1*	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	78*	40 - 115	0	
			Albumin (g/dL)	4.4*	3.6 - 5.1	0	
			Protein (g/dL)	7.3*	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	91*	0 - 60		H
			Bicarbonate (mmol/L)	28*	19 - 30	0	
	Unscheduled	2021-08-16/12:16 (6)	Sodium (mmol/L)	138	135 - 146	0	
			Potassium (mmol/L)	4.0	3.5 - 5.3	0	
			Chloride (mmol/L)	102	98 - 110		
			Urea Nitrogen (mg/dL)	15	7 - 25		

* Baseline value.

Program: 1-lb-chem.sas

2022-06-08 10:02

Page 1 of 52

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2004 (continued)	Unscheduled (continued)	2021-08-16/12:16 (6) (continued)	Creatinine (mg/dL)	0.81	0.7 - 1.25	0	
			Glucose (mg/dL)	84	65 - 99	0	
			Calcium (mg/dL)	9.2	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	23	10 - 35	0	
			Alanine Aminotransferase (U/L)	17	9 - 60	0	
			Bilirubin (mg/dL)	1.5	0.2 - 1.2	1	H
			Alkaline Phosphatase (U/L)	57	40 - 115	0	
			Albumin (g/dL)	4.3	3.6 - 5.1	0	
			Protein (g/dL)	7.0	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	95	0 - 60		H
			Bicarbonate (mmol/L)	30	19 - 30	0	
		2021-08-19/09:58 (9)	Sodium (mmol/L)	142	135 - 146	0	
			Potassium (mmol/L)	3.8	3.5 - 5.3	0	
			Chloride (mmol/L)	107	98 - 110		
			Urea Nitrogen (mg/dL)	11	7 - 25		
			Creatinine (mg/dL)	0.77	0.7 - 1.25	0	
			Glucose (mg/dL)	87	65 - 99	0	
			Calcium (mg/dL)	9.2	8.6 - 10.3	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2004 (continued)	Unscheduled (continued)	2021-08-19/09:58 (9) (continued)	Aspartate Aminotransferase (U/L)	18	10 - 35	0	
			Alanine Aminotransferase (U/L)	12	9 - 60	0	
			Bilirubin (mg/dL)	0.9	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	50	40 - 115	0	
			Albumin (g/dL)	3.9	3.6 - 5.1	0	
			Protein (g/dL)	6.2	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	97	0 - 60		H
			Bicarbonate (mmol/L)	26	19 - 30	0	
		2021-08-24/14:35 (14)	Sodium (mmol/L)	141	135 - 146	0	
			Potassium (mmol/L)	4.1	3.5 - 5.3	0	
			Chloride (mmol/L)	106	98 - 110		
			Urea Nitrogen (mg/dL)	21	7 - 25		
			Creatinine (mg/dL)	0.74	0.7 - 1.25	0	
			Glucose (mg/dL)	95	65 - 99	0	
			Calcium (mg/dL)	9.0	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	30	10 - 35	0	
			Alanine Aminotransferase (U/L)	25	9 - 60	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2004 (continued)	Unscheduled (continued)	2021-08-24/14:35 (14) (continued)	Bilirubin (mg/dL)	0.6	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	75	40 - 115	0	
			Albumin (g/dL)	4.1	3.6 - 5.1	0	
			Protein (g/dL)	6.6	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	98	0 - 60		H
			Bicarbonate (mmol/L)	27	19 - 30	0	
		2021-08-27/13:13 (17)	Sodium (mmol/L)	140	135 - 146	0	
			Potassium (mmol/L)	4.1	3.5 - 5.3	0	
			Chloride (mmol/L)	105	98 - 110		
			Urea Nitrogen (mg/dL)	14	7 - 25		
			Creatinine (mg/dL)	0.82	0.7 - 1.25	0	
			Glucose (mg/dL)	91	65 - 99	0	
			Calcium (mg/dL)	9.1	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	27	10 - 35	0	
			Alanine Aminotransferase (U/L)	26	9 - 60	0	
			Bilirubin (mg/dL)	0.9	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	73	40 - 115	0	
			Albumin (g/dL)	4.4	3.6 - 5.1	0	
			Protein (g/dL)	6.9	6.1 - 8.1		

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2004 (continued)	Unscheduled (continued)	2021-08-27/13:13 (17) (continued)	Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	94	0 - 60		H
			Bicarbonate (mmol/L)	28	19 - 30	0	
		2021-08-31/12:42 (21)	Sodium (mmol/L)	138	135 - 146	0	
			Potassium (mmol/L)	3.9	3.5 - 5.3	0	
			Chloride (mmol/L)	103	98 - 110		
			Urea Nitrogen (mg/dL)	11	7 - 25		
			Creatinine (mg/dL)	0.81	0.7 - 1.25	0	
			Glucose (mg/dL)	83	65 - 99	0	
			Calcium (mg/dL)	9.1	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	21	10 - 35	0	
			Alanine Aminotransferase (U/L)	17	9 - 60	0	
			Bilirubin (mg/dL)	1.0	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	69	40 - 115	0	
			Albumin (g/dL)	4.4	3.6 - 5.1	0	
			Protein (g/dL)	6.9	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	95	0 - 60		H
			Bicarbonate (mmol/L)	25	19 - 30	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2004 (continued)	Unscheduled (continued)	2021-09-10/13:22 (31)	Sodium (mmol/L)	141	135 - 146	0	
			Potassium (mmol/L)	4.3	3.5 - 5.3	0	
			Chloride (mmol/L)	106	98 - 110		
			Urea Nitrogen (mg/dL)	16	7 - 25		
			Creatinine (mg/dL)	0.79	0.7 - 1.25	0	
			Glucose (mg/dL)	107	65 - 99	1	H
			Calcium (mg/dL)	9.1	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	32	10 - 35	0	
			Alanine Aminotransferase (U/L)	42	9 - 60	0	
			Bilirubin (mg/dL)	0.4	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	128	40 - 115	1	H
			Albumin (g/dL)	4.0	3.6 - 5.1	0	
			Protein (g/dL)	6.9	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m ²)	96	0 - 60		H
			Bicarbonate (mmol/L)	25	19 - 30	0	
	Cycle 2 Day 1	2021-09-14/09:59 (35)	Sodium (mmol/L)	137	135 - 146	0	
			Potassium (mmol/L)	4.1	3.5 - 5.3	0	
			Chloride (mmol/L)	103	98 - 110		
			Urea Nitrogen (mg/dL)	14	7 - 25		

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2004 (continued)	Cycle 2 Day 1 (continued)	2021-09-14/09:59 (35) (continued)	Creatinine (mg/dL)	0.81	0.7 - 1.25	0	
			Glucose (mg/dL)	82	65 - 99	0	
			Calcium (mg/dL)	9.4	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	19	10 - 35	0	
			Alanine Aminotransferase (U/L)	23	9 - 60	0	
			Bilirubin (mg/dL)	0.6	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	94	40 - 115	0	
			Albumin (g/dL)	4.1	3.6 - 5.1	0	
			Protein (g/dL)	7.0	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	95	0 - 60		H
			Bicarbonate (mmol/L)	29	19 - 30	0	
	Cycle 3 Day 1	2021-10-05/13:30 (56)	Sodium (mmol/L)	139	135 - 146	0	
			Potassium (mmol/L)	4.1	3.5 - 5.3	0	
			Chloride (mmol/L)	103	98 - 110		
			Urea Nitrogen (mg/dL)	16	7 - 25		
			Creatinine (mg/dL)	0.93	0.7 - 1.25	0	
			Glucose (mg/dL)	91	65 - 99	0	
			Calcium (mg/dL)	9.3	8.6 - 10.3	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standardized Value	Normal Range	Toxicity Grade	Flag
3145-2004 (continued)	Cycle 3 Day 1 (continued)	2021-10-05/13:30 (56) (continued)	Aspartate Aminotransferase (U/L)	20	10 - 35	0	
			Alanine Aminotransferase (U/L)	16	9 - 60	0	
			Bilirubin (mg/dL)	0.6	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	67	40 - 115	0	
			Albumin (g/dL)	4.3	3.6 - 5.1	0	
			Protein (g/dL)	7.1	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	87	0 - 60		H
			Bicarbonate (mmol/L)	28	19 - 30	0	
	Cycle 4 Day 1	2021-10-26/12:04 (77)	Sodium (mmol/L)	142	135 - 146	0	
			Potassium (mmol/L)	4.1	3.5 - 5.3	0	
			Chloride (mmol/L)	105	98 - 110		
			Urea Nitrogen (mg/dL)	17	7 - 25		
			Creatinine (mg/dL)	0.84	0.7 - 1.25	0	
			Glucose (mg/dL)	105	65 - 99	1	H
			Calcium (mg/dL)	9.5	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	20	10 - 35	0	
			Alanine Aminotransferase (U/L)	14	9 - 60	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2004 (continued)	Cycle 4 Day 1 (continued)	2021-10-26/12:04 (77) (continued)	Bilirubin (mg/dL)	0.6	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	59	40 - 115	0	
			Albumin (g/dL)	4.2	3.6 - 5.1	0	
			Protein (g/dL)	6.8	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	93	0 - 60		H
			Bicarbonate (mmol/L)	28	19 - 30	0	
	Post-Treatment Visit	2021-11-12/10:36 (94)	Sodium (mmol/L)	138	135 - 146	0	
			Potassium (mmol/L)	4.3	3.5 - 5.3	0	
			Chloride (mmol/L)	103	98 - 110		
			Urea Nitrogen (mg/dL)	17	7 - 25		
			Creatinine (mg/dL)	0.92	0.7 - 1.25	0	
			Glucose (mg/dL)	81	65 - 99	0	
			Calcium (mg/dL)	8.8	8.6 - 10.3	0	
			Calcium, Ionized				
			Aspartate Aminotransferase (U/L)	22	10 - 35	0	
			Alanine Aminotransferase (U/L)	17	9 - 60	0	
			Bilirubin (mg/dL)	0.5	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	58	40 - 115	0	
			Albumin (g/dL)	4.1	3.6 - 5.1	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2004 (continued)	Post-Treatment Visit (continued)	2021-11-12/10:36 (94) (continued)	Protein (g/dL)	6.6	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	88	0 - 60		H
			Bicarbonate (mmol/L)	26	19 - 30	0	
3145-2007	Screening	2021-08-18/10:03 (-7)	Sodium (mmol/L)	142	135 - 145	0	
			Potassium (mmol/L)	3.9	3.5 - 5.3	0	
			Chloride (mmol/L)	105	98 - 110		
			Urea Nitrogen (mg/dL)	15	7 - 25		
			Creatinine (mg/dL)	0.96	0.5 - 0.99		
			Glucose (mg/dL)	109	65 - 99		H
			Calcium (mg/dL)	9.0	8.6 - 10.4	0	
			Aspartate Aminotransferase (U/L)	16	10 - 35		
			Alanine Aminotransferase (U/L)	15	6 - 40		
			Bilirubin (mg/dL)	0.4	0.2 - 1.2		
			Alkaline Phosphatase (U/L)	63	33 - 130		
			Albumin (g/dL)	4.0	3.6 - 5.1	0	
			Protein (g/dL)	6.4	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	62	0 - 60		H
			Bicarbonate (mmol/L)	23	19 - 30	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2007 (continued)	Cycle 1 Day 1	2021-08-24/13:41 (-1)	Sodium (mmol/L)	142*	135 - 145	0	
			Potassium (mmol/L)	3.9*	3.5 - 5.3	0	
			Chloride (mmol/L)	106*	98 - 110		
			Urea Nitrogen (mg/dL)	11*	7 - 25		
			Creatinine (mg/dL)	0.80*	0.5 - 0.99	0	
			Glucose (mg/dL)	165*	65 - 99	0	H
			Calcium (mg/dL)	8.8*	8.6 - 10.4	0	
			Aspartate Aminotransferase (U/L)	15*	10 - 35	0	
			Alanine Aminotransferase (U/L)	14*	6 - 40	0	
			Bilirubin (mg/dL)	0.3*	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	61*	33 - 130	0	
			Albumin (g/dL)	3.8*	3.6 - 5.1	0	
			Protein (g/dL)	6.2*	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m ²)	77*	0 - 60		H
			Bicarbonate (mmol/L)	26*	19 - 30	0	
	Unscheduled	2021-08-30/13:45 (6)	Sodium (mmol/L)	139	135 - 145	0	
			Potassium (mmol/L)	3.9	3.5 - 5.3	0	
			Chloride (mmol/L)	100	98 - 110		
			Urea Nitrogen (mg/dL)	11	7 - 25		

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2007 (continued)	Unscheduled (continued)	2021-08-30/13:45 (6) (continued)	Creatinine (mg/dL)	0.88	0.5 - 0.99	0	
			Glucose (mg/dL)	130	65 - 99	0	H
			Calcium (mg/dL)	8.5	8.6 - 10.4	1	L
			Aspartate Aminotransferase (U/L)	11	10 - 35	0	
			Alanine Aminotransferase (U/L)	15	6 - 40	0	
			Bilirubin (mg/dL)	1.0	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	151	33 - 130	1	H
			Albumin (g/dL)	3.6	3.6 - 5.1	0	
			Protein (g/dL)	5.9	6.1 - 8.1		L
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	69	0 - 60		H
			Bicarbonate (mmol/L)	28	19 - 30	0	
3145-2501	Screening	2021-06-02/17:31 (-1)	Sodium (mmol/L)	141	135 - 146	0	
			Potassium (mmol/L)	4.1	3.5 - 5.3	0	
			Chloride (mmol/L)	109	98 - 110		
			Urea Nitrogen (mg/dL)	20	7 - 25		
			Creatinine (mg/dL)	1.85	0.7 - 1.25		H
			Glucose (mg/dL)	93	65 - 99		
			Calcium (mg/dL)	8.6	8.6 - 10.3	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Screening (continued)	2021-06-02/17:31 (-1) (continued)	Aspartate Aminotransferase (U/L)	10	10 - 35		
			Alanine Aminotransferase (U/L)	10	9 - 60		
			Bilirubin (mg/dL)	0.2	0.2 - 1.2		
			Alkaline Phosphatase (U/L)	65	40 - 115		
			Albumin (g/dL)	3.6	3.6 - 5.1	0	
			Protein (g/dL)	6.2	6.1 - 8.1		
			Bicarbonate (mmol/L)	26	19 - 30	0	
	Cycle 1 Day 1	2021-06-02/17:31 (-1)	Sodium (mmol/L)	141*	135 - 146	0	
			Potassium (mmol/L)	4.1*	3.5 - 5.3	0	
			Chloride (mmol/L)	109*	98 - 110		
			Urea Nitrogen (mg/dL)	20*	7 - 25		
			Creatinine (mg/dL)	1.85*	0.7 - 1.25	1	H
			Glucose (mg/dL)	93*	65 - 99	0	
			Calcium (mg/dL)	8.6*	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	10*	10 - 35	0	
			Alanine Aminotransferase (U/L)	10*	9 - 60	0	
			Bilirubin (mg/dL)	0.2*	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	65*	40 - 115	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Cycle 1 Day 1 (continued)	2021-06-02/17:31 (-1) (continued)	Albumin (g/dL)	3.6*	3.6 - 5.1	0	
			Protein (g/dL)	6.2*	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	45.4*	0 - 60		
			Bicarbonate (mmol/L)	26*	19 - 30	0	
	Cycle 2 Day 1	2021-06-23/16:30 (21)	Sodium (mmol/L)	139	135 - 146	0	
			Potassium (mmol/L)	4.7	3.5 - 5.3	0	
			Chloride (mmol/L)	106	98 - 110		
			Urea Nitrogen (mg/dL)	20	7 - 25		
			Creatinine (mg/dL)	2.13	0.7 - 1.25	2	H
			Glucose (mg/dL)	71	65 - 99	0	
			Calcium (mg/dL)	9.1	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	12	10 - 35	0	
			Alanine Aminotransferase (U/L)	12	9 - 60	0	
			Bilirubin (mg/dL)	0.3	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	64	40 - 115	0	
			Albumin (g/dL)	4.0	3.6 - 5.1	0	
			Protein (g/dL)	7.1	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	38	0 - 60		

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Cycle 2 Day 1 (continued)	2021-06-23/16:30 (21) (continued)	Bicarbonate (mmol/L)	27	19 - 30	0	
	Cycle 3 Day 1	2021-07-15/12:08 (43)	Sodium (mmol/L)	139	135 - 146	0	
			Potassium (mmol/L)	4.1	3.5 - 5.3	0	
			Chloride (mmol/L)	106	98 - 110		
			Urea Nitrogen (mg/dL)	21	7 - 25		
			Creatinine (mg/dL)	2.04	0.7 - 1.25	2	H
			Glucose (mg/dL)	134	65 - 99	1	H
			Calcium (mg/dL)	8.9	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	12	10 - 35	0	
			Alanine Aminotransferase (U/L)	13	9 - 60	0	
			Bilirubin (mg/dL)	0.3	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	71	40 - 115	0	
			Albumin (g/dL)	3.8	3.6 - 5.1	0	
			Protein (g/dL)	6.6	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	40	0 - 60		
			Bicarbonate (mmol/L)	27	19 - 30	0	
	Unscheduled	2021-08-04/13:08 (63)	Sodium (mmol/L)	142	135 - 146	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Unscheduled (continued)	2021-08-04/13:08 (63) (continued)	Potassium (mmol/L)	4.3	3.5 - 5.3	0	
			Chloride (mmol/L)	111	98 - 110		H
			Urea Nitrogen (mg/dL)	14	7 - 25		
			Creatinine (mg/dL)	1.72	0.7 - 1.25	1	H
			Glucose (mg/dL)	105	65 - 99	1	H
			Calcium (mg/dL)	8.5	8.6 - 10.3	1	L
			Aspartate Aminotransferase (U/L)	15	10 - 35	0	
			Alanine Aminotransferase (U/L)	15	9 - 60	0	
			Bilirubin (mg/dL)	0.3	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	67	40 - 115	0	
			Albumin (g/dL)	3.3	3.6 - 5.1	1	L
			Protein (g/dL)	6.0	6.1 - 8.1		L
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	49	0 - 60		
			Bicarbonate (mmol/L)	25	19 - 30	0	
	Cycle 4 Day 1	2021-08-18/12:10 (77)	Sodium (mmol/L)	140	135 - 146	0	
			Potassium (mmol/L)	4.0	3.5 - 5.3	0	
			Chloride (mmol/L)	106	98 - 110		
			Urea Nitrogen (mg/dL)	25	7 - 25		
			Creatinine (mg/dL)	2.05	0.7 - 1.25	2	H

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Cycle 4 Day 1 (continued)	2021-08-18/12:10 (77) (continued)	Glucose (mg/dL)	146	65 - 99	1	H
			Calcium (mg/dL)	8.7	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	12	10 - 35	0	
			Alanine Aminotransferase (U/L)	11	9 - 60	0	
			Bilirubin (mg/dL)	0.5	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	58	40 - 115	0	
			Albumin (g/dL)	3.7	3.6 - 5.1	0	
			Protein (g/dL)	6.4	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	40	0 - 60		
			Bicarbonate (mmol/L)	28	19 - 30	0	
	Cycle 5 Day 1	2021-09-07/15:49 (97)	Sodium (mmol/L)	140	135 - 146	0	
			Potassium (mmol/L)	4.6	3.5 - 5.3	0	
			Chloride (mmol/L)	105	98 - 110		
			Urea Nitrogen (mg/dL)	21	7 - 25		
			Creatinine (mg/dL)	2.00	0.7 - 1.25	2	H
			Glucose (mg/dL)	97	65 - 99	0	
			Calcium (mg/dL)	9.0	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	15	10 - 35	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Cycle 5 Day 1 (continued)	2021-09-07/15:49 (97) (continued)	Alanine Aminotransferase (U/L)	17	9 - 60	0	
			Bilirubin (mg/dL)	0.4	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	63	40 - 115	0	
			Albumin (g/dL)	3.9	3.6 - 5.1	0	
			Protein (g/dL)	6.8	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	41	0 - 60		
			Bicarbonate (mmol/L)	28	19 - 30	0	
	Unscheduled	2021-09-17/14:45 (107)	Sodium (mmol/L)	139	135 - 146	0	
			Potassium (mmol/L)	4.2	3.5 - 5.3	0	
			Chloride (mmol/L)	106	98 - 110		
			Urea Nitrogen (mg/dL)	31	7 - 25		H
			Creatinine (mg/dL)	2.71	0.7 - 1.25	2	H
			Glucose (mg/dL)	125	65 - 99	1	H
			Calcium (mg/dL)	8.3	8.6 - 10.3	1	L
			Aspartate Aminotransferase (U/L)	12	10 - 35	0	
			Alanine Aminotransferase (U/L)	19	9 - 60	0	
			Bilirubin (mg/dL)	0.4	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	49	40 - 115	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Unscheduled (continued)	2021-09-17/14:45 (107) (continued)	Albumin (g/dL)	3.4	3.6 - 5.1	1	L
			Protein (g/dL)	6.0	6.1 - 8.1		L
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	28	0 - 60		
			Bicarbonate (mmol/L)	26	19 - 30	0	
		2021-09-24/15:27 (114)	Sodium (mmol/L)	142	135 - 146	0	
			Potassium (mmol/L)	3.8	3.5 - 5.3	0	
			Chloride (mmol/L)	107	98 - 110		
			Urea Nitrogen (mg/dL)	16	7 - 25		
			Creatinine (mg/dL)	2.05	0.7 - 1.25	2	H
			Glucose (mg/dL)	84	65 - 99	0	
			Calcium (mg/dL)	8.1	8.6 - 10.3	1	L
			Aspartate Aminotransferase (U/L)	11	10 - 35	0	
			Alanine Aminotransferase (U/L)	11	9 - 60	0	
			Bilirubin (mg/dL)	0.4	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	78	40 - 115	0	
			Albumin (g/dL)	3.1	3.6 - 5.1	1	L
			Protein (g/dL)	5.5	6.1 - 8.1		L
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	40	0 - 60		

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Unscheduled (continued)	2021-09-24/15:27 (114)	Bicarbonate (mmol/L)	26	19 - 30	0	
		2021-09-28/12:43 (118)	Sodium (mmol/L)	141	135 - 146	0	
			Potassium (mmol/L)	4.6	3.5 - 5.3	0	
			Chloride (mmol/L)	106	98 - 110		
			Urea Nitrogen (mg/dL)	18	7 - 25		
			Urea				
			Creatinine (mg/dL)	1.95	0.7 - 1.25	2	H
			Glucose (mg/dL)	94	65 - 99	0	
			Calcium (mg/dL)	8.8	8.6 - 10.3	0	
			Calcium, Ionized				
			Aspartate Aminotransferase (U/L)	21	10 - 35	0	
			Alanine Aminotransferase (U/L)	31	9 - 60	0	
			Bilirubin (mg/dL)	0.4	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	83	40 - 115	0	
			Albumin (g/dL)	3.8	3.6 - 5.1	0	
			Protein (g/dL)	6.4	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	42	0 - 60		
			Bicarbonate (mmol/L)	30	19 - 30	0	

* Baseline value.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
2011-2001	Screening	2021-08-18/14:29 (-22)	Sodium (mmol/L)	128	136 - 145	2	L
			Potassium (mmol/L)	4.79	3.5 - 5.1	0	
			Chloride (mmol/L)	91	98 - 107		L
			Urea Nitrogen (mg/dL)	28	7 - 25		H
			Creatinine (mg/dL)	1.74	0.7 - 1.3		H
			Glucose (mg/dL)	104	70 - 105		
			Calcium (mg/dL)	8.5	8.6 - 10.3	1	L
			Aspartate Aminotransferase (U/L)	14	13 - 39		
			Alanine Aminotransferase (U/L)	13	7 - 52		
			Bilirubin (mg/dL)	0.48	0.3 - 1		
			Alkaline Phosphatase (U/L)	70	34 - 104		
			Albumin (g/dL)	3.60	3.5 - 5.7	0	
			Protein (g/dL)	6.80	6.4 - 8.9		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m ²)	40.5	0 - 60		
			Bicarbonate (mmol/L)	26	98 - 107	1	L
	Cycle 1 Day 1	2021-09-08/10:50 (-1)	Sodium (mmol/L)	136*	136 - 145	0	
			Potassium (mmol/L)	4.52*	3.5 - 5.1	0	
			Chloride (mmol/L)	102*	98 - 107		
			Urea Nitrogen (mg/dL)	15*	7 - 25		

* Baseline value.

Program: 1-lb-chem.sas

2022-06-08 10:02

Page 21 of 52

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
2011-2001 (continued)	Cycle 1 Day 1 (continued)	2021-09-08/10:50 (-1) (continued)	Creatinine (mg/dL)	0.69*	0.7 - 1.3	0	L
			Glucose (mg/dL)	130*	70 - 105	0	H
			Calcium (mg/dL)	8.9*	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	9*	13 - 39	0	L
			Alanine Aminotransferase (U/L)	6*	7 - 52	0	L
			Bilirubin (mg/dL)	0.32*	0.3 - 1	0	
			Alkaline Phosphatase (U/L)	73*	34 - 104	0	
			Albumin (g/dL)	3.60*	3.5 - 5.7	0	
			Protein (g/dL)	6.60*	6.4 - 8.9		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	117.8*	0 - 60		H
			Bicarbonate (mmol/L)	26*	98 - 107	1	L
	Cycle 2 Day 1	2021-10-05/13:55 (27)	Sodium (mmol/L)	136	136 - 145	0	
			Potassium (mmol/L)	4.99	3.5 - 5.1	0	
			Chloride (mmol/L)	100	98 - 107		
			Urea Nitrogen (mg/dL)	16	7 - 25		
			Creatinine (mg/dL)	0.65	0.7 - 1.3	0	L
			Glucose (mg/dL)	165	70 - 105	1	H
			Calcium (mg/dL)	9.2	8.6 - 10.3	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
2011-2001 (continued)	Cycle 2 Day 1 (continued)	2021-10-05/13:55 (27) (continued)	Aspartate Aminotransferase (U/L)	84	13 - 39	1	H
			Alanine Aminotransferase (U/L)	14	7 - 52	0	
			Bilirubin (mg/dL)	0.40	0.3 - 1	0	
			Alkaline Phosphatase (U/L)	84	34 - 104	0	
			Albumin (g/dL)	3.90	3.5 - 5.7	0	
			Protein (g/dL)	7.00	6.4 - 8.9		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	125.7	0 - 60		H
			Bicarbonate (mmol/L)	26	98 - 107	1	L
	Cycle 3 Day 1	2021-10-26/14:07 (48)	Sodium (mmol/L)	131	136 - 145	1	L
			Potassium (mmol/L)	4.80	3.5 - 5.1	0	
			Chloride (mmol/L)	93	98 - 107		L
			Urea Nitrogen (mg/dL)	14	7 - 25		
			Creatinine (mg/dL)	0.73	0.7 - 1.3	0	
			Glucose (mg/dL)	94	70 - 105	0	
			Calcium (mg/dL)	8.8	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	9	13 - 39	0	L
			Alanine Aminotransferase (U/L)	13	7 - 52	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
2011-2001 (continued)	Cycle 3 Day 1 (continued)	2021-10-26/14:07 (48) (continued)	Bilirubin (mg/dL)	0.53	0.3 - 1	0	
			Alkaline Phosphatase (U/L)	84	34 - 104	0	
			Albumin (g/dL)	3.70	3.5 - 5.7	0	
			Protein (g/dL)	6.40	6.4 - 8.9		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	110	0 - 60		H
			Bicarbonate (mmol/L)	25	98 - 107	1	L
	Cycle 4 Day 1	2021-11-16/14:08 (69)	Sodium (mmol/L)	131	136 - 145	1	L
			Potassium (mmol/L)	4.40	3.5 - 5.1	0	
			Chloride (mmol/L)	98	98 - 107		
			Urea Nitrogen (mg/dL)	19	7 - 25		
			Creatinine (mg/dL)	0.74	0.7 - 1.3	0	
			Glucose (mg/dL)	148	70 - 105	1	H
			Calcium (mg/dL)	8.6	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	9	13 - 39	0	L
			Alanine Aminotransferase (U/L)	8	7 - 52	0	
			Bilirubin (mg/dL)	0.43	0.3 - 1	0	
			Alkaline Phosphatase (U/L)	80	34 - 104	0	
			Albumin (g/dL)	3.40	3.5 - 5.7	1	L
			Protein (g/dL)	6.20	6.4 - 8.9		L

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standardized Value	Normal Range	Toxicity Grade	Flag
2011-2001 (continued)	Cycle 4 Day 1 (continued)	2021-11-16/14:08 (69) (continued)	Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	108.3	0 - 60		H
			Bicarbonate (mmol/L)	23	98 - 107	1	L
3145-2005	Screening	2021-07-23/14:35 (-13)	Sodium (mmol/L)	133	135 - 146	1	L
			Potassium (mmol/L)	5.2	3.5 - 5.3	0	
			Chloride (mmol/L)	97	98 - 110		L
			Urea Nitrogen (mg/dL)	13	7 - 25		
			Creatinine (mg/dL)	0.91	0.7 - 1.18		
			Glucose (mg/dL)	77	65 - 99		
			Calcium (mg/dL)	9.3	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	63	10 - 35		H
			Alanine Aminotransferase (U/L)	84	9 - 60		H
			Bilirubin (mg/dL)	0.4	0.2 - 1.2		
			Alkaline Phosphatase (U/L)	108	40 - 115		
			Albumin (g/dL)	4.0	3.6 - 5.1	0	
			Protein (g/dL)	7.7	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	83	0 - 60		H
			Bicarbonate (mmol/L)	22	19 - 30	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2005 (continued)	Cycle 1 Day 1	2021-08-04/14:56 (-1)	Sodium (mmol/L)	139*	135 - 146	0	
			Potassium (mmol/L)	4.1*	3.5 - 5.3	0	
			Chloride (mmol/L)	103*	98 - 110		
			Urea Nitrogen (mg/dL)	16*	7 - 25		
			Creatinine (mg/dL)	1.03*	0.7 - 1.18	0	
			Glucose (mg/dL)	128*	65 - 99	0	H
			Calcium (mg/dL)	9.1*	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	41*	10 - 35	0	H
			Alanine Aminotransferase (U/L)	51*	9 - 60	0	
			Bilirubin (mg/dL)	0.5*	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	116*	40 - 115	0	H
			Albumin (g/dL)	3.8*	3.6 - 5.1	0	
			Protein (g/dL)	7.3*	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m ²)	72*	0 - 60		H
			Bicarbonate (mmol/L)	23*	19 - 30	0	
	Unscheduled	2021-08-09/12:49 (5)	Sodium (mmol/L)	135	135 - 146	0	
			Potassium (mmol/L)	4.3	3.5 - 5.3	0	
			Chloride (mmol/L)	100	98 - 110		
			Urea Nitrogen (mg/dL)	21	7 - 25		

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2005 (continued)	Unscheduled (continued)	2021-08-09/12:49 (5) (continued)	Creatinine (mg/dL)	0.89	0.7 - 1.18	0	
			Glucose (mg/dL)	92	65 - 99	0	
			Calcium (mg/dL)	9.3	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	42	10 - 35	0	H
			Alanine Aminotransferase (U/L)	45	9 - 60	0	
			Bilirubin (mg/dL)	0.8	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	102	40 - 115	0	
			Albumin (g/dL)	3.9	3.6 - 5.1	0	
			Protein (g/dL)	7.5	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	85	0 - 60		H
			Bicarbonate (mmol/L)	23	19 - 30	0	
		2021-08-13/10:19 (9)	Sodium (mmol/L)	136	135 - 146	0	
			Potassium (mmol/L)	4.1	3.5 - 5.3	0	
			Chloride (mmol/L)	102	98 - 110		
			Urea Nitrogen (mg/dL)	11	7 - 25		
			Creatinine (mg/dL)	0.84	0.7 - 1.18	0	
			Glucose (mg/dL)	99	65 - 99	0	
			Calcium (mg/dL)	8.9	8.6 - 10.3	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2005 (continued)	Unscheduled (continued)	2021-08-13/10:19 (9) (continued)	Aspartate Aminotransferase (U/L)	32	10 - 35	0	
			Alanine Aminotransferase (U/L)	28	9 - 60	0	
			Bilirubin (mg/dL)	0.4	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	106	40 - 115	0	
			Albumin (g/dL)	3.6	3.6 - 5.1	0	
			Protein (g/dL)	7.0	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	87	0 - 60		H
			Bicarbonate (mmol/L)	22	19 - 30	0	
		2021-08-16/15:35 (12)	Sodium (mmol/L)	138	135 - 146	0	
			Potassium (mmol/L)	4.0	3.5 - 5.3	0	
			Chloride (mmol/L)	104	98 - 110		
			Urea Nitrogen (mg/dL)	12	7 - 25		
			Creatinine (mg/dL)	0.83	0.7 - 1.18	0	
			Glucose (mg/dL)	104	65 - 99	0	H
			Calcium (mg/dL)	8.7	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	29	10 - 35	0	
			Alanine Aminotransferase (U/L)	21	9 - 60	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2005 (continued)	Unscheduled (continued)	2021-08-16/15:35 (12) (continued)	Bilirubin (mg/dL)	0.3	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	107	40 - 115	0	
			Albumin (g/dL)	3.6	3.6 - 5.1	0	
			Protein (g/dL)	7.0	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	87	0 - 60		H
			Bicarbonate (mmol/L)	27	19 - 30	0	
		2021-08-20/10:43 (16)	Sodium (mmol/L)	140	135 - 146	0	
			Potassium (mmol/L)	4.9	3.5 - 5.3	0	
			Chloride (mmol/L)	103	98 - 110		
			Urea Nitrogen (mg/dL)	16	7 - 25		
			Creatinine (mg/dL)	1.00	0.7 - 1.18	0	
			Glucose (mg/dL)	90	65 - 99	0	
			Calcium (mg/dL)	9.5	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	29	10 - 35	0	
			Alanine Aminotransferase (U/L)	19	9 - 60	0	
			Bilirubin (mg/dL)	0.4	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	121	40 - 115	0	H
			Albumin (g/dL)	3.7	3.6 - 5.1	0	
			Protein (g/dL)	7.3	6.1 - 8.1		

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standardized Value	Normal Range	Toxicity Grade	Flag
3145-2005 (continued)	Unscheduled (continued)	2021-08-20/10:43 (16) (continued)	Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	74	0 - 60		H
			Bicarbonate (mmol/L)	28	19 - 30	0	
	Cycle 2 Day 1	2021-08-25/10:28 (21)	Sodium (mmol/L)	137	135 - 146	0	
			Potassium (mmol/L)	4.4	3.5 - 5.3	0	
			Chloride (mmol/L)	102	98 - 110		
			Urea Nitrogen (mg/dL)	12	7 - 25		
			Creatinine (mg/dL)	0.91	0.7 - 1.18	0	
			Glucose (mg/dL)	93	65 - 99	0	
			Calcium (mg/dL)	9.4	8.6 - 10.3	0	
			Aspartate Aminotransferase (U/L)	27	10 - 35	0	
			Alanine Aminotransferase (U/L)	14	9 - 60	0	
			Bilirubin (mg/dL)	0.5	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	102	40 - 115	0	
			Albumin (g/dL)	3.8	3.6 - 5.1	0	
			Protein (g/dL)	7.5	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	83	0 - 60		H
			Bicarbonate (mmol/L)	26	19 - 30	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2005 (continued)	Unscheduled	2021-09-09/10:02 (36)	Sodium (mmol/L)	132	136 - 145	1	L
			Potassium (mmol/L)	4.6	3.5 - 5	0	
			Chloride (mmol/L)	99	98 - 106		
			Urea Nitrogen (mg/dL)	16.0	8 - 23		
			Creatinine (mg/dL)	1.0	0 - 1.5	0	
			Glucose (mg/dL)	117	75 - 115	0	
			Bicarbonate (mmol/L)	24	21 - 28	0	
	Post-Treatment Visit	2021-11-17/00:00 (105)	Sodium (mmol/L)	135	135 - 146	0	H
			Potassium (mmol/L)	4.5	3.5 - 5.3	0	
			Chloride (mmol/L)	99	98 - 110		
			Urea Nitrogen (mg/dL)	13	7 - 25		
			Creatinine (mg/dL)	0.79	0.7 - 1.18	0	
			Glucose (mg/dL)	88	65 - 99	0	
			Calcium (mg/dL)	9.3	8.6 - 10.3	0	
			Calcium, Ionized				
			Aspartate Aminotransferase (U/L)	19	10 - 35	0	
			Alanine Aminotransferase (U/L)	19	9 - 60	0	
			Bilirubin (mg/dL)	1.0	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	91	40 - 115	0	
			Albumin (g/dL)	3.4	3.6 - 5.1	1	L

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2005 (continued)	Post-Treatment Visit (continued)	2021-11-17/00:00 (105) (continued)	Protein (g/dL)	6.4	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	89	0 - 60		H
			Bicarbonate (mmol/L)	25	19 - 30	0	
3145-2006	Screening	2021-07-28/10:45 (-14)	Sodium (mmol/L)	137	135 - 145	0	
			Potassium (mmol/L)	4.4	3.5 - 5.3	0	
			Chloride (mmol/L)	108	98 - 110		
			Urea Nitrogen (mg/dL)	8	7 - 25		
			Creatinine (mg/dL)	0.69	0.5 - 1.1		
			Glucose (mg/dL)	135	65 - 99		H
			Calcium (mg/dL)	9.3	8.6 - 10.2	0	
			Aspartate Aminotransferase (U/L)	14	10 - 30		
			Alanine Aminotransferase (U/L)	7	6 - 40		
			Bilirubin (mg/dL)	0.3	0.2 - 1.2		
			Alkaline Phosphatase (U/L)	87	33 - 115		
			Albumin (g/dL)	3.8	3.6 - 5.1	0	
			Protein (g/dL)	6.3	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	122	0 - 60		H
			Bicarbonate (mmol/L)	19	19 - 30	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2006 (continued)	Cycle 1 Day 1	2021-08-10/14:29 (-1)	Sodium (mmol/L)	137*	135 - 145	0	
			Potassium (mmol/L)	3.9*	3.5 - 5.3	0	
			Chloride (mmol/L)	104*	98 - 110		
			Urea Nitrogen (mg/dL)	12*	7 - 25		
			Creatinine (mg/dL)	0.72*	0.5 - 1.1	0	
			Glucose (mg/dL)	112*	65 - 99	0	H
			Calcium (mg/dL)	9.6*	8.6 - 10.2	0	
			Aspartate Aminotransferase (U/L)	13*	10 - 30	0	
			Alanine Aminotransferase (U/L)	8*	6 - 40	0	
			Bilirubin (mg/dL)	0.4*	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	87*	33 - 115	0	
			Albumin (g/dL)	4.0*	3.6 - 5.1	0	
			Protein (g/dL)	6.6*	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m ²)	117*	0 - 60		H
			Bicarbonate (mmol/L)	23*	19 - 30	0	
	Unscheduled	2021-08-17/12:57 (7)	Sodium (mmol/L)	137	135 - 145	0	
			Potassium (mmol/L)	4.3	3.5 - 5.3	0	
			Chloride (mmol/L)	107	98 - 110		
			Urea Nitrogen (mg/dL)	8	7 - 25		

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2006 (continued)	Unscheduled (continued)	2021-08-17/12:57 (7) (continued)	Creatinine (mg/dL)	0.70	0.5 - 1.1	0	
			Glucose (mg/dL)	108	65 - 99	0	H
			Calcium (mg/dL)	9.1	8.6 - 10.2	0	
			Aspartate Aminotransferase (U/L)	12	10 - 30	0	
			Alanine Aminotransferase (U/L)	8	6 - 40	0	
			Bilirubin (mg/dL)	0.3	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	86	33 - 115	0	
			Albumin (g/dL)	3.8	3.6 - 5.1	0	
			Protein (g/dL)	6.3	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	121	0 - 60		H
			Bicarbonate (mmol/L)	23	19 - 30	0	
		2021-08-20/12:45 (10)	Sodium (mmol/L)	137	135 - 145	0	
			Potassium (mmol/L)	4.1	3.5 - 5.3	0	
			Chloride (mmol/L)	107	98 - 110		
			Urea Nitrogen (mg/dL)	13	7 - 25		
			Creatinine (mg/dL)	0.70	0.5 - 1.1	0	
			Glucose (mg/dL)	118	65 - 99	1	H
			Calcium (mg/dL)	9.6	8.6 - 10.2	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2006 (continued)	Unscheduled (continued)	2021-08-20/12:45 (10) (continued)	Aspartate Aminotransferase (U/L)	13	10 - 30	0	
			Alanine Aminotransferase (U/L)	8	6 - 40	0	
			Bilirubin (mg/dL)	0.2	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	89	33 - 115	0	
			Albumin (g/dL)	3.9	3.6 - 5.1	0	
			Protein (g/dL)	6.7	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	121	0 - 60		H
			Bicarbonate (mmol/L)	22	19 - 30	0	
		2021-08-24/15:00 (14)	Sodium (mmol/L)	140	135 - 145	0	
			Potassium (mmol/L)	4.5	3.5 - 5.3	0	
			Chloride (mmol/L)	108	98 - 110		
			Urea Nitrogen (mg/dL)	12	7 - 25		
			Creatinine (mg/dL)	0.78	0.5 - 1.1	0	
			Glucose (mg/dL)	86	65 - 99	0	
			Calcium (mg/dL)	8.9	8.6 - 10.2	0	
			Aspartate Aminotransferase (U/L)	15	10 - 30	0	
			Alanine Aminotransferase (U/L)	8	6 - 40	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2006 (continued)	Unscheduled (continued)	2021-08-24/15:00 (14) (continued)	Bilirubin (mg/dL)	0.2	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	75	33 - 115	0	
			Albumin (g/dL)	3.7	3.6 - 5.1	0	
			Protein (g/dL)	6.3	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	106	0 - 60		H
			Bicarbonate (mmol/L)	23	19 - 30	0	
		2021-08-27/11:04 (17)	Sodium (mmol/L)	138	135 - 145	0	
			Potassium (mmol/L)	4.3	3.5 - 5.3	0	
			Chloride (mmol/L)	107	98 - 110		
			Urea Nitrogen (mg/dL)	10	7 - 25		
			Creatinine (mg/dL)	0.67	0.5 - 1.1	0	
			Glucose (mg/dL)	81	65 - 99	0	
			Calcium (mg/dL)	8.8	8.6 - 10.2	0	
			Aspartate Aminotransferase (U/L)	15	10 - 30	0	
			Alanine Aminotransferase (U/L)	8	6 - 40	0	
			Bilirubin (mg/dL)	0.2	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	79	33 - 115	0	
			Albumin (g/dL)	3.8	3.6 - 5.1	0	
			Protein (g/dL)	6.3	6.1 - 8.1		

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2006 (continued)	Unscheduled (continued)	2021-08-27/11:04 (17) (continued)	Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	123	0 - 60		H
			Bicarbonate (mmol/L)	24	19 - 30	0	
	Cycle 2 Day 1	2021-08-31/14:10 (21)	Sodium (mmol/L)	139	135 - 145	0	
			Potassium (mmol/L)	3.8	3.5 - 5.3	0	
			Chloride (mmol/L)	105	98 - 110		
			Urea Nitrogen (mg/dL)	11	7 - 25		
			Creatinine (mg/dL)	0.75	0.5 - 1.1	0	
			Glucose (mg/dL)	85	65 - 99	0	
			Calcium (mg/dL)	9.5	8.6 - 10.2	0	
			Aspartate Aminotransferase (U/L)	14	10 - 30	0	
			Alanine Aminotransferase (U/L)	11	6 - 40	0	
			Bilirubin (mg/dL)	0.3	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	90	33 - 115	0	
			Albumin (g/dL)	4.0	3.6 - 5.1	0	
			Protein (g/dL)	6.8	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	112	0 - 60		H
			Bicarbonate (mmol/L)	25	19 - 30	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2006 (continued)	Cycle 3 Day 1	2021-09-22/09:53 (43)	Sodium (mmol/L)	136	135 - 145	0	
			Potassium (mmol/L)	4.1	3.5 - 5.3	0	
			Chloride (mmol/L)	105	98 - 110		
			Urea Nitrogen (mg/dL)	11	7 - 25		
			Creatinine (mg/dL)	0.75	0.5 - 1.1	0	
			Glucose (mg/dL)	93	65 - 99	0	
			Calcium (mg/dL)	9.4	8.6 - 10.2	0	
			Aspartate Aminotransferase (U/L)	12	10 - 30	0	
			Alanine Aminotransferase (U/L)	8	6 - 40	0	
			Bilirubin (mg/dL)	0.3	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	83	33 - 115	0	
			Albumin (g/dL)	4.1	3.6 - 5.1	0	
			Protein (g/dL)	6.8	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m ²)	112	0 - 60		H
			Bicarbonate (mmol/L)	23	19 - 30	0	
	Cycle 4 Day 1	2021-10-12/12:30 (63)	Sodium (mmol/L)	136	135 - 145	0	
			Potassium (mmol/L)	4.7	3.5 - 5.3	0	
			Chloride (mmol/L)	106	98 - 110		
			Urea Nitrogen (mg/dL)	13	7 - 25		

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2006 (continued)	Cycle 4 Day 1 (continued)	2021-10-12/12:30 (63) (continued)	Creatinine (mg/dL)	0.76	0.5 - 1.1	0	
			Glucose (mg/dL)	96	65 - 99	0	
			Calcium (mg/dL)	9.3	8.6 - 10.2	0	
			Aspartate Aminotransferase (U/L)	15	10 - 30	0	
			Alanine Aminotransferase (U/L)	8	6 - 40	0	
			Bilirubin (mg/dL)	0.2	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	80	33 - 115	0	
			Albumin (g/dL)	3.9	3.6 - 5.1	0	
			Protein (g/dL)	6.3	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	110	0 - 60		H
			Bicarbonate (mmol/L)	26	19 - 30	0	
	Unscheduled	2021-11-03/10:49 (85)	Sodium (mmol/L)	137	135 - 145	0	
			Potassium (mmol/L)	4.3	3.5 - 5.3	0	
			Chloride (mmol/L)	106	98 - 110		
			Urea Nitrogen (mg/dL)	9	7 - 25		
			Creatinine (mg/dL)	0.63	0.5 - 1.1	0	
			Glucose (mg/dL)	84	65 - 99	0	
			Calcium (mg/dL)	9.5	8.6 - 10.2	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2006 (continued)	Unscheduled (continued)	2021-11-03/10:49 (85) (continued)	Aspartate Aminotransferase (U/L)	13	10 - 30	0	
			Alanine Aminotransferase (U/L)	7	6 - 40	0	
			Bilirubin (mg/dL)	0.2	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	69	33 - 115	0	
			Albumin (g/dL)	3.7	3.6 - 5.1	0	
			Protein (g/dL)	6.0	6.1 - 8.1		L
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	126	0 - 60		H
			Bicarbonate (mmol/L)	20	19 - 30	0	
	Post-Treatment Visit	2021-11-11/14:20 (93)	Sodium (mmol/L)	138	135 - 145	0	
			Potassium (mmol/L)	3.9	3.5 - 5.3	0	
			Chloride (mmol/L)	106	98 - 110		
			Urea Nitrogen (mg/dL)	11	7 - 25		
			Creatinine (mg/dL)	0.69	0.5 - 1.1	0	
			Glucose (mg/dL)	98	65 - 99	0	
			Calcium (mg/dL)	9.6	8.6 - 10.2	0	
			Calcium, Ionized				
			Aspartate Aminotransferase (U/L)	17	10 - 30	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2006 (continued)	Post-Treatment Visit (continued)	2021-11-11/14:20 (93) (continued)	Alanine Aminotransferase (U/L)	12	6 - 40	0	
			Bilirubin (mg/dL)	0.3	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	81	33 - 115	0	
			Albumin (g/dL)	3.8	3.6 - 5.1	0	
			Protein (g/dL)	6.3	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	122	0 - 60		H
			Bicarbonate (mmol/L)	24	19 - 30	0	
3145-2008	Screening	2021-09-17/13:40 (-20)	Sodium (mmol/L)	142	135 - 145	0	
			Potassium (mmol/L)	3.5	3.5 - 5.3	0	
			Chloride (mmol/L)	110	98 - 110		
			Urea Nitrogen (mg/dL)	23	7 - 25		
			Creatinine (mg/dL)	1.94	0.5 - 1.05		H
			Glucose (mg/dL)	74	65 - 99		
			Calcium (mg/dL)	9.3	8.6 - 10.4	0	
			Aspartate Aminotransferase (U/L)	9	10 - 35		L
			Alanine Aminotransferase (U/L)	15	6 - 40		
			Bilirubin (mg/dL)	0.5	0.2 - 1.2		
			Alkaline Phosphatase (U/L)	75	33 - 130		

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Screening (continued)	2021-09-17/13:40 (-20) (continued)	Albumin (g/dL)	4.1	3.6 - 5.1	0	
			Protein (g/dL)	6.8	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	33	0 - 60		
			Bicarbonate (mmol/L)	17	19 - 30	1	L
	Cycle 1 Day 1	2021-10-06/10:06 (-1)	Sodium (mmol/L)	142*	135 - 145	0	
			Potassium (mmol/L)	4.0*	3.5 - 5.3	0	
			Chloride (mmol/L)	109*	98 - 110		
			Urea Nitrogen (mg/dL)	20*	7 - 25		
			Creatinine (mg/dL)	1.97*	0.5 - 1.05	2	H
			Glucose (mg/dL)	85*	65 - 99	0	
			Calcium (mg/dL)	9.4*	8.6 - 10.4	0	
			Aspartate Aminotransferase (U/L)	12*	10 - 35	0	
			Alanine Aminotransferase (U/L)	14*	6 - 40	0	
			Bilirubin (mg/dL)	0.6*	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	83*	33 - 130	0	
			Albumin (g/dL)	4.2*	3.6 - 5.1	0	
			Protein (g/dL)	6.7*	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	32*	0 - 60		

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Cycle 1 Day 1 (continued)	2021-10-06/10:06 (-1) (continued)	Bicarbonate (mmol/L)	26*	19 - 30	0	
	Unscheduled	2021-10-12/13:17 (6)	Sodium (mmol/L)	139	135 - 145	0	
			Potassium (mmol/L)	3.6	3.5 - 5.3	0	
			Chloride (mmol/L)	106	98 - 110		
			Urea Nitrogen (mg/dL)	26	7 - 25		H
			Creatinine (mg/dL)	1.72	0.5 - 1.05	2	H
			Glucose (mg/dL)	93	65 - 99	0	
			Calcium (mg/dL)	9.9	8.6 - 10.4	0	
			Aspartate Aminotransferase (U/L)	12	10 - 35	0	
			Alanine Aminotransferase (U/L)	14	6 - 40	0	
			Bilirubin (mg/dL)	1.4	0.2 - 1.2	1	H
			Alkaline Phosphatase (U/L)	78	33 - 130	0	
			Albumin (g/dL)	4.5	3.6 - 5.1	0	
			Protein (g/dL)	7.4	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	37	0 - 60		
			Bicarbonate (mmol/L)	21	19 - 30	0	
		2021-10-15/00:00 (9)	Sodium (mmol/L)	138	135 - 145	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Unscheduled (continued)	2021-10-15/00:00 (9) (continued)	Potassium (mmol/L)	3.8	3.5 - 5.3	0	
			Chloride (mmol/L)	103	98 - 110		
			Urea Nitrogen (mg/dL)	32	7 - 25		H
			Creatinine (mg/dL)	2.35	0.5 - 1.05	2	H
			Glucose (mg/dL)	95	65 - 99	0	
			Calcium (mg/dL)	10.0	8.6 - 10.4	0	
			Aspartate Aminotransferase (U/L)	11	10 - 35	0	
			Alanine Aminotransferase (U/L)	10	6 - 40	0	
			Bilirubin (mg/dL)	0.5	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	74	33 - 130	0	
			Albumin (g/dL)	4.5	3.6 - 5.1	0	
			Protein (g/dL)	7.4	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	26	0 - 60		
			Bicarbonate (mmol/L)	24	19 - 30	0	
		2021-10-19/11:30 (13)	Sodium (mmol/L)	143	135 - 145	0	
			Potassium (mmol/L)	4.1	3.5 - 5.3	0	
			Chloride (mmol/L)	108	98 - 110		
			Urea Nitrogen (mg/dL)	19	7 - 25		
			Creatinine (mg/dL)	2.09	0.5 - 1.05	2	H

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Unscheduled (continued)	2021-10-19/11:30 (13) (continued)	Glucose (mg/dL)	98	65 - 99	0	
			Calcium (mg/dL)	9.6	8.6 - 10.4	0	
			Aspartate Aminotransferase (U/L)	10	10 - 35	0	
			Alanine Aminotransferase (U/L)	11	6 - 40	0	
			Bilirubin (mg/dL)	0.4	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	83	33 - 130	0	
			Albumin (g/dL)	4.2	3.6 - 5.1	0	
			Protein (g/dL)	7.0	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	29	0 - 60		
			Bicarbonate (mmol/L)	24	19 - 30	0	
		2021-10-22/10:48 (16)	Sodium (mmol/L)	141	135 - 145	0	
			Potassium (mmol/L)	3.9	3.5 - 5.3	0	
			Chloride (mmol/L)	106	98 - 110		
			Urea Nitrogen (mg/dL)	17	7 - 25		
			Creatinine (mg/dL)	1.94	0.5 - 1.05	2	H
			Glucose (mg/dL)	95	65 - 99	0	
			Calcium (mg/dL)	9.6	8.6 - 10.4	0	
			Aspartate Aminotransferase (U/L)	13	10 - 35	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Unscheduled (continued)	2021-10-22/10:48 (16) (continued)	Alanine Aminotransferase (U/L)	12	6 - 40	0	
			Bilirubin (mg/dL)	0.5	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	73	33 - 130	0	
			Albumin (g/dL)	4.1	3.6 - 5.1	0	
			Protein (g/dL)	7.1	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	32	0 - 60		
			Bicarbonate (mmol/L)	24	19 - 30	0	
	Cycle 2 Day 1	2021-10-27/11:25 (21)	Sodium (mmol/L)	141	135 - 145	0	
			Potassium (mmol/L)	3.9	3.5 - 5.3	0	
			Chloride (mmol/L)	104	98 - 110		
			Urea Nitrogen (mg/dL)	18	7 - 25		
			Creatinine (mg/dL)	1.72	0.5 - 1.05	2	H
			Glucose (mg/dL)	86	65 - 99	0	
			Calcium (mg/dL)	9.7	8.6 - 10.4	0	
Aspartate Aminotransferase (U/L)			18	10 - 35	0		
Alanine Aminotransferase (U/L)			17	6 - 40	0		
Bilirubin (mg/dL)			0.9	0.2 - 1.2	0		
Alkaline Phosphatase (U/L)	74	33 - 130	0				

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Cycle 2 Day 1 (continued)	2021-10-27/11:25 (21) (continued)	Albumin (g/dL)	4.4	3.6 - 5.1	0	
			Protein (g/dL)	7.2	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	37	0 - 60		
			Bicarbonate (mmol/L)	20	19 - 30	0	
	Cycle 3 Day 1	2021-11-17/11:59 (42)	Sodium (mmol/L)	139	135 - 145	0	
			Potassium (mmol/L)	4.6	3.5 - 5.3	0	
			Chloride (mmol/L)	107	98 - 110		
			Urea Nitrogen (mg/dL)	13	7 - 25		
			Urea				
			Creatinine (mg/dL)	1.6	0.5 - 1.05	2	H
			Glucose (mg/dL)	79	65 - 99	0	
			Calcium (mg/dL)	9.7	8.6 - 10.4	0	
			Calcium, Ionized				
			Aspartate Aminotransferase (U/L)	19	10 - 35	0	
			Alanine Aminotransferase (U/L)	17	6 - 40	0	
			Bilirubin (mg/dL)	1.0	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	117	33 - 130	0	
			Albumin (g/dL)	4.1	3.6 - 5.1	0	
			Protein (g/dL)	7.4	6.1 - 8.1		

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Cycle 3 Day 1 (continued)	2021-11-17/11:59 (42) (continued)	Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	41	0 - 60		
			Bicarbonate (mmol/L)	23	19 - 30	0	
	Unscheduled	2021-11-17/11:59 (42)	Sodium (mmol/L)	139	135 - 145	0	
			Potassium (mmol/L)	4.6	3.5 - 5.3	0	
			Chloride (mmol/L)	107	98 - 110		
			Urea Nitrogen (mg/dL)	13	7 - 25		
			Creatinine (mg/dL)	1.6	0.5 - 1.05	2	H
			Glucose (mg/dL)	79	65 - 99	0	
			Calcium (mg/dL)	9.7	8.6 - 10.4	0	
			Calcium, Ionized				
			Aspartate Aminotransferase (U/L)	19	10 - 35	0	
			Alanine Aminotransferase (U/L)	17	6 - 40	0	
			Bilirubin (mg/dL)	1.0	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	117	33 - 130	0	
			Albumin (g/dL)	4.1	3.6 - 5.1	0	
			Protein (g/dL)	7.4	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	41	0 - 60		
			Bicarbonate (mmol/L)	23	19 - 30	0	

* Baseline value.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Cycle 4 Day 1	2021-12-09/13:27 (64)	Sodium (mmol/L)	142	135 - 145	0	
			Potassium (mmol/L)	4.0	3.5 - 5.3	0	
			Chloride (mmol/L)	109	98 - 110		
			Urea Nitrogen (mg/dL)	17	7 - 25		
			Creatinine (mg/dL)	1.7	0.5 - 1.05	2	H
			Glucose (mg/dL)	90	65 - 99	0	
			Calcium (mg/dL)	9.4	8.6 - 10.4	0	
			Calcium, Ionized				
			Aspartate Aminotransferase (U/L)	18	10 - 35	0	
			Alanine Aminotransferase (U/L)	10	6 - 40	0	
			Bilirubin (mg/dL)	0.7	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	73	33 - 130	0	
			Albumin (g/dL)	4.0	3.6 - 5.1	0	
			Protein (g/dL)	6.7	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	38	0 - 60		
			Bicarbonate (mmol/L)	25	19 - 30	0	
	Cycle 5 Day 1	2021-12-29/15:00 (84)	Sodium (mmol/L)	140	135 - 145	0	
			Potassium (mmol/L)	4.4	3.5 - 5.3	0	
			Chloride (mmol/L)	110	98 - 110		

* Baseline value.

Program: 1-lb-chem.sas

2022-06-08 10:02

Page 49 of 52

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Cycle 5 Day 1 (continued)	2021-12-29/15:00 (84) (continued)	Urea Nitrogen (mg/dL)	15	7 - 25		
			Creatinine (mg/dL)	1.56	0.5 - 1.05	1	H
			Glucose (mg/dL)	115	65 - 99	1	H
			Calcium (mg/dL)	9.2	8.6 - 10.4	0	
			Calcium, Ionized				
			Aspartate Aminotransferase (U/L)	12	10 - 35	0	
			Alanine Aminotransferase (U/L)	12	6 - 40	0	
			Bilirubin (mg/dL)	0.7	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	73	33 - 130	0	
			Albumin (g/dL)	3.9	3.6 - 5.1	0	
			Protein (g/dL)	6.4	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	42	0 - 60		
			Bicarbonate (mmol/L)	23	19 - 30	0	
	Unscheduled	2022-01-19/11:44 (105)	Sodium (mmol/L)	143	135 - 145	0	
			Potassium (mmol/L)	3.9	3.5 - 5.3	0	
			Chloride (mmol/L)	109	98 - 110		
			Urea Nitrogen (mg/dL)	21	7 - 25		
			Creatinine (mg/dL)	1.90	0.5 - 1.05	2	H
			Glucose (mg/dL)	81	65 - 99	0	

* Baseline value.

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Unscheduled (continued)	2022-01-19/11:44 (105) (continued)	Calcium (mg/dL)	8.9	8.6 - 10.4	0	
			Calcium, Ionized				
			Aspartate Aminotransferase (U/L)	10	10 - 35	0	
			Alanine Aminotransferase (U/L)	9	6 - 40	0	
			Bilirubin (mg/dL)	0.4	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	82	33 - 130	0	
			Albumin (g/dL)	4.0	3.6 - 5.1	0	
			Protein (g/dL)	6.2	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	33	0 - 60		
			Bicarbonate (mmol/L)	25	19 - 30	0	
	Post-Treatment Visit	2022-02-02/12:30 (119)	Sodium (mmol/L)	138	135 - 145	0	
			Potassium (mmol/L)	4.6	3.5 - 5.3	0	
			Chloride (mmol/L)	104	98 - 110		
			Urea Nitrogen (mg/dL)	20	7 - 25		
			Creatinine (mg/dL)	1.69	0.5 - 1.05	2	H
			Glucose (mg/dL)	107	65 - 99	1	H
			Calcium (mg/dL)	9.4	8.6 - 10.4	0	
			Calcium, Ionized				

* Baseline value.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.7.1
Laboratory Values - Chemistry
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Post-Treatment Visit (continued)	2022-02-02/12:30 (119) (continued)	Aspartate Aminotransferase (U/L)	13	10 - 35	0	
			Alanine Aminotransferase (U/L)	11	6 - 40	0	
			Bilirubin (mg/dL)	0.7	0.2 - 1.2	0	
			Alkaline Phosphatase (U/L)	72	33 - 130	0	
			Albumin (g/dL)	4.1	3.6 - 5.1	0	
			Protein (g/dL)	6.8	6.1 - 8.1		
			Glomerular Filtration Rate, Estimated (mL/min/1.73m2)	38	0 - 60		
			Bicarbonate (mmol/L)	20	19 - 30	0	

* Baseline value.

Program: 1-lb-chem.sas

2022-06-08 10:02

Page 52 of 52

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) Unk	1a. COUNTRY UNITED STATES	2. DATE OF BIRTH			2a. AGE 63 Years	3. SEX Male	3a. WEIGHT 73.00 kg	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input checked="" type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING
		Day	Month	Year			Day	Month	Year		
			Unk				01	SEP	2021		

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
MSSA sepsis [Staphylococcal sepsis]

Case Description: This case, manufacturer control #G1-000335 received from site 3145 in the United States, is a report of hospitalization due to methicillin sensitive staphylococcus aureus (MSSA) sepsis, grade 3, that occurred in a 63-year-old male. Subject 3145-2004 was enrolled in the G1T28-210 study: A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rdLine Setting (PRESERVE 4).

(Continued on Additional Information Page)

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) TRILACICLIB VS PLACEBO (Code not broken) #2) DOCETAXEL (DOCETAXEL) Solution for infusion (Continued on Additional Information Page)		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
15. DAILY DOSE(S) Blinded, Information withheld. #2) 75 mg/m2 every 21 days	16. ROUTE(S) OF ADMINISTRATION Blinded, Information withheld. #2) IV drip	
17. INDICATION(S) FOR USE #1) myelosuppression (Myelosuppression) #2) Non-small cell lung cancer metastatic (Non- (Continued on Additional Information Page)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) 11-AUG-2021 / 11-AUG-2021 #2) 11-AUG-2021 / 11-AUG-2021	19. THERAPY DURATION #1) 1 day #2) 1 day	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1) CETIRIZINE (CETIRIZINE) ; 2021 / Unknown		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description 01-JAN-2021 to Ongoing Historical Condition Cough (Cough) 01-JAN-2021 to Ongoing Historical Condition Fatigue (Fatigue)		

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER G1 Therapeutics Elizabeth Garcia 700 Park Offices Drive, Suite 200 Research Triangle Park, NC 27709 UNITED STATES Phone: 1 919-909-5187		26. REMARKS
	24b. MFR CONTROL NO. 2021G1US0000100	25b. NAME AND ADDRESS OF REPORTER Dr David Berz Valkyrie Clinical Trials, Inc. 2080 Century City Park E #710 Los Angeles, California 90067 UNITED STATES
24c. DATE RECEIVED BY MANUFACTURER 02-SEP-2021	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input checked="" type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT 22-JUL-2022	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

The subject's medical history included cough (2021), fatigue (2021), weight loss (Feb-2021), cancer pain (2021), nausea (Jun-2021) and anemia (Jul-2021).

On 22-APR-2021, the subject underwent a biopsy (site not specified) and was diagnosed with Stage IV adenocarcinoma of the lung. Initial treatment included combination therapy with carboplatin, pemetrexed and pembrolizumab (from 01-Jun-2021 until 13-Jul-2021), and external beam radiation therapy to the thoracic spine (from 29-Jun-2021 until 12-Jul-2021).

Cetirizine was the only reported concomitant medication the subject was taking at the time of this event.

On 10-AUG-2021, pre cycle 1 laboratory results were notable for white blood cell count 3.7 K/uL (normal range 3.8-10-8), absolute neutrophil (ANC) count 1776 cells/uL (normal range 1500-7800), hemoglobin 11.9 g/dL (normal range 13.2-17.1), platelet count 172 K/uL (normal range 140-400), sodium 139 mEq/L (normal range 135-146), potassium 4.1 mmol/L (normal range 3.5-5.3), chloride 100 mmol/L (normal range 98-110), blood urea nitrogen (BUN) 14 mg/dL (normal range 7-25), creatinine 0.89 mg/dL (normal range 0.7-1.25), estimated glomerular filtration rate (eGFR) 91 mL/min/1.73 (normal range 0-60), alanine aminotransferase 25 U/L (normal range 9-60), aspartate aminotransferase 25 U/L (normal range 10-35), alkaline phosphatase 78 U/L (normal range 40-115), total bilirubin 1.1 mg/dL (normal range 0.2-1.2), and albumin 4.4 g/dL (normal range 3.6-5.1).

On 11-AUG-2021, the subject received the first dose of blinded study drug (Trilaciclib versus placebo) given by intravenous infusion, at a dose of 240 mg/m² (total dose 433 mg). The subject subsequently received docetaxel via intravenous infusion at a dose of 75 mg/m² (total dose 135.3 mg). Per protocol, treatment was scheduled to be administered every 21 days.

On 16-AUG-2021, Cycle 1 Day 5 laboratory results included white blood cell count 1.6 with and ANC of 880, hemoglobin 11.5 and platelet count 158.

On 18-AUG-2021, the subject underwent left Port-A-Cath placement.

On 19-AUG-2021, Cycle 1 Day 9, white blood cell count was 0.9 and the ANC was 360 (post cycle 1 nadir counts).

On 27-AUG-2021, Cycle 1 Day 17 laboratory results were indicative of improving counts; white blood cell count was 2.4 with an ANC of 869; additional results included hemoglobin 11.4 and platelet count 208.

On 01-SEP-2021, 21 days after receiving the first doses of blinded study treatment and docetaxel, the subject was sent to the emergency room with complaints of shortness of breath and was hospitalized for further evaluation for a possible pulmonary embolism. A chest X-Ray revealed left perihilar and right lower lobe infiltrates with moderate right pleural effusion. There was no evidence of pneumothorax. A computerized tomogram (CT) Angiogram of the chest revealed large consolidative and ground-glass opacities of the right middle and lower lobe and the posterior left lower lobe, multiple scattered ground-glass nodules of remaining bilateral lungs measuring up to 2 cm, as well as trace right pleural effusion. Enlarged lymph nodes were also noted. There was no evidence of mediastinal mass or aortic aneurysm. Evaluation of pulmonary arteries was non-diagnostic due to minimal contrast. An echocardiogram was performed and revealed the left ventricle (LV) was of normal size with normal function, LV ejection fraction was 55%. There was a left ventricular filling pattern consistent with diastolic dysfunction. The right atrium and ventricle were normal, there was mild mitral and tricuspid regurgitation. The pericardium appeared normal. A ventilation perfusion scan was obtained, and results showed low probability for a pulmonary embolism. After ruling out pulmonary embolism, ultimately the diagnosis of MSSA sepsis was determined.

On 4-SEP-2021, a lower left and right extremity venous duplex ultrasound was performed and showed no evidence of acute or chronic venous thrombosis.

On 7-SEP-2021, the subject underwent fluoroscopic-guided removal of the Port-A-Cath, which was removed due to bacteremia and concern that the line was infected. He tolerated the procedure well and there were no immediate complications. The Port-A-Cath tip was sent for culture (results were not available).

On 8-SEP-2021, a second chest X-ray was performed showing patchy airspace opacification in the left mid to lower lung, concerning for multifocal pneumonia. There was no definite pleural effusion or pneumothorax.

On 08-SEP-2021, the subject was discharged from the hospital and the event was considered resolved.

On 15-SEP-2021, Cycle 2, Day 1 dosing was administered. Study drug (Trilaciclib versus placebo) and docetaxel doses were unchanged from the previous cycle.

The action taken with the blinded study drug (Trilaciclib versus placebo) and docetaxel as a result of this event was reported as cycle delayed.

The investigator reported that the event of MSSA sepsis was related to the blinded study drug (Trilaciclib versus placebo) and docetaxel but not related to any of the study procedures. The investigator also attributed the event to the disease under study

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

(non-small cell lung cancer).

The sponsor considered the event as unlikely related to the blinded study drug (Trilaciclib versus placebo). Per the Investigator Brochure for G1T28/Trilaciclib at the time of the event (Version 9.0 dated 01-Mar-2021), MSSA sepsis was unexpected, and remains unexpected in the current version of the Investigator Brochure for G1T28/Trilaciclib (Version 10, dated 08-Nov-2021). MSSA sepsis is not listed in the current United States package insert (USPI for Cosela, dated 12-Feb-2021).

Follow-up information received on 10-SEP-2021 included an updated event term (previously possible pulmonary embolism), causality, end date and outcome as well as a hospital discharge date.

Follow-up information was received on 24-SEP-2021. New information included diagnostic test results and the date on which cycle 2 treatment was initiated.

Follow-up information received on 08-Feb-2022. New information included concomitant medication, and laboratory normal ranges.

Follow-up information received on 14-Feb-2022. New information included an update to the reported action taken with the study drugs due to the event (doses not changed) and confirmation that cycle 2 was delayed due to the hospitalization (for this event).

Follow-up information received on 24-Feb-2022 and on 27-Feb-2022. New information included confirmation of the action taken with both study drugs due to the event (Cycle delayed). In addition, it was reported that there were no further source documents were available for submission/review.

13. Lab Data

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1	10-AUG-2021	Alanine aminotransferase	25 enzyme unit per litre	60 9
2	01-SEP-2021	Angiogram		
		Lungs: Large consolidative and ground-glass opacities of the right middle and right lower lobe. Large ground-glass consolidation of the posterior left lowerlobe. Multiple scattered ground-glass nodules of the remaining bilateral lungsmeasure up to 2 cm. Pleura: Trace right pleural effusion. Mediastinum: No mediastinal masses. Cardiovascular: No aortic aneurysm or dissection. Evaluation of the pulmonary arteries is nondiagnostic due to minimal contrast bolus within the pulmonary arteries, as well as motion artifact. There is a left chest port with catheter tip at the lower SVC. Lymph nodes: Enlarged precarinal lymph node measures 13 mm. Musculoskeletal: Degenerative changes of the spine. Upper abdomen: Normal.		
3	10-AUG-2021	Aspartate aminotransferase	25 enzyme unit per litre	35 10
4	10-AUG-2021	Blood albumin	4.4 gram per decilitre	5.1 3.6
5	10-AUG-2021	Blood alkaline phosphatase	78 enzyme unit per litre	115 40
6	10-AUG-2021	Blood bilirubin	1.1 milligram per decilitre	1.2 0.2
7	10-AUG-2021	Blood chloride	100 millimole per litre	110 98
8	10-AUG-2021	Blood creatinine	0.89 milligram per decilitre	1.25 0.7
9	10-AUG-2021	Blood glucose	82 milligram per decilitre	99 65
10	10-AUG-2021	Blood potassium	4.1 millimole per litre	5.3 3.5
11	10-AUG-2021	Blood sodium	139 milliequivalent per litre	146 135
12	10-AUG-2021	Blood urea	14 milligram per decilitre	25

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
				7
13	18-AUG-2021	Chest X-ray	<p>Left subclavian Port-A-Cath with tip at the lower SVC.</p> <p>The cardiomeastinal silhouette demonstrates mild enlargement of the cardiac silhouette. There are aortic calcifications.</p> <p>Bilateral mid to lower lung opacities, right greater than left, with right basilar consolidation</p> <p>Small to moderate right pleural effusion.</p> <p>No definite pneumothorax is seen.</p> <p>No acute osseous abnormality.</p>	
14	01-SEP-2021	Chest X-ray	<p>The heart and mediastinum are within normal limits.</p> <p>There are persistent left perihilar and right lower lobe infiltrates. There is a moderate right pleural effusion.</p> <p>There is a left-sided chest wall port in place.</p> <p>There is no pneumothorax.</p>	
15	08-SEP-2021	Chest X-ray	<p>Left subclavian central venous catheter is removed. Patchy airspace opacification in the left mid to lower lung and the right lower lung are again noted without significant interval change. There is no definite pleural effusion or pneumothorax. The cardiac and mediastinal contours are within normal limits.</p>	
16	01-SEP-2021	Echocardiogram	<p>Normal LV size with normal systolic function eft ventricular filling pattern c/w diastolic dysfunction. There is no left ventricular hypertrophy.</p> <p>Normal right ventricular size.</p> <p>Normal left atrium.</p> <p>Poorly seen aortic valve. There is no aortic regurgitation.</p> <p>Normal mitral valve. There is trace mitral regurgitation. Normal tricuspid valve. There is trace tricuspid regurgitation.</p> <p>Pulmonic valve not well seen.</p>	
17	10-AUG-2021	Glomerular filtration rate	91 millilitre per minute per 1.73 square metre	60
18	10-AUG-2021	Haemoglobin	11.9 gram per decilitre	17.1 13.2
19	16-AUG-2021	Haemoglobin	11.5 gram per decilitre	17.1 13.2
20	19-AUG-2021	Haemoglobin	9.2 gram per decilitre	17.1 13.2
21	24-AUG-2021	Haemoglobin	10.5 gram per decilitre	17.1 13.2
22	27-AUG-2021	Haemoglobin	11.4 gram per decilitre	17.1 13.2
23	10-AUG-2021	Neutrophil count	1776 cells per microlitre	7800 1500
24	16-AUG-2021	Neutrophil count	880 cells per microlitre	7800 1500
25	19-AUG-2021	Neutrophil count	360 cells per microlitre	7800 1500

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
26	24-AUG-2021	Neutrophil count	457 cells per microlitre	7800 1500
27	27-AUG-2021	Neutrophil count	869 cells per microlitre	7800 1500
28	10-AUG-2021	Platelet count	172 thousand per microlitre	400 140
29	16-AUG-2021	Platelet count	158 thousand per microlitre	400 140
30	19-AUG-2021	Platelet count	160 thousand per microlitre	400 140
31	24-AUG-2021	Platelet count	178 thousand per microlitre	400 140
32	27-AUG-2021	Platelet count	208 thousand per microlitre	4000 140
33	04-SEP-2021	Ultrasound Doppler Right Imaging: The common femoral, greater saphenous - thigh, profunda, femoral, popliteal, posterior tibial and peroneal veins coapt well and show no evidence of acute or chronic venous thrombosis. Left Imaging: The common femoral, greater saphenous - thigh, profunda, femoral, popliteal, posterior tibial and peroneal veins coapt well and shows no evidence of acute or chronic venous thrombosis.		
34	01-SEP-2021	Ventilation/perfusion scan Ventilation: Severe extensive clumping of radiotracer within the central airways. Perfusion: Heterogeneous perfusion. Matched defects: Several, small. Mismatch defects: None. Chest x-ray: Dense patchy infiltrates, worse in the right lower lung Impression: Low probability VQ scan.		
35	10-AUG-2021	White blood cell count	3.7 thousand per microlitre	10.8 3.8
36	16-AUG-2021	White blood cell count	1.6 thousand per microlitre	10.8 3.8
37	19-AUG-2021	White blood cell count	0.9 thousand per microlitre	10.8 3.8
38	24-AUG-2021	White blood cell count	1.7 thousand per microlitre	10.8 3.8
39	27-AUG-2021	White blood cell count	2.4 thousand per microlitre	10.8 3.8

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) TRILACICLIB VS PLACEBO (Code not broken) ; Regimen #1	Blinded, Information withheld	myelosuppression (Myelosuppression)	11-AUG-2021 / 11-AUG-2021; 1 day
#1) TRILACICLIB VS PLACEBO (Code not broken)	Blinded, Information withheld	myelosuppression	15-SEP-2021 /

ADDITIONAL INFORMATION**14-19. SUSPECT DRUG(S) continued**

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
broken) ; Regimen #2	withheld	(Myelosuppression)	Unknown; Unknown
#2) DOCETAXEL (DOCETAXEL) Solution for infusion; Regimen #1	75 mg/m2 every 21 days; IV drip	Non-small cell lung cancer metastatic (Non-small cell lung cancer metastatic)	11-AUG-2021 / 11-AUG-2021; 1 day
#2) DOCETAXEL (DOCETAXEL) Solution for infusion; Regimen #2	75 mg/m2 every 21 days; IV drip	Non-small cell lung cancer metastatic (Non-small cell lung cancer metastatic)	15-SEP-2021 / Unknown; Unknown

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
01-JAN-2021 to Ongoing	Historical Condition	Cancer pain (Cancer pain);
01-JUN-2021 to Ongoing	Historical Condition	Nausea (Nausea);
01-FEB-2021 to Ongoing	Historical Condition	Weight loss (Weight decreased);
21-JUL-2021 to Ongoing	Historical Condition	Anemia (Anaemia);
22-APR-2021 to Ongoing	Historical Condition	Lung adenocarcinoma stage IV (Lung adenocarcinoma stage IV);
29-JUN-2021 to 12-JUL-2021	Historical Condition to thoracic spine	External beam radiotherapy (Radiotherapy);
22-APR-2021 to 22-APR-2021	Historical Condition	Biopsy (Biopsy);
18-AUG-2021 to 18-AUG-2021	Historical Condition	Catheter placement (Catheter placement);
01-JUN-2021 to 13-JUL-2021	Historical Drug	carboplatin (carboplatin); Drug Indication: Lung adenocarcinoma (Lung adenocarcinoma)
01-JUN-2021 to 13-JUL-2021	Historical Drug	pemetrexed (pemetrexed); Drug Indication: Lung adenocarcinoma (Lung adenocarcinoma)
01-JUN-2021 to 13-JUL-2021	Historical Drug	pembrolizumab (pembrolizumab); Drug Indication: Lung adenocarcinoma (Lung adenocarcinoma)

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) Unk	1a. COUNTRY UNITED STATES	2. DATE OF BIRTH			2a. AGE 60 Years	3. SEX Male	3a. WEIGHT 113.90 kg	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input checked="" type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING
		Day	Month	Year			Day	Month	Year		
			Unk				26	AUG	2021		

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
Renal failure [Renal failure]

Case Description: This case, manufacturer control #G1-000334 received from site 3145 in the United States of America, is a report of a hospitalization due to renal failure, grade 3, that occurred in a 60 year-old male. Subject 3145-2501 was enrolled in the G1T28-210 study: Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4).

(Continued on Additional Information Page)

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) TRILACICLIB VS PLACEBO (Code not broken) #2) DOCETAXEL (DOCETAXEL) Solution for infusion (Continued on Additional Information Page)		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) Blinded, Information withheld. #2) 75 mg/m2 every 3 weeks	16. ROUTE(S) OF ADMINISTRATION Blinded, Information withheld. #2) IV drip	
17. INDICATION(S) FOR USE #1) myelosuppression (Myelosuppression) #2) Non-small cell lung cancer metastatic (Non- (Continued on Additional Information Page)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) 03-JUN-2021 / 03-JUN-2021 #2) 03-JUN-2021 / 03-JUN-2021	19. THERAPY DURATION #1) 1 day #2) 1 day	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1) BENAZEPRIL (BENAZEPRIL) ; 2020 / SEP-2021 #2) METFORMIN (METFORMIN) ; 2020 / Unknown #3) HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) ; 2020 / SEP-2021 #4) ATORVASTATIN (ATORVASTATIN) ; 2020 / Unknown #5) GABAPENTIN (GABAPENTIN) ; 2020 / Unknown #6) LEVETIRACETAM (LEVETIRACETAM) ; 2020 / Unknown		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates	Type of History / Notes	Description
21-DEC-2020 to Ongoing	Historical Condition grade 1	Weakness generalized (Asthenia)
21-DEC-2020 to Ongoing	Historical Condition grade 1	Diarrhea (Diarrhoea)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER G1 Therapeutics Elizabeth Garcia 700 Park Offices Drive, Suite 200 Research Triangle Park, NC 27709 UNITED STATES Phone: 1 919-909-5187		26. REMARKS
	24b. MFR CONTROL NO. 2021G1US0000124	25b. NAME AND ADDRESS OF REPORTER Dr David Berz Valkyrie Clinical Trials 2080 Century Park East Suite 710 Los Angeles, California 90067 UNITED STATES
24c. DATE RECEIVED BY MANUFACTURER 27-AUG-2021	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input checked="" type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT 22-JUL-2022	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

The subject's medical history included hypertension (2017), generalized weakness (Dec-2020), diarrhea (Dec-2020), and discomfort over the right chest muscle (Dec-2020).

In 2017, the subject was diagnosed with stage IV adenocarcinoma of the lung; treatment with pembrolizumab was initiated in Mar-2017, and in Sep-2017 the subject underwent an unspecified brain surgery. On 23-May-2018, pembrolizumab was discontinued after the subject had confirmed disease progression. Subsequent therapies included sitravatinib in combination with nivolumab (investigational study from 24-May-2018 until 10-Sep-2019), paclitaxel with carboplatin (from Oct-2019 until 12-Apr-2020) and then cisplatin with VP-16 (etoposide) (from Jun-2020 until 20-Sep-2020). It was reported that the subject had not received treatment with radiation therapy.

The subject's concomitant medications included benazepril, metformin, hydrochlorothiazide, atorvastatin, gabapentin, and levetiracetam.

On 02-Jun-2021, screening chemistry laboratory results included blood urea nitrogen BUN 20 mg/dL (normal range 7-25), creatinine 1.85 mg/dL (normal range 0.7-1.25), sodium 141 mEq/L (normal range 135-146), potassium 4.1 mmol/L (normal range 3.5-5.3), chloride 109 mmol/L (normal range 98-110), and bicarbonate 26 mEq/L (normal range 19-30).

On 03-Jun-2021, Cycle 1, Day 1, the subject received the first dose of blinded study drug (Trilaciclib versus placebo) given by intravenous infusion, at a dose of 240 mg/m² (total dose 571.5 mg) and then received intravenous docetaxel at a dose of 75 mg/m² (total dose 178.6 mg). Treatment was continued with minor dose adjustments of both study drugs, based on changes in the subject's weight. Cycle 4 dosing was delayed due to issues relating to venous access.

Blood urea nitrogen and creatine levels remained stable during the subsequent cycles prior to this event.

On 18-Aug-2021, pre-treatment laboratory results included BUN 25 mg/dL and creatinine 2.05 mg/dL. Cycle 4, Day 1 blinded study drug (Trilaciclib versus placebo) was given by intravenous infusion at a dose of 574.41 mg, followed by intravenous docetaxel at a dose of 179.5 mg.

On 26-Aug-2021, Cycle 4, Day 9, the subject was hospitalized due to renal failure secondary to dehydration. He presented to the Emergency Department (ED) with complaints of a 3-day history of abdominal cramping, nausea, vomiting and watery stools. He stated he noticed a small amount of red in one of the stools. He denied shortness of breath, chest pain, fevers, chills, or urinary complaints. Physical exam was unremarkable: heart rate and rhythm were regular, his lungs were clear on auscultation, and his abdomen was soft and non-tender with normal bowel sounds. In the ED, the subject was noted to be hypotensive; his blood pressure improved with intravenous fluids. Laboratory results included white blood cells 1.59, hemoglobin 10.5, hematocrit 33.2, platelets 268, glucose 135, sodium 138, potassium 3.9, chloride 105, BUN 39.0, creatinine 3.20, calcium 8.5, magnesium 1.5, total bilirubin 0.5, alanine aminotransferase (ALT) 19, aspartate aminotransferase 20, and alkaline phosphatase 55 (normal ranges and units of measure not available). A urinalysis was performed and revealed no abnormalities. A computed tomogram of the abdomen and pelvis were unremarkable and showed no cause for the subject's diarrhea and abdominal pain.

On 27-Aug-2021, the subjects vital signs included temperature 97.7 degrees Fahrenheit (F), pulse 103 beats/min, respiratory rate 18 breaths/min, blood pressure 99/65 mmHg, and SpO₂ 98%. Laboratory results included white blood cells 1.46, hemoglobin 10.3, hematocrit 32.7, platelets 263, glucose 100, sodium 139, potassium 4.3, chloride 103, BUN 23.7, creatinine 1.82, and calcium 8.3. A cardiology consultation was obtained to evaluate the subject's near syncope; on his examination, there was no evidence of jugular vein distention, no carotid bruits, and heart sounds were normal without murmurs, rubs or gallops. Lungs were clear to auscultation and his abdomen revealed positive bowel sounds and was soft and non-tender. A magnetic resonance imaging (MRI) scan of the brain on that day revealed mild periventricular and subcortical white matter signal abnormalities most commonly related to microvascular ischemic disease. No new metastases were identified. A transthoracic echocardiogram (TTE) was performed and was notable for normal left ventricular (LV) systolic function with LV ejection fraction 65%, mild diastolic function and reversal of the E to A ratio and/or prolonged deceleration time consistent with impaired left ventricular relaxation. There were no regional wall abnormalities or significant valvular heart disease, and right ventricular systolic function was normal. The subject was placed on telemetry for monitoring, and it was recommended to continue intravenous fluids and to hold the subject's blood pressure medications.

On 28-Aug-2021, vital signs included temperature 97.9 F, pulse 106 beats/min, respiratory rate 18 breaths/min, blood pressure 95/74 mmHg, and SpO₂ 98%. Laboratory results included white blood cells 1.96, hemoglobin 9.6, hematocrit 30.9, platelets 261, glucose 99, sodium 137, potassium 4.2, chloride 106, BUN 18.3, creatinine 1.68, calcium 8.4, magnesium 1.5, and phosphate 2.1. Nephrology was consulted and considered the acute kidney injury on chronic kidney disease stage 3 to be due to volume depletion and advised to continue intravenous normal saline at 75 cc/hour, intravenous iron, and to replete magnesium and phosphorus as needed. In addition, the subject's intake and output and weight was to be monitored daily. An electro-encephalogram (EEG) was performed to evaluate for seizure activity, and revealed persistent low amplitude, right frontal slow seen at 2-6 Hz, but no seizure activity.

On 30- Aug-2021, the event was reported to have resolved and the subject was discharged from the hospital.

The action taken with the blinded study drug (Trilaciclib versus placebo) and docetaxel as a result of this event was reported as dose

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

not changed.

The investigator reported that the event of renal failure was not related to the blinded study drug (Trilaciclib versus placebo) and was assessed as related to docetaxel.

The Sponsor has assessed the relationship of renal failure to the blinded study drug (Trilaciclib versus placebo) as not related. The event was considered unexpected per the Trilaciclib Investigator's Brochure at the time of the event (Version 9, dated 01-Mar-2021), remains unexpected per the current Trilaciclib Investigator's Brochure (Version 10, dated 08-Nov-2021), and is not listed in the current United States package insert (USPI) for Cosela (12-Feb-2021).

Follow-up information received on 27-Sep-2021 included hospital notes with laboratory and diagnostic test results.

Follow-up information received on 08-Feb-2022 included normal ranges and units of measure for laboratory results performed at study visits, a list of concomitant medications, the reason for the delay in administration of cycle 4 protocol therapy, and confirmation that the subject did not experience a seizure during this hospital stay.

Follow-up information received on 08-Feb-2022 included lung cancer diagnostic and treatment history, confirmation of the date the echocardiogram was performed, and confirmation that lab normal ranges and units of measure for the laboratory testing from the hospitalization are not available.

Follow-up information received on 25-Mar-2022 included updated action taken with both study drugs due to the event (from "not applicable" to "dose not changed").

13. Lab Data

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1	26-AUG-2021	Alanine aminotransferase		
		19		
2	26-AUG-2021	Aspartate aminotransferase		
		20		
3	26-AUG-2021	Blood alkaline phosphatase		
		55		
4	02-JUN-2021	Blood bicarbonate	26 milliequivalent per litre	30 19
5	26-AUG-2021	Blood bilirubin		
		0.5		
6	26-AUG-2021	Blood calcium		
		8.5		
7	27-AUG-2021	Blood calcium		
		8.3		
8	28-AUG-2021	Blood calcium		
		8.4		
9	02-JUN-2021	Blood chloride	109 millimole per litre	110 98
10	26-AUG-2021	Blood chloride		
		105		

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
11	27-AUG-2021	Blood chloride		
		106		
12	28-AUG-2021	Blood chloride		
		106		
13	02-JUN-2021	Blood creatinine	1.85 milligram per decilitre	1.25 0.7
14	23-JUN-2021	Blood creatinine	2.13 milligram per decilitre	1.25 0.7
15	15-JUL-2021	Blood creatinine	2.04 milligram per decilitre	1.25 0.7
16	04-AUG-2021	Blood creatinine	1.72 milligram per decilitre	1.25 0.7
17	18-AUG-2021	Blood creatinine	2.05 milligram per decilitre	1.25 0.7
18	26-AUG-2021	Blood creatinine		
		3.70		
19	26-AUG-2021	Blood creatinine		
		3.20		
20	27-AUG-2021	Blood creatinine		
		1.82		
21	27-AUG-2021	Blood creatinine		
		1.82		
22	28-AUG-2021	Blood creatinine		
		1.68		
23	26-AUG-2021	Blood glucose		
		135		
24	27-AUG-2021	Blood glucose		
		100		
25	28-AUG-2021	Blood glucose		
		99		
26	26-AUG-2021	Blood magnesium		
		1.5		
27	28-AUG-2021	Blood magnesium		

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
		1.5		
28	28-AUG-2021	Blood phosphorus		
		2.1		
29	02-JUN-2021	Blood potassium	4.1 millimole per litre	5.3 3.5
30	26-AUG-2021	Blood potassium		
		3.9		
31	27-AUG-2021	Blood potassium		
		4.3		
32	28-AUG-2021	Blood potassium		
		4.2		
33	27-AUG-2021	Blood pressure measurement		
		99/65 mmHg		
34	28-AUG-2021	Blood pressure measurement		
		95/74 mmHg		
35	02-JUN-2021	Blood sodium	141 milliequivalent per litre	146 135
36	26-AUG-2021	Blood sodium		
		138		
37	27-AUG-2021	Blood sodium		
		139		
38	28-AUG-2021	Blood sodium		
		137		
39	02-JUN-2021	Blood urea	20 milligram per decilitre	25 7
40	23-JUN-2021	Blood urea	20 milligram per decilitre	25 7
41	15-JUL-2021	Blood urea	21 milligram per decilitre	25 7
42	04-AUG-2021	Blood urea	14 milligram per decilitre	25 7
43	18-AUG-2021	Blood urea	25 milligram per decilitre	25 7
44	26-AUG-2021	Blood urea		
		39		

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
45	27-AUG-2021	Blood urea		
		23.7		
46	28-AUG-2021	Blood urea		
		18.3		
47	27-AUG-2021	Body temperature	97.7 degree (plane angle)	
48	28-AUG-2021	Body temperature	97.9 degree (plane angle)	
49	26-AUG-2021	Computerised tomogram		
		Unremarkable, reveled no cause for subjects abdominal pain and diarrhea		
50	27-AUG-2021	Echocardiogram		
		TTE Conclusions:		
		1. Normal left ventricular systolic function. LV Ejection Fraction is 65 %. Mild diastolic dysfunction. There is reversal of the E to A ratio and/or prolonged deceleration time consistent with impaired left ventricular relaxation.		
		2. Resting Segmental Wall Motion Analysis: Total wall motion score is 1.00. There are no regional wall motion abnormalities.		
		3. Normal right ventricular systolic function.		
		4. There is no significant valvular heart disease.		
		5. The inferior vena cava is of normal size. The inferior vena cava shows a normal respiratory collapse consistent with normal right atrial pressure (3 mmHg).		
51	28-AUG-2021	Electroencephalogram		
52	26-AUG-2021	Haematocrit		
		33.2		
53	27-AUG-2021	Haematocrit		
		32.7		
54	28-AUG-2021	Haematocrit		
		30.9		
55	26-AUG-2021	Haemoglobin		
		10.5		
56	27-AUG-2021	Haemoglobin		
		10.3		
57	28-AUG-2021	Haemoglobin		
		9.6		

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
58	27-AUG-2021	Heart rate	103 beats/min	
59	28-AUG-2021	Heart rate	106 beats/min	
60	27-AUG-2021	Magnetic resonance imaging head		
61	27-AUG-2021	Oxygen saturation	98 %	
62	28-AUG-2021	Oxygen saturation	98 %	
63	27-AUG-2021	Respiratory rate	18 breaths/min	
64	28-AUG-2021	Respiratory rate	18 breaths/min	
65	26-AUG-2021	Urine analysis	Negative for blood, glucose and protein.	
66	26-AUG-2021	White blood cell count	1.59	
67	27-AUG-2021	White blood cell count	1.46	
68	28-AUG-2021	White blood cell count	1.96	

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) TRILACICLIB VS PLACEBO (Code not broken) ; Regimen #1	Blinded, Information withheld	myelosuppression (Myelosuppression)	03-JUN-2021 / 03-JUN-2021; 1 day
#1) TRILACICLIB VS PLACEBO (Code not broken) ; Regimen #2	Blinded, Information withheld	myelosuppression (Myelosuppression)	24-JUN-2021 / 15-JUL-2021; 22 days

ADDITIONAL INFORMATION**14-19. SUSPECT DRUG(S) continued**

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) TRILACICLIB VS PLACEBO (Code not broken) ; Regimen #3	Blinded, Information withheld	myelosuppression (Myelosuppression)	18-AUG-2021 / Unknown; Unknown
#2) DOCETAXEL (DOCETAXEL) Solution for infusion; Regimen #1	75 mg/m2 every 3 weeks; IV drip	Non-small cell lung cancer metastatic (Non-small cell lung cancer metastatic)	03-JUN-2021 / 03-JUN-2021; 1 day
#2) DOCETAXEL (DOCETAXEL) Solution for infusion; Regimen #2	75 mg/m2 every 3 weeks; IV drip	Non-small cell lung cancer metastatic (Non-small cell lung cancer metastatic)	24-JUN-2021 / 15-JUL-2021; 22 days
#2) DOCETAXEL (DOCETAXEL) Solution for infusion; Regimen #3	75 mg/m2 every 3 weeks; IV drip	Non-small cell lung cancer metastatic (Non-small cell lung cancer metastatic)	Unknown; Unknown

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
01-DEC-2020 to Ongoing	Historical Condition grade 1	Chest wall discomfort (Chest discomfort);
01-JAN-2017 to Ongoing	Historical Condition grade 1	Hypertension (Hypertension);
01-JAN-2001 to Ongoing	Historical Condition	Tobacco user (Tobacco user);
01-JAN-2017 to Ongoing	Historical Condition	Adenocarcinoma lung stage IV (Lung adenocarcinoma stage IV);
01-JAN-2017 to 01-JAN-2017	Historical Condition	Brain operation NOS (Brain operation);
01-MAR-2017 to 23-MAY-2018	Historical Drug	pembrolizumab (pembrolizumab); Drug Indication: Lung cancer metastatic (Lung cancer metastatic)
24-MAY-2018 to 10-SEP-2019	Historical Drug	sitravatinib (sitravatinib); Drug Indication: Lung cancer metastatic (Lung cancer metastatic)
24-MAY-2018 to 10-SEP-2019	Historical Drug	nivolumab (nivolumab); Drug Indication: Lung cancer metastatic (Lung cancer metastatic)
01-OCT-2019 to 12-APR-2020	Historical Drug	paclitaxel (paclitaxel); Drug Indication: Lung cancer metastatic (Lung cancer metastatic)
01-OCT-2019 to 12-APR-2020	Historical Drug	carboplatin (carboplatin); Drug Indication: Lung cancer metastatic (Lung cancer metastatic)
01-JUN-2020 to 20-SEP-2020	Historical Drug	cisplatin (cisplatin); Drug Indication: Lung cancer metastatic (Lung cancer metastatic)
01-JUN-2020 to 20-SEP-2020	Historical Drug	VP16; Drug Indication: Lung cancer metastatic (Lung cancer metastatic)

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) Unk	1a. COUNTRY UNITED STATES	2. DATE OF BIRTH			2a. AGE 65 Years	3. SEX Female	3a. WEIGHT 73.90 kg	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year				Day	Month	Year	
			Unk					01	SEP	2021	

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
urosepsis [Urosepsis]
Acute renal failure [Acute kidney injury]

Case Description: This case, manufacturer control #G1-000337 received from site 3145 in the United States, is a report of a fatal event of urosepsis grade 5 that occurred in a 65 year-old female while she was hospitalized due to acute renal failure grade 3.

(Continued on Additional Information Page)

☒ PATIENT DIED
Date: 05-SEP-2021

☒ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION

☐ INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY

☒ LIFE THREATENING

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) TRILACICLIB VS PLACEBO (Code not broken) #2) DOCETAXEL (DOCETAXEL) Solution for infusion (Continued on Additional Information Page)		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) Blinded, Information withheld. #2) 75 mg/m2 on (Continued on Additional Information Page)	16. ROUTE(S) OF ADMINISTRATION Blinded, Information withheld. #2) IV drip	
17. INDICATION(S) FOR USE #1) Non-small cell lung cancer metastatic () #2) Non-small cell lung cancer metastatic () (Continued on Additional Information Page)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) 25-AUG-2021 12:13:00 / Unknown #2) 25-AUG-2021 15:13:00 / Unknown	19. THERAPY DURATION #1) Unknown #2) Unknown	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1) ALBUTEROL SULFATE (SALBUTAMOL SULFATE) ; Unknown #2) AZELASTINE (AZELASTINE) ; Unknown #3) SYMBICORT (BUDESONIDE, FORMOTEROL FUMARATE) ; Unknown #4) FAMOTIDINE (FAMOTIDINE) ; Unknown #5) FLUTICASONE PROPIONATE (FLUTICASONE PROPIONATE) ; Unknown #6) IBUPROFEN (IBUPROFEN) ; Unknown (Continued on Additional Information Page)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates	Type of History / Notes	Description
01-OCT-2019 to Ongoing	Historical Condition	Cough (Cough)
01-NOV-2012 to Ongoing	Historical Condition	Shortness of breath (Dyspnoea)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER G1 Therapeutics Elizabeth Garcia 700 Park Offices Drive, Suite 200 Research Triangle Park, NC 27709 UNITED STATES Phone: 1 919-909-5187		26. REMARKS
	24b. MFR CONTROL NO. 2021G1US0000125	25b. NAME AND ADDRESS OF REPORTER Dr David Berz Valkyrie Clinical Trials, Inc. 2080 Century Park East Suite 710 Los Angeles, CA 90067 UNITED STATES
24c. DATE RECEIVED BY MANUFACTURER 02-SEP-2021	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input checked="" type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT 22-JUL-2022	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

Subject 3145-2007 was enrolled in the G1T28-210 study: A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rdLine Setting (PRESERVE 4).

The subject's medical history included tobacco (cigarette) use (1975 to 2012), rheumatoid arthritis (2011), chronic obstructive pulmonary disease (2012), shortness of breath (2012), gastritis (2018), nausea (Oct-2019), anxiety (Oct-2019), cough (Oct-2019), biopsy lung (02-Oct-2019), cancer pain (Nov-2019), multiple skin ulcers (01-Feb-2021), conjunctival irritation (01-Jun-2021), hypertension (18-Aug-2021), hyperglycemia (18-Aug-2021), and lymphopenia (18-Aug-2021).

On 02-Oct-2019, the subject underwent a left lung biopsy and pleurocentesis, and was diagnosed with Stage IV squamous cell carcinoma of the lung. Initial treatment included carboplatin with paclitaxel (from 25-Nov-2019 until 19-Mar-2021), and external beam radiation therapy (25-Nov-2019).

Concomitant medications at the time of the event included albuterol sulfate, azelastine, Symbicort (budesonide-formoterol), famotidine, fluticasone propionate, ibuprofen, montelukast, omeprazole, prednisone, and Spiriva Respimat (tiotropium bromide).

On 24-Aug-2021, results of pre-cycle one laboratory testing included creatinine 0.80, blood urea nitrogen (BUN) 11, and estimated glomerular filtration rate (eGFR) 77, white blood cell count 6.4 with 86.8% neutrophils and an absolute neutrophil count (ANC) of 5555, hemoglobin 10.0, and platelet count 267 (normal ranges and units of measure not provided).

On 25-Aug-2021, the subject received the first dose of blinded study drug (Trilaciclib versus placebo) given by intravenous infusion, at a dose of 240 mg/m² (total dose 435.2 mg). The subject subsequently received docetaxel via intravenous infusion at a dose of 75 mg/m² (total dose 136 mg).

On 30-Aug-2021, Cycle 1 Day 5, results of laboratory testing included creatinine 0.88, BUN 11, eGFR 69, hemoglobin 10.0, hematocrit 30.9, white blood cell count 1.6 and ANC 1.1 (normal ranges and units of measure not provided).

On 01-Sep-2021, 6 days after first receiving blinded study drug and docetaxel, the subject was hospitalized due to dehydration and was confirmed to be in acute renal failure. The subject was transported by emergency medical services to a local emergency department (ED); while in transport, her blood pressure was 54/30 mmHg and 700 mL Ringer's lactate (RL) solution was administered during transport to the hospital. The subject reported that for the first two days following protocol therapy she had felt well but since then had developed weakness, decreased appetite, poor fluid intake, dyspnea on exertion, orthopnea, yellow productive cough, intermittent constipation, diarrhea, and abdominal distension. She denied chest pain though she noted mid-sternal chest pain a few days ago, which had resolved. She further denied palpitations, nausea, vomiting, abdominal pain, hematemesis, melena, hematochezia, dysuria, hematuria, fever, chills, headaches, leg swelling, and dizziness/lightheadedness. She reported using home oxygen throughout the day, when she had previously used oxygen only at night. On arrival to the emergency department (ED), her systolic blood pressure was 65 mmHG, and she was administered one liter of intravenous normal saline with slight improvement. At 11:28 AM, vital signs included temperature 97.2 degrees F, pulse rate 100, respiratory rate 18, blood pressure 74/55 mmHg, and pulse oximetry 100% on oxygen 4 liters by nasal cannula. Laboratory results were notable for white blood cell (WBC) count 0.5 Thou/mm³ (normal range: 3.6-11.0), hemoglobin 8.4 g/dL (normal range: 12.0-16.0), hematocrit 25.8 % (normal range: 36.0-46.0), blood urea nitrogen (BUN) 31 mg/dL (normal range: 9-23) mg/dL, creatinine 3.3 mg/dL (normal range: 0.6-1.3), estimated glomerular filtration rate (eGFR)(non-African American) 15 (normal range: > 60), and lactic acid 3 mmol/L (normal range: 0.4-2.0). A SARS-CoV-2 PCR test was negative. Urinalysis revealed cloudy amber urine with WBC 168 hpf (normal range: 0-5), 3+ protein (normal range: negative - trace), blood 1+, and 3+ bacteria. An electrocardiogram (ECG) revealed no acute ST-T changes, no ectopy, no ischemic changes, sinus tachycardia, normal QRS, normal intervals, and normal axis. A chest x-ray revealed a large left lung opacity consistent with an extensive left lung pneumonia, suspicious for superimposed pulmonary vascular congestion and a large left pleural effusion. A computerized tomography (CT) scan of the chest without intravenous contrast revealed left lung atelectasis with extensive left lung pneumonia and a suspicious 5x6 cm partially necrotic left apical tumor mass. Bilateral lower extremity doppler ultrasound was negative for deep vein thrombosis. An abdominal x-ray revealed early small bowel obstruction pattern. A renal ultrasound revealed bilateral renal cortical thickening, moderate bilateral renal parenchymal scar, and no hydronephrosis or renal calculi. BiLevel positive air pressure (BiPAP) was initiated, blood and urine cultures were obtained; initial gram stain of the blood culture was positive for Gram negative rods, and intravenous cefepime and linezolid were initiated. Solumedrol and DuoNeb (Ipratropium bromide/salbutamol) were prescribed, and the subject was admitted to the hospital. During that evening, the subject experienced facial erythema after being administered mucomyst and was treated with prednisone, cimetidine, and Benadryl (diphenhydramine).

On 02-Sep-2021 at 03:32, an ECG, considered abnormal, revealed sinus tachycardia, borderline right axis deviation, moderate intraventricular conduction delay and minimal ST depression. Early morning laboratory results included WBC 1.2 Thou/mm³, hemoglobin 10.0 g/dL, hematocrit 32.2 %, potassium 4.4 mmol/L (normal range: 3.4-5.1), BUN 32 mg/dL, creatinine 3.7 mg/dL, BUN/Creatinine Ratio 9, and eGFR (non-African American) 13 ml/min/1.73m². The subject's respiratory effort was noted to be increasing despite BiPAP. Arterial blood gases (ABG) results were consistent with respiratory acidosis with pH 7.06, partial pressure of carbon dioxide (pCO₂) 66, partial pressure of oxygen (pO₂) 67, bicarbonate (HCO₃) 19, and oxygen saturation 90% on 40% fraction of inspired oxygen (FiO₂). Bilateral lower extremity mottling was noted on examination. A chest x-ray revealed worsening left lung atelectasis when compared with the results from the previous day. Due to due to hypoxemic respiratory failure, the subject was intubated, sedated, and placed on ventilator support. A post-procedure chest x-ray was performed and compared with the

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

examination performed earlier the same day revealed volume loss in the left lung (possible mucous plug in the left mainstem bronchus), large left pleural effusion, and extensive right lung pneumonia; the nasogastric (NG) and endotracheal (ET) tubes were in good position. A bronchoscopy was performed to remove secretions. Vital signs included temperature 97.0 degrees F, pulse rate 128, respiratory rate 35, blood pressure 100/76 (on a Levophed [norepinephrine] drip), and pulse oximetry 91%. An ECG, considered abnormal, revealed sinus tachycardia, borderline right axis deviation, moderate intraventricular conduction delay, and minimal ST depression. A transthoracic echocardiogram revealed normal left ventricular size and function. The approximate ejection fraction was 60%. The mitral valve was slightly prolapsed with trace regurgitation.

On 03-Sep-2021, lab results included BUN 62 mg/dL, creatinine 4.1 mg/dL, eGFR 12 ml/min/1.73m², lactic acid 2.5 mmol/L, and phosphate 9.0 mg/dL (normal range: 2.4-5.1). A nasal screen was negative for methicillin-resistant *Staphylococcus aureus* (MRSA). A chest x-ray was performed and when compared to the images from the previous day showed extensive right and left lung pneumonia, persistent volume loss in the left lung suspicious for a mucous plug in the left mainstem bronchus, left pleural effusion, and ET tube and Port-A-Catheter in good position. An ultrasound of the right and left thorax was performed and showed no pleural effusion in either lung that was safe thoracentesis.

On 04-Sep-2021, laboratory results included BUN 92 mg/dL, creatinine 5.1 mg/dL, eGFR (non-African American) 9 ml/min/1.73m², lactic acid 3.4 mmol/L, and revealed severe hyperkalemia with potassium 6.7 mmol/L (normal range: 3.4-5.1). The final results of the blood culture from admission were positive for *Pseudomonas aeruginosa*. In addition, she had developed coagulopathy and was oliguric. An ECG showed low QRS voltage; sinus tachycardia and intraventricular conduction delay were no longer present. The ST (T wave) deviation was still present. A chest x-ray was performed and as seen previously, there was volume loss in the left lung with shift of the mediastinal structures, again considered possible mucous plug in the left mainstem bronchus. There was residual but improved right lung pneumonia, but persistent left lung pneumonia. The ET and NG tubes were in good position. The subject remained intubated on a Levophed drip at 0.3 mcg/kg per minute and a vasopressin drip at 0.03 units. She was in severe respiratory acidosis. She had been having fevers (maximum temperature reading of 106.6 degrees Fahrenheit, date not specified) and remained hypotensive, bacteremic and in septic shock. WBC count was 51.8 Thou/mm³ with lactic acid continuing to rise at 8.6 mmol/L. Vital signs included temperature 99.2, pulse rate 106, and blood pressure 111/53. A nephrology consultation was obtained and although the subject was on Do Not Resuscitate (DNR) status, at the family's request, a dialysis catheter was placed, and emergent dialysis was initiated, resulting in resolution of the acute renal failure. The subject developed supraventricular tachycardia during dialysis and required cardioversion.

On 05-Sep-2021, laboratory results included BUN 94 mg/dL, creatinine 5.4 mg/dL, eGFR8, ml/min/1.73m², lactic acid was 12.8 mmol/L, and phosphate 15.8 mg/dL. A sputum culture results were reported positive for *Pseudomonas aeruginosa* (growth 3+). The admission urine culture was positive for *Escherichia coli* (>100,000 colonies/mL). On this day, the subject died. An autopsy was not performed; the reported cause of death was urosepsis. The final diagnoses included septic shock, acute respiratory failure, lactic acidosis, acute renal failure, and lung cancer.

The event, urosepsis, was fatal.

The action taken with the blinded study drug (Trilaciclib versus placebo) and docetaxel as a result of urosepsis was reported as dose not changed. The action taken with the blinded study drug and docetaxel as a result of acute renal failure was reported as dose not changed.

The investigator reported that the event of urosepsis was related to both the blinded study drug (Trilaciclib versus placebo) and docetaxel. The investigator considered the event of acute renal failure as not related to the blinded study drug or docetaxel.

The sponsor agrees that the acute renal failure was not related to the blinded study drug.

The sponsor considered the event of urosepsis unlikely related to the blinded study drug, but most likely associated with the acute renal failure ([ARF], from 01-Sep to 04-Sep-2021). The ARF is most likely due to Sepsis. As indicated in the literature [Author manuscript: "Acute kidney injury from sepsis; current concepts, epidemiology, pathophysiology, prevention and treatment"; Kidney International, 2019 Nov; 96 (5)1083-1099] ARF with drastic consequences commonly occurs as a result of sepsis such as in an infectious process. Urosepsis may have occurred before or after ARF, most likely due to sepsis (due to the infectious process).

Per the current Investigator Brochure for G1T28/Trilaciclib at the time the event occurred (Version 9.0 dated 01-Mar-2021), both urosepsis and acute renal failure are unexpected, and both remain unexpected per the current Investigator Brochure for G1T28/Trilaciclib (Version 10, dated 08-Nov-2021). Urosepsis and acute renal failure are not listed in the current United States package insert for Cosela (USPI, dated 12-Feb-2021).

Follow-up information was received on 07-Sep-2021, reporting a second serious and fatal adverse event: urosepsis.

Follow-up information was received on 27-Sep-2021. Hospital records were received which provided presenting symptoms, concomitant medications, treatment details and laboratory and diagnostic test results.

Follow-up information was received on 27-Feb-2022 and on 02-Mar-2022. New information included confirmation that the event of acute renal failure had resolved, that the hypoxic respiratory failure was associated with the urosepsis and did not meet criterion of a separate serious event, that the final event term was urosepsis, and that urosepsis was the cause of death. The action taken with both study drugs due to urosepsis was updated on 02-Mar-2022, to "dose not changed".

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

Follow-up information was received on 25-Mar-2022. The action taken with both study drugs due to the event of acute renal failure was updated to "dose not changed".

13. Lab Data

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1	01-SEP-2021	Abdominal X-ray		
		Early small bowel obstruction pattern		
2	30-AUG-2021	Alanine aminotransferase		
		15		
3	30-AUG-2021	Aspartate aminotransferase		
		11		
4	30-AUG-2021	Blood albumin		
		3.6		
5	30-AUG-2021	Blood alkaline phosphatase		
		151		
6	30-AUG-2021	Blood bicarbonate		
		28		
7	30-AUG-2021	Blood bilirubin		
		1.0		
8	30-AUG-2021	Blood calcium		
		8.5		
9	30-AUG-2021	Blood chloride		
		100		
10	24-AUG-2021	Blood creatinine		
		0.80		
11	30-AUG-2021	Blood creatinine		
		0.88		
12	01-SEP-2021	Blood creatinine	3.3 milligram per decilitre	1.3 0.6
13	02-SEP-2021	Blood creatinine	3.7 milligram per decilitre	1.3 0.6
14	03-SEP-2021	Blood creatinine	4.1 milligram per decilitre	1.3 0.6
15	04-SEP-2021	Blood creatinine	5.1 milligram per decilitre	1.3 0.6

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
16	05-SEP-2021	Blood creatinine	5.4 milligram per decilitre	1.3 0.6
17	03-SEP-2021	Blood culture Gram negative rods		
18	04-SEP-2021	Blood culture Pseudomonas aeruginosa		
19	02-SEP-2021	Blood gases pH 7.06; pCO2 66, pO2 67, HCO3 19		
20	30-AUG-2021	Blood glucose 130		
21	01-SEP-2021	Blood lactic acid	3 millimole per litre	2.0 0.4
22	03-SEP-2021	Blood lactic acid	2.5 millimole per litre	2.0 0.4
23	04-SEP-2021	Blood lactic acid	8.6 millimole per litre	2.0 0.4
24	04-SEP-2021	Blood lactic acid	3.4 millimole per litre	2.0 0.4
25	05-SEP-2021	Blood lactic acid	12.8 millimole per litre	2.0 0.4
26	03-SEP-2021	Blood phosphorus	9 milligram per decilitre	5.1 2.4
27	05-SEP-2021	Blood phosphorus	15.8 milligram per decilitre	5.1 2.4
28	30-AUG-2021	Blood potassium 3.9		
29	02-SEP-2021	Blood potassium	4.4 millimole per litre	5.1 3.4
30	04-SEP-2021	Blood potassium	6.7 millimole per litre	5.1 3.4
31	01-SEP-2021	Blood pressure measurement 74/55 mmHg		
32	02-SEP-2021	Blood pressure measurement 100/76		
33	04-SEP-2021	Blood pressure measurement 111/53		
34	01-SEP-2021	Blood smear test Severe leukopenia, neutropenia and lymphopenia with unremarkable morphology,		

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
		secondary to chemotherapy and normocytic normochromic moderate anemia without anisocytosis. There was no evidence of leukemia.		
35	30-AUG-2021	Blood sodium		
		139		
36	24-AUG-2021	Blood urea		
		11		
37	30-AUG-2021	Blood urea		
		11		
38	01-SEP-2021	Blood urea	31 milligram per decilitre	23 9
39	02-SEP-2021	Blood urea	32 milligram per decilitre	23 9
40	03-SEP-2021	Blood urea	62 milligram per decilitre	23 9
41	04-SEP-2021	Blood urea	93 milligram per decilitre	23 9
42	05-SEP-2021	Blood urea	94 milligram per decilitre	23 9
43	01-SEP-2021	Blood urea nitrogen/creatinine ratio	9 ratio	20 12
44	02-SEP-2021	Blood urea nitrogen/creatinine ratio	9 ratio	20 12
45	03-SEP-2021	Blood urea nitrogen/creatinine ratio	15 ratio	20 12
46	04-SEP-2021	Blood urea nitrogen/creatinine ratio	18 ratio	20 12
47	05-SEP-2021	Blood urea nitrogen/creatinine ratio	18 ratio	20 12
48	01-SEP-2021	Body temperature		
		97.2 degrees F		
49	02-SEP-2021	Body temperature		
		97.0 degrees F		
50	04-SEP-2021	Body temperature		
		99.2 (T-max 106.6)		
51	01-SEP-2021	Chest X-ray		
		Large left lung opacity consistent with an extensive left lung pneumonia, suspicious for superimposed pulmonary vascular congestion. There was a large left pleural effusion.		
52	02-SEP-2021	Chest X-ray		
		Volume loss in the left lung (possible mucous plug in the left mainstem bronchus), large left pleural effusion, and extensive right lung pneumonia. The nasogastric (NG) and		

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
		endotracheal (ET) tubes were in good position.		
53	02-SEP-2021	Chest X-ray	Worsening left lung atelectasis when compared with the results from the previous day.	
54	03-SEP-2021	Chest X-ray	Extensive right and left lung pneumonia, persistent volume loss in the left lung suspicious for a mucous plug in the left mainstem bronchus, left pleural effusion, and ET tube and Port-A-Catheter in good position.	
55	04-SEP-2021	Chest X-ray	Volume loss in the left lung with shift of the mediastinal structures, again considered possible mucous plug in the left mainstem bronchus. Residual right lung pneumonia, considered an improvement, but persistent left lung pneumonia. The ET and NG tubes in good position.	
56	01-SEP-2021	Computerised tomogram thorax	Without intravenous contrast; revealed significant left lung atelectasis with extensive left lung pneumonia and suspicious 5x6 cm partially necrotic left apical tumor mass.	
57	05-SEP-2021	Culture urine	Escherichia coli (>100,000 colonies/mL)	
58	02-SEP-2021	Echocardiogram	Normal left ventricular size and function. The approximate LV ejection fraction was 60%. The mitral valve was slightly prolapsed with trace regurgitation.	
59	01-SEP-2021	Electrocardiogram	No acute ST-T changes, no ectopy, no ischemic changes, sinus tachycardia, normal QRS, normal intervals, and normal axis.	
60	02-SEP-2021	Electrocardiogram	Abnormal ECG; sinus tachycardia, borderline right axis deviation, moderate intraventricular conduction delay and minimal ST depression.	
61	02-SEP-2021	Electrocardiogram	Abnormal rhythm ECG; sinus tachycardia, borderline right axis deviation, moderate intraventricular conduction delay, and minimal ST depression.	
62	04-SEP-2021	Electrocardiogram	Low QRS voltage now present. Sinus tachycardia and intraventricular conduction delay no longer present. The ST (T wave) deviation still present.	
63	24-AUG-2021	Glomerular filtration rate	77	
64	30-AUG-2021	Glomerular filtration rate		

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
		69		
65	01-SEP-2021	Glomerular filtration rate 15 ml/min/1.73 m2		60
66	02-SEP-2021	Glomerular filtration rate 13 ml/min/1.73 m2		60
67	03-SEP-2021	Glomerular filtration rate 12 ml/min/1.73m2		60
68	04-SEP-2021	Glomerular filtration rate 9		60
69	05-SEP-2021	Glomerular filtration rate 8 ml/min/1.73m2		60
70	30-AUG-2021	Haematocrit 30.9		
71	01-SEP-2021	Haematocrit	25.8 percent	46.0 36.0
72	02-SEP-2021	Haematocrit	32.2 percent	46.0 36.0
73	30-AUG-2021	Haemoglobin 10.0		
74	01-SEP-2021	Haemoglobin	8.4 gram per decilitre	16.0 12.0
75	02-SEP-2021	Haemoglobin	10 gram per decilitre	16.0 12.0
76	01-SEP-2021	Heart rate	100 heart beats per minute	
77	02-SEP-2021	Heart rate	128 heart beats per minute	
78	04-SEP-2021	Heart rate	106 heart beats per minute	
79	30-AUG-2021	Lymphocyte count 0.3		
80	30-AUG-2021	Lymphocyte percentage	19 percent	
81	30-AUG-2021	Monocyte count 0.1		
82	30-AUG-2021	Monocyte percentage	7 percent	

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
83	24-AUG-2021	Neutrophil count		
		5555		
84	30-AUG-2021	Neutrophil count		
		1.1		
85	24-AUG-2021	Neutrophil percentage	86.8 percent	
86	30-AUG-2021	Neutrophil percentage	68 percent	
87	01-SEP-2021	Oxygen saturation	100 percent	
88	02-SEP-2021	Oxygen saturation	91 percent	
89	02-SEP-2021	Oxygen saturation	90 percent	
90	02-SEP-2021	PO2		
		67		
91	24-AUG-2021	Platelet count		
		268		
92	30-AUG-2021	Platelet count		
		268		
93	24-AUG-2021	Pregnancy test		
		Negative		
94	30-AUG-2021	Protein total		
		5.9		
95	01-SEP-2021	Respiratory rate		
		18 breaths per minute		
96	02-SEP-2021	Respiratory rate		
		35		
97	01-SEP-2021	SARS-CoV-2 test		
		Negative		
98	05-SEP-2021	Sputum culture		
		Pseudomonas aeruginosa (growth 3+)		
99	01-SEP-2021	Ultrasound Doppler normal		
		Negative for deep vein thrombosis		
100	03-SEP-2021	Ultrasound chest		

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
No sufficient amount of pleural effusion in either lung for safe thoracentesis.				
101	01-SEP-2021	Ultrasound kidney		
		Bilateral renal cortical thickening, moderate bilateral renal parenchymal scar, and no hydronephrosis or renal calculi.		
102	01-SEP-2021	Urine analysis		
		Coudy amber urine, WBC 168 hpf (normal range: 0-5), protein 3+ (normal range: negative - trace), blood 1+, and bacteria 3+.		
103	03-SEP-2021	Viral test		
		Negative for methicillin-resistant Staphylococcus aureus (MRSA)		
104	24-AUG-2021	White blood cell count		
		6.4		
105	30-AUG-2021	White blood cell count		
		1.6		
106	01-SEP-2021	White blood cell count	0.5 thousand per microlitre	11.0 3.6
107	02-SEP-2021	White blood cell count	1.2 thousand per microlitre	11.0 3.6
108	04-SEP-2021	White blood cell count	51.8 thousand per microlitre	11.0 3.6

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) TRILACICLIB VS PLACEBO (Code not broken) ; Regimen #1	Blinded, Information withheld	Non-small cell lung cancer metastatic (Non-small cell lung cancer metastatic)	25-AUG-2021 12:13:00 / Unknown; Unknown
#2) DOCETAXEL (DOCETAXEL) Solution for infusion; Regimen #1	75 mg/m2 on day one of each cycle; IV drip	Non-small cell lung cancer metastatic (Non-small cell lung cancer metastatic)	25-AUG-2021 15:13:00 / Unknown; Unknown

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION continued

#7) MONTELUKAST (MONTELUKAST) ; Unknown

#8) OMEPRAZOLE (OMEPRAZOLE) ; Unknown

#9) PREDNISONE (PREDNISONE) ; Unknown

#10) SPIRIVA RESPIMAT (TIOTROPIUM BROMIDE MONOHYDRATE) ; Unknown

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
01-JAN-2012 to Ongoing 22-Jul-2022 16:18	Historical Condition	COPD (Chronic obstructive pulmonary disease);

ADDITIONAL INFORMATION**23. OTHER RELEVANT HISTORY continued**

From/To Dates	Type of History / Notes	Description
01-NOV-2019 to Ongoing	Historical Condition	Cancer pain (Cancer pain);
01-JUN-2021 to Ongoing	Historical Condition	Conjunctival irritation (Conjunctival irritation);
01-OCT-2019 to Ongoing	Historical Condition	Nausea (Nausea);
01-OCT-2019 to Ongoing	Historical Condition	Anxiety (Anxiety);
01-JAN-2011 to Ongoing	Historical Condition	Rheumatoid arthritis (Rheumatoid arthritis);
01-JAN-2018 to Ongoing	Historical Condition	Gastritis (Gastritis);
18-AUG-2021 to Ongoing	Historical Condition	Hypertension (Hypertension);
18-AUG-2021 to Ongoing	Historical Condition	Hyperglycemia (Hyperglycaemia);
18-AUG-2021 to Ongoing	Historical Condition	Lymphopenia (Lymphopenia);
01-FEB-2021 to Ongoing	Historical Condition	Lower extremities ulcers of (Skin ulcer); Skin ulcers in lower extremities
01-JAN-1975 to 2012	Historical Condition	Cigarette smoker (Tobacco user); Total daily consumption: 20 cigarettes
02-OCT-2019 to Ongoing	Historical Condition	Squamous cell carcinoma of lung stage IV (Lung squamous cell carcinoma stage IV); stage IV at diagnosis
25-NOV-2019 to 23-JAN-2021	Historical Condition	External beam radiotherapy (Radiotherapy);
02-OCT-2019 to 02-OCT-2019	Historical Condition	Biopsy lung (Biopsy lung); Biopsy on left lung
02-OCT-2019 to 02-OCT-2019	Historical Condition	Thoracentesis (Aspiration pleural cavity); Pleurocentesis
25-NOV-2019 to 19-MAR-2020	Historical Drug	Carboplatin (Carboplatin); Drug Indication: Squamous cell carcinoma of lung stage IV (Lung squamous cell carcinoma stage IV)
25-NOV-2019 to 19-MAR-2020	Historical Drug	Paclitaxel (Paclitaxel); Drug Indication: Squamous cell carcinoma of lung stage IV (Lung squamous cell carcinoma stage IV)
27-MAY-2020 to 21-JUL-2021	Historical Drug	Durvalumab (Durvalumab); Drug Indication: Squamous cell carcinoma of lung stage IV (Lung squamous cell carcinoma stage IV)

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) Unk	1a. COUNTRY UNITED STATES	2. DATE OF BIRTH			2a. AGE 73 Years	3. SEX Male	3a. WEIGHT 63.50 kg	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year			Day	Month	Year		
			Unk				10	SEP	2021		

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
**Other Serious Criteria: Other medically imp. condition
Pneumonia [Pneumonia]**

Case Description: This case, manufacturer control # G1-000342 received from site 3145 in the United States, is a report of a medically important event of pneumonia grade 3 that occurred in a 73-year-old male that resulted in hospitalization. Subject 3145-2005 was enrolled in the G1T28-210 study: A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rdLine Setting (PRESERVE 4).

(Continued on Additional Information Page)

☐ PATIENT DIED
☒ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION
☐ INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY
☐ LIFE THREATENING

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) TRILACICLIB VS PLACEBO (Code not broken) #2) DOCETAXEL (DOCETAXEL) Solution for infusion (Continued on Additional Information Page)		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) Blinded, Information withheld. #2) 75 mg/m2 on Day 1 of each cycle	16. ROUTE(S) OF ADMINISTRATION Blinded, Information withheld. #2) IV drip	
17. INDICATION(S) FOR USE #1) Metastatic non-small cell lung cancer () #2) Metastatic non-small cell lung cancer () (Continued on Additional Information Page)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) 05-AUG-2021 / 26-AUG-2021 #2) 05-AUG-2021 / 05-AUG-2021	19. THERAPY DURATION #1) 22 days #2) 1 day	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1) PANTOPRAZOLE (PANTOPRAZOLE) ; 20-FEB-2020 / Unknown #2) LISINAPRIL (LISINAPRIL) ; MAY-2019 / Unknown #3) aspirin ; MAY-2019 / Unknown #4) Percocet ; JAN-2021 / Unknown #5) ONDANSETRON (ONDANSETRON) ; MAR-2021 / Unknown #6) ZOLPIDEM (ZOLPIDEM) ; MAR-2021 / Unknown (Continued on Additional Information Page)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates 19-OCT-2020 to Ongoing 01-OCT-2020 to Ongoing	Type of History / Notes Historical Condition Historical Condition Grade 2	Description Fatigue (Fatigue)

(Continued on Additional Information Page)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER G1 Therapeutics Elizabeth Garcia 700 Park Offices Drive, Suite 200 Research Triangle Park, NC 27709 UNITED STATES Phone: 1 919-909-5187		26. REMARKS
	24b. MFR CONTROL NO. 2021G1US0000127	25b. NAME AND ADDRESS OF REPORTER Dr. David Berz Valkyrie Clinical Trials, Inc. 2080 Century Park East Suite 710 Los Angeles, California 90067 UNITED STATES
24c. DATE RECEIVED BY MANUFACTURER 10-SEP-2021	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input checked="" type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT 22-JUL-2022	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

The subject's medical history included tobacco (cigarette) use (1990 to 2010), gastrointestinal reflux disease (01-Jan-2020), hypertension (01-May-2020), palpitation (01-May-2020), fatigue (01-Oct-2020), cough (01-Nov-2020), shortness of breath (01-Nov-2020), generalized weakness (01-Nov-2020), emphysema (01-Jan-2021), insomnia (01-Mar-2021), anxiety (01-Mar-2021), constipation (01-Mar-2021), anorexia (09-Mar-2021), hyponatremia (23-Jul-2021), hypochloremia (23-Jul-2021), elevated alanine aminotransferase (23-Jul-2021), elevated aspartate aminotransferase (23-Jul-2021), and anemia (23-Jul-2021).

On 19-Oct-2020, the subject underwent a lung biopsy and was diagnosed with adenocarcinoma of lung stage IV. Initial treatment included carboplatin with pemetrexed and pembrolizumab (from 05-Jan-2021 to 30-Mar-2021) and pemetrexed with pembrolizumab (from 01-Jun-2021 to 13-Jul-2021).

Concomitant medications included pantoprazole, lisinopril, Percocet (oxycodone hydrochloride; paracetamol), lorazepam, Colace (docusate sodium), aspirin (acetylsalicylic acid), ondansetron, and zolpidem.

On 05-Aug-2021, the subject received the first dose of blinded study drug (Trilaciclib versus placebo) given by intravenous infusion, at a dose of 240 mg/m² (total dose 413.8 mg). The subject subsequently received docetaxel via intravenous infusion at a dose of 75 mg/m² (total dose 130.5 mg).

On 26-Aug-2021, Cycle 2 Day 1, the subject received the most recent dose of the blinded study drug (Trilaciclib versus placebo) prior to the event onset at the same dose as initially administered. The subject subsequently received docetaxel at a dose of 75 mg/m² (total dose 129.3 mg).

On 09-Sep-2021, 14 days after receiving most recent doses of the blinded study drug (Trilaciclib versus placebo) and docetaxel, the subject presented to the emergency room with complaints of cough, fevers as high as 101 degrees Fahrenheit, nausea, and abdominal pain. In the ER he was noted to be hypoxic (oxygen saturation value not provided). Initial laboratory results included white blood cell count (WBC) 9.31, hemoglobin 9.3, hematocrit 27.9, platelet count 441, sodium 132, potassium 4.6, chloride 99, carbon dioxide 25, creatinine 1.0, urea nitrogen 16, aspartate aminotransferase 48, alanine aminotransferase 40, lipase 11, and glucose 117 (units of measure and normal ranges not provided).

On 10-Sep-2021, vital signs included temperature 98.7 degrees Fahrenheit, heart rate 80 beats per minute, and blood pressure 99/61 mmHg. A single view chest x-ray was notable for extensive interstitial patchy airspace opacities in both lungs, suggestive of chronic interstitial lung disease, congestion, pneumonitis, or chemotherapy reaction. Laboratory results included Troponin I 0.02 and B-type Natriuretic Peptide 53. Blood cultures were obtained, Intravenous fluids, vancomycin and cefepime were initiated, as well as subcutaneous heparin and DuoNeb (ipratropium-albuterol) nebulizer therapy (as needed), and the subject was hospitalized for further evaluation and treatment. A computed tomography (CT) scan of the abdomen was performed and showed a small right pleural effusion and extensive bibasilar groundglass opacities with a right lung base irregular 3.4 x 2.6 cm opacity, and possible mild bronchiectasis at the right lung base. Moderate arterial atherosclerosis was noted. A small hiatal hernia was seen. There was fluid in small bowel loops as well as the right colon, but formed stool is in the left colon, and a few scattered sigmoid diverticula were seen. Severe degenerative changes in the lower lumbar spine with straightening of lumbar lordosis and Grade 1 spondylolisthesis was noted at L3-4. The remainder of the exam was unremarkable. Blood cultures were negative thus far. An infectious disease consultation was obtained; on examination, the subject's lungs were clear, heart rate and rhythm were regular, and his abdomen was soft but slightly distended with mild discomfort on firm palpation. Oral doxycycline was added, and a respiratory panel polymer chain reaction (PCR) via nasopharyngeal swab was obtained, and a dedicated CT scan of the chest was scheduled. The respiratory panel was negative for multiple viruses including SARS-CoV-2, other coronaviruses, influenzas, parainfluenzas, Rhino/enterovirus, Metapneumovirus, RSV, mycoplasma pneumoniae, Bordetella pertussis and paraptussis. A pulmonary consultation was obtained and suspected pneumonia, but given the groundglass process, and negative viral panel, suggested this could be pneumonitis. It was noted that a D-dimer was elevated, and pulmonary embolism was also possible. Arterial blood gases were drawn (on FiO₂ 36%), and results included: pH 7.49, pCO₂ 31, pO₂ 58, Bicarbonate 23.9, and oxygen saturation 90.8%. Intravenous methylprednisolone was initiated.

On 11-Sep-2021, laboratory results included WBC 11.76, hemoglobin 9.1, hematocrit 27.7, platelet count 528, sodium 137, potassium 4.3, chloride 104, carbon dioxide 22, creatinine 0.75, urea nitrogen 12.8, aspartate aminotransferase 33, alanine aminotransferase 27, total bilirubin 0.8, albumin 2.6, and glucose 129, calcium 8.9, and phosphorus 2.4. Blood cultures continued to show no growth. A chest CT angiogram was performed and showed no evidence of pulmonary embolism. Extensive bilateral groundglass airspace opacities, suggesting a diffuse viral pneumonitis, and a right lower lobe irregular mass were noted (which may be the site of the patient's known lung cancer). A small right pleural effusion was again seen. Small and borderline mediastinal and bilateral hilar lymph nodes were also noted. Vital signs included temperature 98.5 degrees Fahrenheit, heart rate 96 beats per minute, respiratory rate 18 breaths per minute, blood pressure 91/60 mmHg, and oxygen saturation 90%. Cardiology was consulted to evaluate supraventricular tachycardia; an electrocardiogram showed normal sinus rhythm without evidence of ischemic changes. Echocardiogram was suggested and given low blood pressure reading, the recommendation was to defer initiation of AV nodal blockers for now.

On 14-Sep-2021, a chest x-ray showed diffuse bilateral ill-defined lung opacities, and a somewhat more confluent appearance in the right mid zone when compared with the initial x-ray. A small right pleural effusion may be present. No cardiomegaly or pneumothorax was seen.

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

On 21-Sep-2021, a chest x-ray showed the cardiac silhouette appears to be at the upper limits of normal in size. Bilateral infiltrates (more likely than interstitial edema) were seen and similar to the previous study. A small right pleural effusion was possible, and there was no pneumothorax visualized.

On 25-Sep-2022, laboratory results included WBC 15.72, hemoglobin 11.0, hematocrit 34.2, platelet count 417, sodium 137, potassium 3.8, chloride 97, carbon dioxide 28, creatinine 0.84, urea nitrogen 24.3, and calcium 9.6. A gastroenterologist was asked to evaluate the subject's abdominal pain and constipation. Vital signs included temperature 97.8 degrees Fahrenheit, heart rate 76 beats per minute, respiratory rate 15 breaths per minute, blood pressure 97/78 mmHG and oxygen saturation 91%. The subject reported a large bowel movement overnight that resulted in an improvement in his pain. On exam, the subject's abdomen was soft and non-distended with mild tenderness in the left lower quadrant; bowel sounds were present. An abdominal CT scan showed the liver, spleen, pancreas, bile ducts, gallbladder, adrenals as unremarkable. Small bilateral renal cysts were seen, but no hydronephrosis. The gastrointestinal tract showed no colonic wall thickening, a few diverticula without inflammatory changes were seen and the appendix was unremarkable. The small bowel was of normal caliber.

On 29-Sep-2021, a chest x-ray revealed extensive bilateral infiltrates, similar to the previous study, a possible small right pleural effusion and possible pneumomediastinum. A trace right peripheral pneumothorax was also possible.

On 30-Sep-2021, a rehabilitation services consultation was obtained. The evaluation noted that the subject exhibited deficits in physical and mobility performance, as well as a drop in oxygen saturation from above 90% to 88% after ambulation withing his room. Skilled physical therapy intervention in a structured setting was recommended.

On 07-Oct-2021, a high-resolution chest CT scan was performed and showed similar appearance to the extensive bilateral groundglass patchy air space opacities since 9/22/2021. There was an increase in the small right pleural effusion, mild atherosclerosis of the aorta, and severe left anterior descending coronary artery calcifications seen. The pulmonary arteries and heart were unremarkable. Increased small pneumomediastinum extending into the neck was noted.

On 11-Oct-2021, vital signs included temperature (temporal) 98.5 degrees Fahrenheit, , pulse 72 beats per minute, , respiratory rate 18 breaths per minute, blood pressure 119/70 mmHg, and oxygen saturation (SpO2) 95%. A physical examination revealed the subject's chest to be clear to auscultation with no wheezing or crackles. The course of intravenous antibiotic and steroid therapy was completed and the subject was started on oral Bactrim (combination trimethoprim and sulfamethoxazole) 400-80 mg daily as a prophylaxis against PCP, and oral prednisone, 20 mg daily. The subject was discharged on that day to a skilled nursing facility. The diagnoses reported on the hospital discharge summary were acute respiratory failure, suspected PNA, and suspected post-chemotherapy pneumonitis. Based on his review of the records, the investigator considered pneumonia as the final diagnosis.

On 17-Nov-2021 the event, pneumonia, was considered resolved.

The action taken with the blinded study drug (Trilaciclib versus placebo) and docetaxel as a result of pneumonia was reported as dose not changed.

The investigator reported that the event of pneumonia was related to both the blinded study drug (Trilaciclib versus placebo) and docetaxel. The investigator also assessed the event to be related to the subject's metastatic lung cancer.

The sponsor assessed the event of pneumonia as related to blinded study drug (Trilaciclib versus placebo).

Per the Investigator Brochure for G1T28/Trilaciclib at the time of the event (Version 9.0 dated 01-Mar-2021) and per the current Investigator Brochure for G1T28/Trilaciclib (Version 10, dated 08-Nov-2021), pneumonia is unexpected. Pneumonia is listed in the current United States package insert (USPI, dated 12-Feb-2021).

Follow-up information was received on 21-Nov-2021. The hospital discharge date and a copy of the discharge summary note, providing the event details, presenting symptoms, treatment, test results, vital signs, and physical examination findings were provided.

Follow-up information was received on 20-Jan-2022. The event outcome and resolution date were provided.

Follow-up was received on 27-Feb-2022 and on 03-Mar-2022. New information included confirmation that the investigator considered the event to be pneumonia (and not pneumonitis, as suggested in hospital records), and that the pneumonia had not resolved and remained serious when the subject was transitioned from acute hospital to the skilled nursing facility for continued care. Extensive hospital records have been submitted providing the results of imaging, laboratory test results, details of treatment administered, and consultation results (cardiology, pulmonary, infectious disease, gastroenterology, and rehabilitation medicine).

Follow-up was received on 07-Apr-2022. The action taken with both study drugs due to the event was updated to "dose not changed">

Analysis of Similar Events

The safety database for G1T28/Trilaciclib was searched on 17-Sep-2021 for the preferred terms (PTs) of "Pneumonia" and "Respiratory tract infection". At the time this event was reported, there had been 25 prior cases of pneumonia (no cases of respiratory

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

tract infection) reported for subjects receiving G1T28/Trilaciclib or Trilaciclib versus placebo from multiple clinical trials, but none of those prior cases were assessed as related to G1T28/Trilaciclib; as a result, there were no previously submitted IND Safety Reports of Pneumonia.

The sponsor believes that this new case of "Pneumonia" does not change the benefit-risk profile of the investigational product.

13. Lab Data

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1	09-SEP-2021	Alanine aminotransferase	40	
2	11-SEP-2021	Alanine aminotransferase	27	
3	09-SEP-2021	Aspartate aminotransferase	48 (H)	
4	11-SEP-2021	Aspartate aminotransferase	33	
5	11-SEP-2021	Blood albumin	2.6	
6	11-SEP-2021	Blood alkaline phosphatase	123	
7	11-SEP-2021	Blood bilirubin	0.8	
8	11-SEP-2021	Blood calcium	8.9	
9	25-SEP-2021	Blood calcium	9.6	
10	09-SEP-2021	Blood chloride	99	
11	11-SEP-2021	Blood chloride	104	
12	25-SEP-2021	Blood chloride	97	
13	09-SEP-2021	Blood creatinine		

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
			1.0	
14	11-SEP-2021	Blood creatinine	0.75	
15	25-SEP-2021	Blood creatinine	0.84	
16	10-SEP-2021	Blood culture	negative	
17	10-SEP-2021	Blood gases	(on FiO2 36%): pH 7.49, pCO2 31, pO2 58, Bicarg 23.9, O2 sat 90.8%	
18	09-SEP-2021	Blood glucose	117 (H)	
19	11-SEP-2021	Blood glucose	129 (H)	
20	11-SEP-2021	Blood phosphorus	2.4	
21	09-SEP-2021	Blood potassium	4.6	
22	11-SEP-2021	Blood potassium	4.3	
23	25-SEP-2021	Blood potassium	3.8	
24	10-SEP-2021	Blood pressure measurement	99/61 mmHg	
25	11-SEP-2021	Blood pressure measurement	91/60 mmHg	
26	25-SEP-2021	Blood pressure measurement	97/78 mmHg	
27	11-OCT-2021	Blood pressure measurement	119/70 mmHg	

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
28	09-SEP-2021	Blood sodium		
		132 (L)		
29	11-SEP-2021	Blood sodium		
		137		
30	25-SEP-2021	Blood sodium		
		137		
31	09-SEP-2021	Blood urea		
		16		
32	11-SEP-2021	Blood urea		
		12.8		
33	25-SEP-2021	Blood urea		
		24.3		
34	10-SEP-2021	Body temperature	98.7	
35	11-SEP-2021	Body temperature	98.5	
36	25-SEP-2021	Body temperature	97.8	
37	11-OCT-2021	Body temperature	98.5	
38	10-SEP-2021	Brain natriuretic peptide		
		53		
39	09-SEP-2021	Carbon dioxide		
		24		
40	11-SEP-2021	Carbon dioxide		
		22		
41	25-SEP-2021	Carbon dioxide		
		28		
42	10-SEP-2021	Chest X-ray		

The cardiac silhouette appears to be at the upper limits of normal in size. There are extensive interstitial and patchy airspace opacities in both lungs. There appears to be a small right pleural effusion. The tip of a right central line appears to be at the right atrium near the junction with superior vena cava. No pneumothorax is visualized. Mild degenerative spurring is seen in the thoracic spine.
Impression: Extensive interstitial and patchy airspace opacities in both lungs.

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
		Possibilities include chronic interstitial lung disease or congestion or pneumonitis or chemotherapy reaction.		
43	14-SEP-2021	Chest X-ray	Diffuse bilateral ill-defined lung opacities are present. A somewhat more confluent appearance is now seen in the right mid zone when compared with 9/10/2021. A small right pleural effusion may be present. No cardiomegaly. No pneumothorax. A right-sided central line is again seen.	
44	17-SEP-2021	Chest X-ray	Extensive bilateral patchy areas of pneumonia are again identified appearing to be worse particularly at the bases where portions of both diaphragms are more obscured. Cardiomedial silhouette is unchanged. Aorta is tortuous and calcified. Right central catheter stable. Possible trace right effusion again may be present.	
45	21-SEP-2021	Chest X-ray	An AP view of the chest was taken with patient upright. The cardiac silhouette appears to be at the upper limits of normal in size. Bilateral infiltrates, more likely than interstitial edema, are similar to the previous study. A right lower lobe mass is better seen on 9/11/2021 CT chest angiogram. A small right pleural effusion is possible. The tip of a right subclavian line is at the right atrium near the junction with the superior vena cava. No pneumothorax is visualized. No change is seen in the skeletal structures. Impression: Bilateral infiltrates, more likely than interstitial previous study.~are similar to the previous study.	
46	29-SEP-2021	Chest X-ray	The cardiac silhouette does not appear enlarged. Extensive bilateral infiltrates are similar to the previous study. A left upper lobe nodule and a right base mass are better seen on the 9/20/2/2021 chest CT. A small right pleural effusion is possible. A right internal jugular line is stable. A pneumomediastinum is possible. A trace right peripheral pneumothorax is possible. No change is seen in the skeletal structures. Impression: Extensive bilateral infiltrates are similar to the previous study. A pneumomediastinum is possible. A trace peripheral right pneumothorax is possible.	
47	05-OCT-2021	Chest X-ray	Extensive bilateral airspace and interstitial opacities are mildly increased at the level of the peripheral right midlung. Sites of known lung cancer are better characterized on prior CT chest. The cardiomedial silhouette is unremarkable. The questionable pneumomediastinum seen on the prior chest radiograph is no longer definitively seen. No definite pneumothorax. No significant pleural effusion. No acute/suspicious osseous disease. Partially visualized nonspecific bowel gas pattern.	
48	10-SEP-2021	Computerised tomogram	Small right pleural effusion and extensive bibasilar groundglass opacities with a right lung base irregular 3.4 x 2.6 cm opacity. Mild bronchiectasis at the right lung base may be present. The liver, spleen, pancreas, bile ducts, gallbladder, adrenals are unremarkable. Small bilateral renal cysts, mostly under 1.2 cm. Moderate arterial atherosclerosis. Veins, lymph nodes and peritoneum/retroperitoneum are unremarkable. Small hiatal hernia. Fluid in small bowel loops as well as the right colon, but formed stool is in the left colon. Few scattered sigmoid diverticula.~Appendix is normal and urinary bladder, abdominal wall and soft tissues are unremarkable. Severe degenerative changes in the lower lumbar spine with straightening of lumbar lordosis	

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
		and Grade 1 spondylolisthesis L3-4. Impression: 1.~Extensive bibasilar groundglass airspace opacities with a small right pleural effusion and right lower lobe irregular masslike opacity in this patient with known lung cancer with probable superimposed viral pneumonitis. 2.~No acute findings in the abdomen and pelvis.		
49	25-SEP-2021	Computerised tomogram		
		Similar diffuse groundglass and interstitial opacities. Small right pleural effusion, unchanged; Interval increase in pneumomediastinum along the esophagus and anterior mediastinum. The liver, spleen, pancreas, bile ducts, gallbladder, adrenals are unremarkable. Small bilateral renal cysts, no hydronephrosis. The GI tract showed no colonic wall thickening, a few diverticula without inflammatory changes; appendix was unremarkable. Small bowel was of normal caliber, and the stomach was distended with oral contrast. Impression: no acute abnormality in the abdomen or pelvis. Interval increase in pneumomediastinum, similar diffuse groundglass and interstitial opacities, an no change in the small pleural effusion.		
50	25-SEP-2021	Computerised tomogram abdomen		
		Visualized lung bases: Similar diffuse groundglass and interstitial opacities compared to 9/22/2021. Small right pleural effusion unchanged. Interval increase in pneumomediastinum along the esophagus and anterior mediastinum partially visualized. Liver, bile ducts, gallbladder, pancreas, spleen, adrenals are unremarkable. Small right renal cysts and additional subcentimeter too small to characterize hypodensities bilaterally. No hydronephrosis. Moderate atherosclerosis of the abdominal aorta and iliac vessels. Focal stenosis of the proximal celiac artery, unchanged. No colonic wall thickening. A few colonic diverticula without adjacent inflammatory change. Unremarkable appendix. Small bowel is normal caliber. Stomach is distended with oral contrast. Lymph node, peritoneum, bladder and extra-abdominal soft tissues are unremarkable. Multilevel degenerative changes of the thoracolumbar spine with severe degenerative disc disease in the lower lumbar spine. Grade 1 anterolisthesis of L3 / L4. No suspicious osseous lesion Impression: No acute abnormality in the abdomenorr pelvis. Interval increase in partially visualized pneumomediastinum compared to 9/22/2021. Similar partially visualized diffuse groundglass opacities compared to recent CT chest 9/22/2021. Small right pleural effusion is unchanged.		
51	11-SEP-2021	Computerised tomogram thorax		
		The aorta is unremarkable. No evidence of pulmonary embolism. A right lower lobe irregular 3.4 x 2.6 cm mass is seen. Diffuse groundglass airspace opacities are seen throughout the lungs, worse in the mid and lower lung zones with patchy areas of involvement of the upper lobes. Small right pleural effusion is again seen. Severe left anterior descending coronary artery calcifications. The heart is unremarkable. Multiple small mediastinal and hilar lymph nodes. Chest wall lower neck, and upper abdomen are unremarkable. Schmorl's node at superior endplate of T11 as well as a smaller one at T7 with mild degenerative changes in the upper thoracic spine. Impression: 1.~No evidence of pulmonary embolism. 2.~Extensive bilateral groundglass airspace opacities, suggesting a diffuse viral pneumonitis with a right lower lobe irregular mass which may be the site of the patient's known lung cancer. Small right pleural effusion is again seen. 3.~Small and borderline mediastinal and bilateral hilar lymph nodes.		
52	22-SEP-2021	Computerised tomogram thorax		

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
		<p>Improving bilateral diffuse groundglass airspace opacities since 9/11/2021 with small residual. A spiculated nodule in the left upper lobe apicoposterior segment is again seen, approximately 13 x 8 mm on image 2-15. Right lung base irregular 3.4 x 2.6 cm mass is again seen. Small right pleural effusion has decreased. Aorta unremarkable. Severe left anterior descending coronary artery calcifications. Pulmonary arteries and heart are unremarkable. New small pneumomediastinum.</p> <p>Chest wall, lower neck, upper abdomen are unremarkable. Mild degenerative changes in the spine with a Schmorl's node at the superior endplate of T11 again seen as well as smaller one at T7.</p> <p>Impression: New small pneumomediastinum. Improving bilateral extensive groundglass airspace opacities suggesting a diffuse viral pneumonitis with unchanged right lower lobe irregular mass and left upper lobe spiculated nodule which may be sites of the patient's known lung cancer. Small right pleural effusion is decreased.</p>		
53	11-SEP-2021	Electrocardiogram	normal sinus rhythm without evidence of ischemic changes	
54	09-SEP-2021	Haematocrit	27.9 (L)	
55	11-SEP-2021	Haematocrit	27.7(L)	
56	25-SEP-2021	Haematocrit	34.2	
57	09-SEP-2021	Haemoglobin	9.3 (L)	
58	11-SEP-2021	Haemoglobin	9.1 (L)	
59	25-SEP-2021	Haemoglobin	11.0	
60	10-SEP-2021	Heart rate	80 beats per minute	
61	11-SEP-2021	Heart rate	96 beats per minute	
62	25-SEP-2021	Heart rate	76 beats per minute	
63	11-OCT-2021	Heart rate		

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
		72 beats per minute		
64	07-OCT-2021	High-resolution computerised tomogram of lung		
		<p>Similar appearance to extensive bilateral groundglass patchy air space opacities since 9/22/2021. A spiculated nodule in the left upper lobe apicoposterior segment is unchanged approximately 13 x 8 mm, image 4-16. Right lung base irregular 3.4 x 2.6 cm mass is unchanged. Increased small right pleural effusion. Mild atherosclerosis of the aorta. Severe left anterior descending coronary artery calcifications Pulmonary arteries, heart are unremarkable. Increased~small pneumomediastinum extending into the neck Calcified right thyroid nodule is unchanged. Upper abdomen is unremarkable. Mild degenerative changes in the spine. Impression: Increased small right pleural effusion and increased small pneumomediastinum. Otherwise no change with spiculated left upper lobe nodule and right lung base mass along with bilateral interstitial pneumonia.</p>		
65	09-SEP-2021	Lipase		
		11		
66	11-SEP-2021	Oxygen saturation	90 percent	
67	25-SEP-2021	Oxygen saturation	91 percent	
68	11-OCT-2021	Oxygen saturation	95 percent	
69	11-OCT-2021	Physical examination		
		Chest: clear to auscultation with no wheezing or crackles.		
70	09-SEP-2021	Platelet count		
		441		
71	11-SEP-2021	Platelet count		
		528		
72	25-SEP-2021	Platelet count		
		417		
73	2021	Pneumocystis test		
		Negative		
74	SEP-2021	Procalcitonin		
		elevated		
75	10-SEP-2021	Protein urine		
		trace		
76	11-SEP-2021	Respiratory rate		
		18 breaths per minute		

ADDITIONAL INFORMATION**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
77	25-SEP-2021	Respiratory rate		
		15 breaths per minute		
78	11-OCT-2021	Respiratory rate		
		18 breaths per minute		
79	10-SEP-2021	Respiratory viral panel		
		negative for SARS-CoV-2, other coronaviruses, Influenzas, parainfluenzas, Rhino/enterovirus, Metapneumovirus, RSV, mycoplasma pneumoniae, Bordetella pertussis and parapertussis		
80	10-SEP-2021	Troponin I		
		0.02		
81	09-SEP-2021	White blood cell count		
		9.31		
82	11-SEP-2021	White blood cell count		
		11.76		
83	25-SEP-2021	White blood cell count		
		15.72		

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) TRILACICLIB VS PLACEBO (Code not broken) ; Regimen #1	Blinded, Information withheld	Metastatic non-small cell lung cancer (Non-small cell lung cancer metastatic)	05-AUG-2021 / 26-AUG-2021; 22 days
#2) DOCETAXEL (DOCETAXEL) Solution for infusion; Regimen #1	75 mg/m2 on Day 1 of each cycle; IV drip	Metastatic non-small cell lung cancer (Non-small cell lung cancer metastatic)	05-AUG-2021 / 05-AUG-2021; 1 day
#2) DOCETAXEL (DOCETAXEL) Solution for infusion; Regimen #2	75 mg/m2 on Day 1 of each cycle; IV drip	Metastatic non-small cell lung cancer (Non-small cell lung cancer metastatic)	26-AUG-2021 / 26-AUG-2021; 1 day

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION continued

#7) LORAZEPAM (LORAZEPAM) ; MAR-2021 / Unknown

#8) COLACE (DOCUSATE SODIUM) ; MAR-2021 / Unknown

#9) oxycodone-acetaminophen 5-325 ; 26-AUG-2021 / Unknown

ADDITIONAL INFORMATION**23. OTHER RELEVANT HISTORY continued**

From/To Dates	Type of History / Notes	Description
19-OCT-2020 to Ongoing	Historical Condition	Adenocarcinoma of lung stage IV (Lung adenocarcinoma stage IV);
01-NOV-2020 to Ongoing	Historical Condition Grade 1	Cough (Cough);
01-NOV-2020 to Ongoing	Historical Condition Grade 1	Shortness of breath (Dyspnoea);
01-NOV-2020 to Ongoing	Historical Condition Grade 1	Weakness generalized (Asthenia);
01-MAY-2020 to Ongoing	Historical Condition Grade 1	Hypertension (Hypertension);
01-MAY-2020 to Ongoing	Historical Condition Grade 1	Palpitation (Palpitations);
09-MAR-2021 to Ongoing	Historical Condition Grade 1	Anorexia (Decreased appetite);
01-JAN-2021 to Ongoing	Historical Condition	Emphysema (Emphysema);
01-JAN-2020 to Ongoing	Historical Condition	GERD (Gastroesophageal reflux disease);
01-MAR-2021 to Ongoing	Historical Condition Grade 1	Insomnia (Insomnia);
01-MAR-2021 to Ongoing	Historical Condition Grade 1	Anxiety (Anxiety);
01-MAR-2021 to Ongoing	Historical Condition Grade 1	Constipation (Constipation);
23-JUL-2021 to Ongoing	Historical Condition Grade 1	Hyponatremia (Hyponatraemia);
23-JUL-2021 to Ongoing	Historical Condition Grade 1	Hypochloremia (Hypochloraemia);
23-JUL-2021 to Ongoing	Historical Condition Grade 1	Alanine aminotransferase increase (Alanine aminotransferase increased);
23-JUL-2021 to Ongoing	Historical Condition Grade 1	Aspartate aminotransferase increase (Aspartate aminotransferase increased);
23-JUL-2021 to Ongoing	Historical Condition Grade 1	Anemia (Anaemia);
1990 to 2010	Historical Condition	Cigarette smoker (Tobacco user); Total daily consumption: 3 cigarettes
19-OCT-2020 to 19-OCT-2020	Historical Condition	Lung biopsy (Biopsy lung);
05-JAN-2021 to 30-MAR-2021	Historical Drug	Carboplatin;Pembrolizumab;Pemetrexed
22-Jul-2022 16:18		

ADDITIONAL INFORMATION**23. OTHER RELEVANT HISTORY continued**

From/To Dates	Type of History / Notes	Description
		(Carboplatin;Pembrolizumab;Pemetrexed); Drug Indication: Adenocarcinoma of lung stage IV (Lung adenocarcinoma stage IV)
01-JUN-2021 to 13-JUL-2021	Historical Drug	Pemetrexed (Pemetrexed); Drug Indication: Adenocarcinoma of lung stage IV (Lung adenocarcinoma stage IV)
01-JUN-2021 to 13-JUL-2021	Historical Drug	Pembrolizumab (Pembrolizumab); Drug Indication: Adenocarcinoma of lung stage IV (Lung adenocarcinoma stage IV)

TABLE OF CONTENTS

6.4 Individual Patient Data Listings and Data Tables	1
Listing: 16.1.7.1 Patient Enrollment and Randomization Schedule All Enrolled Patients	3
Listing: 16.2.4.1 Medical History All Randomized Patients	6
Listing: 16.2.4.2 Lung Cancer History All Randomized Patients	21
Listing: 16.2.4.3 Smoking History All Randomized Patients	28
Listing: 16.2.4.4 Concomitant Surgeries/Procedures/Radiotherapy All Randomized Patients	30
Listing: 16.2.4.5 Prior and Concomitant Medications All Randomized Patients	32
Listing: 16.2.5.1 Study Drug Administration Safety Population	56
Listing: 16.2.5.2 Total Exposure Safety Population	69
Listing: 16.2.5.3 Cycle Day Status and Overall Summary Safety Population	71
Listing: 16.2.6.2 Adverse Events of Special Interest for Trilaciclib Safety Population	73
Listing: 16.2.6.3 Adverse Events Leading to Dose Reductions Safety Population	74
Listing: 16.2.6.4 Adverse Events Leading to Cycle Delays Safety Population	75
Listing: 16.2.6.5 TEAEs Leading to Discontinuation of Any Study Drug Safety Population	76
Listing: 16.2.6.6 Adverse Events Leading to Dose Interruptions Safety Population	77
Listing: 16.2.6.7 Serious Adverse Events Safety Population	78
Listing: 16.2.7.2 Laboratory Values - Hematology All Randomized Patients	81
Listing: 16.2.8 Pregnancy Test All Randomized Patients	116
Listing: 16.2.9 Vital Signs All Randomized Patients	118
Listing: 16.2.10 12-Lead Electrocardiograms All Randomized Patients	141
Listing: 16.2.11 ECOG Performance Status All Randomized Patients	153
Listing: 16.2.12 Physical Exam All Randomized Patients	156
Table: 14.1.1.1 Patient Disposition All Screened Patients	159

Table: 14.1.3.1 Demographics and Baseline Disease Characteristics All Randomized Patients	162
Table: 14.3.1.1 Overall Summary of Adverse Events Safety Population	165

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.1.7.1
Patient Enrollment and Randomization Schedule
All Enrolled Patients

Screen Failure

Country	Subject Number	Date of Consent	ECOG Score at Screening	Eligibility Status	Date of Randomization	Randomization Number
USA	3145-2001	2021-04-30		SUBJECT DID NOT MEET ALL ELIGIBILITY CRITERIA		
	3145-2002	2021-06-09		SUBJECT DID NOT MEET ALL ELIGIBILITY CRITERIA		
	3145-2003	2021-07-02		SUBJECT DID NOT MEET ALL ELIGIBILITY CRITERIA		

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.1.7.1
Patient Enrollment and Randomization Schedule
All Enrolled Patients

Treatment: Placebo

Country	Subject Number	Date of Consent	ECOG Score at Screening	Eligibility Status	Date of Randomization	Randomization Number
USA	3145-2004	2021-07-21	1	SUBJECT MET ALL ELIGIBILITY CRITERIA	2021-08-11	23507
	3145-2007	2021-08-06	1	SUBJECT MET ALL ELIGIBILITY CRITERIA	2021-08-25	23509
	3145-2501	2021-05-28	0	SUBJECT MET ALL ELIGIBILITY CRITERIA	2021-06-03	23505

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.1.7.1
Patient Enrollment and Randomization Schedule
All Enrolled Patients

Treatment: Trilaciclib

Country	Subject Number	Date of Consent	ECOG Score at Screening	Eligibility Status	Date of Randomization	Randomization Number
USA	2011-2001	2021-08-18	2	SUBJECT MET ALL ELIGIBILITY CRITERIA	2021-09-09	23651
	3145-2005	2021-07-23	1	SUBJECT MET ALL ELIGIBILITY CRITERIA	2021-08-05	23506
	3145-2006	2021-07-26	0	SUBJECT MET ALL ELIGIBILITY CRITERIA	2021-08-11	23508
	3145-2008	2021-09-17	1	SUBJECT MET ALL ELIGIBILITY CRITERIA	2021-10-07	23510

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
3145-2004	General disorders and administration site conditions/ Fatigue/ FATIGUE	2021/ ONGOING	1
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)/ Cancer pain/ GENERALIZED CANCER PAIN	2021/ ONGOING	1
	Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2021/ ONGOING	1
	Investigations/ Weight decreased/ WEIGHT LOSS	2021-02/ ONGOING	1
	Gastrointestinal disorders/ Nausea/ NAUSEA	2021-06/ ONGOING	1

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 1 of 15

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
3145-2004 (continued)	Blood and lymphatic system disorders/ Anaemia/ ANEMIA	2021-07-21 (-21) / ONGOING	1
3145-2007	Musculoskeletal and connective tissue disorders/ Rheumatoid arthritis/ RHEUMATOID ARTHRITIS	2011/ ONGOING	1
	Respiratory, thoracic and mediastinal disorders/ Chronic obstructive pulmonary disease/ COPD	2012-01/ ONGOING	1
	Respiratory, thoracic and mediastinal disorders/ Dyspnoea/ SHORTNESS OF BREATH	2012-11/ ONGOING	1
	Gastrointestinal disorders/ Gastritis/ GASTRITIS	2018/ ONGOING	1

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 2 of 15

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
3145-2007 (continued)	Gastrointestinal disorders/ Nausea/ NAUSEA	2019-10/ ONGOING	1
	Psychiatric disorders/ Anxiety/ ANXIETY	2019-10/ ONGOING	1
	Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2019-10/ ONGOING	1
	Neoplasms benign, malignant and unspecified (incl cysts and polyps) / Cancer pain/ GENERALIZED CANCER PAIN	2019-11/ ONGOING	1
	Skin and subcutaneous tissue disorders/ Skin ulcer/ SKIN ULCERS IN LOWER EXTREMITIES	2021-02/ ONGOING	1

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 3 of 15

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
3145-2007 (continued)	Eye disorders/ Conjunctival irritation/ CONJUNCTIVAL IRRITATION	2021-06/ ONGOING	1
	Blood and lymphatic system disorders/ Anaemia/ ANEMIA	2021-08-18 (-7) / ONGOING	1
	Blood and lymphatic system disorders/ Lymphopenia/ LYMPHOPENIA	2021-08-18 (-7) / ONGOING	1
	Metabolism and nutrition disorders/ Hyperglycaemia/ HYPERGLYCEMIA	2021-08-18 (-7) / ONGOING	1
	Vascular disorders/ Hypertension/ HYPERTENSION	2021-08-18 (-7) / ONGOING	1

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 4 of 15

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
3145-2501	Vascular disorders/ Hypertension/ HYPERTENSION	2017/ ONGOING	1
	General disorders and administration site conditions/ Chest discomfort/ DISCOMFORT OVER RIGHT CHEST MUSCLE	2020-12-01 (-184) / ONGOING	1
	Gastrointestinal disorders/ Diarrhoea/ DIARRHEA	2020-12-21 (-164) / ONGOING	1
	General disorders and administration site conditions/ Asthenia/ GENERALIZED WEAKNESS	2020-12-21 (-164) / ONGOING	1
	Blood and lymphatic system disorders/ Anaemia/ ANEMIA	2021-01-02 (-152) / ONGOING	1

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 5 of 15

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
3145-2501 (continued)	Investigations/ Blood creatinine increased/ ELEVATED CREATININE	2021-01-02 (-152) / ONGOING	1

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 6 of 15

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
2011-2001	Congenital, familial and genetic disorders/ Cystic lymphangioma/ LEFT ARM BENIGN CYSTIC LYMPHANGIOMA	1962/ 1962	
	Surgical and medical procedures/ Lymphoid tissue operation/ LEFT ARM BENIGN CYSTIC LYMPHANGIOMA REPAIR	1962/ 1962	
	Injury, poisoning and procedural complications/ Jaw fracture/ CRACKED MANDIBLE	1984/ 1984	
	Injury, poisoning and procedural complications/ Scar/ LEFT ARM SCAR TISSUE BUILD UP	1985/ 1985	
	Surgical and medical procedures/ Scar excision/ LEFT ARM SCAR TISSUE DEBRIDEMENT	1985/ 1985	

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 7 of 15

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
2011-2001 (continued)	Surgical and medical procedures/ Jaw operation/ CRACKED MANDIBLE REPAIR	1994/ 1994	
	Respiratory, thoracic and mediastinal disorders/ Wheezing/ WHEEZING	2020-10/ ONGOING	
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)/ Bone neoplasm/ NEOPLASM OF BONE	2020-12-09 (-274) / ONGOING	
	Psychiatric disorders/ Anxiety/ ANXIETY	2020-12-09 (-274) / ONGOING	
	Metabolism and nutrition disorders/ Calcium deficiency/ CALCIUM DEFICIENCY	2021-01/ ONGOING	

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 8 of 15

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
2011-2001 (continued)	Metabolism and nutrition disorders/ Vitamin D deficiency/ VITAMIN D DEFICIENCY	2021-01/ ONGOING	
	Musculoskeletal and connective tissue disorders/ Pain in extremity/ RIGHT ARM PAIN	2021-09/ ONGOING	
3145-2005	Gastrointestinal disorders/ Gastroesophageal reflux disease/ GERD	2020/ ONGOING	
	Cardiac disorders/ Palpitations/ PALPITATION	2020-05/ ONGOING	1
	Vascular disorders/ Hypertension/ HYPERTENSION	2020-05/ ONGOING	1

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 9 of 15

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
3145-2005 (continued)	General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-10/ ONGOING	2
	General disorders and administration site conditions/ Asthenia/ GENERALIZED WEAKNESS	2020-11/ ONGOING	1
	Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2020-11/ ONGOING	1
	Respiratory, thoracic and mediastinal disorders/ Dyspnoea/ SHORTNESS OF BREATH	2020-11/ ONGOING	1
	Respiratory, thoracic and mediastinal disorders/ Emphysema/ EMPHYSEMA	2021/ ONGOING	

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 10 of 15

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
3145-2005 (continued)	Gastrointestinal disorders/ Constipation/ CONSTIPATION	2021-03/ ONGOING	1
	Psychiatric disorders/ Anxiety/ ANXIETY	2021-03/ ONGOING	1
	Psychiatric disorders/ Insomnia/ INSOMNIA	2021-03/ ONGOING	1
	Metabolism and nutrition disorders/ Decreased appetite/ ANOREXIA	2021-03-09 (-149) / ONGOING	1
	Blood and lymphatic system disorders/ Anaemia/ ANEMIA	2021-07-23 (-13) / ONGOING	1

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 11 of 15

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
3145-2005 (continued)	Investigations/ Alanine aminotransferase increased/ ELEVATED ALT	2021-07-23 (-13) / ONGOING	1
	Investigations/ Aspartate aminotransferase increased/ ELEVATED AST	2021-07-23 (-13) / ONGOING	1
	Metabolism and nutrition disorders/ Hypochloraemia/ HYPOCHLOREMIA	2021-07-23 (-13) / ONGOING	1
	Metabolism and nutrition disorders/ Hyponatraemia/ HYPONATREMIA	2021-07-23 (-13) / ONGOING	1
3145-2006	General disorders and administration site conditions/ Catheter site pain/ PAIN AT PORT CATHETER SITE	2016/ ONGOING	1

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 12 of 15

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
3145-2006 (continued)	General disorders and administration site conditions/ Fatigue/ FATIGUE	2016/ ONGOING	1
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)/ Cancer pain/ GENERALIZED CANCER PAIN	2016/ ONGOING	1
	Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2016/ ONGOING	1
	Gastrointestinal disorders/ Constipation/ CONSTIPATION	2021/ ONGOING	1
3145-2008	Vascular disorders/ Hypertension/ HYPERTENSION	2019/ ONGOING	1

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 13 of 15

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
3145-2008 (continued)	Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2020-02/ ONGOING	1
	Respiratory, thoracic and mediastinal disorders/ Dyspnoea/ SHORTNESS OF BREATH	2020-02/ ONGOING	1
	General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-02-24 (-591) / ONGOING	1
	Neoplasms benign, malignant and unspecified (incl cysts and polyps) / Cancer pain/ GENERALIZED CANCER PAIN	2020-03/ ONGOING	1
	Nervous system disorders/ Neuropathy peripheral/ PERIPHERAL NEUROPATHY	2021/ ONGOING	1

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 14 of 15

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.1
Medical History
All Randomized Patients

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Reported Term	Start Date (Study Day) / End Date (Study Day)	Toxicity Grade
3145-2008 (continued)	Renal and urinary disorders/ Renal failure/ RENAL FAILURE	2021/ ONGOING	1
	Renal and urinary disorders/ Nocturia/ NOCTURIA	2021-04-13 (-177) / ONGOING	1
	Metabolism and nutrition disorders/ Decreased appetite/ ANOREXIA	2021-06/ ONGOING	1

MedDRA = Medical Dictionary for Regulatory Activities
Note: Medications are coded using MedDRA version 24.0.

Program: l-mh.sas

2022-05-24 10:09

Page 15 of 15

Listing: 16.2.4.2
Lung Cancer History
All Randomized Patients

Treatment: Placebo

Subject Number	Category	Therapy/ Procedure Name	Start/End Date of Therapy/ Procedure (Study Day)	Anatomical Location/ Total dose (unit)	Regimen/ Treatment Setting/ Treatment Intent	Progress on or after this regimen (Date of Progression)
3145-2004	ANTI-CANCER THERAPIES	CARBOPLATIN, PEMETREXED, PEMBROLIZUMAB	2021-06-01 (-71) / 2021-07-13 (-29)		1/ ADJUVANT/ CURATIVE	Yes (2021-06-06)
	RADIOTHERAPIES	EXTERNAL BEAM RADIATION THERAPY	2021-06-29 (-43) / 2021-07-12 (-30)	THORACIC SPINE/ 300.5 (cGy)		
	SURGERIES OR PROCEDURES	BIOPSY	2021-04-22 (-111) / 2021-04-22 (-111)			
3145-2007	ANTI-CANCER THERAPIES	CARBOPLATIN, PACLITAXEL	2019-11-25 (-639) / 2020-03-19 (-524)		1/ NEO-ADJUVANT/ CURATIVE	Yes (2021-07-21)
	ANTI-CANCER THERAPIES	DURVALUMAB	2020-05-27 (-455) / 2021-07-21 (-35)		1/ NEO-ADJUVANT/ CURATIVE	Yes (2021-07-21)

Prior systemic anti-cancer therapies are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.2
Lung Cancer History
All Randomized Patients

Treatment: Placebo

Subject Number	Category	Therapy/ Procedure Name	Start/End Date of Therapy/ Procedure (Study Day)	Anatomical Location/ Total dose (unit)	Regimen/ Treatment Setting/ Treatment Intent	Progress on or after this regimen (Date of Progression)
3145-2007 (continued)	RADIOTHERAPIES	EXTERNAL BEAM RADIATION THERAPY	2019-11-25 (-639) / 2021-01-23 (-214)	LUNG, LEFT/ N/A (UNK)		
	SURGERIES OR PROCEDURES	BIOPSY ON LEFT LUNG	2019-10-02 (-693) / 2019-10-02 (-693)			
	SURGERIES OR PROCEDURES	PLEUROCENTESIS	2019-10-02 (-693) / 2019-10-02 (-693)			
3145-2501	ANTI-CANCER THERAPIES	PEMBROLIZUMAB	2017-03-27 (-1529) / 2018-05-23 (-1107)		1/ METASTATIC/ PALLIATIVE	Yes (2018-05-23)
	ANTI-CANCER THERAPIES	NIVOLUMAB	2018-05-24 (-1106) / 2019-09-10 (-632)		1/ METASTATIC/ PALLIATIVE	Yes (2018-05-23)

Prior systemic anti-cancer therapies are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.2
Lung Cancer History
All Randomized Patients

Treatment: Placebo

Subject Number	Category	Therapy/ Procedure Name	Start/End Date of Therapy/ Procedure (Study Day)	Anatomical Location/ Total dose (unit)	Regimen/ Treatment Setting/ Treatment Intent	Progress on or after this regimen (Date of Progression)
3145-2501 (continued)	ANTI-CANCER THERAPIES	SITRAVATINIB	2018-05-24 (-1106) / 2019-09-10 (-632)		1/ METASTATIC/ PALLIATIVE	Yes (2018-05-23)
	ANTI-CANCER THERAPIES	PACLITAXEL + CARBOPLATIN AUC5	2019-10/ 2020-04-12 (-417)		1/ METASTATIC/ PALLIATIVE	Yes (2018-05-23)
	ANTI-CANCER THERAPIES	CISPLATIN + VP16	2020-06/ 2020-09-20 (-256)		1/ METASTATIC/ PALLIATIVE	Yes (2018-05-23)
	SURGERIES OR PROCEDURES	BRAIN SURGERY	2017-02-10 (-1574) / 2017-02-10 (-1574)			

Prior systemic anti-cancer therapies are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.2
Lung Cancer History
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Category	Therapy/ Procedure Name	Start/End Date of Therapy/ Procedure (Study Day)	Anatomical Location/ Total dose (unit)	Regimen/ Treatment Setting/ Treatment Intent	Progress on or after this regimen (Date of Progression)
2011-2001	ANTI-CANCER THERAPIES	CARBOPLATIN	2021-01-21 (-231) / 2021-07-13 (-58)		1/ METASTATIC/ PALLIATIVE	Yes (2021-07-08)
	ANTI-CANCER THERAPIES	KEYTRUDA	2021-01-21 (-231) / 2021-07-13 (-58)		1/ METASTATIC/ PALLIATIVE	Yes (2021-07-08)
	ANTI-CANCER THERAPIES	PACLITAXEL	2021-01-21 (-231) / 2021-07-13 (-58)		1/ METASTATIC/ PALLIATIVE	Yes (2021-07-08)
	RADIOTHERAPIES	OTHER	2021-01-26 (-226) / 2021-02-10 (-211)	SPINE AND ILIAC		
	RADIOTHERAPIES	OTHER	2021-07-20 (-51) / 2021-07-28 (-43)	RIGHT HUMERUS		

Prior systemic anti-cancer therapies are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.2
Lung Cancer History
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Category	Therapy/ Procedure Name	Start/End Date of Therapy/ Procedure (Study Day)	Anatomical Location/ Total dose (unit)	Regimen/ Treatment Setting/ Treatment Intent	Progress on or after this regimen (Date of Progression)
3145-2005	ANTI-CANCER THERAPIES	CARBOPLATIN, PEMETREXED, PEMBROLIZUMAB	2021-01-05 (-212) / 2021-03-30 (-128)		1/ ADJUVANT/ CURATIVE	Yes (2021-03-30)
	ANTI-CANCER THERAPIES	PEMBROLIZUMAB	2021-06-01 (-65) / 2021-07-13 (-23)		1/ ADJUVANT/ CURATIVE	Yes (2021-03-30)
	ANTI-CANCER THERAPIES	PEMETREXED	2021-06-01 (-65) / 2021-07-13 (-23)		1/ ADJUVANT/ CURATIVE	Yes (2021-03-30)
	SURGERIES OR PROCEDURES	BIOPSY	2020-10-19 (-290) / 2020-10-19 (-290)			
3145-2006	ANTI-CANCER THERAPIES	CARBOPLATIN, PEMETREXED	2016-06-01 (-1897) / 2016-06-10 (-1888)		1/ ADJUVANT/ OTHER/ THERAPY CHANGED	Unknown

Prior systemic anti-cancer therapies are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.2
Lung Cancer History
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Category	Therapy/ Procedure Name	Start/End Date of Therapy/ Procedure (Study Day)	Anatomical Location/ Total dose (unit)	Regimen/ Treatment Setting/ Treatment Intent	Progress on or after this regimen (Date of Progression)
3145-2006 (continued)	ANTI-CANCER THERAPIES	NIVOLUMAB	2016-07-08 (-1860) / 2017-10-18 (-1393)		1/ ADJUVANT/ OTHER/ THERAPY CHANGED	Unknown
	ANTI-CANCER THERAPIES	NIVOLUMAB	2017-10-24 (-1387) / 2018-02-13 (-1275)		1/ ADJUVANT/ OTHER/ THERAPY CHANGED	Unknown
	ANTI-CANCER THERAPIES	SITRAVATINIB	2017-10-24 (-1387) / 2018-02-13 (-1275)		1/ ADJUVANT/ OTHER/ THERAPY CHANGED	Unknown
3145-2008	ANTI-CANCER THERAPIES	CARBOPLATIN, PEMETREXED, PEMBROLIZUMAB	2020-04-07 (-548) / 2020-07-27 (-437)		1/ ADJUVANT/ CURATIVE	Yes (2021-01-26)
	ANTI-CANCER THERAPIES	PEMETREXED, PEMBROLIZUMAB	2020-08-18 (-415) / 2021-01-26 (-254)		1/ ADJUVANT/ CURATIVE	Yes (2021-01-26)

Prior systemic anti-cancer therapies are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.2
Lung Cancer History
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Category	Therapy/ Procedure Name	Start/End Date of Therapy/ Procedure (Study Day)	Anatomical Location/ Total dose (unit)	Regimen/ Treatment Setting/ Treatment Intent	Progress on or after this regimen (Date of Progression)
3145-2008 (continued)	SURGERIES OR PROCEDURES	BIOPSY	2020-02-12 (-603) / 2020-02-12 (-603)			
	SURGERIES OR PROCEDURES	BIOPSY	2021-09-02 (-35) / 2021-09-02 (-35)			

Prior systemic anti-cancer therapies are coded using WHO drug dictionary version 2021-03.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.3
Smoking History
All Randomized Patients

Treatment: Placebo

Subject Number	Smoking Status	Start Date/ End Date of Smoking	Total Daily Consumption	Unit
3145-2004	FORMER	1988/ 1990	3	CIGARETTE
3145-2007	FORMER	1975/ 2012	20	CIGARETTE
3145-2501	CURRENT	2001/ ONGOING	5	CIGARETTE

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.3
Smoking History
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Smoking Status	Start Date/ End Date of Smoking	Total Daily Consumption	Unit
2011-2001	FORMER	1980-01-01/ 2021-07-21	1	PACK
3145-2005	FORMER	1990/ 2010	3	CIGARETTE
3145-2006	FORMER	1996/ 2018	1	CIGARETTE
3145-2008	FORMER	1999/ 2019	3	CIGARETTE

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.4
Concomitant Surgeries/Procedures/Radiotherapy
All Randomized Patients

Treatment: Placebo

Subject Number	Category	Therapy/ Procedure Name	Start/End Date of Therapy/ Procedure (Study Day)	Disease- Related?	Anatomical Location/ Total Dose (unit)	Treatment Intent/ Number of Fractions
3145-2501	CONCOMITANT SURGERIES OR PROCEDURES RELATED TO LUNG CANCER	TRANSTHORACIC ECHOCARDIOGRAM	2021-08-27 (86) / 2021-08-27 (86)	Yes		

Listing: 16.2.4.4
 Concomitant Surgeries/Procedures/Radiotherapy
 All Randomized Patients

 Treatment: Trilaciclib

Subject Number	Category	Therapy/ Procedure Name	Start/End Date of Therapy/ Procedure (Study Day)	Disease- Related?	Anatomical Location/ Total Dose (unit)	Treatment Intent/ Number of Fractions
3145-2005	CONCOMITANT SURGERIES OR PROCEDURES RELATED TO LUNG CANCER	CHEST X-RAYS	2021-09-10 (37) / 2021-09-10 (37)	Yes		
		CHEST X-RAYS	2021-09-14 (41) / 2021-09-14 (41)	Yes		
		CHEST X-RAYS	2021-09-17 (44) / 2021-09-17 (44)	Yes		
		COMPUTED TOMOGRAPHY	2021-09-21 (48) / 2021-09-21 (48)	Yes		
		COMPUTED TOMOGRAPHY ANGIOGRAM OF CHEST	2021-09-11 (38) / 2021-09-11 (38)	Yes		
		COMPUTED TOMOGRAPHY OF ABDOMEN AND PELVIS	2021-09-10 (37) / 2021-09-10 (37)	Yes		

G1 Therapeutics, Inc.

G1T28-210
Database lock date: 2022-04-27

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Placebo

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2004	PIPERAZINE DERIVATIVES/ CETIRIZINE	SEASONAL ALLERGY	2021/ ONGOING	10 mg	PRN	ORAL
	OTHER COUGH SUPPRESSANTS/ BENZONATATE	COUGH	2021-05-11 (-92) / ONGOING	1 TABLET	TID	ORAL
	NATURAL OPIUM ALKALOIDS/ MORPHINE SULFATE	GENERALIZED CANCER PAIN	2021-06-29 (-43) / ONGOING	15 mg	BID	ORAL
	SEROTONIN (5HT3) ANTAGONISTS/ ONDANSETRON	NAUSEA	2021-06-29 (-43) / ONGOING	4 mg	PRN	ORAL
	AMINOALKYL ETHERS/ DIPHENHYDRAMINE	PREMEDICATION	2021-08-11 (1) / 2021-08-11 (1)	25 mg	ONCE	INTRAVENOUS

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Program: 1-cm.sas

2022-05-24 10:06

Page 1 of 24

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Placebo

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2004 (continued)	GLUCOCORTICOIDs/ DEXAMETHASONE	PREMEDICATION	2021-08-11 (1) / 2021-08-11 (1)	20 mg	ONCE	INTRAVENOUS
	H2-RECEPTOR ANTAGONISTS/ FAMOTIDINE	PREMEDICATION	2021-08-11 (1) / 2021-08-11 (1)	20 mg	ONCE	INTRAVENOUS
	SEROTONIN (5HT3) ANTAGONISTS/ ONDANSETRON	PREMEDICATION	2021-08-11 (1) / 2021-08-11 (1)	16 mg	ONCE	INTRAVENOUS
	AMINOALKYL ETHERS/ DIPHENHYDRAMINE	PREMEDICATION	2021-09-15 (36) / 2021-09-15 (36)	25 mg	ONCE	INTRAVENOUS

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Placebo

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2004 (continued)	GLUCOCORTICOIDs/ DEXAMETHASONE	PREMEDICATION	2021-09-15 (36) / 2021-09-15 (36)	20 mg	ONCE	INTRAVENOUS
	H2-RECEPTOR ANTAGONISTS/ FAMOTIDINE	PREMEDICATION	2021-09-15 (36) / 2021-09-15 (36)	20 mg	ONCE	INTRAVENOUS
	SEROTONIN (5HT3) ANTAGONISTS/ ONDANSETRON	PREMEDICATION	2021-09-15 (36) / 2021-09-15 (36)	16 mg	ONCE	INTRAVENOUS
	AMINOALKYL ETHERS/ DIPHENHYDRAMINE	PREMEDICATION	2021-10-06 (57) / 2021-10-06 (57)	25 mg	ONCE	INTRAVENOUS

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Placebo

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2004 (continued)	GLUCOCORTICOIDS/ DEXAMETHASONE	PREMEDICATION	2021-10-06 (57) / 2021-10-06 (57)	20 mg	ONCE	INTRAVENOUS
	H2-RECEPTOR ANTAGONISTS/ FAMOTIDINE	PREMEDICATION	2021-10-06 (57) / 2021-10-06 (57)	20 mg	ONCE	INTRAVENOUS
	SEROTONIN (5HT3) ANTAGONISTS/ ONDANSETRON	PREMEDICATION	2021-10-06 (57) / 2021-10-06 (57)	16 mg	ONCE	INTRAVENOUS
	AMINOALKYL ETHERS/ DIPHENHYDRAMINE	PREMEDICATION	2021-10-27 (78) / 2021-10-27 (78)	25 mg	ONCE	INTRAVENOUS

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Placebo

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2004 (continued)	GLUCOCORTICOIDS/ DEXAMETHASONE	PREMEDICATION	2021-10-27 (78) / 2021-10-27 (78)	20 mg	ONCE	INTRAVENOUS
	H2-RECEPTOR ANTAGONISTS/ FAMOTIDINE	PREMEDICATION	2021-10-27 (78) / 2021-10-27 (78)	20 mg	ONCE	INTRAVENOUS
	SEROTONIN (5HT3) ANTAGONISTS/ ONDANSETRON	PREMEDICATION	2021-10-27 (78) / 2021-10-27 (78)	16 mg	ONCE	INTRAVENOUS
3145-2007	GLUCOCORTICOIDS/ PREDNISONE	COPD	2012/ 2021-09-04 (11)	5 mg	QD	ORAL

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Placebo

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2007 (continued)	LEUKOTRIENE RECEPTOR ANTAGONISTS/ MONTELUKAST	COPD	2012/ 2021-09-04 (11)	100 mg	QD	ORAL
	SELECTIVE BETA-2- ADRENORECEPTOR AGONISTS/ SALBUTAMOL	COPD	2012/ 2021-09-04 (11)	2.5 mL	BID	RESPIRATORY (INHALATION)
	SELECTIVE BETA-2- ADRENORECEPTOR AGONISTS/ SALBUTAMOL SULFATE	COPD	2012/ 2021-09-04 (11)	90 ug	QID	RESPIRATORY (INHALATION)
	ANTICHOLINERGICS/ TIOTROPIUM BROMIDE MONOHYDRATE	COPD	2012-01/ 2021-09-04 (11)	2 SPRAY	QD	RESPIRATORY (INHALATION)

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Placebo

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2007 (continued)	ADRENERGICS IN COMBINATION WITH CORTICOSTEROIDS OR OTHER DRUGS, EXCL. ANTICHOLINERGICS/ BUDESONIDE;FORMOTEROL FUMARATE	COPD	2012-11/ 2021-09-04 (11)	2 SPRAY	BID	RESPIRATORY (INHALATION)
	H2-RECEPTOR ANTAGONISTS/ FAMOTIDINE	GASTRITIS	2018/ 2021-09-04 (11)	40 mg	BID	ORAL
	PROTON PUMP INHIBITORS/ OMEPRAZOLE	GASTRITIS	2018/ 2021-09-04 (11)	40 mg	BID	ORAL
	PROPIONIC ACID DERIVATIVES/ IBUPROFEN	GENERALIZED CANCER PAIN	2019/ 2021-09-04 (11)	400 mg	BID	ORAL

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Placebo

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2007 (continued)	SEROTONIN (5HT3) ANTAGONISTS/ ONDANSETRON	NAUSEA	2019/ 2021-09-04 (11)	4 mg	PRN	ORAL
	ASCORBIC ACID (VITAMIN C), PLAIN/ ASCORBIC ACID	DIETARY SUPPLEMENT	2020/ 2021-09-04 (11)	1 TABLET	QD	ORAL
	VITAMIN D AND ANALOGUES/ COLECALCIFEROL	DIETARY SUPPLEMENT	2020/ 2021-09-04 (11)	2000 U	QD	ORAL
	OTHER ANTIALLERGICS/ AZELASTINE	EYE ALLERGY	2021-08-17 (-8) / 2021-09-04 (11)	1 APPLICATION BID		OPHTHALMIC

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Placebo

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2007 (continued)	ANTIBIOTICS/ GENTAMICIN SULFATE	EYE ALLERGY	2021-08-28 (4) / 2021-09-04 (11)	1 APPLICATION	Q4H	OPHTHALMIC
3145-2501	BIGUANIDES/ METFORMIN	DIABETES MELLITUS	2020/ ONGOING	500 mg	QD	ORAL
	HMG COA REDUCTASE INHIBITORS/ ATORVASTATIN	HYPERCHOLESTEROLEMIA	2020/ ONGOING	20 mg	QD	ORAL
	OTHER ANTIEPILEPTICS/ LEVETIRACETAM	SEIZURE PREVENTION	2020/ ONGOING	500 mg	BID	ORAL
	OTHER NERVOUS SYSTEM DRUGS/ GABAPENTIN	PERIPHERAL NEUROPATHY	2020/ ONGOING	500 mg	BID	ORAL

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Placebo

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2501 (continued)	ACE INHIBITORS, PLAIN/ BENAZEPRIL	HYPERTENSION	2020/ 2021-09	40 mg	QD	ORAL
	THIAZIDES, PLAIN/ HYDROCHLOROTHIAZIDE	HYPERTENSION	2020/ 2021-09	12.5 mg	QD	ORAL
	ELECTROLYTE SOLUTIONS/ SODIUM CHLORIDE	DEHYDRATION	2021-09-24 (114) / 2021-09-24 (114)	1000 mL	ONCE	INTRAVENOUS

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Program: l-cm.sas

2022-05-24 10:06

Page 10 of 24

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Trilaciclib

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
2011-2001	ANILIDES/ PARACETAMOL	PAIN	2020-10-25 (-319) / 2021-09-30 (22)	325 mg	PRN	ORAL
	NATURAL OPIUM ALKALOIDS/ HYDROCODONE	PAIN	2020-10-25 (-319) / 2021-09-30 (22)	7.5 mg	PRN	ORAL
	PROPIONIC ACID DERIVATIVES/ IBUPROFEN	PAIN	2020-11-01 (-312) / 2021-09-30 (22)	200 mg	PRN	ORAL
	CALCIUM/ CALCIUM	CALCIUM DEFICIENCY	2021-01/ ONGOING	0.25 mg	QD	ORAL
	VITAMIN D AND ANALOGUES/ ERGOCALCIFEROL	VITAMIN D DEFICIENCY	2021-01/ ONGOING	50 OTHER	QD	ORAL

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Program: l-cm.sas

2022-05-24 10:06

Page 11 of 24

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Trilaciclib

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
2011-2001 (continued)	OTHER DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION/ DENOSUMAB	BONE HEALTH	2021-01-28 (-224) / 2021-09-09 (1)	16 mg	Q28D	INTRAVENOUS
	BENZODIAZEPINE DERIVATIVES/ ALPRAZOLAM	ANXIETY	2021-02/ ONGOING	0.5 mg	QD	ORAL
	NATURAL OPIUM ALKALOIDS/ MORPHINE	PAIN	2021-08-23 (-17) / ONGOING	60 mg	PRN	ORAL
	MACROLIDES/ AZITHROMYCIN	WHEEZING	2021-08-30 (-10) / 2021-09-03 (-6)	500 mg	QD	ORAL

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Trilaciclib

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
2011-2001 (continued)	PROTON PUMP INHIBITORS/ OMEPRazole	WHEEZING	2021-08-30 (-10) / 2021-09-27 (19)	20 mg	QD	ORAL
	GLUCOCORTICOIDs/ PREDNISONE	WHEEZING	2021-09-02 (-7) / 2021-09-30 (22)	10 mg	Q4D	INTRAVENOUS
	AMINOALKYL ETHERS/ DIPHENHYDRAMINE	PREMEDICATION	2021-09-09 (1) / 2021-09-09 (1)	25 mg	QD	INTRAVENOUS
	GLUCOCORTICOIDs/ DEXAMETHASONE	PREMEDICATION	2021-09-09 (1) / 2021-09-09 (1)	10 mg	QD	INTRAVENOUS

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Trilaciclib

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
2011-2001 (continued)	H2-RECEPTOR ANTAGONISTS/ FAMOTIDINE	PREMEDICATION	2021-09-09 (1) / 2021-09-09 (1)	20 mg	QD	INTRAVENOUS
	OTHER DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION/ DENOSUMAB	PROPHYLAXIS	2021-09-09 (1) / 2021-09-09 (1)	120 mg	ONCE	SUBCUTANEOUS
	SEROTONIN (5HT3) ANTAGONISTS/ ONDANSETRON	PREMEDICATION	2021-09-09 (1) / 2021-09-09 (1)	16 mg	QD	INTRAVENOUS
	COLONY STIMULATING FACTORS/ PEGFILGRASTIM APGF	PROPHYLAXIS	2021-09-10 (2) / 2021-09-10 (2)	6 mg	QD	SUBCUTANEOUS

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Trilaciclib

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
2011-2001 (continued)	SEROTONIN (5HT3) ANTAGONISTS/ ONDANSETRON	NAUSEA	2021-09-14 (6) / 2021-09-16 (8)	8 mg	TID	ORAL
	ANTIINFECTIVES AND ANTISEPTICS FOR LOCAL ORAL TREATMENT/ MAGIC MOUTHWASH	MUCOSITIS	2021-09-14 (6) / 2021-10-06 (28)	4 mL	QID	ORAL
	OTHER DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION/ DENOSUMAB	PROPHYLAXIS	2021-10-13 (35) / 2021-10-13 (35)	120 mg	ONCE	SUBCUTANEOUS
	INVESTIGATIONAL DRUG/ TRILACICLIB	NON SMALL CELL LUNG CANCER	2021-11-17 (70) / 2021-11-17 (70)	240 OTHER	ONCE	INTRAVENOUS

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Trilaciclib

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2005	ACE INHIBITORS, PLAIN/ LISINOPRIL	HYPERTENSION	2019-05-01 (-827) / ONGOING	10 mg	QD	ORAL
	PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN/ ACETYLSALICYLIC ACID	CVD PROPHYLAXIS	2019-05-01 (-827) / ONGOING	10 mg	QD	ORAL
	PROTON PUMP INHIBITORS/ PANTOPRAZOLE	GERD	2020-02-20 (-532) / ONGOING	40 mg	QD	ORAL
	OPIOIDS IN COMBINATION WITH NON-OPIOID ANALGESICS/ OXYCODONE HYDROCHLORIDE; PARACETAMOL	GENERALIZED CANCER PAIN	2021-01/ ONGOING	1 TABLET	BID	ORAL

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Trilaciclib

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2005 (continued)	BENZODIAZEPINE DERIVATIVES/ LORAZEPAM	ANXIETY	2021-03/ ONGOING	1 mg	QD	ORAL
	BENZODIAZEPINE RELATED DRUGS/ ZOLPIDEM	INSOMNIA	2021-03/ ONGOING	5 mg	PRN	ORAL
	BENZODIAZEPINE RELATED DRUGS/ ZOLPIDEM TARTRATE	INSOMNIA	2021-03/ ONGOING	5 mg	QD	ORAL
	SEROTONIN (5HT3) ANTAGONISTS/ ONDANSETRON	NAUSEA	2021-03/ ONGOING	4 mg	PRN	ORAL
	SOFTENERS, EMOLLIENTS/ DOCUSATE SODIUM	CONSTIPATION	2021-03/ ONGOING	1 OTHER	UNKNOWN	ORAL

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Trilaciclib

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2005 (continued)	AMINOALKYL ETHERS/ DIPHENHYDRAMINE	PREMEDICATION	2021-08-05 (1) / 2021-08-05 (1)	25 mg	ONCE	INTRAVENOUS
	GLUCOCORTICOIDS/ DEXAMETHASONE	PREMEDICATION	2021-08-05 (1) / 2021-08-05 (1)	20 mg	ONCE	INTRAVENOUS
	H2-RECEPTOR ANTAGONISTS/ FAMOTIDINE	PREMEDICATION	2021-08-05 (1) / 2021-08-05 (1)	20 mg	ONCE	INTRAVENOUS
	SEROTONIN (5HT3) ANTAGONISTS/ ONDANSETRON	PREMEDICATION	2021-08-05 (1) / 2021-08-05 (1)	16 mg	ONCE	INTRAVENOUS

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Trilaciclib

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2005 (continued)	OPIOIDS IN COMBINATION WITH NON-OPIOID ANALGESICS/ OXYCODONE HYDROCHLORIDE; PARACETAMOL	GENERALIZED CANCER PAIN	2021-08-26 (22) / ONGOING	1 TABLET	Q6H, PRN	ORAL
	AMINOALKYL ETHERS/ DIPHENHYDRAMINE	PREMEDICATION	2021-08-26 (22) / 2021-08-26 (22)	25 mg	ONCE	INTRAVENOUS
	GLUCOCORTICOID/ DEXAMETHASONE	PREMEDICATION	2021-08-26 (22) / 2021-08-26 (22)	20 mg	ONCE	INTRAVENOUS
	H2-RECEPTOR ANTAGONISTS/ FAMOTIDINE	PREMEDICATION	2021-08-26 (22) / 2021-08-26 (22)	20 mg	ONCE	INTRAVENOUS

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Trilaciclib

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2005 (continued)	SEROTONIN (5HT3) ANTAGONISTS/ ONDANSETRON	PREMEDICATION	2021-08-26 (22) / 2021-08-26 (22)	16 mg	ONCE	INTRAVENOUS
3145-2006	BENZODIAZEPINE DERIVATIVES/ LORAZEPAM	ANXIETY	2019/ ONGOING	2 mg	QD	ORAL
	OTHER NERVOUS SYSTEM DRUGS/ GABAPENTIN	PERIPHERAL NEUROPATHY	2019/ ONGOING	300 mg	QD	ORAL
	OSMOTICALLY ACTING LAXATIVES/ MACROGOL 3350	CONSTIPATION	2021-08-19 (9) / ONGOING	1 OTHER	PRN	ORAL
3145-2008	ACE INHIBITORS, PLAIN/ LISINOPRIL	HYPERTENSION	2019-05-01 (-890) / ONGOING	10 mg	QD	ORAL

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Trilaciclib

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2008 (continued)	PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN/ ACETYLSALICYLIC ACID	CVD PROPHYLAXIS	2019-05-01 (-890) / ONGOING	81 mg	QD	ORAL
	PROTON PUMP INHIBITORS/ PANTOPRAZOLE	GERD	2020-02-20 (-595) / ONGOING	40 mg	QD	ORAL
	OPIOIDS IN COMBINATION WITH NON-OPIOID ANALGESICS/ OXYCODONE HYDROCHLORIDE; PARACETAMOL	GENERALIZED CANCER PAIN	2021-01/ ONGOING	1 TABLET	BID	ORAL
	BENZODIAZEPINE DERIVATIVES/ LORAZEPAM	ANXIETY	2021-03/ ONGOING	1 mg	QD	ORAL

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Trilaciclib

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2008 (continued)	BENZODIAZEPINE RELATED DRUGS/ ZOLPIDEM	INSOMNIA	2021-03/ ONGOING	5 mg	PRN	ORAL
	BENZODIAZEPINE RELATED DRUGS/ ZOLPIDEM TARTRATE	INSOMNIA	2021-03/ ONGOING	5 mg	QD	ORAL
	SEROTONIN (5HT3) ANTAGONISTS/ ONDANSETRON	NAUSEA	2021-03/ ONGOING	4 mg	PRN	ORAL
	SOFTENERS, EMOLLIENTS/ DOCUSATE SODIUM	CONSTIPATION	2021-03/ ONGOING	1 OTHER	QD	ORAL
	OTHER NERVOUS SYSTEM DRUGS/ GABAPENTIN	PERIPHERAL NEUROPATHY	2021-09-17 (-20) / ONGOING	300 mg	TID	ORAL

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Program: l-cm.sas

2022-05-24 10:06

Page 22 of 24

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Trilaciclib

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2008 (continued)	CORTICOSTEROIDS, MODERATELY POTENT (GROUP II) / HYDROCORTISONE	SKIN RASH	2021-10-15 (9) / ONGOING	1 APPLICATION	QD	TOPICAL
	GLUCOCORTICOID / DEXAMETHASONE	PROPHYLAXIS, CHEMO SUPPORTIVE CARE	2021-10-15 (9) / ONGOING	4 mg	DAY BEFORE, DAY OF, DAY AFTER CHEMOTHERAPY	ORAL
	ANTIHISTAMINES FOR TOPICAL USE / DIPHENHYDRAMINE HYDROCHLORIDE	SKIN RASH	2021-10-28 (22) / ONGOING	1 APPLICATION	QD	TOPICAL
	APPETITE STIMULANTS / MEGESTROL ACETATE	ANOREXIA	2021-10-28 (22) / ONGOING	10 mL	QD	ORAL

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.4.5
Prior and Concomitant Medications
All Randomized Patients

Treatment: Trilaciclib

Subject Number	ATC (Chemical Subgroup)/ Preferred Term	Reason for Medication	Start Date (Study Day) / End Date (Study Day)	Dose (units)	Frequency	Route
3145-2008 (continued)	OTHER ANTIHISTAMINES FOR SYSTEMIC USE/ LORATADINE	PHLEBITIS	2021-10-28 (22) / ONGOING	1 TABLET	QD	ORAL
	ANTIINFECTIVES FOR TREATMENT OF ACNE/ CLINDAMYCIN	SKIN RASH	2021-12-30 (85) / ONGOING	1 APPLICATION	BID	TOPICAL
	CARBAMIDE PRODUCTS/ UREA	XERODERMIA	2022-02-02 (119) / ONGOING	40 %	BID	TOPICAL
	OTHER ANTIPRURITICS/ DOXEPIN HYDROCHLORIDE	PRURITUS	2022-02-02 (119) / ONGOING	10MG CAPSULE	TID	ORAL

ATC = Anatomical Therapeutic Chemical; BID = twice a day; PRN = as needed; QD = once a day; QID = 4 times a day; Q28D = every 28 days; Q4H = every 4 hours; Q6H = every 6 hours; TID = three times a day
Concomitant medications are coded using WHO drug dictionary version 2021-03.

Program: l-cm.sas

2022-05-24 10:06

Page 24 of 24

Listing: 16.2.5.1
Study Drug Administration
Safety Population

Treatment: Placebo

Subject Number	Visit	Drug	Dose Given?/ Dosing Date (Study Day)/ Infusion Start Time	Actual Dose (mg/m2) / Calculated Dose (mg)	Planned Infusion Volume (mL) / Actual Volume Infused (mL)	Trilaciclib: Injection Site Reaction?/ Infusion Interrupted? (Reason)	Doxetaxel: Dose Reduced?/ Reason for Reduction
3145-2004	Cycle 1 Day 1	PLACEBO	Yes/ 2021-08-11 (1) / 11:59	240/433	265/265	No/ No	
	Cycle 1 Day 1	DOCETAXEL	Yes/ 2021-08-11 (1) / 13:58	75/135.3	265/265		No
	Cycle 2 Day 1	PLACEBO	Yes/ 2021-09-15 (36) / 12:12	240/433	275/275	No/ No	
	Cycle 2 Day 1	DOCETAXEL	Yes/ 2021-09-15 (36) / 13:44	75/135.3	275/275		No

Listing: 16.2.5.1
Study Drug Administration
Safety Population

Treatment: Placebo

Subject Number	Visit	Drug	Dose Given?/ Dosing Date (Study Day) / Infusion Start Time	Actual Dose (mg/m2) / Calculated Dose (mg)	Planned Infusion Volume (mL) / Actual Volume Infused (mL)	Trilaciclib: Injection Site Reaction?/ Infusion Interrupted? (Reason)	Doxetaxel: Dose Reduced?/ Reason for Reduction
3145-2004 (continued)	Cycle 3 Day 1	PLACEBO	Yes/ 2021-10-06 (57) / 11:40	240/433	250/250	No/ No	
	Cycle 3 Day 1	DOCETAXEL	Yes/ 2021-10-06 (57) / 13:09	75/135.3	265/265		No
	Cycle 4 Day 1	PLACEBO	Yes/ 2021-10-27 (78) / 12:43	240/433	275/275	No/ No	
	Cycle 4 Day 1	DOCETAXEL	Yes/ 2021-10-27 (78) / 14:03	75/135.3	250/250		No

Listing: 16.2.5.1
Study Drug Administration
Safety Population

Treatment: Placebo

Subject Number	Visit	Drug	Dose Given?/ Dosing Date (Study Day)/ Infusion Start Time	Actual Dose (mg/m2)/ Calculated Dose (mg)	Planned Infusion Volume (mL)/ Actual Volume Infused (mL)	Trilaciclib: Injection Site Reaction?/ Infusion Interrupted? (Reason)	Doxetaxel: Dose Reduced?/ Reason for Reduction
3145-2007	Cycle 1 Day 1	PLACEBO	Yes/ 2021-08-25 (1)/ 12:13	240/435.2	250/250	No/ No	
	Cycle 1 Day 1	DOCETAXEL	Yes/ 2021-08-25 (1)/ 15:13	75/136	250/250		No
3145-2501	Cycle 1 Day 1	PLACEBO	Yes/ 2021-06-03 (1)/ 15:45	240/571.5	250/250	No/ No	
	Cycle 1 Day 1	DOCETAXEL	Yes/ 2021-06-03 (1)/ 18:03	75/178.6	250/250		No

Listing: 16.2.5.1
Study Drug Administration
Safety Population

Treatment: Placebo

Subject Number	Visit	Drug	Dose Given?/ Dosing Date (Study Day)/ Infusion Start Time	Actual Dose (mg/m2)/ Calculated Dose (mg)	Planned Infusion Volume (mL)/ Actual Volume Infused (mL)	Trilaciclib: Injection Site Reaction?/ Infusion Interrupted? (Reason)	Doxetaxel: Dose Reduced?/ Reason for Reduction
3145-2501 (continued)	Cycle 2 Day 1	PLACEBO	Yes/ 2021-06-24 (22)/ 13:19	240/577.3	250/250	No/ No	
	Cycle 2 Day 1	DOCETAXEL	Yes/ 2021-06-24 (22)/ 14:20	75/180.4	250/250		No
	Cycle 3 Day 1	PLACEBO	Yes/ 2021-07-15 (43)/ 16:55	240/577.3	250/250	No/ No	
	Cycle 3 Day 1	DOCETAXEL	Yes/ 2021-07-15 (43)/ 17:31	75/180.4	250/250		No

Listing: 16.2.5.1
Study Drug Administration
Safety Population

Treatment: Placebo

Subject Number	Visit	Drug	Dose Given?/ Dosing Date (Study Day) / Infusion Start Time	Actual Dose (mg/m2) / Calculated Dose (mg)	Planned Infusion Volume (mL) / Actual Volume Infused (mL)	Trilaciclib: Injection Site Reaction?/ Infusion Interrupted? (Reason)	Doxetaxel: Dose Reduced?/ Reason for Reduction
3145-2501 (continued)	Cycle 4 Day 1	PLACEBO	Yes/ 2021-08-18 (77) / 16:40	240/574.41	275/275	No/ No	
	Cycle 4 Day 1	DOCETAXEL	Yes/ 2021-08-18 (77) / 17:50	75/179.5	284/284		No
	Cycle 5 Day 1	PLACEBO	Yes/ 2021-09-08 (98) / 15:45	240/574.41	270/270	No/ No	
	Cycle 5 Day 1	DOCETAXEL	Yes/ 2021-09-08 (98) / 17:12	75/179.5	270/270		No

Listing: 16.2.5.1
Study Drug Administration
Safety Population

Treatment: Trilaciclib

Subject Number	Visit	Drug	Dose Given?/ Dosing Date (Study Day)/ Infusion Start Time	Actual Dose (mg/m2)/ Calculated Dose (mg)	Planned Infusion Volume (mL)/ Actual Volume Infused (mL)	Trilaciclib: Injection Site Reaction?/ Infusion Interrupted? (Reason)	Doxetaxel: Dose Reduced?/ Reason for Reduction
2011-2001	Cycle 1 Day 1	TRILACICLIB	Yes/ 2021-09-09 (1)/ 11:11	240/367	250/250	No/ No	
	Cycle 1 Day 1	DOCETAXEL	Yes/ 2021-09-09 (1)/ 13:46	75/114.8	250/250		No
	Cycle 2 Day 1	TRILACICLIB	Yes/ 2021-10-06 (28)/ 10:49	240/365	250/250	No/ No	
	Cycle 2 Day 1	DOCETAXEL	Yes/ 2021-10-06 (28)/ 13:12	75/114.8	250/250		No

Listing: 16.2.5.1
Study Drug Administration
Safety Population

Treatment: Trilaciclib

Subject Number	Visit	Drug	Dose Given?/ Dosing Date (Study Day) / Infusion Start Time	Actual Dose (mg/m2) / Calculated Dose (mg)	Planned Infusion Volume (mL) / Actual Volume Infused (mL)	Trilaciclib: Injection Site Reaction?/ Infusion Interrupted? (Reason)	Doxetaxel: Dose Reduced?/ Reason for Reduction
2011-2001 (continued)	Cycle 3 Day 1	TRILACICLIB	Yes/ 2021-10-27 (49) / 10:56	240/358	250/250	No/ No	
	Cycle 3 Day 1	DOCETAXEL	Yes/ 2021-10-27 (49) / 13:14	75/111.8	250/250		No
	Cycle 4 Day 1	TRILACICLIB	No				
	Cycle 4 Day 1	DOCETAXEL	Yes/ 2021-11-17 (70) / 12:21	75/107.2	250/250		No
3145-2005	Cycle 1 Day 1	TRILACICLIB	Yes/ 2021-08-05 (1) / 11:29	240/413.8	302/302	No/ No	

Listing: 16.2.5.1
Study Drug Administration
Safety Population

Treatment: Trilaciclib

Subject Number	Visit	Drug	Dose Given?/ Dosing Date (Study Day) / Infusion Start Time	Actual Dose (mg/m2) / Calculated Dose (mg)	Planned Infusion Volume (mL) / Actual Volume Infused (mL)	Trilaciclib: Injection Site Reaction?/ Infusion Interrupted? (Reason)	Doxetaxel: Dose Reduced?/ Reason for Reduction
3145-2005 (continued)	Cycle 1 Day 1	DOCETAXEL	Yes/ 2021-08-05 (1) / 13:10	75/130.5	270/270		No
	Cycle 2 Day 1	TRILACICLIB	Yes/ 2021-08-26 (22) / 12:43	240/413.8	278/278	No/ No	
	Cycle 2 Day 1	DOCETAXEL	Yes/ 2021-08-26 (22) / 14:06	75/129.3	250/250		No
3145-2006	Cycle 1 Day 1	TRILACICLIB	Yes/ 2021-08-11 (1) / 12:05	240/403.6	302/302	No/ No	

Listing: 16.2.5.1
Study Drug Administration
Safety Population

Treatment: Trilaciclib

Subject Number	Visit	Drug	Dose Given?/ Dosing Date (Study Day) / Infusion Start Time	Actual Dose (mg/m2) / Calculated Dose (mg)	Planned Infusion Volume (mL) / Actual Volume Infused (mL)	Trilaciclib: Injection Site Reaction?/ Infusion Interrupted? (Reason)	Doxetaxel: Dose Reduced?/ Reason for Reduction
3145-2006 (continued)	Cycle 1 Day 1	DOCETAXEL	Yes/ 2021-08-11 (1) / 13:52	75/126.1	265/265		No
	Cycle 2 Day 1	TRILACICLIB	Yes/ 2021-09-01 (22) / 12:03	240/403.6	302/302	No/ No	
	Cycle 2 Day 1	DOCETAXEL	Yes/ 2021-09-01 (22) / 13:54	75/126.1	260/260		No
	Cycle 3 Day 1	TRILACICLIB	Yes/ 2021-09-22 (43) / 14:10	240/403.6	302/302	No/ No	

Listing: 16.2.5.1
Study Drug Administration
Safety Population

Treatment: Trilaciclib

Subject Number	Visit	Drug	Dose Given?/ Dosing Date (Study Day)/ Infusion Start Time	Actual Dose (mg/m2)/ Calculated Dose (mg)	Planned Infusion Volume (mL)/ Actual Volume Infused (mL)	Trilaciclib: Injection Site Reaction?/ Infusion Interrupted? (Reason)	Doxetaxel: Dose Reduced?/ Reason for Reduction
3145-2006 (continued)	Cycle 3 Day 1	DOCETAXEL	Yes/ 2021-09-22 (43)/ 15:20	75/126.1	260/260		No
	Cycle 4 Day 1	TRILACICLIB	Yes/ 2021-10-13 (64)/ 11:47	240/403.6	302/302	Yes/ Yes (AE)	
	Cycle 4 Day 1	DOCETAXEL	Yes/ 2021-10-13 (64)/ 13:37	75/100	250/250		No
3145-2008	Cycle 1 Day 1	TRILACICLIB	Yes/ 2021-10-07 (1)/ 12:47	240/437	300/300	No/ No	

Listing: 16.2.5.1
Study Drug Administration
Safety Population

Treatment: Trilaciclib

Subject Number	Visit	Drug	Dose Given?/ Dosing Date (Study Day)/ Infusion Start Time	Actual Dose (mg/m2)/ Calculated Dose (mg)	Planned Infusion Volume (mL)/ Actual Volume Infused (mL)	Trilaciclib: Injection Site Reaction?/ Infusion Interrupted? (Reason)	Doxetaxel: Dose Reduced?/ Reason for Reduction
3145-2008 (continued)	Cycle 1 Day 1	DOCETAXEL	Yes/ 2021-10-07 (1)/ 14:40	75/136.5	250/250		No
	Cycle 2 Day 1	TRILACICLIB	Yes/ 2021-10-28 (22)/ 13:55	240/437	257/257	No/ No	
	Cycle 2 Day 1	DOCETAXEL	Yes/ 2021-10-28 (22)/ 15:34	75/136.5	250/250		No
	Cycle 3 Day 1	TRILACICLIB	Yes/ 2021-11-19 (44)/ 13:21	240/437	304/304	No/ No	

Listing: 16.2.5.1
Study Drug Administration
Safety Population

Treatment: Trilaciclib

Subject Number	Visit	Drug	Dose Given?/ Dosing Date (Study Day)/ Infusion Start Time	Actual Dose (mg/m2) / Calculated Dose (mg)	Planned Infusion Volume (mL) / Actual Volume Infused (mL)	Trilaciclib: Injection Site Reaction?/ Infusion Interrupted? (Reason)	Doxetaxel: Dose Reduced?/ Reason for Reduction
3145-2008 (continued)	Cycle 3 Day 1	DOCETAXEL	Yes/ 2021-11-19 (44) / 14:46	75/136.5	250/250		No
	Cycle 4 Day 1	TRILACICLIB	Yes/ 2021-12-10 (65) / 14:13	240/437	250/250	No/ No	
	Cycle 4 Day 1	DOCETAXEL	Yes/ 2021-12-10 (65) / 15:44	75/136.5	250/250		No
	Cycle 5 Day 1	TRILACICLIB	Yes/ 2021-12-30 (85) / 13:53	240/437	250/250	No/ No	

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.5.1
Study Drug Administration
Safety Population

Treatment: Trilaciclib

Subject Number	Visit	Drug	Dose Given?/ Dosing Date (Study Day)/ Infusion Start Time	Actual Dose (mg/m2) / Calculated Dose (mg)	Planned Infusion Volume (mL) / Actual Volume Infused (mL)	Trilaciclib:	Doxetaxel:	
						Injection		Dose
						Site Reaction?/ Infusion Interrupted? (Reason)		Reduced?/ Reason for Reduction
3145-2008 (continued)	Cycle 5 Day 1	DOCETAXEL	Yes/ 2021-12-30 (85) / 15:15	75/136.5	250/250		No	

Listing: 16.2.5.2

Total Exposure

Safety Population

Treatment: Placebo

Study Drug	Subject Number	Cumulative Actual Dose (mg/m2)	Dose Intensity (mg/m2/week)	Relative Dose (%)	Relative Dose Intensity (%)	For Docetaxel:		
						Number of Doses Reduced	Number of Dose Interruptions	Number of Missed Doses
Docetaxel	3145-2004	300	22.34	100	89.36	0	0	0
	3145-2007	75	16.94	100	67.74	0	0	0
	3145-2501	375	20.51	100	82.03	0	0	0
Placebo	3145-2004	960	71.49	100	89.36			
	3145-2007	240	54.19	100	67.74			
	3145-2501	1200	65.63	100	82.03			

Listing: 16.2.5.2
Total Exposure
Safety Population

Treatment: Trilaciclib

Study Drug	Subject Number	Cumulative Actual Dose (mg/m2)	Dose Intensity (mg/m2/week)	Relative Dose (%)	Relative Dose Intensity (%)	For Docetaxel:		
						Number of Doses Reduced	Number of Dose Interruptions	Number of Missed Doses
Docetaxel	2011-2001	300	21.00	100	84.00	0	0	0
	3145-2005	150	10.00	100	40.00	0	0	0
	3145-2006	300	22.58	100	90.32	0	0	0
	3145-2008	375	22.06	100	88.24	0	0	0
Trilaciclib	2011-2001	720	50.40	75	63.00			
	3145-2005	480	32.00	100	40.00			
	3145-2006	960	72.26	100	90.32			
	3145-2008	1200	70.59	100	88.24			

Listing: 16.2.5.3
Cycle Day Status and Overall Summary
Safety Population

Treatment: Placebo

Subject Number	Cycle	Date of Visit	Cycle Delayed?	Primary Reason for Delayed Cycle	Total Cycles	Duration of Exposure (days)	Number of Cycle Delayed
3145-2004	Cycle 1 Day 1	2021-08-11	No	OTHER: SAE #1 (Staphylococcal sepsis)	4	94	1
	Cycle 2 Day 1	2021-09-15	Yes				
	Cycle 3 Day 1	2021-10-06	No				
	Cycle 4 Day 1	2021-10-27	No				
3145-2007	Cycle 1 Day 1	2021-08-25	No		1	31	0
3145-2501	Cycle 1 Day 1	2021-06-03	No	OTHER: IV ACCESS WAS UNOBTAINABLE	5	128	1
	Cycle 2 Day 1	2021-06-24	No				
	Cycle 3 Day 1	2021-07-15	No				
	Cycle 4 Day 1	2021-08-18	Yes				
	Cycle 5 Day 1	2021-09-08	No				

Listing: 16.2.5.3
 Cycle Day Status and Overall Summary
 Safety Population

 Treatment: Trilaciclib

Subject Number	Cycle	Date of Visit	Cycle Delayed?	Primary Reason for Delayed Cycle	Total Cycles	Duration of Exposure (days)	Number of Cycle Delayed
2011-2001	Cycle 1 Day 1	2021-09-09	No	OTHER: PHYSICIAN DECISION	4	100	1
	Cycle 2 Day 1	2021-10-06	Yes				
	Cycle 3 Day 1	2021-10-27	No				
	Cycle 4 Day 1	2021-11-17	No				
3145-2005	Cycle 1 Day 1	2021-08-05	No		2	105	0
	Cycle 2 Day 1	2021-08-26	No				
3145-2006	Cycle 1 Day 1	2021-08-11	No		4	93	0
	Cycle 2 Day 1	2021-09-01	No				
	Cycle 3 Day 1	2021-09-22	No				
	Cycle 4 Day 1	2021-10-13	No				
3145-2008	Cycle 1 Day 1	2021-10-07	No		5	119	0
	Cycle 2 Day 1	2021-10-28	No				
	Cycle 3 Day 1	2021-11-19	No				
	Cycle 4 Day 1	2021-12-10	No				
	Cycle 5 Day 1	2021-12-30	No				

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.2
Adverse Events of Special Interest for Trilaciclib
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trila/Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2008	Vascular disorders/ Phlebitis/ PHLEBITIS (8)	2021-10-28 (22)/ Ongoing	No/ 1	NOT RECOVERED/ NOT RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	CONCOMITANT MEDICATIONS

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-aesi.sas

2022-06-08 10:00

Page 1 of 1

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.3
Adverse Events Leading to Dose Reductions
Safety Population

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trila/Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
-------------------	--	-----------------------------------	-------------------------	---------	---	---	-----------------------

No observations meet the criteria for this display.

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-dosered.sas

2022-06-08 10:01

Page 1 of 1

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.4
Adverse Events Leading to Cycle Delays
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trila/Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2004	Infections and infestations/ Staphylococcal sepsis/ MSSA SEPSIS (1)	2021-09-01 (22) / 2021-09-08 (29)	Yes/ 3	RECOVERED/ RESOLVED	RELATED/ CYCLE DELAYED	RELATED/ CYCLE DELAYED	OTHER: ADMITTED TO HOSPITAL

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event

Note: AEs are coded using MedDRA version 24.0.

Program: 1-ae-dosedelay.sas

2022-06-08 10:00

Page 1 of 1

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.5

TEAEs Leading to Discontinuation of Any Study Drug
Safety Population

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trila/Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken

No observations meet the criteria for this display.

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-dosedisc.sas

2022-06-08 10:01

Page 1 of 1

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.6
Adverse Events Leading to Dose Interruptions
Safety Population

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trila/Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
-------------------	--	-----------------------------------	-------------------------	---------	---	---	-----------------------

No observations meet the criteria for this display.

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event
Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-doseint.sas

2022-06-08 10:01

Page 1 of 1

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.7
Serious Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trila/Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2004	Infections and infestations/ Staphylococcal sepsis/ MSSA SEPSIS (1)	2021-09-01 (22) / 2021-09-08 (29)	Yes/ 3	RECOVERED/ RESOLVED	RELATED/ CYCLE DELAYED	RELATED/ CYCLE DELAYED	OTHER: ADMITTED TO HOSPITAL
3145-2007	Renal and urinary disorders/ Acute kidney injury/ ACUTE RENAL FAILURE (1)	2021-09-01 (8) / 2021-09-04 (11)	Yes/ 3	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	NOT RELATED/ DOSE NOT CHANGED	OTHER: HOSPITALIZATION
	Infections and infestations/ Urosepsis/ UROSEPSIS (2)	2021-09-05 (12) / 2021-09-05 (12)	Yes/ 5	FATAL	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	CONCOMITANT MEDICATIONS

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event

Note: AEs are coded using MedDRA version 24.0.

Program: 1-ae-sae.sas

2022-06-08 10:01

Page 1 of 3

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.7
Serious Adverse Events
Safety Population

Treatment: Placebo

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trila/Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2501	Renal and urinary disorders/ Renal failure/ RENAL FAILURE (1)	2021-08-26 (85) / 2021-08-30 (89)	Yes/ 3	RECOVERED/ RESOLVED	NOT RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	CONCOMITANT MEDICATIONS, OTHER: IV FLUID RESUSCITATION

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event

Note: AEs are coded using MedDRA version 24.0.

Program: 1-ae-sae.sas

2022-06-08 10:01

Page 2 of 3

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.6.7
Serious Adverse Events
Safety Population

Treatment: Trilaciclib

Subject Number	System Organ Class/ Preferred Term/ Verbatim Term (AE Number)	Start/End Date (Study Days)	SAE?/ CTCAE Grade	Outcome	Relationship to Trila/Placebo/ Action Taken	Relationship to Docetaxel/ Action Taken	Other Action Taken
3145-2005	Infections and infestations/ Pneumonia/ PNEUMONIA (1)	2021-09-10 (37) / 2021-11-17 (105)	Yes/ 3	RECOVERED/ RESOLVED	RELATED/ DOSE NOT CHANGED	RELATED/ DOSE NOT CHANGED	CONCOMITANT MEDICATIONS, CONCOMITANT PROCEDURES, OTHER: HOSPITAL ADMISSION

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = Serious Adverse Event

Note: AEs are coded using MedDRA version 24.0.

Program: l-ae-sae.sas

2022-06-08 10:01

Page 3 of 3

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2004	Screening	2021-08-10/12:12 (-1)	Hemoglobin (g/dL)	11.9*	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	172*	140 - 400	0	
			Leukocytes (10 ⁹ /L)	3.7*	3.8 - 10.8	1	L
			Neutrophils (10 ⁹ /L)	1.776*	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	1.036*	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.74*	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	48*	40 - 70		
			Lymphocytes/Leukocytes (%)	28*	22 - 44		
			Monocytes/Leukocytes (%)	20*	4 - 11		H
			Hematocrit (%)	35.4*	38.5 - 50		L
	Cycle 1 Day 5	2021-08-16/12:16 (6)	Hemoglobin (g/dL)	11.5	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	158	140 - 400	0	
			Leukocytes (10 ⁹ /L)	1.6	3.8 - 10.8	3	L
			Neutrophils (10 ⁹ /L)	0.88	1.5 - 7.8	3	L
			Lymphocytes (10 ⁹ /L)	0.592	0.85 - 3.9	2	L
			Monocytes (10 ⁹ /L)	0.08	0.2 - 0.95		L
			Neutrophils/Leukocytes (%)	55	40 - 70		
			Lymphocytes/Leukocytes (%)	37	22 - 44		
			Monocytes/Leukocytes (%)	5	4 - 11		
			Hematocrit (%)	33.6	38.5 - 50		L
	Cycle 1 Day 9	2021-08-19/09:58 (9)	Hemoglobin (g/dL)	9.2	13.2 - 17.1	2	L

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2004 (continued)	Cycle 1 Day 9 (continued)	2021-08-19/09:58 (9) (continued)	Platelets (10 ⁹ /L)	160	140 - 400	0	
			Leukocytes (10 ⁹ /L)	0.9	3.8 - 10.8	4	L
			Neutrophils (10 ⁹ /L)	0.36	1.5 - 7.8	4	L
			Lymphocytes (10 ⁹ /L)	0.296	0.85 - 3.9	3	L
			Monocytes (10 ⁹ /L)	0.233	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	40	40 - 70		
			Lymphocytes/Leukocytes (%)	32.9	22 - 44		
			Monocytes/Leukocytes (%)	25.9	4 - 11		H
			Hematocrit (%)	27.2	38.5 - 50		L
	Cycle 1 Day 13	2021-08-24/14:35 (14)	Hemoglobin (g/dL)	10.5	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	178	140 - 400	0	
			Leukocytes (10 ⁹ /L)	1.7	3.8 - 10.8	3	L
			Neutrophils (10 ⁹ /L)	0.367	1.5 - 7.8	4	L
			Lymphocytes (10 ⁹ /L)	0.457	0.85 - 3.9	3	L
			Monocytes (10 ⁹ /L)	0.835	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	21.6	40 - 70		L
			Lymphocytes/Leukocytes (%)	26.9	22 - 44		
			Monocytes/Leukocytes (%)	49.1	4 - 11		H
			Hematocrit (%)	31.3	38.5 - 50		L
	Cycle 1 Day 17	2021-08-27/13:13 (17)	Hemoglobin (g/dL)	11.4	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	208	140 - 400	0	

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2004 (continued)	Cycle 1 Day 17 (continued)	2021-08-27/13:13 (17) (continued)	Leukocytes (10 ⁹ /L)	2.4	3.8 - 10.8	2	L
			Neutrophils (10 ⁹ /L)	0.869	1.5 - 7.8	3	L
			Lymphocytes (10 ⁹ /L)	0.655	0.85 - 3.9	2	L
			Monocytes (10 ⁹ /L)	0.847	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	36.2	40 - 70		L
			Lymphocytes/Leukocytes (%)	27.3	22 - 44		
			Monocytes/Leukocytes (%)	35.3	4 - 11		H
			Hematocrit (%)	33.2	38.5 - 50		L
	Unscheduled	2021-08-31/12:42 (21)	Hemoglobin (g/dL)	12.0	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	220	140 - 400	0	
			Leukocytes (10 ⁹ /L)	10.8	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	8.964	1.5 - 7.8	0	H
			Lymphocytes (10 ⁹ /L)	0.734	0.85 - 3.9	2	L
			Monocytes (10 ⁹ /L)	1.048	0.2 - 0.95		H
			Neutrophils/Leukocytes (%)	83	40 - 70		H
			Lymphocytes/Leukocytes (%)	6.8	22 - 44		L
			Monocytes/Leukocytes (%)	9.7	4 - 11		
			Hematocrit (%)	34.6	38.5 - 50		L
		2021-09-10/13:22 (31)	Hemoglobin (g/dL)	11.8	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	211	140 - 400	0	
			Leukocytes (10 ⁹ /L)	3.9	3.8 - 10.8	0	

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2004 (continued)	Unscheduled (continued)	2021-09-10/13:22 (31) (continued)	Neutrophils (10 ⁹ /L)	2.282	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	0.69	0.85 - 3.9	2	L
			Monocytes (10 ⁹ /L)	0.62	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	58.5	40 - 70		
			Lymphocytes/Leukocytes (%)	17.7	22 - 44		L
			Monocytes/Leukocytes (%)	15.9	4 - 11		H
			Hematocrit (%)	34.5	38.5 - 50		L
	Cycle 2 Day 1	2021-09-14/09:59 (35)	Hemoglobin (g/dL)	12.4	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	253	140 - 400	0	
			Leukocytes (10 ⁹ /L)	4.9	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	2.896	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	1.107	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.666	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	59.1	40 - 70		
			Lymphocytes/Leukocytes (%)	22.6	22 - 44		
			Monocytes/Leukocytes (%)	13.6	4 - 11		H
			Hematocrit (%)	36.7	38.5 - 50		L
	Cycle 3 Day 1	2021-10-05/13:30 (56)	Hemoglobin (g/dL)	13.0	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	200	140 - 400	0	
			Leukocytes (10 ⁹ /L)	5.7	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	3.426	1.5 - 7.8	0	

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2004 (continued)	Cycle 3 Day 1 (continued)	2021-10-05/13:30 (56) (continued)	Lymphocytes (10 ⁹ /L)	1.391	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.775	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	60.1	40 - 70		
			Lymphocytes/Leukocytes (%)	24.4	22 - 44		
			Monocytes/Leukocytes (%)	13.6	4 - 11		H
			Hematocrit (%)	38.4	38.5 - 50		L
	Cycle 4 Day 1	2021-10-26/12:04 (77)	Hemoglobin (g/dL)	14.2	13.2 - 17.1	0	
			Platelets (10 ⁹ /L)	218	140 - 400	0	
			Leukocytes (10 ⁹ /L)	4.8	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	2.923	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	1.013	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.816	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	60.9	40 - 70		
			Lymphocytes/Leukocytes (%)	21.1	22 - 44		L
			Monocytes/Leukocytes (%)	17.0	4 - 11		H
			Hematocrit (%)	40.9	38.5 - 50		
	Post-Treatment Visit	2021-11-12/10:36 (94)	Hemoglobin (g/dL)	13.0	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	204	140 - 400	0	
			Leukocytes (10 ⁹ /L)	2.5	3.8 - 10.8	2	L
			Neutrophils (10 ⁹ /L)	0.583	1.5 - 7.8	3	L
			Lymphocytes (10 ⁹ /L)	0.9	0.85 - 3.9	0	

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2004 (continued)	Post-Treatment Visit (continued)	2021-11-12/10:36 (94) (continued)	Monocytes (10 ⁹ /L)	0.978	0.2 - 0.95		H
			Neutrophils/Leukocytes (%)	23.3	40 - 70		L
			Lymphocytes/Leukocytes (%)	36.0	22 - 44		
			Monocytes/Leukocytes (%)	39.1	4 - 11		H
			Hematocrit (%)	38.4	38.5 - 50		L
3145-2007	Screening	2021-08-18/10:03 (-7)	Hemoglobin (g/dL)	10.6	11.7 - 15.5	1	L
			Platelets (10 ⁹ /L)	232	140 - 400	0	
			Leukocytes (10 ⁹ /L)	5.9	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	4.944	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	0.519	0.85 - 3.9	2	L
			Monocytes (10 ⁹ /L)	0.242	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	83.8	40 - 70		H
			Lymphocytes/Leukocytes (%)	8.8	22 - 44		L
			Monocytes/Leukocytes (%)	4.1	4 - 11		
			Hematocrit (%)	32.6	35 - 45		L
	Cycle 1 Day 1	2021-08-24/13:41 (-1)	Hemoglobin (g/dL)	10.0*	11.7 - 15.5	1	L
			Platelets (10 ⁹ /L)	267*	140 - 400	0	
			Leukocytes (10 ⁹ /L)	6.4*	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	5.555*	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	0.525*	0.85 - 3.9	2	L
			Monocytes (10 ⁹ /L)	0.224*	0.2 - 0.95		

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2007 (continued)	Cycle 1 Day 1 (continued)	2021-08-24/13:41 (-1) (continued)	Neutrophils/Leukocytes (%)	86.8*	40 - 70		H
			Lymphocytes/Leukocytes (%)	8.2*	22 - 44		L
			Monocytes/Leukocytes (%)	3.5*	4 - 11		L
			Hematocrit (%)	30.9*	35 - 45		L
	Cycle 1 Day 5	2021-08-30/13:45 (6)	Hemoglobin (g/dL)	10.0	12 - 16	1	L
			Platelets (10 ⁹ /L)	268	150 - 350	0	
			Leukocytes (10 ⁹ /L)	1.6	4.5 - 11	3	L
			Neutrophils (10 ⁹ /L)	1.1	1.5 - 8	2	L
			Lymphocytes (10 ⁹ /L)	0.3	0.7 - 3.1	3	L
			Monocytes (10 ⁹ /L)	0.1	0.1 - 0.9		
			Neutrophils/Leukocytes (%)	68	40 - 70		
			Lymphocytes/Leukocytes (%)	19	22 - 44		L
			Monocytes/Leukocytes (%)	7	4 - 11		
			Hematocrit (%)	30.9	36 - 46		L
3145-2501	Screening	2021-06-02/17:31 (-1)	Hemoglobin (g/dL)	12.5	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	254	140 - 400	0	
			Leukocytes (10 ⁹ /L)	7.5	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	4.733	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	1.613	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.855	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	63.1	40 - 70		

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Screening (continued)	2021-06-02/17:31 (-1) (continued)	Lymphocytes/Leukocytes (%)	21.5	22 - 44		L
			Monocytes/Leukocytes (%)	11.4	4 - 11		H
			Hematocrit (%)	37.1	38.5 - 50		L
	Cycle 1 Day 1	2021-06-02/17:31 (-1)	Hemoglobin (g/dL)	12.5*	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	254*	140 - 400	0	
			Leukocytes (10 ⁹ /L)	7.5*	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	4.733*	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	1.613*	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.855*	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	63.1*	40 - 70		
			Lymphocytes/Leukocytes (%)	21.5*	22 - 44		L
			Monocytes/Leukocytes (%)	11.4*	4 - 11		H
			Hematocrit (%)	37.1*	38.5 - 50		L
	Cycle 1 Day 5	2021-06-07/13:46 (5)	Hemoglobin (g/dL)	11.8	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	157	140 - 400	0	
			Leukocytes (10 ⁹ /L)	6.7	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	5.44	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	0.958	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.181	0.2 - 0.95		L
			Neutrophils/Leukocytes (%)	81.2	40 - 70		H
			Lymphocytes/Leukocytes (%)	14.3	22 - 44		L

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Cycle 1 Day 5 (continued)	2021-06-07/13:46 (5) (continued)	Monocytes/Leukocytes (%)	2.7	4 - 11		L
			Hematocrit (%)	34.9	38.5 - 50		L
	Cycle 1 Day 9	2021-06-11/13:40 (9)	Hemoglobin (g/dL)	11.4	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	194	140 - 400	0	
			Leukocytes (10 ⁹ /L)	1.6	3.8 - 10.8	3	L
			Neutrophils (10 ⁹ /L)	0.525	1.5 - 7.8	3	L
			Lymphocytes (10 ⁹ /L)	0.819	0.85 - 3.9	1	L
			Monocytes (10 ⁹ /L)	0.218	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	32.8	40 - 70		L
			Lymphocytes/Leukocytes (%)	51.2	22 - 44		H
			Monocytes/Leukocytes (%)	13.6	4 - 11		H
			Hematocrit (%)	33.4	38.5 - 50		L
	Cycle 1 Day 13	2021-06-15/13:01 (13)	Hemoglobin (g/dL)	11.0	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	261	140 - 400	0	
			Leukocytes (10 ⁹ /L)	3.67	3.8 - 10.8	1	L
			Neutrophils (10 ⁹ /L)	0.176	1.5 - 7.8	4	L
			Lymphocytes (10 ⁹ /L)	1.364	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.528	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	8	40 - 70		L
			Lymphocytes/Leukocytes (%)	62	22 - 44		H
			Monocytes/Leukocytes (%)	24	4 - 11		H

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Cycle 1 Day 13 (continued)	2021-06-15/13:01 (13) (continued)	Hematocrit (%)	32.8	38.5 - 50		L
	Cycle 1 Day 17	2021-06-18/13:24 (16)	Hemoglobin (g/dL)	11.4	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	266	140 - 400	0	
			Leukocytes (10 ⁹ /L)	4.7	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	2.439	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	1.316	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.907	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	51.9	40 - 70		
			Lymphocytes/Leukocytes (%)	28.0	22 - 44		
			Monocytes/Leukocytes (%)	19.3	4 - 11		H
			Hematocrit (%)	34.4	38.5 - 50		L
	Cycle 2 Day 1	2021-06-23/16:30 (21)	Hemoglobin (g/dL)	12.3	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	310	140 - 400	0	
			Leukocytes (10 ⁹ /L)	9.0	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	6.21	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	1.62	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	1.17	0.2 - 0.95		H
			Neutrophils/Leukocytes (%)	69	40 - 70		
			Lymphocytes/Leukocytes (%)	18	22 - 44		L
			Monocytes/Leukocytes (%)	13	4 - 11		H

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standardized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Cycle 2 Day 1 (continued)	2021-06-23/16:30 (21) (continued)	Hematocrit (%)	36.5	38.5 - 50		L
	Cycle 3 Day 1	2021-07-15/12:08 (43)	Hemoglobin (g/dL)	12.5	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	321	140 - 400	0	
			Leukocytes (10 ⁹ /L)	11.0	3.8 - 10.8	0	H
			Neutrophils (10 ⁹ /L)	8.14	1.5 - 7.8	0	H
			Lymphocytes (10 ⁹ /L)	1.65	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	1.155	0.2 - 0.95		H
			Neutrophils/Leukocytes (%)	74.0	40 - 70		H
			Lymphocytes/Leukocytes (%)	15.0	22 - 44		L
			Monocytes/Leukocytes (%)	10.5	4 - 11		
			Hematocrit (%)	37.3	38.5 - 50		L
	Unscheduled	2021-08-04/13:08 (63)	Hemoglobin (g/dL)	10.6	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	285	140 - 400	0	
			Leukocytes (10 ⁹ /L)	9.3	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	6.984	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	1.404	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.865	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	75.1	40 - 70		H
			Lymphocytes/Leukocytes (%)	15.1	22 - 44		L
			Monocytes/Leukocytes (%)	9.3	4 - 11		

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Unscheduled (continued)	2021-08-04/13:08 (63) (continued)	Hematocrit (%)	32.2	38.5 - 50		L
	Cycle 4 Day 1	2021-08-18/12:10 (77)	Hemoglobin (g/dL)	11.5	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	310	140 - 400	0	
			Leukocytes (10 ⁹ /L)	7.4	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	4.41	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	1.539	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	1.154	0.2 - 0.95		H
			Neutrophils/Leukocytes (%)	59.6	40 - 70		
			Lymphocytes/Leukocytes (%)	20.8	22 - 44		L
			Monocytes/Leukocytes (%)	15.6	4 - 11		H
			Hematocrit (%)	35.1	38.5 - 50		L
	Cycle 5 Day 1	2021-09-07/15:49 (97)	Hemoglobin (g/dL)	11.4	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	301	140 - 400	0	
			Leukocytes (10 ⁹ /L)	10.1	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	6.727	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	2.081	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	1.212	0.2 - 0.95		H
			Neutrophils/Leukocytes (%)	66.6	40 - 70		
			Lymphocytes/Leukocytes (%)	20.6	22 - 44		L
			Monocytes/Leukocytes (%)	12.0	4 - 11		H

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Cycle 5 Day 1 (continued)	2021-09-07/15:49 (97) (continued)	Hematocrit (%)	33.9	38.5 - 50		L
	Unscheduled	2021-09-17/14:45 (107)	Hemoglobin (g/dL)	9.5	13.2 - 17.1	2	L
			Platelets (10 ⁹ /L)	217	140 - 400	0	
			Leukocytes (10 ⁹ /L)	2.3	3.8 - 10.8	2	L
			Neutrophils (10 ⁹ /L)	0.276	1.5 - 7.8	4	L
			Lymphocytes (10 ⁹ /L)	1.343	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.621	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	12	40 - 70		L
			Lymphocytes/Leukocytes (%)	58.4	22 - 44		H
			Monocytes/Leukocytes (%)	27.0	4 - 11		H
			Hematocrit (%)	28.8	38.5 - 50		L
		2021-09-24/15:27 (114)	Hemoglobin (g/dL)	9.3	13.2 - 17.1	2	L
			Platelets (10 ⁹ /L)	219	140 - 400	0	
			Leukocytes (10 ⁹ /L)	45.5	3.8 - 10.8	0	H
			Neutrophils (10 ⁹ /L)	40.814	1.5 - 7.8	0	H
			Lymphocytes (10 ⁹ /L)	2.093	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	2.366	0.2 - 0.95		H
			Neutrophils/Leukocytes (%)	89.7	40 - 70		H
			Lymphocytes/Leukocytes (%)	4.6	22 - 44		L
			Monocytes/Leukocytes (%)	5.2	4 - 11		

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2501 (continued)	Unscheduled (continued)	2021-09-24/15:27 (114) (continued)	Hematocrit (%)	28.5	38.5 - 50		L
		2021-09-28/12:43 (118)	Hemoglobin (g/dL)	10.8	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	302	140 - 400	0	
			Leukocytes (10 ⁹ /L)	9.6	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	5.76	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	1.248	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	2.4	0.2 - 0.95		H
			Neutrophils/Leukocytes (%)	60	40 - 70		
			Lymphocytes/Leukocytes (%)	13	22 - 44		L
			Monocytes/Leukocytes (%)	25	4 - 11		H
			Hematocrit (%)	33.4	38.5 - 50		L

* Baseline value.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
2011-2001	Screening	2021-08-18/14:29 (-22)	Hemoglobin (g/dL)	10.7	12.5 - 17	1	L
			Platelets (10 ⁹ /L)	241	140 - 415	0	
			Leukocytes (10 ⁹ /L)	9.7	4 - 10.5	0	
			Neutrophils (10 ⁹ /L)	6.9	0 - 750	0	
			Lymphocytes (10 ⁹ /L)	1.5	0.7 - 4.5	0	
			Monocytes (10 ⁹ /L)	0.8	0.1 - 1		
			Neutrophils/Leukocytes (%)	70	40 - 74		
			Lymphocytes/Leukocytes (%)	16	14 - 46		
			Monocytes/Leukocytes (%)	9	4 - 13		
			Hematocrit (%)	22	36 - 50		
	Cycle 1 Day 1	2021-09-08/10:50 (-1)	Hemoglobin (g/dL)	9*	12.5 - 17	2	L
			Platelets (10 ⁹ /L)	321*	140 - 415	0	
			Leukocytes (10 ⁹ /L)	9.8*	4 - 10.5	0	
			Neutrophils (10 ⁹ /L)	7.1*	0 - 750	0	
			Lymphocytes (10 ⁹ /L)	1.4*	0.7 - 4.5	0	
			Monocytes (10 ⁹ /L)	1.0*	0.1 - 1		
			Neutrophils/Leukocytes (%)	72*	40 - 74		
			Lymphocytes/Leukocytes (%)	15*	14 - 46		
			Monocytes/Leukocytes (%)	10*	4 - 13		
			Hematocrit (%)	28.3*	36 - 50		
	Cycle 1 Day 5	2021-09-13/13:35 (5)	Hemoglobin (g/dL)	8.6	12.5 - 17	2	L

* Baseline value.

Program: 1-lb-hem.sas

2022-06-08 10:02

Page 15 of 35

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
2011-2001 (continued)	Cycle 1 Day 5 (continued)	2021-09-13/13:35 (5) (continued)	Platelets (10 ⁹ /L)	291	140 - 415	0	
			Leukocytes (10 ⁹ /L)	20.7	4 - 10.5	0	H
			Neutrophils (10 ⁹ /L)	17.8	0 - 750	0	
			Lymphocytes (10 ⁹ /L)	1.2	0.7 - 4.5	0	
			Monocytes (10 ⁹ /L)	0.2	0.1 - 1		
			Neutrophils/Leukocytes (%)	81	40 - 74		H
			Lymphocytes/Leukocytes (%)	6	14 - 46		L
			Monocytes/Leukocytes (%)	1	4 - 13		L
			Hematocrit (%)	26.3	36 - 50		L
	Cycle 1 Day 9	2021-09-16/12:40 (8)	Hemoglobin (g/dL)	8.6	12.5 - 17	2	L
			Platelets (10 ⁹ /L)	268	140 - 415	0	
			Leukocytes (10 ⁹ /L)	21.1	4 - 10.5	0	H
			Neutrophils (10 ⁹ /L)	17.7	0 - 750	0	
			Lymphocytes (10 ⁹ /L)	1.1	0.7 - 4.5	0	
			Monocytes (10 ⁹ /L)	1.6	0.1 - 1		H
			Neutrophils/Leukocytes (%)	85	40 - 74		H
			Lymphocytes/Leukocytes (%)	5	14 - 46		L
			Monocytes/Leukocytes (%)	7	4 - 13		
			Hematocrit (%)	25.9	36 - 50		L
	Cycle 1 Day 13	2021-09-21/11:24 (13)	Hemoglobin (g/dL)	9.1	12.5 - 17	2	L
			Platelets (10 ⁹ /L)	267	140 - 415	0	

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
2011-2001 (continued)	Cycle 1 Day 13 (continued)	2021-09-21/11:24 (13) (continued)	Leukocytes (10 ⁹ /L)	26.8	4 - 10.5	0	H
			Neutrophils (10 ⁹ /L)	22.8	0 - 750	0	
			Lymphocytes (10 ⁹ /L)	1.6	0.7 - 4.5	0	
			Monocytes (10 ⁹ /L)	1.9	0.1 - 1		H
			Neutrophils/Leukocytes (%)	77	40 - 74		H
			Lymphocytes/Leukocytes (%)	6	14 - 46		L
			Monocytes/Leukocytes (%)	7	4 - 13		
			Hematocrit (%)	27	36 - 50		L
	Cycle 1 Day 17	2021-09-24/12:27 (16)	Hemoglobin (g/dL)	9.7	12.5 - 17	2	L
			Platelets (10 ⁹ /L)	361	140 - 415	0	
			Leukocytes (10 ⁹ /L)	21.5	4 - 10.5	0	H
			Neutrophils (10 ⁹ /L)	17.9	0 - 750	0	
			Lymphocytes (10 ⁹ /L)	1.6	0.7 - 4.5	0	
			Monocytes (10 ⁹ /L)	1.2	0.1 - 1		H
			Neutrophils/Leukocytes (%)	83	40 - 74		H
			Lymphocytes/Leukocytes (%)	7	14 - 46		L
			Monocytes/Leukocytes (%)	6	4 - 13		
			Hematocrit (%)	29.8	36 - 50		L
	Cycle 2 Day 1	2021-10-05/13:55 (27)	Hemoglobin (g/dL)	8.9	12.5 - 17	2	L
			Platelets (10 ⁹ /L)	386	140 - 415	0	
			Leukocytes (10 ⁹ /L)	21.5	4 - 10.5	0	H

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
2011-2001 (continued)	Cycle 2 Day 1 (continued)	2021-10-05/13:55 (27) (continued)	Neutrophils (10 ⁹ /L)	19	0 - 750	0	
			Lymphocytes (10 ⁹ /L)	1	0.7 - 4.5	0	
			Monocytes (10 ⁹ /L)	0.7	0.1 - 1		
			Neutrophils/Leukocytes (%)	88	40 - 74		H
			Lymphocytes/Leukocytes (%)	5	14 - 46		L
			Monocytes/Leukocytes (%)	3	4 - 13		L
			Hematocrit (%)	26.8	36 - 50		L
	Cycle 3 Day 1	2021-10-26/14:07 (48)	Hemoglobin (g/dL)	8.4	12.5 - 17	2	L
			Platelets (10 ⁹ /L)	336	140 - 415	0	
			Leukocytes (10 ⁹ /L)	20.4	4 - 10.5	0	H
			Neutrophils (10 ⁹ /L)	18.2	0 - 750	0	
			Lymphocytes (10 ⁹ /L)	0.7	0.7 - 4.5	2	
			Monocytes (10 ⁹ /L)	0.9	0.1 - 1		
			Neutrophils/Leukocytes (%)	88	40 - 74		H
			Lymphocytes/Leukocytes (%)	4	14 - 46		L
	Cycle 4 Day 1	2021-11-16/14:08 (69)	Monocytes/Leukocytes (%)	5	4 - 13		
			Hematocrit (%)	25.3	36 - 50		L
			Hemoglobin (g/dL)	8.7	12.5 - 17	2	L
			Platelets (10 ⁹ /L)	352	140 - 415	0	
			Leukocytes (10 ⁹ /L)	16.8	4 - 10.5	0	H
			Neutrophils (10 ⁹ /L)	15.2	0 - 750	0	

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
2011-2001 (continued)	Cycle 4 Day 1 (continued)	2021-11-16/14:08 (69) (continued)	Lymphocytes (10 ⁹ /L)	0.7	0.7 - 4.5	2	
			Monocytes (10 ⁹ /L)	0.5	0.1 - 1		
			Neutrophils/Leukocytes (%)	91	40 - 74		H
			Lymphocytes/Leukocytes (%)	4	14 - 46		L
			Monocytes/Leukocytes (%)	3	4 - 13		L
			Hematocrit (%)	26.9	36 - 50		L
3145-2005	Screening	2021-07-23/14:35 (-13)	Hemoglobin (g/dL)	12.5	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	200	140 - 400	0	
			Leukocytes (10 ⁹ /L)	6.5	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	3.634	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	1.989	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.449	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	55.9	40 - 70		
			Lymphocytes/Leukocytes (%)	30.6	22 - 44		
			Monocytes/Leukocytes (%)	6.9	4 - 11		
			Hematocrit (%)	36.5	38.5 - 50		L
	Cycle 1 Day 1	2021-08-04/14:56 (-1)	Hemoglobin (g/dL)	13.0*	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	333*	140 - 400	0	
			Leukocytes (10 ⁹ /L)	6.8*	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	4.379*	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	1.7*	0.85 - 3.9	0	

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2005 (continued)	Cycle 1 Day 1 (continued)	2021-08-04/14:56 (-1) (continued)	Monocytes (10 ⁹ /L)	0.551*	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	64.4*	40 - 70		
			Lymphocytes/Leukocytes (%)	25.0*	22 - 44		
			Monocytes/Leukocytes (%)	8.1*	4 - 11		
			Hematocrit (%)	38.0*	38.5 - 50		L
	Cycle 1 Day 5	2021-08-09/12:49 (5)	Hemoglobin (g/dL)	13.1	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	226	140 - 400	0	
			Leukocytes (10 ⁹ /L)	5.0	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	3.265	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	1.525	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.13	0.2 - 0.95		L
			Neutrophils/Leukocytes (%)	65.3	40 - 70		
			Lymphocytes/Leukocytes (%)	30.5	22 - 44		
			Monocytes/Leukocytes (%)	2.6	4 - 11		L
			Hematocrit (%)	38.3	38.5 - 50		L
	Cycle 1 Day 9	2021-08-13/10:19 (9)	Hemoglobin (g/dL)	11.7	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	233	140 - 400	0	
			Leukocytes (10 ⁹ /L)	2.3	3.8 - 10.8	2	L
			Neutrophils (10 ⁹ /L)	0.63	1.5 - 7.8	3	L
			Lymphocytes (10 ⁹ /L)	1.334	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.202	0.2 - 0.95		

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2005 (continued)	Cycle 1 Day 9 (continued)	2021-08-13/10:19 (9) (continued)	Neutrophils/Leukocytes (%)	27.4	40 - 70		L
			Lymphocytes/Leukocytes (%)	58	22 - 44		H
			Monocytes/Leukocytes (%)	8.8	4 - 11		
			Hematocrit (%)	34.4	38.5 - 50		L
	Cycle 1 Day 13	2021-08-16/15:35 (12)	Hemoglobin (g/dL)	11.4	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	234	140 - 400	0	
			Leukocytes (10 ⁹ /L)	2.8	3.8 - 10.8	2	L
			Neutrophils (10 ⁹ /L)	0.605	1.5 - 7.8	3	L
			Lymphocytes (10 ⁹ /L)	1.652	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.412	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	21.6	40 - 70		L
			Lymphocytes/Leukocytes (%)	59.0	22 - 44		H
			Monocytes/Leukocytes (%)	14.7	4 - 11		H
			Hematocrit (%)	33.1	38.5 - 50		L
	Cycle 1 Day 17	2021-08-20/10:43 (16)	Hemoglobin (g/dL)	12.7	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	266	140 - 400	0	
			Leukocytes (10 ⁹ /L)	5.0	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	2.235	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	2.02	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.535	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	44.7	40 - 70		

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2005 (continued)	Cycle 1 Day 17 (continued)	2021-08-20/10:43 (16) (continued)	Lymphocytes/Leukocytes (%)	40.4	22 - 44		
			Monocytes/Leukocytes (%)	10.7	4 - 11		
			Hematocrit (%)	39.0	38.5 - 50		
	Cycle 2 Day 1	2021-08-25/10:28 (21)	Hemoglobin (g/dL)	12.8	13.2 - 17.1	1	L
			Platelets (10 ⁹ /L)	349	140 - 400	0	
			Leukocytes (10 ⁹ /L)	8.2	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	4.83	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	2.386	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.672	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	58.9	40 - 70		
			Lymphocytes/Leukocytes (%)	29.1	22 - 44		
			Monocytes/Leukocytes (%)	8.2	4 - 11		
			Hematocrit (%)	37.6	38.5 - 50		L
	Unscheduled	2021-09-09/10:02 (36)	Hemoglobin (g/dL)	9.3	13.5 - 17.5	2	L
			Platelets (10 ⁹ /L)	441	150 - 350	0	H
			Leukocytes (10 ⁹ /L)	9.31	4.5 - 11	0	
	Post-Treatment Visit	2021-11-17/00:00 (105)	Hemoglobin (g/dL)	13.3	13.2 - 17.1	0	
			Platelets (10 ⁹ /L)	220	140 - 400	0	
			Leukocytes (10 ⁹ /L)	10.7	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	6.741	1.5 - 7.8	0	

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2005 (continued)	Post-Treatment Visit (continued)	2021-11-17/00:00 (105) (continued)	Lymphocytes (10 ⁹ /L)	2.921	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.653	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	63	40 - 70		
			Lymphocytes/Leukocytes (%)	27.3	22 - 44		
			Monocytes/Leukocytes (%)	6.1	4 - 11		
			Hematocrit (%)	39.0	38.5 - 50		
3145-2006	Screening	2021-07-28/10:45 (-14)	Hemoglobin (g/dL)	12.2	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	358	140 - 400	0	
			Leukocytes (10 ⁹ /L)	12.4	3.8 - 10.8	0	H
			Neutrophils (10 ⁹ /L)	6.485	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	5.158	0.85 - 3.9	2	H
			Monocytes (10 ⁹ /L)	0.508	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	52.3	40 - 70		
			Lymphocytes/Leukocytes (%)	41.6	22 - 44		
			Monocytes/Leukocytes (%)	4.1	4 - 11		
			Hematocrit (%)	36.5	35 - 45		
	Cycle 1 Day 1	2021-08-10/14:29 (-1)	Hemoglobin (g/dL)	12.1*	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	350*	140 - 400	0	
			Leukocytes (10 ⁹ /L)	11.9*	3.8 - 10.8	0	H
			Neutrophils (10 ⁹ /L)	4.76*	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	6.664*	0.85 - 3.9	2	H

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2006 (continued)	Cycle 1 Day 1 (continued)	2021-08-10/14:29 (-1) (continued)	Monocytes (10 ⁹ /L)	0.476*	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	40*	40 - 70		
			Lymphocytes/Leukocytes (%)	48*	22 - 44		H
			Monocytes/Leukocytes (%)	4*	4 - 11		
			Hematocrit (%)	37.5*	35 - 45		
	Cycle 1 Day 5	2021-08-17/12:57 (7)	Hemoglobin (g/dL)	11.3	11.7 - 15.5	1	L
			Platelets (10 ⁹ /L)	288	140 - 400	0	
			Leukocytes (10 ⁹ /L)	5.3	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	1.993	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	3.063	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.191	0.2 - 0.95		L
			Neutrophils/Leukocytes (%)	37.6	40 - 70		L
			Lymphocytes/Leukocytes (%)	57.8	22 - 44		H
			Monocytes/Leukocytes (%)	3.6	4 - 11		L
			Hematocrit (%)	34.2	35 - 45		L
	Cycle 1 Day 9	2021-08-20/12:45 (10)	Hemoglobin (g/dL)	11.4	11.7 - 15.5	1	L
			Platelets (10 ⁹ /L)	293	140 - 400	0	
			Leukocytes (10 ⁹ /L)	5.9	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	1.298	1.5 - 7.8	2	L
			Lymphocytes (10 ⁹ /L)	3.823	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.708	0.2 - 0.95		

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2006 (continued)	Cycle 1 Day 9 (continued)	2021-08-20/12:45 (10) (continued)	Neutrophils/Leukocytes (%)	22	40 - 70		L
			Lymphocytes/Leukocytes (%)	64.8	22 - 44		H
			Monocytes/Leukocytes (%)	12.0	4 - 11		H
			Hematocrit (%)	33.7	35 - 45		L
	Cycle 1 Day 13	2021-08-24/15:00 (14)	Hemoglobin (g/dL)	11.5	11.7 - 15.5	1	L
			Platelets (10 ⁹ /L)	300	140 - 400	0	
			Leukocytes (10 ⁹ /L)	7.9	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	1.999	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	4.598	0.85 - 3.9	2	H
			Monocytes (10 ⁹ /L)	0.988	0.2 - 0.95		H
			Neutrophils/Leukocytes (%)	25.3	40 - 70		L
			Lymphocytes/Leukocytes (%)	58.2	22 - 44		H
			Monocytes/Leukocytes (%)	12.5	4 - 11		H
			Hematocrit (%)	33.6	35 - 45		L
	Cycle 1 Day 17	2021-08-27/11:04 (17)	Hemoglobin (g/dL)	11.7	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	286	140 - 400	0	
			Leukocytes (10 ⁹ /L)	9.9	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	4.01	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	4.673	0.85 - 3.9	2	H
			Monocytes (10 ⁹ /L)	0.891	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	40.5	40 - 70		

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2006 (continued)	Cycle 1 Day 17 (continued)	2021-08-27/11:04 (17) (continued)	Lymphocytes/Leukocytes (%)	47.2	22 - 44		H
			Monocytes/Leukocytes (%)	9.0	4 - 11		
			Hematocrit (%)	35.0	35 - 45		
	Cycle 2 Day 1	2021-08-31/14:10 (21)	Hemoglobin (g/dL)	12.4	11.7 - 15.5	0	H
			Platelets (10 ⁹ /L)	333	140 - 400	0	
			Leukocytes (10 ⁹ /L)	13.3	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	5.972	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	6.078	0.85 - 3.9	2	
			Monocytes (10 ⁹ /L)	0.745	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	44.9	40 - 70		
			Lymphocytes/Leukocytes (%)	45.7	22 - 44		
			Monocytes/Leukocytes (%)	5.6	4 - 11		
			Hematocrit (%)	37.3	35 - 45		
	Cycle 3 Day 1	2021-09-22/09:53 (43)	Hemoglobin (g/dL)	12.5	11.7 - 15.5	0	H
			Platelets (10 ⁹ /L)	379	140 - 400	0	
			Leukocytes (10 ⁹ /L)	12.9	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	6.373	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	5.134	0.85 - 3.9	2	
			Monocytes (10 ⁹ /L)	1.148	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	49.4	40 - 70		
			Lymphocytes/Leukocytes (%)	39.8	22 - 44		

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard-ized Value	Normal Range	Toxicity Grade	Flag
3145-2006 (continued)	Cycle 3 Day 1 (continued)	2021-09-22/09:53 (43) (continued)	Monocytes/Leukocytes (%)	8.9	4 - 11		
			Hematocrit (%)	36.7	35 - 45		
	Cycle 4 Day 1	2021-10-12/12:30 (63)	Hemoglobin (g/dL)	11.7	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	361	140 - 400	0	
			Leukocytes (10 ⁹ /L)	13.2	3.8 - 10.8	0	H
			Neutrophils (10 ⁹ /L)	6.613	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	5.227	0.85 - 3.9	2	H
			Monocytes (10 ⁹ /L)	1.188	0.2 - 0.95		H
			Neutrophils/Leukocytes (%)	50.1	40 - 70		
			Lymphocytes/Leukocytes (%)	39.6	22 - 44		
			Monocytes/Leukocytes (%)	9.0	4 - 11		
			Hematocrit (%)	35.1	35 - 45		
	Unscheduled	2021-11-03/10:49 (85)	Hemoglobin (g/dL)	11.6	11.7 - 15.5	1	L
			Platelets (10 ⁹ /L)	359	140 - 400	0	
			Leukocytes (10 ⁹ /L)	13.7	3.8 - 10.8	0	H
			Neutrophils (10 ⁹ /L)	7.384	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	5.083	0.85 - 3.9	2	H
			Monocytes (10 ⁹ /L)	1.041	0.2 - 0.95		H
			Neutrophils/Leukocytes (%)	53.9	40 - 70		
			Lymphocytes/Leukocytes (%)	37.1	22 - 44		
			Monocytes/Leukocytes (%)	7.6	4 - 11		

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standardized Value	Normal Range	Toxicity Grade	Flag
3145-2006 (continued)	Unscheduled (continued)	2021-11-03/10:49 (85) (continued)	Hematocrit (%)	35.8	35 - 45		
	Post-Treatment Visit	2021-11-11/14:20 (93)	Hemoglobin (g/dL)	12.0	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	322	140 - 400	0	
			Leukocytes (10 ⁹ /L)	9.6	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	4.138	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	4.262	0.85 - 3.9	2	H
			Monocytes (10 ⁹ /L)	0.931	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	43.1	40 - 70		
			Lymphocytes/Leukocytes (%)	44.4	22 - 44		H
			Monocytes/Leukocytes (%)	9.7	4 - 11		
			Hematocrit (%)	36.5	35 - 45		
3145-2008	Screening	2021-09-17/13:40 (-20)	Hemoglobin (g/dL)	14.4	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	251	140 - 400	0	
			Leukocytes (10 ⁹ /L)	17.3	3.8 - 10.8	0	H
			Neutrophils (10 ⁹ /L)	9.307	1.5 - 7.8	0	H
			Lymphocytes (10 ⁹ /L)	6.712	0.85 - 3.9	2	H
			Monocytes (10 ⁹ /L)	1.159	0.2 - 0.95		H
			Neutrophils/Leukocytes (%)	53.8	40 - 70		
			Lymphocytes/Leukocytes (%)	38.8	22 - 44		
			Monocytes/Leukocytes (%)	6.7	4 - 11		

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standardized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Screening (continued)	2021-09-17/13:40 (-20) (continued)	Hematocrit (%)	42.0	35 - 45		
	Cycle 1 Day 1	2021-10-06/10:06 (-1)	Hemoglobin (g/dL)	13.9*	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	249*	140 - 400	0	
			Leukocytes (10 ⁹ /L)	13.1*	3.8 - 10.8	0	H
			Neutrophils (10 ⁹ /L)	6.065*	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	6.262*	0.85 - 3.9	2	H
			Monocytes (10 ⁹ /L)	0.655*	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	46.3*	40 - 70		
			Lymphocytes/Leukocytes (%)	47.8*	22 - 44		H
			Monocytes/Leukocytes (%)	5.0*	4 - 11		
			Hematocrit (%)	43.4*	35 - 45		
	Cycle 1 Day 5	2021-10-12/13:17 (6)	Hemoglobin (g/dL)	15.4	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	195	140 - 400	0	
			Leukocytes (10 ⁹ /L)	7.6	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	3.922	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	3.526	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.099	0.2 - 0.95		L
			Neutrophils/Leukocytes (%)	51.6	40 - 70		
			Lymphocytes/Leukocytes (%)	46.4	22 - 44		H
			Monocytes/Leukocytes (%)	1.3	4 - 11		L

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standardized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Cycle 1 Day 5 (continued)	2021-10-12/13:17 (6) (continued)	Hematocrit (%)	47.1	35 - 45		H
	Cycle 1 Day 9	2021-10-15/00:00 (9)	Hemoglobin (g/dL)	13.9	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	223	140 - 400	0	
			Leukocytes (10 ⁹ /L)	4.5	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	1.62	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	2.52	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.302	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	36	40 - 70		L
			Lymphocytes/Leukocytes (%)	56.0	22 - 44		H
			Monocytes/Leukocytes (%)	6.7	4 - 11		
			Hematocrit (%)	43.2	35 - 45		
	Cycle 1 Day 13	2021-10-19/11:30 (13)	Hemoglobin (g/dL)	14.2	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	222	140 - 400	0	
			Leukocytes (10 ⁹ /L)	8.8	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	3.74	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	3.678	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	1.329	0.2 - 0.95		H
			Neutrophils/Leukocytes (%)	42.5	40 - 70		
			Lymphocytes/Leukocytes (%)	41.8	22 - 44		
			Monocytes/Leukocytes (%)	15.1	4 - 11		H

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Cycle 1 Day 13 (continued)	2021-10-19/11:30 (13) (continued)	Hematocrit (%)	42.6	35 - 45		
	Cycle 1 Day 17	2021-10-22/10:48 (16)	Hemoglobin (g/dL)	14.5	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	200	140 - 400	0	
			Leukocytes (10 ⁹ /L)	13.8	3.8 - 10.8	0	H
			Neutrophils (10 ⁹ /L)	6.541	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	6.376	0.85 - 3.9	2	H
			Monocytes (10 ⁹ /L)	0.787	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	47.4	40 - 70		
			Lymphocytes/Leukocytes (%)	46.2	22 - 44		H
			Monocytes/Leukocytes (%)	5.7	4 - 11		
			Hematocrit (%)	46.0	35 - 45		H
	Cycle 2 Day 1	2021-10-27/11:25 (21)	Hemoglobin (g/dL)	14.6	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	260	140 - 400	0	
			Leukocytes (10 ⁹ /L)	21.0	3.8 - 10.8	0	H
			Neutrophils (10 ⁹ /L)	13.44	1.5 - 7.8	0	H
			Lymphocytes (10 ⁹ /L)	6.636	0.85 - 3.9	2	H
			Monocytes (10 ⁹ /L)	0.882	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	64	40 - 70		
			Lymphocytes/Leukocytes (%)	31.6	22 - 44		
			Monocytes/Leukocytes (%)	4.2	4 - 11		

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standardized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Cycle 2 Day 1 (continued)	2021-10-27/11:25 (21) (continued)	Hematocrit (%)	44.4	35 - 45		
	Unscheduled	2021-11-17/11:59 (42)	Hemoglobin (g/dL)	13.3	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	290	140 - 400	0	
			Leukocytes (10 ⁹ /L)	10.7	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	6.7	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	0.32	0.85 - 3.9	3	L
			Monocytes (10 ⁹ /L)	0.06	0.2 - 0.95		L
			Neutrophils/Leukocytes (%)	62.1	40 - 70		
			Lymphocytes/Leukocytes (%)	30.0	22 - 44		
			Monocytes/Leukocytes (%)	5.5	4 - 11		
			Hematocrit (%)	42.6	35 - 45		
	Cycle 3 Day 1	2021-11-18/11:37 (43)	Hemoglobin (g/dL)	13.4	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	284	140 - 400	0	
			Leukocytes (10 ⁹ /L)	10.9	3.8 - 10.8	0	H
			Neutrophils (10 ⁹ /L)	6.289	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	3.728	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.774	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	57.7	40 - 70		
			Lymphocytes/Leukocytes (%)	34.2	22 - 44		
			Monocytes/Leukocytes (%)	7.1	4 - 11		

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standardized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Cycle 3 Day 1 (continued)	2021-11-18/11:37 (43) (continued)	Hematocrit (%)	41.6	35 - 45		
	Cycle 4 Day 1	2021-12-09/13:27 (64)	Hemoglobin (g/dL)	13.6	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	255	140 - 400	0	
			Leukocytes (10 ⁹ /L)	12.7	3.8 - 10.8	0	H
			Neutrophils (10 ⁹ /L)	8.3	1.5 - 7.8	0	H
			Lymphocytes (10 ⁹ /L)	3.4	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.8	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	65.3	40 - 70		
			Lymphocytes/Leukocytes (%)	26.9	22 - 44		
			Monocytes/Leukocytes (%)	5.9	4 - 11		
			Hematocrit (%)	44.5	35 - 45		
	Cycle 5 Day 1	2021-12-29/15:00 (84)	Hemoglobin (g/dL)	12.7	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	244	140 - 400	0	
			Leukocytes (10 ⁹ /L)	10.5	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	6.132	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	3.15	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.851	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	58.4	40 - 70		
			Lymphocytes/Leukocytes (%)	30.0	22 - 44		
			Monocytes/Leukocytes (%)	8.1	4 - 11		

* Baseline value.

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standardized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Cycle 5 Day 1 (continued)	2021-12-29/15:00 (84) (continued)	Hematocrit (%)	37.8	35 - 45		
	Unscheduled	2022-01-19/11:44 (105)	Hemoglobin (g/dL)	12.1	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	294	140 - 400	0	
			Leukocytes (10 ⁹ /L)	20.1	3.8 - 10.8	0	H
			Neutrophils (10 ⁹ /L)	13.869	1.5 - 7.8	0	H
			Lymphocytes (10 ⁹ /L)	4.864	0.85 - 3.9	2	H
			Monocytes (10 ⁹ /L)	1.206	0.2 - 0.95		H
			Neutrophils/Leukocytes (%)	69	40 - 70		
			Lymphocytes/Leukocytes (%)	24.2	22 - 44		
			Monocytes/Leukocytes (%)	6.0	4 - 11		
			Hematocrit (%)	37.0	35 - 45		
	Post-Treatment Visit	2022-02-02/12:30 (119)	Hemoglobin (g/dL)	12.4	11.7 - 15.5	0	
			Platelets (10 ⁹ /L)	313	140 - 400	0	
			Leukocytes (10 ⁹ /L)	8.9	3.8 - 10.8	0	
			Neutrophils (10 ⁹ /L)	7.209	1.5 - 7.8	0	
			Lymphocytes (10 ⁹ /L)	1.202	0.85 - 3.9	0	
			Monocytes (10 ⁹ /L)	0.223	0.2 - 0.95		
			Neutrophils/Leukocytes (%)	81	40 - 70		H
			Lymphocytes/Leukocytes (%)	13.5	22 - 44		L
			Monocytes/Leukocytes (%)	2.5	4 - 11		L

* Baseline value.

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.7.2
Laboratory Values - Hematology
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Date/Time (Study Day)	Lab Test (unit)	Standard- ized Value	Normal Range	Toxicity Grade	Flag
3145-2008 (continued)	Post-Treatment Visit (continued)	2022-02-02/12:30 (119) (continued)	Hematocrit (%)	38.5	35 - 45		

* Baseline value.

Program: 1-lb-hem.sas

2022-06-08 10:02

Page 35 of 35

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.8
Pregnancy Test
All Randomized Patients

Treatment: Placebo					
Subject Number	Visit	Pregnancy Test Performed?	Date	Type	Result
3145-2007	Randomization Cycle 1 Day 1	Yes No	2021-08-24	SERUM	NEGATIVE

Listing: 16.2.8
Pregnancy Test
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Pregnancy Test Performed?	Date	Type	Result
3145-2006	Randomization	Yes	2021-08-10	SERUM	NEGATIVE
	Cycle 1 Day 1	Yes	2021-08-10	SERUM	NEGATIVE
	Cycle 2 Day 1	Yes	2021-08-31	SERUM	NEGATIVE
	Cycle 3 Day 1	Yes	2021-09-22	SERUM	NEGATIVE
	Cycle 4 Day 1	Yes	2021-10-12	SERUM	NEGATIVE
	Unscheduled	Yes	2021-11-03	SERUM	NEGATIVE
	Post-Treatment Visit	Yes	2021-11-11	SERUM	NEGATIVE
3145-2008	Randomization	Yes	2021-10-06	SERUM	NEGATIVE
	Cycle 1 Day 1	Yes	2021-10-06	SERUM	NEGATIVE
	Cycle 2 Day 1	Yes	2021-10-27	SERUM	NEGATIVE
	Cycle 3 Day 1	Yes	2021-11-17	URINE	NEGATIVE
	Unscheduled	Yes	2021-11-17	SERUM	NEGATIVE
	Cycle 4 Day 1	Yes	2021-12-09	SERUM	NEGATIVE
	Cycle 5 Day 1	Yes	2021-12-29	SERUM	NEGATIVE
	Unscheduled	Yes	2022-01-19	SERUM	NEGATIVE
	Post-Treatment Visit	Yes	2022-02-02	SERUM	NEGATIVE

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Placebo

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2004	Screening	Yes	2021-07-21 (-21)	165.1	73.0	1.8	127/72	91	37.3
	Cycle 1 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-08-11/ 11:53 (1)		73.0	1.8	115/72	70	37.1
	Cycle 1 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-08-11/ 12:15 (1)		73.0	1.8	123/71	67	36.8
	Unscheduled 13.01	Yes	2021-08-19/ 09:00 (9)		73.9		108/61	73	36.8

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 1 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Placebo

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2004 (continued)	Unscheduled 15.03	Yes	2021-09-01/ 09:46 (22)		74.8	1.82	143/71	116	36.7
	Unscheduled 15.04	Yes	2021-09-10/ 13:30 (31)		73.6		109/75	104	36.4
	Cycle 2 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-09-15/ 12:10 (36)		73.5	1.81	133/70	67	36.5
	Cycle 2 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-09-15/ 12:27 (36)		73.5	1.81	131/76	66	36.6

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 2 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Placebo

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2004 (continued)	Cycle 3 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-10-06/ 11:39 (57)		76.7	1.84	105/63	63	36.8
	Cycle 3 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-10-06/ 11:54 (57)		76.7	1.84	102/65	96	36.8
	Cycle 4 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-10-27/ 12:40 (78)		76.7	1.84	115/53	78	36.8

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 3 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Placebo

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2004 (continued)	Cycle 4 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-10-27/ 12:58 (78)		76.7	1.84	140/70	72	36.7
	Post-Treatment Visit	Yes	2021-11-12/ 09:58 (94)		80.3	1.77	117/63	82	36.8
3145-2007	Screening	Yes	2021-08-18 (-7)	170.2	74.2	1.86	131/76	84	36.6
	Cycle 1 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-08-25/ 12:05 (1)		73.9	1.81	105/64	80	36.7

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 4 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Placebo

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2007 (continued)	Cycle 1 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-08-25/ 13:00 (1)		73.9	1.81	106/68	77	36.8
3145-2501	Screening	Yes	2021-05-28 (-6)	187	112	2.33	110/75	94	36.7
	Cycle 1 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-06-03/ 14:21 (1)		112	2.38	128/85	90	36.8
	Cycle 1 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-06-03/ 16:00 (1)		112	2.38	130/75	88	36.3

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 5 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Placebo

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2501 (continued)	Unscheduled 10.01	Yes	2021-06-04/ 15:30 (2)		112.5		110/75	94	36.8
	Cycle 2 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-06-24/ 13:00 (22)		112.4	2.41	97/68	86	36.3
	Cycle 2 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-06-24/ 13:34 (22)		112.4	2.41	94/65	85	36.3

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 6 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Placebo

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2501 (continued)	Cycle 3 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-07-15/ 16:53 (43)		115	2.40	121/88	87	36.7
	Cycle 3 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-07-15/ 17:10 (43)		115	2.40	114/71	85	36.9
	Unscheduled 31.02	Yes	2021-08-05/ 11:00 (64)		117	2.42	120/76	90	36.6

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 7 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Placebo

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2501 (continued)	Cycle 4 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-08-18/ 16:28 (77)		113.9	2.39	96/69	82	36.7
	Cycle 4 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-08-18/ 16:52 (77)		113.9	2.39	94/63	82	37.2
	Unscheduled 41.01	Yes	2021-08-26/ 10:00 (85)		110.6	2.36	65/34	104	36.4

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 8 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Placebo

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2501 (continued)	Cycle 5 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-09-08/ 15:39 (98)		110.7	2.37	102/76	91	36.6
	Cycle 5 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-09-08/ 16:00 (98)		110.7	2.37	117/75	89	36.6
	Unscheduled 51.01	Yes	2021-09-10/ 13:32 (100)		111.8		106/56	107	36.6
	Unscheduled 51.02	Yes	2021-09-17/ 14:34 (107)		113.9	2.35	74/47	103	36.9

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 9 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Placebo

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2501 (continued)	Unscheduled 51.03	Yes	2021-09-22/ 14:40 (112)		114.5	2.40	97/70	100	36.7
	Unscheduled 51.04	Yes	2021-09-24/ 14:01 (114)		115.5	2.41	100/72	107	36.7
	Unscheduled 51.06	Yes	2021-09-29/ 10:30 (119)		114	2.4	118/73	104	36.3

BSA = body surface area; BP = blood pressure

Program: 1-vs.sas

2022-05-24 10:12

Page 10 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
2011-2001	Screening	Yes	2021-08-18 (-22)	168.9	46.7	1.52	91/49	59	36.2
	Cycle 1 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-09-09/ 10:55 (1)		47.9	1.53	119/70	68	36.1
	Cycle 1 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-09-09/ 11:56 (1)		47.9	1.53	119/70	79	36.3
	Cycle 2 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-10-06/ 10:40 (28)		47.3	1.52	120/74	101	37.1

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 11 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
2011-2001 (continued)	Cycle 2 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-10-06/ 11:25 (28)		47.3	1.52	127/76	92	37.1
	Cycle 3 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-10-27/ 09:30 (49)		45	1.49	112/60	70	36.2
	Cycle 3 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-10-27/ 11:43 (49)		45	1.49	110/67	69	36.9

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 12 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
2011-2001 (continued)	Cycle 4 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-11-17/ 09:25 (70)		40.5	1.43	118/72	74	36.2
	Cycle 4 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-11-17/ 10:08 (70)		40.5	1.43	124/75	76	36.8
3145-2005	Screening	Yes	2021-07-23 (-13)	167.6	65.3	1.74	138/77	62	36.2
	Cycle 1 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-08-05/ 11:20 (1)		64	1.72	153/77	56	36.8

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 13 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2005 (continued)	Cycle 1 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-08-05/ 11:45 (1)		64	1.72	127/71	57	36.6
	Cycle 2 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-08-26/ 12:30 (22)		63.5	1.72	148/73	80	36.6
	Cycle 2 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-08-26/ 13:06 (22)		63.5	1.72	143/81	66	36.6

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 14 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2005 (continued)	Post-Treatment Visit	Yes	2021-11-17/ 12:17 (105)		53.1	1.59	134/81	75	36.4
3145-2006	Screening	Yes	2021-07-28 (-14)	156.2	68.0	1.68	122/70	83	36.5
	Cycle 1 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-08-11/ 11:55 (1)		68.0	1.68	118/72	73	36.9
	Cycle 1 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-08-11/ 12:20 (1)		68.0	1.68	115/71	81	36.6

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 15 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2006 (continued)	Unscheduled 13.01	Yes	2021-08-20/ 11:00 (10)		67.1		120/69	86	36.9
	Unscheduled 14.01	Yes	2021-08-24/ 12:15 (14)		67.6		129/74	75	36.7
	Unscheduled 15.01	Yes	2021-08-27/ 10:30 (17)		66.7	1.67	148/83	75	37.1
	Cycle 2 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-09-01/ 12:02 (22)		66.2	1.67	127/73	71	36.8

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 16 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2006 (continued)	Cycle 2 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-09-01/ 12:18 (22)		66.2	1.67	133/89	78	36.8
	Unscheduled 21.01	Yes	2021-09-10/ 14:00 (31)		66.2	1.67	121/76	89	36.9
	Cycle 3 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-09-22/ 14:04 (43)		66.2	1.66	128/71	66	36.7

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 17 of 23

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2006 (continued)	Cycle 3 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-09-22/ 14:25 (43)		66.2	1.66	134/88	78	36.7
	Cycle 4 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-10-13/ 11:42 (64)		68.9	1.69	129/68	80	36.8
	Cycle 4 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-10-13/ 12:19 (64)		68.9	1.69	113/64	77	36.8

BSA = body surface area; BP = blood pressure

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2006 (continued)	Unscheduled 50.01	Yes	2021-11-03/ 09:45 (85)		69.8	1.71	114/52	95	36.9
	Post-Treatment Visit	Yes	2021-11-11/ 14:57 (93)		68.0	1.69	128/78	78	36.7
3145-2008	Screening	Yes	2021-09-17 (-20)	170.2	68.9	1.80	154/87	43	36.9
	Cycle 1 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-10-07/ 12:44 (1)		70.8	1.82	151/81	47	36.9

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 19 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2008 (continued)	Cycle 1 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-10-07/ 13:00 (1)		70.8	1.82	137/80	61	36.8
	Unscheduled 13.01	Yes	2021-10-15/ 12:23 (9)		68.9	1.80	125/78	75	37.1
	Unscheduled 14.01	Yes	2021-10-19/ 11:57 (13)		71.7	1.83	177/90	69	36.8
	Cycle 2 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-10-28/ 13:50 (22)		70.8	1.82	134/76	53	36.7

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 20 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2008 (continued)	Cycle 2 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-10-28/ 14:10 (22)		70.8	1.82	105/68	60	37
	Cycle 3 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-11-19/ 13:15 (44)		69.8	1.8	124/80	72	37.6
	Cycle 3 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-11-19/ 13:36 (44)		69.8	1.8	132/71	45	37.3

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 21 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2008 (continued)	Cycle 4 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-12-10/ 14:05 (65)		69.3	1.8	113/68	55	36.9
	Cycle 4 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-12-10/ 14:28 (65)		69.3	1.8	122/68	55	37.0
	Cycle 5 Day 1, 15 minutes before trilaciclib/ placebo infusion	Yes	2021-12-30/ 13:52 (85)		75.2	1.8	141/65	48	36.8

BSA = body surface area; BP = blood pressure

Program: l-vs.sas

2022-05-24 10:12

Page 22 of 23

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.9
Vital Signs
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit, Timepoint	Vital Signs Performed?	Vitals Date/ Time (Study Day)	Height (cm)	Weight (kg)	BSA (m2)	Systolic/ Diastolic BP (mmHg)	Heart Rate (beats/min)	Temperature (C)
3145-2008 (continued)	Cycle 5 Day 1, 15 minutes after trilaciclib/ placebo infusion	Yes	2021-12-30/ 14:07 (85)		75.2	1.8	134/67	56	36.8
	Post-Treatment Visit	Yes	2022-02-02/ 11:17 (119)		73.5	1.85	132/66	70	36.9

BSA = body surface area; BP = blood pressure

Program: 1-vs.sas

2022-05-24 10:12

Page 23 of 23

Listing: 16.2.10
12-Lead Electrocardiograms
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	ECG Performed?	ECG Date/Time (Study Day)	Parameter	Result	Result Clinically Significant?
3145-2004	Screening	Yes	2021-07-26/12:55 (-16)	ECG Mean Heart Rate (beats/min)	65	
				PR Interval, Aggregate (msec)	174	
				QRS Duration, Aggregate (msec)	84	
				QT Interval, Aggregate (msec)	380	
				RR Interval, Aggregate (msec)	937	
				QTcF Interval, Aggregate (msec)	388	
				ECG Interpretation	Normal	
	Cycle 1 Day 1	Yes	2021-08-11/11:15 (1)	ECG Mean Heart Rate (beats/min)	65	
				PR Interval, Aggregate (msec)	180	
				QRS Duration, Aggregate (msec)	80	
				QT Interval, Aggregate (msec)	374	
				RR Interval, Aggregate (msec)	937	
				QTcF Interval, Aggregate (msec)	382	
				ECG Interpretation	Normal	
		Yes	2021-08-11/12:59 (1)	ECG Mean Heart Rate (beats/min)	64	
				PR Interval, Aggregate (msec)	182	
				QRS Duration, Aggregate (msec)	80	
				QT Interval, Aggregate (msec)	404	
				RR Interval, Aggregate (msec)	952	
				QTcF Interval, Aggregate (msec)	404	
				ECG Interpretation	Normal	

Listing: 16.2.10
12-Lead Electrocardiograms
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	ECG Performed?	ECG Date/Time (Study Day)	Parameter	Result	Result Clinically Significant?
3145-2004 (continued)	Unscheduled 15.04	Yes	2021-09-10/13:11 (31)	ECG Mean Heart Rate (beats/min)	93	
				PR Interval, Aggregate (msec)	184	
				QRS Duration, Aggregate (msec)	80	
				QT Interval, Aggregate (msec)	336	
				RR Interval, Aggregate (msec)	652	
				QTcF Interval, Aggregate (msec)	387	
				ECG Interpretation	Normal	
	Cycle 2 Day 1	Yes	2021-09-15/10:54 (36)	ECG Mean Heart Rate (beats/min)	78	
				PR Interval, Aggregate (msec)	174	
				QRS Duration, Aggregate (msec)	80	
				QT Interval, Aggregate (msec)	346	
				RR Interval, Aggregate (msec)	779	
				QTcF Interval, Aggregate (msec)	376	
				ECG Interpretation	Normal	
		Yes	2021-09-15/13:03 (36)	ECG Mean Heart Rate (beats/min)	59	
				PR Interval, Aggregate (msec)	190	
				QRS Duration, Aggregate (msec)	84	
				QT Interval, Aggregate (msec)	402	
				RR Interval, Aggregate (msec)	1034	
				QTcF Interval, Aggregate (msec)	397	
				ECG Interpretation	Normal	No

Listing: 16.2.10
12-Lead Electrocardiograms
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	ECG Performed?	ECG Date/Time (Study Day)	Parameter	Result	Result Clinically Significant?
3145-2007	Screening	Yes	2021-08-18/14:52 (-7)	ECG Mean Heart Rate (beats/min)	75	
				PR Interval, Aggregate (msec)	120	
				QRS Duration, Aggregate (msec)	82	
				QT Interval, Aggregate (msec)	406	
				RR Interval, Aggregate (msec)	800	
				QTcF Interval, Aggregate (msec)	437	
				ECG Interpretation	Normal	
	Cycle 1 Day 1	Yes	2021-08-25/10:43 (1)	ECG Mean Heart Rate (beats/min)	78	
				PR Interval, Aggregate (msec)	112	
				QRS Duration, Aggregate (msec)	90	
				QT Interval, Aggregate (msec)	410	
				RR Interval, Aggregate (msec)	779	
				QTcF Interval, Aggregate (msec)	445	
				ECG Interpretation	Abnormal	No
		Yes	2021-08-25/12:51 (1)	ECG Mean Heart Rate (beats/min)	78	
				PR Interval, Aggregate (msec)	126	
				QRS Duration, Aggregate (msec)	82	
				QT Interval, Aggregate (msec)	420	
				RR Interval, Aggregate (msec)	779	
				QTcF Interval, Aggregate (msec)	456	
				ECG Interpretation	Normal	

Listing: 16.2.10
12-Lead Electrocardiograms
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	ECG Performed?	ECG Date/Time (Study Day)	Parameter	Result	Result Clinically Significant?
3145-2501	Screening	Yes	2021-05-28/12:42 (-6)	ECG Mean Heart Rate (beats/min)	84	Yes: SINUS RHYTHM, LEFTWARD AXIS, RIGHT BUNDLE BRANCH BLOCK
				PR Interval, Aggregate (msec)	150	
				QRS Duration, Aggregate (msec)	106	
				QT Interval, Aggregate (msec)	386	
				RR Interval, Aggregate (msec)	722	
				QTcF Interval, Aggregate (msec)	430	
				ECG Interpretation	Abnormal	
	Cycle 1 Day 1	Yes	2021-06-03/11:24 (1)	ECG Mean Heart Rate (beats/min)	92	No
				PR Interval, Aggregate		
				QRS Duration, Aggregate		
				QT Interval, Aggregate		
				RR Interval, Aggregate (msec)	659	
				QTcF Interval, Aggregate		
				ECG Interpretation	Abnormal	
		Yes	2021-06-03/17:41 (1)	ECG Mean Heart Rate (beats/min)	85	
				PR Interval, Aggregate (msec)	154	
				QRS Duration, Aggregate (msec)	100	
				QT Interval, Aggregate (msec)	432	
				RR Interval, Aggregate (msec)	714	

Listing: 16.2.10
12-Lead Electrocardiograms
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	ECG Performed?	ECG Date/Time (Study Day)	Parameter	Result	Result Clinically Significant?
3145-2501 (continued)	Cycle 2 Day 1	Yes	2021-06-24/11:27 (22)	QTcF Interval, Aggregate(msec)	483	No
				ECG Interpretation	Abnormal	
				ECG Mean Heart Rate(beats/min)	82	
				PR Interval, Aggregate(msec)	150	
				QRS Duration, Aggregate(msec)	82	
				QT Interval, Aggregate(msec)	396	
				RR Interval, Aggregate(msec)	740	
				QTcF Interval, Aggregate(msec)	437	
		Yes	2021-06-24/14:12 (22)	ECG Interpretation	Abnormal	No
				ECG Mean Heart Rate(beats/min)	86	
				PR Interval, Aggregate(msec)	146	
				QRS Duration, Aggregate(msec)	106	
				QT Interval, Aggregate(msec)	394	
				RR Interval, Aggregate(msec)	705	
				QTcF Interval, Aggregate(msec)	442	
				ECG Interpretation	Abnormal	

Listing: 16.2.10
12-Lead Electrocardiograms
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	ECG Performed?	ECG Date/Time (Study Day)	Parameter	Result	Result Clinically Significant?
2011-2001	Screening	Yes	2021-08-18/14:38 (-22)	ECG Mean Heart Rate (beats/min)	84	
				PR Interval, Aggregate (msec)	153	
				QRS Duration, Aggregate (msec)	90	
				QT Interval, Aggregate (msec)	384	
				RR Interval, Aggregate (msec)	714	
				QTcF Interval, Aggregate (msec)	429	
				ECG Interpretation	Abnormal	
	Cycle 1 Day 1	Yes	2021-09-09/08:50 (1)	ECG Mean Heart Rate (beats/min)	106	
				PR Interval, Aggregate (msec)	142	
				QRS Duration, Aggregate (msec)	94	
				QT Interval, Aggregate (msec)	299	
				RR Interval, Aggregate (msec)	566	
				QTcF Interval, Aggregate (msec)	361	
				ECG Interpretation	Abnormal	
		Yes	2021-09-09/11:58 (1)	ECG Mean Heart Rate (beats/min)	93	
				PR Interval, Aggregate (msec)	149	
				QRS Duration, Aggregate (msec)	89	
				QT Interval, Aggregate (msec)	314	
				RR Interval, Aggregate (msec)	645	
				QTcF Interval, Aggregate (msec)	363	
				ECG Interpretation	Abnormal	

Listing: 16.2.10
12-Lead Electrocardiograms
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	ECG Performed?	ECG Date/Time (Study Day)	Parameter	Result	Result Clinically Significant?
2011-2001 (continued)	Cycle 2 Day 1	Yes	2021-10-06/09:35 (28)	ECG Mean Heart Rate (beats/min)	115	No
				PR Interval, Aggregate (msec)	134	
				QRS Duration, Aggregate (msec)	93	
				QT Interval, Aggregate (msec)	301	
				RR Interval, Aggregate (msec)	522	
				QTcF Interval, Aggregate (msec)	374	
				ECG Interpretation	Abnormal	
		Yes	2021-10-06/11:48 (28)	ECG Mean Heart Rate (beats/min)	95	
				PR Interval, Aggregate (msec)	137	
				QRS Duration, Aggregate (msec)	92	
				QT Interval, Aggregate (msec)	340	
				RR Interval, Aggregate (msec)	632	
				QTcF Interval, Aggregate (msec)	396	
				ECG Interpretation	Normal	
3145-2005	Screening	Yes	2021-07-28/13:56 (-8)	ECG Mean Heart Rate (beats/min)	53	No
				PR Interval, Aggregate (msec)	194	
				QRS Duration, Aggregate (msec)	120	
				QT Interval, Aggregate (msec)	482	
				RR Interval, Aggregate (msec)	1153	
				QTcF Interval, Aggregate (msec)	459	
				ECG Interpretation	Abnormal	

Listing: 16.2.10
12-Lead Electrocardiograms
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	ECG Performed?	ECG Date/Time (Study Day)	Parameter	Result	Result Clinically Significant?
3145-2005 (continued)	Cycle 1 Day 1	Yes	2021-08-05/10:54 (1)	ECG Mean Heart Rate (beats/min)	54	
				PR Interval, Aggregate (msec)	236	
				QRS Duration, Aggregate (msec)	128	
				QT Interval, Aggregate (msec)	494	
				RR Interval, Aggregate (msec)	1132	
				QTcF Interval, Aggregate (msec)	473	
				ECG Interpretation	Abnormal	No
	Cycle 1 Day 1	Yes	2021-08-05/12:08 (1)	ECG Mean Heart Rate (beats/min)	63	
				PR Interval, Aggregate (msec)	214	
				QRS Duration, Aggregate (msec)	96	
				QT Interval, Aggregate (msec)	466	
				RR Interval, Aggregate (msec)	967	
				QTcF Interval, Aggregate (msec)	471	
				ECG Interpretation	Abnormal	No
	Cycle 2 Day 1	Yes	2021-08-26/11:08 (22)	ECG Mean Heart Rate (beats/min)	70	
				PR Interval, Aggregate (msec)	188	
				QRS Duration, Aggregate (msec)	110	
				QT Interval, Aggregate (msec)	458	
				RR Interval, Aggregate (msec)	869	
				QTcF Interval, Aggregate (msec)	479	
				ECG Interpretation	Abnormal	No

Listing: 16.2.10
12-Lead Electrocardiograms
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	ECG Performed?	ECG Date/Time (Study Day)	Parameter	Result	Result Clinically Significant?
3145-2005 (continued)		Yes	2021-08-26/13:22 (22)	ECG Mean Heart Rate (beats/min)	72	No
				PR Interval, Aggregate (msec)	204	
				QRS Duration, Aggregate (msec)	118	
				QT Interval, Aggregate (msec)	452	
				RR Interval, Aggregate (msec)	845	
				QTcF Interval, Aggregate (msec)	478	
				ECG Interpretation	Abnormal	
3145-2006	Screening	Yes	2021-07-28/09:53 (-14)	ECG Mean Heart Rate (beats/min)	83	
				PR Interval, Aggregate (msec)	156	
				QRS Duration, Aggregate (msec)	96	
				QT Interval, Aggregate (msec)	392	
				RR Interval, Aggregate (msec)	731	
				QTcF Interval, Aggregate (msec)	435	
				ECG Interpretation	Normal	
	Cycle 1 Day 1	Yes	2021-08-11/10:50 (1)	ECG Mean Heart Rate (beats/min)	80	
				PR Interval, Aggregate (msec)	166	
				QRS Duration, Aggregate (msec)	88	
				QT Interval, Aggregate (msec)	400	
				RR Interval, Aggregate (msec)	759	
				QTcF Interval, Aggregate (msec)	438	
				ECG Interpretation	Normal	

Listing: 16.2.10
12-Lead Electrocardiograms
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	ECG Performed?	ECG Date/Time (Study Day)	Parameter	Result	Result Clinically Significant?
3145-2006 (continued)		Yes	2021-08-11/12:55 (1)	ECG Mean Heart Rate (beats/min)	80	
				PR Interval, Aggregate (msec)	190	
				QRS Duration, Aggregate (msec)	88	
				QT Interval, Aggregate (msec)	434	
				RR Interval, Aggregate (msec)	759	
				QTcF Interval, Aggregate (msec)	434	
				ECG Interpretation	Normal	
	Cycle 2 Day 1	Yes	2021-09-01/11:14 (22)	ECG Mean Heart Rate (beats/min)	80	
				PR Interval, Aggregate (msec)	182	
				QRS Duration, Aggregate (msec)	86	
				QT Interval, Aggregate (msec)	402	
				RR Interval, Aggregate (msec)	750	
				QTcF Interval, Aggregate (msec)	442	
				ECG Interpretation	Normal	
		Yes	2021-09-01/12:37 (22)	ECG Mean Heart Rate (beats/min)	79	
				PR Interval, Aggregate (msec)	194	
				QRS Duration, Aggregate (msec)	88	
				QT Interval, Aggregate (msec)	414	
				RR Interval, Aggregate (msec)	769	
				QTcF Interval, Aggregate (msec)	451	
				ECG Interpretation	Normal	

Listing: 16.2.10
12-Lead Electrocardiograms
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	ECG Performed?	ECG Date/Time (Study Day)	Parameter	Result	Result Clinically Significant?
3145-2008	Screening	Yes	2021-10-01/12:28 (-6)	ECG Mean Heart Rate (beats/min)	53	
				PR Interval, Aggregate (msec)	160	
				QRS Duration, Aggregate (msec)	82	
				QT Interval, Aggregate (msec)	444	
				RR Interval, Aggregate (msec)	1153	
				QTcF Interval, Aggregate (msec)	423	
				ECG Interpretation	Normal	
	Cycle 1 Day 1	Yes	2021-10-07/12:33 (1)	ECG Mean Heart Rate (beats/min)	53	
				PR Interval, Aggregate (msec)	158	
				QRS Duration, Aggregate (msec)	88	
				QT Interval, Aggregate (msec)	466	
				RR Interval, Aggregate (msec)	1153	
				QTcF Interval, Aggregate (msec)	444	
				ECG Interpretation	Normal	
		Yes	2021-10-07/13:27 (1)	ECG Mean Heart Rate (beats/min)	69	
				PR Interval, Aggregate (msec)	168	
				QRS Duration, Aggregate (msec)	78	
				QT Interval, Aggregate (msec)	414	
				RR Interval, Aggregate (msec)	882	
				QTcF Interval, Aggregate (msec)	431	
				ECG Interpretation	Normal	

Listing: 16.2.10
12-Lead Electrocardiograms
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	ECG Performed?	ECG Date/Time (Study Day)	Parameter	Result	Result Clinically Significant?
3145-2008 (continued)	Cycle 2 Day 1	Yes	2021-10-28/12:51 (22)	ECG Mean Heart Rate (beats/min)	57	
				PR Interval, Aggregate (msec)	158	
				QRS Duration, Aggregate (msec)	80	
				QT Interval, Aggregate (msec)	438	
				RR Interval, Aggregate (msec)	1071	
				QTcF Interval, Aggregate (msec)	428	
				ECG Interpretation	Abnormal	No
		Yes	2021-10-28/14:44 (22)	ECG Mean Heart Rate (beats/min)	64	
				PR Interval, Aggregate (msec)	162	
				QRS Duration, Aggregate (msec)	78	
				QT Interval, Aggregate (msec)	406	
				RR Interval, Aggregate (msec)	952	
				QTcF Interval, Aggregate (msec)	412	
				ECG Interpretation	Abnormal	No

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.11
ECOG Performance Status
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	ECOG Performed?	Date of Assessment (Study Day)	ECOG Performance Status
3145-2004	Screening	Yes	2021-07-21 (-21)	1
	Cycle 1 Day 1	Yes	2021-08-11 (1)	1
	Unscheduled	Yes	2021-09-01 (22)	1
	Unscheduled	Yes	2021-09-10 (31)	1
	Cycle 2 Day 1	Yes	2021-09-15 (36)	1
	Cycle 3 Day 1	Yes	2021-10-06 (57)	1
	Cycle 4 Day 1	Yes	2021-10-27 (78)	1
	Post-Treatment Visit	Yes	2021-11-12 (94)	1
3145-2007	Screening	Yes	2021-08-18 (-7)	1
	Cycle 1 Day 1	Yes	2021-08-25 (1)	1
3145-2501	Screening	Yes	2021-05-28 (-6)	0
	Cycle 1 Day 1	Yes	2021-06-03 (1)	0
	Unscheduled	Yes	2021-06-04 (2)	0
	Cycle 2 Day 1	Yes	2021-06-24 (22)	0
	Cycle 3 Day 1	Yes	2021-07-15 (43)	0
	Unscheduled	Yes	2021-08-05 (64)	0
	Cycle 4 Day 1	Yes	2021-08-18 (77)	0
	Unscheduled	Yes	2021-08-26 (85)	1
	Cycle 5 Day 1	Yes	2021-09-08 (98)	1
	Unscheduled	Yes	2021-09-10 (100)	1
	Unscheduled	Yes	2021-09-17 (107)	1
	Unscheduled	Yes	2021-09-22 (112)	1
	Unscheduled	Yes	2021-09-24 (114)	1
	Unscheduled	Yes	2021-09-29 (119)	1

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.11
ECOG Performance Status
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	ECOG Performed?	Date of Assessment (Study Day)	ECOG Performance Status
2011-2001	Screening	Yes	2021-08-18 (-22)	2
	Cycle 1 Day 1	Yes	2021-09-09 (1)	2
	Cycle 2 Day 1	Yes	2021-10-06 (28)	2
	Cycle 3 Day 1	Yes	2021-10-27 (49)	2
	Cycle 4 Day 1	Yes	2021-11-17 (70)	2
3145-2005	Screening	Yes	2021-07-23 (-13)	1
	Cycle 1 Day 1	Yes	2021-08-05 (1)	1
	Cycle 2 Day 1	Yes	2021-08-26 (22)	1
	Post-Treatment Visit	Yes	2021-11-17 (105)	1
3145-2006	Screening	Yes	2021-07-26 (-16)	0
	Cycle 1 Day 1	Yes	2021-08-11 (1)	1
	Cycle 2 Day 1	Yes	2021-09-01 (22)	1
	Unscheduled	Yes	2021-09-10 (31)	1
	Cycle 3 Day 1	Yes	2021-09-22 (43)	1
	Cycle 4 Day 1	Yes	2021-10-13 (64)	1
	Unscheduled	Yes	2021-11-03 (85)	1
	Post-Treatment Visit	Yes	2021-11-11 (93)	1
3145-2008	Screening	Yes	2021-09-17 (-20)	1
	Cycle 1 Day 1	Yes	2021-10-07 (1)	1
	Unscheduled	Yes	2021-10-15 (9)	1
	Cycle 2 Day 1	Yes	2021-10-28 (22)	1
	Cycle 3 Day 1	Yes	2021-11-19 (44)	1
	Cycle 4 Day 1	Yes	2021-12-10 (65)	1

Program: l-qs-ecog.sas

2022-05-24 10:10

Page 2 of 3

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.11
ECOG Performance Status
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	ECOG Performed?	Date of Assessment (Study Day)	ECOG Performance Status
3145-2008	Cycle 5 Day 1	Yes	2021-12-30 (85)	1
(continued)	Post-Treatment Visit	Yes	2022-02-02 (119)	1

Listing: 16.2.12
Physical Exam
All Randomized Patients

Treatment: Placebo

Subject Number	Visit	Exam Performed	Exam Date (Study Day)
3145-2004	Screening	Yes	2021-07-21 (-21)
	Cycle 1 Day 1	Yes	2021-08-11 (1)
	Unscheduled	Yes	2021-09-01 (22)
	Unscheduled	Yes	2021-09-10 (31)
	Cycle 2 Day 1	Yes	2021-09-15 (36)
	Cycle 3 Day 1	Yes	2021-10-06 (57)
	Cycle 4 Day 1	Yes	2021-10-27 (78)
	Post-Treatment Visit	Yes	2021-11-12 (94)
3145-2007	Screening	Yes	2021-08-18 (-7)
	Cycle 1 Day 1	Yes	2021-08-25 (1)
3145-2501	Screening	Yes	2021-05-28 (-6)
	Cycle 1 Day 1	Yes	2021-06-03 (1)
	Unscheduled	Yes	2021-06-04 (2)
	Cycle 2 Day 1	Yes	2021-06-24 (22)
	Cycle 3 Day 1	Yes	2021-07-15 (43)
	Unscheduled	Yes	2021-08-05 (64)
	Cycle 4 Day 1	Yes	2021-08-18 (77)
	Unscheduled	Yes	2021-08-26 (85)
	Cycle 5 Day 1	Yes	2021-09-08 (98)
	Unscheduled	Yes	2021-09-10 (100)
	Unscheduled	Yes	2021-09-17 (107)
	Unscheduled	Yes	2021-09-22 (112)
	Unscheduled	Yes	2021-09-24 (114)
	Unscheduled	Yes	2021-09-29 (119)

Listing: 16.2.12
Physical Exam
All Randomized Patients

Treatment: Trilaciclib

Subject Number	Visit	Exam Performed	Exam Date (Study Day)
2011-2001	Screening	Yes	2021-08-18 (-22)
	Cycle 1 Day 1	Yes	2021-09-09 (1)
	Cycle 2 Day 1	Yes	2021-10-06 (28)
	Cycle 3 Day 1	Yes	2021-10-27 (49)
	Cycle 4 Day 1	Yes	2021-11-17 (70)
3145-2005	Screening	Yes	2021-07-23 (-13)
	Cycle 1 Day 1	Yes	2021-08-05 (1)
	Cycle 2 Day 1	Yes	2021-08-26 (22)
	Post-Treatment Visit	Yes	2021-11-17 (105)
3145-2006	Screening	Yes	2021-07-26 (-16)
	Cycle 1 Day 1	Yes	2021-08-11 (1)
	Cycle 2 Day 1	Yes	2021-09-01 (22)
	Unscheduled	Yes	2021-09-10 (31)
	Cycle 3 Day 1	Yes	2021-09-22 (43)
	Cycle 4 Day 1	Yes	2021-10-13 (64)
	Unscheduled	Yes	2021-11-03 (85)
	Post-Treatment Visit	Yes	2021-11-11 (93)
3145-2008	Screening	Yes	2021-09-17 (-20)
	Cycle 1 Day 1	Yes	2021-10-07 (1)
	Unscheduled	Yes	2021-10-15 (9)
	Cycle 2 Day 1	Yes	2021-10-28 (22)
	Cycle 3 Day 1	Yes	2021-11-19 (44)
	Cycle 4 Day 1	Yes	2021-12-10 (65)
	Cycle 5 Day 1	Yes	2021-12-30 (85)

G1 Therapeutics, Inc.

G1T28-210

Database lock date: 2022-04-27

Listing: 16.2.12
Physical Exam
All Randomized Patients

Treatment: Trilaciclib			
<hr/>			
Subject Number	Visit	Exam Performed	Exam Date (Study Day)
<hr/>			
3145-2008 (continued)	Post-Treatment Visit	Yes	2022-02-02 (119)

Table: 14.1.1.1
Patient Disposition
All Screened Patients

Category	Placebo + Chemo	Trilaciclib + Chemo	Overall
Patients Screened	NA	NA	10
Screen Failure	NA	NA	3
Patients Randomized	3	4	7
Patients with at least one dose of study drug [a]	3 (100.0)	4 (100.0)	7 (100.0)
Patients without any study drug [a]	0	0	0
Study Drug (Trilaciclib/Placebo) Disposition			
Ongoing [b]	0	0	0
Discontinued [b]	3 (100.0)	4 (100.0)	7 (100.0)
Primary Reason for Discontinued [c]			
Adverse Event	0	0	0
Death	1 (33.3)	0	1 (14.3)
Lost to Follow-Up	0	0	0
Physician Decision	0	0	0
Progressive Disease	0	0	0
Study Terminated by Sponsor	1 (33.3)	3 (75.0)	4 (57.1)
Withdrawal by Patient	1 (33.3)	1 (25.0)	2 (28.6)
Other	0	0	0

Note: [a] Percentages are based on the number of patients randomized.

[b] Percentages are based on the number of patients treated.

[c] Percentages are based on the number of patients who discontinued the study drug.

[d] Percentages are based on the number of patients who discontinued the study.

[e] Percentages are based on the number of patients who died.

Table: 14.1.1.1
Patient Disposition
All Screened Patients

Category	Placebo + Chemo	Trilaciclib + Chemo	Overall
Study Drug (Docetaxel) Disposition			
Ongoing [b]	0	0	0
Discontinued [b]	3 (100.0)	4 (100.0)	7 (100.0)
Primary Reason for Discontinued [c]			
Adverse Event	0	0	0
Death	1 (33.3)	0	1 (14.3)
Lost to Follow-Up	0	0	0
Physician Decision	0	0	0
Progressive Disease	0	0	0
Study Terminated by Sponsor	1 (33.3)	3 (75.0)	4 (57.1)
Withdrawal by Patient	1 (33.3)	1 (25.0)	2 (28.6)
Other	0	0	0
Entering Survival Follow-up [b]	0	1 (25.0)	1 (14.3)

Note: [a] Percentages are based on the number of patients randomized.

[b] Percentages are based on the number of patients treated.

[c] Percentages are based on the number of patients who discontinued the study drug.

[d] Percentages are based on the number of patients who discontinued the study.

[e] Percentages are based on the number of patients who died.

Table: 14.1.1.1
Patient Disposition
All Screened Patients

Category	Placebo + Chemo	Trilaciclib + Chemo	Overall
Study Disposition			
Ongoing [a]	0	0	0
Discontinued [a]	3 (100.0)	4 (100.0)	7 (100.0)
Primary Reason for Discontinued [d]			
Death	1 (33.3)	0	1 (14.3)
Lost to Follow-Up	0	0	0
Study Terminated by Sponsor	1 (33.3)	4 (100.0)	5 (71.4)
Withdrawal by Patient	1 (33.3)	0	1 (14.3)
Other	0	0	0
Patients who Died [a]	1 (33.3)	0	1 (14.3)
Primary Reason for Death [e]			
Adverse Event	1 (100.0)	0	1 (100.0)
Progressive Disease	0	0	0
Other	0	0	0

Note: [a] Percentages are based on the number of patients randomized.

[b] Percentages are based on the number of patients treated.

[c] Percentages are based on the number of patients who discontinued the study drug.

[d] Percentages are based on the number of patients who discontinued the study.

[e] Percentages are based on the number of patients who died.

Table: 14.1.3.1
Demographics and Baseline Disease Characteristics
All Randomized Patients

Category	Placebo + Chemo (N=3)	Trilaciclib + Chemo (N=4)	Overall (N=7)
Age (years)			
n	3	4	7
Mean (SD)	62.7 (2.52)	58.3 (11.47)	60.1 (8.57)
Median	63.0	57.5	60.0
Min, Max	60, 65	45, 73	45, 73
Age Group, n (%)			
18-65	2 (66.7)	3 (75.0)	5 (71.4)
>= 65	1 (33.3)	1 (25.0)	2 (28.6)
Gender, n (%)			
Male	2 (66.7)	2 (50.0)	4 (57.1)
Female	1 (33.3)	2 (50.0)	3 (42.9)
Unknown	0	0	0
Race, n (%)			
White	2 (66.7)	2 (50.0)	4 (57.1)
Black or African American	1 (33.3)	2 (50.0)	3 (42.9)
Asian	0	0	0
American Indian or Alaska Native	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Other	0	0	0
Not Reported	0	0	0
Unknown	0	0	0

Note: Unless otherwise specified, percentages are based on the number of patients in each treatment group (i.e., N).

Table: 14.1.3.1
Demographics and Baseline Disease Characteristics
All Randomized Patients

Category	Placebo + Chemo (N=3)	Trilaciclib + Chemo (N=4)	Overall (N=7)
Ethnicity, n (%)			
Hispanic or Latino	1 (33.3)	1 (25.0)	2 (28.6)
Not Hispanic or Latino	2 (66.7)	3 (75.0)	5 (71.4)
Not Reported	0	0	0
Unknown	0	0	0
ECOG score, n (%)			
0	1 (33.3)	1 (25.0)	2 (28.6)
1	2 (66.7)	2 (50.0)	4 (57.1)
2	0	1 (25.0)	1 (14.3)
Stage at Diagnosis, n (%)			
I	0	0	0
II	0	0	0
III	0	0	0
IV	3 (100.0)	4 (100.0)	7 (100.0)
Unknown	0	0	0
Stage at Screening, n (%)			
I	0	0	0
II	0	0	0
III	0	0	0
IV	3 (100.0)	4 (100.0)	7 (100.0)
Unknown	0	0	0

Note: Unless otherwise specified, percentages are based on the number of patients in each treatment group (i.e., N).

Table: 14.1.3.1
Demographics and Baseline Disease Characteristics
All Randomized Patients

Category	Placebo + Chemo (N=3)	Trilaciclib + Chemo (N=4)	Overall (N=7)
Histopathologic Type, n (%)			
Adenocarcinoma	2 (66.7)	3 (75.0)	5 (71.4)
Large Cell Carcinoma	0	0	0
Squamous Cell Carcinoma	1 (33.3)	1 (25.0)	2 (28.6)
Undifferentiated	0	0	0
Unknown	0	0	0
Other	0	0	0
Country, n (%)			
United States	3 (100.0)	4 (100.0)	7 (100.0)

Note: Unless otherwise specified, percentages are based on the number of patients in each treatment group (i.e., N).

Table: 14.3.1.1
Overall Summary of Adverse Events
Safety Population

Category	Placebo + Chemo (N=3)	Trilaciclib + Chemo (N=4)	Overall (N=7)
Number of patients with any AE	3 (100.0)	4 (100.0)	7 (100.0)
Number of patients with any AE of CTCAE grade \geq 3	3 (100.0)	2 (50.0)	5 (71.4)
Number of patients with any AE of CTCAE grade \geq 4	3 (100.0)	0	3 (42.9)
Number of patients with any study drug-related AE	3 (100.0)	4 (100.0)	7 (100.0)
Trilaciclib/Placebo-related AE	3 (100.0)	4 (100.0)	7 (100.0)
Docetaxel-related AE	3 (100.0)	4 (100.0)	7 (100.0)
Number of patients with any serious AE	3 (100.0)	1 (25.0)	4 (57.1)
Number of patients with AE leading to discontinuation of any study drug	0	0	0
Leading to Trilaciclib/Placebo discontinuation	0	0	0
Leading to Docetaxel discontinuation	0	0	0
Number of patients with AE leading to death	1 (33.3)	0	1 (14.3)

Note: Adverse Events (AE) are coded using MedDRA Version 24.0.

Note: AEs are defined as those AEs that started on or after the day of the first dose of study drug. AEs with an unknown/not reported onset date are also included.

Note: AEs with missing information concerning relationship, severity, or action taken are excluded from any specific analysis related to those parameters, however, these are included where appropriate in the overall summary.

Note: Related refers to those events that are Possibly, Probably, or Definitely Related.

Note: Unless otherwise specified, percentages are based on the number of patients in each treatment group (i.e., N).

Table: 14.3.1.1
Overall Summary of Adverse Events
Safety Population

Category	Placebo + Chemo (N=3)	Trilaciclib + Chemo (N=4)	Overall (N=7)
Number of patients with AE of special interest (AESI) for Trilaciclib	0	1 (25.0)	1 (14.3)

Note: Adverse Events (AE) are coded using MedDRA Version 24.0.

Note: AEs are defined as those AEs that started on or after the day of the first dose of study drug. AEs with an unknown/not reported onset date are also included.

Note: AEs with missing information concerning relationship, severity, or action taken are excluded from any specific analysis related to those parameters, however, these are included where appropriate in the overall summary.

Note: Related refers to those events that are Possibly, Probably, or Definitely Related.

Note: Unless otherwise specified, percentages are based on the number of patients in each treatment group (i.e., N).